

ANTER OUT AREAD CANADES OF THE CANADARICA

TO AND TO WHOM THESE PRESENTS SHAVE COMES

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

March 05, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/487,064

FILING DATE: July 11, 2003

RELATED PCT APPLICATION NUMBER: PCT/US03/41273

By Authority of the COMMISSIONER OF PATENTS AND TRADEMARKS

W. MONTGOMERY

Certifying Officer

PRIORITY
DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1 (a) OR (b)

PART (1) OF (2) PART(S)

PATENT	APPLICATION	SERIAL	NO.	•

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FEE RECORD SHEET

07/16/2003 KZEWDIE 00000025 60487064

01 FC:2005

80.00 OP

PTO-1556 (5/87)

*U.S. Government Printing Office: 2002 — 489-267/69033



IN THE U.S. PATENT AND TRADEMARK OFFICE Provisional Application Cover Sheet

COMMISSIONER FOR PATENTS Washington, D.C. 20231

Sir:

·	INVENT	DR(s)/APPLICANT(s)
Last Name	First Name, MI	Residence (City and Either State or Foreign Country)
Hickey	Magali Bourghol	Medford, MA
Peterson	Matthew	Framingham, MA
Almarsson	Om .	Shrewsbury, MA
·		
	TITLE O	F THE INVENTION
PHARMACEUTI	CAL CO-CRYSTAL COMPOSITIO	NS
	CORRESP	ONDENCE ADDRESS
	Customer No. 34846	
	John Lucas	
•	Transform Pharmaceuti	cals. Inc.
	· 29 Hartwell Avenue	
	. Lexington, MA	
 	: ENCLOSED ADDITO	TION PARTS (check all that apply)
	ENCLOSED AT TOTCA	THOM TAKES (check all that apply)
	ring(s) Number of Pages or of Attorney	
	МЕТН	OD OF PAYMENT
		Contract to the contract
A check in the amo	unt of \$_80.00 to cover the filing	iee is enclosed.
Charge \$ to	o Deposit Account	
Charge 5	o Deposit Account	-
•	•	
		Respectfully submitted,
"Express Mail" label no.	. EV331911901US	lot hudas
		John Lucas
Date of Deposit: July 1	1, 2003	Attorney/Agent for Applicant(s)
I hereby certify that this	is being deposited with the United States	
Postal Service 'Express'	Mail Post Office to Addressee' service un	·
37 CFR 1.10 on the date	e indicated above and is addressed to the	Date: July 11, 2003
	nts, PO Box 1450, Alexandria, VA 22313	
1450.	•	Telephone No.: <u>781-674-7852</u>
· ()	· mi	
By	16 // J. CO	

PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS

Inventors:

Magali Bourghol Hickey 342 Malden Street Medford, MA 02155 Citizenship: US

Matthew Peterson 60 Linda Avenue Framingham, MA 01701 Citizenship: US

Orn Almarsson 22 Farmington Drive Shrewsbury, MA 01545 Citizenship: Iceland

Pharmaceutical Compositions

INCORPORATION BY REFERENCE

The content of US Patent Application No. 60/451,213 filed on February 28, 2003 is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to co-crystal api-containing compositions, pharmaceutical compositions comprising such apis, and methods for preparing the same.

BACKGROUND OF THE INVENTION

Active pharmaceutical ingredients (api or apis (plural)) in pharmaceutical compositions can be prepared in a variety of different forms. Such apis can be prepared so as to have a variety of different chemical forms including chemical derivatives or salts. Such apis can also be prepared to have different physical forms. For example, the apis may be amorphous or may have different crystalline polymorphs, perhaps existing in different solvation or hydration states. By varying the form of an api, it is possible to vary the physical properties thereof. For example, crystalline polymorphs typically have different solubilities from one another, such that a more thermodynamically stable polymorph is less soluble than a less thermodynamically stable polymorph. Pharmaceutical polymorphs can also differ in properties such as shelf-life, bioavailability, morphology, vapour pressure, density, colour, and compressibility. Accordingly, variation of the crystallinic state of an api is one of many ways in which to modulate the physical properties thereof.

It would be advantageous to have new forms of these apis that have improved properties, in particular, as oral formulations. Specifically, it is desirable to identify improved forms of apis that exhibit significantly improved properties including increased aqueous solubility and stability. Further, it is desirable to improve the processability, or preparation of pharmaceutical formulations. For example, needle-like crystal forms or habits of apis can cause aggregation, even in compositions where the api is mixed with other substances, such that a non-uniform mixture is obtained. It is also desirable to

increase the dissolution rate of api-containing pharmaceutical compositions in water, increase the bioavailability of orally-administered compositions, and provide a more rapid onset to therapeutic effect. It is also desirable to have a form of the api which, when administered to a subject, reaches a peak plasma level faster, has a longer lasting therapeutic plasma concentration, and higher overall exposure at high doses when compared to equivalent amounts of the api in its presently-known form.

SUMMARY OF THE INVENTION

It has now been found that new co-crystalline forms of apis can be obtained which improve the properties of apis as compared to the apis in a non-co-crystalline state (free acid, free base, zwitter ions, salts, etc.).

Accordingly, in a first aspect, the present invention provides a co-crystal pharmaceutical composition comprising an api compound and a co-crystal forming compound, such that the api and co-crystal forming compound are capable of co-crystallizing from a solid or solution phase under crystallization conditions.

Another aspect of the present invention provides a process for the production of a pharmaceutical composition, which process comprises:

- (1) providing an api which has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (2) providing a co-crystal forming compound which has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic

ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

- (3) grinding, heating or contacting in solution the api with the co-crystal forming compound under crystallization conditions, and
 - (4) isolating co-crystals formed thereby; and
 - (5) incorporating the co-crystals into a pharmaceutical composition.

A further aspect of the present invention provides a process for the production of a pharmaceutical composition, which comprises:

- grinding, heating or contacting in solution an api compound with a cocrystal forming compound, under crystallization conditions, so as to form a solid phase;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

In a further aspect, the present invention provides a process for the production of a pharmaceutical composition, which comprises:

- (1) providing (i) an api or a plurality of different apis, and (ii) a co-crystal forming compound or a plurality of different co-crystal forming compounds, wherein at least one of the api and the co-crystal forming compound is provided as a plurality thereof;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Solubility Modulation:

In a further aspect, the present invention provides a process for modulating the solubility of an api, which process comprises:

(1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;

(2) isolating co-crystals comprising the api and the co-crystal forming compound.

Dissolution Modulation:

In a further aspect, the present invention provides a process for modulating the dissolution of an api, whereby the aqueous dissolution rate or the dissolution rate in simulated gastric fluid or in simulated intestinal fluid, or in a solvent or plurality of solvents is increased or decreased, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

In a preferred embodiment, the dissolution of the api is increased.

Bioavailability Modulation:

In a further aspect, the present invention provides a process for modulating the bioavailability of an api, whereby the AUC is increased, the time to T_{max} is reduced, the length of time the concentration of the api is above ½ T_{max} is increased, or C_{max} is increased, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Dose Response Modulation:

In a further aspect the present invention provides a process for improving the linearity of a dose response of an api, which process comprises:

- (1) contacting in solution an api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Increased Stability:

In a still further aspect the present invention provides a process for improving the stability of a pharmaceutical salt, which process comprises:

- (1) grinding, heating or contacting in solution the pharmaceutical salt with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Difficult to Salt or Unsaltable Compounds:

In a still further aspect the present invention provides a process for making co-crystals of difficult to salt or unsaltable api which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Decreasing Hygroscopicity:

In a still further aspect the present invention provides a method for decreasing the hygroscopicity of an api, which method comprises:

(1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;

(2) isolating co-crystals comprising the api and the co-crystal forming compound.

Crystallizing Amorphous Compounds:

In a still further embodiment aspect the present invention provides a process for crystallizing an amorphous compound, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Decreasing Form Diversity:

In a still further embodiment aspect the present invention provides a process for reducing the form diversity of an api, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Morphology Modulation:

In a still further embodiment aspect the present invention provides a process for modifying the morphology of an api, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Co-Crystal Compositions:

In a further aspect, the present invention provides a co-crystal composition comprising a co-crystal, wherein said co-crystal comprises an api compound and a co-crystal forming compound. In further embodiments the co-crystal has an improved property as compared to the free form (including a free acid, free base, zwitter ion, hydrate, solvate, etc.) or a salt (which includes salt hydrates and solvates). In further embodiments, the improved property is selected from the group consisting of: increased solubility, increased dissolution, increased bioavailability, increased dose response, decreased hygroscopicity, a crystalline form of a normally amorphous compound, a crystalline form of a difficult or unsaltable compound, decreased form diversity, more desired morphology, or other property described herein.

BRIEF DESCRIPTION OF THE DRAWINGS

- Fig. 1 PXRD pattern for a co-crystal of carbamazepine and saccharin
- Fig. 2 DSC thermogram for a co-crystal of carbamazepine and saccharin
- Fig. 3 PXRD pattern for a co-crystal of carbamazepine and Nicotinamide
- Fig. 4 DSC thermogram for a co-crystal of carbamazepine and Nicotinamide
- Fig. 5 PXRD pattern for a co-crystal of carbamazepine and trimesic acid
- Fig. 6 PXRD pattern for a co-crystal of topiramate and 18-crown-6
- Fig. 7 DSC thermogram for a co-crystal of topiramate and 18-crown-6
- Fig. 8 PXRD pattern for a co-crystal of Olanzapine and Nicotinamide
- Fig. 9 DSC thermogram for a co-crystal of Olanzapine and Nicotinamide
- Fig. 10 PXRD pattern for a co-crystal of Celecoxib and 18-crown-6
- Fig. 11 DSC thermogram for a co-crystal of Celecoxib and 18-crown-6
- Fig. 12 PXRD pattern for a co-crystal of Itraconazole and Succinic acid
- Fig. 13 DSC thermogram for a co-crystal of Itraconazole and Succinic acid
- Fig. 14 PXRD pattern for a co-crystal of Itraconazole and Fumaric acid
- Fig. 15 DSC thermogram for a co-crystal of Itraconazole and Fumaric acid
- Fig. 16 PXRD pattern for a co-crystal of Itraconazole and tartaric acid
- Fig. 17 DSC thermogram for a co-crystal of Itraconazole and tartaric acid
- Fig. 18 PXRD pattern for a co-crystal of Itraconazole and malic acid
- Fig. 19 DSC thermogram for a co-crystal of Itraconazole and malic acid

Fig. 20 PXRD pattern for a co-crystal of Itraconazole.HCl and tartaric acid

Fig. 21 DSC thermogram for a co-crystal of Itraconazole HCl and tartaric acid

Fig. 22 PXRD pattern for a co-crystal of modafinil and Nicotinamide

Fig. 23 PXRD pattern for a co-crystal of modafinil and Benzamide

Fig. 24 PXRD pattern for a co-crystal of modafinil and Mandelic acid

Fig. 25 PXRD pattern for a co-crystal of modafinil and glycolic acid

Fig. 26 PXRD pattern for a co-crystal of modafinil and Fumaric acid

Fig. 27 Dissolution profile for a co-crystal of Celecoxib and Nicotinamide vs. Celecoxib free base

Fig. 28 Dissolution profile for co-crystals of itraconazole and Succinic, tartaric and malic acid vs. itraconazole free base

Fig. 29 Hygroscopicity profile for a co-crystal of itraconazole.HCl and tartaric acid vs. itraconazole.HCl

Fig. 30 Hygroscopicity profile for a co-crystal of Celecoxib and Nicotinamide vs. Celecoxib sodium

Fig. 31 PXRD pattern for a co-crystal of olanzepine and Nicotinamide (Form III). DETAILED DESCRIPTION OF THE INVENTION

The term "co-crystal" as used herein means a crystalline material comprised of two or more unique solids at room temperature, each containing distinctive physical characteristics, such as structure, melting point and heats of fusion, with the exception that, if specifically stated, the api may be a liquid at room temperature. The co-crystals of the present invention comprise a co-crystal former H-bonded to an api. The co-crystal former may be H-bonded directly to the api or may be H-bonded to an additional molecule which is bound to the api. The additional molecule may be H-bonded to the api, bound or bound ionically or covalently to the api. The additional molecule could also be a different api. Solvates of api compounds that do not further comprise a co-crystal forming compound are not co-crystals according to the present invention. The co-crystals may however, include one or more solvent molecules in the crystalline lattice. That is, solvates of co-crystals, or a co-crystal further comprising a solvent or compound that is a liquid at room temperature, is included in the present invention, but crystalline material comprised of only one solid and one or more liquids (at room temperature) are

not included in the present invention. The co-crystals may also be a co-crystal between a co-crystal former and a salt of an api, but the api and the co-crystal former of the present invention are constructed or bonded together through hydrogen bonds. Other modes of molecular recognition may also be present including, II-stacking; guest-host complexation and Van-Der-Waals interactions. Of the interactions listed above, hydrogen-bonding is the dominant interaction in the formation of the co-crystal, (and a required interaction according to the present invention) whereby a non-covalent bond is formed between a hydrogen bond donor of one of the moieties and a hydrogen bond acceptor of the other. An alternative embodiment provides for a co-crystal wherein the co-crystal former is a second api. In another embodiment, the co-crystal former is not an api. In another embodiment to the co-crystal comprises two co-crystal formers. Cocrystals may also be formed where the api is a "guest" molecule in regions of a crystalline lattice formed by the co-crystal forming compound, thus forming an inclusion complex. For purposes of the present invention, the chemical and physical properties of an api in the form of a co-crystal may be compared to a reference compound that is the same api in a different form. The reference compound may be specified as a free form, or more specifically, a free acid, free base, or zwitterion; a salt, or more specifically for example, an inorganic base addition salt such as sodium, potassium, lithium, calcium, magnesium, ammonium, aluminum salts or organic base addition salts, or an inorganic acid addition salts such as HBr, HCl, sulfuric, nitric, or phosphoric acid addition salts or an organic acid addition salt such as acetic, proprionic, pyruvic, malanic, succinic, malic, maleic, fumaric, tartaric, citric, benzoic, methanesulfonic, ethanesulforic, stearic or lactic acid addition salt; an anhydrate or hydrate of a free form or salt, or more specifically, for example, a hemihydrate, dihydrate, trihydrate, quadrahydrate, pentahydrate; or a solvate of a free form or salt. The reference compound may also be specified as crystalline or amorphous.

It has surprisingly been found that when an api and a selected co-crystal forming compound are allowed to form co-crystals, the resulting co-crystals give rise to improved properties of the api, as compared to the api in a free form (including free acids, free bases, and zwitter ions, hydrates, solvates, etc.), or an acid or base salt thereof particularly with respect to: solubility, dissolution, bioavailability, stability, Cmax, Tmax,

processability, longer lasting therapeutic plasma concentration, hygroscopicity, crystallization of amorphous compounds, decrease in form diversity (including polymorphism and crystal habit), change in morphology or crystal habit, etc. For example, a co-crystal form of an api is particularly advantageous where the original api is insoluble or sparingly soluble in water. Additionally, the co-crystal properties conferred upon the api are also useful because the bioavailability of the api can be improved and the plasma concentration and/or serum concentration of the api can be improved. This is particularly advantageous for orally-administrable formulations. Moreover, the dose response of the api can be improved, for example by increasing the maximum attainable response and/or increasing the potency of the api by increasing the biological activity per dosing equivalent.

Accordingly, in a first aspect, the present invention provides a pharmaceutical composition comprising a co-crystal of an api and a co-crystal forming compound, such that the api and co-crystal forming compound are capable of co-crystallizing from a solution phase under crystallization conditions or from the solid-state, for example, through grinding or heating. In another aspect, the api has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, oheterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal forming compound has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto, methyl thio, or a functional group in a Table herein, such that the api and co-crystal forming compound are capable of co-crystallizing from a solution phase under crystallization conditions.

The co-crystals of the present invention are formed where the api and co-crystal forming compound are bonded together through a hydrogen bonds. Other non-covalent interactions, including Π -stacking and van-der-waals interactions, may also be present.

In one embodiment, the co-crystal former is selected from the co-crystal formers of Table I or Table II. In other embodiments, the co-crystal former of Table I is specified as a Class 1, Class 2, or Class 3 co-crystal former (see column labeled "class" Table I). In another embodiment, the pK_a value of the co-crystal former and the api is less than 2. In other embodiments, the difference in pK_a values of the co-crystal former and api is less than 3, less than 4, less than 5, between 2-3, between 3-4 or between 4 and 5. Table I lists multiple pK_a values for co-crystal formers having multiple functionalities. It is readily apparent to one skilled in the art the particular functional group corresponding to a particular pK_a value.

In another embodiment the particular functional group of a co-crystal former interacting with the api is specified (see for example Table I, columns labeled "Functionality" and "Molecular Structure" and the column of Table II labeled "Co-Crystal Former Functional Group". In a further embodiment the functional group of the api interacting with the co-crystal former functional group is specified (see, for example, Tables II and III).

In a further embodiment, the api is selected from an api of Table IV or elsewhere herein. In further embodiments, the functional group of the particular api interacting with the co-crystal former is specified. A specific functional group of a co-crystal former, a specific co-crystal former, or a specified functional group or a specific co-crystal former interacting with the particular api may also be specified. It is noted that for Table II, the co-crystal former, and optionally the specific functionality, and each of the listed corresponding interacting groups are included as individual species of the present invention. Thus, each specific combination of a co-crystal former and one of the interacting groups in the same row may be specified as a species of the present invention. The same is true for other combinations as discussed in the Tables and elsewhere herein.

In each process according to the invention, there is a need to contact the api with the co-crystal forming compound. This may involve grinding the two solids together or melting one or both components and allowing them to recrystallize. This may also involve either solubilising the api and adding the co-crystal forming compound, or solubilising the co-crystal forming compound and adding the api. In a preferred arrangement, the api may be solubilised in the co-crystal forming compound.

Crystallisation conditions are applied to the api and co-crystal forming compound. This may entail altering a property of the solution, such as pH or temperature and may require concentration of solute, usually by removal of the solvent, typically by drying the solution. Solvent removal results in the concentration of api increasing over time so as to facilitate crystallisation. Once the solid phase comprising any crystals is formed, this may be tested as described herein.

The co-crystals obtained as a result of such process steps may be readily incorporated into a pharmaceutical composition by conventional means. Pharmaceutical compositions in general are discussed in further detail below and may further comprise a pharmaceutically-acceptable diluent, excipient or carrier.

In a further aspect, the present invention provides a process for the production of a pharmaceutical composition, which process comprises:

- (1) providing an api which has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine or of Table II or III;
- (2) providing a co-crystal forming compound which has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carboxyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio or of Tables I, II, or III;
- (3) grinding, heating or contacting in solution the api with the co-crystal forming compound under crystallization conditions, and
 - (4) isolating co-crystals formed thereby; and
 - (5) incorporating the co-crystals into a pharmaceutical composition.

In a still further aspect the present invention provides a process for the production of a pharmaceutical composition, which comprises:

- (1) grinding, heating or contacting in solution an api with a co-crystal forming compound, under crystallization conditions, so as to form a solid phase;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Assaying the solid phase for the presence of co-crystals of the api and the co-crystal forming compound may be carried out by conventional methods known in the art. For example, it is convenient and routine to use powder X-ray diffraction techniques to assess the presence of the co-crystals. This may be affected by comparing the spectra of the api, the crystal forming compound and putative co-crystals in order to establish whether or not true co-crystals had been formed. Other techniques, used in an analogous fashion, include differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and Raman spectroscopy. Single crystal X-ray diffraction is especially useful in identifying co-crystal structures.

In a further aspect, the present invention therefore provides a process of screening for cocrystal compounds, which comprises:

- (1) providing (i) an api compound, and (ii) a co-crystal forming compound;
- (2) screening for co-crystals of apis with co-crystal forming compounds by subjecting each combination of api and co-crystal forming compound to a step comprising:
- (a) grinding, heating or contacting in solution the api with the co-crystal forming compound under crystallization conditions so as to form a solid phase;
- (b) isolating co-crystals comprising the api and the co-crystal forming compound.

An alternative embodiment is drawn to a process of screening for co-crystal compounds, which comprises:

(1) providing (i) an api or a plurality of different apis, and (ii) a co-crystal forming compound or a plurality of different co-crystal forming compounds, wherein at

least one of the api and the co-crystal forming compound is provided as a plurality thereof;

- (2) screening for co-crystals of apis with co-crystal forming compounds by subjecting each combination of api and co-crystal forming compound to a step comprising
- (a) grinding, heating or contacting in solution the api with the co-crystal forming compound under crystallization conditions so as to form a solid phase;
- (b) isolating co-crystals comprising the api and the co-crystal forming compound.

Solubility Modulation:

In a further aspect, the present invention provides a process for modulating the solubility of an api, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

In one embodiment, the solubility of the api is modulated such that the aqueous solubility is increased. Solubility of apis may be measured by any conventional means such as chromatography (e.g., HPLC) or spectroscopic determination of the amount of api in a saturated solution of the api, such as UV-spectroscopy, IR-spectroscopy, Raman spectroscopy, quantitative mass spectroscopy or gass chromatography.

In another aspect of the invention, the api may have low aqueous solubility. Typically, low aqueous solubility in the present application refers to a compound having a solubility in water which is less than or equal to 10mg/ml, when measured at 37°C, and preferably less than or equal to 5mg/ml or 1mg/ml. "Low aqueous solubility" can further be specifically defined as less than or equal to 900, 800, 700, 600, 500, 400, 300, 200 150 100, 90, 80, 70, 60, 50, 40, 30, 20 micrograms/ml, or further 10, 5 or 1 micrograms/ml, or further 900, 800, 700, 600, 500, 400, 300, 200 150, 100 90, 80, 70, 60, 50, 40, 30, 20, or

10 ng/ml, or less than 10 ng/ml when measured at 37°C. Aqueous solubility can also be specified as less than 500, 400, 300, 200, 150, 100, 75, 50 or 25 mg/ml. As embodiments of the present invention, solubility can be increased 2, 3, 4, 5, 7, 10, 15, 20, 25, 50, 75, 100, 200, 300, 500, 750, 1000, 5000, or 10,000 times by making a co-crystal of the reference form (e.g., crystalline or amorphous free acid, free base or zwitter ion, hydrates or solvates), or salt. Further aqueous solubility can be measured in simulated gastric fluid (SGF) or simulated intestinal fluid (SIF) rather than water. SGF (non-diluted) of the present invention is made by combining 1 g/L Triton X-100 and 2 g/L NaCl in water and adjusting the pH with 20mM HCl to obtain a solution with a final pH=1.7 (SIF is 0.68% monobasic potassium phosphate, 1% pancreatin, and sodium hydroxide where the pH of the final solution is 7.5). The pH of the solvent used may also be specified as 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.5, 4, 4.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, or 12.

Examples of embodiments includes: co-crystal compositions with an aqueous solubility, at 37 degrees C and a pH of 7.0, that is increased at least 5 fold over the free form, co-crystal compositions with a solubility in SGF that is increased at least 5 fold over the free form, co-crystal compositions with a solubility in SIF that is increased at least 5 fold over the free form.

Dissolution Modulation:

In another aspect of the present invention, the dissolution profile of the api is modulated whereby the aqueous dissolution rate or the dissolution rate in simulated gastric fluid or in simulated intestinal fluid, or in a solvent or plurality of solvents is increased. Dissolution rate is the rate at which api solids dissolve in a dissolution media. For apis whose absorption rates are faster than the dissolution rates (e.g., steroids), the rate-limiting step in the absorption process is often the dissolution rate. Because of a limited residence time at the absorption site, apis that are not dissolved before they are removed from intestinal absorption site are considered useless. Therefore, the rate of dissolution has a major impact on the performance of apis that are poorly soluble. Because of this factor, the dissolution rate of apis in solid dosage forms is an important, routine, quality control parameter used in the api manufacturing process.

Dissolution rate = $KS(C_s-C)$

where K is dissolution rate constant, S is the surface area, C, is the apparent solubility, and C is the concentration of api in the dissolution media.

For rapid api absorption, C_s-C is approximately equal to C_s

The dissolution rate of apis may be measured by conventional means known in the art.

The increase in the dissolution rate of a co-crystal, as compared to the reference form (e.g., free form or salt), may be specified, such as by 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100%, or by 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 500, 1000, 10,000, or 100,000 fold greater than the reference form (e.g., free form or salt form) in the same solution. Conditions under which the dissolution rate is measured is the same as discussed above. The increase in dissolution may be further specified by the time the composition remains supersaturated before reaching equilibrium solubility.

Examples of above embodiments includes: co-crystal compositions with a dissolution rate, at 37 degrees C and a pH of 7.0, that is increased at least 5 fold over the co-crystal compositions with a dissolution rate in SGF that is increased at least 5 fold over the free form, co-crystal compositions with a dissolution rate in SIF that is increased at least 5 fold over the free form.

Bioavailability Modulation:

The methods of the present invention are used to make a pharmaceutical api formulation with greater solubility, dissolution, and bioavailability, AUC, reduced time to T_{max} , (the time to reach peak blood serum levels), or increased C_{max} , plasma or when compared to the neutral form or salt alone.

AUC is the area under the plot of plasma concentration of api (not logarithm of the concentration) against time after api administration. The area is conveniently determined by the "trapezoidal rule": the data points are connected by straight line segments, perpendiculars are erected from the abscissa to each data point, and the sum of the areas of the triangles and trapezoids so constructed is computed. When the last

measured concentration (C_n , at time t_n) is not zero, the AUC from t_n to infinite time is estimated by C_n/k_{el} .

The AUC is of particular use in estimating bioavailability of apis, and in estimating total clearance of apis (Cl_T). Following single intravenous doses, AUC = D/Cl_T , for single compartment systems obeying first-order elimination kinetics; alternatively, AUC = C_0/k_{el} . With routes other than the intravenous, for such systems, AUC = $F \cdot D/Cl_T$, where F is the availability of the api.

Thus, in a further aspect, the present invention provides a process for modulating the bioavailability of an api when administered in its normal and effective dose range as a co-crystal, whereby the AUC is increased, the time to T_{max} is reduced, or C_{max} is increased, as compared to a reference form, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Examples of the above embodiments includes: co-crystal compositions with a time to T_{max} that is reduced by at least 10% as compared to the free form, co-crystal compositions with a time to T_{max} that is reduced by at least 20% over the free form, co-crystal compositions with a time to T_{max} that is reduced by at least 40% over the free form, co-crystal compositions with a time to T_{max} that is reduced by at least 50% over the free form, co-crystal compositions with a T_{max} that is reduced by at least 60% over the free form, co-crystal compositions with a T_{max} that is reduced by at least 70% over the free form, co-crystal compositions with a T_{max} that is reduced by at least 80% over the free form, co-crystal compositions with a T_{max} that is increased by at least 20% over the free form, co-crystal compositions with a C_{max} that is increased by at least 30% over the free form, co-crystal compositions with a C_{max} that is increased by at least 40% over the free form, co-crystal compositions with a C_{max} that is increased by at least 50% over the free form, co-crystal compositions with a C_{max} that is increased by at least 50% over the free form, co-crystal compositions with a C_{max} that is increased by at least 50% over the free form, co-crystal compositions with a C_{max} that is increased by at least 50% over the free form, co-crystal compositions with a C_{max} that is increased by at least 50% over the free form, co-crystal compositions with a C_{max} that is increased by at least 50% over the free form, co-crystal compositions with a C_{max} that is increased by at least 50% over the free form, co-crystal compositions with a C_{max} that is increased by at least 50% over the free form, co-crystal compositions with a C_{max} that is increased by at least 50% over the free form, co-crystal compositions with a C_{max} that is increased by at least 50% over the

free form; co-crystal compositions with a C_{max} that is increased by at least 80% over the free form, co-crystal compositions with a Cmax that is increased by at least 2 fold, 3 fold, 5 fold, 7.5 fold, 10 fold, 25 fold, 50 fold or 100 fold, co-crystal compositions with an AUC that is increased by at least 10% over the free form, co-crystal compositions with an AUC that is increased by at least 20% over the free form, co-crystal compositions with an AUC that is increased by at least 30% over the free form, co-crystal compositions with an AUC that is increased by at least 40% over the free form, co-crystal compositions with an AUC that is increased by at least 50% over the free form, co-crystal compositions with an AUC that is increased by at least 60% over the free form, co-crystal compositions with an AUC that is increased by at least 70% over the free form, co-crystal compositions with an AUC that is increased by at least 80% over the free form or co-crystal compositions with an AUC that is increased by at least 2 fold, 3 fold, 4 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, and 10 fold. Other examples include wherein the reference form is crystalline, wherein the reference form is amorphous wherein the reference form is an anhydrous crystalline sodium salt or wherein the reference form is an anhydrous, crystalline HCl salt.

Dose Response Modulation:

In a further aspect the present invention provides a process for improving the dose response of an api, which process comprises:

- (1) contacting in solution an api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Dose response is the quantitative relationship between the magnitude of response and the dose inducing the response and may be measured by conventional means known in the art. The curve relating effect (as the dependent variable) to dose (as the independent variable) for an api-cell system is the "dose-response curve". Typically, the dose-response curve is the measured response to an api plotted against the dose of the api

(mg/kg) given. The dose response curve can also be a curve of AUC against the dose of the api given.

In an embodiment of the present invention, a co-crystal of the present invention has an increased dose response curve or more linear dose response curve than the corresponding reference compound.

Increased Stability:

In a still further aspect the present invention provides a process for improving the stability of an api (as compared to a reference form such as its free form or a salt thereof), which process comprises:

- (1) Grinding, heating or contacting in solution the pharmaceutical salt with a cocrystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

In a preferred embodiment, the compositions of the present invention, including the api or active pharmaceutical ingredient (api) and formulations comprising the api, are suitably stable for pharmaceutical use. Preferably, the api or formulations thereof of the present invention are stable such that when stored at 30 deg. C for 2 years, less than 0.2% of any one degradant is formed. The term degradant refers herein to product(s) of a single type of chemical reaction. For example, if a hydrolysis event occurs that cleaves a molecule into two products, for the purpose of the present invention, it would be considered a single degradant. More preferably, when stored at 40 deg. C for 2 years, less than 0.2% of any one degradant is formed. Alternatively, when stored at 30 deg. C for 3 months, less than 0.2% or 0.15%, or 0.1% of any one degradant is formed, or when stored at 40 deg. C for 3 months, less than 0.2% or 0.15%, or 0.1% of any one degradant is formed. Further alternatively, when stored at 60 deg. C for 4 weeks, less than 0.2% or 0.15%, or 0.1% of any one degradant is formed. The relative humidity (RH) may be specified as ambient (RH), 75% (RH), or as any single integer between 1 to 99%.

Difficult to Salt or Unsaltable Compounds:

In a still further aspect the present invention provides a process for making co-crystals of unsaltable apis which process comprises:

- (1) grinding, heating or contacting in solution an api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Difficult to salt compounds include bases with a pKa < 3 or acids with a pKa > 10. Zwitterions are also difficult to salt or unsaltable compounds according to the present invention.

Decreasing Hygroscopicity:

In a still further aspect, the present invention provides a method for decreasing the hygroscopicity of an api, which method comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions;
- (3) forming a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

An aspect of the present invention provides a pharmaceutical composition comprising a co-crystal of an api that is less hygroscopic than amorphous or crystalline, free form or salt (including metal salts such as sodium, potassium, lithium, calcium, magnesium) or another reference compound. Hygroscopicity can be assessed by dynamic vapor sorption analysis, in which 5-50 mg of the compound is suspended from a Cahn microbalance. The compound being analyzed should be placed in a non-hygroscopic pan and its weight should be measured relative to an empty pan composed of identical material and having nearly identical size, shape, and weight. Ideally, platinum pans should be used. The pans should be suspended in a chamber through which a gas, such as air or nitrogen, having a controlled and known percent relative humidity (%RH) is flowed until eqilibrium criteria are met. Typical equilibrium criteria include weight

changes of less than 0.01 % change over 3 minutes at constant humidity and temperature. The relative humidity should be measured for samples dried under dry nitrogen to constant weight (<0.01 % change in 3 minutes) at 40oc unless doing so would de-solvate or otherwise convert the material to an amorphous compound. In one aspect, the hygroscopicity of a dried compound can be assessed by increasing the RH from 5 to 95 % in increments of 5 % RH and then decreasing the RH from 95 to 5 % in 5 % increments to generate a moisture sorption isotherm. The sample weight should be allowed to equilibrate between each change in %RH. If the compound deliquesces or becomes amorphous between above 75 % RH, but below 95 % RH, the experiment should be repeated with a fresh sample and the relative humidity range for the cycling should be narrowed to 5-75 % RH or 10-75 % RH instead of 5-95 %RH. If the sample cannot be dried prior to testing due to lack of form stability, than the sample should be studied using two complete humidity cycles of either 10-75 % RH or 5-95 % RH, and the results of the second cycle should be used if there is significant weight loss at the end of the first cycle.

Hygroscopicity can be defined using various parameters. For purposes of the present invention, a non-hygroscopic molecule should not gain or lose more than 1.0%, or more preferably, 0.5 % weight at 25degrees C when cycled between 10 and 75 % RH (relative humidity at 25 degrees C). The non-hygroscopic molecule more preferably should not gain or lose more than 1.0%, or more preferably, 0.5 % weight when cycled between 5 and 95 %RH at 25 degrees C, or more than 0.25 % of its weight between 10 and 75 % RH. Most preferably, a non-hygroscopic molecule will not gain or lose more than 0.25 % of its weight when cycled between 5 and 95 % RH.

Alternatively, for purposes of the present invention, hygroscopicity can be defined using the parameters of Callaghan et al., Equilibrium moisture content of pharmaceutical excipients, in Api Dev. Ind. Pharm., Vol. 8, pp. 335-369 (1982). Callaghan et al. classified the degree of hygroscopicity into four classes.

Class 1: Non-hygroscopic

Essentially no moisture increases occur at relative humidities below 90%.

Class 2: Slightly hygroscopic

Essentially no moisture increases occur at relative

humidities below 80%.

Class 3: Moderately hygroscopic

Moisture content does not increase more than 5%

after storage for 1 week at relative humidities below

60%.

Class 4: Very hygroscopic

Moisture content increase may degrees occur at

relative humidities as low as 40 to 50%.

Alternatively, for purposes of the present invention, hygroscopicity can be defined using the parameters of the European Pharmacopoeia Technical Guide (1999, p. 86) which has defined hygrospocity, based on the static method, after storage at 25°C for 24 h at 80 percent RH:

Slightly hygroscopic: Increase in mass is less than 2 percent m/m and equal to or greater than 0.2 percent m/m.

Hygroscopic: Increase in mass is less than 15 percent m/m and equal to or greater than 0.2 percent m/m.

Very Hygroscopic: Increase in mass is equal to or greater than 15 percent m/m.

Deliquescent: Sufficient water is absorbed to form a liquid.

Co-crystals of the present invention can be set forth as being in Class 1, Class 2, or Class 3, or as being Slightly hygroscopic, Hygroscopic, or Very Hygroscopic. Co-crystals of the present invention can also be set forth based on their ability to reduce hygroscopicity. Thus, preferred co-crystals of the present invention are less hygroscopic than a reference compound. The reference compound can be specified as the api in free form (free acid, free base, hydrate, solvate, etc.) or salt (e.g., especially metal salts such

as sodium, potassium, lithium, calcium, or magnesium). Further included in the present invention are co-crystals that do not gain or lose more than 1.0% weight at 25 degrees C when cycled between 10 and 75 % RH, wherein the reference compound gains or loses more than 1.0% weight under the same conditions. Further included in the present invention are co-crystals that do not gain or lose more than 0.5% weight at 25 degrees C when cycled between 10 and 75 % RH, wherein the reference compound gains or loses more than 0.5% or more than 1.0% weight under the same conditions. Further included in the present invention are co-crystals that do not gain or lose more than 1.0% weight at 25 degrees C when cycled between 5 and 95 % RH, wherein the reference compound gains or loses more than 1.0% weight under the same conditions. Further included in the present invention are co-crystals that do not gain or lose more than 0.5% weight at 25 degrees C when cycled between 5 and 95 % RH, wherein the reference compound gains or loses more than 0.5% or more than 1.0% weight under the same conditions. Further included in the present invention are co-crystals that do not gain or lose more than 0.25% weight at 25 degrees C when cycled between 5 and 95 % RH, wherein the reference compound gains or loses more than 0.5% or more than 1.0% weight under the same conditions.

Further included in the present invention are co-crystals that have a hygroscopicity (according to Callaghan et al.) that is at least one class lower than the reference compound or at least two classes lower than the reference compound. Included are a Class 1 co-crystals of a Class 2 reference compound, a Class 2 co-crystals of a Class 3 reference compound, a Class 3 co-crystals of a Class 4 reference compound, a Class 1 co-crystals of a Class 3 reference compound, a Class 1 co-crystals of a Class 2 co-crystals of a Class 4 reference compound, or a Class 2 co-crystals of a Class 4 reference compound.

Further included in the present invention are co-crystals that have a hygroscopicity (according to the European Pharmacopoeia Technical Guide) that is at least one class lower than the reference compound or at least two classes lower than the reference compound. Non-limiting examples include; a Slightly hygroscopic co-crystals of a Hygroscopic reference compound, a Hygroscopic co-crystals of a Very Hygroscopic reference compound, a Very Hygroscopic co-crystals of a Deliquescent reference compound, a Slightly hygroscopic co-crystals of a Very Hygroscopic reference

compound, a Slightly hygroscopic co-crystals of a Deliquescent reference compound, a Hygroscopic co-crystals of a Deliquescent reference compound.

Crystallizing Amorphous Compounds:

In a further aspect, the present invention provides a process for crystallizing an amorphous compound, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

An amorphous compound includes compounds that do not crystallize using routine methods in the art.

Decreasing Form Diversity:

In a still further embodiment aspect the present invention provides a process for reducing the form diversity of an api, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

For purposes of the present invention, the number of forms of a co-crystal is compared to the number of forms of a reference compound (e.g. the free form or a salt of the api) that can be made using routine methods in the art.

Morphology Modulation:

In a still further embodiment aspect the present invention provides a process for modifying the morphology of an api, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

In an embodiment the co-crystal comprises or consists of a co-crystal former and a pharmaceutical wherein the interaction between the two, e.g., H-bonding, occurs between a functional group of Table III of an api with a corresponding interacting group of Table III. In a further embodiment, the co-crystal comprises a co-crystal former of Table I or II and an api with a corresponding interacting group of Table II. In a further embodiment the co-crystal comprises an api from Table IV and a co-crystal former with a function group of Table III. In a further embodiment, the co-crystal api from Table I or II. In an aspect of the invention, only co-crystals having an H-bond acceptor on the first molecule and an H-bond donor on the second molecule, where the first and second molecules are either co-crystal former and api respectively or api and co-crystal former respectively, are included in the present invention. Table IV includes the CAS number, chemical name or a PCT or patent reference (each incorporated herein in their entireties). Thus, whether a particular api contains an H-bond donor, acceptor or both is readily apparent.

In another embodiment, the co-crystal former and api each have only one H-bond donor/acceptor. In another aspect, the molecular weight of the api is less than 2000, 1500, 1000, 750, 500, 350, 200, or 150 Daltons. In another embodiment, the molecular weight of the api is between 100-200, 200-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, 900-1000, 1000-1200, 1200-1400, 1400-1600, 1600-1800, or 1800-2000. Apis with the above molecular weights may also be specifically excluded from the present invention.

In another embodiment, peptides, proteins, nucleic acids or other biological apis are excluded from the present invention. In another embodiment, all non-pharmaceutically acceptable co-crystal formers are excluded from the present invention. In another embodiment, organometalic apis are excluded from the present invention. In another embodiment, a co-crystal former comprising any one or more of the functional

groups of Table III may be specifically excluded from the present invention. In another embodiment, any one or more of the co-crystal formers of Table I or II may be specifically excluded from the present invention. Any apis currently known in the art may also be specifically excluded from the present invention. For example, carbanazepine, itraconazole, nabumetone, fluoxetine, acetaminophen and theophylline can each be specifically excluded from the present invention. In another embodiment, the api is not a salt, is not a non-metal salt, or is not a metal salt, e.g., sodium, potassium, lithium, calcium or magnesium. In another embodiment, the api is a salt, is a non-metal salt, or is a metal salt, e.g., sodium, potassium, lithium, calcium, magnesium. In one embodiment, the api does not contain a halogen. In one embodiment, the api does contain a halogen.

Excipients employed in pharmaceutical compositions of the present invention can be solids, semi-solids, liquids or combinations thereof. Preferably, excipients are solids. Compositions of the invention containing excipients can be prepared by any known technique of pharmacy that comprises admixing an excipient with an api or therapeutic agent. A pharmaceutical composition of the invention contains a desired amount of api per dose unit and, if intended for oral administration, can be in the form, for example, of a tablet, a caplet, a pill, a hard or soft capsule, a lozenge, a cachet, a dispensable powder, granules, a suspension, an elixir, a dispersion, a liquid, or any other form reasonably adapted for such administration. If intended for parenteral administration, it can be in the form, for example, of a suspension or transdermal patch. If intended for rectal administration, it can be in the form, for example, of a suppository. Presently preferred are oral dosage forms that are discrete dose units each containing a predetermined amount of the api, such as tablets or capsules.

Non-limiting examples follow of excipients that can be used to prepare pharmaceutical compositions of the invention.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable carriers or diluents as excipients. Suitable carriers or diluents illustratively include, but are not limited to, either individually or in combination, lactose, including anhydrous lactose and lactose monohydrate; starches, including directly compressible starch and hydrolyzed starches (e.g., CelutabTM and

EmdexTM); mannitol; sorbitol; xylitol; dextrose (e.g., CereloseTM 2000) and dextrose monohydrate; dibasic calcium phosphate dihydrate; sucrose-based diluents; confectioner's sugar; monobasic calcium sulfate monohydrate; calcium sulfate dihydrate; granular calcium lactate trihydrate; dextrates; inositol; hydrolyzed cereal solids; amylose; celluloses including microcrystalline cellulose, food grade sources of alpha- and amorphous cellulose (e.g., Rexcell), powdered cellulose, hydroxypropylcellulose (HPC) and hydroxypropylmethylcellulose (HPMC); calcium carbonate; glycine; bentonite; block co-polymers; polyvinylpyrrolidone; and the like. Such carriers or diluents, if present, constitute in total about 5% to about 99%, preferably about 10% to about 85%, and more preferably about 20% to about 80%, of the total weight of the composition. The carrier, carriers, diluent, or diluents selected preferably exhibit suitable flow properties and, where tablets are desired, compressibility.

Lactose, mannitol, dibasic sodium phosphate, and microcrystalline cellulose (particularly Avicel PH microcrystalline cellulose such as Avicel PH 101), either individually or in combination, are preferred diluents. These diluents are chemically compatible with celecoxib. The use of extragranular microcrystalline cellulose (that is, microcrystalline cellulose added to a granulated composition) can be used to improve hardness (for tablets) and/or disintegration time. Lactose, especially lactose monohydrate, is particularly preferred. Lactose typically provides compositions having suitable release rates of celecoxib, stability, pre-compression flowability, and/or drying properties at a relatively low diluent cost. It provides a high density substrate that aids densification during granulation (where wet granulation is employed) and therefore improves blend flow properties and tablet properties.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable disintegrants as excipients, particularly for tablet formulations. Suitable disintegrants include, but are not limited to, either individually or in combination, starches, including sodium starch glycolate (e.g., ExplotabTM of PenWest) and pregelatinized corn starches (e.g., NationalTM 1551 of National Starch and Chemical Company, NationalTM 1550, and ColocornTM 1500), clays (e.g., VeegumTM HV of R.T. Vanderbilt), celluloses such as purified cellulose, microcrystalline cellulose, methylcellulose, carboxymethylcellulose and sodium carboxymethylcellulose,

croscarmellose sodium (e.g., Ac-Di-SolTM of FMC), alginates, crospovidone, and gums such as agar, guar, locust bean, karaya, pectin and tragacanth gums.

Disintegrants may be added at any suitable step during the preparation of the composition, particularly prior to granulation or during a lubrication step prior to compression. Such disintegrants, if present, constitute in total about 0.2% to about 30%, preferably about 0.2% to about 10%, and more preferably about 0.2% to about 5%, of the total weight of the composition.

Croscarmellose sodium is a preferred disintegrant for tablet or capsule disintegration, and, if present, preferably constitutes about 0.2% to about 10%, more preferably about 0.2% to about 7%, and still more preferably about 0.2% to about 5%, of the total weight of the composition. Croscarmellose sodium confers superior intragranular disintegration capabilities to granulated pharmaceutical compositions of the present invention.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable binding agents or adhesives as excipients, particularly for tablet formulations. Such binding agents and adhesives preferably impart sufficient cohesion to the powder being tableted to allow for normal processing operations such as sizing, lubrication, compression and packaging, but still allow the tablet to disintegrate and the composition to be absorbed upon ingestion. Such binding agents may also prevent or inhibit crystallization or recrystallization of a co-crsytal of the present invention once the salt has been dissolved in a solution. Suitable binding agents and adhesives include, but are not limited to, either individually or in combination, acacia; tragacanth; sucrose; gelatin; glucose; starches such as, but not limited to, pregelatinized starches (e.g., NationalTM 1511 and NationalTM 1500); celluloses such as, but not limited to, methylcellulose and carmellose sodium (e.g., TyloseTM); alginic acid and salts of alginic acid; magnesium aluminum silicate; PEG; guar gum; polysaccharide acids; bentonites; povidone, for example povidone K-15, K-30 and K-29/32; polymethacrylates; HPMC; hydroxypropylcellulose (e.g., KlucelTM of Aqualon); and ethylcellulose (e.g., EthocelTM of the Dow Chemical Company). Such binding agents and/or adhesives, if present, constitute in total about 0.5% to about 25%, preferably about 0.75% to about 15%, and more preferably about 1% to about 10%, of the total weight of the pharmaceutical composition.

Many of the binding agents are polymers comprising amide, ester, ether, alcohol or ketone groups and, as such, are preferably included in pharmaceutical compositions of the present invention. Polyvinylpyrrolidones such as povidone K-30 are especially preferred. Polymeric binding agents can have varying molecular weight, degrees of crosslinking, and grades of polymer. Polymeric binding agents can also be copolymers, such as block co-polymers that contain mixtures of ethylene oxide and propylene oxide units. Variation in these units' ratios in a given polymer affects properties and performance. Examples of block co-polymers with varying compositions of block units are Poloxamer 188 and Poloxamer 237 (BASF Corporation).

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable wetting agents as excipients. Such wetting agents are preferably selected to maintain the celecoxib in close association with water, a condition that is believed to improve bioavailability of the composition. Such wetting agents can also be useful in solubilizing or increasing the solubility of co-crystals.

Non-limiting examples of surfactants that can be used as wetting agents in pharmaceutical compositions of the invention include quaternary ammonium compounds, for example benzalkonium chloride, benzethonium chloride and cetylpyridinium chloride, dioctyl sodium sulfosuccinate, polyoxyethylene alkylphenyl ethers, for example nonoxynol 9, nonoxynol 10, and degrees Ctoxynol 9, poloxamers (polyoxyethylene and polyoxypropylene block copolymers), polyoxyethylene fatty acid glycerides and oils, for example polyoxyethylene (8) caprylic/capric mono- and diglycerides (e.g., LabrasolTM of Gattefosse), polyoxyethylene (35) castor oil and polyoxyethylene (40) hydrogenated castor oil; polyoxyethylene alkyl ethers, for example polyoxyethylene (20) cetostearyl ether, polyoxyethylene fatty acid esters, for example polyoxyethylene (40) stearate, polyoxyethylene sorbitan esters, for example polyosrbate 20 and polyosrbate 80 (e.g., TweenTM 80 of ICI), propylene glycol fatty acid esters, for example propylene glycol laurate (e.g., LauroglycolTM of Gattefosse), sodium lauryl sulfate, fatty acids and salts thereof, for example oleic acid, sodium oleate and triethanolamine oleate, glyceryl fatty acid esters, for example glyceryl monostearate, sorbitan esters, for example sorbitan

monolaurate, sorbitan monooleate, sorbitan monopalmitate and sorbitan monostearate, tyloxapol, and mixtures thereof. Such wetting agents, if present, constitute in total about 0.25% to about 15%, preferably about 0.4% to about 10%, and more preferably about 0.5% to about 5%, of the total weight of the pharmaceutical composition.

Wetting agents that are anionic surfactants are preferred. sodium lauryl sulfate is a particularly preferred wetting agent. sodium lauryl sulfate, if present, constitutes about 0.25% to about 7%, more preferably about 0.4% to about 4%, and still more preferably about 0.5% to about 2%, of the total weight of the pharmaceutical composition.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable lubricants (including anti-adherents and/or glidants) as excipients. Suitable lubricants include, but are not limited to, either individually or in combination, glyceryl behapate (e.g., CompritolTM 888 of Gattefosse); stearic acid and salts thereof, including magnesium, calcium and sodium stearates; hydrogenated vegetable oils (e.g., SterotexTM of Abitec); colloidal silica; talc; waxes; boric acid; sodium benzoate; sodium acetate; sodium fumarate; sodium chloride; DL-leucine; PEG (e.g., CarbowaxTM 4000 and CarbowaxTM 6000 of the Dow Chemical Company); sodium oleate; sodium lauryl sulfate; and magnesium lauryl sulfate. Such lubricants, if present, constitute in total about 0. 1% to about 10%, preferably about 0.2% to about 8%, and more preferably about 0.25% to about 5%, of the total weight of the pharmaceutical composition.

Magnesium stearate is a preferred lubricant used, for example, to reduce friction between the equipment and granulated mixture during compression of tablet formulations.

Suitable anti-adherents include, but are not limited to, talc, cornstarch, DL-leucine, sodium lauryl sulfate and metallic stearates. Talc is a preferred anti-adherent or glidant used, for example, to reduce formulation sticking to equipment surfaces and also to reduce static in the blend. Talc, if present, constitutes about 0.1% to about 10%, more preferably about 0.25% to about 5%, and still more preferably about 0.5% to about 2%, of the total weight of the pharmaceutical composition.

Glidants can be used to promote powder flow of a solid formulation. Suitable glidants include, but are not limited to, colloidal silicon dioxide, starch, talc, tribasic

calcium phosphate, powdered cellulose and magnesium trisilicate. Colloidal silicon dioxide is particularly preferred.

Other excipients such as colorants, flavors and sweeteners are known in the pharmaceutical art and can be used in pharmaceutical compositions of the present invention. Tablets can be coated, for example with an enteric coating, or uncoated. Compositions of the invention can further comprise, for example, buffering agents.

Optionally, one or more effervescent agents can be used as disintegrants and/or to enhance organoleptic properties of pharmaceutical compositions of the invention. When present in pharmaceutical compositions of the invention to promote dosage form disintegration, one or more effervescent agents are preferably present in a total amount of about 30% to about 75%, and preferably about 45% to about 70%, for example about 60%, by weight of the pharmaceutical composition.

According to a particularly preferred embodiment of the invention, an effervescent agent, present in a solid dosage form in an amount less than that effective to promote disintegration of the dosage form, provides improved dispersion of the api in an aqueous medium. Without being bound by theory, it is believed that the effervescent agent is effective to accelerate dispersion of the api from the dosage form in the gastrointestinal tract, thereby further enhancing absorption and rapid onset of therapeutic effect. When present in a pharmaceutical composition of the invention to promote intragastrointestinal dispersion but not to enhance disintegration, an effervescent agent is preferably present in an amount of about 1% to about 20%, more preferably about 2.5% to about 15%, and still more preferably about 5% to about 10%, by weight of the pharmaceutical composition.

An "effervescent agent" herein is an agent comprising one or more compounds which, acting together or individually, evolve a gas on contact with water. The gas evolved is generally oxygen or, most commonly, carbon dioxide. Preferred effervescent agents comprise an acid and a base that react in the presence of water to generate carbon dioxide gas. Preferably, the base comprises an alkali metal or alkaline earth metal carbonate or bicarbonate and the acid comprises an aliphatic carboxylic acid.

Non-limiting examples of suitable bases as components of effervescent agents useful in the invention include carbonate salts (e.g., calcium carbonate), bicarbonate salts

(e.g., sodium bicarbonate), sesquicarbonate salts, and mixtures thereof. Calcium carbonate is a preferred base.

Non-limiting examples of suitable acids as components of effervescent agents and/or solid organic acids useful in the invention include citric acid, tartaric acid (as D-, L-, or D/L-tartaric acid), malic acid (as D-, L-, or DL-malic acid), maleic acid, fumaric acid, adipic acid, succinic acid, acid anhydrides of such acids, acid salts of such acids, and mixtures thereof. Citric acid is a preferred acid.

In a preferred embodiment of the invention, where the effervescent agent comprises an acid and a base, the weight ratio of the acid to the base is about 1:100 to about 100:1, more preferably about 1:50 to about 50:1, and still more preferably about 1:10 to about 10:1. In a further preferred embodiment of the invention, where the effervescent agent comprises an acid and a base, the ratio of the acid to the base is approximately stoichiometric.

Excipients which solubilize apis typically have both hydrophilic and hydrophobic regions, or are preferably amphiphilic or have amphiphilic regions. One type of amphiphilic or partially-amphiphilic excipient comprises an amphiphilic polymer or is an amphiphilic polymer. A specific amphiphilic polymer is a polyalkylene glycol, which is commonly comprised of ethylene glycol and/or propylene glycol subunits. Such polyalkylene glycols can be esterified at their termini by a carboxylic acid, ester, acid anhyride or other suitable moiety. Examples of such excipients include poloxamers (symmetric block copolymers of ethylene glycol and propylene glycol; e.g., poloxamer 237), polyalkyene glycolated esters of tocopherol (including esters formed from a di- or multi-functional carboxylic acid; e.g., d-alpha-tocopherol polyethylene glycol-1000 succinate), and macrogolglycerides (formed by alcoholysis of an oil and esterification of a polyalkylene glycol to produce a mixture of mono-, di- and tri-glycerides and mono- and di-esters; e.g., stearoyl macrogol-32 glycerides). Such pharmaceutical compositions are advantageously administered orally.

Pharmaceutical compositions of the present invention can comprise about 10% to about 50%, about 25% to about 50%, about 30% to about 45%, or about 30% to about 35% by weight of a co-crystal; about 10% to about 50%, about 25% to about 50%, about 30% to about 45%, or about 30% to about 35% by weight of a an excipient which inhibits

crystallization; and about 5% to about 50%, about 10% to about 40%, about 15% to about 35%, or about 30% to about 35% by weight of a binding agent. In one example, the weight ratio of the co-crystal to the excipient which inhibits crystallization to binding agent is about 1 to 1 to 1.

Solid dosage forms of the invention can be prepared by any suitable process, not limited to processes described herein.

An illustrative process comprises (a) a step of blending an api of the invention with one or more excipients to form a blend, and (b) a step of tableting or encapsulating the blend to form tablets or capsules, respectively.

In a preferred process, solid dosage forms are prepared by a process comprising (a) a step of blending a co-crystal of the invention with one or more excipients to form a blend, (b) a step of granulating the blend to form a granulate, and (c) a step of tableting or encapsulating the blend to form tablets or capsules respectively. Step (b) can be accomplished by any dry or wet granulation technique known in the art, but is preferably a dry granulation step. A salt of the present invention is advantageously granulated to form particles of about 1 micrometer to about 100 micrometer, about 5 micrometer to about 50 micrometer, or about 10 micrometer to about 25 micrometer. One or more diluents, one or more disintegrants and one or more binding agents are preferably added, for example in the blending step, a wetting agent can optionally be added, for example in the granulating step, and one or more disintegrants are preferably added after granulating but before tableting or encapsulating. A lubricant is preferably added before tableting. Blending and granulating can be performed independently under low or high shear. A process is preferably selected that forms a granulate that is uniform in api content, that readily disintegrates, that flows with sufficient ease so that weight variation can be reliably controlled during capsule filling or tableting, and that is dense enough in bulk so that a batch can be processed in the selected equipment and individual doses fit into the specified capsules or tablet dies.

In an alternative embodiment, solid dosage forms are prepared by a process that includes a spray drying step, wherein an api is suspended with one or more excipients in one or more sprayable liquids, preferably a non-protic (e.g., non-aqueous or non-alcoholic) sprayable liquid, and then is rapidly spray dried over a current of warm air.

A granulate or spray dried powder resulting from any of the above illustrative processes can be compressed or molded to prepare tablets or encapsulated to prepare capsules. Conventional tableting and encapsulation techniques known in the art can be employed. Where coated tablets are desired, conventional coating techniques are suitable.

Excipients for tablet compositions of the invention are preferably selected to provide a disintegration time of less than about 30 minutes, preferably about 25 minutes or less, more preferably about 20 minutes or less, and still more preferably about 15 minutes or less, in a standard disintegration assay.

The invention will now be described in further detail, by way of example only, with reference to the accompanying drawings.

EXEMPLIFICATION

General Methods for the Preparation of Co-Crystals

a) High Throughput crystallization using the CrystalMax platform^{1,2}

CrystalMaxTM comprises a sequence of automated, integrated high throughput robotic stations capable of rapid generation, identification and characterization of polymorphs, salts and co-crystals of drugs and drug candidates.

Worksheet generation and combinatorial mixture design is carried out using proprietary design software InFormTM. Typically, a drug or drug candidate (API) is dispensed from an organic solvent into tubes and dried under a stream of nitrogen. Salts and/or co-crystal formers may also be dispensed and dried in the same fashion. Water and organic solvents may be combinatorially dispensed into the tubes using a multi-channel dispenser. Each tube in a 96-tube array is then sealed within 15 seconds of combinatorial dispensing to avoid solvent evaporation. The mixtures are then rendered supersaturated by heating to 70 °C for 2 hours followed by a 1 °C/minute cooling ramp to 5 °C. Optical checks are then conducted to detect crystals and/or solid material. Once a solid has been identified in a tube, it is isolated through aspiration and drying. Raman spectra are then obtained on

the solids and cluster classification of the spectral patterns is performed using proprietary software (QFormTM).

b) Crystallization from solution

Co-crystals may be obtained by dissolving the separate components in a solvent and adding one to the other. The co-crystal may then precipitate or crystallize as the solvent mixture is evaporated slowly. The co-crystal may also be obtained by dissolving the two components in the same solvent or a mixture of solvents.

c) Crystallization from the melt

A co-crystal may be obtained by melting the two components together and allowing recrystallization to occur. In some cases, an anti-solvent may be added to facilitate crystallization.

d) Thermal microscopy³

A co-crystal may be obtained by melting the higher melting component on a glass slide and allowing it to recrystallize. The second component is then melted and is also allowed to recrystallize. The co-crystal may form as a separated phase/band in between the eutectic bands of the two original components.

e) Mixing and/or grinding

A co-crystal may be obtained by mixing or grinding two components together in the solid state.

Analytical Methods

Procedure for DSC analysis

DSC analysis of the samples was performed using a Q1000 Differential Scanning Calorimeter (TA Instruments, New Castle, DE, U.S.A.), which uses Advantage for QW-Series, version 1.0.0.78, Thermal Advantage Release 2.0 (82001 TA Instruments-Water LLC). In addition, the analysis software used was Universal Analysis 2000 for Windows 95/95/2000/NT, version 3.1E;Build 3.1.0.40 (82001 TA Instruments-Water LLC).

For the DSC analysis, the purge gas used was dry nitrogen, the reference material was an empty aluminum pan that was crimped, and the sample purge was 50 mL/minute.

DSC analysis of the sample was performed by placing ≤ 2 mg of sample in an aluminum pan with a crimped pan closure. The starting temperature was typically 20°C with a heating rate of 10°C/minute, and the ending temperature was 300°C.

Procedure for TGA analysis

TGA analysis of samples was performed using a Q500 Thermogravimetric Analyzer (TA Instruments, New Castle, DE, U.S.A.), which uses Advantage for QW-Series, version 1.0.0.78, Thermal Advantage Release 2.0 (82001 TA Instruments-Water LLC). In addition, the analysis software used was Universal Analysis 2000 for Windows 95/95/2000/NT, version 3.1E;Build 3.1.0.40 (82001 TA Instruments-Water LLC).

For all of the TGA experiments, the purge gas used was dry nitrogen, the balance purge was 40 mL/minute N₂, and the sample purge was 60 mL/minute N₂.

TGA of the sample was performed by placing ≤ 2 mg of sample in a platinum pan. The starting temperature was typically 20°C with a heating rate of 10°C/minute, and the ending temperature was 300°C.

Procedure for PXRD analysis

A powder X-ray diffraction pattern for the samples was obtained using a D/Max Rapid, Contact (Rigaku/MSC, The Woodlands, TX, U.S.A.), which uses as its control software RINT Rapid Control software, Rigaku Rapid/XRD, version 1.0.0 (81999 Rigaku Co.). In addition, the analysis software used were RINT Rapid display software, version 1.18 (Rigaku/MSC), and JADE XRD Pattern Processing, versions 5.0 and 6.0 ((81995-2002, Materials Data, Inc.).

For the PXRD analysis, the acquisition parameters were as follows: source was Cu with a K line at 1.5406Å; x-y stage was manual; collimator size was 0.3 or 0.8 mm; capillary tube (Charles Supper Company, Natick, MA, U.S.A.) was 0.3 mm ID; reflection mode was used; the power to the X-ray tube was 46 kV; the current to the X-ray tube was 40

mA; the omega-axis was oscillating in a range of 0-5 degrees at a speed of 1 degree/minute; the phi-axis was spinning at an angle of 360 degrees at a speed of 2 degrees/second; 0.3 or 0.8 mm collimator; the collection time was 60 minutes; the temperature was room temperature; and the heater was not used. The sample was presented to the X-ray source in a boron rich glass capillary.

In addition, the analysis parameters were as follows: the integration 2-theta range was 2-40 or 60 degrees; the integration chi range was 0-360 degrees; the number of chi segments was 1; the step size used was 0.02; the integration utility was cylint; normalization was used; dark counts were 8; omega offset was 180; and chi and phi offsets were 0.

Procedure for Raman Acquisition, Filtering and Binning

Acquisition

The sample was either left in the glass vial in which it was processed or an aliquot of the sample was transferred to a glass slide. The glass vial or slide was positioned in the sample chamber. The measurement was made using an AlmegaTM Dispersive Raman (AlmegaTM Dispersive Raman, Thermo-Nicolet, 5225 Verona Road, Madison, WI 53711-4495) system fitted with a 785nm laser source. The sample was manually brought into focus using the microscope portion of the apparatus with a 10x power objective (unless otherwise noted), thus directing the laser onto the surface of the sample. The spectrum was acquired using the parameters outlined in Table 1. (Exposure times and number of exposures may vary; changes to parameters will be indicated for each acquisition.)

Filtering and Binning

Each spectrum in a set was filtered using a matched filter of feature size 25 to remove background signals, including glass contributions and sample fluorescence. This is particularly important as large background signal or fluorescence limit the ability to accurately pick and assign peak positions in the subsequent steps of the binning process. Filtered spectra were binned using the peak pick and bin algorithm with the parameters

given in Table 2. The sorted cluster diagrams for each sample set and the corresponding cluster assignments for each spectral file were used to identify groups of samples with similar spectra, which was used to identify samples for secondary analyses.

Table 1. Raman Spectral acquisition parameters

Parameter	Setting Used
Exposure time (s)	2.0
Number of exposures	10
Laser source wavelength (nm)	785
Laser power (%)	100
Aperture shape	pin hole
Aperture size (um)	100
Spectral range	104-3428
Grating position	Single
Temperature at acquisition (°C)	24.0

Table 2. Raman Filtering and Binning Parameters

Parameter	Setting Used
Filtering Parameters.	
Filter type	Matched
Filter size	25
QC Parameters	
Peak Height Threshold	1000
Region for noise test (cm ⁻¹)	0-10000
RMS noise threshold	10000
Automatically eliminate failed	Yes
spectra	·
Region of Interest	
Include (cm ⁻¹)	104-3428
Exclude region I (cm ⁻¹)	
Exclude region II (cm ⁻¹)	
Exclude region III (cm ⁻¹)	<u> </u>
Exclude region IV (cm ⁻¹)	
Peak Pick Parameters	
Peak Pick Sensitivity	Variable
Peak Pick Threshold	100
Peak Comparison Parameters	·
Peak Window (cm ⁻¹)	2
Analysis Parameters	
Number of clusters ,	Variable

The co-crystals of the present invention can be characterized, e.g., by the TGA or DSC data or by any one, any two, any three, any four, any five, any six, any seven, any eight, any nine, any ten, or any single integer number of 2-theta angle peaks listed herein or disclosed in a figure.

Example 1

1:1 Carbamazepine: Saccharin co-crystals were prepared. A 12-block experiment was designed with 12 solvent. 1152 crystallization experiments were carried out using the CMAX platform. The co-crystal was obtained from a mixture of isopropyl acetate and heptane. Detailed characterization of the co-crystal is listed in Table 7.

Example 2

1:1 Carbamazepine: Nicotinamide co-crystals were prepared. A 12-block experiment was designed with 12 solvent. 1152 crystallization experiments were carried out using the CMAX platform. The co-crystal was obtained from tubess containing toluene, acetone or isopropyl acetate. Detailed characterization of the co-crystal is listed in Table 7.

Example 3

1:1 Carbamazepine: Trimesic acid co-crystals were prepared. A 9-block experiment was designed with 10 solvents. 864 crystallization experiments with 8 co-crystal formers and 3 concentrations were carried out using the CMAX platform. The co-crystal was obtained from tubes containing methanol. Detailed characterization of the co-crystal is listed in Table 7.

Example 4

1:1 Celecoxib: Nicotinamide co-crystals were prepared. Celecoxib (100 mg, 0.26 mmol) and Nicotinamide (32.0 mg, 0.26 mmol) were each dissolved in acetone (2 mL). The two solutions were mixed and the resulting mixture was allowed to evaporate slowly

overnight. The precipitated solid was collected and characterized. Detailed characterization of the co-crystal is listed in Table 7.

Example 5

Co-crystals of topiramate and 18-crown-6 were prepared. An equimolar amount of topiramate and 18-crown-6 were dissolved in ether separately. The solution containing topiramate was then added to the solution containing 18-crown-6. A white solid precipitated after minor agitation and was collected and dried. Detailed characterization of the co-crystal is listed in Table 7.

Example 6

Co-crystals of Olanzapine and Nicotinamide were prepared. A 9-block experiment was designed with 12 solvents. 864 crystallization experiments with 10 co-crystal formers and 3 concentrations were carried out using the CMAX platform. The co-crystal was obtained from tubes containing isopropyl acetate. PXRD and DSC characterization of the co-crystal is listed in Table 7.

Example 7

Co-crystals of Celecoxib and 18-crown-6 were prepared. A solution of Celecoxib (157.8 mg, 0.4138 mmol) in Et₂O (10.0 mL) was added to 18-crown-6 (118.1 mg, 0.447 mmol). The opaque solid dissolves immediately and a white solid subsequently began to crystallize very rapidly. The solid was collected via filtration and was washed with additional Et₂O (5 mL). Detailed characterization of the co-crystal is listed in Table 7.

Example 8

Co-crystals of Itraconazole and Succinic acid were prepared. Approximately 51.1 mg of cis-itraconazole free base (Lot # KEO 0026, Química Sinética S.A), 0.75 ml of THF, and a magnetic stir bar were charged into a screw cap vial, heated to reflux to dissolve, and then the vial was closed with the screw cap and placed on top of a hot plate maintained at a temperature between 60 and 75°C. A solution of 77.7 mg of succinic acid in 1.58 ml of THF was prepared. 0.20 ml of the succinic acid solution was added to the cis-

itraconazole solution and the solution remained clear. 0.75 ml of iso-propylacetate was added and the solution was seeded with <1 mg of the L-tartaric acid co-crystal salt from Example 10 below. The heat was turned off and the sample crystallized as it cooled to room temperature. The cooled sample was suction filtered. It was rinsed with 0.2-0.3 ml of THF. The filter cake was broken-up and allowed to air-dry for 1 hour prior to analysis.

Example 9

Co-crystals of Itraconazole and fumaric acid were prepared. Approximately 500 mg of cis-itraconazole free base (Lot # KEO 0026, Química Sinética S.A.) was placed in a 50 ml screw top bottle along with 33.33 ml of tetrahydrofuran ("THF") (Lot # 50K1485, Sigma Chemicals Co.). 3088.7 µl of fumaric acid stock solution (prepared in Example 1) was then added to the beaker (resulting in a 1.05:1 ratio of salt former to free base). The cap was screwed on to seal the bottle and the bottle was placed in a 70°C oven (Model # 1400E, VWR Scientific) and heated for approximately 1 hour. Thereafter, the bottle was removed from the oven, the cap from the bottle was removed, and the sample was allowed to evaporate under flowing air under ambient conditions. When all but about 5 ml of the solvent had evaporated, the remaining solvent was removed by decantation and the solid was isolated by filtering over a Whatman filter using suction. This solid was returned back into the 50 ml bottle with the remaining solid and the bottle was placed into the vacuum oven at approximately 25 mm Hg and the solid was allowed to dry for 4 days.

Example 10

Co-crystals of Itraconazole and tartaric acid were prepared. Approximately100.4 mg of *cis*-itraconazole free base (Lot # KEO 0026, Química Sinética S.A), 0.90 ml of THF, and a magnetic stir bar were charged into a screw cap vial, heated to reflux to dissolve, and then the vial was closed with the screw cap and placed in an oil bath maintained at 70°C. A solution of 138.5 mg of L(+) tartaric acid in 1.15 ml of THF was prepared. 0.21 ml of the L(+)tartaric acid solution was added to the cis-Itraconazole

solution and the solution remained clear. 0.90 ml of iso-propylacetate was added and the solution was seeded with <1 mg of the salt from a preparation of DL-tartaric acid co-crystal. The sample was allowed to crystallize over about 5 minutes in the 70 °C oil bath before it was removed and allowed to cool to room temperature. The cooled sample was suction filtered. It was rinsed with 0.2-0.3 ml of THF. The filter cake was broken-up and allowed to air-dry for 4 hours prior to analysis.

Example 11

Co-crystals of Itraconazole and malic acid were prepared. To prepare the L-malic acid co-crystal salt of *cis*-itraconazole, 100.4 mg of *cis*-itraconazole free base (Lot # KEO 0026, Química Sinética S.A), 0.50 ml of THF, and a magnetic stir bar were charged into a screw cap vial. A solution of 191.3 mg of Ll(-)malic acid in 5.0 ml of THF was prepared. 0.50 ml of the Ll-malic acid solution was added to the vial containing cis-itraconazole and the solution was heated with a heat gun to dissolve. The solution was allowed to cool and was then seeded with <1 mg of the salt from *cis*-itraconazole-Ll-tartaric acid co-crystal. The cooled crystals were filtered in a centrifuge filter tube. The filter cake was broken-up and allowed to air-dry prior to analysis.

Example 12

Co-crystals of Itraconazole HCl and tartaric acid were prepared. Approximately 212.7mg of L-tartaric acid and 118 µL of 37% HCl were dissolved in 25mL of hot dioxane. This solution was added to 1.0 g of cis-itraconazole dissolved in 50mL of hot dioxane wit stirring. The resulting clear solution was filtered on a 0.2µm syringe filter into a 250 mL Erlenmeyer flask. Seed crystals from a previous preparation of the HCl-tartaric acid co-crystal salt were added, the solution was sonicated and left to stir overnight. The next day 50 mL tert-butyl methyl ether were added and the crystals were harvested by vacuum filtration on a Buchner funnel with #4 Whatman filter paper. The crystals were washed 3X with 5mL aliquots of cold tert-butyl methyl ether and left to air dry. Approximately 573 mg of a crystalline form of cis-itraconazole HCl-tartaric acid co-crystal were obtained.

Example 13

Co-crystals of modafinil and Nicotinamide were prepared. Modafinil (1 mg, 0.0037mmol) and Nicotinamide (0.45 mg, 0.0037 mmol) were dissolved in acetone (400 µL). The solution was allowed to evaporate to dryness and the resulting solid was characterized using PXRD. PXRD data for the co-crystal is listed in Table 7.

Example 14

Co-crystals of modafinil and Benzamide were prepared. Modafinil (1 mg, 0.0037mmol) and benzamide (0.45 mg, 0.0037 mmol) were dissolved in 1,2-dichloroethane (400 μ L). The solution was allowed to evaporate to dryness and the resulting solid was characterized using PXRD. PXRD data for the co-crystal is listed in Table 7.

Example 15

Co-crystals of modafinil and Mandelic acid were prepared. Modafinil (1 mg, 0.0037mmol) and Mandelic acid (0.55 mg, 0.0037 mmol) were dissolved in acetone (400 µL). The solution was allowed to evaporate to dryness and the resulting solid was characterized using PXRD. PXRD data for the co-crystal is listed in Table 7.

Example 16

Co-crystals of modafinil and glycolic acid were prepared. Modafinil (1 mg, 0.0037 mmol) and glycolic acid (0.30 mg, 0.0037 mmol) were dissolved in acetone ($400 \text{ }\mu\text{L}$). The solution was allowed to evaporate to dryness and the resulting solid was characterized using PXRD. PXRD data for the co-crystal is listed in Table 7.

Example 17

Co-crystals of modafinil and Fumaric acid were prepared. Modafinil (1 mg, $0.0037 \, \text{mmol}$) and Fumaric acid ($0.42 \, \text{mg}$, $0.0037 \, \text{mmol}$) were dissolved in 1,2-dichloroethane ($400 \, \mu \text{L}$). The solution was allowed to evaporate to dryness and the resulting solid was characterized using PXRD. PXRD data for the co-crystal is listed in Table 7.

Table X. Detailed Characterization of Co-Crystals

Carbamazepine: Saccharin

PXRD: 7.01, 12.07, 14.09, 15.41, 18.47, 20.13, 22.01, 23.57, 24.41, 28.31 (Fig. 1)

DSC: Broad endotherm at 161.9 °C (Fig. 2)

TGA: Decomposition above 200 °C

Raman:

Method: CMAX

Carbamazepine: Nicotinamide

PXRD: 4.97, 6.67, 8.75, 10.25, 13.25, 17.91, 18.49, 19.95, 20.49, 22.73, 24.39, 26.49

(Fig. 3)

DSC: Sharp endotherm at 156.9 °C.

TGA: Decomposition beginning at ~150 °C

Raman:

Method: CMAX

Carbamazepine: Trimesic acid

PXRD: 10.89, 12.23, 14.83, 16.25, 17.05, 18.13, 18.47, 21.47, 21.95, 24.57, 25.11, 27.99

(Fig. 5) Raman:

Method: CMAX

Celecoxib: Nicotinamide

PXRD: 3.77, 7.57, 9.63, 14.73, 15.21, 16.03, 17.81, 18.71, 19.33, 20.49, 21.21, 22.13

DSC: Two phase transitions at 117.2 and 118.8 °C and a sharp endotherm at 129.7 °C

TGA: Decomposition beginning at ~150 °C

Raman:

Method: Slow evaporation of a 1:1 solution from acetone

Topiramate: 18-Crown-6

PXRD: 10.79, 11.07, 12.17, 13.83, 16.13, 18.03, 18.51, 18.79, 19.21, 21.43, 22.25, 24.11

(Fig. 6)

DSC: Sharp endotherm at 134.7 °C, followed by an exotherm at 203 °C (Fig. 7)

TGA: Rapid decomposition beginning at ~ 135 °C and leveling off slightly after 200 °C

Raman: 2994.5, 2942.7, 1471.6, 1427.4, 1261.7, 849.4, 804.5, 745.1, 629.2, 280.4, 225.9

Method: Addition of an ether solution containing 1 equivalent of topiramate to an ether solution containing 18-crown-6. Product precipitated following minor agitation of the combined mixture and was collected.

Olanzapine: Nicotinamide

PXRD (Form I): 4.89, 8.65, 12.51, 14.19, 15.59, 17.15, 19.71, 21.05, 23.95, 24.59, 25.53,

·26.71 (Fig. 7)

PXRD (Form II): 6.41, 12.85, 18.67, 21.85, 24.37

DSC (Form I): Slightly broad endotherm at 126.1 °C (Fig. 9)

Raman:

Method: CMAX

Celecoxib: 18-Crown-6

PXRD: 8.73, 11.89, 12.57, 13.13, 15.01, 16.37, 17.03, 17.75, 18.45, 20.75, 22.37, 23.11,

24.33, 24.97, 26.61, 28.15 (Fig. 10)

DSC: Sharp endotherm at 189.6 °C (Fig. 11)

TGA: Decomposition above 200 °C with a 25% weight loss between ~190-210 °C

Raman:

Method: A solution containing one equivalent of Celecoxib in ether was added to a solution containing 18-crown-6. A white solid formed immediately and was collected.

Itraconazole: Succinic Acid

PXRD: 3.0, 6.0, 8.1, 9.0, 17.1, 24.5 (Fig. 12)

DSC: Single endothermic transition at 160.1 °C ± 1.0°C (Fig. 13)

TGA: Less than 0.1 % volatile components by weight

Raman:

Method: See above

Itraconazole: Fumaric Acid

PXRD: 4.6, 5.9, 9.2, 10.6, 19.1, 20.8

DSC: The material had a weak endothermic transition at 141.7 °C ± 1 °C and a strong

endothermic transition at 179.58 °C ±1 °C (Fig. 15)

TGA: The sample loses 0.5 % of its weight on the TGA between room temperature and

100 °C Raman: Method:

Itraconazole: Tartaric Acid

PXRD: 4.1, 6.2, 8.3, 20.7, 25.6, 26.3 (Fig. 16)

DSC: An endothermic transition at 180.74 °C \pm 1.0 °C (Fig. 17)

TGA: Less than 0.1 % volatile components by weight by TGA.

Raman:

Method: See above

Itraconazole: Malic acid

PXRD: 4.4, 5.9, 8.8, 17.7, 20.0, 21.1, 22.6 (Fig. 18)

DSC: The sample has a strong endothermic transition at 154.36 °C ±1.0 °C (Fig. 19)

TGA: The sample contained less than 0.1% volatile components by weight

Raman:

Method: See above

ItraconazoleHCl: Tartaric acid

PXRD: 3.7, 11.0, 13.8, 16.5, 17.8 (Fig. 20)

DSC: The sample has a peak endothermic transition at $161^{\circ}\text{C} \pm 1.0^{\circ}\text{C}$ (Fig. 21)

TGA: The sample contained less than 0.1 % volatile components by weight

Raman:

Method: See above

Modafinil: Nicotinamide

PXRD: 5.95, 18.61, 20.07, 20.65, 21.83, 23.19, 24.03, 25.67, 26.53, 30.75, 31.04, 32.78

(Fig. 22)

Method: Slow evaporation from a 1:1 solution in acetone

Modafinil: Benzamide

PXRD: 5.11, 9.35, 10.25, 10.79, 14.07, 16.87, 18.33, 19.53, 21.38, 22.05, 22.89, 23.57,

24.73, 25.19, 25.81, 26.51, 28.60 (Fig. 23)

Method: Slow evaporation from a 1:1 solution in 1,2-dichoroethane

Modafinil: Mandelic acid

PXRD: 6.11, 6.75, 9.53, 10.31, 14.77, 15.77, 16.99, 18.03, 20.01, 21.61, 22.47, 23.27,

25.27, 25.75, 27.23 (Fig. 24)

Method: Slow evaporation from a 1:1 solution in acetone

Modafinil: Glycolic acid

PXRD: 6.09, 9.51, 14.91, 15.97, 19.01, 20.03, 21.59, 22.43, 22.75, 23.75, 25.03, 25.71

(Fig. 25)

Method: Slow evaporation from a 1:1 solution in acetone

Modafinil: Fumaric acid

PXRD: 5.87, 7.19, 8.95, 12.49, 13.99, 16.13, 17.09, 18.19, 19.99, 21.57, 23.48, 25.01,

25.79, 28.17, 28.87, 29.69, 32.19 (Fig. 26)

Method: Slow evaporation from a 1:1 solution in 1,2-dichoroethane

Example 18

A co-crystal with a modulated dissolution profile has been prepared. Celecoxib: Nicotinamide co-crystals were prepared to methods shown in example 4.

Example 19

A co-crystal with a modulated dissolution profile has been prepared. Itraconazole: Succinic acid, tartaric acid and malic acid co-crystals were prepared to methods shown in examples 8, 10 and 11. See Fig. 2B.

Example 20

A co-crystal of a salt with a modulated dissolution profile has been prepared.

Itraconazole HCl: tartaric acid co-crystals were prepared to methods shown in example 12.

Example 21

A co-crystal of an unsaltable or difficult to salt drug has been prepared. Celecoxib: Nicotinamide co-crystals were prepared to methods shown in example 4.

Example 22

A co-crystal with an improved hygroscopicity profile has been prepared. Celecoxib: Nicotinamide co-crystals were prepared to methods shown in example 4.

Example 23

A co-crystal with reduced form diversity as compared to the drug has been prepared. Co-crystals of carbamazepine and saccharin have been prepared to method shown in example 1.

CLAIMS:

- 1. A pharmaceutical composition comprising a co-crystal of a drug and a co-crystal forming compound; wherein the drug has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal forming compound has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the drug and co-crystal forming compound are capable of co-crystallizing from a solution phase under crystallization conditions.
- 2. A pharmaceutical composition according to claim 1, wherein (i) one of the drug and co-crystal forming compound has at least one hydrogen bond donor group and (ii) the other has at least one hydrogen bond acceptor group.
- 3. A pharmaceutical composition according to claim 2, wherein the difference in Pka between the drug and the co-crystal forming compound does not exceed 2.
- 4. A pharmaceutical composition according to claim 1, wherein the drug is selected from celecoxib, carbamazepine, itraconazole, olanzapine, topiramate and modafinil.
- 5. A pharmaceutical composition according to claim 1, wherein the co-crystal forming compound is selected from saccharin, nicotinamide, pyridoxine(4-pyridoxic acid), acesulfame, glycine, arginine, asparagine, cysteine, glutamine, histidine, isoleucine, lysine, methionine, phenylalanine, proline, threonine, tyrosine, valine, aspartic acid, glutamic acid, tryptophan, adenine, acetohydroxamic acid, alanine, allopurinaol, 4-

aminobenzoic acid, cyclamic acid, 4-ethoxyphenyl urea, 4-aminopyridine, leucine, nicotinic acid, serine, TRIS, vitamin k5, xylito, succinic acid, tartaric acid, pyridoxamine, biotin, ascorbic acid, hydroquinone, salicylic acid, benzoic acid, caffeine, benzenesulfonic acid, 4-chlorobenzene-sulfonic acid, citric acid, fumaric acid, gluconic acid, glutaric acid, glycolic acid, hippuric acid, maleic, malic acid, mandelic acid, malonic, 1,5-napthalene-disulfonic acid, clemizole, imidazole, glucosamine, piperazine, procaine, tromethamine, and urea.

- 6. A pharmaceutical composition according to claim 1, which further comprises a pharmaceutically acceptable diluent, excipient or carrier.
- 7. A co-crystal comprising carbamazepine and saccharin
- 8. A co-crystal comprising carbamazepine and nicotinamide
- 9. A co-crystal comprising carbamazepine and trimesic acid
- 10. A co-crystal comprising celecoxib and nicotinamide
 - 11. A co-crystal comprising olanzepine and nicotinamide
 - 12. A co-crystal comprising Olanzapine and nicotinamide
 - 13. A co-crystal comprising Celecoxib and 18-crown-6
 - 14. A co-crystal comprising itraconazole and Succinic acid
- 15. A co-crystal comprising itraconazole and fumaric acid
- 16. A co-crystal comprising itraconazole and tartaric acid

- 17. A co-crystal comprising itraconazole and malic acid
- 18. A co-crystal comprising itraconazole.HCl and tartaric acid
- 19. A co-crystal comprising modafinil and nicotinamide
- 20. A co-crystal comprising modafinil and benzamide
- 21. A co-crystal comprising modafinil and Mandelic acid
- 22. A co-crystal comprising modafinil and glycolic acid
- 23. A co-crystal comprising modafinil and Fumaric acid
- 24. A process for the production of a pharmaceutical composition, which process comprises:
- (1) providing a drug which has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (2) providing a co-crystal forming compound which has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carboxyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio;
- (3) contacting in solution the drug with the co-crystal forming compound under crystallization conditions, and
 - (4) isolating co-crystals formed thereby; and
 - (5) incorporating the co-crystals into a pharmaceutical composition.

- 25. A process according to claim 24, wherein (i) one of the drug and co-crystal forming compound has at least one hydrogen bond donor group and (ii) the other has at least one hydrogen bond acceptor group.
- 26. A process according to claim 24, wherein wherein the difference in Pka between the drug and the co-crystal forming compound does not exceed 2.
- 27. A process according to claim 24, wherein the drug is selected from celecoxib, carbamazepine, itraconazole, topiramate, Olanzapine and modafinil.
- 28. A process according to claim 24, wherein the co-crystal forming compound is selected from saccharin, nicotinamide, pyridoxine(4-pyridoxic acid), acesulfame, glycine, arginine, asparagine, cysteine, glutamine, histidine, isoleucine, lysine, methionine, phenylalanine, proline, threonine, tyrosine, valine, aspartic acid, glutamic acid, tryptophan, adenine, acetohydroxamic acid, alanine, allopurinaol, 4-aminobenzoic acid, éyclamic acid, 4-ethoxyphenyl urea, 4-aminopyridine, leucine, nicotinic acid, serine, TRIS, vitamin k5, xylito, succinic acid, tartaric acid, pyridoxamine, biotin, ascorbic acid, hydroquinone, salicylic acid, benzoic acid, caffeine, benzenesulfonic acid, 4-chlorobenzene-sulfonic acid, citric acid, fumaric acid, gluconic acid, glutaric acid, glycolic acid, hippuric acid, maleic, malic acid, mandelic acid, malonic, 1,5-napthalene-disulfonic acid, clemizole, imidazole, glucosamine, piperazine, procaine, tromethamine, and urea.
- 29. A process according to claim 24, which further comprises incorporating into the pharmaceutical composition a pharmaceutically acceptable diluent, excipient or carrier
- 30. A process for the production of a pharmaceutical composition, which comprises:
- (1) contacting in solution a drug with a co-crystal forming compound, under crystallization conditions, so as to form a solid phase;
 - (2) isolating the solid phase;

- (3) testing the solid phase for the presence of co-crystals of the drug and the co-crystal forming compound; and
- (4) incorporating the co-crystals when formed in step (3) into a pharmaceutical composition.
- 31. A process for the production of a pharmaceutical composition, which comprises:
- (1) providing (i) a drug or a plurality of different drugs, and (ii) a co-crystal forming compound or a plurality of different co-crystal forming compounds, wherein at least one of the drug and the co-crystal forming compound is provided as a plurality thereof;
- (2) screening for co-crystals of drugs with co-crystal forming compounds by subjecting each combination of drug and co-crystal forming compound to a step comprising
- (a) contacting in solution the drug with the co-crystal forming compound under crystallization conditions so as to form a solid phase;
 - (b) isolating the solid phase; and
 - (c) testing the solid phase for the presence of co-crystals of the drug and the co-crystal forming compound; and
- (3) incorporating the co-crystals when formed in step (c) into a pharmaceutical composition.
- 32. A process for modulating the solubility of a drug for use in a pharmaceutical composition, which process comprises:
- contacting in solution the drug with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the drug and the co-crystal forming compound;
 - (2) isolating the co-crystal;
- (3) testing the co-crystal for modulated solubility as compared to the drug; and
- (4) incorporating the co-crystal having modulated solubility into a pharmaceutical composition.

- 33. A process for modulating the dose response of a drug for use in a pharmaceutical composition, which process comprises:
- (1) contacting in solution the drug with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the drug and the co-crystal forming compound;
 - (2) isolating the co-crystal;
- (3) testing the co-crystal for modulated dose response as compared to the drug; and
- (4) incorporating the co-crystal having modulated dose response into a pharmaceutical composition.

Abstract

Pharmaceutical Compositions

A pharmaceutical composition comprising a co-crystal of a drug and a co-crystal forming compound; wherein the drug has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal forming compound has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the drug and co-crystal forming compound are capable of co-crystallizing from a solution phase under crystallization conditions.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21





Figure 22






Figure 24




Figure 25





Figure 26

Insert Figure 27

Figure 27



Dissolution profiles into 0.1 N HCl at 25 °C

Sporanox Beads (amorphous freebase)

l-Malate

· l-Tartrate

Succinate

Crystalline Freebase

Figure 28




Fig. 31

MW MP (°C) Class (g/mol)
2 Carboxylic acid, alcohol
2 carboxylic acid
3 Amine, pyridine
3 Amide, NH
.1 Alcohol, Ketone
3 SO ₂ , Amide

Co-Crystal Former	MW. (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	Pka Values
Acetohydroxamic acid	75.07	89-92		Amide, NH, OH	2	2	о — н	8,7
Adenine	135.13	220 (sub.)	1	Amine, NH	. 3	3	HN NH3	3.8
Adipic Acid	146.14	152	-	Carboxylic acid			ноос/сн₂),соон	4.44, 5.44
Alanine	89.09	289-291	1	Amine, carboxillic acid	1	К	H ₂ N ₂ H	2.35, 9.87
Allopurinaol	136.11	> 350	3.	НИ НО	4	2	## P	10.2
Arginine	174.2	244 (dec.)		Amine, COOH	.2	7	H ₂ M M ₁ H ₂ M M ₁ H ₂ M M ₂	2.18, 9.09, 13.2
Ascorbic acid	176.12	190-192	-	С=0, ОН	9	4.	P. O. Ho.	4.17, 11.57

Co-Crystal Former	MW. (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	Pka Values
. Asparagine	132.12	234-235	-	Amine, amide, COOH	m		H ₂ N _{M2} H	2:02, 8:5
Aspartic acid	133.1	270-271	Π.	Amine, COOH	. 2	4	HO OH	1.88, 3.65, 9.60
Benzenesulfonic Acid	158.18	43.44		SO ₃ H	2	F-1	H _c OS	0.70, 1.58
Benzoic acid*.	122.12	122-123	. 2	НООЭ	1	П	£ 0	4.19
caffeine	194.19	238	3	C=0	, es	0		
Camphoric acid	200.23	186-189	8	Carboxylic acid	7	2	Н ₃ С ССООН ССН ₃	4.72, 5.83
Capric acid	172.27	31.4	-	Carboxylic acid		· ·	CH ₃ (CH ₂) ₈ COOH	4.9
. . .]

Pka	3	4.4	3.13, 4.76,	<u> </u>		. 33,
N eV		. 4	3.13, 4. 6.40		?	1.71, 8.33,
Molecular Strucutre	φ - δ	***	HOOD		H _e cos	S = \$\frac{1}{2}\$
s # donors	8	-	4	0	2	. 4
# acceptors	Q	-	4	w.	2	7
Functionality	Phenol, ether, ketone	Carboxylic acid	ОН, СООН	Pyrrolidine	NH, SO ₃ H	Amine, COOH,
Class	V-	က	1	1	3	' · ←
MP (°C)	285	133	153	167	169-170	1
MW (g/mol).	254.24	144.2	192.12	325.84	179.24	121.15
Co-Crystal Former	Chrysin	Cinnamic acid	Citric Acid	Clemizole	Cyclamic acid	Cysteine

:

	,	_			•		• •
Pka	2.5		3.03, 4.38	3.08, 3.63		2.93	8.03(B)
Molecular Strucutre	HO-0-HO-N	of Fo	\$ \$	HOCO — HO HO HO	- 5 - 5	PO PH	HO NOTE OF STREET OF STREE
# donors	1	4	2	ω	ო	ო	ဖ
# acceptors	2	1	5	81	Ņ	-	
Functionality	Amine, Carboxylic acid	Alcohol, ether	СООН	Carboxylic acid, alcohol	Alcohol, Phenol, ether, ketone	Carboxylic acid, alcohol, phenol	Alcohol, Amine
Class	1		-	-	-	٠. ۵	-
MP (°C)	178-192	87	287	255 (dec)	297-298	199-200 form 1, 205 form II	128-129
MW (g/mol)	103.1	150.13	116.07	210.14	270.24	154.12	195.22
Co-Crystal Former	Dimethylglycine	D-Ribose	Fumaric acid	Galactaric acid	Genistein	Gentisic acid	Glucamine, N-Methyl

Object Continuent Continu			
196.15 131 1 OH, COOH 179.17 88 1 OH 194.14 165 1 Carboxylic acid, alcohol, aldehyde 147.13 160 1 Amine, Amide, COOH 132.11 98-98 1 COOH	tionality # acceptors # donors Molecular Strucutre		
179.17 88 1 OH 194.14 165 1 Carboxylic acid, alcohol, aldehyde 147.13 160 1 Amine, COOH 146.15 185-186 1 COOH 132.11 98-98 1 COOH	но но но но HOOO	уа lues ———————————————————————————————————	SS
d 194.14 165 1 Carboxylic acid, alcohol, aldehyde 147.13 160 1 Amine, COOH COOH COOH 132.11 98-98 1 COOH 2	2	6.9	· .
147.13 160 1 Amine, COOH 146.15 185-186 1 Amine, Amide, COOH 132.11 98-98 1 COOH		3.18	T
185-186 1 Amine, Amide, COOH 28-98 1 COOH	2 4 ±0	2.19, 4.25,	ທີ່
132.11 ~ 98-98 1 COOH	2 S	он 2.17, 9.13	
		2.7, 4.5	1

Co-Crystal Former	MM (lom/p)	MP (°C)	Class	Functionality	# acceptors # donors	# donors	Molecular Strucutre	Pka
Glycine	75.07	182	-	Атіпе, СООН	5		H ₀ N ₂ H	2.34, 9.6
Glycolic acid	76.05	08	· · · · · · · · · · · · · · · · · · ·	0н, соон	2	7	HO OH	3.82
Hippuric acid	179.17	187-188	-	Amide, NH, COOH	2	. 2		3.55
Histidine	155.16	287 (dec.)		Amine, COOH, Imidazole	2	4	HO NHH.	1.78, 5.97, 8.97
Hydroquinone*	110.11	170-171	2	OH, Phenol	2	2	НО	-10
Imidazole	68.08	90-91	1	HN	1,	1	H	6.92
Ipriflavone	280.32	.115-117		Ketone, ether	m	0	H ₂ C C C C C C C C C C C C C C C C C C C	

Co-Crystal Former	(lom/g)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	Pka
Isoleucine	131.17	168-170 (sub.)	1	Amine, COOH	-	. w	Н3С	2.32, 9.76
Lactobionic acid	358.3	128-130	8	Alcohol, carboxylic acid, ether	-	ത.		3.2
Lauric acid	200.32	44-48	-	Carboxylic acid	1	-	CH ₃ (CH ₂) ₁₀ COOH	-4.5
Leucine	131.17	145-148 (sub.)	-	Carboxylic acid, amine	1,		O Noth	2.36, 9.6
Lysine	146.19	225 (dec.)	П	Amine, COOH	1	5	N ₂ H	2.2, 8.9,
Maleic	116.07	138-139		Н000	2	2	ноос	1.92, 6.23

Co-Crystal Former	MM	() () () () () () () () () ()	<u> </u>					
	(g/mol)	MP (°C)	Class	Functionality	# acceptors # donors	# donors	Molecular Strucutre	Pka.
Malic acid	134.09	131-132	:	он, соон	.; €	w	HO HO	3.46, 5.1
Malonic	104.06	135		нооэ	2	. 2		2:83, 5.70
Mandelic acid	152.15	119	-	ОН, СООН	5	2	5 5	3.37
Methionine	149.21	280-282 (dec.)	-	Amine, COOH, S. Me	. 2	к	NO SOLUTION OF THE PROPERTY OF	2.3.9
Nicotinamide	122.12	128-131		Pyridine, amide	7	. 7	NH ₂	3.3
Nicotinic acid	123.11	236-237	2	Carboxylic acid, pyridine	2			2.07(B), 4.85

ادامیسی دی	MW	. .						•
Co-Ciystal rormer	(g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	-Pka Values
Orotic acid	156.1	345-346	2	. Carboxilic acid, lactam	m	<i>w</i> .	HN HOOD	5.85, 8.95
Oxalic acid	90.04	189 (dec)	N	Carboxilic acid	8	01	Q Q	1.27, 4.27
Palmitic acid	256.43	63-64	-	Carboxylic acid	-	-	СН3(СН2)14СООН	4.9
Pamoic	388.38	280 (dec)	α	Carboxylic acid, phenol	C)	4	HOOD HOOD	2.51, 3.1
Phenylalanine	165.19	283 (dec.)	- i	Amine, COOH	1	en .		6~ '2~
Piperazine	86.14	106	1	HN	0	2	H	9.82(B)
Procaine	236.31	61	Ţ	Amine, C=0	2	. 2	142 A	8:9(B)

,		 	т —	 		· ·	<u> </u>
Pka	Values 1.99, 10.6	-1.34	6	.67	3.32		
Molecular Strucutre	0 = \frac{1}{2}	H ₃ C	Die State of the S	Po Ho	Нооо	\$ 5 6 \$ 6	HO HO
# donors	2	1	4	,m	a	ĸ	က
# acceptors	-	8	ά	m	C)	à	0
Functionality	соон, ин	Sulfonic acid	OH, Amine, Pyridine	Alcohol, Pyridine	Carboxylic acid, Lactam	Phenol, ether, ketone	Phenol
Class	-	ત	2	. 2	2	1.	τ-
MP (C)	220-222 (dec.)	106-107	193-194	160	162	314 dec.	253-255
MW (g/mol)	115.13	172.2	168	170	129.12	302.24	228.24
Co-Crystal Former	Proline	p-Toluenesulfonic acid	Pyridoxamine	Pyridoxine	Pyroglutamic acid	Quercetin	Resveratrol

Co-Crystal Former	MM	MP (°C)	Class	Functionality	# occontone	# Jones		Pka
	(g/mor)		. 1	Carrier -		# dollors	Molecular Strucutre	Values
Saccharin	183.19	228-230	1	Amide, C=0, S=0, N-H	6	-		2
Salicylic acid, 4-amino	153.14	150-151	3	COOH, OH, Analine	-	. 4	H ₂ N	3.25, 10, 3.5(B)
Salicylic acid	138.12	159	ω,	соон, он	2	2	5	2.98, 13.82
Sebacic acid	202.25	134.5	· <u>-</u>	Carboxylic acid	81	, aj	HOOC(CH ₂)%COOH	4.59, 5.59
Serine	105.09	228 (dec.)	-	Carboxylic acid, amine, OH	7	m	OH HO	2.21, 9.45
Stearic acid	284.47	70-71	-	Carboxylic acid	-	-	СН3(СН2)16СООН	6.4
Succinic acid	118.09	185-187		Carboxylic acid	2	. 73	OH HO	4.21, 5.64
							=0	

. .

Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Strucutre	Pka
Tartaric acid	150.09	205-206		Carboxylic acid	4	4	P P P P P P P P P P P P P P P P P P P	3.02, 4.36
Threonine	119.12	255-257 (dec.)	1	Amine, COOH, OH	2	4	O HO	2.15, 9.12
TRIS	121.13	171-172	. 2	Amine, OH	3	5	HO OH	5.91, 8.3
Tryptophan	204.23	289 (dec.)	.1	Amine, COOH, Indole	1	4	ž _{ilito} .	2.38, 9.39
Fyrosine	181.19	342-344	П	Amine, COOH, OH	2	3	HO NH1	2.2, 9.11, 10.07
Urea	60.06	Dec.		C=0,NH2		4 .	N ₂ N	& .
Valine	117.15	315		Amine, COOH	1	60	HO FHU	-4.5, -9

Co-Crystal Former	MW MP (°C)	MP (°C)	Class	Functionality # acceptors # donors	# acceptors	# donors	Molecular Strucutre	Pka Values
Vitamin K5	209.68	280-282 (dec.)	3	Amine, OH	Ţ,	3	# 10	. 62
Xylitol	152.15	152.15 93-95 (I)	. 7	НО	5		HO HO	6

		•					
	Co-crystat Former			•	•		
Co-crystal Former	Functional Group	Interacting Group	g Group			•	
1,5-Napthalene-disulfonic Acid	Sulfonic Acid	pyridine	ketone	aldehyde	ether	ester	amide
1-Hydroxy-2-naphthoic acid	Carboxylic Acid	alcohol	· euotey	thiol	amide	amine	analine
1-Hydroxy-2-naphthoic acid	alcohol	alcohol	ketone	thiol	amide	. amine	analine
4-Aminobenzoic Acid	Amine	alcohol	ketone	thiol	amide	amine	analine
4:Aminobenzoic, Acid	Carboxylic Acid	alcohol	ketone "	thiol	amide	amine	analine
4-aminopyridine	Amine	alcohol	ketone	thiol	amide	amine	analine
4-aminopyridine	Pyridine	*alcohol	pyridinium	•	*amide	nitro	amine
4-Chlorobenzene-Sulfonic Acid	Sulfonic Acid	pyridine	ketone	aldehyde	ether	ester	amide
4-ethoxyphenyl Urea	Amide	alcohol	ketone	thiol	amide	amine	analine
4-ethoxyphenyl Urea	Amine	alcohol	ketone	thiol	amide	amine	analine.
7-oxo-DHEA	alcohol	alcohol	ketone .	thiol	amide	amine	analine
7-oxo-DHEA	Ketone	alcohol		thiol	amide	amine	analine
Acesulfame	Sultone	bvridine	ketone) aldehvde	ether	ester	amida
Acesulfame	Amide	alcohol	ketone	thiol	amide	amine	analine
Acetohydroxamic Acid	Amide	alcohol	ketone.	thiol	amide .	amine	analine
Acetohydroxamic Acid	Amine	alcohol	ketone :	thiol	amide	amine	analine
Acetohydroxamic Acid	Alcohol	alcohol	ketone	thiol .	amide	amine	analine
Adenine .	Amine	alcohol.	ketone	thiol	amide:	amine	analine
Adenine	Z	*alcohol	pyridinlum		*amide	. ·	*amine
Adipic acid	Carboxylic Acid.	alcohol	ketone	thiol	amide	amine	analine .
. Alanine	Amine .	alcohol	ketone	thiol	amide	amine.	analine
Alanine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine
Allopurinaol .	Alcohol	alcohol	ketone .	thiol	amide	amine	analine
Allopurinaoi	Amine · · ·	alcohol	Ketone	thiol	amide ·	amine	analine
Arginine	Amine	alcohol	ketone	thiol	amide	amine	analine
Arginine	Carboxylic Acid	alcohol	ketone	thiol	amide .	amine	analine
Ascorbic Acid		alcohol		thiol	amide	amine	analine
Ascorbic Acid		alcohol	ketonė	thiol·	amide	amine .	analine .
Ascorbic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine
Asparagine	Amine	alcohol	ketone	thiol	amide .	amine	analine
						1	

		:	•				•	
Co-crystal Former		. •	٠					
	oil or dred							
1.5-Naothalene-disulfonic Acid	Acid	, i	. <u>.</u>	11 - 11	· .	:		
1-Hydrow-O-pophthological	, 2017	anilli id	metals	nioemer		sultate :	alcohol	-
יייייייייייייייייייייייייייייייייייייי	bueud	prospnate	sulfate.	sultone	nitrate	pyridine	carboxilic acid	metals
I-Hydroxy-Z-naphthoic acid	phenol	phosphate	sulfate	sulfone.	nitrate	Dyridine	carboxilic acid	metals
4-Aminobenzoic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridina		pioc cilivodreo.
4-Aminobenzoic Acid	phenol .	phosphate	sulfate	Sulfone	nitrate	. Dyridine		Carbonalio Apid
4-aminopyridine	phenol	phosphate	sulfate	Sulfone	nitrate	Dirigino		Carboxylic Acid
	*Carboxylic	П			200	Dillining.		carooxilic acid
4-aminopyridine	Acid	*suffonamide	*ketone	ether	triazole	:	ammonium	ovime
	Carboxylic		Ė					Dijiyo
4-Chlorobenzene-Sulfonic Acid	Acid	amine	metals	thioether		sulfate	alcohol	
4-ernoxypnenyi Urea	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxvlic Acid
4-emoxypnenyi Urea	phenol	phosphate	sulfate	enojins	nitrate	pyridine		carboxilic acid
7-0x0-DHEA	phenol	phosphate	sulfate	enolius	nitrate	pyridine	carboxilic acid	metals
/-0x0-UHEA	phenol	phosphate.	sulfate	sulfone	nitrate	pyridine	Ī	Carboxvlic Acid
	carboxilic	• :						
Acesultame · ·	acid	amine	metals	thioether		sulfate	alcohol .	
Acesuirame	phenol	phosphate	sülfate	sulfone	nitrate	pyridine		Carboxylic Acid
Acetonydroxamic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid
Acetohydroxamic Acid	phenol	phosphate	sulfate	sulfone.	nitrate	pyridine		Carboxilic acid
Acetonydroxamic Acid	phenol.	phosphate	sulfate	sulfone	nitrate	ovridine		Carbowlin Arid
Adenine	phenol	phosphate	sulfate	F	nitrate	nvridine '	-	Carbovilic acid
	*carboxilic			Τ		2		ממיים מיים
	acid	*sulfonamide	*ketone	ether	triazole : :		ammonium	oxime
Cia	phenol	phosphate	sulfate .	sulfone	nitrate	pyridine		carboxilic acid
	phenol	phosphate	sulfate	sultone .	nitrate	pyridine .		carboxille acid
	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid
	phenol	phosphate	sulfate	sulfone	nitrate	pyridine.		Carboxylic Acid
aoi :	phenol	phosphate	sulfate	sulfone	nitrate ·	pyridine ·		carboxilic acid
	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid
	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid
Ascorbic Acid	phenol		sulfate		nitrate	pyridine		Carboxylic Acid
		•	sulfate		nitrate	pyridine	O	Carboxylic Acid
,,,			sulfate		nitrate	pyridine	Ö	carboxilic acid
Pille	риелог	pnosphate	sulfate	sulfone	nitrate	pyridine	S	carboxilic acid

Co-crystal Former		· .				:		
1.5:Nanthalene-disulfonic Acid								
1-Hydroxy-2-naphtholc acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
1-Hydroxy-2-naphthoic acid	aldehyde	ester	ether	cyano		furan	bromine	chlorine
4-Aminobenzoic Acid	metals		ester	ether	cyano.		furan	bromine
4-Aminobenzoic Acid	metals	aldehyde	ester	ether	cyano		furan	bromine.
4-aminopyridine	metals	aldehyde	ester	ether	cyano		furan :	bromine .
		: :-	-	n-heterocyclic		 - 		
4-aminopyridine	chlorine		thiol	ring	thionedisulfide pyrrolidindione	pyrrolidindione	iodine .	hydrazone
4-Chlorobenzene-Sulfonic Acid	•	•		:				
4-ethoxyphenyl Urea	metals	aldehyde	ester	ether	cyano		furan	bromine
4-ethoxyphenyl Urea	metals	aldehyde	ester	ether	cyano		furan	bromine
7-0xo-DHEA	aldehyde	ester	ether	cyano		furan .	bromine .	chlorine .
7-oxo-DHEA	metals .	aldehyde.	ester	ether	cyano		furan	bromine
Acesulfame.								
Acesulfame	metals ·	aldehyde	ester	ether	cyano.		furan	bromine
Acetohydroxamic Acid	metals	aldehyde .	ester.	ether	cyano ·		furan .	bromine
Acetohydroxamic Acid	metals:	aldehyde	ester .	ether .	cyano .		furan	bromine.
Acetohydroxamic Acid	metals	aldehyde	ester		cyano		furan	bromine .
Adenine	metals	aldehyde	ester	ether	cyano .		furan	bromine
:				n-heterocyclic				
Author soid	Chlorine	Т	INIO		disultide	pyrrolidindione		hydrazone
Alanina	metale	aldehinde	ester	eitler	cyano			promine
Alanine	motale	1	T		Cyano			Drorning Line
naol	metals	Т			CVano		inian .	bromine
Allopurinaol	-	Γ	Γ		cyano			bromine
			ester	ether	cyano			bromine
Arginine	als .			ether	cyano .		furan	bromine
		[Ĭ.		cyano .		furan t	bromine
	$\overline{\cdot}$	\neg			cyano	•		bromine
Ş	als ·		1		cyano /	_		bromine
Asparagine	metals	aldehyde	ester	ether	cyano .		furan	bromine
	٠.	•		٠	•	•		

s-heterocyclic s-heterocyclic chlorine chlorine chlorine	pyridine pyridine				.
0 N N N N N N N N N N N N N N N N N N N	pyridine pyridine			.	
);;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;	pyridine pyridine				
9 9	pyridine pyridine	_	•		
O S	pyridine	cvano	n-heterocyclic	ketone	- todocodo
	11	cvano	n-heterocyclic	ketone	phosphate ester
	S-rielerocyclic	Dvridine	GVano	n-hotorousia	priospriate ester
	s-heterocyclic.	Ovridine	Cyano	n hotorogicalio	Kelüne
	s-heterocyclic	Dividine	Cyario .	n-neterocyclic	Ketone
		2111212	Oligio Company	III-TIETETOCYCIIC	Kerone
	*bromine		hydroxamic acid	cyano	carboxamide
			. •		
	s-heterocyclic.	pyridine	cvano	n-heterocyclic	katona
chlorine .	s-heterocyclic	Г	Cyano	Т	Pototion Totolio
yclic	pyridine		n-heterocyclic	300	heiulie
Г	cyclic	. I.	Gvano .	· Cilcuit	priospirate ester
	1	1	olino.		
chlorine		T	. 0000	$\overline{\cdot}$	
·.	T	П	cyario	7	ketone
	Τ.	1	cyano	. 1	ketone
	7	Т	cyano	7	ketone
1	Т	- 1	Syano		ketone
			Syano	n-heterocyclic	ketone
thiocyanate *t	oromine ·	· ·	•		carboxamida
	Γ.	Ť		cvclic .	ketone
		1 1	yano	T	ketone.
			yano	\top	ketone
		ı I			ketone · ·
				Π	ketone
			٠	Г	ketone
		•]			ketone
		٠ ا			ketone
•	1				ketone
	Т	- 1		-	ketone .
]	7	\neg			ketone
chlorin chlorin chlorin chlorin chlorin chlorin chlorine		e s-heterocyclic c s-heterocyclic e s-heterocyclic c s-he	e s-heterocyclic pyridine	e s-heterocyclic pyridine cyano	S-heterocyclic pyridine cyano n-heterocyclic s-heterocyclic pyridine cyano n-heterocyclic k-heterocyclic s-heterocyclic pyridine cyano n-heterocyclic k-heterocyclic pyridine cyano n-heterocyclic k-heterocyclic k-heterocyclic pyridine cyano n-heterocyclic k-heterocyclic pyridine cyano n-heterocyclic k-heterocyclic k-heterocyclic k-heterocyclic k-heterocyclic k-heterocyclic pyridine cyano n-heterocyclic k-heterocyclic k-heterocyclic k-heterocyclic k-heterocyclic k-heterocyclic k-heterocyclic k-hete

Co-crystal Former	•				. ·	•		
1;5-Napthalene-disulfonic Acid				,	ļ 	<u> </u>	<u></u>	
1-Hydroxy-2-naphthoic acid		fluorine	carbamate	imidazole	RF4	•		
1-Hydroxy-2-naphtholc acid		fluorine	carbamate	imidazole	BF4	<u> </u>	<u> </u>	
4-Aminobenzoic Acid	phosphate ester		fluorine	carbamate	imidazole	BF4		
4-Aminobenzoic Acid	phosphate ester		fluorine	carbamate	imidazole	BF4		
4-aminopyridine	phosphate ester		fluorine	carbamate	imidazole	BF4	.	
4-aminopyridine	*sulfonic acid	*phosphoric acid	N-oxide	ester	ether	fluorine	acetate	thione
4-Chlorobenzene-Sulfonic Acid								
4-ethoxyphenyl Urea	phosphate ester		fluorine	carbamate	Imidazole	BF4		
4-ethoxyphenyl Urea	phosphate ester		fluorine	carbamate	imidazole	BF4		
7-oxo-DHEA		fluorine	carbamate	imidazole	BF4			
7-0xo-DHEA	phosphate ester	•	fluorine	carbamate	imidazole	BF4		
Acesulfame .								
Acesulfame	phosphate ester		fluorine	carbamate	imidazole	BF4	ļ.	
Acetohydroxamic Acid	phosphate ester		fluorine	carbamate	imidazole	BF4	-	
Acetohydroxamic Acid	phosphate ester		fluorine	carbamate	imidazole	BF4		
Acetohydroxamic Acid	phosphate ester		fluorine	carbamate	imidazole	BF4		
Adenine	phosphate ester		fluorine	carbamate	imidazole	BF4		
Adenine	*sulfonic acid	*phosphoric acid	N-oxide	: ester	ether	fluorine	acetate	thione
Adipic acid	phosphate ester		fluorine	carbamate	imidazole	BF4		
Alanine	phosphate ester		fluorine	carbamate	imidazole	BF4		
Alanine	phosphate ester		fluorine	carbamate	Imidazole	BF4.		
Allopurinaoi	phosphate ester	-3.	fluorine	carbamate	imidazole	BF4		
Allopurinaoi	phosphate ester			carbamate	imidazole	BF4.		
Arginine	phosphate ester			carbamate	imidazole	BF4		
Alginine A	phosphate ester	•		carbamate	Imidazole	BF4		
Ascorbic Acid	phosphate ester		٠	carbamate	imidazole.	BF4		
Ascorbic Acid	phosphate ester		fluorine	carbamate	imidazole	BF4		
P.	phosphate ester			carbamate	imidazole	BF4		
Asparagine	phosphate ester		fluorine	carbamate ·	imidazole	BF4	-	

•					
Co-crystal Former			۷.		•
1.5-Napthalene-disulfonio Acid		-	-	-	.
1-Hydroxy-2-naphtholc acid		1	·	•	·
1-Hvdroxv-2-nanhthnic acid			-		
4-Aminobenzoic Acid	COS N				-
4-Aminobenzoic Acid	1N-502	thiourea	aliodine	6	
4-aminonvriding	.N-502	thiourea	,		-
	N-SO2	thiourea	T -		1
4-aminopyridine	dithiadiazocyclopentadlenyl		·		
4-Chlorobenzene-Sulfonic Acid	. :		<u> </u> -	. 	-
4-ethoxyphenyl Urea	N-SO2	11.	[7	
4-ethoxyphenyl Urea	N-SO2	miourea	T	epoxide	peroxide
7-oxo-DHEA	200	thiourea	iodine		
7-oxo-DHEA	N-SO2		Т		
		thiourea	iodine		
Acesulfame	•	<u></u>	•		
Acesulfame	N-SO2				
Acetohydroxamic Acid	N-SO9	mourea	iodine	epoxide	peroxide
Acetohydroxamic Acid	N. O.O.	thiourea	lodine	epoxide	peroxide
Acetohydroxamic Acid	200-N	thiourea	lodine		
Adenine	305-71	thiourea	lodine	epoxide	
	N-802	thiourea	iodine]:
Adenine	dithiadiazocyclonentadienw				
Adipic acid	N-S02	thiourea	iodina		
Alanino	N-SO2	thiourea	iodina		
Albariane	N-SO2	thiourea	iodina		Ì
All	N-SO2	thiourea	20100	opinion o	
Ailopurinaoi	N-S02	thioures		enixoda	
Arginine	N-SO2	thioring			
Arginine	N-S02	7	logine		
	N-SO2	Ŧ	eupo.		
	N-S02	_	logine	•	
. pi	N-SO2	$\neg \tau$	eulpoi	epixode	
Asparagine	N-SOS	Т	logine		
	700	thiourea	iodine.		

Co-crystal Former Purctional Group Interacting Group Antide Antid		-						
State Former Functional Group Interacting Group (Retone thio) amide amine alcohol (Retone thio) amide amine amine alcohol (Retone thio) amide amine amine alcohol (Retone thio) amide amine alcohol (Retone thio) amide amine amine alcohol (Retone thio) amide amine alcohol alcohol (Retone thio) amide amine alcohol (Retone thio) amide amine alcohol (Retone thio) amide amine alcohol		Co-crystal Former			:			
gine Graboxylic Acid alcohol ketone thiol amide amine of Acid Acid alcohol ketone thiol amide amine alcohol ketone thiol amide amine of Carboxylic Acid alcohol ketone thiol amide amine acid (Carboxylic Acid alcohol ketone thiol amide amine acid (Carboxylic Acid alcohol ketone thiol amide amine acid (Carboxylic Acid alcohol ketone thiol amide amine carboxylic Acid alcohol ketone thiol amide amine acid alcohol ketone thiol amide amine carboxylic Acid alcohol ketone thiol amide amine acid alcohol ketone thiol amide amine carboxylic Acid alcohol ketone thiol amide amine carboxylic Acid alcohol ketone thiol amide amine alcohol ketone thiol amide amine alcohol ketone thiol amide amine acid alcohol ketone thiol amide amine alcohol ketone alcohol ketone alcohol ketone thiol amide amine alcohol ketone alcohol ketone thiol amide amine alcohol alcohol ketone thiol amide amine alcohol alcohol ketone thiol amide amine alcohol alcohol alcohol alcohol alcohol alcohol alcoh	Co-crystal Former	Functional Group	Interacting	Group				
Gractopylic Acid salochol kestone thiol amide amine c Acid Cartooylic Acid alcochol kestone thiol amide amine o Acid Cartooylic Acid alcohol kestone thiol amide amine o Acid Cartooylic Acid alcohol kestone thiol amide amine o Acid Cartooylic Acid alcohol kestone thiol amide amine o Cartooylic Acid alcohol kestone thiol amide amine acid Cartooylic Acid alcohol kestone thiol amine acid Cartooylic Acid alcohol kestone thiol amine acid Alcohol kestone thiol amine amine oid Cartooylic Acid alcohol kestone thiol amine oid Cartooylic Acid alcohol kestone thiol amine oid Cartooylic Acid alco	Asparagine	Amide	alcohol	ketone	thiol .	amide	amine	analine .
Acid Arnine alcohol ketone thiol amide amine carbonic Acid alcohol ketone thiol amide amine carbonyllo Acid alcohol ketone thiol amide amine and acceptor carbonyllo Acid alcohol ketone thiol amide amine and alcohol ketone thiol amide amine alcohol alcohol ketone thiol amide amine alcohol alcohol ketone thiol amide amine alcohol alcoho	Asparagine	Carboxylic Acid	alcohol.	ketone	thiol	amide	amine	analine
Sutronic Acid alechol ketone thiol arnide arnine ester setter carboxylic Acid alechol ketone thiol arnide arnine and alechol ketone thiol arnide arnine and alechol ketone thiol arnide arnine and acid carboxylic Acid alechol ketone thiol arnide arnine and acid carboxylic Acid alechol ketone thiol arnide arnine and acid Carboxylic Acid alechol ketone thiol arnide arnine and Alechol alechol ketone thiol arnide arnine and Alechol alechol ketone thiol arnide arnine cid Alechol alechol ketone thiol arnide arnine alechol ketone thiol arnide arnine cid Alechol alechol ketone thiol arnide arnine	Aspartic Acid	Amine	alcohol	ketone	thiol	amide .	amine	änaline
Sutionic Acid alcohol ketone thiol amide amine of annine acid carboxylic Acid alcohol ketone thiol amide amine amine of Carboxylic Acid alcohol ketone thiol amide amine acid (Carboxylic Acid alcohol ketone thiol amide amine acid amine acid amine acid amine acid amine acid amine acid amine amide amine amine amide amine amine acid amine acid Acohol ketone thiol amide amine amine acid Acohol ketone thiol amide amine amine acid acid Acohol ketone thiol amide amine amine acid acid Acid alcohol ketone thiol amide amine ami	Aspartic Acid	Carboxylic Acid	alcohol ··	ketone	thiol	amide	amine.	analine
Pyriolitic Acid alcohol ketone thiol amide amine orde acid (Satone alcohol ketone thiol amide amine orde acid (Satone alcohol ketone thiol amide amine orde acid (Satone alcohol ketone thiol amide amine acid (Satone alcohol ketone thiol amide amine alcohol alcohol ketone thiol amide amine alcohol alcohol ketone thiol amide amine alcohol alcohol alcohol ketone thiol amide amine alcohol alcoh			=		. 1 1 1			
c Acid deconomic Acid alcohol ketone thiol amide amine onto acid (Carboxylic Acid alcohol ketone thiol amide amine acid (Carboxylic Acid alcohol ketone thiol amide amine amine acid (Carboxylic Acid alcohol ketone thiol amide amine alcohol ketone thiol amide amine cid Acid alcohol ketone thiol amide amine alcohol secone alcohol ketone thiol amide amine alcohol alcohol alcohol ketone thiol amide amine alcohol alcoh	Benzenesultonic, Acid	Suitonic Acid	pyridine	Ketone	aldenyde	erner	ester	amide.
dicohol ketone thiol amide amine amine alcohol ketone thiol amide amine amine and alcohol ketone thiol amide amine amine alcohol ketone thiol amide amine amine alcohol ketone thiol amide amine alcohol ketone thiol amide amine cid Alcohol Alcohol ketone thiol amide amine tided alcohol ketone thiol amide amine alcohol ketone thiol amide amine tided alcohol ketone thiol amide amine tided alcohol ketone thiol amide amine alcohol ketone thiol amide amine tided alcohol ketone thiol amide amine tided alcohol ketone thiol amide amine alcohol ketone thiol amide amine tided alcohol ketone thiol amide amine tided alcohol ketone thiol amide amine alcohol ketone thiol amide amine alcohol ketone thiol amide amine alcohol ketone amide amine alcohol ketone amide amine alcohol amide amide amine alcohol amide amide amine amide amine alcohol amide amide amide amine amide amine alcohol amide amide amine amide amine amide amide amine amide amide amine amide ami	Benzoic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide .	amine	analine
acid Carboxylic Acid alcohol ketone thiol amide amine amine acid (Sarboxylic Acid alcohol ketone thiol amide amine acid (Sarboxylic Acid alcohol ketone thiol amide amine amine cid Anine Amine alcohol ketone thiol amide amine amine tide acid alcohol ketone thiol amide amine alcohol ketone thiol amide amine tide acid alcohol ketone thiol amide amine tide acid alcohol ketone thiol amide amine tide acid alcohol ketone thiol amide amine alcohol ketone thiol amide amine alcohol ketone thiol amide amine tide acid alcohol ketone thiol amide amine alcohol ketone thiol amide amine alcohol ketone thiol amide amine tide acid alcohol ketone thiol amide amine alcohol alcohol alcohol ketone thiol amide amine alcohol alcohol ketone thiol amide amine alcohol alcoh	Caffeine	Ketone	alcohol .	. :	thiol	amide	amine	analine
acid Carboxylic Acid alcohol ketone thiol amide amine amine line thiol amide amine amine amine amine amine amine amine alcohol ketone thiol amide amine amine amide amine amine amide a	Camphoric acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine
in Ketone aucohol thiol amide amide amine amine sulfoxide n pyridine sin amide sulfoxide n pyridine sin amide sulfoxide n suchos solutoxide n suchos solutoxide n suchos solutoxide solutox	Capric acid	Carboxylic Acid	alcohoi	ketone	thiol	amide .	-amine	analine
in Ether amine amine sulfoxide n pyridine lie acid amine aromatic.s Sp2 amine lie acid Carboxylic Acid alcohol ketone thiol amide amine amine amine amine amine alcohol ketone thiol amide amine alcohol ketone thiol amide amine lie Acid alcohol ketone thiol amide amine lie Acid alcohol ketone thiol amide amine tic acid alcohol ketone thiol amide amine alcohol alcohol alcohol ketone thiol amide amide amine alcohol amide amide amine	Genistein	Ketone	alcohol		thiol	amide	: amine	analine
in acid Carboxylic Acid alcohol ketone thiol amide amine and and alcohol ketone thiol amide amine amine cid alcohol ketone thiol amide amine amine cid alcohol ketone thiol amide amine alcohol ketone amine amide amine alcohol ketone amide amide amine alcohol ketone amide amide amine amine alcohol alcohol ketone thiol amide amine amine amine alcohol alcohol ketone thiol amide amine a	Genistein	Phenol	amine	amide	sulfoxide	u	pyridine	cyano
itic acid Carboxylic Acid alcohol ketone thiol amide amine cid Alcohol Alcohol alcohol ketone thiol amide amine cid Alcohol Alcohol alcohol ketone thiol amide amine cid Alcohol Amine alcohol ketone thiol amide amine alcohol ketone thiol amide amine alcohol ketone thiol amide amine acid acid sodium aldehyde ketone alcohol ketone thiol amide amine acid acid sodium aldehyde ketone amine alcohol ketone thiol amide amine amide amine alcohol amide amine amide amine alcohol amide amide amine am	Genistein	Ether : '	aromatic-N	amide	amine	aromatic_s	Sp2 amine	sulfoxide
cid Carboxylic Acid alcohol ketone thiol amide amine cid accomplete alcohol ketone thiol amide amine amine alcohol alcohol amide amine	Cinnamic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine
cid Carboxylic Acid alcohol ketone thiol amide amine sic Arilne alcohol ketone thiol amide amine fc Arilne alcohol ketone thiol amine e Amine alcohol ketone thiol amine e Carboxylic Acid alcohol ketone thiol amine e Thiol ariloe amine amine de Carboxylic Acid alcohol ketone thiol amine diglycine Carboxylic Acid alcohol ketone thiol amine a Amine alcohol ketone thiol amine a Alcohol ketone thiol amide amine a Alcohol ketone thiol amide amine a Carboxylic Acid alcohol ketone thiol amide amine a Carboxylic Acid	Citric Acid · · · ·	Alcohol	alcohol	ketone .	thio!	amide	amine	analine
le Acid Amine alcohol ketone thiol amide amine carboxylic Acid alcohol ketone thiol amide amine alcohol ketone aldehyde ether ester ester alcabaylic e acid sodium aldehyde ether ester ester alcohol ketone thiol amide amine fit acid alcohol ketone thiol amide amine fither amide amine fither amide amine fither amide amine amide amine fither fither amine fither amine fither fither amine fither fither amine fither	Citric Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine
fic Acid Amine alcohol ketone thiol amine e Carboxylic Acid alcohol ketone thiol amine e Carboxylic Acid alcohol ketone thiol amine e Thiol acid sodium aldehyde ketone -N flglycine Carboxylic Acid alcohol ketone thiol amide amine g Amine alcohol ketone thiol amide amine g Alcohol alcohol ketone thiol amide amine g Acid alcohol ketone thiol amide amine <tr< td=""><td></td><td></td><td>*alcohol :</td><td>pyridinium</td><td></td><td>^amide</td><td>nitro</td><td>*amine</td></tr<>			*alcohol :	pyridinium		^amide	nitro	*amine
Carboxylic Acid pyridine ketone aldehyde ether ester e Amine alcohol ketone thiol amide amine e Carboxylic Acid acid sodium aldehyde ketone -N e Thiol acid sodium aldehyde ketone -N //glycine Carboxylic Acid alcohol ketone thiol amide amine a Alcohol alcohol ketone thiol amide amine a Alcohol alcohol ketone thiol amide amine a Alcohol alcohol ketone thiol amide amine a Acid Carboxylic Acid alcohol ketone thiol amide amine a alcohol ketone thiol amide amine a b alcohol ketone thiol amide amine b b alcohol ketone thiol amide amine c c alcohol ketone thiol amide amine d d alcohol alcohol amide a	Cyclamic Acid	Amine	alcohol	ketone	thiol .	amide.	amine .	analine
Amine alcohol ketone thiol amide amine amine alcohol ketone thiol amide amine amine and carboxylic Acid acid sodium aldehyde ketone amine amine alcohol ketone thiol amide amine alcohol alcohol ketone thiol amide amine amine alcohol alcohol amide amine amine alcohol amide amine amine alcohol amide amine amine alcohol amide amine and amine am	Cyclamic Acid	Suffanic Acid	ovridine	ketone ·	aldehvde	ether	ester	amide.
e Carboxylic Acid alcohol ketone thiol amide amine Thiol acid alcohol ketone thiol amide amine Amine alcohol ketone thiol amide amine Acid Carboxylic Acid alcohol ketone thiol amide amine Alcohol alcohol ketone thiol amide amine Acid Carboxylic Acid alcohol ketone thiol amide amine Acid Carboxylic Acid alcohol ketone thiol amide amine Acid Carboxylic Acid alcohol ketone thiol amide amine Alcohol alcohol ketone thiol amide amine Acid alcohol amide sulfoxide amine Ether anine amine amide amine amine amine amine Ether aromatic-N amide amine aromatic s Sp2 amine	Ovsteine	Amine	alcohol.	ketone	thiol	amide	amine	analine
Thiol acid sodium aldehyde ketone -N Amine Amine alcohol ketone thiol amide amine Acid Acid Acid alcohol ketone thiol amide amine Alcohol alcohol ketone thiol amide amine Alcohol alcohol ketone thiol amide amine Acid Carboxylic Acid alcohol ketone thiol amide amine Alcohol amide amine amine amine aromatics Sp2 amine	Cysteine	Carboxylic Acid	alcohol	ketone .	thiol:	amide	amine	analine
Thiol acid sodium aldehyde ketone -N Aglycine Carboxylic Acid alcohol ketone thiol amide amine Bether aromatic-N amide amine aromatic_s Sp2 amine Alcohol alcohol ketone thiol amide amine Acid Carboxylic Acid alcohol ketone thiol amide amine Acid Carboxylic Acid alcohol ketone thiol amide amine Acid amine amine amine amine aromatic s Sp2 amine aromatic s Sp2 amine			carboxylic					
Alglycine Carboxylic Acid alcohol ketone thiol amide amine and alcohol ketone thiol amide amine aromatic. Sp2 amine aromatic. Sp2 amine alcohol ketone thiol amide amine aromatic and a amine alcohol ketone thiol amide amine alcohol ketone thiol amide amine ric acid alcohol ketone thiol amide amine alcohol ketone thiol amide amine alcohol ketone thiol amide amine alcohol amide amine aromatic. Sp2 amine aromatic.	Cysteine	Thiol	acid	sodium .	aldehyde .	ketone	2	cadminm
Agycine Amine alcohol ketone thiol amide amine Ether aromatic-N amide amine aromatic_s Sp2 amine Alcohol alcohol ketone thiol amide amine ic acid alcohol ketone thiol amide amine fic acid alcohol ketone thiol amide amine Alcohol alcohol ketone thiol amide amine alcohol alcohol amide amine Alcohol amide amine Alcohol amide amine Alcohol amide amine Alcohol amide amine amine Ether aromatic-N amide amine aromatic s Sp2 amine	Dimethylglycine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine.
Ether aromatic-N amide amine aromatic_s Sp2 amine, a Alcohol alcohol ketone thiol amide amine amine from alcohol ketone thiol amide amine alcohol ketone thiol amide amine alcohol ketone thiol amide amine from alcohol alcohol alcohol amide amine amine frher amine amide amine amine amide amine amine amine amide amine amine amide amine amide amine amine amide amine aromatic s Sp2 amine aromatic s Sp2 amine aromatic s Sp2 amine amine aromatic s Sp2 amine s Sp2 amine aromatic s Sp2 amine s	Dimethylglycine	Amine		ketone	thiol	amide	amine	analine
Alcohol alcohol ketone thiol amide alcohol ketone thiol amide ric acid Carboxylic Acid alcohol ketone thiol amide ric acid alcohol alcohol ketone thiol amide alcohol ketone thiol amide alcohol ketone thiol amide alcohol ketone thiol amide Ether amine amide amine amine amine aromatic s	D-ribose		Z-	amide	amine	ු'	Sp2 amine	sulfoxide
ric acid Carboxylic Acid alcohol ketone thiol amide ric acid ketone alcohol ketone thiol amide ric acid alcohol amine amide ric acid bhenol amine amide aromatic s	D-ribose	•	alcohol	ketone	thiol	amide	amine	analine
ric acid Carboxylic Acid alcohol ketone thiol amide ric acid alcohol ketone thiol amide alcohol Ketone alcohol thiol amide amine amide sulfoxide n amine amine aromatic s aromatic.N amide aromatic s	Fumaric Acid	Carboxylic Acid ,	alcohol	ketone	thiol	amide .	amine	analine
ric acid alcohol anide thiol amide thiol amide thiol amide thiol amide thiol amide the sulfoxide n anine aromatic s aromatic. N amide aromatic s	Galactaric acid	· Carboxylic Acid	alcohol	ketone	thiol	amide	amine .	analine .
Ketone amide Ami	Galactaric acid	alcohol	alcohol .	ketone '	thiol .	amide	amine	analine .
Phenol amine amide sulfoxide n	Chrysin	Ketone	alcohol	٠	thiol	amide	amine	analine
Ether aromatic s aromatic s	Chrysin ·	Phenol	amine	amide .	sulfoxide	Ę.	pyridine	cyano
	Chrysin	Ether	aromatic-N	amide	amine	aromatic_s	Sp2 amine	sulfoxide

	-	•			•			
Asparagine	phenol	phosphate	Sulfate	sulfone	nitrate	nvridine		i de ciliare de color
Asparagine	phenol ,	phosphate	Sulfate	Stilfone	nitrato	Silding.		Carboxylic Acid
Aspartic Acid .	loneha	phosphate	Stilfato .	or of or or	nitrato	pyridine	;	carboxilic acid
Aspartic Acid	phenol	1	Criffsto	Dioline .	Titale	pyridine		carboxilic acid
	Carboxvlic	+-	odilaic	el loline	mirate	pyridine		carboxilic acid
Benzenesulfonic Acid	Acid	amine	metals	thioather				•
Benzoic Acid	bhenol	phosphate	Sufate	Sufford	Different	Sulaie	alconol	
Caffeine .	openol	phosphate	Culfato	. Ollows	יוווומום	pyriaine		carboxilic acid
Camphoric acid	loueda	phosphate	oulfato	allolle:	nitrate	pyridine		Carboxylic Acid
Capric acid ·	phenol	phosphate	onlight or lifeto	allolle	nitrate	byridine		carboxilic acid
Genistein	onedo	phosphate.	Sullate	anione	nitrate	pyridine	-	carboxilic acid
Genistein	phological	nicepitate transpirate	Sulfate	Sulfone	nitrate	pyridine		Carboxylic Acid
Genistein	chlorate	chloring	alchorol		ester	ether	n-oxide	chlorine.
Cinnamic acid	chiciate	e ligitie		cyano	ester	amine	· nitro	nitrate
Citrio Apid	phenol	prosphate	sulfate .	sulfone .	nitrate	- pyridine		carboxilic acid
Oltrio Apid	phenol	phosphate	sulfate	sultone	nitrate	pyridine		Carbovylic Acid
HIC ACID	phenol	phosphate	sulfate	sulfone	nitrate	Dyridine		Carhovilic acid
. ologimal	: carboxilic		•					
Cyclemic Acid	acid	sultonamide	*кетопе	ether	triazole	•	ammonium.	owiwo
· Biot of the	phenoi	phosphate	sulfate	sultone	nitrate .	pyridine		Carboxilic acid
Cvolamic Acid	Carboxylic							
Cysteine	- Coode	allille .	merais	thioether		sulfate.	alcohol	
Ovetoine		phosphare	sulfate	sulfone	nitrate	pyridine		carboxilic acid
DI III DI	pnenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid
Cysteine		arsenic	chloring	lohole			•	
Dimethylglycine	phenol	phosphate	Sulfate		potassium	מוליות מייו		
Dimethylglycine	phenol	phosphate	Cilipto	T	nitale.	pyridine		carboxilic acid
D-ribose		chlorine	T		rillate	pyridine		carboxilic acid
D-ribose		٩	or Ifodo		ester	amine	nitro	nitrate
Fumaric Acid		T			nitrate	pyridine		Carboxylic Acid
Galactaric acid				. T	nitrate .	pyridine		carboxilic acid
Galactaric acid	1	T		T	nitrate ·	pyridine		carboxilic acid
Chrysin		phosphale	Sulfate		nitrate	pyridine	carboxilic acid	metals
Chrysin	٩	1.	<u>-</u> آ-	allouins	nitrate	pyridine		Carboxylic Acid
Chrysin		chloring	Ŀ	00000	colei		n-oxide	chlorine
		-			2701	-	•	

Co-crystal Former								
Asparagine ·	metals	aldehyde	ester	ether	cyano		furan	bromine
Asparagine	metals	aldehyde	ester	ether .	cyano		furan	bromine
Aspartic Acid	metals	aldehyde	ester	ether	cyano		furan	bromine
Aspartic Acid	metals	aldehyde	ester	ether	cyano		furan	bromine ·
Benzenesulfonic Acid				· ·			•	
Benzoic Acid	metals	aldehyde	ester	ether	cyano .		furan	bromine
Caffeine	metals	aldehyde	ester	ether	cyano		furan	bromine
Camphoric acid .	metals	aldehyde	ester	ether	cyano .		furan	bromine
Capric acid	metals ·	aldehyde	ester	ether	cyano		furan	bromine
Genistein	. metals	aldehyde	ester	ether	cyano		furan	bromine
Genistein	fluorine	bromine	iodine	ketone .	sulfonic acid	sulfate	phosphate	phosphonic acid
Genistein	· bromine	aldehyde	ketone	peroxide	epoxide			heterocyclic-S
Cinnamic acid	metals	aldehyde	ester .	ether	cyano		furan	bromine
Citric Acid	metals	aldehyde	ester	ether	cyano .	•	furan	bromine
Citric Acid .	metals	aldehyde	ester.	ether:	cyario .		furan	bromine .
Clemizole	*chlorine		: : thiol	n-heterocyclic rina	thionedisulfide	pvrrolidindione	iodine	hvdrazone
Cyclamic Acid	metals	aldehyde	ester	ether	cyano		furan .	bromine
Cuclamic Acid								
Cysteine	metals	aldehyde	ester	ether	cvano		furan	bromine
Cysteine	metals	aldehyde	ester	ether	cyano		furan	bromine
Cysteine	 8							
Dimethylglycine	metals	aldehyde	ester	ether .	cyano		furan	bromine
Dimethylglycine	metals	aldehyde	ester	ether	cyano		furan	bromine
D-ribose	bromine	aldehyde	ketone	peroxide	epoxide			heterocyclic-S
D-ribose	metals	aldehyde	ester	ether ·	cyano .		furan	bromine
Fumaric Acid	metals	aldehyde	ester	ether	cyano		furan	bromine
Galactaric acid	metals ·	aldehyde	ester	ether	cyano .		furan	bromine
Galactaric acid.	aldehyde	ester	ether	cyano ·		furan	bromine	chlorine
Chrysin	metals	aldehyde	ester	ether		·	furan	bromine
Chrysin	fluorine	bromine	iodine		acid	sulfate	phosphate	phosphonic acid
Chrysin	hromino	plobyyda	Outotod.	Opinor	Chicker			Potono polini

	 -					
Co-crystal Former	. 7.			·· .		
Asparagine	chlorine .	s-heterocyclic	pyridine	cyano	in-heterocyclic	ketone
Asparagine.	chlorine .	s-heterocyclic	pyridine	cyano.	n-heterocyclic	ketone
Aspartic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Aspartic Acid .	chlorine	s-heterocyclic	pyridine	cyano.	n-heterocyclic	ketone
Benzenesulfonic Acid			٠.			
Benzoic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Caffeine	chlorine.	s-heterocyclic	pyridine	cyano .	· n-heterocyclic	ketone
. Camphoric acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Capric acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone ·
Genistein	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Genistein	carboxylic acid	nitro	sulfone	analine ·	,	
Genistein	lodine :	ester	ether	carboxylic acid	sulfate	sulfone
Cinnamic acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Citric Acid	chlorine	s-heterocyclic	pyridine	cyano	in-heterocyclic	ketone .
Citric Acid	chlorine · ·	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone ·
Clemizole	thiocyanate	*bromine	• •	hydroxamic acid	суано	carboxamide
Cyclamic Acid	chlorine · ·	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Cyclamic Acid					- ·	•
Cysteine	chlorine: .	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Cysteine	chlorine	s-heterocyclic	pyridine.	cyano.	n-heterocyclic	ketone
Cysteine				· · ·		
Dimethylglycine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Dimethylglycine	chlorine	s-heterocyclic	pyridine .	cyano .	n-heterocyclic	ketone
D-ribose	iodine	ester	ether	carboxylic acid	sulfate	sulfore
D-ribose	chlorine			cyano.	n-heterocyclic	ketone
Fumaric Acid	chlorine	1		cyano .	n-heterocyclic	ketone
Galactaric acid	chlorine	s-heterocyclic	0	cyano .	n-heterocyclic	ketone
Galactaric acid	cyclic	1	cyano	n-heterocyclic	ketone	phosphate ester .
Chrysin	\neg	erocyclic .	pyridine	cyano ´	n-heterocyclic	ketone
Chrysin	ylic acid	nitro	9	analine ·		
Chrysin	iodine	ester	ether	carboxylic acid	sulfate	sulfone.
		•				

Co-ci ystal roulier		•						
Asparagine	phosphate ester		fluorine	carbamate	imidazole	BF4		.,
Asparagine	phosphate ester		fluorine	carbamate	imidazole	BF4		
Aspartic Acid	phosphate ester		fluorine	carbamate	imidazole	BF4		
Aspartic Acld	phosphate ester	· -	fluorine	carbamate	imidazole	BF4		
Benzenesulfonic Acid					•			
Benzoic Acid	phosphate ester		fluorine	carbamate	imidazole	BF4		· <u>·</u>
Caffeine	phosphate ester			carbamate	imidazole	BF4		Ŀ
Camphoric acid	phosphate ester		fluorine	carbamate	imidazole	BF4	ŀ	
Capric acid	phosphate ester		fluorine	carbamate	imidazolė	BF4		
Genistein.	phosphate ester		fluorine	carbamate	imidazole	BF4		 -
Genistein								
Genistein .	• •	alcohol		phospphate	cyanamide	<u>.</u>		
Cinnamic acid	phosphate ester		fluorine	carbamate	imidazole	BF4		
Citric Acid	phosphate ester		fluorine	cárbamate	· imidazole	BF4		
Citric Acid	phosphate ester	•	fluorine	carbamate	imidazole	BF4		
Ciemizole	*sulfonic acid	*phosphoric acid	N-oxide	ester	ether	fluorine	acetate	thione
Cyclamic Acid ·	phosphate ester		fluorine	carbamate	imidazole	BF4		:
	•					•		
Cyclamic Acid								
Cysteine .	phosphate ester		fluorine .	carbamate	imidazole	BF4		
Cysteine	phosphate ester		fluorine	carbamate	.lmidazole	BF4		
Cysteine			•				•	
Dimethylglycine	phosphate ester		fluorine	carbamate	imidazole	BF4		
Dimethylglycine	phosphate ester		fluorine	carbamate	imidazole	BF4		
D-ribose		alcohol		phospphate	cyanamide		٠	
D-ribose	phosphate ester	٠	fluorine	carbamate	imidazole.	BF4		
Fumaric Acid	phosphate ester		fluorine ~	carbamate	imidazole .	BF4		
Galactaric acid	phosphate ester-		fluorine	carbamate	imidazole	BF4		
Galactaric acid ·		fluorine	carbamate	imidazole	BE4			
Chrysin	phosphate ester		fluorine	carbamate	imidazole	BF4		
Chrysin				٠				
Chrysin		lodonia		phoennhato	. objection			•

ζ.

Co-crystal Former	-			•	
Asparagine	N-SO2	thiourea	iodine	epoxide	epoxide peroxide
Asparagine	N-SO2.	thiourea	iodine		-
Aspartic Acid	N-SO2	thiourea	iodine		
Aspartic Acid	N-SO2	thiourea	iodine		
Bonzonger Ilfonio Acid			٠.		
Benzaic Acid	N-SO2	thiourea	iodine		
Caffeine	N-SO2	thiourea	iodine		
Camphoric acid	N-SO2	thiourea	iodine		
Capric acid	N-SO2	thiourea	iodine	•	
Genistein	N-SO2	thiourea	iodine		
Genistein					
Genistein					
Cinnamic.acid	N-SO2	thiourea	lodine		
Citric Acid	N-S02	thionrea	iodine	epoxide	-
Citric Acid	N-SO2	thionrea	iodine		
Clemizole	dithiadiazocyclopentadienyl			•	
Cyclamic Acid	N-SO2	thiourea	iodine		:
-		•			
Cyclamic Acid .			1		
Cysteine	N-SO2	thiourea	euro.		
Cysteine	N-SO2	thiourea	odine		
Cycteine				•	
Dimethylalycine	N-SO2	thiourea	iodine		
Dimethylglycine	N-SO2	thionrea	iodine		
D-ribose					
D-ribose	N-SO2	thiourea	euipoi	epoxide	
Fumaric Acid	N-SO2	thiourea.	iodine		
Galactaric acid ·	N-SO2	thiourea	lódine		
Galactaric acid			٠.		
Chrysin .	N-SO2	thiourea	iodine		
Chrysin					
Chrysin	·				

					•		
	Co-crystal Former						
Co-crystal Former	Functional Group	Interacting Group	ig Group				
Gentisic acid	Carboxylic Acid	alcohiol	ketone	thiol	amide	amine	analine
Gentisic acid	Phenol	amine	amide	sulfoxide.	C	· pvridine	Chano
Giucamine, N-methyl	alcohol	alcohol	ketone	thiol	amide	amine	analine
Glucamine, N-methyl	Amine	alcohol	ketone	thiol	amide .	amine	analine
Gluconic Acid	Alcohol ·	alcohol	ketone	thiol	amide	amine	analine
Gluconic Acid	Carboxylic Acid	alcohol:	ketone	thiol	amide	amine	analine .
Giucosamine	alcohol	alcohol	ketone	thiol	amide	amine	analine
Glucuronic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine
Gluceronic acid	alcohol .	alcohol	ketone	thiol	amide	amine	analine.
Glucuronic acid	Aldehyde	alcohol	ketone.	thiol	amide	amine	analine
Glutamic Acid	· Amine	alcohol	ketone	thiol	amide	amine	- analice
Glutamic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine
Біцтатіле	Amine ·	alcohol	. ketone	thiol	amide.	amine	analine
Giutamine	Amide .	alcohol	ketone	thiol	amide	amine	analine
Glutamine	Carboxylic Acid ·	alcohol	ketone	thiol	amide	amine	analine
Giutaric Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine
Glycine	Amine	alcohol	ketone	thiol	amide	amine	analine
Glycine	Carboxylic Acid	alcohol	ketone	thio	amide	amine	analine
Glycolic Acid	Alcohol	alcohol	ketone .	thiol	amide	amine	analine
Glycolic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine
	Amide	alcohol	ketone	thiol	amide	amine	analine
· Hippuric Acid	Amine	alcohol	ketone	thiol	amide	amine	analine
Hippuric Acid	Carboxylic Acid	alcohol	ketone .	thiol	amide .	amine	analine
Histidine	Amine .	alcohol	ketone	thiol	amide	amine	analine
Histidine	Carboxylic Acid	alcohol	ketone.	thiol	amide	amine	analine
 							•
Histidine	. Imidazole	· · · · imidazola			4.00		
Hydroquinone	Alcohol	· lohole	Potono.	thio	carboxylate		triione
Hydroguinone	Phonoi	diod io	neturie omide	UIIO	arride	amine	analine
Imidazola	Cimy.	alling	alilloe	SUITOXIGE	_	pyridine	cyano
Intiflation	Allille	alconol	Ketone	thiol	amide	amine	analine
ipilitavolle Drifforono		aromatic-N	amide	Э	aromatic_s	Sp2 amine	sulfoxide
ipimavoire.		_			amide .	amine	analine
isoleucine	Amine	alcohol	ketone	thiol	amide	amine	analine

								L: 1
Gentisic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid
Gentisic acid	aldehyde		alchohol		ester	ether	n-oxide	chlorine
Glucamine, N-methyl	phenol	phosphate	sulfate	sulfone	nitrate.	pyridine	carboxilic acid	metals
Glicamine, N-methyl	loueda	phosphate	sulfate	sulfone	irate	pyridine		carboxilic acid
Gliconic Acid	phenol	phosphate	sulfate	sultone	nitrate	pyridine		Carboxylic Acid
Gliconic Acid	phenol	. phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid
Glicosamiae	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acld
Glicuronic acid	phenol	phosphate	suifate	sulfone	nitrate.	pyridine.		carboxilic acid
Glicuronic acid	phenol	phosphate	sulfate	sulfone	nitrate.	pyridine	carboxilic acid	metals .
Glucuronic acid	lonena	phosphate	sulfate	sulfone	nitrate	pyridine	aromatic	carboxilic acid
Glutamic Acid	phenol	phosphate	sulfate	sulfone	nitrate '	pyridine		carboxilic acid
Glutamic Acid	loheno	phosphate	sulfate	sulfore	nitrate	pyridine		carboxilic acid
Glutamine	. phenol.	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid
Glutamine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Glutamine	·· phenol	phosphate	sulfate	sulfone	nitrate	pyridine	,	carboxilic acid
Glutaric Acid ··	phenol	phosphate	sulfate	sulfone .	nitrate	pyridine		carboxllic acid
Glycine	phenol	phosphate.	sulfate	sulfone	nitrate	pyridine		carboxilic acid.
Glycine	phenol	phosphate	sulfate	sulfone .	nitrate	pyridine		carboxilic acid
Glycolic Acid	phenol	phosphate	sulfate	sulfone	nitrate .	pyridine		Carboxylic Acid
Glycolic Acid	phenol ·	phosphate	sulfate	enitorie	initrate	pyridine	•	carboxilic acid
Hippuric Acid	phenol	phosphate	sulfate	sulfone.	nitrate	pyridine		carboxilic acid
Hippuric Acid	phenol	phosphate	sulfate	sulfone	nitrate:	pyridine		carboxilic acid
Hippuric Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid
Histidine	phenol	phosphate	sulfate	sulfone	nitrate.	pyridine		carboxilic acid
Histidine	phenol	phosphate .	sulfate	sulfone	nitrate ···	pyridine		carboxilic acid
								•
	•	•		•				
ָרָיִייָּיִינְיִינְיִינְיִינְיִינְיִינְיִינְיִינ	·	cvanamide	ketone	cvano.	Carboxylic Acid	alcohoi	•	thiol
Hydroduinone	phenol	phosphate	sulfate	sulfone	nitrate.	pyridine		Carboxylic Acid
Hydroguinone	. aldehyde		alchohol		ester	ether .	n-oxide	chlorine
midazole	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	-	carboxilic acid
Inriflavone	chlorate	chlorine		cyano	ester	amine	nitro	nitrate
Ipriflavone	loueud	phosphate .	sulfate	sultone	nitrate	pyridine		Carboxylic Acid
				1000	-186-	D. Widing		

Gentisic acid Gentisic acid Glucamine, N-methyl Glucamine, N-methyl Gluconic Acid Glucosamine Glucoronic acid Glucuronic acid Glucuronic acid Glucuronic acid Glutamic Acid Glutamine	metals	aldehyde	ester	ether	cvano	_		
Gentisic acid Glucamine, N-methyl Glucamine, N-methyl Gluconic Acid Glucosamine Glucosamine Glucuronic acid Glucuronic acid Glucuronic acid Glucuronic acid Glutamic Acid Glutamine		L. Comino	i		(2			DIOMINIC
Glucamine, N-methyl Glucamine, N-methyl Gluconic Acid Glucosamine Glucosamine Glucuronic acid Glucuronic acid Glucuronic acid Glutamic Acid Glutamine	TIUONIDE		iodine	ketone	sulfonic acid	sulfate ·	phosphate	phosphonic acid
Glucamine, N-methyl Gluconic Acid Glucosamine Glucuronic acid Glucuronic acid Glucuronic acid Glutamic Acid Glutamine	aldehvde.	ester	ether	cvario		furan	bromine	chlorine
Gluconic Acid Glucosamine Glucosamine Glucuronic acid Glucuronic acid Glucuronic acid Glutamic Acid Glutamine	metals	aldehvde	Γ	ether	cyano		furan	bromine
Gluconic Acid Glucosamine Glucoronic acid Glucuronic acid Glucuronic acid Glutamic Acid Glutamine	metals	aldehyde	Γ	ether	cyano		furan	bromine ·
Glucosamine Glucosamine Glucuronic acid Glucuronic acid Glutamic Acid Glutamine Acid	metals	aldehyde		ether	cyano		furan	brominė
Glucuronic acid Glucuronic acid Glucuronic acid Glutamic Acid Glutamic Acid Glutamine Acid	metals	aldehyde		ether	cyano		furan	bromine
Glucuronic acid Glucuronic acid Glutamic Acid Glutamic Acid Glutamine	etals	aldehyde	1	ether	cyano		furan	bromine
Glucuronic acid Glutamic Acid Glutamic Acid Glutamine	epvye	ester].	cyano		furan	bromine	chlorine
Glutamic Acid Glutamic Acid Glutamine	etals	aldehyde		ether	cyano		furan	bromine
Glutamic Acid Glutamine	metals	aldehyde		ether .:	cyano		furan	bromine
Glutamine	metals	aldehyde	Γ	ether	cyano		furan	bromine
	metals	aldehyde		ether	cyano		furan	bromine
Clutamine	metals	aldehyde	Γ	ether .	cyano		furan	bromine
Chitamine	metals	aldehyde	Γ	ether	cyano		furan	bromine
Clutario Acid.	metals	aldehyde	Γ	ether	cyano		furan	bromine
Christo	metals	aldehvde		ether	cyano	•	furan	bromine
Glycine	metals	aldehyde		ether .	cyano		furan	bromine
Givenie Acid	metals	aldehyde	ŀ	ether	cyano		furan	bromine
Glycolic Acid	metals	aldehyde	ester	ether	cyano		furan	bromine
Hippuric Acid	metals	aldehyde	ester	ether	cyano.		furan	bromine
Hippuric Acid	metals	aldehyde	ester	ether	cyano		füran	bromine
Hipping Acid	metals	aldehyde	ester	ether	cyano		furan .	bromine
Histidine	metals	aldehyde		ether .	cyano	٠. ا	furan	bromine
Histidine	metals	aldehyde	ester	ether ·	cyano	·	furan	promine
		phosphinic				·		•
		acid	•					
		hemihydrat			(P)(X())	objud	fluorine	sulfonate ester
Histidine	amine	Ī	2	Sulidiny	SUIIONING	Spilling	furan	bromine
Hydroquinone	metals		Т	emer	cyano .	Oruboto	phoenhata	phosphonic acid
Hydroquinone	fluorine			Ketone	SUITOTHIC ACIO	online.	furan	hromine
Imidazole	metals	$\cdot \top$		erner	Cyallo		3	heterocyclic-S
Ipriflavone	bromine	aldenyde	٥	peroxide	epuvide		- tiron	hromine
Ipriflavone	metals	: 1		ether	суапо		iniaii firon	bromine
Isoleucine	metals	aldehyde	ester .	ether	cyano		Turan	Digital 19

- Indiana in the second of the		٠	·			
Co-crystal rormer					citer concept at	Catoro
Gentisic acid	chlorine	s-neterocyclic	pyridine	cyano	n-neterocyclic	Ketone .
Gentisic acid	carbóxylic acid	nitro	sultone	analine		
Glucamine, N-methyl	s-heterocyclic	pyridine	· cyano	n-heterocyclic	. ketone	phosphate ester
Glucamine, N-methyl	chlorine	s-heterocyclic ·	pyridine	cyano	n-heterocyclic	ketone
Gluconic Acid	chlorine	s-heterocyclic	pyridine	cyano.	n-heterocyclic.	кетопе .
Gluconic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glucosamine	chlorine .	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glucuronic acid ·	chlorine .	s-heterocyclic	pyridine	cyano	- n-heterocyclic	ketone
Glucuronic ácid	:s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester
Glucuronic acid	chlorine	s-heterocyclic	pyridine	cyano .	n-heterocyclic	ketone
Glutamic Acid .	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone .
Glutamic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone .
Glutamine · ·	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glutamine	chlorine	s-heterocyclic	pyridine	cyano · · ·	n-heterocyclic	ketone
Glutamine	chlorine	s-heterocyclic.	pyridinė	cyano	n-heterocyclic	ketone
Glutaric Acid	chlorine · ·	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glycine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone .
Glycine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glycolic Acid	chlorine ·	s-heterocyclic	pyrldine.	cyano	n-heterocyclic	ketone
Glycolic Acid	chlorine	s-heterocyclic	pyridine	cyano .	n-heterocyclic	ketone
Hippuric Acid	chlorine .	s-heterocyclic	pyridinė	cyano:	n-heterocyclic -	ketone
Hippuric Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Hippuric Acid	chlorine	s-heterocyclic	pyridine	cyano .	n-heterocyclic	ketonė
Histidine	chlorine .	s-heterocyclic ·	pyridine .	суапо.	n-heterocyclic	ketone
Histidine	chlorine	s-heterocyclic	pyridine	cyano -	n-heterocyclic	ketone
						•
Histidine	•	•	٠.			
Hydroquinone	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Hydroquinone	carboxylic acid	nitro	sülfone	analine		•
lmidazole .	chlorine	s-heterocyclic	pỳridine	cyano ·	ocyclic	ketone
Ipriflavone	iodine	ester	ether	carboxylic acid	sulfate	sulfone
Іргія	chlorine	s-heterocyclic.	pyridine	cyano	n-heterocyclic	ketone
Isoleucine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone

- Company of Course				· :·			•	
Contists and	nhosnhate ester		fluorine	carbamate	imidazole	BF4		-
Continuo con di	ממס משוולסוול							
Genusic acid .		- Ociocula	. carbamata	imidazole	BF4			
Glucamine, N-memyl	phoenhate actor	HIGORILO	fluoring	carbamate	imidazole	BF4		
Chicopic Acid.	phosphate ester		fluorine	carbamate	imidazole	BF4 ·	_	
Glaconic Acid	phosphate ester		fluorine	carbamate	imidazole	BF4		
Glicosamine	phosphate ester		fluorine	carbamate :	imidazole	BF4		
Glicironic acid	phosphate ester		fluorine	carbamate	Imidazole	BF4	·	_
Glicuronic acid		fluorine	carbamate	imidazole	BF4			
Glucuronic acid	phosphate ester	·	fluorine	carbamate	imidazole	BF4 ··	alkane	aromatic
Glutamic Acid	phosphate ester.		fluorine	carbamate	imidazole .	BF4		
Glutamic Acid	phosphate ester.		fluorine	carbamate	imidazole	BF4		-
Glutamine	phosphate ester		fluorine	carbamate	imidazole	BF4		
Glutamine	phosphate ester		fluorine	carbamate	imidazole	BF4		
Glutamine	phosphate ester		fluorine	carbamate	imidazole	BF4		
Glutaric Acid	phosphate ester		fluorine	carbamate	imidazole	BF4		
Glycine	phosphate ester	-	fluorine	carbamate	imidazole	BF4		
Glycine	phosphate ester		fluorine	carbamate	imidazole	BF4		
Glycolic Acid	phósphate ester		fluorine	carbamate	imidazole	BF4	.	
Glycolic Acid	phosphate ester	·	fluorine	carbamate	imidazole	BF4		
Hippuric Acid	phosphate ester		fluorine .	carbamate	imidazole	BF4		
Hippuric Acid	phosphate ester		fluorine ·	carbamate	imidazole	BF4		
Hippuric Acid	phosphate ester		fluorine	carbamate	imidazole	BF4		
Histidine	phosphate ester		fluorine	carbamate	imidazole	BF4		-
Histidine	phosphate ester		fluorine	carbamate	imidazole	BF4		Ť
						·		
		•		· .	————————————————————————————————————			· ·
		•:					·	
Histidine						į		
Hydroquinone	phosphate ester		fluorine	carbamate	imidazole	874		
Hydroguinone						.		
Imidazole	phosphate ester		fluorine	carbamate	imidazole	974		
Ipriflavone		alcohol		phospphate	cyanamide	ì		ŀ
Ipriflavone	phosphate ester		fluorine	carbamate	Imidazole	874		
Isoleucine	phosphate ester		fluorine	carbamate	imidazole	B-4 ·		
						,		•

Co-crystal Former. Gentisic acid Gentisic acid Glucamine, N-methyl Glucamine, N-methyl Gluconic Acid Glucosamine Glucoronic acid Glucuronic acid Glucuronic acid Glucuronic acid Glutamic Acid Glutamic Acid	N-SO2 N-SO2 N-SO2 N-SO2 N-SO2 N-SO2 N-SO2	thiourea	iodine		
Co-crystal Former Gentisic acid Gentisic acid Glucamine, N-methyl Glucamine, N-methyl Gluconic Acid Glucosamine Glucuronic acid Glucuronic acid Glucuronic acid Glutamic Acid Glutamic Acid	N-SO2 N-SO2 N-SO2 N-SO2 N-SO2 N-SO2	thiourea	euipoi		
Gentisic acid Gentisic acid Glucamine, N-methyl Glucamine, N-methyl Gluconic Acid Glucosamine Glucuronic acid Glucuronic acid Glucuronic acid Glutamic Acid Glutamine	N-SO2 N-SO2 N-SO2 N-SO2 N-SO2 N-SO2	thiourea	logine		
Gentisic acid Glucamine, N-methyl Glucamine, N-methyl Gluconic Acid Glucosamine Glucuronic acid Glucuronic acid Glucuronic acid Glutamic Acid Glutamic Acid	N-SO2 N-SO2 N-SO2 N-SO2 N-SO2				
Glucamine, N-methyl Glucamine, N-methyl Gluconic Acid Glucosamine Glucuronic acid Glucuronic acid Glucuronic acid Glutamic Acid Glutamic Acid Glutamine	N-SO2 N-SO2 N-SO2 N-SO2 N-SO2				
Glucamine, N-methyl Gluconic Acid Glucosamine Glucuronic acid Glucuronic acid Glucuronic acid Glutamic Acid Glutamine Glutamine	N-SO2 N-SO2 N-SO2 N-SO2 N-SO2				
Gluconic Acid Glucosamine Glucosamine Glucuronic acid Glucuronic acid Glucuronic acid Glutamic Acid Glutamine	N-SO2 N-SO2 N-SO2 N-SO2	thiourea	iodine		
Gluconic Acid Glucosamine Glucuronic acid Glucuronic acid Glucuronic acid Glutamic Acid Glutamine	N-SO2 N-SO2 N-SO2	thiourea	iodine	epoxide	
Glucosamine Glucuronic acid Glucuronic acid Glucuronic acid Glutamic Acid Glutamic Acid Glutamine	N-SO2 N-SO2	thiourea	lodine	·	
Glucuronic acid Glucuronic acid Glucuronic acid Glutamlc Acid Glutamic Acid Glutamine	N-S02	thiourea	iodine	epoxide	
Glucuronic acid Glucuronic acid Glutamlc Acid Glutamic Acid Glutamine		thionrea	iodine		
Glucuronic acid Glutamic Acid Glutamic Acid Glutamine					
Glutamic Acid Glutamic Acid Glutamine	N-SO2	. thiourea	iodine	epoxide	
Glutamic Acid Glutamine Glutamine	N-SO2	thiourea.	lodine		
Glutamine	N-SO2	thiourea	iodine		
Glittamine	N-SO2	: thiourea	odine		
	N-SO2	thiourea.	iodine.	epixode	peroxide
Glutamine	N-SO2	thiourea	euipoi.		
Glutaric Acid	N-SO2	thiourea	lodine		
Glycine	N-SO2	thiourea	iodine	٠	
Glycine	N-SO2	thiourea	iodine		
Glycolic Acid	N-SO2	thiourea	iodine	epoxide	
Glycolic Acid	N-SO2	thiourea	iodine		
Hippuric Acid	N-SO2	thiourea	iodine	epoxide	peroxide
Hippuric Acid	N-SO2	thiourea	iodine		
Hippuric Acid	N-SO2	thionrea	iodine	-	
Histidine	N-SO2	thiourea	lodine		
Histidine	N-SO2	thiourea	iodine		
	•	• •			
•	•		•		•
		,			•
al individual	COSIN	thiourea	indine	enoxide	
nydrodulione Lidden ingen	300-1				
ei inilinhoinkei	000	. Councids	Solino		
Imidazole	N-SOS	monea			
Ipriflavone				-	
Iprifiavone	N-SO2:		$\overline{}$		
Isoleucine	N-SO2	thiourea	iodine	:	

stal Former Functional Group Interacting Group Retone Thiol amide nic acid Carboxylic Acid alcohol ketone thiol amide nic acid Ether alcohol ketone thiol amide nic acid Ether alcohol ketone thiol amide dato Carboxylic Acid alcohol ketone thiol amide <t< th=""><th></th><th>Co-crystal Former</th><th></th><th></th><th></th><th></th><th></th><th></th></t<>		Co-crystal Former						
acid Carboxylic Acid alcohol ketone thiol amide acid alcohol ketone thiol amide acid alcohol ketone thiol amide acid Carboxylic Acid alcohol ketone thiol amide amide acid Carboxylic Acid alcohol ketone thiol amide amide Amine alcohol ketone thiol amide amide alcohol ketone thiol amide acid Carboxylic Acid alcohol ketone thiol amide acid Amine alcohol ketone thiol amide acid Amine alcohol ketone thiol amide alcohol ketone t	Co-crystal Former	Functional Group	Interacting	Group				
acid carboxylic Acid alcohol ketone thiol amide acid alcohol alcohol ketone thiol amide amide acid carboxylic Acid alcohol ketone thiol amide amide Anine accord carboxylic Acid alcohol ketone thiol amide amide alcohol ketone thiol amide alcohol alcohol alcohol alcohol alcohol alcohol alcohol al	Isoleucine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine
acid alcohol, alcohol ketone ithiol amide aromatica. Ether aromatic-N amide thiol amide aromatica. Carboxylir Acid alcohol ketone thiol amide amide alcohol ketone thiol amide alcohol alcohol ketone thiol amide alcohol alcohol ketone thiol amide alcohol alcohol alcohol alcohol alc	lactobionic acid	Carboxylic Acid	alcohol	ketone	thiol	amidė	amine	analine
acid Carboxylic Acid alcohol ketone thiol amride amride alcohol ketone thiol amride amride alcohol ketone thiol amride amride Amrine alcohol ketone thiol amride amride alcohol ketone thiol amride alcohol alcohol ketone thiol amride alcohol ketone thiol	Lactobionic acid	alcohol	alcohol	ketone	thiol .	amide	amine	analine
Carboxylic Acid alcohol ketone thiol amide Amine alcohol ketone thiol amide Amine alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide Alcohol alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide Alcohol alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide Alcohol alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide Amine Amine alcohol ketone thiol amide	Lactobionic acid	Ether	aromatic-N		amine .	aromatic_s	Sp2 amine	sulfoxide
Carboxylic Acid alcohol ketone thiol amide amide Alcohol Alcohol alcohol ketone thiol amide amide Alcohol Alcohol alcohol ketone thiol amide alcohol ketone thiol amide alcohol ketone thiol amide amide alcohol alcohol ketone thiol amide amide alcohol alcohol alcohol alcohol alcoho	Lauric acid	Carboxylic Acid	alcohol	ketone	thiol .	amide	amine ·	analine
Annine Annine alcohol ketone thiol amide	Leucine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine
Arnine	Leucine	Amine	alcohol	ketone	thiol	amide	amine.	analine.
Carboxylic Acid alcohol ketone thiol amide Id Alcohol alcohol ketone thiol amide Id Alcohol alcohol ketone thiol amide Id Alcohol alcohol ketone thiol amide Id Amine alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide Ibhenol alcohol ketone thiol amide Icachoxylic Acid alcohol ketone thiol amide Ibhenol amine amide sullobol ketone thiol amide Icachoxylic Acid alcohol amide Icachoxylic Acid alcohol Acid alcohol ketone thiol	Lysine	Amine	alcohoi	ketone	thiol	amide	amine -··	analine
Carboxylic Acid alcohol ketone thiol amide Alcohol Amide Alcohol Amide Alcohol Alcohol Amide Alcohol Alcohol Amide Alcohol Alcohol Amide Alcohol Alcohol Alcohol Alcohol Alcohol Amide Alcohol Allohol Alcohol Alc	Lysine	Carboxylic Acid :	alcohol	ketone	(thiol	amide	amine	analine
Alcohol alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide Amine Carboxylic Acid alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide Pyridine alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide Amine alcohol ketone thiol amide	Maleic	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine
Carboxylic Acid alcohol ketone thiol amide amide alcohol alcohol ketone thiol amide alcohol alcohol alcohol alcohol ketone thiol amide alcohol alcohol alcohol alcohol ketone thiol amide alcohol al	Malic Acid	Alcohol :	alcohol	ketone	thiol	amide .	amine .	analine
Carboxylic Acid Alcohol Ketone thiol amide	Malic Acid.	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine
id Alcohol alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide Thioether	Malonic	Carboxylic Acid	alcohol	ketone	thiol .	amide	amine .	analine
id Carboxylic Acid alcohol ketone thiol amide Garboxylic Acid alcohol ketone thiol amide Garboxylic Acid alcohol ketone thiol amide e Pyridine alcohol ketone thiol amide d. Carboxylic Acid alcohol ketone thiol amide d. Carboxylic Acid alcohol ketone thiol amide	Mandelic Acid	Alcohol	alcohol	ketone ·	thiol	. amide	amine :	analine ·
Amine Amine alcohol ketone thiol amide	Mandelic Acid	Carboxylic Acid ·	alcohol	ketone ·	thiol	amide	amine	analine
e Pyridine "alcohol ketone thiol amide amide and Earboxylic Acid alcohol ketone thiol amide amide alcohol ketone thiol amide alcohol alcohol ketone thiol amide amide amide alcohol ketone thiol amide amide amide alcohol ketone thiol amide amide amide alcohol alcohol ketone thiol amide amide amide amide amide amide amide alcohol alcohol amide	Methionine	Amine	alcohol	ketone	thiol .	amide	amine	analine
e Pyridine *alcohol ketone thiol amide d Carboxylic Acid alcohol ketone thiol amide c Carboxylic Acid alcohol ketone thiol amide alcohol amine amide sulfoxide n Amine alcohol ketone thiol amide	Methionine ·	Carboxylic Acid	alcohol	ketone .	thiol	amide.	amine	analine
Pyridine *alcohol ketone thiol amide alcohol ketone thiol amide amide alcohol ketone thiol amide amide carboxylic Acid alcohol ketone thiol amide alcohol carboxylic Acid alcohol ketone thiol amide carboxylic Acid alcohol ketone thiol amide alcohol alcohol ketone thiol amide alcohol alcohol ketone thiol amide alcohol amide alcohol ketone thiol amide	Methionine	Thioether	Z-	amide	amine	· s_	Sp2 amine	sulfoxide
Amide alcohol ketone thiol amide amide alcohol amide alcohol ketone thiol amide alcohol ketone thiol amide alcohol amide alcohol ketone thiol amide amide alcohol ketone thiol amide amide alcohol ketone thiol amide		C	, lodoolo*			*amida		anima anima
alcohol ketone thiol amide d. Carboxylic Acid alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide alcohol alcohol ketone thiol amide alcohol alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide alcohol alcohol ketone thiol amide carboxylic Acid alcohol ketone thiol amide alcohol ketone thiol amide Amine alcohol ketone thiol amide Amine alcohol ketone thiol amide	ואוכסוווימוויותב	ryildiile .	alcollol .					2
d. Carboxylic Acid alcohol ketone thiol amide alcohol alcohol ketone thiol amide alcohol amide amide Carboxylic Acid alcohol ketone thiol amide Amine alcohol ketone thiol amide alcohol ketone thiol amide Amine alcohol ketone thiol amide Amine alcohol ketone thiol amide Amine alcohol ketone thiol amide	Nicotinamide	: Amide	alcohol	ketone	thiol	amide	amine .	analine
to Carboxylic Acid alcohol ketone thiol amide amide Carboxylic Acid alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide alcohol carboxylic Acid alcohol ketone thiol amide alcohol alcohol ketone thiol amide alcohol alcohol ketone thiol amide alcohol amide alcohol amide alcohol amide alcohol ketone thiol amide	Nicotinic Acid.	Carboxylic Acid	alcohol	ketone .	thiol	amide	amine	analine
Pyridine								
Carboxylic Acid alcohol ketone thiol amide Lactam alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide alcohol alcohol ketone thiol amide alcohol alcohol ketone thiol amide alcohol amine amine sulfoxide n Amine alcohol ketone thiol amide alcohol amide sulfoxide amide alcohol ketone thiol amide alcohol ketone thiol amide alcohol ketone thiol amide alcohol ketone thiol amide	Nicotinic Acid	Pyridine	*alcohol	j	*	*amide	nitro	*amine
Lactam alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide alcohol alcohol amine amide sulfoxide n Amine alcohol ketone thiol amide e Amine alcohol ketone thiol amide	Orotic acid	Carboxylic Acid	alcohol	ketone	thiol .	amide	amine	analine
Carboxylic Acid alcohol ketone thiol amide Carboxylic Acid alcohol ketone thiol amide alcohol alcohol amine thiol amide alcohol amine alcohol ketone thiol amide Amine alcohol ketone thiol amide alcohol ketone thiol amide Amine alcohol ketone thiol amide Amine alcohol ketone thiol amide Amine alcohol ketone thiol amide	Orotic acid .	Lactam	alcohol	ketone	thiol	amide	amine	analine
Carboxylic Acid alcohol ketone thiol amide alcohol alcohol ketone thiol amide alcohol alcohol ketone thiol amide phenol amine amide sulfoxide nalcohol ketone thiol amide amide alcohol ketone thiol amide amide Amine alcohol ketone thiol amide amide alcohol ketone thiol amide	Oxalic acid	Carboxylic Acid	alcohol	ketone ·	thiol	amide		analine
Carbòxylic Acid alcohol ketone thiol amide alcohol amine amide n Phenol amine amide n e Amine alcohol ketone thiol amide e Carboxylic Acid alcohol ketone thiol amide Amine alcohol ketone thiol amide	Palmitic acid	Carboxylic Acid .	alcohol .	ketone	thiol .	amide		analine
alcohol alcohol ketone thiol amide Phenol amine amide sulfoxide n alcohol ketone thiol amide Amine alcohol ketone thiol amide	Pamolc acid	Carboxylic Acid	alcohol	ketone	thiol			analine
e Amine amide sulfoxide n alcohol ketone thiol amide e Carboxylic Acid alcohol ketone thiol amide amide Amine alcohol ketone thiol amide	Pamoic acid	alcohol	alcohol	ketone	thiol			analine
anine Amine alcohol ketone thiol amide anine Carboxylic Acid alcohol ketone thiol amide alcohol ketone thiol amide	Pamolc acid			amide	sulfoxide	·		cyano
anine Carboxylic Acid alcohol ketone thiol amide le Amine alcohol ketone thiol amide	Phenylalanine	Amine	alcohol	ketone	thiol	amide.		analine .
le Amine alcohol ketone thiol amide	Phenylalanine	Carboxylic Acid	alcohol	ketone	thiol			analine
	Piperazine	Amine	alcohol	ketone	thiol			analine
Amine alconol ketone trilol amide	Procaine	Amine	alcohol	ketone .	thiol	amide	amine	analine

÷

•					·				Г
Co-cristal Former	•			·. :		:			
. Isolaticina	openol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	_
ליס הייסיוליקיסין	lonedo	phoenhate	cultate	Stilfone	nitrate	pvridine		carboxilic acid	
י בייסי וייסיולסייסי י	lonedic	phosphate	Sulfate	Sulfone	nitrate	pyridine	carboxilic acid	metals	Т
Lactobionic acid	chlorate	chlorine	·	cvano	ester	amine	nitro	nitrate	
	phenol	bhosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	-
Laucine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	
Leucine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	٠	carboxilic acid	
Lysine	phenol	phosphate	sulfate	sulfone.	nitrate	pyridine		carboxilic acid	
Lysine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	, 1
Maleic	phenol	phosphate	sulfate	sulfone	nitrațe .	pyridine		carboxilic acid	
Malic Acid	lohenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	_
Malic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	-7
Malonic	phenol	phosphate	sulfate ·	sulfone	nitrate	pyridine		carboxilic acid.	''
Mandelic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	÷
Mandelic Acid	phenol	phosphate	sulfate	sultone	nitrate	pyridine		carboxilic acid	. :1
Methionine	phenal .	phosphate	sulfate .	sulfone	nitrate	pyridine		carboxilic acid	• 1
Methionine	phenol	phosphate	sulfate.	sulfone	nitrate	pyridine	-	carboxilic acld	7
Methionine	chlorate	chlorine		cyano	ester	amine	nitro	nitrate	7
	*Carboxylic			:		•			_
Nicotinamide	Acid	*sulfonamide	*ketone.	ether	triazole ·		ammonium .	oxime	न
Nicotinamide	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid	
Nicotinic Acid	phenol	phosphate	sulfate	sülfone.	nitrate	pyridine		Carboxylic Acid	•
	*Carboxylic			•					÷
Nicotinic Acid	Acid	*sulfonamide	*ketone	ether	triazole		ammonium	oxime	· 1
Orotic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	÷
Orotic acid	phenol	phosphate	sulfate	sulfone	nitrate .	pyridine		Carboxylic Acid	_
Oxalic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	
Palmitic acid	phenol	phosphate .	sulfate	sultone	nitrate	pyridine		carboxilic acid	_
	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	
	phenol	phosphate	sulfate	sultone	nitrate	<u>9</u>	carboxilic acid	metals	
	aldehyde		alchohol		ester		n-oxide	chlorine	
Phenylalanine	phenol	phosphate	sulfate	sulfone .	nitrate ·	pyridine		carboxilic acid	
Phenylalanine ·	phenol	phosphate	sulfate	sulfone	nitrate .	pyridine		carboxilic acid	- , , ,
Piperazine	phenol	phosphate	sulfate	sulfone	nitrate .	pyridine		carboxilic acid	_
Procaine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid	+-
		•			•		•		

3							· · .	
Co-crystal Former	2	- Spiralopia	0000	other	Cyano		furan	bromine
Isoleucine	metals	alderiyde	12162		cyano		furan	bromine
lactobionic acid	metals	aldenyde	ester	emer	cyano.		hromina	chlorine
Lactoblonic acid	aldehyde	ester	ether	cyano		Iulari	SHIRINGIA	heterocyclic-S
Lactobionic acid	- bromine	aldehyde	ketone	peroxide	ebixode			handing .
Lauric acid		aldehyde .	ester	ether	cyano		ruran	Droume .
. I eucine	metals	aldehyde	ester	ether	cyano		ruran	Dromine
I plicing	metals	aldehyde	ester	ether	суапо	•	furan	promine
l veine	metals	aldehyde	ester	ether	cyano		furan	bromine
Lyano	metals	aldehvde	ester	ether	cyano		furan	promine.
Lysii id	motals	aldehyde	ester	ether	cyano		furan	bromine
Maleic Marie Asia	metale	aldehyde	ester	ether	cyano .		furan	bromine
IMAIIC ACID	motele	aldehyde	ester	ether	cvano		furan	bromine
Mailc Acid	motolo	aldehide	pater	ether	CVano		furan	bromine
Majonic	motolò	aldohida aldohida	peter	ather	cvano		furan.	bromine ·
	IIICIAIS	alden yes	2000	othor	Cyano		furan	bromine
· Mandelic Acid.	metals	aldenyde	ester	ether	cyallo	-	furan.	hromine .
Methionine	metals	aldehyde	ester		cyano		idial i	promino
Methionine	metals	aldehyde	ester		cyano		Turarı	DIOINING
-	bromine.	aldehyde	ketone.	peroxide	epoxide	Ag	Se	neterocyclic-5
				n-heterocyclic .		•		. (
Nicotinamide	*chlorine		thiol	ring	thionedisulfide pyrrolidindione		iodine.	nydrazorie
	metals	aldehyde	ester	ether	cyano		turan	promine
	metals	aldehyde ·	ester ·	ether	cyano		turan .	Dromine
				n-heterocyclic			:	
- Nicotinic Acid			thiol	ring	thionedisulfide pyrrolidindione		iodine	nydrazone
Orotic acid		aldehyde	ester .	ether	cyano		ruran	profilire
Orotic acid	metals	aldehyde	ester	ether:	cyano 🗀 ,		furan	promine
Oxalic acid		aldehyde	ester	ether	cyano		turan	Dromine
Delmitic acid] 	aldehyde	ester	ether	cyano		furan	Dromine
Damoic acid		aldehyde	ester	ether	cyano.		furan	bromine.
Damoic acid	aldehvde	ester		cyano		furan	bromine	chlorine.
Demoir acid	fluorine	bromine	iodine	ketone ·	sulfonic acid	sulfate.	phosphate	phosphonic acid
Deportationing	metals	٦	ester	ether	cyano		furan	bromine .
Desirelation	metals	1.	ester		cyano		furan	bromine
DIM	metals	aldehyde	ester		суало	·	furan ,	bromine ·
<u>a</u>	metals	aldehyde	ester		cyano		furan	bromine
Procaine	Ingrais	diverized.						

Co-crystal Former			•			••
Isoleucine	chlorine	-s-heterocyclic	pyrldine	cyano	In-heterocyclic	ketone
lactobionic acid	. chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Lactobionic acid	s-heterocyclic	pyridine	cyano.	in-heterocyclic	ketone ·	phosphate ester
Lactobionic acid	iodine	ester	ether	carboxylic acid	sulfate	sulfone
Lauric acid	chlorine .	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
reincine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Leucine	Chlorine	s-heterocyclic	pyridine	cyano .	n-heterocyclic	ketone
Lysine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Lysine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Maleic	. chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Malic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Malic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone ·
Malonic	chlorine	s-heterocyclic	pyridine	cyano ·	n-heterocyclic	ketone ·
Mandelic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Mandelic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Methionine	. chlorine .	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Methionine	chlorine	s-heterocyclic	pyridine:	cyano	n-heterocyclic	ketone .
Methionine	iodine	ester	ether	carboxylic acid	sulfate ·	sulfone
Nicotinamide	thiocyanate	*bromine	:	hydroxamic acid	cyano	carboxamide
Nicotinamide	chlorine	s-heterocyclic ·	pyridine	cyano	n-heterocyclic	ketone .
Nicotinic Acid	. chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone.
Nicotinic Acid	thiocvariate	*bromine		hydroxamic acid	cvano	carboxamide
Orotic acid	chlorine	s-heterocyclic ·	pyridine	cyano	n-heterocyclic	ketone .
Orotic acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone .
Oxalic acid	chlorine	s-heterocyclic.	pyridine	cyano	n-heterocyclic	Ketone
Palmitic acid	. chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Pamoic acid .	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic.	ketone .
Pamoic acid	s-heterocyclic	pyridine .	cyano	n-heterocyclic	ketone ·	phosphate ester
Pamoic acid	carboxylic acid	nitro	sulfone	analine		
Phenylalanine	chlorine	s-heterocyclic ·	pyridine .	cyano	n-heterocyclic	ketone
Phenylalanine .	chlorine	s-heterocyclic		cyano .	n-heterocyclic	ketone
Piperazine	chlorine	s-heterocyclic	-	cyano .	n-heterocyclic	ketone
Proceine	chloring	s-heterocyclic	nvridine	cvano	n-heterocyclic	ketone

						-		
	:	`	· .					
Co-crystal Former		-						
Soleucine	phosphate ester		fluorine	carbamate	IMIGAZOIB	BF4		
lactobionic acid	phosphate ester		fluorine	carbamate	imidazole	BF4		
Lactobionic acid		fluorine ·	carbamate	·imidazole·	BF4	•		
L'actobionic acid		alcohol .		phospphate	cyanamide			
· Lauric acid	phosphate ester		fluorine	carbamate ·	imidazole	BF4		
Leucine	phosphate ester		fluorine	carbamate	imidazole	BF4		
Leucine	phosphate ester -		fluorine	carbamate	imidazole	BF4		
· · · · euisy	phosphate ester		fluorine	carbamate	imidazole	BF4	;	
l vsina	phosphate ester		fluorine	carbamate	imidazole	BF4		
Maleic	phosphate ester		fluorine	carbamaté:	imidazole	-BF4		
Malic Acid	phosphate ester		fluorine	carbamate	imidazole	BF4		
Malic Acid	phosphate ester		fluorine	carbamate	imidazole	BF4		
Majoric	phosphate ester		fluorine	carbamate:	imidazole	·BF4		
Mandelic Acid	ohosohate ester		fluorine	carbamate	imidazole	BF4		
Mandelle Acid	phosphate ester		fluorine	carbamate	imidazole	BF4		
Methionine	phosphate ester		fluorine	carbamate	imidazole	BF4	-	•
Methionine	phosphate ester		fluorine	carbamate	imidazole	BF4		
Methionine		alcohol		phospphate .				7.
					•			
Nicotinamide	*sulfonic acid	*phosphoric acid N-oxide	N-oxide	ester	ether	fluorine	acetate thione	thione
Nicotinamide	phosphate ester		fluorine	carbamate	limidazole	.BF4		
Nicotinic Acid	phosphate ester		fluorine .	carbamate	imidazole	BF4		
			•					
Nicotinic Acid	*sulfonic acid	*phosphoric acid	N-oxide	ester	ether	fluorine	acetate	thione
Orotic acid	phosphate ester		fluorine	carbamate	imidazole	BF4		
Orotic acid .	phosphate ester		fluorine	carbamate	imidazole	BF4		
Oxalic acid	phosphate ester	•	fluorine	carbamate	imidazole:	BF4		
Palmitic acid	phosphate ester		fluorine	carbamate	imidazole	BF4	·	·
Pamoic acid	phosphate ester		fluorine	carbamate	imidazole	BF4		
Pamoic acid	1	fluorine	carbamaté	imidazole	BF4			
Pamoic acid .							,	
Phenylalanine	phosphate ester	•	fluorine	carbamate	imidazole	BF4		
Phenylalanine	phosphate ester		fluorine	çarbamate	imidazole	BF4		
Piperazine	phosphate ester		fluorine ·	carbamate	imidazole	8-4		1
Procaine	phosphate ester		fluorine	carbamate	imidazole :	BF4		
							•	

				•	
Co-covetal Former			•		
Isoleucine	N-S02	thiourea	iodine		
lactobionic acid	N-S02	thiourea	iodine		-
Lactobionic acid					
Lactobionic acid.					
Lauric acid	N-SO2	thiourea	lodine.		
Leucine	N-SO2	thiourea	iodine	•	
Leucine	N-SO2.	thiourea	iodine		
Lysine	N-SO2	thionrea	iodine		
Lysine	N-SO2	thiourea	iodine		
Maleic	N-SO2	thiourea	iodine		
Malic Acid	N-SO2	thiourea	iodine	epixode	
Malic Acid	N-SO2	thiourea	iodine		
Malonic	N-S02	thiourea	iodine		
Mandelic Acid	N-SO2	thiourea	iodine	epixode	
Mandelic Acid	N-SO2	thiourea	iodine		
Methionine	N-SO2	thiourea	iodine	:	
Methionine	N-SO2	thiourea	iodine.		•
Methionine					
Nicotinamide	dithiadiazocyclopentadienyl	·		:	
Nicotinamide	N-S02	thiourea	iodine	epoxide	epoxide peroxide
Nicotinic Acid	N-S02	thiourea	iodine		
Nicotinic Acid	dithiadiazocyclopentadienyl			•	
Orotic acid	N-SO2	thiourea	iodine		
Orotic acid	N-SO2	thionrea	iodine	epixode	peroxide
Oxalic acid	N-SO2	thiourea	lodine		
Palmitic acid	N-SO2	thiourea	iodine		
Pamoic acid	N-S02	thionrea	iodine		
Pamoic acid					
Pamolc acid .			,		
Phenylalanine		thiourea	eupo.		
Phenylalanine	N-SO2	thionrea	iodine		
Piperazine ·	N-SO2	thiourea	iodine		
Procaine	N-SO2	thionrea	iodine		_

	Co concetal Ecomos	-].
			-				•
Co-crystal Former	Functional Group	Interacting Group	Group		•		•
Procaine	Ketone	alcohol.		thiol	amide	amine	analine
Proline	Carboxylic Acid ·	alcohol	ketone ·	thiol	amide	amine	analine
Proline	Amine .	. alcohoi	ketone	thiol	· amide	amine	analine
					٠.	٠.	
p-Toluenesulfonic acid	Sulfonic Acid	pyridine	ketorie	aldehyde	ether	ester	amide
- Pyridoxamine	Alcohol	alcohol .	ketone	thiol	amide	amine	analine
Pyridoxamine	- Amine	alcohol.	ketone	thiol	amide	amine	analine
Pyridoxamine	Pyridine	*alcohol			*amide	nitro	*amine
Pyridoxine			:				
(4-Pyridoxic Acid)	Pyridine ·	*alcohol	pyridinium	•	*amide	nitro	*amine
Pyridoxine	* .						
(4-Pyridoxic Acid)	Alcohol	alcohol	ketone	thiol	amide	amine	analine
Pyroglutamic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine .
Pyroglutamic acid	Lactam	alcohol	ketone	thiol	amide	amine	analine
. Quercetin	Ketone	alcohol·		thiol	amide	amine	analine
Quercetin	Phenol	amine	amide .	sulfoxide	. u	pyridine	cyano
Quercetin	Ether	aromatic-N	amide :	amine ·	aromatic_s	Sp2 amine	sulfoxide
Resveratrol	Ketone	alcohol		thiol	amide	amine	analine
Resveratrol .	Phenol	amine	amide.	sulfoxide	n .	pyridine	cyano
Saccharin	Amide	alcohol	ketone .	thiol	amide	amine	analine
Saccharin	Ketone · ·	alcohol .		thiói	amide	amine	analine
Section	Stilfoxide	ouipino.	Votone	·	other	·	omino
Saccharin	Amine	alcohol	ketone	thiol	amide		analine
Salicylic Acid	Carboxylic Acid	alcohol		thiol	amide	amine	analine
Salicylic Acid .	Alcohol	alcohol	ketone	thiol	amide	amine	analine ·
Salicylic Acid, 4-amino	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine
Salicylic. Acid, 4-amino	alcohol	alcohol	ketorie	thiol	amide .	amine	analine
Salicylic Acid, 4-amino	Amine	alcohol	ketone .	thiol	amide	amine	analine
Sebacic acid	Carboxylic Acid	alcohol	ketone .	thiol	amide	amine	analine
Serine	Carboxylic Acid	alcohol	-	thiol	amide	amine	analine
Serine	Amine	alcohol	ketone	thiol	amide	amine	analine
Serine	'Alcohol .	alcohoi	ketone	thiol	amide	amine	analine
Stearic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine
							•

٠.

	,	· .	-			•		
Co-crystal Former					•1			
Procaine	phenol	-phosphate -	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Proline	phenol	phosphate	sulfate	sulfone	nitrate	pyridine.		carboxilic acid
Proline	phenoi	phosphate	sulfate	sulfone	nitrate ·	pyridine		carboxilic acid
	Carboxylic					. •	· .	
p-Toluenesulfonic acid	Acid	amine	metals.	thioether		sulfate .	alcohoi	- - -
Pyridoxamine	phenol	phosphate ·	sulfate :	sulfone	nitrate	pyridine .		Carboxylic Acid
	phenol	phosphate	sulfate	sultone:	nitrate	pyridine		carboxillc acid
	*Carboxylic		:			•		
Pyridoxamine	Acid .	*sulfonamide	*ketone	ether	triazole	•	ammonium	oxime
	*Carboxylic				· ·			
(4-Pyridoxic Acid)	Acid	*sulfonamide	*ketone	ether	triazole		ammonium	oxime
Pyridoxine						:	· ·	•
(4-Pyridoxic Acid)	phenoi	phosphate:	sulfate	sulfone.	nitrate .	pyridine		Carboxylic Acid
Pyroglutamic acid ·	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid
	phenol	phosphate	sulfate	enojins	nitrate	pyridine	•	Carboxylic Acid
Quercetin	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Quercetin	aldehyde		alchohol		ester	ether	n-oxide	chlorine
Quercetin	chlorate	chlorine		cyano	ester	amine	nitro	nitrate
Resveratrol	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Resveratrol	aldehyde		alchohol	:	ester .	ether	n-oxide	chlorine
Saccharin	phenol	phosphate	sulfate	sulfone :	nitrate ·	pyridine		Carboxylic Acid
Saccharin	phenol	phosphate	sulfate	sulfone	nitrate .	pyridine		Carboxylic Acid
	Carboxylic	-			•		•	
Saccharin	Acid	amine	metals .	thioether	•	sulfate	alcohol .	
	phenol	phosphate	sulfate ·	sulfone	nitrate:	pyridine	•	Carboxylic Acid
Salicylic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	•	carboxilic acid
Salicylic Acid	lonedq	phosphate	sulfate	sulfone	nitrate	pyridine	•	Carboxylic Acid
Salicylic Acid, 4-amino	phenol	phosphate .	sulfate	sulfone.	nitraté	pyridine		carboxilic acid
4-amino	phenol		sulfate	sulfone	nitrate		carboxilic acid	metals
Salicylic Acid, 4-amino	phenol	phosphate	sulfate	sulfone	nitrate ·	pyridine .		carboxilic acid
	phenol	phosphate	sulfate	enojins	nitrate	pyridine		carboxilic acid
Serine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	•	Carboxylic Acid
Serine	loueyd	phosphate	sulfate	enitone	nitrate	pyridine		carboxilic acid
Serine	phenol.	phosphate	sulfate	sulfone	nitrate .	pyridine		Carboxylic Acid .
Stearic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid
							•	

Procaine								
	metals	aldehyde	ester	ether	cyano		furan	bromine
Proline	· metals	aldehyde	ester	ether	cyano		furan	bromine
Proline ·	metals.	aldehydė	ester	ether	cyano		furan	bromine
: p-Toluenesulfonic acid			· 					
Pyridoxamine	metals	aldehyde	ester	ether	cyano	-	furan	bromine
Pyridoxamine	· metals	aldehyde	ester	ether	cyano		furan	bromine
			:	n-heterocyclic				
Pyridoxaminė	*chlorine		thiol	ring	thionedisulfide		jodine	hydrazone
Pyridoxine			٠.	n-heterocyclic	:			
(4-Pyridoxic Acid)	*chlorine		thiol	ring.	thionedisulfide	pyrrolidindione	iodine	hydrazone
Pyridoxine	· 							
(4-Pyridoxic Acid)	metals	aldehyde	ester	ether	cyano	·	furan	bromine
Pyroglutamic acid	metals	aldehyda	ester	ether	cyano		furan	bromine
Pyroglutamic acid	metals	aldehyde	ester	ether	cyano		furan	bromine
Quercetin	: metals.	aldehyde	ester.	ether	cyano.		furan	bromlne
Quercetin	fluorine	bromine	iodine .	ketone	sulfonic acid	sulfate	phosphate	phosphonic acid
Quercetin .	bromine	aldehyde	ketone	peroxide	epoxide	•	٠.	heterocyclic-S:
Resveratrol	metals	aldehyde	ester	ether	суапо .	٠.	furan	bromine
Resveratrol	:: fluorine	bromine	iodine -	ketone	sulfonic acid	sulfate	phosphate	phosphonic acid
Saccharin	metals.	aldehyde	ester	ether	cyano		furan .	bromine.
Saccharin	metals	aldehyde	ester	ether	cyano.		furan	bromine ·
						•		
Saccharin								
Saccharin	metals	aldehyde	ester	ether	cyano	•	furan	bromine
Salicylic Acid .	metals	aldehyde	ester	ether	cyano			bromine
Salicylic Acid	metals	aldehyde	ester	ether .	cyano.			bromine
Salicylic Acid, 4-amino	metals	aldehyde	ester	ether .	cyano		furan	bromine
Salicylic Acid, 4-amino	aldehyde	ester.	ether	cyano		furan	ne	chlorine .
Salicylic Acid, 4-amino	. metals	aldehyde	ester	ether	cyano			bromine
Sebacic acid	metals	aldehyde	ester .	ether	cyano		furan	bromine
Serine	metals	aldehyde	ester	-	cyano		furan	bromine
Serine	metals.	aldehyde	ester	ether	cyano			bromine
Serine '	metals	aldehyde	ester		суапо			bromine
Stearic acid	metals	aldehyde	ester	ether	cyano		furan	bromine

Co-crystal Former		•				
Procaine.	chlorine.	s-heterocyclic	pyridine	cyano	In-heterocyclic	ketone
Proline	chlorine ·	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Proline	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
p-Toluenesulfonic acid			·			
Pyridoxamine :	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Pyridoxamine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Pyridoxamine	thiocyanate	*bromine		hydroxamic acid	cvano	carboxamide
Pyridoxine (4-Pyridoxic Acid)	thiocyanate	*bromine		hydroxamic acid	cvano	carboxamide
Pyridoxine						
(4-Pyridoxic Acid)	chlorine	s-neterocyclic	pyridine	cyano	n-heterocyclic	ketone
Pyroglutarnic acid	Chiorine	s-neterocyclic	pyridine	cyano	n-neterocyclic	ketone
Pyrogiumic acid	chlorine	s-heterocyclic	pyridine	cyano .	n-heterocyclic	ketone
Quercetin	chiorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Quercetin	carboxylic acid	nitro	sultone	analine		
Quercetin	lodine	ester	ether	carboxylic acid	sulfate	sulfone
Hesveratrol	chlorine	s-heterocyclic	pyridine	cyano ·	n-heterocyclic	ketone
Resveratro	carboxylic acid	nitro	sultone	analine		
Saccharin	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Saccharin	chlorine	s-heterocyclic	pyridine ·	cyano	n-heterocyclic	ketone
Saccharin			· ·			
Saccharin	chlorine	s-heterocyclic.	pyridine ·	суапо.	n-heterocyclic	ketone
Salicylic Acid .	chlorine	s-heterocyclic	pyridinė	cyanó	n-heterocyclic	ketone
	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic .	ketone .
Salicylic Acid, 4-amino		s-heterocyclic.		cyano	n-heterocyclic	ketone
Salicylic Acid, 4-amino	cyclic		cyano	n-heterocyclic	ketone .	phosphate ester
Salicylic Acid, 4-amino				cyano	n-heterocyclic	ketone
Sebacic acid			\neg	cyano	n-heterocyclic	ketone
Serine		- "		cyano	n-heterocyclic	ketone
Serine			$\neg \tau$	cyano	\neg	ketone
Serine				cyano		ketone
Stearic acid	chlorine	s-heterocyclic.	pyridine	cyano	n-heterocyclic	ketone
	•					

. .

			٠			•		
Co-crystal Former								
Procaine	phosphate ester		fluorine . ,	carbamate.	imidazole	BF4		
Proline	phosphate ester		fluorine	carbamate.	imidazole	BF4		
Proline	phosphate ester		fluorine	carbamate	imidazole	.BF4		
n-Tolliepesuifonic acid			•					
Pyridoxamine	phosphate ester		fluorine	carbamate	imidazole	BF4		
Pyridoxamine	phosphate ester	,	fluorine	carbamate	imidazole	BF4		
Pyridoxamine	*sulfonic acid	*phosphoric acid	N-oxide	ester	ether	fluorine	acetate	thione
Pyridoxine							1	
(4-Pyridoxic Acid)	*sulfonic acid	*phosphoric acid	N-oxide	ester	ether	fluorine	acetate	thione
Pyridoxlne								
(4-Pyridoxic Acid)	phosphate ester		fluorine	carbamate	imidazole	BF4		
Pyroglutamic acid	phosphate ester	•	fluorine	carbamate	imidazole.	BF4		
Pyroglutamic acid	phosphate ester		fluorine	carbamate.	imidazole	BF4		
Quercetin	phosphate ester		fluorine	carbamate	Imidazole	BF4 ·		
Quercetin					•			
Quercetin		alcohol		phospphate	cyanamide			
Resveratrol	phosphate ester		fluorine	carbamate	imidazole ·	BF4	•	
Resveratroj .				•				
Saccharin	phosphate ester	******	fluorine	carbamate	imidazole	BF4		
Saccharin	phosphate ester		fluorine	carbamate	imidazole	BF4		
Saccharin			,·					
Saccharin	phosphate ester		fluorine	carbamate	imidazole	BF4	-	
Salicylic Acid	phosphate ester		fluorine	carbamate.	imidazole	BF4		
Salicylic Acid	phosphate ester		fluorine .	carbamate	imidazole	BF4		٠
Salicylic Acid, 4-amino	phosphate ester		fluorine	carbamate	imidazole	BF4		
Salicylic Acid, 4-amino		fluorine	carbamate	imidazole	BF4			
Salicylic Acid, 4-amino.	phosphate ester		fluorine	carbamate		BF4		
Sebacic acid ·	phosphate ester	••	fluorine	carbamate		BF4		
Serine	phosphate ester		fluorine	carbamate .		BF4		
Serine	phosphate ester		fluorine	carbamate ·	•	BF4		
Serine	phosphate ester		fluorine	carbamate ·		BF4		
Stearic acid	phosphate ester		fluorine.	carbamate	imidazole	BF4	·	
					٠			•

; ·..

Co-crystal Former					
Procaine .	N-SO2	thiourea	iodine		
Proline	N-SO2	thiourea	iodine		
Proline	N-SO2	thiourea	iodine	`,	
o-Toluenesulfonic acid		<u>.</u>		·	
Pyridoxamine	N-SO2	thiourea	iodine	epoxide	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Pyridoxamine	N-S02	thiourea	iodine		
Pyridoxamine	dithiadiazocyclopentadienyl		·		
Pyridoxine	L		 		
Pyridoxine	out nadiazocyclopernadienyi	-	1.		
(4-Pyridoxic Acid)	N-S02	thiourea	iodine	epoxide	.·
Pyroglutamic acid	N-SO2	thiourea	iodine		
Pyroglutamic acid	N-S02	thiourea	iodine	epoxide	peroxide
Quercetin .	N-SO2	thiourea	lodine		
Quercetin					
Quercetin					 - -
Resveratrol	N-S02	thiourea.	iodine	 	
Resveratrol				ļ. -	
Saccharin	N-SO2	thiourea	lodine	epoxide.	epoxide peroxide
Saccharin	N-SO2	thionrea	iodine		
Saccharin					
Saccharin	N-SO2	thiourea	iodine		
Salicylic, Acid	N-SO2	thiourea	iodine		
Salicylic Acid	N-SO2	thiourea	iodine	epixode	
Salicylic Acid, 4-amino.	N-SO2	thiourea	iodine		
Salicylic Acid, 4-amino					
Salicylic Acid, 4-amino	N:SO2	thiourea	iodine		
Sebacic acid	N-S02	thiourea	iodine.		
Serine ·	N-SO2	thiourea	iodine	٠	
Serine	N-SO2	thiourea	iodine		
Serine	N-SO2	thiourea	, euipoi	epoxide	
Stearic acid	N-SO2	thiourea	iodine		

	Co-crystal F rmer					.	
Co-crystal Former	Functional Group	Interacting Groun	. Group		:		
Succinic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	gine	· ·
Tartaric Acid	Carboxylic. Acid	alcohol	ketone	this.	opime:.	amino	ariallile
Threonine	Amine	lohola	Potono	loid	diago.	al III I	aliali le
Threonine	Carbondio Acid	lodolo lodolo	Matol 10	OII O	ariide	amine	analine
	ספום אוני שכום	alconor	Ketone	thiol	amide	amine	analine .
Infection	alcohol	alcohol	ketone.	thiol	amide	amine	analine
. rris	Amine	alcohol	ketone	thiol	amide .	amine	analine
- Ins	Alcohol	alcohol	ketone .	thiol	amide	amine	analine
Tryptophan	. Amine	alcohol	ketone	thiol	amide	amine	analine
l ryptophan	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine
Tryptophan	Indole	*alcohol	ovriction		(T; see *	1	
Tyrosine	Amine	Johode	Paris de la constante de la co) didt	aring	Olimin.	ariine
	Line of the Control		שנחום	Din	arnide	amine.	analine
	Caliboxylic Acid	alconol	кетоле	thio	amide	amine	analine
DING	Alconol	alcohol	ketone	thiol	amide	amine	analine
	Ketone	alcohol		thiol	amide	amine	analine .
	Amine	alcohol	ketone .	thiol	amide	amine	analine
	Amide	alcohoj	ketone ·	thiol	amide.	amine	analine
	Amine	alcohol	ketone	thiol	amide	amine	analine
	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	analine :
	Amine	alcohol	ketonė	thiol.	amide	amine	analine
II KO	Alcohol	alcohol ·	ketone	thiol	amide .	amine	analine
Aylitol.	Alcohol	alcohol	ketone	thiol	amide	amine	analinė
		3	•				

Co-crystal Former		•	• •		· ; · · · · · · · · · · · · · · · · · ·	·. ·	•	· ·
Succinic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Tartaric Acid	phenol	phosphate .	sulfate	sulfone	nitraté	pyridine		Carboxylic Acid
Threonine	pheriol	phosphate	sulfate	sulfone	nitrate .	pyridine	•	carboxilic acid
Threonine	phenol	phosphate	sulfate	enolione.	nitrate .	pyridine		carboxilic acid.
Threonine.	phenol	phosphate	sulfate	, sulfone	nitrate	pyridine		Carboxylic Acid
Tris	phenol	phosphate:	sulfate	sulfone	nitrate	pyridine		carboxilic acid
Tris	phenol	phosphate	sulfate	· sulfone	nitrate	pyridine		Carboxylic Acid
Tryptophan .	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid
Tryptophan	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxilic acid
	*carboxilic							
Tryptophan	acid	*sulfonamide	*ketorie	ether	triazole		ammönium	oxime
Tyrosine ·	phenol	phosphate.	sulfate	Sulfone	nitrate	pyridine		carboxilic acid .
Tyrosine	phenol.	phosphate	sulfate	sulfone .	nitrate	pyridine		carboxilic acid
Tyrosine .	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Urea	phenol	phosphate ·	sulfate	sulfone	nitrate	pyridine	-	Carboxylic Acid
Urea	phenol	phosphate	sulfate	sulfone.	nitrate	pyridine		carboxilic acid
	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Valine	phenol	phosphate	sulfate	sulfone .	nitrate	- pyridine		carboxilic acid
	phenol	phosphate	sulfate .	sulfone	ńitrate	pyridine		carboxilic acid.
	phenol	phosphate	sulfate	suffone	nitrate	pyridine		carboxilic acid
Vitamin K5	phenol	phosphate	sulfate.	sultone	nitrate	pyridine		Carboxylic Acid
Xylitol ··	phenol	phosphate	sulfate	sulfone	nitrate ^	pyridine.		Carboxylic Acid ·
			,					٠

	-								
Co-crystal Former					•	•			· ·
Succinic Acid	metals	aldehyde	ester	ether	cyano		furan	bromine	T
Tartaric Acid	metals.	aldehyde	ester	ether	cyano		furan	bromine	T
	metals ·	aldehyde	ester	ether	cyano		furan	. bromine .	1.
	metals	aldehyde	ester	ether	cyano		furan	bromine	Ť
onine	metals	aldehyde	ester	ether	cyano		furan	bromine	\top
	metals	aldehyde	ester	ether	cyano		furan	Dromine	\top
::	metals	aldehyde	. ester	ether -	cyano		furan	bromine	Т
Iryptophan	metals	aldehyde.	ester	ether	cyano	·	furan	bromine	Т`
l ryptophan	metals	aldehyde	ester	ether	cyano		furan .	bromine	Τ.
				n-heterocyclic					Т
Tryptophan	*chlorine	•	thiol	ring	thionedisulfide	thionedisulfide pyrrolidindione	iodine	hydrazone.	
	metals .	aldehyde	ester	ether	cyano.		furan	bromine	Т
	metals	aldehyde	ester	ether	cyano.		furan	bromine	1,-
. 90	metals	aldehyde	ester	ether	cyano .	,	furan	bromine	_
	metals	aldehyde	ester	ether	cyario		furan	bromine.	Ť
	metals	aldehyde	ester	ether	cyano		furan	bromine	1
	metals	aldehyde .	ester	ether	cyano		furan	bromine	T
•	metals.	aldehyde	ester	ether	cyano		furan	bromine	Τ.
•	metals	aldehyde	ester	ether	cyano		furan	bromine	T
	metais		ester	ether .	cyano .		furan	bromine	;.
in K5	metals	-]	ester	ether	cyano		furan	bromine	· ·
Xylitol	metals	aldehyde	ester	ether	cyano		furan	bromine	<u> </u>
									

Co-crystal Former			· .		•		
Succinic/Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone .	
Tartaric Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic:	ketone	
Threonine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone ·	_
Threonine	chlorine .	s-heterocyclic	pyridine	cyano .	n-heterocyclic	ketone .	_
Threonine	chlorine	. s-heterocyclic	pyridine	cyano .	n-heterocyclic	ketone	_
Tris	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone .	÷
Tris.	chlorine	s-heterocyclic.	pyridine	cyano.	n-heterocyclic	ketone	·
Tryptophan	chlorine	s-heterocyclic ·	pyridine	cyano ·	n-heterocyclic	ketone .	
Fryptophan .	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic ketone	ketone	
Tryptophan	thiocyanate	*bromine		hydroxamic acid	cyano	carboxamide	
Tyrosine	chlorine	s-heterocyclic	pyridine	cyano.	n-heterocyclic	ketone ·	_
Tyrosine	· chlorinė	s-heterocyclic .	pyridine .	cyano	n-heterocyclic	ketone	·
Tyrosine	chlorine.	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	<u>. </u>
Urea	chlorine	s-heterocyclic .	pyridine	cyano ·	n-heterocyclic	ketone	
Urea	chlorine	s-heterocyclic	pyridine	cyano :	n-heterocyclic	ketone	
Urea	chlorine	s-heterocyclic	pyridine	cyano .	n-heterocyclic	ketone	
Valine	chlorine .	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	
Valine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	
Vitamin K5	chlorine .	s-heterocyclic	pyrldine.	cyano	n-heterocyclic	ketone.	
Vitamin K5	chlorine	s-heterocyclic .	pyridine.	cyano.	n-heterocyclic	ketone	
Xylitol	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone ·	نن.
•					•		_

Co-crystal Former	•	• .		· · ·			•	
Succinic Acid	phosphate ester		fluorine	carbamate	imidazole	BF4		
Tartaric Acid	phosphate ester	-	fluorine	carbamate	imidazole	BF4		
Threonine ·	phosphate ester	-	fluorine	carbamate.	imidazole	BF4		
Threonine	phosphate ester		fluorine	carbamate	imidazole	BF4	<u> </u>	:
Threonine.	phosphate ester	:	fluorine	carbamate	imidazole	BF4		
Tris	phosphate ester		fluorine	carbamate	imidazole	BF4		
Tris	phosphate ester	•	fluorine	carbamate	imidazole	BF4		
Tryptophan	phosphate ester		fluorine	carbamate	imidazole	BF4		
Tryptophan	phosphate ester		fluorine	carbamate	imidazole	BF4	- -	
Tryptophan	*sulfonic acid	*phosphoric acid	N-oxide	ester	ether.	fluorine	acetate	thione
Tyrosine	phosphate ester	•	fluorine:	carbamate	imidazole	BF4	-	
Tyrosine	phosphate ester	•	fluorine	carbamate	imidazole	BF4		
Tyrosine	phosphate ester .		fluorine	carbamate	imidazole .	BF4		
Urea	phosphate ester		fluorine	carbamate ·	imidazole	BF4.		
Urea	phosphate ester		fluorine	carbamate	imidazole	BF4		
Urea .	phosphate ester		fluorine	carbamate	imidazole	BF4		
Valine	phosphate ester		fluorine .	carbamate	Imidażole	BF4		•
Valine	phosphate ester		fluorine	carbamate	imidazole	BF4	ŀ	
Vitamin K5	phosphate ester		flùorine	carbamate	imidazole	BF4	:	
Vitamin K5	phosphate ester		fluorine .	carbamate	imidazole	BF4		
Xylitol	phosphate ester		fluorine	carbamate	imidazole	BF4		
		•						

Co-crystal Former			•		
Succinic Acid	N-SO2	thiourea	iodine	-	-
Tartaric Acid	N-SO2	thiourea	iodine		
Threonine.	N-S02	thiourea	lodine		. '
Threonine	N-S02	thiourea	iodine		
Threonine	N-S02	thiourea	iodine	epoxide	
Tris	N-SO2	thiourea	iodine		
Tris	. N-SO2	thiourea	iòdine	epixode	
Tryptophan	N-SO2	thiourea	iodine		
Tryptophan .	N-SO2	thiourea	iodine	<u></u>	
				<u> </u>	
Tryptophan	dithiadiazocyclopentadienyl			•	
Tyrosine	N-SO2	thiourea	iodine		
Tyrosine	N-S02	thiourea	iodine		ŀ
Tyrosine	N-SO2	thiourea	jodine	epixode	:
Urea	. N-SO2	thiourea	iodine		
Urea	N-SO2	thiourea	iodine		· -
Urea	N-SO2	thiourea	iodine	epoxide	peroxide
Valine	N-SO2	thiourea	iodine		
Valine	N-SO2	thiourea	iodine		
Vitamin K5	N-SO2	thiourea	iodine		
Vitamin K5	N-SO2	thiourea	iodine	epoxide	
Xylitol · .	N-SO2	thiourea	iodine	epoxide	

Emotional Group	Emotional Grain Standard	Internating Cra			 	
runchollar Group	רעווכווטווםו פוסחף אין חכוחופ	meracing aroup	4	,		
		-				
				:		•
pyridine	N	.*alcohol	pyridinium	*amide	nitro	*amine
	IZ				· .	
Imidazole	N	imidazole	chlorine	acetamide	carboxylate	thione
	o=		· · ·			
Hydroxamic acid	но М	hvdroxamic acid		phosphinic ester	alkane ·	nvridine
			. .			
	- HO					٠,
	•		•		. ;	
peroxide	-	ester	peroxide	amide	erner	alkarie
	<				•	
epoxid	1	alkane	, bromine	alcohol	ester	epoxide
·	·					,
		•				
thioester	고 2	aromatic	thioester	alkane	sultamide	nyaroxy
·	· •					
	-					
thioketon	R R	alkane	thioketone	ketone	SULFAMIDE	AMINE
	•					

Functional Group									
	•			. •		· ·	•		
pyridin	*carboxilic acid_sulfonamide	*sulfonamide	*ketone	ether	triazolė	alkane	ammonium oxime	oxime	*chlorine
				•	•				
				٠.,			•		
imidazole	nitro	cyanamide	ketone	cyano	carboxilic	alcohol	alkane	thiol	amine
	·	•		Į.		-			
							•		
Hydroxamic acid	amide	sulfonamide	cárboxylate	phosphine	amine.	aromatic	,	· :	
		٠				÷	·		
				•	•				
peroxide ·	N-heterocycle	aromatic	alcohol	pyrimidinedione		thiazole	peroxy acid ketone	ketone	carboxilic acid
									·
	•				•				¥
poxide	amide	alkene	hydrazone	aromatic	thioether	ketone	aldehyde	chlorine	carboxilic acid
		٠.							
					•		··.	-	
thio st r	bromine	iodine	amine	cyano	thioketone	amide		chlorine	nitro
								•	•
thioketone	thiol .	sulfoxide	. oxo	chlorine	cbromine	AROMATIC alkene			
					7				

Functional Group					•	•			
								•	
pyridine	alkyne	thiol	n-heterocyclic ring	. epijinsipeuoiti	pyrrolidindione lodine		hydrazonė	hydrazone thiocyanate	*bromine
	phosphinic acid hemihydrate	chlorine	sulfonvi	suľoxide	amide	fluorine	sulfonate ester		
ic acid									
	azide	phosphine oxide	sulfonamide						·
epoxide	alkyne		ammonium	fluorine	nitro	amine	cyano		
						<i>:</i>			
thioketone	AZOXY		,						<i>'</i>

Functional Group					 - 		 			
				•						•
pyridine	aromatic	hydroxamic acid	cyano	carboxamide	*sulfonic	*phosphoric acid	N-oxide	ester	ether	fluorine
	•								· .	
							٠.			
Hydroxamic acid							·	·	_	
ran y							- ·			•
epoxid										
thioester							·			·
totor		·								
THE MOUNT									-	

Eunctional Group		•				-		
door microna								
·.								:
•		•		:	•		•	
pvridin	acetate thione	thione	dithiadiazocyclop		· ·	_		
		·						·
imidazole				. •				
	•						:	
Hydroxamic acid							•	
						:		
peroxide								· • · · · · · · · · · · · · · · · · · ·
			-		,			
epoxide					• :.			•
thioester						,		
			·					
thioketone	,							

2						
Functional Group	Functional Group Structure	Interacting Group	dr		!	
	. (
	NO ₂		:	····		
nitrate ester		aromatic	amide:	alkane	chlorine	nitrate ester
	· · · · · · · · · · · · · · · · · · ·		, -			
Thiophosphate	0			-		
st r-0	HO	amine '	imidazole	cyclic amide		
	0					
40		,	•	phosphaté	aromatic N-	
riiospiiale ester	5	aromatic	alcohol	ester	ring	pyridine
	ω <u> </u>		·			
Thioketon	۳, ک۳	sulfone	potassium	epoxide	i-oxide	cyano
	0					·
Ketone	R H	alcohol	ketone	thiol	amide	amine
	0-					·
Aldehyde	± ±	alcohol	ketone	thiol	amide	amine
	R——9					
Thiol		carboxylic acid	sodium	aldehyde	ketone	aromatic-N

TABLE

				•				~	
Functional Group		•			-	į			
		•	•		· ·				
• • •		· ·					 :		
nitrate ster	bromine	alcohol	ether	acetate		· ·		·	
	•							:	
Thiophosphate st r-0	·	 .	· · ·			· .			
						-			
		· ·		•	· ·		· · · ·		
Phosphate ester	analine	amine	:	sodium	potassium	lithium	carboxylic	amide .	alkane
Thioketone	thiol	iron	bromine	, alkane	aromatic-N		iodine	ketone	cobalt
-1:									•
				-					
Ketone	analine	phenol	phosphate.	sulfate .	sulfone	nitrate	pyridine	aromatic	carboxilic acid
		· ·.		•					
					•	:		:	
Aldehyde . a	analine .	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	aromatic	carboxilic acid
				•.				·:.	
Thiol	cadmium	alkane .	arsenic	chlorine	alcohol	potassium	2	aromatic	92
					1	1		7	

				٠.			•		
Functional Gr up	•								
			 - -					ĺ	
		· .			•				-
				·-			_		
-	_	· ;							••
		· -		-	•		•		
nitrate ester	•			•	,	· ·	•		
i			•						
•		-	•	•		•			
		•	,	•••	•		•	•	•
raiopnospinate	- .				•		•		•
St ro									
						-			
	_		·	_					
		:	•	•				<i>:</i>	•
	•	•		•					
Phosphate ester		•	· ·	•	•			•	
		-		1					
			·, 	-	-				
		•	•	•					
				·-	· ·				
Thioketone	amine	sulfate			·	•			···.
							-		T
-				· -					
					•		•	•	·
Ketone	matále	واستطحاماها						•	
	- Indians	ancellane	ester	emer	cyano .		furan	bromine.	chlorine
	·							•	
		•	(•		
Ald hyde	metals	aldehyde ·	ester	. ether	cyano	•	furan	bromine	chloring
	•								
				•				•	
Thiol ·	g	٠					•		-
							-		_

						•				
Functional Group		•								
			-		.	.				
·			_		•		•			
•			•		·,		_		· 	
		•	•	•			•			
nitrate ester	:			•			•		•	
	-									
Thionhocahato			•			<u>.</u>		_		
octor-O				<u>.</u>		· 		-		•
0-1016					•				•	
•		. !	•		·			1	-	
•	•			•••			_			
				٠					. .	•
					·_	•	•		•	
Phosphate ester	• .	•	•							·-
			-							
			•				-:			
		-			•			,-		
		-	•					•	•	•
ınıoketone										
•		•								-
•		· 	•				- ·		•	
	•					•	•			
Ketone	s-heterocyclic	pyridine	суапо	n-heterocyclic	ketone	phosphate			•	
	:				.	1000	Yn:		carpamate	imidazole.
•		• .	:			· · ·				
No. de la constanta de la cons				•		phosphate		•	•	
	s-neterocyclic	pyridine	cyano	n-heterocyclic ketone		ester	fluo	fluorine	carbamate	imidazole
			•	•	·			-	_	
Thio	:	•		•	· · ·		•			
			•							
	•							-		

Functional Gr up	۲.							
		·						
nitrate ester					•			
			· .					
Thi phosphate ester-O								
			· · ·					•
Phosphate ester					•			
	·		., ·				•	
Thioketone		,		. •			•	
	·.					÷		
Ketone	BF4	alkane	aromatic	N-SO2	thiourea.	lodine	·	
		•						
Aldehyde	BF4	alkane	aromatic	N-SO2	thiourea	iodine	epoxide	
Thiol					·			

TABLE III

Functional Group	Functional Group Structure	Interacting Group	dr			
•					•	1.
	я—ен		•		· ·	
Alcohol		alcohol	ketonė	thiol	amide	amine .
				;		
	S/R			•		
Thloether		aromatic-N	amide	amine	aromatic_s	Sp2 amine
•						
		•				
Ether		aromatic-N	amide	amine	aromatic_s	Sp2 amine
	· · · · · · · · · · · · · · · · · · ·		•			
	N		•			
Cyanamide		cyano .	amine .	potassium	aromatic-N	bromine
			•			
		•				
Thiocyanate		aromatic-S	ester	ether	•	
	¥				· ·	
ı						:
sP2 amine	ac.	thioether	ether .	metals	MoOCI4	BF4
	RNH2		-		•	
Amine primary		alcohol	ketone	thiol	amide	amine

Eurotional Group				`			•		
dans in inchair		:							
		,	·					٠.	
		·		•	•		•	٠	
Alcohol	analine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	aromatic	carboxilic acid
						_			•
					•			•••	
Thioether	sulfoxide	chlorate	chlorine	alkyne	cyano	ester	amine	nitro	nitrate .
	·			•				:	
•						•			
Ether	sulfoxide	chlorate	chlorine	alkyne	cyano	ester	amine	nitro	nitrate
		٠.							
							٠,		
Cyanamide	sodium	imidazole	ether	n-heterocyclic	alcohol.	cesium	. Ag		
		• •		•			•		
			·.·		· .	· · · ·			
Thiocvanate						•		•	
	•		•						
sP2 amine	bromine	chlorine		Sp2 amine	sulfate	Osmium			
·			. ~	•					
Amine primary	analine	phenol .	phosphate	sulfate ·	sulfone	nitrate	pyridine	aromatic	carboxilic acid,

Functional Group	•			•					
					. .	•		•	·
Alcohol	metals	aldehyde	ester	ether	cyano		furan	bromine	chlorine
	hromine		ketone	peroxide	epoxide	Ā		heterocyclic-S	iodine
	bromine	1 .	Ketone					heterocyclic-S	iodine
epi E						·			
Thiocyanat	·								
sP2 amin	٠.						,		
	. · <u>-</u>				,		6	hromine	r ori ori
Amine-primary	metais	aldenyde .	ester	emer	cyano			İ	2111211

			•							
Functional Group										
							•		•	
		•	•			phosphate	•		-	
Alconol	s-nererocyclic	pyridine	суапо	n-neterocyclic	Ketone	ester		TIUOLINE	carbamate	imidazole
~	· :				:					
Thioether	ester	ether	carboxylic	sulfate	 sulfone	alkane	alcohol		phospphate	
			,							
			carboxylic				•	•	•	
Ether	ester	ether	٠,	sulfate	sulfone .	alkane	alcohol.		phospphate cyanamide	cyanamide
				•						
	•	٠.			•				•	
Cvanamide				:			•			
			•				•		•	
				-		•			•	
Thiocyanate										
			• • • •	•	•					
							•	•		
srz amine										
•		•.	·				•			
		•				phosphate				•
Amine primary	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	ester		fluorine	fluorine carbamate	imidazole

Functional Gr up						•	٠	
	i			Co	· ·	gijoi		
Alcohol	Br4	aikane	aromatic	14-30g	unoniea		חוועסקם.	
·		•						
								•
Thiother			•			: '	•	
					•			
•		•		٠				
1				٠				
Emer								
•	```````````````````````````````````````		· .		•	•		• •
			••		•			•
· Original						•		
Cyantaning								
					•			
		•			· ·		•	
Thiocyanate								
			•				•	•
				•	•			•
		•	: ·					
srz amine								
•					•			
	•			•	•		:	
Amin primary	BF4	alkane	alkane aromatic	N-SO2	thiourea	iodine		
		ı					•	

	Transfer Court Charles					
runculonal Group	runctional group suructure	meracing Group	2			
•				•	•	
	. R ₂ ——NH	•				:
Amine secondary		aiconol	Ketone	thiol	amide	amine
•				. •		•
	R ₃ N					,
Amine tertiary		alcohol	ketone	thiol	amide	amine .
	0:				•	
		•		•		
	$= \langle$			•		
Amide	R NH2	alcohol ·	ketone ·	thiol	amide	amine
	·:					
	R				•	
Sulfonic acid	 	pyridine	ketone	aldehyde	ether	ester
	RP0.				•	:
Phosphinic acid	a	alkane	notassium	lithium	n-heterocyclic	·
	B - 0.				•	
Phosphonic acid		alkane	potassium	ilithium	n-heterocyclic oxime	oxime
· ·						
	-	•				
Carboxylic acid		alcohol	ketone	thiol	amide	amine

Functional Group									. •
							٠.		•
•									
Amin secondary analine	analine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	aromatic	carboxilic acld
			•						
Amine tertiary	analine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	aromatic	carboxilic acid
		·.	•		٠.		·.		
	•				•				
Amide .	analine	phenol .	phosphate	sulfate	sulfone	nitrate	pyridine	aromatic	carboxilic acid.
	·		•	•		,			
	•					•	•		
Sulfonic acid	amide	carboxilic acid amine		metals	thioether	٠	sulfate	alcohol	•
٠			·	•					
	•					•		•	·
Phosphinic acid	amide	loueda	aromatic	amine	alcohol		metals		- :
					· ·			-, -,	
				٠			. :	carboxylic	•
Phosphonic acid	amide	phenol :	aromatic	amine	aicohol		metals	acid	Sp2 amine
	•.						-		
					• .		•		
Carboxvlic acid	analine	phenol	phosphate	sulfate	sulfonė	nitrate	pyridine	aromatic	carboxilic acid
1			1		.•		•		

Eunctional Group					·				
Amine secondary :	metals	aldehyde	ester	ether	cyano	·	furan	bromine	chlorine
						•		•	
Amine tertiary	metals	aldehyde	ester	ether	cyano		furan .	bromine	chlorine
								÷	
		•			•	•	•		
Amid	metals	aldehyde	ester	ether	cyano		furan	bromine	chlorine
					,*	٠.	· .		
	· .		•					•	
Sulfonic acid									
		· · ·						·	
Phosphinic acid	. •		•						
		:.	·	•	• .			•	
	orijo	othor	phosphonic	aromatic-N	ketone	· aldehydė	imidazole	•	
Prospione act									
Carboxylic acid	metals	aldehyde	ester	ether	cyano		furan	bromine	chlorine

Functional Group		•			٠				
			•			·.	••		
Amine secondary	s-heterocyclic	pyridine	cyano .	n-heterocyclic	ketone	phosphate ester	fluorin	fluorine carbamate	imidazole
1		Ĭ .				· .			. •
Amine tertiary	s-heterocyclic .	pyridine	суапо	n-heterocyclic	ketone	phosphate ester	fluorine	e carbamate	imidazole
					: .·				
						phosphate		·	olozabimi
Amide	s-heterocyclic	pyridine	cyano	n-neterocyclic	Ketone	ester		INUOINI CALDAINAG	וווותמדחום
	·								
				•		· ·			
Sulfonic acid									
							•		•
					•		· .	······	•
Phosphinic acid		i	-		:				
					•		-:	. ·	•
	• •	• .•			•		· 		•
Phosphonic acld					·	- 1			
			•			<u>-</u>			
				-		· ·			·.
Carboxvlicacid	s-heterocyclic	pvridine	cvano	n-heterocyclic	ketone	phosphate ester	fluorin	fluorine carbamate	imidazole
].	1	١.				

Functi nal Group			•					
	• .						•	
Amine secondary	BF4	alkane	aromatic .	N-SO2	thiourea	iodine		
Amine tertiary	8F4	alkane	aromatic	N-SO2	thiourea	iodine		
	ŀ							•
					,	•		•
Amide	BF4	alkane	aromatic	N-SO2	thiourea.	iodine	epoxide	peroxide
:			÷.	•	٠.			·. ;
Sulfonic acid				•		·		
				• .				-
					•			•
Phoenhinic acid		•	•	-			. •	
								•
	·							
Phosphonic acld			-		•	•		
					١			
•								
			•	S C U	· · · · · · ·	∴ eiloci		•
Carboxylic acid	6 74	alkane .	alkane . aromatic		uilouiea			

i						
Functional Group	Functional Group Structure	Interacting Group				
Sulfate octor) ===0	·	ketone	aldehyde	ether	ester
	C===NOH			ļ	amide	ether
Oxime		·	\		alcohoi	
	RH2CCH2R			· ·		•
Diazo		Oxime .		·		
Nitro	NO ₂	pyridine	ketone	aldehyde	ether	ester
	S					
S-het rocyclic ring	/u	alcohol	thioketone	thioether	s-heterocyclic	kėtone
	S	• . : ·	. <i>*</i> ·			
Thiophen		chlorine	fluorine	amide	ketone	. ON

Functional Gr up									
:				***			 •		
•	•					*	•	•	•
									đ
Sulfate ester	amide	carboxilic acid amine		metals.	thioether	sulfate	alcohol		
								•	
Ś.						N	. 050		
Охіше	Jaisa	pyridine	II-aromanc						cyallo
	:	:			-		:	·	
Nitrile	cyano	amine	analine	bromine	amide	alkane	carboxylic. acid	chlorine	n-heterocyclic
•									
•			<u>, , , , , , , , , , , , , , , , , , , </u>						
			•	•	•	•	•		
Diazo			•						
	÷	-							•
Nitro	amide	carboxilic acid amine		metals	thioether	sulfate	alcohol	•	<i>:</i>
			•						
						•	•		
• :	٠.								1
S-heterocyclic ring aromatic		alkene	amine _ c	chlorine	BF4	sultate	ester	2	erner
			•				•		
			<u>·</u>		•	•		•	-
Thiophene	SO	8						·	

					· ·				
Functional Group									
	! • !				<u>ج</u> .				
		•	•			•		,	
			• .		•			. •	
			•				•		•
Sulfate ester			i						
					•				
•	•	•	•	•	•	•		•	٠.
Oxime	n-oxide	ketone	aldehyde	carboxylic acid bromine	bromine	aromatic	pyridine	BF4	·
					•				
•	.					ځ .	•		
Nitrile	aromatic	potassium aldehyde	aldehyde .	thioether	pyridine .	omatic	bromine	ether	s-aromatic.
	•			·					
		•	,					•	
				٠.			•		
Diazo				•		·			
			•						
Nitro							•		
				•	•				
S-heterocyclic ring	amide ·	iodine	carboxylic acid sodium		cyano	chloride	furan		
							•		
	•	•	•						
			•	:	•		•		
Thiophene									
									•

Functional Group								• •			
			·					-			
•					•				•		:
					•	• ,				•	
		;·									
•	,		•					•			
Sulfate ester						•	. !			-	
		٠			r			•			
		:	.·	•	. '	• .					
owinc.				. •		٠.		•			
		:						t			
			•			:		•			-
•		•			:			:	٠.		•
Nitrile		•				•	•		•	·	
											•
•						•				_•	
•		,			•	·	• •	<u> </u>			
Diazo							٠				
					•		•	• • •	•		
Nitro					•	:			···.		• .
		•						 			
	•	•			•	_					
			•			.		**			•
S-heterocyclic ring	•			-	٠.	•					·
				_			:				
•		•			•				•		
1.0.1.0.1.0.1.0.1.0.1.0.1.0.1.0.1.0.1.0		•			. •						
) monare								ľ			

Functional Group	Functional Group Structure	Interacting Group	Q			
·	TZ		:			
N-heterocyclic ring		alcohol	thioketone	thioether	s-heterocyclic ketone	ketone
			. •		·	
O-het rocyclic ring	/	aicohol	thioketone	thioether	s-heterocyclic ketone	ketone .
	IZ					
Pyrrole		chlorine	fluorine	amide	ketone	NO
Furan		s-heterocyclic	•		•	
			,			
Epoxide `		bromine	alcohol	alkane	ester .	analine
Peroxide	КООН	Nitro	amide	analine		

Functional Group							-		
							,		
N-heterocyclic ring aromatic	aromatic	alkene	amine	chlorine	BF4	sulfate .	ester	N _O	ether
-			orimo	poloripe	BF4	Sulfate	ester	, ° 9	ether
o-necerocyclic find		alkalla						•	
Purole	·	8	imidazole	pyridine	n-aromatic	aldehyde	carboxylic acid	sulfate	chlorine
Furan									
Epoxide	aromatic	epoxide	aldehyde	alkyne	amine	amide	thioether		
Peroxide									-

		-							
Functional Gr up							ì	. [
						•		:	
N-heterocyclic ring amide	amide	eulpoi	carboxylic acid sodium		cyano	chloride	aldehyde		
		:					,		1
O-heterocyclic ring amide	amide	iodine	carboxylic acid sodium	sodium	cyano	chloride aldehyde	aldehyde		
			•						
Pyrrole	oromine	AUIXO	arcorror	prierio		פווופו			
	•		•						: · .
•		-	• ;				•	•	
Furan					• • •				
,								•	
				.••					•
Epoxid				•	٠		٠		
				•		•			
	•		• .		•		·.		
Peroxide.			•	•			·		

runctional Group												-
	•				-			•	•			
•	•		_			<u></u>						
					*	 -,	•					
N-heterocyclic ring			·	•	<i>,</i>	• •		•		•		
						ļ			-			
		·			•		•					
O-heterocyclic ring												
						•				-	··	- - -
·		٠.	•		-				•			
			•			· 	•					
Pyrrole		•				· .		•			-	
		·									- -	
	•	:	•		· :	•	٠.			٠		
Füran			•	•		• .				ί	· 	
						-		<u> </u>				
	•		ŀ	٠	. •	· ·		<u>. </u>		_	:	
	•		•		· ·	<u>.</u>		<u> </u>				
Epoxide		·				•						
		•						<u></u> -			•	
					<u>:</u>		.			•		
Per xid		•	•	•					•			•
												I

									1		١	
Functional Group								•		i		
	· .	·		-								
	•				•			,		٠		
	٠.		٠.	•			٠	.			-	
N-heterocyclic ring								•	_		.	
			•					•	•		·:	
O-heterocyclic ring	•		: 	٠.				·.·			•	
				-				ļ. 	 -	· .		
	•		•						•		•	•
•			·.			•						
Pyrrol			٠		•			•				
	•		•					•				
	٠.						,	,	<u>·</u>	•		
Furan		•	. ,					•	 -			
	٠.										•	
•				٠.		-	· .·		<u> </u>	•		•
Epoxide		•			•		٠.			.		
						• .			.			
Peroxide				\dashv		\dashv	ŀ		\dashv	·		

			Patent	. III	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chloroptenyl)-				
(-)-amlodipine	ester, (S)-[CAS]	103129-82-4	WO	9310779.	Antihypertensive, other
	(-)-Benzeneacetic acid, 4-chloro-Alpha-[3-: (trifluoromethyl)-phenoxy]-, 2-	, ,	<u>.:</u>		
(-)-halofenate	(acetylamino)ethyl ester		US.	6262118	Antidiabetic
	1,3-Benzenedimethanol, Alpha1-(((1,1-dimithylethyl)amino)methyl)-4-hydroxy-				•
(R)-salbutarnol	[CAS]	,			Formulation, modified-release, <=24nr
	1,3-Benzenedimethanol, Alpha1-(((1,1-dimethylethyl)amino)methyl-4-hydroxy	·. ·	• • • • • • • • • • • • • • • • • • • •	• • •	
(R)-salbutamol	[CAS]	34391-04-3	S	5547994	Antiasthma
	Formamide, N-(2-hydroxy-5-(1-hydroxy-2-	••			
	((2-(4-methoxypnenyl)-1* methylethyl)amino)ethyl)phenyl)- (R-			• •	· .
(R,R)-formoterol	(R*,R*))- [CAS]	67346-49-0	us.	5795564	Antiasthma
	. (S)-1-(4-amino-6,7-dimethoxy-2-quinazolinyi)-4-(1,4-benzodioxan-2-yl	•			-
(S)-doxazosin	carbonyl)piperazine	70918-18-2	8	9409785	Prostate disorders
	Benzenepropanamide, N-methyl-Gamma- (4-(trifluoromethyl)phenoxy)- (S)	•			
(S)-fluoxetine					Antimigraine
	Benzeneacetic acid, Alpha-cyclohexyl- Alpha-hydroxy 4-(diethylamino)-2-butynyl	•			
(S)-oxybutynin	ester, (S)- [CAS]	119618-22-3			Urological
1,2-Naphthoquinone		524-42-5			
17a-		68-96-2			· · · · · · · · · · · · · · · · · · ·
Hydroxyprogesterone					
17-Methyltestosterone		58-18-4			
	Platinum-195m, diamminedichloro, (SP-4-2)-	•	•		
195mPt-cisplatin			S	6074626	Anticancer, alkylating-
		41294-56-8			
Hydroxycholecalciferol					
1-Naphthyl Salicylate		550-97-0	·		
					•

Cancer, liver

	· .		Patent	
API Generic Name	API Chemical Name	CAS No.	Reference	Example of Therapeutic Use
ije		84:86-6		
Suironic Acid		ER14. FR. 9		
1-i neopromineaceuc		1	• •	
2,4,6-Tribromo-m-cresol		4619-74-3		
2,6-Diamino-2'-butyloxy-		617-19-6		
3,5'-azopyridine			• •	
21.	-	566-78-9		
Acetoxypregnenolone :				
2-Amino-4-picoline		695-34-1		
2-Aminothiazole		96-50-4		·
2-ethoxyhenzoic acid	2-Ethoxybenzoic acid		DE 5134001	Analgesic, NSAID
2-Naphthol		.135-19-3	•	
2-Naphthyl Benzoate		93-44-7		
2-Naphthyl Lactate		93-43-6		
2-Naphthyi Salicylate		613-78-5		
2-p-		80-02-4		
Sulfanilylanilinoethanol				
2-Thiouracil		141-90-2		
3,3",5',5"		76-62-0		
Tetrabromophenolphthal				
3-Amino-4-		589-44-6		
A-Bromo-d-camphor		76-29-9		
3-Hydroxycamphor		. 10373-81-6		
3-O-Lauroylpyridoxol		1562-13-6		
Diacetat				
3-Pentadecylcatechol ·		492-89-7		
3-Quinuclidinol		1619-34-7		
4,4'-Oxydi-2-butanol		821-33-0		

	·. 		•		• • • •	
Example of Indication				Pain, general		

			Patent	
API Gen ric Nam	API Chemical Name	CAS No.	Reference	Example of Therapeutic Use
4,4'-SulfinyIdlaniline		119-59-5		
4-Amino-3-		352-21-6	•	
hydroxybutyric Acid				
4-Amino-3-phenylbutyric		1078-21-3	· 	
Acid				
4-aminosalicylic acid	Benzoic acid; 4-amino-2-hydroxy- [CAS]	65-49-6	· · · · · · · · · · · · · · · · · · ·	Gl Inflammatory/bowel disorders
4-Chlor -m-cresol		59-50-7		
4-Hexylresorcinol		136-77-6		
4-Salicyloylmorpholine		3202-84-4	*	
5'-Nitro-2'-		553-20-8	·	
propoxyacetanilide				
5-aminolevulinic acid, DUSA	Pentanoic acid, 5-amino-4-oxo- [CAS]	106-60-5		Dermatological
5-azacilidina	1,3,5-Trlazin-2(1H)-one, 4-amino-1-B-D- ribofuranosvi-[CASI	320-67-2		Anticancer, antimetabolite
		5700 04 7		
		7-48-88-6		
Bromosalicylhydroxamic			•	
Acid				
	2-(4-Amino-3-methylphenyl)-6- hydroxybenzothiazole		· ·	
5F-DF-203		.•		Anticancer, other
5-FU ·	2,4(1H,3H)-Pyrimidinedione, 5-fluoro (CAS)	51-21-8		Formulation, parenteral, targeted
5-HT3 antagonists			US :6037360	Male sexual dysfunction
6-Azauridine		54-25-1		
6-Mercaptopurine		50-44-2	•	
8-Hydroxyquinoline		148-24-3	•	
		91421-43-1		
	N-{2-(2,2,2-Trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-naphthalen-1-yl]			
A-151892	amide			Urological T
a:-Antitropsin		9041-92-3		

·	 ١ .		· 		· . ·		·		•	-1	· ·	
ion		ase			e e							
of-Indication	. ·	Inflammatory bowel disease	.	•	syndrame				ejaculation			 bladder
		Itory bo	\ \ \ \ \ .		s splastic	•	breast	general	12		1	tive blac
Example				•	Keratosis Myelodysplastic		Sancer,	Cancer,	Premature			Overactive

			1	•	
API Generic Nam	API Chemical Name	CAS No.	R ferei	raien. R ference	Example of Therapeutic Use
:	6H-Purin-6-one, 2-amino-9-(((1S,2R)-1,2-bis(hvdroxymethyl)-0-19-		<u>.</u>		
A-5021	dihydro-[CAS]	145512-85-2			Antiviral, other
Abacavír ·		136470-78-5			-
abacavir sulfate	2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1S-cis)-, sulfate (2:1) (satl) [CAS]	136470-78-5 188062-50-2	. 85	434450	Antiviral, anti-HIV
	7-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yí)piperídín-1-yí[propoxy]-3- (hydroxymethyí)chromen-4-one.				
abaperidone hydrochloride	hydrochloride	183849-43-6	8	9632389	Neuroleptic · · · ·
	D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-			·	
abarelix .	leucyt-N6-(1-methylethyl)-L-tysyl-L-prolyf- [CAS]	183552-38-7	ns	5843902	Anticancer, hormonal
Abciximab		143653-53-6			
Abecarnil		111841-85-1			
abetimus	-	169147-32-4	Sn	5552391	Immunosuppressant
abiraterone	Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (36)- [CAS]:	154229-18-2	GB	2265624	Anticancer, hormonal
α-Bisabolol		515-69-5			·
ABLC	Amphotericin B (CAS)	1397-89-3 30652-87-0			Formulation, conjugate, carbohydrate
ABT-751	Benzenesulfonamide, N-{2-{(4- hydroxyphenyl)amino}-3-pyridinyl}-4- methoxy- {CAS}	141430-65-1	. , d	472053	Anticancer, other
AC-6216	N-benzyl-N-ethyl-2-(7,8-dihydro-7-methyl-8 oxo-2-phenyl-9H-purin-9-yl)acetamide				Anxiolytic
Acadesine		2627-69-2			
acamprosate	1-Propanesulionic acid, 3-(acetylamino)- 7 [CAS]	77337-76-9	GB,	2051789	Dependence treatment
Acamprosate		77337-73-6			
•					

. ·		· · · · · · · · · · · · · · · · · · ·	:	· · · · ·	 	
indication	zoster virus			a l	general	
of India	varicella zo	V/AIDS	prostate	erythematosus nic r, prostate	, Candida, go general	general n, alcohol
kample	Infection, va	Infection, HIV/	ancer, pros	Lupus erythe systemic cancer, pros	Infection, Ca	unxiety, gen
<u>`</u> ```	. Infe	Sch lafe	San	Lupus system Cancel	Can	Ag Aš

			Patent	Ħ	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Acarbose		56180-94-0			
	7H-Purine-7-acetic acid, 1,2,3,6-tetrahydro-1,3-dimethyl-2,8-dioxo-,compd. with trans-			• .	
acebrophylline	4-[[(2-amino-3.5- dibromophenyl)methyl]amino]cyclohexanol (1:1) [CAS]	86989-76-3	BE	3425007	Antiasthma
				· :	
acebutolol	methylethyl)aminojpropoxyjpnenyij-, (+/-)- [CAS]	34381-68-5 37517-30-9	ns	3726919	Antihypertensive, adrenergic
Acecainide		32795-44-1			
Acecarbromal					
	Benzeneacetic acid, 2-[(2,6-dichlorophenyl)aminoj-, carboxymethyl	9-00-90208		119932	Anit-Inflammatory
Accionente		77-46-3		T	
Acediasulfone		80-03-5			
Acefvllin		652-37-9			
Acequtamide		2490-97-3			
aceglutamide	Atuminum, pentakis(N2-acetyl-L- glutaminato)tetrahydroxytri- [CAS]	12607-92-0	DE	2127176	Antiulcer
	(4- 2-methyl-,			;- <u> </u>	
acemetacin	carboxymethyl ester [CAS]	53164-05-9	S	3910952	Anti-inilammatory
Acemetacin		152-72-7			
Acendouniaro		105-57-7			
Acetamidoeugenol		305-13-5			
		103-90-2			
Acetaminosalol		118-57-0			
Acetanilide		103-84-4			
Acetarsone		97-44-9 50-86-5	T		
Acetazolamide		29-00-5	T		
Ac tohexamide		968-81-0			
Acetohydroxamic Acid		546-88-3			
Ac toph nazine		2751-68-0			
		•			

Exampl of Indication Asthma Ulcer, Gl, general
--

Patent				-		
CAS No. Reference Page 2 Page 3 Page 3		•		Pat	ent	
128-16-1 128-17-14-14-14-14-14-14-14-14-14-14-14-14-14-		API Chemical Name	CAS No.	Ref	erence .	Example of Therapeutic Use
126-12-1 126-12-12-1 126-12-12-1 126-12-12-1 126-12-12-1 126-12-12-1 126-12-12-1 126-12-12-1 126-12-12-	Acetophenone		. 2-98-86	Ŀ	Ŀ	
Sept. 1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-	Acetosulfone		128-12-1	ŀ		
Colon Colo	Acetoxolone		6277-14-1	_		
129-63-5 129-63-5 129-63-5 129-63-5 129-63-5 14992-62-2 14992-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-	acetoxolone	Olean-12-en-30-olc acid, 38-hydroxy-11-, oxo-acetate, aluminium salt ICAS	29728-34-5	Sn	3764618	Antiulcer
14992-62-2 14992-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-	Acetrizoate		129-63-5			
14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-2 14992-62-3-9 14992-62-3-9 14992-62-3-9 14992-62-3-9 14992-62-3-1 14992-62-3 14992-	Acetyl					
14992-62-2 14992-62-2 14992-62-3-9 14992-62-3-9 14992-62-3-9 14992-62-3-9 14992-62-3-9 14992-62-3-9 14992-62-3-9 14992-62-3-1 14992-62-3-1 14992-62-3-1 14992-62-3-3-3 14992-62-3-3 14992-62-3-3 14992-62-3-3 14992-62-3-3-3-3 14992-62-3-3-3-3-3 14992-62-3-3-3-3-3 14992-62-3-3-3-3-3-3-3-3 14992-62-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3	Sulfamethoxypyrazine		3590-05-4	•		,
Interesting 199, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27	Acetylcarnitine		14992-62-2	<u> </u>		
Icholine 60-31-1 19-90-6 149-90-6 149-90-6 149-90-6 149-90-6 149-90-6 149-90-6 149-90-6 149-90-6 13402-08-9 13402-08-9 13402-08-9 13402-08-9 13402-08-9 13402-08-9 13402-08-9 13402-08-9 13402-08-9 13402-08-9 1381967 13402-08-9 1381967 138198915 1381968	Acetylcholine		66-23-9			
Feb. 91-1 149-90-6	Acetylcholine .		60-31-1			
149-90-6 149-90-6	Acetylcysteine	•	616-91-1		-	
13402-08-9 13402-08-9 13402-08-9 13402-08-9 13402-08-9 13402-08-9 13402-08-9 13402-08-9 13402-08-9 13402-08-2 13402-08-2 13402-08-2 13402-08-2 13402-08-3 134	Ac tylleucine		149-90-6			
13402-08-9 13402-08-9 13402-08-9 13402-08-9 13402-08-9 13402-08-9 15402-08-2 15402-08-2 1540-15-6 1540-15-	Monoethanolamine			·		
Salicylic acid, Eurand Benzolc acid, 2-(acetyloxy)- [CAS] 50-76-2 Salicylsalicylic 530-75-6 Salicylsalicylic 530-75-6 Salicylsalicylic 530-75-6 Salicylsalicylic 530-75-6 Salicylsalicylic 541-64-7-89-3 Salicylsalicylic 541-64-7-9-1 Acetylpheneturide		13402-08-9				
15879-93-3 15879-93-3 15879-93-3 15879-93-3 15879-93-3 15879-93-3 15879-93-3 15879-93-3 15879-93-3 15879-93-3 172420-38-3 1724200-38-3 1724200-38-38-38-38-38-38-38-38-38-38-38-38-38-	cetylsalicylic acid, Eurand		50-78-2	Ĺ		Formulation, optimized, microencapsulate
15879-93-3 15879-93-3 15879-93-3 15879-93-3 15879-93-3 15879-93-3 15877-89-3 15877-89-3 15877-89-3 15877-89-3 168	Acetylsalicylsalicylic	-	530-75-6			
15879-93-3 15879-93-3 15879-93-3 15879-93-3 15879-93-3 15879-93-3 15879-93-3 15879-93-3 172420-38-3 1724200-38-3 172420-38-3 172420-38-3 172420-38-3 172420-38-3 172420-38-3 172420-38-3 172420-38-3 1724200-38-3 172420	lcid					
6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(2-) n hydroxyethoxy)methylj- [CAS] Pyrazinecarboxylic acid, 5-methyl-, 4-oxide (CAS] Acelic acid, oxol[3-(1H-tetrazol-5-) 114607-46-4 EP 256507 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3-6-4-0) 2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-E) (CAS] In Mapadisilate Inim Napadisilate	-Chloralose		15879-93-3		•	
Pyrazinecarboxylic acid, 5-methyl-, 4-oxide 72420-38-3 Pyrazinecarboxylic acid, 5-methyl-, 4-oxide 51037-30-0 GB 1361967	siclovir	•	6-68-77-69			Formulation dermal topical
Pyrazinecarboxylic acid, 5-methyl-, 4-oxide 51037-30-0 GB 1361967 CAS Acelic acid, oxol[3-(1H-tetrazol-5- 114607-46-4 EP 256507 2,4,6,8-Nonatetraenolc acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-E) 55079-83-9 GB 1468401 CAS	cifran		72420-38-3			
olast :	inimox			8	1981067	Line in a month of the factor of the second
114007-40-4 CF 200507 2,46;8-Nonatetraenole acid, 9-(4-methoxy-2,3-6;8-trimethylphenyl)-3,7-dimethyl-, (all-E) 55079-83-9 GB 1468401 57576-44-0 75443-99-1 US 3988315 Inlum Napadisilate 55077-30-0 1684-42-0	itazanolaet	etrazol-5-]	00000	Typoipaomer manierosee osis
2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-E)- CAS (CAS 55079-83-9 GB 1468401 57576-44-0 155076-44-0 75443-99-1 US 3988315 1684-42-0 1684-42-0 1684-42-0 1684-42-0		٠,		٦.	/00007	Oprintalinoogical
in 55079-83-9 GB 1468401 57576-44-0 57576-44-0 105 3988315 106 55077-30-0 55077-30-0 108 108 108 109 109 109 109 109 109 109 109 109 109		-				
57576-44-0 76443-99-1 US 3988315 7547-30-0 302-27-2 1684-42-0	altretin					Antipsoriasis
302-27-2 1684-42-0	darubicin · ·	2				Anticancer, antibiotic
	clatonium Napadisilate					
				$\overline{\cdot}$		
	conitine		302-27-2			
	cranil®		1684-42-0			
	Acriflavine		8048-52-0	-		

	·	··		
Example of Indication		Pain, general	Infection, herpes simplex virus Hyperlipidaemia, general	Conjunctivitis

:

· ·			Patent .	
API Generic Name	API Chemical Name	CAS No.	Reference	Example of Therapeutic Use
Acrisorcin		7527-91-5		
	2-Propenoic acid, 3-(6-[1-(4-methylphenyl)-		· ·	•
acrivastine	3-(1-pyricum))-1-property, 2-pyricumy, (E,E)-[CAS]	87848-99-5	EP 85959	Antipruritic/inflamm, allergic
	Benzenemethanol, Alpha-[1			
	(R*,R*)]-, mixtwith 2-Propenoic acid, 3-[6-[1	·	·	
acrivastine + pseudoephedrine	(4-memylpnenyl)->-(1-pyrralialinyl)-1- propenyl]-2-pyridinyl]-, (E,E)-			Antiallergic, non-asthma
actagardine derivative	3,3-dimethyl-1-propylamide HCl monocarboxamide actagardine			Peptide antibiotic
Actarit		18699-02-0		
ACTH		9002-60-2		
Acyclovir		59277-89-3	·	
	2-Naphthalenecarboxylic acid; 6-(4-	•		
adapalene	metroxy-3-troyclot 3.5.1.35,7 jdec-1- .yiphenyl)- [CAS]:	106685-40-9	EP 199636	- Antiacne
Adapalene		106685-40-9		
ADCON-L	GL 402 [CAS]	137802-74-5	1.	Formulation, other
Adefovir		106941-25-7	٠	
	Propanoic acid, 2,2-dimethyl., (((2-(-6-		· · · · · · · · · · · · · · · · · · ·	
adefovir dipivoxii	yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene)ester- ICASI	142340-99-6	EP 205826	Antiviral, other
	ranosyl-9H-purine			Imaging adout
Adenoscan Adenoscan Trinhocuhate	icas)	56-65-5		
אמפווספווופ דוואווספאוומנפ				
ADEPT, CRT		156079-88-8	•	Immunoconjugate, other
Adinazolam		37115-32-5		
Adiphenine		64-95-9		
ADL-10-0101			WO: 9732857	Analgesic, other
Adrafinil		63547-13-7	•	
Adrenaione		99-45-6		
Adrenochrome		54-06-8		
			•	-

	'		
Example of Indication. Rhinits, allergic, general	Rhinitis, allergic, seasonal Infection, general	Acne Fibrosis, epidural Infection, hepatitis-B virus Diagnosis, coronary	

. .

٠.;

			ļ		
٠			Patent	Ħ	
API Generic Name	API Chemical Name	CAS No.	Ref	Ref rence	Example of Therapeutic Use
	Benzo(f)thieno(2,3-c)quinoline-9,10-diol, 4,5,5a,6,7,11b-hexahydro-2-propyl-,				
	diacetate (ester), hydrochloride (5aR-trans) 166591-11-3	166591-11-3 171752-56-0	. 8	5597832	Debendence treatment
AFOI -10150			2	6103714 .	Neuroprotective
AET .		56-10-0	L		
α-Ethvibenzvi Alcohol		93-54-9	_		
	Benzeneacetic acid, Alpha-methyl-4-(2-	•			
AF-2259	[CAS]	66332-77-2.	9	2726435	Anti-inflammatory
Afloguatione		56287-74-2			
	1H-Indole-3-acetamide, 1-(2,2-				
·	methylphenyl)-3-((((4-		· 	·.	
AG-041R	menyipnenyikanino)carbonyiyanino)rz- oxo-, (3R)- [CAS]	199800-49-2	. 8	9419322	Alimentary/Metabolic, other
••	N-(5-[2-(2-amino-4(3H)-oxo-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)ethy]-,		•	• • •	
AG-2037	4-methylthieno-2-yi)giutamic acid		•	•	Anticancer, antimetabolite
α-Glucose-1-phosphate		59-56-3			
AGN.194310	Benzolc acid, 4-((4-(4-ethylphenyl)-2,2-dimethyl-2H-1-benzothiopyran-6-yl)ettymyl)-ICASI	229961-45-9	9	. 2626026	Dermatological
agomelatine	mide, N-(2-(7-methoxy-1- hatenyt)ethyl)- [CAS]	138112-76-2	9	447285.	Antidepressant
Ahistan		518-61-6			
AHL-157		•	S	5411972	Hypolipaemic/Antiatherosclerosis
	9H-Purine-9-propanamide, 1,8-dihydro-6-		• .	•	
AIT-034		138117-48-3	ns	5447939	Cognition enhancer
	N-[2-(5-Hydroxy-1H-indot-3-yl)ethyl]-3-(6- oxo-6,9-dihydro-1H-purin-9-				•••.
AIT-202	yi)propionamide		WO	9957120	Antidepressant
			2	· ·	•

Example of Indication Addiction, cocaine Unspecified Unspecified Cancer, general Sleep disorder, general Atherosclerasis Atherosclerasis

ric Name	API Chemical Name		Patent Defend	ınt	
ric Name	API Chemical Name	1 1 1 1	900		The second of the second secon
		CAS No.	200	Reference	Example of Inerapeutic Use
	Acetic acld, ((3-((2R)-2-(((2R)-2-(3-				
AJG-049 Ajmaline	ilno)propyl)-1H-indol-7-	244081-42-3	_	• :	Antidiabetic
Ajmaline			. 0	9733885	Gastroprokinetic
1:-1		12/7/4360			
Alac prii		74258-86-9			•
•	4(3H)-Quinazolinone, 7-chloro-3-[(4.R,2R)-	•••		·.	
2- albaconazole	2-(2,4-difluorophenyi)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-vf)propyll- ICASi	187949-02-6	, 0M	- 9705131	Antifungal
	Carbamic acid, [5-(propythio)-1:H- benzimidazol-2-vll-, methyl ester [CAS]		GB	1484326	Antheimintic
		6			
Albuterol		·			
Albutoin		830-89-7	·		٠
	Benzeneacetic acid, 3-chloro-4-(2- propenyloxy)- [CAS]	22131-79-9	. g5	1174535	Anti-inflammatory
Alclometasone		67452-97-5			
:	Pregna-1,4-diene-3,20-dione; 7-chloro-11- hydroxy-16-methyl-17,21-bis(1- oxopropoxy)-, (7Alphe,1113,16Alpha)-			:	
alclometasone (C.	•	66734-13-2	S	4124707	Antipruritic/inflamm, allergic
Alclometasone .				•	
Alcuronium .		23214-96-2			
Aldioxa		5579-81-7		- :	
Aldol		107-89-1			
Ald sterone		52-39-1			
Ph hyc alendronate sodium (C/C)	Phosphonic acid, (4-amino-1- hydroxybutylidene)bis-, monosodium salt- [CAS]	121268-17-5 129318-43-0	89	2118042	Osteoporosis treatment
Alendronic Acid		66376-36-1			
Alexidine		22573-93-9	-		
affacalcidof, Teva	9,10-Secocholesta-5,7,10(19)-triene-1,3-diol, (1Alpha,38,5Z,7E)- [CAS]	41294-56-8		•	Osteoporosis treatment
Alfadolone Acetate		23930-37-2			
Alfaxalone	7	23930-19-0	٦	-	

		· · · · · · · · · · · · · · · · · · ·	<u> </u>	
Exampl of Indication Diabetes, Type II Motility dysfunction, GI, general	Infection, Candida, general Infection, helminth, general	Inflammation, dermal	Osteoporosis	Osteodystrophy

				-	
			Patent	ıtı	
API Gen ric Nam	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Alfentanil		71195-58-9	٠		
alfimeprase		259074-76-5			Fibrinolytic
	2-Furancarboxamide, N-[3-[(4-amino-6,7-				
ulizozi) e	durneuroxy-z- quinazolinyl)methylamino]propyljtetrahydro-81403-68-1 ICASI	81403-68-1 81403-80-7	89	2013679	Prostate disorders
	2-Furancarboxamide, N-[3-[(4-amino-6,7-				1
	omenoxy-z- quinazolinyl)methylamino]propyljtetrahydro-81403-68-1	81403-68-1		٠.	omilation modifical release offer
alfuzosin, GEOMATRIX	[CAS]	61403-50-7	1		Cilinate de la company de la c
Algestone		393-77-7			
Algestone Acetophenide		24356-94-3.			
Alain		9005-38-3			
Alolucerase		143003-46-7			
Alibendol		26750-81-2		•	
					··
	(2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl-2-		•	:	
•	metnoxy-2-(3-methoxypropoxy)benzylj-8-	•	•	•	
	methylnonanamide	173334-57.1			Antihvoertensive, renin system
Alitation		5300-03-8			
Antremoni	7	20000			
alitretinoin, Basilea	9-cis retinoic acid				Antipruritic/Inflamm, allergic
	1H-Benzotriazole-5-carboxamide, 6-	· · ·		.`.	
alizapride	pyrolidinyl]methyl]- [CAS]	59338-93-1	GB	1475234	Antiemetic
Alkannin		517-88-4			
Alkofanone		7527-94-8			
Allantoin		9-65-26		:	
Allobarbital		52-43-7			
Allopurinol		315-30-0			
Allopurinol					
Allyl Isothiocyanate		27-06-7			
Allyl strenol		432-60-0			
		•			

Exam Periphe Benign	Bengn prostatic-nyperplasta	Eczema, general Nausea and vomiting, general
	•	

			Patent	ant	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Th rapeutic Us
	Magnesium, [carbonato(2-	66827-12-1			
almagate	[CAS]	72526-11-5	Sn	4447417	Antacid/Antiflatulent
Almagate		66827-12-1			
alminoprofen	Benzeneacetic acid, Alpha-methyl-4-[(2-methyl-2-propenyl)amino]- [CAS]	39718-89-3	ട്ട	3957850	Analgesic, NSAID
Alminoprofen		39718-89-3			
almitrine	1,3,5-Triazine-2,4-diamine, 6-[4-[bis(4-fluorophenyl]methyl]-1-piperazinyl]-N.N'-di- 27469-53-0 2-propenyl-, dimethanesulfonate [CAS]	27469-53-0 29608-49-9	89	1256513	Respiratory
almotriptan	Pyrrolidine, 1-(((3-(2-(dimethylamino)ethyi)-1H-indol-5-yi)methyi)sulfonyi)- [CAS]	154323-57-6	O'W	9402460	Antimigraine
Alo -Emodin	•	481-72-1			
Aloin		5133-19-7			
	2,3,4,5-Tetrahydro-5-methyl-2-[(5-methyl-	122852-42-0			
alosetron	1 H-Imidazor-4-yi)memyij-1 H-pyridoj4,3- bjindol-1-one [CAS]	122852-69-1 132414-02-9	G.	306323 /	GI Inflammatory/bowel disorders
alovudine .	Thymidine, 3'-deoxy-3'-fluoro- [CAS]	25526-93-6	Ш	470355	Antiviral, anti-HIV
Aloxiprin		9014-67-9			
Alpha-1 protease Inhibitor, Nektar			Sn	5780014	Formulation, inhalable, topical
Alpha-dihydroergocryptine, Poli	Ergocryptine, 9,10-dihydro- methanesulfonate (salt)- [CAS]	29261-93-6			Formulation, other
Alphaprodine		77-20-3			
Alpid m		82626-01-5			
Alpiropride ·		81982-32-3		•	
alprazolam	4H-[1,2,4]Triazolo[4,3-al][1,4]benzodiazepine, 8-chloro-1-methyl-6-phenyl-[CAS]	28981-97-7	. Sn	3987052	Anxiolytic
	4H-[1,2,4]Triazolo[4,3-				
alprazolam, I2R		28981-97-7			immediate
Alprenolol		13655-52-2			
. ```	9-17-{N				•
alsactide	(4-aminobutyl)-L-lysinamide]- [CAS]	34765-96-3	S)	3749704	АСТН
-					

· · ·	 7 .	·		· · ·		 				<u>.</u>	•					•
Exampl of Indication				Bronchitis, chronic 1	Migraine		Irritable bowel syndrome	Infection, HIV/AIDS	Emphysema, alpha-1 antitrypsin deficiency	Parkinson's disease		Anxiety, general	Panic disorder	٠	Arthritis, rheumatoid	

	···.		Patent	int	
API Generic Nam	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
ALT-711	Thlazolium, 4,5-dimethyl-3-(2-oxo-2- phenylethyl)-, bromide [CAS]	181069-80-7	⊗	9622095	Symptomatic antidiabetic
Althiazide		5588-16-9			
altinicline	Pyridine, 3-ethynyl-5-((2S)-1-methyl-2-pyrrolidinyl)- [CAS]	179120-92-4	. Sn	5594011	Antiparklusonian
altretamine	1,3,5-Triazine-2,4,6-triamine, N,N,N,N",N"-hexamethyl- [CAS]	645-05-6	S	3424752	Anticancer, alkylating
		7446-70-0			
aluminium chloride hexahydrate	aluminium chloride hexahydrate Aluminium chloride, hexahydrate	7784-13-6		-	Dermatological .
Aluminon		569-58-4			
Aluminum.Acetate		8006-13-1	ļ _	L.	
Solution				•.	
Aluminum Chlorate		15477-33-5			•
Aluminum		1327-41-9			
Hydroxychloride					
Aluminum Potassium Sulfate		10043-67-1		. :	
Aluminum Sodium		10102-71-3			
Sulfate					
alusuif	Aluminum hydroxide sulfate (AI7(OH)17(SO4)2), dodecahydrate [CAS]: 61115-28-4		DE .	2510663	Urological
Alverine		150-59-4		T	
alvimopari	Glycine, N-[(2S)-2-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-	156053-89-3		657428	Gl infammator/bowel disorders
alvocidib	4H-1-Benzopyran-4-one, z-{z- chlorophenyl}-5,7-dlhydroxy-8-{3-hydroxy-1} {131740-09-5 methyl-4-piperidinyl}-, cls-(-)-{CAS}	131740-09-5 146426-40-6	·.	·.	Anticancer, other
ALX-0646			0M	9506638	Antimigraine
AM-24	2,4,6-Triiodophenal	609-23-4			Gl inflammatory/bowel disorders
AM-36	1-Piperazineethanol, 4-[[3,5-bis(1,1-dimethyl]-dimethylethyl]-Apha-(4-chlorophenyl)- [CAS]	199467-52-2		· <u>·</u> <u> </u>	Neuroprotective
			1		

		· · · · ·		. ·	 							· ·					
Example of Indication	Hypertension, general	Parkinson's disease	Cancer, ovarian	Hyperhidrosis	.:			. ''	Hyperphosphataemia	-	• •	. snall	Cancer, renal	Migraine	Crohn's disease	Unspecified	-
	,					. ·.		ï		-			 				

			Patent		
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
AM-477	2-Methoxyoestradiol				Antiasthma
Amantadine		768-94-5			
	1-Decanaminium, N,N-dimethyl-N-[2-				
amantanium	[((arcyclo)3:3.1:19,7]dec-1- [ylcarbonyi)oxy]ethyl]-, bromide [CAS]	58158-77-3	S	4288609	Antifungal
Ambazon		539-21-9			
Ambenonlum		115-79-7			
	(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-	•			
ambrisentan		177036-94-1			Vasodilator, peripheral
	Cyclohexanol, 4-[(2-amino-3,5-	1 40 60 04 5			
ambroxol·		23828-92-4	. gg	1178034	COPD treatment
Ambroxol		18683-91-5			
Ambucain		119-29-9			
Ambuphylline .		5634-34-4			
Ambuside		3754-19-6			
Ambutonium Bromide		115-51-5			
	Pregna-1,4-diene-3,20-dione, 21-	:			
	(acetyloxy)-15,17- [cyclopentylidenebis(oxy)]-9-fluoro-11				
amcinonide .		51022-69-6	E	2437847	Antipsoriasis
	1,4,8,11-Tetraazacyclotetradecane, 1,11-				
AMD-3100	(1,4-phenylenebis(methylene))bis-, octahydrochloride [CAS]	155148-31-5	2	5612478	Haematological
Amdinocillin		32887-01-7	T.		
Amdinocillin Pivoxil		32886-97-8			
amdoxovir	1,3-Dioxolane-2-methanol, 4-(2,6-diamino-9H-purin-9-yl)- (2R-cis)- [CAS]	145514-04-1	G.	656778	Antiviral, anti-HIV
	Carbamic acid, ((4-()3-((4-(1-(4-		-		
amelubant	anyl)metho	346735-24-8		10000907	COPD treatment:
	1	1	1	1	

				 •			<i>:</i> .		• • •	
Example of Indication	Asthma		Infection, general	Heart failure	Bronchitis, chronic			Chemotherapy-induced injury, bone marrow, leucopenia	Infection, HIV/AIDS	Chronic obstructive pulmonary disease
		•								• .

		<u> </u>			
			Patent	ıı	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	Benzenemethanaminium, N.N-dimethyl-N-				
	[2-[2-[4-(1,1,3,3-		٠.	•	
•	[tetramethylbutyl]phenoxy]ethoxy]ethyl]-,			•	
	chloride, mixt. with ethyl 4-aminobenzoate		•	-:	
Americainė :	[CAS]	129128-13-8			Formulation, innalable, otner
Amezinium		30578-37-1	·	٠.	
Amfenac	•	51579-82-9			•
Amidephrine		3354-67-4			
Amidinomycin		3572-60-9		•	•
	Ethanethiot, 2-[(3-aminopropyl)amino]-,	20537-88-6:			
amifostine	dihydrogen phosphate (ester)- [CAS]	63717-27-1	E)	131500	Radio/chemoprotective
	Pentanoic acid, 5-(dipentylamino):4-((2-				
•	naphthalenylcarbonyl)amino)-5-oxo- (R)-		9		
amiglumide	[CAS]	119363-62-1	8	8805774	GI inflammatory/bowel disorders
		37517-28-5			Formulation, optimized:
amikacin		39831-55-5			microencapsulate
Amiloride		2609-46-3			
Aminacrine.		90-45-9	·		
				··-	
. entinentine	Heptanoic acid, 7-[(10,11-dihydro-5H 30272-08-3 diheazola diectohepten-5-vilaminol-[CASI 57574-09-1	30272-08-3 57574-09-1	ns	3758528	Antidepressant
Aminitrozole		140-40-9			
Amino Acid			·		
Preparations					
Aminocaproic Acid		•	·		
opinido de Joseph	2,6-Piperidinedione, 3-(4-aminophenyl)-3-	125-84-R	. 0	3944671	Anticancer: hormonal
Aminoquanidine			7	Γ.	
Aminohippurate					
Sodium					
Aminometradine		642-44-4	1		*.
Aminopentamide		60-46-8			
Aminophylline		317-34-0			-
	1H-Purine-2,6-dione, 3,7-dihydro-1,3-	•			-
aminophylline		317-34-0	•	·:	Formulation, modified-release, other
Aminopromazine		58-37-7			
		•			

•

Pain, general Chemotherapy-induced injury, renal Infection, general Cancer, breast	Example of Indication	
Pain, general Chemotherapy-induced injury, renal Infection, general Infection, general Sathma		•
Chemotherapy-induced injury, renal Pancreatitis Infection, general Cancer, breast	Pain, general	
Cancer, breast		
Chemotherapy-induced injury, renal Pancreatitis Infection, general Cancer, breast Sathma		
neral st	Chemotherapy-induced	
neral st		
reral St	Pancreatitis .	
	Infection, general	
breast		
breast		•
breast (
breast		
Cancer, breast		
Cancer, breast Asthma		
Asthma	Cancer, breast	
Asthma	•	
Asthma		
	Asthma	
	•	

			Patent-	ant.	
API Generic Name	API Chemical Name	CAS No.	Ref	Refer nce	Example of Therapeutic Use
Aminopyrine		58-15-1			
Aminoquinuride	•	3811-56-1			
Aminorex		2207-50-3		 -	
	Methanone, (2-butyl-3-benzofurany)][4-[2- (diethylamino)ethoxy]-3,5-diiodophenyi]-	1951-25-3	<u> </u>		
amiodarone	[CAS]	19774-82-4	2	3248401	Antiarrhythmic
Amiphenazole		490-55-1			
Amiprilose		56824-20-5			
	Benzamide, 4-amino-N-f(1-ethyl-2-				,
amisulpride	methoxy- [CAS]	71675-85-9	SN	4401.822	Neuroleptic
Amitriptyline		50-48-6			•
	1-Propanamine,3-(10,11-dihydro-5H-				
	dibenzo[a,d]cyclohepten-5-yildene)-N,N-	•			
•	dimethyl + cyclohexanone,2-(2-		·	· ·	
amitriptyline+ketamine					Formulation, fixed-dose combinations
Amitriptylinoxide		4317-14-0			
•	5H-[1]Benzopyrano[2,3-b]pyridine-3-				•
amlexanox	5-0xo- [CAS]	68302-57-8	Sn	4299963	Antiasthma
	1				
· ·	aminoethoxy)methyl]-4-(2-chlorophenyl)	111470-99-6			•
amfodipine	ester [CAS]	88150-47-4	, . 🖺	89167	Antianginal
Amlodipine		88150-42-9			
Ammoniacum		0006/2/8			
Ammonium Benzoate		1863-63-4			
Ammonium Mandelate		530-31-4			
Ammonium Salicylate		528-94-9			•
		42739-38-8	·	•	
Amobarbital		57-43-2		. :	
Amocarzin		36590-19-9			
Amodiaquin		86-42-0			
	Morpholine, 4-{3-{4,1,1- dimethylpropyl)phenyl}-2-methylpropyl]-2,6- 78613-35-1	78613-35-1			
amorolfine	dimethyl-, cis- [CAS]	•	<u>.</u>	24334	Antifungal

			l		
		-	Patent	int	
API Generic Name	API Chemical Name	CAS No.	Ref	Reference.	Example of Therapeutic Use
Amoscanate		26328-53-0			
				٠.	
	Benzenesulfonamide, 5-[1-hydroxy-2-[[2-(2	_			
	methoxyphenoxy)ethyljaminojethylj-2-	70958-86-0			
amosulator .	methyl-, (+/-)- [CAS]	85320-68-9	9	136103	Antihypertensive, adrenergic
Amotriphene		5585-64-8			
	Dibenzib,fi[1,4]oxazepine, 2-chloro:11-(1-				
amoxapine	piperazinyl)- [CAS]	14028-44-5	89	1192812	Antidepressant
Amoxapine		14028-44-5.	L.		
			Ŀ		
	4-Thia-1-azobicyclo[3,2,0]heptane-2-			·:·	···
÷	carboxyfic acid, 6-[[amino(4-			•	
٠.	hydroxyphenyl)acetyl]aminol-3,3-dimethyl-	•	·.		
amoxicillin, Advancis	7-oxo-,[2S-[2Alpha,5Alpha,6B(S*)]] [CAS]	26787-78-0		·,.	Formulation, modified-release, other
amoxicillin, CSL		61336-70-7	· .		Formulation, other
•	4-Thia-1-azabicyclo[3.2.0]heptane-2-			•	
· .	carboxylic acid, 6-[[amino(4-	:			
·	hydroxyphenyl)acetyl]amino]-3,3-dimethyl-	• •			
amoxicillin	7-oxo-, [2S-[2Alpha,5Alpha,68(S*)]]- [CAS] 26787-78-0	26787-78-0	•	•	Formulation, other.
amoxicillin+potassium clavulan	* .	74469-00-4	GB	1508977	Formulation, fixed-dose combinations
	Piperidine 1-(8-numovalinulearhonul).				·
AMPAlex	•	154235-83-3	္ဌ	5650409	Psychostimulant
Amphetamine		300-62-9	Ι,		
Amphetaminil		17590-01-1			
amphotericin B, BDSi	Amphotericin B [CAS]	1397-89-3	*:*		Formulation, optimized, microencapsulate
	- Amphotericin B compd with (30) holest-5.				
amphotericin B, InterMune		120895-52-5	- SN	4822777	Formulation, optimized, liposomes
	4-Thia-1-azabicyclof3.2.0theotang-2-				
	carboxylic acid, 8-	٠.	•		
	methyl-7-	39-53-4	•	.:	
ampicillin	oxo-, [2S-[2Alpha,5Alpha,6B(S*)]]	7177-48-2		-	Formulation, fixed-dose combinations
Ampiroxicam		99464-64-9	•		
Ampligen		38640-92-5			

_			•	 	••		<u>. </u>		٠.	 ••			•	•	••					
	Example of Indication		Livrortencion general	Depression, general		٠	:	Infection, general	Infection, general		Infection, general	Infection, respiratory tract, general.		Attention delicit disorder .	infection funcial general	100	Infection, general		Infection, general	

			Pat	ent	
API Generic Name	API Chemical Name	CAS No.	R ferei	ference	Example of Therapeutic Use
		:			
•	Carbamic acid, (3-((4- aminophenylsi iffonyl)/2-			• .	
· ·	methylpropyl)amino)-2-hydroxy-1-				
amprenavir	(phenylmethyl)propyl)-, tetrahydro-3- furanyl ester, (3S-(3R*(1R*,2S*)))- [CAS]	161814-49-9	S)	5783701	Antiviral, anti-HIV
		60719-84-8			
amrinone	[3,4'-Bipyridin]-6(1H)-one, 5-amino- [CAS]	75898-90-7	S	4004012	Cardiostimulant
	5,12-Naphthacenedione, 9-acetyl-9-amino-		_	.:	
	7-[(2-deoxy-ß-D-erythro-			· ·	
	pentopyranosyl)oxyl-7,8,9,10-tetrahydro-				
amrubicin	6, i i -diriydroxy-, iiydrodiilofide, (78-cis)- [CAS]	92395-36-3	<u>B</u>	107486	Anticancer, antibiotic
	Methanesulfonamide, N-[4-(9-				
amsacrine	acridinylamino)-3-methoxyphenyl]- [CAS]	51264-14-3			Anticancer, other
	Glycine, N-[[1-methyl-5-(4-methylbenzoyl)-	•			
amtolmetin quàcil	1H-pyrrol-z-yijaceryij-, z-meuroxypnenyi ester [CAS]	87344-06-7	89	2115417	Analgesic, NSAID
Amylocaine		532-59-2			
Hydrochloride		•	•		
AN-152			ΟM	9719954	Anticancer; antibiotic
anabolic steroids, IC Innov			.OM	9848812	Cardiovascular
Anagestone		2740-52-5			
Anagrelide		68475-42-3			
				: ·	
anagrelide	dichioro-1,5-dinyaro-, mononyarachioride [CAS]	56579-51-4 68475-42-3	GB	1418822	Haematological
	1,3-Benzenediacetonitrile, Alpha Aloha Aloha Aloha-tetramethyl-5-				
anastrozole	•	120511-73-1	EP.	296749 · ·	Anticancer, hormonal
Anazolene		3861-73-2			
Ancitabine		31698-14-3.			
Ancrod		9046-56-4			
	N-4'-[5-Tetrazolyl]-phenyl-4-(5-tetrazolyl)-	· .			
andolast		132640-22-3	<u>а</u>	460083	Antiasthma .
Androisoxazole		360-66-7	•		

			8	Pat nt	
API Generic Name	API Chemical Name	CAS No.	Re	Reference	Example of Therapeutic Ilse
Androstenediol		521-17-5			Training of Tielapeutic Ose
	21-(Acetyloxy)-17-hydroxynregge 4 g/11)				
·	diene-3,20-dione		·	•	
anecortave acetate	:	7753-60-8 · · ·		~ ,	Ophthalmological
Anethol		4180-23-8:	ŀ		
		104-46-1		:	
		(unspecified)		· ·:	
Anethole Trithlone		532-11-6	-		
Angiogenix			2	6417205	Cardiovascular
Angiotensin		1407-47-2			
anhydrovinblastine	Vincaleukoblastine, 3',4'-didehydro-4'-	38300.45.3	<u> </u>	6044044	Andreas
		201	3	100	Anticancer, orner
	Echinocandin B, 1-((4R,5R)-4,5-dihydroxy-				
anidulafungin	NZ-((4"-(pentyloxy)(1,1"4',1"-terphenyl)-4- yl)carbonyl)-L-ornithine)- [CAS]	166663-25-8	S	6384013	Antifungal
Anileridine		144-14-9			
Aniracetam		72432-10-1			
Anisindione		117-37-3			
Anlsomycin		22862-76-6			
Anisotropine		80-50-2	L		
Methylbromide		·			٠.
anistreplase	Anistreplase [CAS]	81669-57-0	G G	28489	Fibrinolytic
Antazolin		91-75-8	ŀ		
Anthiolimine		305-97-5			
Anthralin		1143-38-0			
Anthramycin		4803-27-4			
Anthrarobin		577-33-3			
anthrax inhibitor			ns	6436933	Anti-infective, other
antiangiogenic dendrimers			Sn	6426067	Anticancer, other
	L-Ascorbic acid, mixt with 2- (diethylamino)ethyl 4-aminobenzoate monohydrochloride, disodium hydrogen				
Anticort	prospinate, potassium benzoate and zinc sulfate (1:1) [CAS]	186646-39-9	· S	9640038	
antidépressants, Nutrition				T	Antidonomen
anti-invasins, Microbla			7	1	Anticopie
			7	7	a ununigati

		_	 	1					_		_	_	- (_	_	_	_	<u>. </u>	· 		1.	
of Indication		eneration		ischaemic	ral				•	myocardial	.				·	ırax	. Jaj	•	•	.· ;	general	al, general
Example		Macular degeneration		Cardiomyopathy,	Cancer, general	· ·	Infection, Car			Infarction, my						Infection, anthrax	Cançer, general		•	Sobovia	Ìġ	Ę

	•	·.	Patent	i ti	···
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Antimony Potassium		28300-74-5			
Antimony Sodium		539-54-8	<u> </u>		
Thioglycollate		7 01 0010			
Antimony		6533-78-4	·· .		
	19-Norpregna-4,9-dien-3-				
	one,(acetylphenyl)-20,20,21,21,21-		. ·	•	-
Antipropestin	pentafluoro-17-hydroxy-(118,17Alpha) . ICASI	211254-73-8	<u>ଅ</u>	19706061	Anticancer, hormonal
Antipyrin		0-08-09			
Antipyrin Salicylate		520-07-0			
III, Kabi	Antithrombin, III [CAS]	9000-94-6 90170-80-2			Blood fraction
anxiolytics, Drug Discovery			S	5756538	Anxiolytic.
	N-Piperonyi-2-amino-1;2,3,4- tetrahydrobenzo(b)thieno(2,3-c)pyridine-3-				
AP-521	carbamide	151227-08-6	8	9321189	Anxiolytic
AP-5280			S	5965118	Anticancer, alkylating .
Apalcillin		63469-19-2		•	
	1H-Indole-4,7-dlone, 5-(1-aziridinyl)-3-	•			
apaziduone ·	(injuracy) - (CAS) - (CAS) - (CAS)	114560-48-4	WO:	WO 8706227	Anticancer, alkylating
Apazone		13539-59-8	٠.		
a-Phenylbutyramide		90-56-6		·	
		641-36-1			
	Phosphonic acid, (2-(3,5-bis(1,1-dimethylethyl)-4-				
spomine enimoda	nyaroxyprienyrjeu iyinderietidis- retrakis(1- methylethyl) ester [CAS]	126411-13-0			Anticancer, other
Apomorphine		58-00-4			
	4H-Dibenzolde, glquinoline-10,11-diol, 5,6,8a,7-tetrahydro-6-methyl-, hydrochloride				
apomorphine		314-19-2		· .	Formulation, transmucosal, nasal
apraclonidine	1,4-Benzenediamine, 2,6-dichloro-N1-(4,5- 66711-21-5 dihydro-1H-imidazol-2-yl)- [CAS]	66711-21-5 73218-79-8	Sn	4517199	Antiglaucoma

east neral aneral anera		 ·: ·		
	cample of Indication	Cancer, breast	genera genera genera preast	ાં કાં. કા

			١		
			Patent	ent	
API Generic Name	API Chemical Name	CAS No.	Ref	Reference	Example of Therapeutic Use
:					
	3H-1.2.4-Triazol-3-one. 5-II(2B.3S)-2-I(1B)-				
	1-f3.5-his/friflingmethy/hohenyllethoxyl-3-		_	<u>. </u>	
١	// [Colombook] 4-mombolipy[]mothyl-1 2-		<u>:</u>	<u>:</u>	
apreplant	(4-moorphiensy) - rinolphiennyijrije dibydm=[CAS]	170799-80-3	<u>u</u>	5710177	
		11012-00-0	3	1410110	יייייייייייייייייייייייייייייייייייייי
	1,3-Propanediamine, N-(2,3-dinydro-1H-	33237-74-0	_		:
aprillome	Inden-2-yi)-n',n'-diemyi-n-pnenyi-(CAS)	3/640-71-4	8	1321424	Antiarrhythmic
Aprobarbital		77-02-1	Ŀ	·	
Apronalid		528-92-7	ŀ	·.	
Aprotinin		9087-70-1			
Apticanel		137150.02.9		-	
	77 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	101103-25-0			
	adione, 1,4-bis((2- mino)ethyl)amino)-5,8-				
AQ4N	dihydroxy-[CAS]	136470-65-0	S	5132327	Anticancer, other
Aquavan · ·			Sn	6204257	Anaesthetic, Injectable
AR-116081			SO:	6107324	Neuroleptic
	(R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-				
	1,2,3,4-tetrahydro-2-naphthyl]-4-	•		•	· · · · · · · · · · · · · · · · · · ·
	morpholinobenzamide			:	
AR-A2					Anxiolytic ·
Arachidonic Acid	•	506-32-1			
,	3,5-Pyridinėdicarboxylic acid, 1,4-difiydro-			-	
	shenyl)-, methyl 2-	•		•	
aranidipine	oxopropyl ester- [CAS]	86780-90-7	GB	2111978	Antihypertensive, other
			·		
•	D-Streptamine, O-3-amino-3-deoxy-Alpha-	•			
_	D-glucopyranosyl-(1-6)-O-[2,6-diamino-				
			•		
			-		-
arbekacın	_	75282-65-4	മ	4001208	Aminoglycoside antibiotic
	1H-indole-3-carboxylic acid, 6-bromo-4-			•	
	((dimethylamino)methyi)-5-hydroxy-1-	•	•		•
Arbidol	metnyl-z-((pnenyimio)metnyi)-, etnylester, monohydmethoride ICASI	191707-99.8	. 6	. 3619000	and inclinations and
	0 114 /4		_	1	יוויותוספיתות שוול' סתובי
	1,2-belizeliedioi, 4-11-liyaloxy-z-[[4-(4- hidroxrahend)kityilemieoleikid] (0)	•			•
arbutamine .	:	128470-16-6	NO W	9220324	Diagnostic
Arcitumomab		154361-48-5	١.		
	Henarin [CAS]	9005-40-R		-	Antionaulant
		0.000	1		unicoagorain.
	•				

	٠.			•		•					•	•			••
Example of Indication		Chemotherapy-induced nausea and vomiting			Cancer, general	Anaesthesia	Únspecified ·	Anxiety, general	Hypertension, general			Infection, general	Infection, Influenza virus	Diagnosis, coronary	Thrombosis, venous
			•		•			٠.		•					•

		•	Patent	ant	
API Generic Name	API Chemical Name	CAS No.	Œ	R ference	Example of Therapeutic Use
	1,2,5,6-Tetrahydro-1-methyl-3-pyridine carboxylic acid methyl ester			. <u>.</u>	
arecoline, transdermal				٠.	Formulation, transdermal, patch
	2-Piperidinecarboxylic acid, 1-[5-			· .	
	.[(aminoiminomethyl)aminoj-1-0xo-2-	:			
• •	ll(\		<u>:</u>	•	
argatroban .	[CAS]	74863-84-6	品	8746.	Anticoagulant
Argatroban		74863-84-6			
Arginine .		74-79-3			
Ariflo@ .		153259-65-5			1
	2(1H)-Quinolinone, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinylibutoxyl-3,4-	•			
aripiprazole	dihydro-[CAS]	129722-12-9	Œ.	367141	Neuroleptic ·
<i>1</i> 3	1H-Purine-2,6-dione, 3-(4-chlorophenyl)-	·	·.		
arofylline	3,7-dihydro-1-propyl- [CAS]	136145-07-8	G.	435811	COPD treatment
	* *** C3 C3 C3 C4 C7 C4			ζ.	
. •.	z- niopnenecatooxamide, >-[z-1 3-1(1,1- dimethylethyl)amino]-2-hydroxypropyljthio]- 104766-23-6	104766-23-6	•		
arotinolol	4-thiazolyi]-, (±)- [CAS]	68377-92-4	S	3932400	Antihypertenslve, adrenergic
Arotinolol		68377-92-4			
Arsacetin		618-22-4			
arsenic trioxide	Arsenic oxide (As2O3) [CAS]	1327-53-3			Anticancer, other
Arsphenamine		139-93-5			
Arsthinol		119-96-0			
Arteeth r		75887-54-6			
Arteflene		123407-36-3 (Z-	•		• •
		form)	`		
Artemether		71963-77-4			
Artemisinin		63968-64-9		•	
	3,12-Epoxy-12H-pyrano[4,3-i]-1,2-benzodioxepin, 10-ethoxydecahydro-3,6,9-		•		
•				•	
artemotil .	12aR*)]- [CAS]	75887-54-6			Antimalarial
		•			•

	:		· ·	٠.	· .			٠	· . :.	•	· .•
of Indication			rial		ve pulmonary	neral	la, acute				•
Example of Ir		·	Thrombosis, arterial	Schizonhronia	Chronic obstructive pulmonary	Hypertension, general	Cancer, leukaemia, myelogenous				infection, malaria

:

			L			
			Patent	ent		
API Generic Name ::.	API Chemical Name	CAS No.	Ref	Reference	Exampl of Therapeutic Use	•
	:		Ŀ			
	Butanedioic acid mono-		<u>:</u> _	· .		
	[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-	-	•	•		-
	decahydro-3,6,9-trimethyl-3,12-epoxy-,12H-	· .		·. ·	٠	
	pyrano[4,3-j]-1,2-benzodioxepin-10-yilester		·:		•	
artesunate ·		88495-63-0	:	•	Formulation, transmucosal, systemic	
	Benzo(b)thiophene-6-ol, 2-(4-					
· -	methoxyphenyl)-3-(4-(2-(1-	•	· ·	. •		
	piperidinyl)ethoxy)phenoxy)-, hydrochloride	•				
arzoxifene hydrochloride	[CAS]	182133-27-3	8	9609041	Anticancer, hormonal	
	Spiro(pvrrolidine-3,4'(1'H)-pvrrolo(1,2-		L	:		
	a)pyrazine)-1',2,3',5(2'H)-tetrone, 2'-((4-	•	•			
	bromo-2-fluorophenyl)methyl)-, (3'R)-					
AS-3201	[CAS]	147254-64-6	<u>m</u>	520320.	Symptomatic antidiabetic	
		50-78-2				
ASA, Benzon	Benzoic acid, 2-(acetyloxy)- [CAS]	56449-07-1		: ·	Formulation, modified-release, other	
ASA, Маупе	Benzoio acid, 2-(acetyloxy)- [CAS]	50-78-2	ŀ		Formulation, modified-release, other	
					Formulation, optimized,	
ASA, Micropump	Benzoic acid, 2-(acetyloxy)- [CAS]	50-78-2			microencapsulate .	
ASA, Verex	Benzolc acid, 2-(acetyloxy)- [CAS]	50-78-2 56449-07-1	. Sn	4375468	Formulation, modified-release, >24hr	
α-Santonin		481-06-1				
Ascaridol		512-85-6	ŀ			
Ascorbic Acid		50-81-7		ŀ		•
· · · ·	1.H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole; 5-					
	chloro-2,3,3a,12b-tetrahydro-2-methyl-,			.,		
asenapine maleate	trans-, (Z)-2-butenedioate (1:1) [CAS]	85650-58-2	80	9523600	Neuroleptic	
	Benzeneacetamide, N-[2-(3-hydroxy-1-					
	-pyrrolidinyl)-1-phenylethyl]-N-methyl-Alpha-		ì	•		
asimadollite	pnenyi-, [3-(11,11-)]- [CAS]	153205-46-0	2	4215213	Gl inflammatory/bowel-disorders	
	11B-[4-(Hydroxyiminomethyl)phenyl]-17B- -methoxy-17Alpha-(methoxymethyl)estra-		·:-·			
asoprisnil.		199396-76-4	<u>.</u>	0648778	Menstruation disorders	
Asoxime Chloride		34433-31-3	ľ			
Aspartic Acid		56-84-8	:			
Aspldin		584-28-1	1			
Aspidinol		519-40-4	ŀ			
Aspirin · · ·	•	50-78-2	1			
			1			

,		<u> </u>	• •	·
Example of Indication	Cancer, breast	Diabetic complication, general Pain, general Thrombosis, general Infarction, myocardial Arthritis, general	Psychosis, general Irritable bowel syndrome	Endometriosis
:			•	•

•			Patent	E	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Aspirin, Diovridamole		.· :			
	Givcinamide. N-methyl-D-asparadinyl-N-(2-				
	carboxy-3,3-dimethyl-7-oxo-4-thia-1-	· :			
	azablcyclo[3.2.0]hept-6-yl)-D-2-(4-		•	_	
1	hydroxyphenyl)-, [2S-(ZAIpna,5AIpna,6b)]-	63358.40.6	ď	1533413	Penicillin, injectable
aspoxiciini Act 420	(SAS)	90597-58-3			Urological
A character		G8844-77-9			
Asiemizoi	- Name of O of the second of t	2			
	xamide, 9-[/2-menioxy-4- /amino]phenyl]amino]-N,5-	80841-47-0	1		
asulacrine .	dimethyl- [CAS]	80841-48-1	di l	39224	Anticancer, other
	(N-[2-[4-(5H-Dibenzo[a,d]cyclohepten-5-	•			:
· .	yligene)-piperginojeuriyi-1-torinyi-4- piperidinecarboxamide monohydrochloride				
	monohydrate	•			Aptithrombotic
AT-1015					
atamestane	Androsta-1,4-diene-3,17-dione, 1-methyl- [CAS]	96301-34-7	E.	3338212	Anticancer, hormonal
			•	•	
•	2,5,6,10,13-Pentaazatetradecanedioic	•		•	
	acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-				
	4,11-dioxo-9-(phenylmethyl)-6-((4-(2-	•	•		
	pyridinyl)phenyl)methyl)- dimethyl ester,	7.20 320000			Antiviral anti-HIV
atazanavir	(35,85,95,125)-, sulfate (1:1) (sail) [CAD]	7-76-01-677			All ship the
atenolol	Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- [CAS]	29122-68-7 73677-19-7	GB	1285038	Antihypertensive, adrenergic
	Benzeneacetamide, 4-iz-nydroxy-3-i(1-		•	•	
•	chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-		:		
atenotol + chlorthalidone	isoindol-1-yl)benzenesulfonamide [CAS]	73677-19-7	SA	3836671	Formulation, fixed-dose combinations
	Benzeneacetamide, 4-[2-hydroxy-3-[(1-	•	•	· · .	
··.	memylemyl)anunojpropoxyj- + 4-(<- hitropienyl)-2,6-dimethyl-3,5-			•	
	dicarbomethoxy-1,4-dihydropyridine				andipolitance cook hours and all and
atenofol + nifedipine	٠				Formulation, alxed-dose combinations
α-Terpineol		98-55-5			
Atevirdine		136816-75-6			·

Example of Indic Infection, respiratory t general Renal failure Cancer, general Thrombosis, general Cancer, breast Chrombosis, general Hypertension, general
--

			l		
,			Patent	=	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
atinamazole	·1H-Imidazole, 4-(2-ethyl-2,3-dihydro-1H- inden-2-vi)- [CAS]	104054-27-5	G.	183492	Reproductive/gonadal, general
	2-Azaspivo[4.5]decane-2-propanamine,			···	
ofcolomily bomin-its	N,N-dietnyi-e,e-dipropyi, dimaledie	130065-61-1	. S	57,44495	Antiarthritic, immunological
ATI 1486			ns	6232297	Imaging agent
Toophoro!		59-02-9			
Q-1 Ocopiter of	Benzenepropanamine, N-methyl-Gamma- (2-methylohenoxy)-, (R)- [CAS]	82248-59-7 83015-26-3	싎	52492	Neurological
Ë		134523-00-5			
	1H-Pyrrole-1-heptanoic acid, 2-(4- fluorophenyl)-8,delta-dihydroxy-5-(1-		1		
otonoctatio calcium	methylethyl)-3-phenyl-4- [[phenylamino]carbonyl]-, calcium salt [R- (R+R-)-ICASI	134523-03-8	. W	409281	Hypolipaemic/Antiatherosclerosis
מנון ענטוניון כמסופון	Oxytocin, 1-(3-mercaptopropanoic acid)-2-			· ·~	
atosiban	omithine-[CAS]	90779-69-4	G.	112809	Labour inhibitor
Atosiban	·	90779-69-4		·	
alovacijone	1,4-Naphthalenedlone, 2-{4-(4-chiorophenyl)cyclohexyl]-3-hydroxy-, trans-(CAS)	95233-18-4	. a	123238	Antifungal
	1,4-Naphthalenedione,2-[4-(4-chlorophenyl)cyclohexyll-3-hydroxy-,trans				
atovanuone + proquanii. GSK	+ N-(4-cind to-plietry) - 4-(1) methylethyl)imidiodicarbonimidic diamide				Antimalarial
	Isoquinolinium, 2,2-(1,5- pentanediylbis[oxy(3-oxo-3,1- propanediyl]]bis[1-{(3,4- dimethoxynheny)methyll-1,2,3,4-				
atracurium besilate	tetrahydro-6,7-dimethoxy-2-methyl- dibenzenesulfonate [CAS]	64228-81-5 ··	S)	4179557	Muscle relaxant
	3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-, (PR 3R 4S)- [CAS]	173937-91-2	. o	9730045	Anticancer, other
arasentan	(41)01,177 (77)				

_	••		
<u>, щ</u>	xample of Indication		
Ű	exual dysfunction, female	· .	
٠.,	1.		
₹	Arthritis, rheumatold		
ΞÌ	Unspecified .		
₹	Attention deficit disorder		
1		•	
<u> </u>			
<u> </u>	•		
	eimoclosofodomos		
= 1	lyperonoresterorection		
<u> </u>	abour, preterm		
		<u>_</u>	
루	Infection, Pneumocystis jiroveci		
		_	
	.:	· ·	
		•	
≕i	infection, malaria		
	٠.		
<u> </u>			
	Surgery adjunct		
-	٠.		
<u> </u>	Sancer, prostate	_	

:		•	Patent		
ADI Generic Name	API Chemical Name	CAS No.	R fe	R ferenc	Exampl of Therapeutic Use
Atrial Natriuretic Peptide		85637-73-6			
44144		2019-68-3			
Atrolaciamine		51-55-8	_		•
Atropine		74469-00-4			Formulation, modified-release, other
	Gold, (1-thio-B-D-glucopyranose 2,3,4,6-	34031-32-8	. Su	3708579	Antiarthritic, other
Aurathiodin		12192-57-3			
	Sulfamic acid, [[2,4,6-tris(1-metryletrylphenyl]acetyl]-, 2,6-bis(1-metryletryllohenyl ester [CAS]	166518-60-1	Sn	5491172	Hypolipaemlc/Antiatherosclerosis
dvasumo		70356-09-1	Ŀ		
AVODERIZORE	AWD 12-281 [CAS]	257892-33-4			Antiallergic, non-asthma
Azacitidine		320-67-2			
Ανασινοίοποί		115-46-8	\cdot		
azapidazole	(2-Pyrimidinamine, 4-[2-(1:methyl-5-nitro-1H-imidazol-2-yl)ethenyl]-,(E)- [CAS]	62973-76-6	Sn	3882105	Antibacterial, other
	11.3(2H)-dione, 5-(dimethylamino)-9-methyl-	13539-59-8	Æ	1440629	Anti-Inflammatory
azapropazone	Constitution of the consti	115-02-6			
Azaserine	2H-1 4-Benzoxazine-8-carboxamide. N-1-				
	azabicyclo[2.2.2]oct-3-yl-6-chloro-3,4-	123040-16-4	•	· 	•
	dihydro-4-methyl-3-oxo-, monohydrochloride- [CAS]	123040-94-8	Ш	313393 . :	Antiemetic
Asserve		123040-69-7			·
Azatadine		3964-81-6			
Azəthlonrine		446-86-6			
Acamopuno	6-[(1-Methyl-4-nitro-1H-imidazol-5-yl)thlo]- 1H-purine		:		Formulation, oral, other
azathioprine		0-00-044		.	
AZD-4282	glycine		•		Analgesic, other
AZD-6140	3,4 Diffuorophenylcyclopropylamine	·	:	۹.	Antithrombotic
Azolain Anid		123-99-9			
Actiain Avia				· ·	

Example of Indication Infection, respiratory tract, general Arthritis, rheumatoid Arthritis, allergic, general Infection, trichomoniasis Infection, trichomoniasis Anasplant rejection, bone marrow Pain, neuropathic Thrombosis, arterial

		•	Patent	int	
API Generic Name	API Chemical Name	CAS No.	H +	R f rence	Exampl of Therapeutic Use
azelaic acid	Nonanedloic acid [CAS]	123-99-9			Antlacne.
Az lastin		58581-89-8		-	
	1(2H)-Phthalazinone; 4-[(4-	•		•	
	methyl-1H-azepin-4-yl)-,	58581-89-8			
. azelastine	monohydrochloride [CAS]	79307-93-0	3	13//231	Antiastrinia
	3,5-Pyrldinedicarboxylic acid, 2-amino-1;4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-[1-dihpenylmethyl-3-azetidinyl] 5-(1-			·	
	methylethyljester, (+/-)-[CAS]	123524-52-7	G	266922	Antihypertensive, other
Azidamfenicol		13838-08-9			
Azidocillin		17243-38-8	·	.]	
Azimilid		149908-53-2			
Azintamide		1830-32-6		.]	
		76801-85-9			
· · · · · · · · · · · · · · · · · · ·	9-deoxo-9a-aza-9a-methyl-9a- homosodhomycin-A	83905-01-5 92395-24-9	.s	4328334	Macrolide antibiotic
Azithromycin		83905-01-5			
	9-deoxo-9a-aza-9a-methyl-9a-				•
··	homoerythromycin-A				Formulation, modified-release, other
	0 0000000000000000000000000000000000000				
	4-Thia-1-azaoicycio(3.2.u/neptane-z-carboxylic acid, 3,3-dimethyl-7-oxo-6-[[[(2-	٠.	:	•	
	oxo-1-				
· · · · · · · · · · · · · · · · · · ·	imidazolidinyi)carbonyijamiinojpnenyiacetyij aminoj-, [2S-[2.alpha.,5Alpha,68(S*)]]-				
azlociliin	[CAS]	7	<u>n</u>	1392849	Penicillin, injectable
Azosemide		27589-33-9			
	Propanoic acid, 2-[[11-(2-amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)aminol-2-			,	
aztreonam	oxoethylidenejaminojoxyj-2-methyl-, [2S- [2Aipha,38(2)]]-[CAS]	104184-69-2 78110-38-0	ĊВ	2071650	Beta-lactam antibiotic
	Propanoic acid, 2-[[[1-(2-amino-4-thiazoly!)-				
artronam	azetidinyl)amino]2- loxoethylidene]amino]oxy}-2-methyl-, [2S- [2Alnha.38/2]]- [GAS]	104184-69-2 78110-38-0			Formulation, inhalable, topical
athoulan			.	·	

Example of Indication	•
	•
Asthma	
Hypertension, general	
Infortion recoveration tract	
respinatory .	
	•
	•
Conjunctivitis	•
	•
	•
Infection, general	
Infection deneral	
•	
Infection, respiratory tract,	
general.	_

· ·		•	Patent	, t	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
azulene .	Sodium 5-isopropyl-3,8-dimethyl-1-azulene sulfonate	6223-35-4	G.	88958	Formulation, modified-release, other
·	4-Thia-1-azabicyclo[3.2.0]heptane-2-		•		
	carboxylic acid, 6- I/aminophenylacetyllaminol-3.3-dimethyl-7-	•		•	
•	oxo- 1-[(ethoxycarbonyl)oxy]ethyl ester,	37661-08-8		1383808	Denicillin oral
bacampicillin	[2S-{2Apha,5Apha,68(S-)]]- [CAS]	50972-17-3	3	200000	
Bacampicillin		50972-17-3			
Bacitracin		1405-87-4			
baclofen	6-(Aminomethyl)-4- chlorobenzenepropanoic acid [CAS]	1134-47-0			Formulation, Implant
Baicalein		491-67-8		,	
	3-Quinolinecarboxylic acid, 1-cyclopropyl-6		•		
balofloxacin	(methylamino)-1-piperidinyl]-4-oxo-[CAS]	127294-70-6	급	342675	Quinolone antibacterial
o principal di	Benzoic acid, 5-[14-[1(2-carboxyethyl)amino]carboxyethyl]amino]carbonyl]phenyl]azo]-2-hydroxy- (FI-CAS)	80573-04-2		4412992	GI inflammatory/bowel disorders
Bambuterol	facility (a) the facility	81732-65-2	-		-
dilibarcioi		 			
	Carbamic acld, dimethyl-, 5-[2-[(1,1-dimethylethyl)]-1,3-	· · ·		•	
bambuterol	phenylene ester, monohydrochloride [CAS] 81732-46-9	81732-46-9	<u>ا</u>	43807	Antiasthma
Bamethan · ·		3703-79-5	-		
Bamifvlline		2016-63-9		•	
Bamipine		4945-47-5			
Barbital		57-44-3			
	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl), methyl-1-		٠.		
. ·	(phenylmethyl)-3-pyrrolidinyl ester, (S-	104713-75-9 104757-53-1	•		
barnidipine '		71863-56-4	Sin	4220649	Antihypertensive, other
Barnidipin		104713-75-9			
97	N-Methyl-3-{2-(2- napthyl)acetylamino]benzamide		•		Antibacterial; other
BAS-110] .		

Example of Indication	•
nfection, general	
Spastic paralysis	
	•
infection, urinary tract	
	••
Colitis, ulcerative	
Ashina	
	•
Infection, Helicobacter pylori	
	_

			Patent		
API Generic Name	API Chemical Name		Refe	Reference	Example of Therapeutic Use
Basic Aluminum		1339-92-0	•		
Carbonate Gel			7	•	
Raciliyimah		179045-86-4	7		
Datimoctot		130370-60-4	-		
Batrovohin		9039-61-6			
Dallovonin	É cuclearond-2-[1/2-fluoro-benzyl)-1H-				
	pvrazolo[3,4-b]pvridine-3-v]pvrimidin-		<u> </u>	•	
•	4ylamine	•	•	•••	
Bav-41-2272					Male sexual dysrunction
	2-[1-(2-Fluorobanzyi)-1H-pyrazolo[3,4-	•		•	•
•	b]pyridin-3-yl]-5-(4-mopholinyl)pyrimidine-			•	
	4,6-diamine		•	٠.	Cardiovascular
Bay-41-8543					
	N-(4-chioro-3-(trifluoromethyl)phenyl)-N'-(4-				
•	(2-(N-methylcarbamoyl)-4-	(
	pyridyloxy)phenyl)urea				Anticancer, other
BAY-43-9006			T		
	N-[5(aminosulfonyl)-4-methyl-1,3-thiazol-2-				
	yl]-N-methyl-2-[4-(2-	:		•	
	pyridinyl)phenyljaceramide .	•			Antiviral, other
BAY-57-1293		108481.33.3	a	802183	Osteoporosis treatment
bazedoxifen	TSE 424 [CAS]	1900 171	1		
R-Benzalbutyramide		7236-47-7			
	Platinum(4+), hexaaminedichlorobis(u-(1,6	•	-	· ·	
	hexanediamine-N:N'))tri- stereoisomer,	172903-00-3	SN	5744497	Anticancer, alkylating
BBH-3464	ובתקוווומום (סעס)		П	5519029	Anticancer, antibiotic
BBR-3576			Т	6060616	Anticancer, alkylating
BBR-3610		7235-40-7			
8-Carotene	in a single in the single in t		[
	(-)-2-H-dinydroxypnospriinyor-3-(-)-(guaiiii) 9-v -methyl)tetrahydrofuran			••	etilodetemine zonecites
BCH-1868					Anticaricer, artimotacomo
Boho rine		477-60-1			
Borlamide		501-68-8			
	Pregna-1,4-dlene-3,20-dione, 9-chloro-				
	118,17,21-trihydroxy-16β-methyl, 17,21-dipropipate ICASI	5534-09-8	WO.	0006132	Formulation, inhalable, solution
Decinitions of the second of t					

	·		· .	· · · · · · · · · · · · · · · · · · ·	· .	· · · ·	
Example of Indication		Sexual dysfunction, male, general	Unspecified Cancer, liver	Infection, herpes simplex virus Osteoporosis	Cancer, lung, non-small cell	Jancer, general	Sthma

API Generic Name Pregna-1,4-diene-3,20-dione, 9-chloro-11,17,21-trihydroxy-16-metryl-, (118,16 [CAS] Befloxatone Ethanone, 1-[7-[2-hydroxy-3-f(1-methylethyl)aminolpropoxy]-2-benzoturanyl]-[CAS] Benactyzine Benactyzine Benactyzine Benactyzine Benactyzine 1H-1-Benzazepine-1-acetic acid, 3-f[1-(ethoxycarbonyl)-3-phenylpropyl]amino 2,3,4,5-tetrahydro-2-oxo-, [S-(R*,R*)]-(CAS] Bencyclane 1-Prognammine, N,N-dimetryl-3-f[1-(phenylmetryl)-y-(E)-2-butenedioate (1:1) [CAS] Bendazac Bendazac Bendazac Ethanol, 2-[1-methyl-2-[3-(trilluoromethyl)phenyl]athilo-1-	(g)	CAS No. 6419-39-0 134564-82-2 38543-79-8 39552-01-7 64-65-3 302-40-9 86541-75-5 86541-75	Referent Reference Referen	nce 352	Example of Therapeutic Use Formulation, Inhalable, dry powder Antiglaucoma Antihypertensive, renin system Vasodilator, peripheral
Name		5-7-7-2	WO EP ON		Example of Inerapeutic User Formulation, Inhalable, dry powder Antiglaucoma Antihypertensive, renin system Vasodilator, peripheral
ethiazide		88 8 8 5-7 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			Formulation, Inhalable, dry powder Antiglaucoma Antihypertensive, renin system
ethiazide		5-7			Formulation, Inhalable, dry powder Antiglaucoma Antihypertensive, renin system Vasodilator, peripheral
ethiazide	1. id, 3-[[1- y/jamino]- 	88 8 8 8 8 9 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		72352	Antiglaucoma Antihypertensive, renin system Vasodilator, peripheral
e e e e e e e e e e e e e e e e e e e	1. id, 3-[[1- y/jamino]- 	8 2 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5		72352	Antiglaucoma Antihypertensive, renin system Vasodilator, peripheral
e e nethiazide	io, 3-[[1- 7, R"]]- 7-([1- 7-(E)-2-	5 7-5		72352	Antiglaucoma Antihypertensive, renin system Vasodilator, peripheral
e e e e e e e e e e e e e e e e e e e	-acetic acid, 3-[[1- henylpropyljamino]- oxo-, [S-(R*,R*)]- -dimethyl-3-[[1- heptyljoxy]-, (E)-2- SAS]	8 8 8 5-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7		72352	Antihypertensive, renin system
e nethiazide		8 8 8 9 7 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 -		72352	Antihypertensive, renin system
ane ac ac lumethiazide le	5			72352	Antihypertensive, renin system
ane e ac lumethiazide le	Ġ	2		72352	Antihypertensive, renin system Vasodilator, peripheral
ane e ac Iumethiazide le				72352	Antihypertensive, renin system Vasodilator, peripheral
ane ac Iumethiazide le		7			Vasodilator, peripheral
g		7-1			Vasodilator, peripheral
ep ep		7-		•	Vasodilator, peripheral.
g		0187-55-7		9829409	
de			٦		
de		81919-14-4	GB	2081708	Ophthalmological
2		73-48-3			
		78718-25-9			
(trifluoromethyl)phen	· -	•			· .
henzoate (ester) [CAS]	ethyljaminoJ-,	23602-78-0	GB .	1175516	Hypolipaemic/Antiatherosclerosis
		22457-89-2			
Benfurodil		3447-95-8			
H misuccinate			1		
	3.5-Pvridinedicarboxylic acid, 1,4-dihydro-	• . •			
2,6-dimethyl-4-(3-nit		105979-17-7			•
(pnenylmetnyl)-3-ptperfatryl sater, monohydrochloride (R*,R*)-(4/-)-[C	· [S		Е	63365 · ·	Antihypertensive, other
10		5003-48-5			
Bonovanrofan		67434-14-4			
Benovinste		99-43-4			
Benoaridol		2062-84-2		••	
Donardon		2156-27-6			

·	·.	•		<u>:</u>	-, · -			T -T		-		1 (:					1	_
	5		-				٠.					-	}	•				
	·	\cdot $\left \cdot \right $		$ \cdot $	1	ara .		1.	:						eral			
1 !		· .		$ \cdot $, general	· :			ľ					, general			Ì
	0 0				.1	nsion			[•	ļ			٠.	pertension			
	Kam	sthma				pertension,				.	· .	1.1			yperte	.		1
يـــا	ш	ह्यां	L				<u></u>	ليا		<u> </u>	<u> </u>	4		 -	£	بــــ	٢	

			Patent		
	ADI Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
API Generic Name	Ari Ordinical value	322-35-0			
Benserazide			T		
	2H-[1]Benzothieno[2,3-e]-1,4-diazepin-2-	29462-18-8	<u>.</u> " B	2005276	Anxiolytic
bentazepam	מופי וימימין מימין מימין מימין מימין מימין	37106-97-1			
Bentiromide		1340-69-8	[•
		8001-54-5	-		
Benzalkonium Chloride					
Benzaron		1477-19-6			
	Methanone, (3,5-dibromo-4- hydroxypheny))(2-ethyl-3-benzofuranyl)-	3562-84-3	. S	3012042	Antigout
benzbromarone Benzethonlum Chloride		121-54-0			
		14051-33-3			
Benzetimide		1050-48-2		:	
Benzilonium Bromide		68-90-6			•
Benziodarone	N-henzyl-9-nitmimidazole-1-acetamide	22994-85-0	88	1138529.	Protożoacide
Denzhidazule		94-09-7			
Benzocaine					
Вепхосатие		7 00 70			Formulation, fixed-dose combinations
benzocaine, Vinas	Benzoic acid, 4-amino-, ethyl ester	44-09-7			
Benzoctamine		17243-39-9			7
R nzonatate		104-31-4			
B nzoxonium Chloride		19379-90-9			
Borovida		94-36-0	·		
benzoyi reloxide	Peroxide, dibenzoyl.[CAS]	94-36-0			Formulation, other
Delizing peroxida		13898-58-3			
Denzoyipas		156-08-1		·	•
Benzpheralon		53-89-4			
Donzelinamide		63-12-7		:	
Denzihiazida		91-33-8			
Dentioning Maculate		132-17-2	·		
Denzirophile mesylare		642-72-8			
В пхудаппие				١.	

Exa

Patent						
API Chemical Name CAS No. Refer nce N-(Alpha Alpha-Urilluor-m toly) antranylate of 1-benzyl-3 3- dimethylamine-propoxil-1H-imidazol 132-69-4 1-propanamine, N,N-dimethyl-3- 1- 132-69-4 (phenylmethyl)-1H-indazol-3-yljoxyl- (CAS) 642-72-8 (phenylmethyl)-1H-indazol-3-yljoxyl- (CAS) 642-72-8 1-propanamine, N,N-dimethyl-3- 1- 14297-87-1 1-propanamine, N,N-dimethyl-3- 1- 14297-87-1 1-propanamine, N,N-dimethyl-N-h-yl-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-	•	:		Paten		
Ni-(Alpha Alpha-Alpha-Arifiuor-m	API Generic Name	API Chemical Name		Refer	nce	Example of Therapeutic Use
1-Propanamine, N,N-dimethyl-3-[[1-4] 132-69-4 120-51-4 120-51-4 120-51-4 120-51-4 120-51-4 1824-50-6 120-51-4 1824-50-6 120-51-4 1824-50-6 120-51-4 1824-50-6 1-Propanamine, D-(1-4-4-4-4-3-7-4-4-4-4-4-4-4-4-4-4-4-4-4-4	benzvdamine flufenamate	N-(Alpha, Alpha, Alpha-trifluor-m tolyl)antranylate of 1-benzyl-3[3- dimethylamine-propoxi]-1H-imidazol			· .	Anti-inflammatory, topical
hiazi hiazi hiazi hiazi hiazi hiazi hiazi hiazi hiazi 120-51-4 14297-87-1 14297-87-1 14297-87-1 190786-43-7 190786-43-7 190786-43-7 1-Pyrolidineethanamine, 0-{(4-(4-6-6-6-6-6-6-6-6-6-6-6-6-6-6-6-6-6-		CAS	132-69-4 642-72-8	· · ·		Stomatological, reproductive/gonadal, anti-inflammatory
1824-50-6 1824-50-6 1824-50-6 1824-50-6 1824-50-6 180786-43-7 1-71peridinebutanote acid, 4-((4-chlorophenyl)-2-pyridinylmethoxy)-, (S)-, 190786-44-8 WO 9829409 WO 9829409 WO WO WO WO WO WO WO W	Denzydamine					
14297-87-1 14297-87-1 11-Pipertdinebutanole acid, 4-((4- chlorophenyl)-2-pyridinylmethoxyl-, (S)-, monobenzenesulfonate Jel(2- 1-Pyrrolidineethamamine, 9-((2- 1-Pyrrolidineethamamine, 9-((2- 1-Pyrrolidineethamamine, 9-((2- 1-Pyrrolidineethamamine, 9-((2- 1-Pyrrolidineethamamine, 9-((2- 1-Pyrolopentalp)penzofuran-5-butanolc acid, 2,3,3a,8b-ferrahydroxy-1-(3- 144-20-8 144-20-8 11-0-2-Pyridineethamamine, N-methyl-, (181,68)-107-43-7 11-0-2-Pyridineethamamine, N-methyl-, (181,68)-107-43-7 11-17,21-trihydroxy-16-methyl-, (118,168)-107-43-5 11-17,21-trihydroxy-16-methyl-, (118,168)-10-28-6 11-17,21-trihydroxy-16-methyl-, (118,168)-10-28-6 11-17,21-trihydroxy-16-methyl-, (118,168)-10-28-6 11-2-2-2-2-1-1-1-2-2-2-1-1-2-2-2-1-1-2-2-2-1-1-2-2-2-2-1-1-2-2-2-2-1-2	izyi belizoate izyihydrochlor		1824-50-6	•		
190786-43-7 190786-43-7 190786-43-7 190786-44-8 190786-44-8 190786-44-8 190786-44-8 190786-44-8 190786-44-8 1-Pytrolidineethanamine, G-{(2-1)	de.		14297-87-1			
190786-43-7 1-Pipertdinebutanoic acid, 4-((4- chlorophenyl)-2-pyridinylmethoxy)-, (S)-, monobenzenesulfonate [CAS] 1-Pyrrolidineethanamine, B-((2- methylpropoxy)methyl]-N-phenyl-N- (phenylmethyl)- [CAS] 1H-Cyclopenta[b]benzofuran-5-butanoic acid, 2,3,3a,8b-fetrahydro-2-hydroxy-1-(3- hydroxy-4-methyl-1-octen-6-ynyl)- [CAS] R8430-56-6 Betaine- [CAS] 2-Pyridineethanamine, N-methyl-, G579-84-0 Ginydrochloride Betaine- [CAS] Pregna-1,4-diene-3,20-dione, 9-filuoro- 11,17,21-trihydroxy-16-methyl-, (18,169)- [CAS] S734,24-6 Bregna-1,4-diene-3,20-dione, 9-filuoro- 11,17,21-trihydroxy-16-methyl-, (18,169)- [CAS] S734,24-6 S734,24-6 S734,24-6 S734,24-6	Benzyilliorphille		3818-50-6			
190786-43-7 1-Piperidinebutanoic acid, 4-((4- chlorophenyl)-2-pyridinylmethoxy)-, (S)-, monobenzenesulfonate [CAS] 1-Pyrolidineethanamine, 0-{(2- methylpropoxy)methyl}-N-phenyl-N- (phenylmethyl)- [CAS] 1-H-Cyclopenta[b]benzofuran-5-butanoic acid, 2,3,3a,8b-fetrahydro-2-hydroxy-1-(3- hydroxy-4-methyl-1-octen-6-ynyl)- [CAS] 2-Pyridineethanamine, N-methyl-, g579-84-0 ginydrochloride Betaine- [CAS] Pregna-1,4-diene-3,20-dione, 9-filuoro- 11,17,21-trihydroxy-16-methyl-, (118,169)- [CAS] 3734,24-5	D piterituiri Hydroxynanhthoate					
tine chlorophenyl)-2-pyridinylmethoxy)- (S)- I-Pyrrolidineethanamine, G-{(4- chlorophenyl)-2-pyridinylmethoxy)- (S)- methylpropoxy)methyll-N-phenyl-N- refine chloropentalb benzofuran-5-butanolc acid, 2,3,3a,8b-fatrahydro-2-hydroxy-1-(3- hydroxy-4-methyl-1-octen-6-ynyl)- [CAS] IH-Cyclopentalb benzofuran-5-butanolc acid, 2,3,3a,8b-fatrahydro-2-hydroxy-1-(3- hydroxy-4-methyl-1-octen-6-ynyl)- [CAS] ppen pten pprofen (119257-34-0 clinydrochloride 5579-84-0 dinydrochloride 5539-7-6 Betaine- [CAS] Interport (118,169)- Pregna-1,4-diene-3,20-dione, 9-fluoro- Interport (11,17,21-trihydroxy-16-methyl-, (118,169)- profen (CAS) Interport (118,169)- Betaine- [CAS] Interport (118,169)- Interport (118,16	Benotastine		190786-43-7			
The control of the		1-Piperidinebutanolo acid, 4-((4-chiorophenyl)-2-pyridinylmethoxy)-, (S)-,	190786-44-8			, , Antiallergic, non-asthma
1-Pyrrolidineethanamine, 19-(12-7-74764-40-2) (phenylmethyl)- [CAS] 11-Pyrrolidineethanamine, N-methyl-, (118,168)- (phenylmethyl)- [CAS] (phenylmethyl)- [C	bepotastine	monobenzenesunonale [cxo]	24.00.00		1.	
the properties of the properties of the properties of the profession of the properties of the properti			74764-40-2			
1H-Cyclopenta[b]benzofuran-5-butanoic acid, 2,3,3a,8b-fetranydro-2-hydroxy-1-(3-1474802 acid, 2,3,3a,8b-fetranydro-2-hydroxy-1-(3-18430-50-6 acid, 2,3,3a,8b-fetranydro-2-hydroxy-1-(3-18430-50-6 acid, 2,3,3a,8b-fetranydro-2-hydroxy-1-(3-14-20-8 acid, 2,3,3a,8b-fetranydro-2-hydroxy-1-(3-14-20-8 acid, 2,3,3a,8b-fetranydro-2-hydroxy-1-(3-14-20-8 acid, 2,3,3a,8b-fetranydroxy-1-(3-14-20-8 acid, 2,3,3a,3a,8b-fetranydroxy-1-(3-18,169)-acid, 2,3,3a,3a,4b-fetranydroxy-1-(3-18,169)-acid, 2,3,3a,3a,3a,4b-fetranydroxy-1-(3-14-1618-3,20-dione, 9-fluoro-11,17,21-trhydroxy-1-(3-18,169)-acid, 2,3,3a,3a,4b-fetranydroxy-1-(3-18,169)-acid, 2,3,3a,4b-fetranydroxy-1-(3-18,169)-acid, 2,3,3a,4a,5a,5a,5a,5a,5a,5a,5a,5a,5a,5a,5a,5a,5a			74764-75-3	1	146155	Antianginal
st. 1H-Cyclopenta[b]benzofuran-5-buttanotc acid, 2,33a,8b-fetrahydro-2-hydroxy-1-(3-88430-56-6 rost hydroxy-4-methyl-1-octen-6-ynyl)- [CAS] 88430-56-6 pten hydroxy-4-methyl-1-octen-6-ynyl)- [CAS] 88430-56-6 pten hydroxy-4-methyl-1-octen-6-ynyl)- [CAS] 88430-56-6 pten hydroxy-4-methyl-1-octen-6-ynyl)- [CAS] 98430-56-6 pten hydroxy-16-methyl-1-octen-6-ynyl)- [CAS] 98430-50-6 pten hydroxy-16-methyl-1-octen-6-ynyl)- [CAS] 9734-24-5 pten hydroxy-16-methyl-1-octen-6-ynyl)- [CAS] 9734-24-5						•
tost rost rost rost rine pten		1H-Cyclopenta[b]benzofuran-5-butanoic		<u></u>		
riost 88430-50-6 rine 2086-83-1 pten 484-20-8 rdine 2-Pyridineethanamine, N-methyl-, dihydrochloride 5579-84-0 fine Betaine- [CAS] 107-43-7 prasone In 17,21-trihydroxy-16-methyl-, (18,169)-17-4-6 3734-94-6 prosone ICAS] 3740-28-6 prosone 3734-24-5	heraprost	acia, z,s,sa,ob-tenanyuro-z-riyuroxy-1 (O) hydroxy-4-methy(-1-octen-6-ynyl)- [CAS]	88475-69-8		474802	Proștaglandin
rine 2086-83-1 pten 484-20-8 sprofen 78499-27-1 rdine 2-Pyridineethanamine, N-methyl-, G579-84-0 5579-84-0 dihydrochloride 5639-76-6 5638-76-6 me Betaine- [CAS] 107-43-7 Pregna-1,4-diene-3,20-dione, 9-fluoro-, 11,17,21-trihydroxy-16-methyl-, (118,163)-, 378-44-9 378-44-9 phasone [CAS] 3440-28-6 phron 3734-24-5	Beraprost		88430-50-6			
pten 484-20-8 pprofen 78499-27-1 rdine 2-Pyridineethanamine, N-methyl-, dihydrochloride 5579-84-0 fine Betaine- [CAS] 107-43-7 Pregna-1,4-dlene-3,20-dione, 9-fluoro-, 11,17,21-trihydroxy-16-methyl-, (118,168)-, 378-44-8 378-44-8 Ipron 3734-24-5	Rerherine	•	2086-83-1			
pprofen 78499-27-1 rdine 2-Pyridineethanamine, N-methyl-, dinydrochloride 5579-84-0 ine Betaine-[CAS] 107-43-7 Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (118,169)-378-44-8 378-44-8 ilpron 3734-24-5	Bergapten		484-20-8			
rdine 2-Pyridineethanamine, N-methyl-, G579-84-0 dihydrochloride 5579-84-0 5638-76-6 5638-76-6 107-43-7 ne Betaine- [CAS] 107-43-7 11,17,21-trihydroxy-16-methyl-, (118,169)- 378-44-8 [CAS] hasone [CAS] 378-44-8 374-28-6 3734-24-5	Bermoprofen		78499-27-1			
2-Pyridineerhanamine, N-methyl-, 5579-84-0 dihydrochloride 5539-76-6 5539-76-6 107-43-7 107-43-7 11,17,21-trihydroxy-16-methyl-, (118,163)- 378-44-9 107-83 107-83-6 11,17,21-trihydroxy-16-methyl-, (118,163)- 378-44-9 107-83 107-83-6 107-	Besipirdine		119257-34-0			
ine Betaine- [CAS] 107-43-7 Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (118,168)-1378-44-8 [CAS] 3440-28-6 3440-28-6		2-Pyridineethanamine, N-methyl-, dihydrochloride	5579-84-0	••		7/2/2000 for bodilloon or the last
Betaine- [CAS] 107-43-7 Pregna-1,4-diene-3,20-dione, 9-fluoro-	betahistine		5638-76-6	-		Formulation, modilied-release, <=2****
Pregna-1,4-dlene-3,20-dione, 9-fluoro- 11,17,21-trihydroxy-16-methyl-, (118,168)- hasone [CAS] 378-44-9 ilpron 3440-28-6	betaine	Betaine- [CAS]	107-43-7			Metabolic and enzyme disorders
one (CAS) 3440-28-6 3734-24-5		Pregna-1,4-diene-3,20-dione, 9-fluoro- 11,17,21-trihydroxy-16-methyt-, (118,168)-				Formulation dermal, topical
uo.	betamethasone	[CAS]	0.00.075	1		
	Betamipron		3440-28-6	1		
	Retasine		3734-24-5		1	

ple of Indication	nation, general	lergy, general ngina, general	əral vascular disəasə	Meniera's disease Homocystinuria Psoriasis
Example	Inflammation,	Allergy, g	Peripheral	Mentere's disea Homocystinuria Psortasis

				-:	
			Pat nt	1	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	2-Propanol, 1-[4-[2-	63659-18-7			
Johnston	(cyclopropylineuroxy) en (cyclopropyl) en (cyclopropyl) en (cyclopropylineuroxy) en (cyclopropyl	63659-19-8	US.	4252984	Antihypertensive, adrenergic
Botoscolo		105-20-4			
Bothanochol Chlorida		590-63-6			
		55-73-2.			
Delitamunio		3818-62-0			
Beloxycanie 8-Euvaina		500-34-5			
	2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyljamino]-3-(3-methydhenyyl) [CAS]	42864-78-8 59170-23-9	Sn	3857891	Antlhypertensive, adrenergic
B vonium Methyl	Constant Con	5205-82-3		. •	
Sulfate				·	
	Benzolc acid, 4-(1-(5,6,7,8-tetrahydro-	•			
hevarotene	3,5,5,8,8-pentamethyl-2- naphthalenyl)ethenyl)- [CAS]	153559-49-0	WO	9321.146	Anticancer, other
	Propanoic acid, 2-[4-[2-[(4-			٠	
	chlorobenzoyl)aminojethyljphenoxyj-2- methyl- (CAS)	41859-67-0	89	1359264	Hypolipaemic/Antiatherosclerosis
Boritramida		15301-48-1			
		166374-48-7			Cardiostimulant
0766-00	10 11 dihadro-10-hadroxvimino-5H-				· · · · · ·
BIA-2-024	dibenzib,frazepine-5-carboxamide	199997-15-4	WO	9745416	Antiepileptic
200 0 410	(S)-(-)-10-acetoxy-10,11-dihydro-5H- rihenzo(h fizzenine-5-carboxamide- [CAS] [236395-14-5	236395-14-5			Antieplieptic
	1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-				
BIA-3-202	ethanone	274925-86-9	ËΡ	1010688	Antiparkinsonian
Bialamicol		493-75-4			
	5H-Pyrazolo[1,2-a][1,2,4]triazol-4-ium, 6-	•	· ·	·.	
	[[2-carboxy-6-(1-hydroxyeny)]-4-meury-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl[thio]-6,7-dihydro-, hydroxide, inner salt, [4R-		·. 8		Reta-lactam antibiotic
biapenem ·	[[4Alpha,58,68(R*)]]- [CAS]	120410-24-4	<u> </u>	100607	

Example of Indication. Hypertension, general, glaucoma Hypertension, general Cancer, lymphoma, T-cell Epilepsy, general Epilepsy, general Epilepsy, general Parkinson's disease Infection, beta-lactamase resistant		•			 		·:		· ·				 	:	-		-
	. 6	. <u>6</u> .				P		Heart failure		Epilepsy, general	Eniloney denotal	Section (Federal				, beta	

API Ceneric Name						
Propanamide, N-(4-cyano-3- (15685-70-3 15685-70-3				Pate		Evample of Therapeutic Use
15585-70-3 15585-70-3 15585-70-3 15585-70-3 15585-70-3 15585-70-3 15585-70-3 15585-70-3 15585-70-3 15585-70-4 15585-70-6 155	API Generic Name		CAS No.	Here	T	Example of Hielapeans coc
Propanamida, N-l44-oyano-3 Propanamida, N-l44-oyano-3 (triiluoromethyl)phenyl -2-l44 (triiluoromethyl)phenyl -2-lydroxy-2-methyl1	Ribenzonium Bromide		15585-70-3		•	
Propanamida, N. (4-cyano-3- (utiluoromathyl)phenyll-3-(14- (utiluoromathyl)phenyll-3-(14- (utiluoromathyl)phenyll-3-(14- (ut)-10, los) (ut)-10	Ribrocathol		6915-57-7			
(unindromeny)pureny)		Propanamide, N-[4-cyano-3-		•		
(4-7)- [CAS] GEO-75-4 DE 2740562 DE 274		(unidorophenyl)sulfonyl]-2-hydroxy-2-methyl-;		•	100172	Anticancer, hormonal
### BEDUA-12-4 DE 2740662	bicalutamide	(+/-)- [CAS]	2007/2008	Т		
## 116078-65-0 ## 116078-65-0	Hickorine .	3-Azabicyclo[3.1.0]hexane, 1-(4- methylphenyl)-, (+/-)- [CAS]	66504-75-4 71195-57-8		2740562	Analgesiç, other
116078-65-0 176078-65-0	hievelic monotemene dials			די	6294585	Dermatological
## 1479-81-2 1-Butanamine, N-methyl4- 2	Didicomide		11:6078-65-0			
1-Butanamine, N-methyl4+ 2:	Digionity ring		479-81-2			
1-Butanamine, N-methyl/4-12: (phenylmethyl)phenoxyl-, hydrochloride (5222-46-6) (CAS) 1-H-Imidazole, 1-(1,11-biphenyl)-4-(50629-09-6) (1-H-Imidazole, 1-(1,11-biphenyl)-4-(50629-09-6) (1-H-Imidazole, 1-(1,11-biphenyl)-4-(50629-09-6) (1-H-Imidazole, 1-(1,11-biphenyl)-4-(50629-09-6) (1-H-Imidazole, 1-(1,11-biphenyl)-5-(6029-09-6) (1-H-Imidazole, 1-(1,11-biphenyl)-5-(6029-09-6) (1-H-Imidazole, 1-(1,11-biphenyl)-5-(6029-09-6) (1-H-Imidazole, 1-(1,11-biphenyl)-5-(6029-09-6) (1-H-Imidazole, 1-(1,11-biphenyl)-5-(1,11-biphenyl)-5-(1,11-biphenyl)-5-(1,11-biphenyl)-5-(1,11-biphenyl)-3-acetic acid, 3',3"-(1,6-6) (1,11-Biphenyl)-3-acetic acid, 3',3"-(1,6	Dietalily Ille		6888-11-5			and a
1-Butanamine, N-methyl4-l2- (CAS)	Biotocernine		53-18-9		•	
H-Imidazole, 1-([1,1-b phenyl]-4- 60628-96-8		1-Butanamine, N-methyl/4-[2:- (phenylmethyl)phenoxy]-, hydrochloride	62232-46-6			Cognition enhancer
1H-Imidazole, 1-(1,1'-biphenyl)-4- 60629-09-6 US 4118487 ylphenylmethyl)- [CAS] S-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-peritenyl)cyclopentyl)- N-ethyl (1R- (1Apha(Z)28(1E,3S,3Alpha,5Alpha)) (CAS) N-(2-hydroxy-3-(1-piperidinyl)propoxyl-3- 130493-04-8 US 5147874 butanedioate (1:1) (1,1'-Biphenyl)-3-acetic acid, 3',3"-(1,6-houtanediyl)bis(6'-Alpha-D-mannopyranosyloxy)-, [CAS] Maenosine, 2- (cyclohexylmethylene)hydrazino)- [CAS] (Gyclohexylmethylene)hydrazino)- [CAS]	bitemelane		34633-34-6	<u> </u>		•
1H-Imidazole, 1-([1,1'-b phenyl]-4- 60629-09-6 US 4118487 ylphenylmethyl)- [CAS] 5-dihydroxy-2-(3- hydroxy-5-phenyl-1-penitenyl) -2-(3-6-00-1)	Billuranoi		60628-96-8			· .
5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-2-(3-hydroxy-5-phenyl-1-penitenyl)cyclopentyl)- N-ethyl (18-(1Alpha(2)28(1E,3S,3Alpha,5Alpha)) (CAS) (1Alpha(2)28(1E,3S,3Alpha,5Alpha)) (CAS) (1Alpha(2)28(1E,3S,3Alpha,5Alpha)) (A-(2-hydroxy-3-(1-piperidinyl)propoxyl-3- pyridinecarboxlmidoyl chloride, (Z)-2-pyridinecarboxlmidoyl chloride, (Z)-2-hexanediyl)bis(6'-Alpha-D-hexanediyl)bis(hionazole		60629-08-5 60629-09-6	Sn	4118487	Antifungal
N-ethyl (1R-		5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-	.•			
N-[2-hydroxy-3-(1-piperidinyl)propoxy]-3-		N-ethyl (1R- (1Alpha(Z)28(1E,3S,3Alpha,5Alpha)) ICAS	155206-00-1	 Sa	5688819	Prostaglandin
N-[2-hydroxy-3-(1-pipendinfyl)propoxyl-3- pyridinecarboximidoyl chloride, (Z)-2- butanedioate (1:1) (1,1'-Biphenyl)-3-acetic acid, 3',3"-(1,6- hexanediyl)bis(6'-Alpha-D- mannopyranosyloxy)-, [CAS] Adenosine, 2- ((cyclohexylmethylene)hydrazino)- [CAS] ((cyclohexylmethylene)hydrazino)- [CAS] 58-85-5 514-65-8	bimatoprost	[040]				
(1,1'-Biphenyl)-3-acetic acid, 3',3"-(1,6-hexanediylbis(6'-Alpha-D-hexa	himoclomol	(N-[2-hydroxy-3-(1-piperidiny))propoxy]-3- pyridinecarboximidoyl chloride, (Z)-2- butanedioate (1:1)	1.30493-04-8	S	5147874	Symptomatic antidiabetic
Mannopyranosyloxy)-, ICASJ (69047-39-8		(1,1'-Biphenyl)-3-acetic acid, 3',3"-(1,6-lexanediyl)bis(6'-Alpha-D-	107050-70-5	<u>e</u>	5444050	Antiasthma
Adenosine, 2- ((cyclohexylmethylene)hydrazino)- [CAS] 144348-08-3 (159-23744	bimosiamose	mannopyranosyloxy)-, [CAS]	60047-30-8	3		,
Adenosine, 2- ((cyclohexylmethylene)hydrazino)- [CAS] 144348-08-3 US 6423744 58-85-5 514-65-8	Binifibrate		0-60-74060			
58-85-5 514-65-8		Adenosine, 2-	144348-08-3			Vasodilator, coronary
	Direction 101			Sn	6423744	Anticancer, other
	ioi-palling		58-85-5	L.		
	Diolin		514-65-8	Ŀ		
	Biperiden					

xample of Indication ancer, prostate altr, general Inspecified Infection, fungal, general Asthma Asthma Cancer, renal Cancer, renal			· · · · · · · · · · · · · · · · · · ·	- - - - - - - - - - 		
		age .	cit disorder	gal, general	diabetic	oronary
	xample of	Cancer, prostit	Attention defic	Infection, func	≥ ·	

			L		
			Patent	int ·	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Birlcodar		159997-94-1	·		
			Ŀ		
	2-Piperidinecarboxylic acid, 1-(oxo(3,4,5-trimethoxyohenylacetyl)-,4-(3-pyridinyl)-1-		•		
	(3-(3-pyridinyl)propyl)butyl ester, (S)-, 2-				
birlcodar dicitrate	hydroxy-1,2,3-propanetricarboxylate (1:2) [CAS]	174254-13-8			Radio/chemosensitizer
	1-Butanone, 1-(4-fluorophenyl)-4-		·		
-	. ((3,4,6,7,12,12a- hexabydronyrazino[1,2**1 6]pyrido[3,4-			· · .	
bíríperone	bjindol-2(1H)-yl)- [CAS]	42021-34-1	DE	2333922	Neuroleptic
Bisacodyl		603-20-8			
Bisantr ne		78186-34-2			
Bisbentiamine		2667-89-2	·		
Bisdequalinium Chloride		52951-36-7		•	•
•				÷	
Bismuth Aluminate		12284-76-3			
Bismuth		53897-25-9		· .	
Butylthiolaurate					
Bismuth Ethyl		52951-37-8	•	. •	
Camphorate					
Bismuth lodosubgallate		138-58-9			
Bismuth Sodium lodide		53778-50-0			
Blsmuth Sodium		5798-43-6	•		
		F000 40 4			
		2092-10-4			
Bismuth Subgallate	÷	1304-85-4			
bismuin submitate		1/882-18-0			
Dismuth		5175-83-7			
Tribromophenate				•	
	2-Propanol, 1-[4-[[2-(1-methyllphenoxy]-3-[(1-104344-23-2	•	·œ		Anthymetencive adrenardic
bisoproloi	memylemyljaminoj-[CAS]		7	7	מומוואלים וביוסוסים ליים מומומל מומו

,	•	•				•		-			•				•			 ••		,
Indication		•	- -	·.			•			•].			•	
Example of		• •		·	Cancer, breast	:	٠. <u>-نــنــ</u>						••							Heart failure

	ADI Chemical Name	CAS No	Patent Refere	Patent :	Example of Therapeutic Use
API Generic Name	API Chemical Name				
	2-Propanol, 1-[4-[[2-(1-metrylethoxy]ethoxy]metrylethoxy]ethoxy]metrylethoxy]				
hisomolol + HCTZ	metnyletnylaminoj mixt. with 6-chloro-3,4-dinydro-2H-1,2,4-benzothladiazine-7-sulfonamide 1,1-dioxide				Formulation, fixed-dose combinations
	2-Propanol, 1-[4-[[2-(1-methyl]phenoxy]-3-[(1-				
	methylethyl)amino] mixt.with.6-chloro-3- (dichloromethyl)-3,4-dihydro-2H-1,2,4-				
	epixoip		•		Formulation, fixed-dose combinations
bisoprolol+meniorometrilazide		14008-48-1			
Disoxalifi Acetate		97-18-7.			
Ritolterol .		30392-40-6			
Ritographe		4044-65-9	·		
BL-3875			OM	0218378	Anti-Inflammatory
hleomycin sulfate	Bleomycin sulphate (salt) [CAS]	11056-08-7 9041-93-4			Formulation, transdermal, enhanced
	Cycloocta[b]pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-		· · .		
blonanserin .	hexahydro- [CAS]	132810-10-7	- 1	385237	Neuroleptic
BMS-184478			G.	639577	Anticancer, other
	cis-(+/-)-2-(Ethylthio)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-4H-1-		Ş	07/00/0	Antirancer, other
BMS-387032	benzopyran-4-one	,	_	2145040	
RN-82451	4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,5-dl- tert-butylphenol, dihydrochloride	:			Neuroprotective
	Ethanesulfonic acid, 2,2'-dithiobis-,	· ·			
BNP-7787	disodium salt [CAS]	16208-51-8			Radio/chemoprotective
626 0	5-Benzofuranol, 4,6-bis(1,1-dimethylethyl)-2-3-dimethyl-1CAS)	157360-23-1	Ş.	9408930	Hypolipaemic/Antiatherosclerosis
Bolondial		19793-20-5			٠
Bolast rone		1605-89-6	·		
Doldonomo		846-48-0			
ססומפנוסוופ				•	

ton, general ton, general ad and neck east repy-induced nausea d rapy-induced nausea ng	 		•	·.				•	 •	 	
Hypertens Hypertens Hypertens Hypertens Cancer, he Cancer, be Cancer, ge Cancer, ge Cancer, ge Atheroscie	Atherosclerosis	motherapy-induced vomiting		Cancer, general	Schizophrenia Cancer, breast	Cancer, head and neck	Unspecified		Hypertension, general	 Hypertension, general	 -

					•
			Patent		
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	dimethylethyl)amino]-3- -4-yl)oxy]-, benzoate	62658-63-3 92857-38-3		4340541	Antihypertensive, adrenergic
bopindolol	(estel), (+v-)-[cx-o]	464-41-5		T :	
Bornyi Ciliolide		560-88-3			
Bornyi Salicylate	Boronic acid, [(1R)-3-methyl-1-[(2S)-1-oxo-				
· · · · · · · · · · · · · · · · · · ·	3-phenyi-2- [(foyrazinyicarbonyi)amino]propyi]amino]but vil- fCASi	179324-69-7	Š	6271199.	Anticancer, other
Contexconne	Benzenesulfonamide, 4-(1,1-dimethylethyl);				
	N-[6-(2-hydroxyethoxy)-5-(2-				
bosentan	[CAS]	147536-97-8	ш	633259	Vasodilator, peripheral
BP2.94	Phenol, 2-[[[(1R)-2-(1H-imidazol-4-yi)-1-methylethyl]imino]phenylmethyli- [CAS]	139191-80-3	ΝÓ	9117146	Respiratory
	N-[4-[4-(2-methoxyphenyl)-1-	·	•		
:	piperazinyijoutyijnapiiutarene-c	•			· · · · · · · · · · · · · · · · · · ·
BP4.897			ונ	1/8264	Department incament
8-Propiolactone		57-57-8			
Bradvcor		140661-97-8			
Brain Natriuretic Peptide	di	114471-18-0	•		
Brottoharbital		561-86-4			
Diamonal Dirai	a_Azahimulo(3.9.1)octana-2-			:	
	carboxaldehyde, 3-(3,4-dichlorophenyl)-8-		•	•	
	methyl-, O-methyloxime, (1fR- (1Aloha 28(E) 3Aloha 5Aloha))- [CAS]	171655-91-7	MO	9528401	Antiparkinsonian
		96187-53-0			
Dreuginal. Dr. tulium Toevlate		61-75-6	.		•
Brilliant Green		633-03-4			
brimonidine	6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)- [CAS]	59803-98-4	H	2538620	Antiglaucoma
	2H-Thieno(3,2-e)-1,2-thiazine-6-				
	sultonamide, 4-(ethylamino)-3,4-dihydro-2- //3-methoxygropyl)-, 1,1-dloxide, (R)- [CAS] 138890-62-7	138890-62-7	US	5378703	Antiglaucoma
Drinzolari ilde				ŀ	

Hypertension, general Cancer, myeloma Hypertension, pulmonary Addiction, cocaine Parkinson's disease Glaucoma	Evenue of Indication
로 * 로 로 트 트 8 * * * * * * * * * * * * * * *	
) 중 를 열 · 8 - 현	sion, general
품 를 할 수 있다는 사는 그리 하다 다 다 다 다 다 다 다 다 다 다 다 다 다 다 다 다 다 다	
등 글 열	
로 열 : 8	ancer, myeloma
	Hypertension, pulmonary -
	eneral
	cocaine

	•				
			300		Theranel of Theranellic Ilse
API Generic Name	API Chemical Name	CAS No.	ĮĘ.	200	Example of Therapeutic Osc
	Uridine, 5:(2-bromoethenyl)-2'-deoxy, (E)-	. 8-24-7-8			Antiviral, other
Diryudin	i cuo	56518-41-3	1		
Programopram		1010.20.0			
Bromazepam		7-00-7101].		
Bromfenac		91714-94-2		•	
	Benzeneacetic acid, 2-amino-3-(4-	91714-93-1		•	
bromfenac .	bromobenzoyl)-[CAS]	91714-94-2 ·		•	Formulation, mucosal, topical
Rmmh vine		3572-43-8			
Rr mindlone		1146-98-1			
Bromleonalium		496-67-3			
Bromorintine		25614-03-3			
Bromodiphenhydramine		118-23-0			
Bromoform		75-25-2			-
Bromonride		4093-35-0			
Bromosalicylchloranilide		3679-64-9			
	1-Butanone, 4-[4-(4-bromophenyl)-4- hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-				
biomperidol	-	10457-90-6	S)	3438991	Neuroleptic
Brompheniramine		86-22-6			
Bronaroestrol		479-68-5			
Bronirimine		56741-95-8		•	
	4-(2-Bromoacrylamido)-N"-(2-			•	•
•.	guanidinoethyl)-1,1',1'',1''-tetramethyl- N.4':N',4'':N'',4'''-quater-fpyrrole-2-	<u>. </u>		• • •	
brostallicin	carboxamide) [CAS]		_,		Anticancer, other
	6H-Thleno[3,2-f][1,2,4]triazolo[4,3-		·	;	
hmisolam	. a][1,4]diazepine, 2-bromo-4-(2-chlorophenvl-9-methyl- [CAS]	57801-81-7	SD	4094984	Hypnotic/Sedative
Browincamine		57475-17-9			
Broviridin		59-14-3	·		•
Broxvauinoline		521-74-4		٠.	
Brucine		357-57-3			-
R-Sitosterol		83-46-5			
Bucetin		1083-57-4			
Bucillamine		65002-17-7			

Patent R ference It Septemble It It It It It It It I						-
API Chr mical Name CAS No. R ference Interpretation Interpretati			٠	Pater	· ·	i .
71119-11-4	API Generic Name	API Ch. mical Name	CAS No.	R fe	rence	Example of Therapeutic Use
## Adenosine, N-(1-oxbutyl)-, cyclic 3-5: ## Adenosine, N-(1-oxbutyl)-, cyclic 3-6: ## Adenosine, N-(1-oxbuty	Rincindoloi		71119-11-4			
Interest Itriyatrogen prospiratory 2 Consequency 12-34-fetralrydro-page 14-73-6 14-73-6 15-75-74-6 15-75-72-7 15-75-75-7-7 15-75-75-7-7 15-75-75-7-7 15-75-75-7-7 15-75-75-7-7 15-75-75-7-7 15-75-75-7-7-7-7-75-7-7-7-7-7-7-7-7-7-7-					•	Cardiostimulant
11de	bucladesine	Т.	362-74-3	Τ		
10 10 10 10 10 10 10 10	Bucladesine		82-95-1			
9-Acridinamine, N-butyl-1,2,3,4-tetrahydro- 82636-28-0 1.0-17-6 1.0-17	Buclizine		575-74-6			
9-Acridinamine, N-buty-1,2,3,4-tetrahydro- innohydrochloride [CAS] 58409-59-9 Pregna-1,4-diene-3,20-dione, 16,17- [butylidenebis(oxy)]-11,21-dihydroxy- (116,1bdpha) - [CAS] 51333-22-3 GB 1429922 (116,1bdpha) - [CAS] 61333-22-3 GB 1429922 (116,1bdpha) - formamide, N-12-hydroxy- (116,1bdpha) + formamide, N-12-hydroxy- (116,1bdpha) + formamide, N-12-hydroxy- (116,1bdpha) - formamide, N-12-hydroxy- (116,1bdpha) - formamide, N-12-hydroxy- (116,1bdpha) - [CAS] 61333-22-3 (116,1bdpha) - [CAS] 61333-22-3 (116,1ddpha) - [CAS] 61339-79-5 (116,1ddpha) - [CAS] 61368-49-4 (116,1ddpha) - [CAS] 61368-49-4 (116,1ddpha) - [CAS] 61368-49-4 (116,1ddpha) - [CAS] 61368-49-4 (116,1ddpha) - [CAS] 61368-79-5 (116,1ddpha) - [CAS] 61368-79-5 (116,1ddpha) - [CAS] 61368-72-7 (116,1d	Buclosamide		841-73-6			
Monohydrochloride [CAS] 82836-28-0	Bucolome	9-Acridinamine, N-butyl-1,2,3,4-tetrahydro-		:		Ansesthetic focal
Pregna-1,4-diane-3,20-dione, 16,17-	bucricaine	, monohydrochloride [CAS]	82635-26-0			
Pregna-1,4-diene-3,20-dione, 16,17-	Bucumolol		58409-59-8			
Pregna-1,4-diene-3,20-dione, 16,17-		Pregna-1,4-diene-3,20-dione, 16,17- [butylidenebis(oxy)]-11,21-dihydroxy-, (118,16Albha)-[CAS]	51333-22-3		1428922	Antiasthma
Pregna-1,4-diene-3,20-dione, 16,17- [butylidenebis(oxy)]-11,21-dihydroxy(116,1bApha) + formamide,N-[2-Hydroxy(116,1bApha) + formamide,N-[2-Hydroxy- 5-{1-hydroxy-2-[[2-(4-methoxyphenol)-1- methylethyljaminojethyljphenyl]-(R.,R.)-(±) methylethyljaminojethyljphenyl]-(R.,R.)-(±) [putylidenebis(oxy)]-11,21-dihydroxy(116,16Apha)-[CAS] .(116,16Apha)-[CAS] .(116,16Apha)-[CAPha)-[CAPha)-[CAPha)-[CAPha)-[CAPha)-[CAPha)-[CAPha)-[CAPha)-[CAPha)-[CAPha)-[CAPha)-[CAPha)-[CAPha)-[CAPha)-	- incention		:			
Pregna-1,4-diene-3,20-dione, 16,17- [butylidenebis(oxy)]-11,21-diitydroxy- (,116,1bAlpha) + formamide, N-{2-tydroxy- 5-{1-hydroxy-2-{12-(4-methoxyphenol)-1- methylethyljamino]ethyljphenyl]-(R*,R*)-(±) methylethyljamino]ethyljphenyl]-(R*,R*)-(±) [butylidenebis(oxy)]-11,21-diitydroxy- (,116,16Alpha)- [CAS] [putylidenebis(oxy)]-11,21-diitydroxy- (,116,16Alpha)- [CAS] [putylidenebis(oxy)]-11,21-diitydroxy- (,116,16Alpha)- [CAS] [phenyl- [CAS				·		: .
[butylidenebis(oxy)]-11,21-dihydroxy- (,116,1bAlpha) + formamide, N-{2-hydroxy- (,116,1bAlpha) + formamide, N-{2-hydroxy- 5-{1-hydroxy-2-{12-{4-methoxyphenol}-1-} methylethyljaminojethyljphenyl]-(R*,R')-(±) Pregna-1,4,diane-3,20-dione,16,17- [butylidenebis(oxy)]-11,21-dihydroxy- (,116,16Alpha)- [CAS]		Pregna-1 4-diene-3.20-dione, 16,17-	· · ·		•	
(,11f1,1bAlpha) + formamide, N-{2-hydroxy-} 5-{1-hydroxy-2-{[2-(4-methoxyphenol)-1-methylethyl]amino]ethyl]phenyl-(R*,R*)-(±) methylethyl]amino]ethyl]phenyl-(R*,R*)-(±) [butylidenebis(oxy)]-11,21-dihydroxy-(11f1,121-dihydroxy-16,12) [putylidenebis(oxy)]-11,21-dihydroxy-(11f1,121-dihydroxy-16,12] [putylidenebis(oxy)]-11,21-dihydroxy-(11f1,121-d	•	(butvlidenebis(oxy)]-1.1,21-dihydroxy-				
ol Pregna-1,4, diene-3,20-dione,16,17- [butylidenebis(oxy)]-11,21-dihydroxy- [(118,16Alpha)- [CAS]	•	(116,1bAlpha) + formamide,-N-[2-hydroxy-				
ol Pregna-1,4,diene-3,20-dione,16,17- [butylidenebis(oxy)]-11,21-dihydroxy- (116,16Alpha)- [CAS] (116,16Alpha)- [C		5-[1-hydroxy-2-[[2-(4-methoxyphenol)-1-	•		٠	
Pregna-1,4,diane-3,20-dione,16,17- Pregna-1,4,diane-3,20-dione,16,17- 118,16Alpha)-1,121-dihydroxy- 1333-22-3 118,16Alpha)-1,121-dihydroxy-1 118,16Alpha)-1,121-dihydroxy-1 119,16AS 12,1082-78-2 136,1082-		methylethyljaminojethyljphenylj-(HT,HT)-(#)				Formulation, fixed-dose combinations
Pregna-1,4,diene-3,20-dione,16,1/- putylidenebis(oxy)]-11,21-dihydroxy- putylidenebis(oxy)]-11,21-dihydroxy- (118,16Apha)- [CAS]	budesonide + formoterol					
(118,16Apha)- [CAS] 51333-22-3 Piperidine, 1-(1,1-dimethylethyl)-4,4 57982-78-2 Giphenyl- [CAS] 57982-78-2 Giphenyl- [CAS] 57982-78-2 Giphenyl- [CAS] 57982-78-2 Debutoxyacetohydroxamic acid 53684-49-4 Debutoxyacetohydroxamic acid 2438-72-4 Debutoxyacetohydroxamic acid 2438-72-4 Debutoxyacetohydroxamic acid 25387-25-7 Debutoxyacetohydroxamic acid 25387-25-7 Debutoxyacetohydroxamic acid 25387-25-7 Debutoxyacetohydroxamic acid 25387-25-7 Debutoxyacetohydroxamic acid 2438-72-4 Deb		Pregna-1,4,diene-3,20-dione,16,17- [butylidenebis(oxy)]-11,21-dihydroxy-			.•	Cormulation inhalable solution
Piperidine, 1-(1,1-dimethylethyl)-4,4	pndesonide	,(118,16Alpha)- [CAS]	51333-22-3	ĺ		Official and the second
ne 57982-78-2 azine 36798-79-5 od 22103-14-6 od 53684-49-4 loi p-butoxyacetohydroxamic acid 2438-72-4 US 3478396 ac 1-Butanone, 4-(1-pyrrolidinyl)-1-(2.4,6-35543-24-9 35543-24-9 GB 1325192 iii trimethoxyphenyl)- [CAS] 55837-25-7 GB 1325192 nin 54340-62-4 55837-25-7 CB	enidibine	Piperidine, 1-(1,1-dimethylethyl)-4,4-diphenyl- [CAS]	57982-78-2 63661-61-0	ᆵ	2825322	Antiparkinsonian
36798-79-5 22103-14-6 53684-49-4 53684-49-4 1-Butanone, 4-(1-pyrrolidinyl)-1-(2.4,8-35587-25-7 trimethoxyphenyl)-1-(2.4,8-35587-25-7 692-13-7 692-13-7 54340-62-4	Budinine	·	57982-78-2			
22103-14-6 53684-49-4 p-butoxyacetohydroxamic acid 2438-72-4 1-Butanone, 4-(1-pyrrolidinyl)-1-(2.4,6-35537-25-7 trimethoxyphenyl)-[CAS] 55837-25-7 692-13-7 54340-62-4	Budrafazine		36798-79-5			
53684-49-4 p-butoxyacetohydroxamic acid 2438-72-4 1-Butanone, 4-(1-pyrrolidinyl)-1-(2-4,6- 35543-24-9 trimethoxyphenyl)- [CAS] 55837-25-7 55837-25-7 55837-25-7 55837-25-7 55837-25-7 55837-25-7 55837-25-7	Bufeniod		22103-14-6			
p-butoxyacetohydroxamic acid 2438-72-4 US 3478396 1-Butanone, 4-(1-pyrrolidinyl)-1-(2,4,6- 35543-24-9 trimethoxyphenyl)- [CAS] 55837-25-7 GB 1325192 55837-25-7 GB 25837-25-7 GB 1325192 55837-25-7 55837-25-7 55837-25-7 55837-25-7 692-4-7 54340-62-4	Bufetoloi		53684-49-4	·		
1-Butanone, 4-(1-pyrrolidinyl)-1-(2,4,6- 35543-24-9 trimethoxyphenyl)- [CAS] 55837-25-7 GB: 1325192 55837-25-7 GB: 1325192 55837-25-7 G92-13-7 54340-62-4	hirlexamac		2438-72-4	SD	3478396	Anti-inflammatory
	huflomedil	1-Butanone, 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)- [CAS]	35543-24-9 55837-25-7		1325192	Vasodilator, peripheral
	Buflomedil		55837-25-7			
	Buformin		692-13-7			
	Bufuralol		54340-62-4		,	
1.0260-0-10000 i	D.modiy n		3583-64-0			

•. •	•	<u> </u>	
Example of Indication	Wound healing	Asthma	Asthma, Crohn's disease Parkinson's disease

				-	
			Patent	ı,	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
bumetanide	Benzoic acid, 3-(aminosulfonyl)-5- (butylamino)-4-phenoxy- [CAS]	28395-03-1	US	3806534	Antihypertensive, diuretic
binaffine	1-Naphthalenecarboxamide, N-butyl:N-[2- (diethylamino)ethyl]- [CAS]	32421-46-8		2009894	Antiarrhythmic
Bunaffine		32421-46-8			
Bunamiodyl Sodium		1923-76-8			
	1H-1,4-Diazepine, 1-(4-amino-6,7-cimethoxy-2-quinazoliny)hexahydro-4-(1-cychund), 1CASI	52712-76-2 80755-51-7	GB.	1398455	Antihypertensive, adrenergic
Bunazoein	in a life and	80755-51-7]	:	
La	Benzontrile, 2-[3-[(1,1-dimetrylethy)]amino]-2-hydroxypropoxy]-ICAS]	34915-68-9	. Sn	3940489	Antihypertensive, adrenergic
Bunitolol		34915-68-9			
Bunivacaine		2180-92-9			
buoivacaine	2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)- [CAS]	38396-39-3	·		Formulation, modified-release, >24hr
hinivacaine	2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)- [CAS]				Formulation, parenteral, other
Bunranolol		14556-46-8			
	6,14-Ethenomorphinan-7-methanol, 17- (cyclopropylmethyl)-Alpha-(1,1-		•	•	
	dimetnyletnyl)-4,5-epoxy-16,19-dinydig-3- hydroxy-6-methoxy-Alpha-methyl-, [5Alpha,7Alpha(S)]- [CAS]	52485-79-7 53152-21-9	Sn	3433791	Analgesic, other
pnoropion	1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)aminoj-, (+/-)- [CAS]	31677-93-7 34911-55-2	US .	4425363	Antidepressant
bupropion	1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, (+/-)- [CAS]	31677-93-7 34911-55-2			Formulation, modified-release, <=24hr
Buramate		4663-83-6			
	Luteinizing hormone-releasing factor (pig), 6-(O-(1,1-dimethylethyl)-D-serine]-9-(N-ethylinclinamide)-10-deglycinamide-	57982-77-1	•		
buserelin	[cAS]	68630-75-1	8	1.523623	Releasing hormones
euozidsnq	8-Azaspiro[4.5]decane-7,9-dione, 8-[4-{4- (2-pyrimidinyl)-1-piperazinyl]butyl]-[CAS]	36505-84-7	. 6	276536	Anxiolytic
busulfan	1,4-Butanediol, dimethanesulfonate [CAS] 55-98-1	55-98-1			Formulation, optimized, microparticles
		•		•	

Example of	f Indication	•
Hypertension,	general	
•		1
		ĺ
		٠.
Hypertension,	, general	
•	•	
Anaesthesia		٠.
Anaesthesia	• • • • • • • • • • • • • • • • • • • •	
· ·	•	
· :		•
Depression, 6	general	
Depression, g	general	•
	-	
Cancer, prostate	itate	
Anxiety, general	eral	-
Cancar deneral	·	
	ciai	•

API Generic Name		•	Patent		
40					
	API Chemical Name	CAS No.	Refer	Reference	Example of Therapeutic Use
•	15.08-1	55-08-1			Formulation, parenteral, other
	1,4-butaireuroi, unineritairesumorator	142.81.7	T		
Butabarbital Sodium		149-16-F	+		
Butacaine		2010010	†	-	
Butacetin		L-52-6012	1		
Rutalamine		22131-35-7	1		
Butalhital		77-26-9	Ť		
Dulaibilai		1142-70-7	- -		
Butanylonal		94-25-7			
Eu	4 Aminobenzole acid butyl ester (CAS)	94-25-7	-		Formulation, modified-release, other
		18109-80-3			
Butamirate			F		
	Benzeneacetic acid, Alpha-ethyl-, 2-[2-		٠	•	
· ·	(diethylamino)ethoxyjethylester, 2-hydroxy- 1 2 3-propapetricarboxylate (1:1).[CAS]	18109-81-4	•	• .	Antitussive
		3785-21-5			•
Dutamicanie		653-03-2			
Dulaperazine		55837-14-4			
Butaverine		16790-49-1			
Dutazolali inc		51395-42-7	.		
But dronic Acid	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				
	1-Naphthalenemethanamine, tv-((4-(1,1-dimethylethyl)phenyl)methyl]-N-methyl-	101827-46-7		. 164697	Antifungal
butenafine	[CA3]	101828-21-1	1		
Butenafine		77-28-1	T		
Butethal		4.4007-64.B			
Butethamate		2000 80.3	1		
Butethamine		2400002	T		
Buthalital Sodium		210-80-7			
Buthlazid		2043-38-1	1		
Butibufen		55837-18-8			
Butidrine Hydrochloride		1506-12-3		. [
	benzoic acid, 3,4,5-trimethoxy-, 1,2- ethanedlylbis[(methylimino)(2-ethyl-2,1-	55769-64-7	. 9.		and the state of t
butobendine	ethanediyl)] ester, [S-(R*,R*)]- [CAS]	55769-65-8	3	US 4021473	Ananinguing
Butobendine		55769-65-8	\cdot		

	· .			· · · · · · · · · · · · · · · · · · ·	·
Example of Indication Cancer, leukaemia, acute		Pain, caricer	Cough		Arrhythmia, general

					•
		•	Patent	=	
ADI Canaria Name	API Chemical Name	CAS No.	Refe	Refer nce	Example of Therapeutic Us
API Geliene Ivallie					
	1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-64872-76-0 dichlorophenylthiolbulyl]. (4/-)-[CAS]	64872-76-0 64872-77-1	. ag	1567431	Antifungal
DUIDOUIIAZOID	1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-			•	
butoconazole, KV	dichlorophenyl)thio]butyl]-, (+/-)-[CAS]				
Butoctamide					
Rutofilolo		64552-17-6			
	-(Withamphidology) Tr. Join 180	· ·			· ·
	Jihydroxybutanedioate	42408-82-2 58786-99-5	. 89	1412129	Analgesic, other
butorphanol	(1:1) (san) lovo)	3772-43-8	·		
Butoxycaine		35941-65-2			
		29025-14-7			
Butroplum Bromide		0001 01 0			
Buzepide		3-17-1600	S	0208178	Anorectic/Antiobesity
BVT-5182			2		
BXT-51072	2H-1,2-Benzoselenazine, 3,4-dihydro-4,4 dimethyl- [CAS]	173026-17-0		·	Gl inflammatory/bowel disorders
	6H-Imidazo[4,5,1-de]acridin-6-one, 5-[[2:-				
	2HCI, 2H2O				Anticancer, other
0-15:1	Transportson o contraction N. 13.		Ŀ	· •	
	(dimethylamino)propyl]-N-		····		
	[(ethylamino)carbonyl]-6-(2-propenyl)-,	81409-90-7 85329-89-1	GB ;	2103603	Antiprolactin
Oshermolino.		81409-90-7		÷	
Capalyonne Cacodylic Acid		75-60-5	·		
Cactinomycin .		8052-16-2			
cadexomer indine	Cadexomer lodine [CAS]	94820-09-4	_		Anti-intective, other
Codminm Califylate		19010-79-8			
		64241-34-5			
Cataminol		30924-31-3			
Caffeine		58-08-2			
	1,2,3,-Propanetricarboxylic acid, 2-hydroxy-mixt, with 3,7-dihydro-1,3,7-trimethyl-1H-	7-23-19		·.	Respiratorý /
caffeine citrate	purine-2,6-dione [CAS]				

dication i.general			·
Example of Indication infection, Candida, general infection, gynaecological	Obesity Colitis, ulcerative	Galactorrhoea Ulcer, vehostasis	Apnoea

c Name			Patent	-	
c Name	And Chamical Name	CAS No.	Reference		Example of Therapeutic Use
		5.3	 		
Calciledio		112965-21-6	- - -	-	
Calcipotriene	T	-	<u> </u> -		
	9,10-Secochola-5,7,10(19),22-tetraene- 11,3,24-triol, 24-cyclopropyl- 71 Ainha 38 57 7E 22E- [CAS]	112965-21-6	WO. 8700834	· .	Antipsoriasis
carcipotrioi			_		
	9,10-Secochola-5,7,10(19),22-tetraene- 1,3,24-triol, 24-cyclopropyl- ,(1Alpha,38,52,7E,22E) + Pregna-1,4- diene-3,20-dione, 9-chloro-118,17,21-		· · ·	· · ·	
calcinotriol+beclometasone	trihydroxy-16B-methyl, 17,21-dipropionate				Formulation, fixed-dose combinations
1	9,10-Secocholesta-5,7,10(19)-triene- 1,3,25-triol, (1Alpha,38,52,7E)-[CAS]	32222-06-3	• •		Antipsoriasis
m 3-Aurothio-2-		5743-29-3	··		
Calcium Acetylsalicylate		69:46-5			
		33659-28-8			
Bromolactobionate		471-34-1	-		
Calcium Carponate		299-28-5			
Calcium		27214-00-2		: .	
Glycerophosphate	0. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.		1	1.	
	Calcium D-(+)-4-(2, 4-dinyaraxy-3, 3-dimethylbutyramido)butyrate (hemihydrate)	. 9 97 7007	FD 117960		Neurological
calcium hopantothenate	[CAS]	1319-91-1	7	1.	
Calcium Indostearate		1301-16-2			
Calcium Lactate		814-80-2	1	:	
Calcium Levulinate		591-64-0			
Calcium Mesoxalate		16649-79-9	-	1	
Carbamoylaspartate	:				
Calcium Polycarbophil		8-78-8008	-	1	
anomin'i l'ideochee en teles	Colorathonhii calcium salt- (CAS)	126040-58-2			GI inflammatory/bowel disorders

	-T	<u>'</u>		 	 <u> </u>	i -	7		<u>.</u>	T	7	T.	· F	 		[]	.	Τ		
Example of Indication			Psoriasis · ·	· .	Psoriasis		Psoriasis	· ·							Attention deficit disorder					Irritable bowel syndrome

				-	•
	.•	•	Patent		
API Generic Name	API Chemical Name	CAS No.	R ferenc	enc	Example of 1n Tapeune ose
Orlein Bronionate		4075-81-4			
Calcium Propionate		140-99-8			
Calcium Succinate	chodilisocorred desired				
	5-methyl-2-(1-piperazinyi)-benzenesunomo		<u> </u>	•	
		133804-44-1			Cardiostimulant
caldalet		17021-26-0			
Calusterone		36104-80-0			
Camazepam	Possessition of A-114-				
	Information of the second of t	59721-28-7			
	(dimethylamino)-2-oxoethyl ester,	59721-29-8		•	Stophooily Jones 4
	monomethanesulfonate [CAS]	71079-09-9	S S	4021472	GI inflammatory/bowel disorders
Califosial .		76-22-2			
Camphor		4876-45-3			
Camphotamide					
:	4-Ethyl-4-hydroxy-1H-pyrano- na-4-6 zundelizinell 2-b:lguineline-			٠.	
· ·	13,14(4H,12H)-dione	W. * * * * * * * * * * * * * * * * * * *			Formulation, optimized, microemulsion
camptothecin. Sonus					
Candesartan		139481-59-7			
	1H-Benzimidazole-7-carboxylic acid, 2-				
	ethoxy-1-[[2-(1H-tetrazol-5-yl)[1,1'-				
	[biphenyi]-4-yi metnyi]-, 1- rr/amlobowibwycerhonyiloxylethyl ester.				
 candecartan cilexetii	(+/-)- [CAS]	145040-37-5	G)	520423	Antihypertensive, renin system
Candovatril		123122-55-4			
Calludyann	-	,	:		
	N-[4-(3-(Chloro-4-fluoro-phenylamino)-7-(3-				
	morpholin-4-yl-propoxy)-quinazolin-6-ylj-				
	acrylamide dinydrocnioride	289499-45-2	• .		Anticancer, other
canarinio dinyarocaroride		976-71-6			
Canrenone		56-25-7			
Cantharidin	Mardaneine N2-deacetyl-N2-(3-mercapto-				
	1-oxopropyl)-, conjugated humanized				
	C242 monoclonal antibody	139504-50-0	. '		[mimunotoxin
cantuzumab mertansine		100001			
	Cytidine, 5-deoxy-5-filloro-N-	154361-50-9	급	602454	Anticancer, antimetabolite
capecitabine	(Changly only of the control of the	21434-91-3			٠
Capobenic Acid					

Г		-		<u> </u>	П	•	 1	- 1							$\overline{}$	 	<u> </u>	· -T	Т	•		_		7
	Indication				.												ali cell		ľ					
	Indic		•.							•				general		•	non-small		1	•	•	ectal.	72	ľ
	ple of		failure				atitis		.		r, general	•	•	ertension,			ē.					r, colorectal	r, breast	
	Example		Heart fa				Pancreatitis		.		Cancer,			Hypert			Cancer,			•		Cancer,	Cancer,	

			1.		
			Patent Pefere	Patent Peference	Example of Therapeutic Use
API Generic Name	API Chemical Name	CAS NO.		3	
	1H-imidazole-2-methanol, 5-(3,5-	•			·. ·
capravirine	pyridinyl)methyl carbamate (ester) [CAS]	178979-85-6			Antiviral, anti-HIV
Capromab		151763-64-3		-	
Mornichi	N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-	404-86-4			Formulation, dermal, topical
Capsaicili cream, marusin		486-17-9			
· repropries	L-Proline, 1-(3-mercapto-2-methyl-1- oxopropyl-, (S)- [CAS]	62571-86-2	Sn	4105776	Antihypertensive, renin system
·	I -Proline 1-(3-mercapto-2-methyl-1-				
	oxopropyl)-, (S)-, mixt. with 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-	44007E 07.E	. <u>u</u>	4917347	Antihvoertensive, renin system
captopril + HCTZ	suitonamide 1,1-dioxide [CAS]	5570-13-5	T		
Capuride		0-01-0700			
caraharsat	Benzamide, N-(6-acetyr-3,4-dihydro-3-hydroxy-2,2-dimetryl-2H-1-benzopyran-4-yl-4-fluoro, (3R-trans)- [CAS]	184653-84-7	WO	9811890	Antiepileptic
Corominhon		77-22-5			
carazolol	2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[(1-methylethyl)amino]- [CAS]	57775-29-8	3	2240599	Antihypertensive, adrenergic
Carazoloi		57775-29-8			
Carpachol		51-83-2	:		
Carbamazenine		298-46-4			
carbamazeoine. Microtrol	5H-Dibenz[b,f]azepine-5-carboxamide [CAS]	298-46-4	·		Formulation, modified-release, other
Carbamide Peroxide		124-43-6			
Carbarsone		121-59-5			
Carbaryl		63-25-2			
Carbazochrome		13051-01-9	•	•	
		51/80.26.F			
Carbazochrome Sodlum		01400-20-0		-	
	Methyl-2-benzimidazolecarbamate				Anticancer, other
Carponiolilia		4697-36-3			
Cal Define		5697-56-3			•
Carpelloxololle					

Example of Ind Pain, post-herpetic Hypertension, general Epilepsy, general Cancer, general
--

			1	,	
	ADI Chemical Name	CAS No.	Refere	nce	Example of Therapeutic Use
API Generic Nam		77-23-6			
Carbetapentane	## + 1 =		+		
	Carbonic acid disodium sait, mixt. with	72227-05-5			Alimentary/Metabolic, other
Carolcaro		28860-95-9	ŀ		
Carbidopa	Adala				
	S-Alpha Hydrazino-3,4-dinydroxy-rybra metryl benzene propanolc acid monohydrate +3-hydroxy-L-tyrosine	•			Commission fixed-dose combinations
carbidopa+levodopa-1,Nouvel					in the state of th
	S-Alpha Hydrazino-3,4-dihydroxy-Alpha methyl benzene propanoic acid		·		•
carbidopa+levodopa-	monohydrate+3-hydroxy-L-tyrosine	•			Formulation, fixed-dose combinations
Z,Neornarma		22232-54-8			
Carolmazole		486-16-8			
Carbinoxamine		541-79-7			
Carbociorai		638-23-3			
Carbocysteine					
		151756-26-2	G.	546272	Cystic fibrosis treatment
Carbon Tetrachloride		56-23-5			
	Platinum, dlammine[1,1-cyclobutanedicarboxylato(2-)]-, (SP-4-2)-	41575-94-4			Anticancer, alkylating
carboplatin	(cya)	35700-23-3			
Carboprost					
	Prosta-5,13-dien-1-oic acid, 9,11,15-	. ·		•	
	trihydroxy-15-metryi-, (5Z,9.alpha.,11Alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-	58551-69-2			
carboprost trometamol	propanedioi(1:1) [CAS]	74849-93-7	ရွ	3728382	Prostagiandin
	2,5-Cyclohexadiene-1,4-dione, 2-[2-1/2-minocarbonyllaxyl-1-methoxyethyl]-3,6-				
Carboquone	bis(1-aziridinyf)-5-methyl- [CAS]	24279-91-2	긤.	1905224	Anticancer, antibiotic
Carbonione		24279-91-2			
Carbromal		77-65-6			
Carbirbarh		960-05-4			•
Carbutamide		339-43-5		.	
Carbuterol	-	34866-47-2			
Carlimate		3567-38-2			
Callilland				· ·.	

ation		· · · · · · · · · · · · · · · · · · ·		
Example of Indica	Acidosis Parkinson's disease	Parkinson's disease	Cancer, ovarian	Abortion

API Generic Name N-Carbamoyl-L-glutamic acid cargutucin Carindacillin cariporide Cariporide Carmofur Carmotur Carnitine Caroxazone Caroxazone Caroxazone Caroxazone Caroxazone Carphenazine		CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
seric Name seric Name cit, Orphan Europe cit, Orphan Europe cit, Orphan Europe de codol	٠.	Refer	ence	Example of Inerapeutic Use	
cit, Orphan Europe cin cilin cilin cide rodol codol co		188-38-1	_		•
cin codol codol codol codol codol codol codol codol codol codol cone ine one azine					Metabolic and enzyme disorders
de rodol rodol Guilford Guilfo		33605-67-3			
rodol rodol role Guilford Guilford J. Samchundang Ine		35531-88-5			
rodol rodol role , Guilford , Samchundang , Direct Therapeutics e ine nazine amine	T	159138-80-4 159138-81-5	FP	589336	Antianginal
rodol Ir Irole I, Guilford I, Samchundang I, Samchundang Ine	_	159138-80-4			
ir Irole , Guilford a, Samchundang b, Direct Therapeutics e ine ine ine amine		78-44-4			
ir Irole , Guilford s, Samchundang b, Direct Therapeutics e ine ine ine azine azine	Joro-N-	61422-45-5	. Sn	4071519	Anticancer, antimetabolite
role , Guilford , Samchundang , Direct Therapeutics e ine ine azine amine		61422-45-5			
amine		98323-83-2			
s, Samchundang s, Direct Therapeutics e ine ine amine amine		154-93-8	·		Formulation, implant
b, Direct Therapeutics e ine ine nazine amine	oroethyl)-N-nitroso-	154-93-8	•		Formulation, implant
ine ine amine					Formulation, parenteral, other
ine ine cone azine amine		461-06-3			
one nazine amine		23465-76-1			
nazine amine m		18464-39-6			
amine n		2622-30-2			
		5942-95-0			
n	1, 6-chloro-		S	3896145	Anti-inflammatory
Caroniani.		2037-95-8			
2(1H)-Quinolinone, 5-[3-[(1,1: dimethylethyl)amino]-2-hydroxypropoxy]-		51781-06-7 51781-21-6	. S	3910924	Antihypertensive, adrenergic
2(1H)-Quinollnone, 5-[3-[(1,1-dinollnone, 5-[3-[(1,1-dinollnone, 5-[3-[(1,1-dinolpowy]-		51781-06-7 51781-21-6			Formulation, mucosal, topical
		23964-58-1			
Caricanie		50935-04-1			
Carimonam		87638-04-8			
Caracrol		499-75-2			

	·					٠	 	 	 	 i	7
tlon				.		· .					
of Indication	amia										
ple of	yperammonaemia	general		brain	ancer; brain	r, brain			oma		.
Example	Hypera	Angina,		Cancer,	Cance	Cancer,			. Glaucoma		

			Patent	=	:
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
carvediloi*	2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyohanoxy)ethyllamino]-[CAS]	72956-09-3	. G	4920	Antihypertensive, adrenergic
Canton		99-49-0			
Caccarillin		10118-56-6			
	Pneumocandin B0, 1-((4R,5S)-5-((2-aminoethyl)amino)-N2-(10,12-dImethyl-1-				
•	oxotetradecy)-4-hydroxy-L-omithine)-5- (threo-3-hydroxy-L-omithine)-, diacetate	162808-62-0	Q		Antitungal
caspotungin	(san) loas	154-23-4			
Catecriff cathoreth Kinhibitore Calora			80	9613523	Osteoporosis treatment
	N-(1-benzothlen-2-ylcarbonyl)-N-[2-(2-fluorophenyl)-4-oxo-1,2,3,4 tetrahydropyrimidin-5-yl]-L-leucinamide	. •			
cathepsin K inhibitors, NAEJA					Osteoporosis treatment
oothonela Cinhibitate NAEIA	N-(1-benzothien-2-ylcarbonyl)-N-[2-(2- fluorophenyl)-4-oxo-1.2,3,4- tetrahydropyrimidin-5-yl]-L-leucinamide				Antiasthma
- 1			.sn	6342595	Immunosuppressant
24 John 24 Joh	Rapamycin 42-(3-hydroxy-2- (hydroxymethyl)-2-methylpropanoate)	162635-04-3			Anticancer, antibiotic
			O _M	9732019	Antiviral, anti-HIV
CCR5 antagonists, Euroscreen			_	634061	Anticancer, other
CDC-394			T	5605914	GI inflammatory/bowel disorders · .
CER-03-340	1H.3-Benzazepin-7-ol, 5-(2,3-dlhydro-7-benzofuranyl)-2,3,4,5,-tetrahydro-3-methyk-8-nitro, (5S)- [CAS]	128022-68-4	Gi Gi	347672	Dependence treatment
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-				
cefacior	[(aminophenylacetyl)amino]-3-chloro-8-oxo-53994-73-3 , [6R-[6Alpha,78(R*)]]- [CAS]	53994-73-3 70356-03-5	89	1461323	Cephalosporin, oral
Cefacior		70356-03-5			

	• •								 		<u> </u>		•	 ·	<u> </u>	
Example of Indication	Hypertensjon, general		Infection, Aspergillus	Osteoporosis	Osteoporosis	· .	. Asthma	Arthritis, rheumatoid	Cancer, renal	Infection, HIV/AIDS	Cancer, myeloma	Crohn's disease	Addiction, alcohol	Infection, Haemophilus influenzae prophylaxis		•
٠.	-											•				

•			Patent	: =	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-				
	hydroxyphenyi)acetyijaminoj-3-meuryi-5- oxo-, [6R-[6Alpha,78(R*)]]- [CAS]	50370-12-2	GB	1240687	Cephalosporin, oral · ·
Cefadroxil		66592-87-8			
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-		.:	: ·	
	carboxylic acid, 7- [(aminophenylacetyl)amino]-3-methyl-8-		•	• •	
cefalexin HCl monohydrate	oxo-, monohydrochloride, monohydrate, [6R-[6Alpha,78(R*)]]- [CAS]	105879-42-3	ns	4775751	Cephalosporin, oral
		•			· · · · · · · · · · · · · · · · · · ·
· ·	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-	:	•		
	[(aminophenylacetyl)amino]-3-methyl-8-			•	
	oxo-, (2,2-dimethyl-1-oxopropoxy)methyl	•		•	
cefalexin pivoxil	ester, monohydrochlonde, [6H- [6Alpha,78(R*)]]- [CAS]	27726-31-4			Cephalospòrin, oral
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-	•		•	.:
	carboxylic acid, 7-	: .		•	
cefatexin, Shlonogi	[(aminophenylacetyl)amino]-3-metnyr-8- oxo-, [6R-[6Alpha,713(R*)]]- [CAS]	15686-71-2			Formulation, modified-release, other
	7-D-mandelamido-3[[(1-methyl-1H-tetrazol-			•	
cefamandole	5-yl)tniojmetnyij-3-cepnem-4-carboxyiic acid	34444-01-4	Si	3641021	Cephalosporin, injectable
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-				
	carboxylic acid, 7-[[amino(4-			•	
-	nyaroxypnenyijacetyjaminoj-o-o-o-o-trini 1,2,3-triazol-4-ylthio)methyl]-, [6R-		1		
cefatrizine · ·	[6Aipha,76(R*)]]- [CAS]	51627-14-6	88	1460914	Cepnalosporin, oral
-	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-				•
·	carboxylic acid, 7-[[amino(4-			•	
	nydroxyphenyljacetyjaniinoj-oxy-ormini 1.2.3-triazol-4-vithio)methyli-, [6R-				
cefatrizine, Ausonia	[6Alpha,78(R*)]]- [CAS]	51627-14-6			Cephalosporin, oral
Cefazedone		56187-47-4			
Cefazolin		25953-19-9			
Cefbuoerazone		76610-84-9			
Scientification of the second					

	. '	. •				<u> </u>			 · -		 _
Example of Indication	Infection, general		infection, respiratory tract, upper		Infection, general	Infection, general	Infection, general	 		Infection, general	

	•		Detent	•	. •
		•	שמני		•
API Generic Name	API Chemical Name	CAS No.	Ref	Ref rence	Example of Therapeutic Use
	78-[(Z)-2-(2-amino-4-thiazolyi)-2-			.•	
	pentencylaminol-3-carbamoyloxymethyl-3-	105889-45-0		٠.	
cefcapene pivoxil	pivaloyloxymethyl ester HCI- [CAS]	105889-46-1	gB	2173194	Cephalosporin, oral
Cafeguana Divoxil		105889-45-0			
Cefclidin		105239-91-6			
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-	•			•
:	carboxylic acid, 7-[[(2-amino-4-	•			,
	thiazolyt) (hydroxylmino)acetyljaminoj-3-	91832-40-5	E	105459	Cephalosporin, oral
cefdinir	2	2000			
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-	•	•		•
	carboxylic acid, 7-[[(2-amino-4-		•	•	
	thiazolyl)(methoxylmino)acetylaninoj-5-[2-	104145-95-1			
•	(4-metryt-5-triazoly)eurerryj-6-oxo-, (2,2-	104146-53-4	٠		
cefditoren bivoxil	(3(Z),6Alpha,78(Z)]]- [CAS]	117467-28-4	ď	61178991	Cephalosporin, oral
	Pyrrolidinium, 1-[[7-[](2-amino-4-			•	
	thiazolyl)(methoxyimino)acetytjaminoj-2-	107648-80-6		•	
	o on a vilmethyll 1-methyl- hydroxide	123171-59-5			
	inner salt, [6R-[6Alpha,78(Z)]]- [CAS]	88040-23-7	Q.	531981	Cephalosporin, injectable
forime		88040-23-7			
		65052-63-3			
Celetanier	E Thin's arabicuming 2 Oloci-2-ang-2:				
	Carboxviic acid. 7-III2-amino-4-				
	thiazolyl)(methoxylmino)acetyl]amino]-3-			•	
	methyl-8-oxo-, (2,2-dimethyl-1				·
	oxopropoxy)methyl ester,			٠,	
sofotomiat nivoxil	monohydrocnioride, [6H-[6Alpna,/15(2)]]- [CAS]	111696-23-2	89	1581854	Cephalosporin, oral
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-				
	carboxylic acid, 7-[[(2-amino-4-				
•	thiazoly)](carboxymetroxy)iitiirojacetyjaii inoj-3-ethenyl-8-oxo-, [6R-[6Alpha,78(Z)]]-				
cefixime	[CAS]	79350-37-1	G.	30630	Cepnalosporin, oral

Example of Indication	. :
Infection, respiratory tract, general	
	•
Infection, dermatological	
)	
Infection, general	
	•
٠.	
Infection, respiratory tract, lower	
	_
Infection, general	•
· .	
Infection, general	

			ŀ		
			Patent	Ħ	•
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-	• • •			
	carboxylic acid, 7-[[(2-amino-4-	•			•
	[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8- loxo-, [6R-[6Alpha,78(Z)]]- [CAS]	65085-01-0 75738-58-8	GB	1536281	Cephalosporin, injectable
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-				
	carboxylic acid, 7-		•		
: 	[[[(cyanomethyl)thio]acetyl]amino]-7-	A 00 90593	•		· ·
 cefmetazole	memoxy-3-I(()-memyr-1n-terazor-5-yl)thio]methyl]-8-oxo-, (6R-cis)- [CAS]	56796-39-5	89	1449420 -	Cephalosporin, injectable
-					
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-	•		•••	
	carboxylic acid, 7-[[(2-amino-2-	•	_		
	carboxyethyl)thio]acetyl]amino]-7-methoxy-	•		•	-
	3-[[(1-methyl-1H-tetrazol-5-yl)thio]methylj-8	0.17-305-4	Q	. 62876	Cephalosporin, injectable
cetminox	oxo-, loH-loAlbua, / Albua, / (3)]]- (CAS)	S-14-C0040	<u>i</u>	2121	
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-				
	carboxylic acid, /-[[(Z-amino-4-	•			
. ·	mazoly)(meuloxyuminojacety)amiloj-c-				
	thiazolyilthio]methyll-8-oxo-, [6R-	69739-16-8		•	
cefodizime	[6Apha,78(Z)]]- [CAS]	86329-79-5	Si	4590267	Cephalosporin, injectable
Cefonicid		61270-58-4			
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-				
	carboxylic acid, 7-	•		•	
• • • • • • • • • • • • • • • • • • • •	[(hydroxyphenylacetyl)amino]-8-oxo-3-[[[1-	•			· .
cefonicid sodium	disodium salt, [6R-[6Alpha,78(R*)]]- [CAS]	61270-78-8	GB	1547473	Cephalosporin, injectable
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-				
•	carboxylic acid, 7-[[[(4-ethyl-2,3-dioxo-1-	•		•	
	piperazinyl)carbonyljaminoj(4-		:		
· · · · · · · · · · · · · · · · · · ·	hydroxyphenyi)acetyijaminoj-3-[[(1-metnyi-	•			
	1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6H-	62893-19-0	GB	1508071	Cephalosporin, injectable
ceioperazone	י יייייייייייייייייייייייייייייייייייי	02730-15-R	5	4234579	Antibiotic, other
ceroperazone + suipacram		0-01-02-0	3		
Ceforanide		60925-61-3			

Indication		it tract,		
Example of Indic	Infection, general	Infection, unnary tract Infection, respiratory tower	Infection, general	Infection, general Infection, general

		٠	Patent	int	·.
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	5-Thla-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[[2,3-dihydro-2-(2-hydroxyethyl)-3-imino-1H				
cefoselis	pyrazor-1-ylimemyij-a-oxo-, lon- [6Alpha,78(Z)]]	122841-12-7	G	307804	Cephalosporin, injectable.
Cefoselis		122841-10-5			
Cefotaxime		63527-52-6		-	
cefotaxime sodium	(6R,7R)-7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]ceph alsporanic acidsodium salt	64485-93-4	ĠВ	1580621	Cephalosporin, injectable
Cefotetan		69712-56-7			
cefotiam	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazoly)]acetyljamino]-3-[[[1-[2-(dimethylamino]ethyl]-1H-tetrazol-5-yi]thio]methyll-8-oxo-, (6R-trans)-[CAS]	61622-34-2 66309-69-1	Sn	4080498	Cephalosporin, injectable
cefotiam hexetil	. 1-(cyclohexyloxycarbonyloxy)ethyl 76-[2-(2-aminothiazol-4-y/)acetamidol-3-[[[1-(2-dimethylaminoethyl)-1H-tetrazol-5-yl]thio]methyl]ceph-3-em-4-carboxylate 2HCI [CAS]	95789-30-3		128029	r Cephalosporin, oral
Cefoxitin		35607-66-0			
cefoxitin sodium	5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-,monosodium salt, (6R-cis)-[CAS]	33564-30-6	. 8	1348984	Cephalosporin, oral
cefozopran	Imidazo[1,2-b]pyridazinium, 1-[[7-[[(5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabioyclo[4,2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6Abha,78[2]]- [CAS]	113359-04-9	<u> </u>	203271	Cephalosporin, injectable

Example of Indication infection, general infection, general infection, general infection, respiratory tract, lower
--

Patent				١		
Puridinium, 1-[[2-carboxy-7-[[[[6]-carboxy-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1			•	Pate	.	
Pyridinum, 1-[[2-carboxy-7-t[[[(5-carboxy-1-t[[carboxy-1-t[carboxy-1-t[carboxy-1-t[carboxy-1-t[carboxy-1-t[carboxy-1-t[carboxy-1-t[carboxy-1-t[carboxy-1-t[carboxy-1-t[carboxy-1-t[carboxy-1-t[carboxy-1-t[carboxy-1-t[carboxy-1-t[carboxy-1-t[carboxy-1-t[ca	ADI Generic Name	API Chemical Name		Refe	rence	Example of Therapeutic Use
Pyridintum, 1-I[2-carboxy-7-III[(6-carboxy-7-IIII(6-carboxy-7-IIII(6-carboxy-7-IIII(6-carboxy-7-IIII(6-carboxy-7-IIII(6-carboxy-6-m-6-1-2-1-2-1-2-1-2-1-2-1-2-1-2-1-2-1-2-1				1.		
Virtuinuazura- Virtuinuazura- virtuinuazura- virtuinuazura- virtuinuazura- virtuinuazura- virtuinuazura- virtuinuazura- virtuinuazura- virtuinua-virtuinua- pridityila-t-azabicyclot4.2.0jcct-2-ne-2- carboxylia acid, 7-[[[[(4-hqha,78[R']]]-[CAS]] pridityila-t-azabicyclot4.2.0jcct-2-ne-2- carboxylia acid, 7-[[[(2-amino-4- thiazaoly)(methoxylimino]acely amino]-2- carboxylia acid, 7-[[(2-amino-4- thiazaoly)(methoxylimino]acely amino]-2- carboxylia acid, 7-[[(2-amino-4- thiazaoly)(methoxylimino]acely amino]-2- carboxylia acid, 7-[[(amino-1-4- propenyl-, [BR-[6Ahpha,78[R']]]-[CAS] g2865-29-7 GB 2173798 g2665-29-7 carboxylia acid, 7-[[amino-1-4- propenyl-, [BR-[6Ahpha,78[R']]]- [CAS] g2665-29-7 carboxylia acid, 7-[[amino-1-4- propenyl-, [BR-[6Ahpha,78[R']]]- [CAS] g2665-29-7 carboxylia acid, 7-[[amino-1-4- propenyl-, [BR-[6Ahpha,78[R']]]- [CAS] g2665-29-7 carboxylia acid, 7-[[amino-1-4- p2665-29-7 gB-[6Ahpha,78[R']]]- [GAS] gB 1435111 gAS5111 g		Pyridinium, 1-[[2-carboxy-7-[[[[5-carboxy-	•	•		
10 1.0	•	yl)carbonyljaminojphenylacetyljaminoj-8-				
10 10 10 10 10 10 10 10		oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-			•	
184880-03-5		yljmethyl]-4-(2-sulfoethyl)-, hydroxide, (ingeringentyl)-(2-sulfoethyl)-(CAS)			60028	Cephalosporin, injectable
18	cerpirmizore	יייום פפול ומן ומן ייים אליים אינים ומן ייים ומן ייים אינים ומן ייים ומים ומן ייים ומן	84880-03-5			•
5-Thia-1-azabicyclo(4.2.0)cot-2-ene-2- carboxylic acid, 7-[II[(4-hydroxy-6-methyl-3- pyndinyl)achonyllamino](4- hydroxyphanylpachyllamino](4- hydroxyphanylpachyllamino]-3-[I(1-methyl- 1H-tetrazol-5-yihtolmethyll-6-oxo-, IGR- III-tetrazol-7-yihtolmethyll-6-oxo-, IGR- III-tetrazol-7-yihtolmethyll-6-oxo-, IGR- III-tetrazol-7-yihtolmethyll-6-oxo-, IGR- III-tetrazol-8-yihtolmethyll-6 III-tetrazol-8-yihtolmethyll-8	Cefpimizole		20000			
pyridinyl)carbonyljaminoj(4- hydroxyphenyl)acetyljaminoj-3-[[(1-methyl- 1H-tetrazol-5-yl)thiojmethyl)-8-oxo-, [6R- [6A pha,78(R')]]-[CAS] 5H-1-Pyrindinium, 1-[[7-][(2-amino-4- thiazolyl)(methoxyiminojacetyljaminoj-2- carboxy-8-oxo-5-thia-1-azabicycioj(4.2.0)oxt 2-en-3-yljmethylj-6,7-dihydro-,hydroxide,		5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxvlic acid, 7-[[[(4-hydroxy-6-methyl-3-				. · . · . · .
hydroxyphenyl)acety/laminoj-3-[[(1-methyl-14-tetrazol-5-yl)thio]methyl-8-oxo-, [6R- 70797-11-4 US 4156724 [6Alpha,7B(R)]]- [CAS] 5H-1-Pyrindinium, 1-[[7-[[(2-amino-4-thiazoly)(methoxyimhro)acetyl]aminoj-2-carboxy-8-oxo-5-thia-1-azabicyclot4.2-0]oxt-2-9-6-ginner saft, [6R-[6Alpha,7B(Z)]]- [CAS] imer saft, [6R-[6Alpha,7B(Z)]]- [CAS] 5-Thia-1-azabicycloj4.2.0]oxt-2-ene-2-carboxyic acid, 7-[[aminoi(4-hydroxyimhro)-8-oxo-3-(1-poxo-2-2-7-2-2-7-9-7-2-2-2-7-2-2-7-2-2-7-2-2-2-2		pyridinyl)carbonyl]amino](4-			•	
Thereazor		hydroxyphenyl)acetyljaminoj-3-[[(1-methyl-			•	
### SH-1-Pyrindinium, 1-[[7-[[(2-amino-4-thiazolyty)(methoxyinnino]acebyljamino]-2-carboxy-8-oxo-5-thia-1-azabicycio[4.2.0]oct 2-en-3-yijmethylj-6,7-dihydro-,hydroxide, 98753-19-6	ofoiremide	1H-tetrazor-5-ylytniojmetriyij-6-0x0-, [on- [6Aloha,76(R')]]- [CAS]		S	4156724	Cephalosporin, injectable
### Proxettl #### Proxettl ##### Proxettl ##################################	confinancia.					
tritazolyt)(methoxylmino)acetyljamino)-2- carboxy-8-oxo-5-trila-1-azabicycio(4.2.0)oot 2-en-3-yljmethylj-6,7-dihydro-,hydroxide, 2-en-3-yljmethylj-6,7-dihydro-,hydroxide, 2-en-3-yljmethylj-6,7-dihydro-,hydroxide, 2-en-3-yljmethylj-6,7-dihydro-,hydroxide, 2-en-3-yljmethylj-6,7-dihydro-,hydroxide, 3-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid, 7-[(amino-1,4- cyclohexadien-1-ylacetyl)amino]-3- methoxy-8-oxo-, [6R-[6Alpha,78(R*)]]- [CAS] striaz-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid, 7-[(amino-1,4- cyclohexadien-1-ylacetyl)amino]-3- methoxy-8-oxo-, [6R-[6Alpha,78(R*)]]- [CAS]		5H-1-Pyrindinium, 1-[[7-[](2-amino-4-			•	
Canboxy-6-oxo-3-ritie-1-azatioy-cut-x-2-y-6-6 84957-29-8 EP 64740	:	thiazolyl)(methoxyimino)acetyljaminoj-2-	•			·
Inner salt, [6R-[6Alpha,78(Z)]]- [CAS] 98753-19-6 EP 64740	•	Carboxy-8-0x0-5-mia-1-azabicycio(4-z-v)os	84957-29-9		•	
ime Proxetil 5-Thia-1-azabloyclo[4.2.0]oct-2-ene-2- carboxylic acid, 7-[[amino]-8-oxo-3-(1- propenyl)-, [8R-[6Alpha,78(R*)]]- [CAS] propenyly, acid, 7-[(amino-1,4- cyclohexadien-1-ylacetyl)amino]-3- methoxy-8-oxo-, [8R-[6Alpha,78(R*)]]- [51762-05-1 GB 1435111	cefnimme	[inner salt, [6R-[6Alpha,78(Z)]]- [CAS]		$\neg \neg$	64740	Cephalosporin, injectable
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid, 7-[[amino(4- hydroxyphenyl)acetyl]amino[4- hydroxyphenyl)acetyl]amino[4- hydroxyphenyl)acetyl]amino[4- propenyl-, [6R-[6Alpha,78(R*)]]- [CAS] propenyl-, [6R-[6Alpha,78(R*)]]- [CAS] (anhiydrous); (an	September 1		87239-81-4			
5-Thia-1-azabicycloi(4.2.0)oct-2-ene-2- carboxylic acid, 7-[[amino(4- hydroxyphenyl)acieyl]amino(4- propenyl)-, [8R-[6Alpha,78(R¹)]]- [CAS] 92665-29-7 GB 2173798 (anhydrous); (anhydrous); 121123-17-9 (annohydrate) 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid, 7-[(amino-1,4- cyclohexadien-1-ylacetyl)amino]-3- methoxy-8-oxo-, [6R-[6Alpha,78(R²)]]- 51762-05-1 GB 1435111	Cerponoville Frozen	-	٤			
carboxylic acid, 7-[[amino(4- hydroxyplic acid, 7-[[amino]-8-oxo-3-(1- propenyl)-, [8R-[6Alpha,78(R*)]]- [CAS] 92665-29-7 GB 2173798 Garhydrous); 121123-17-9 (monohydrate) 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid, 7-[(amino-1,4- cyclohexadien-1-ylacetyl)amino]-3- methoxy-8-oxo-, [6R-[6Alpha,78(R*)]]- 51762-05-1 GB 1435111	:	5.Thia-1-azabicyclof4.2.0loct-2-ene-2-				
hydroxyphenyl)acetyllaminol-8-oxo-3-(1- propenyll-, [6R-[6Alpha,78(R*)]]- [CAS] propenyll-, [6R-[6Alpha,78(R*)]]- [CAS] propenyll-, [6R-[6Alpha,78(R*)]]- (anhydrous); (anhydrous); (121123-17-9 (monohydrate) (mono	·	carboxylic acid, 7-[[amino(4-	•			
propenyl-, [6R-[6Alpha,7B(R')]]- [CAS] 92665-29-7 (anhydrous); (anhydrous); (121123-17-9 (monohydrate) (anchoxylic acid, 7-[(amino-1,4-cyclohexadien-1-ylacetyl)amino]-3-methoxy-8-oxo-, [6R-[6Alpha,7B(R')]]- 51762-05-1 GB 1435111		hydroxyphenyl)acetyljamino]-8-oxo-3-(1-		. 8	. 80707.10	
92665-29-/ (anhydrous); (121123-17-9 (monohydrate) 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid, 7-[(amino-1,4- cyclohexadien-1-ylacetyl)amino]-3- methoxy-8-oxo-, [6R-[6Alpha,78(R*)]]- [CAS]	cefprozil	propenyl)-, [6R-[6Alpha,78(R*)]]- [CAS]	92665-29:/	9	21/3/30	Ochimosponii ota
[annydrous]; 121123-17-9 121123-17-9 (monohydrate) 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid, 7-[(amino-1,4- cyclohexadien-1-y/acetyl)amino]-3- methoxy-8-oxo-, [6R-[6Alpha,78(R*)]]- [CAS]	Cefprozil		92665-29-7			
121123-1 7-9 (monohydrate) (monohydrate) (carboxylic acid, 7-[(amino-1,4-cyclohexadien-1-ylacetyl)aminoj-3-methoxy-8-oxo-, [6R-[6Alpha,78(R*)]]- [51762-05-1 GB 1435111	,		(annyarous);		•	
5-Thia-1-azabicyclof4.2.0]oct-2-ene-2- carboxylic acid, 7-[(amino-1,4- cyclohexadien-1-ylacetyl)aminoj-3- methoxy-8-oxo-, [6R-[6Alpha,78(R*)]]- [CAS]		•••	121123-17-9			
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid, 7-[(amino-1,4- cyclohexadien-1-ylacetyl)amino]-3- methoxy-8-oxo-, [6R-[6Alpha,78(R*)]]- [CAS]			(monohydrate)			
carboxylic acid, 7-[(amino-1,4- cyclohexadien-1-ylacetyl)amino]-3- methoxy-8-oxo-, [6R-[6Alpha,78(R*)]]- [CAS]		5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-				
Godolitezaderi 17,120-05, [6R-[6Alpha,76(R*)]]- 51762-05-1 GB 1435111 [CAS]		carboxylic acid, 7-[(amino-1,4-				
[CAS] [51762-05-1 [GB [1453711		methoxy-8-oxo-, [6R-[6Alpha,78(R*)]]-				ero rivornoladaso
	cefroxadine	[CAS]	51762-05-1	3	145011	Cepitalospoint, oras

	· .	· · · · · ·	: :	. ·	
Example of Indication	Infection, respiratory tract, general	Infection, general	Infection, respiratory tract, lower	Infection, dermatological	Infection, general

API Generic Name	API Chemical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
cefsulodin	Pyridinium, 4-(aminocarbonyl)-1-[[2-carboxy-8-oxo-7-[(phenylsulfoacetyl)amino] 5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yilmethyly-, hydroxide, inner salt, [6R-[6Ajoha,78(R')]]-[CAS]	62152-93-9 62587-73-9	g5	1387656	Cephalosporin, ínjectable
officelline	Pyridinium, 1-[[7-[[(2-amino-4-thiazolyl)[(15-carboxy-1-carboxy-1-metrylethoxy)]mino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct_2-en-3-ylmetryl]-, hydroxide, inner satt, 172 inner satt,	558-82-8		GB 2025398	J J Cephalosporin, injectable
Cefteram	7 17/- \ 1	82547-58-8			
Ceffezole		26973-24-0	7		
ceftibuten	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-(2-amino-4-thiazolyl)-4-carboxy-1-oxo-2-butenylamino]-8-oxo-, [6R-(6Alpha,78(2)]]- [CAS]	97519-39-6		136721	Cephalosporin, oral
cettizoxime	ct-2-ene-2- o-4- etyljaminoj-8- CASj	68401-81-0 68401-82-1	89	1600735	Cephalosporin, injectable
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-{[[2-{Ramino-1-	1	٠		
ceftizoxime alapivoxil	oxopropyljaminoj-4- thiazolylj(methoxylmino)acetyljaminoj-8- oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, monohydrochloride, [6R- [6Alphe,78(Z(S*))]]- [CAS]	113812-94-5 135767-36-1	م	62209112	Cephalosporin, oral
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazoly)](methoxyimino]acetyljamlno]-8-oxo-3-[[(1.2,5,6-tertahydro-2-methyl-5,6-dioxo-1,2,4-thiazin-3-vilthiomethyl-16R-dioxo-1,2-4-thi	73384-59-5			
ceftriaxone	$\neg \neg$		8	2022090	Cephalosporin, injectable
Cefuroxime		55268-75-2	7		
	• •				

· [·	Indication		onal		ny tract,		· · · · · · · · · · · · · · · · · · ·	· ·					:		ory tract;
	Example of Ind	•	Infection, pseudomonal		Infection, respiratory		Infection, respiratory lower		Infection, general	•		, , ,	Infection, general	Intection, general	Infection, general Infection, respiratory

			Patent	int	
API Generic Name	API Chemical Name	CAS No.	Ref	Reference	Example of Therapeutic Use
	5-Thia-1-azablcyclo[4:2.0]oct-2-ene-2-				
	carboxylic acid, 3-	•			•
<u>:</u>	[[(aminocarbonyl)oxy/methyl]-7-[[2-		:	•	
	11.10-chilomiethyl ester 16R.	15886-71-2	<u>.</u>	•	
cefuroxime axetil:	[(6Alpha,78(Z)]]- [CAS]	64544-07-6	GB	1571683	Cephalosporin, oral
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-	÷			
	carboxylic acid, 3-				
•	[[(aminoćarbonyl)oxy]methyl]-7-[[2-				
	furanyl(methoxyimino)acetyl]amino]-8-oxo-, [55268-75-2	55268-75-2	٠ (270017	
ceturoxime sodlum	[6R-[6Alpha,78(Z)]]- [CAS]	56238-63-2	3	1453048	Cephalospoini, injecianie
Cefuzonam		82219-78-1			
	Benzenesulfonamide, 4-(5-(4-		•		
celecoxib	methylphenyl)-3-(utituoromethyl)-1r- pyrazol-1-yl)- [CAS]	169590-42-5	Sn	5760068	Antiarthritic, other
	Butanoic acid, octahydro-1,7,8-trihydroxy-6-				
•	Indolizinyi ester, [15-		9		Activity Other
celgosivir	(1Alpha,6B,7Alpha,8B,8aB)j-[CAS]	121104-90-9	3	201/202	Anwid, onlei
		:		··	
	Urea, N-{3-acetyl-4-{3-{(1,1	. 03.0		•	
- C	hydroxyntropoxylphonyll-N N-diethyl- (CAS)		GB	1441359	Antihypertensive, adrenergic
Ceripion	The state of the s	7 02 7000			
Cellulose Ethyl		9004-58-4		•	
Hydroxyethyl Ether					
Centchroman		31477-60-8			
	9,12-Epoxy-1H-dlindolo[1,2,3-fg:3,2,1-				
	carboxviic acid 5.16-bis(fethylthlo)methyl)-				
•	2,3,9,10,11,12-hexahydro-10-hydroxy-9-	•			
	methyl-1-oxo-, methyl ester, (9S,10R,12R)-	156177.65.0	. Š	9731002	Antiparkinsonian
CEP-134/	0.12 Enavir 14 - Allindoloft 9 3:fr:3: 9:1'.		2 .		
•	Klpyrrolo(3,4-i)[1,6]benzodiazocin-1-one,			•	
	2,3,9,10,11,12-hexahydro-10-hydroxy-10-)
	(hydroxymethyl)-9-methyl-, (9S,10S,12H)-			· .	
CEP-701	[CAS]	111358-88-4			Anticancer, antimetabolite
Cephacetrile Sodium		23239-41-0			
		483-17-0			
Cephalexin	٠	15686-71-2			
					•

•		,	· ·	· · · · · · · · · · · · · · · · · · ·		
Exampl of Indication	Infection, respiratory tract, upper	Infection, general	Arthritis, rheumatoid Infection, hepatitis virus, general	Angina, unstable	Parkinson's disease	Cancer, prostate

	<u> </u>				
			Patent		
API Generic Name	API Chemical Name	CAS-No.	Reference	۹	Example of Therapeutic Use
Cephaloglycin		3577-1-3			
Cephaloridine		50-59-9	-		
Cephalosporin C		61-24-5			
Cephalothin		153-61-7			·
Cephapirin Sodium		24356-60-3		,	
Cephradine		38821-53-3			
Cerivastatin		145599-86-6			
Ceronapril .		111223-26-8	-		
certoparin .	Heparin [CAS]	9005-49-6			Anticoagulant
Ceruletide		,17650-98-5		·	
·	Prosta-5,13-dien-1-ole acid, 11,15-dihydroxy-8-oxo-, (5Z,11Alpha,13E,-15S)-	363-24-6			Formulation, dermal, topical
Catalkanium Chlorida		122-18-9	-		
		34019-98-7	-		
Cethexonium Bromide		1794-74-7	-		
	2H-Oxacyclotetradecino(4,3-d)oxazole-			•	
	2,6,8,14(1H,7H,9H)-tetrone 4-		<u>:</u> _		
	emylocianyoro-sa,7,3;11,13,13- hexamethyl-11-(/3-/3-orinofinyl)-2-				
	propenyl)oxy)-10-((3,4,6-trideoxy-3-		:		
•	(dimethylamino)-B-D-xylo-	•	· ·		•
	hexapyranosyl)oxy)-,(3a				
cethromycin	0,4h,/h,3h, loh, lih, loh, loh, loh, loh, loh, loh, loh, lo	205110-48-1	EP 929563		Macrollde antibiotic
Cetiedil		14176-10-4			
Cetirizine		83881-51-0	,		
cetirizine dihydrochloride	Acetic acid, [2-[4-[(4-chlorophenyl)phenylmetryl]-1-piperazinyl]ethoxyl-, dilydrochloride [CAS]	83881-51-0 83881-52-1	EP 58146		Antiallergic, non-asthma
	Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxyl-, dihyrochloride,		, - -		
cetirizine+pseudoephedrine,UC B		83881-52-1 90-82-4	·.	<u></u> <u></u>	Formulation, optimized, microencapsulate
Cetotiamine		137-76-8			
				, •	

Example of Indication Thrombosis, venous Infection, respiratory tract, general Allergy, general	· · ·	· ·; 	· ·	··		 ·	· · · · · · · · · · · · · · · · · · ·	
	. 6.			1-11		 , respiratory	m, general	gy, general

			l		
			Patent	Ĭ	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
C toxime		25394-78-9			
	Benzenepropandic ecid, 4-[[[4- (aminomethyl)cyclohexyl]carbonyl]oxyl-,	27724-96-5 34675-84-8	٠ ق	48075547	Antiulcer
cellavale	in the second second	24875.94.9			
		57-09-0			
Cerrimonium bromide		0 20 00 7			
Cetrorelix		120287-85-6	\cdot		
Cetyldimethylethylammo		124-03-8			- !
Cetylpyridinium Chloride		123-03-5			· .
cevimeline	Spiro[1-azablcyclo[2.2.2]octane-3,5'- [1,3]oxathiolane], 2'-methyl-, cis- [CAS]	107220-27-9	. G	205247	Stornatological .
	7-phenyl-2,4,6-heptatrienoylhydroxamic				
CG-1521					Anticancer, other
Chaulmooaric Acid		29106-32-9			
Chenodiol		474-25-9			
CHE-3381			EP	951465	Analgesic, other
Chlophedianol		791-35-5	•		
Chloracizine		800-22-6	:		
Chloral Betaine		2218-68-0	·		
Chloral Formamide		515-82-2			
chloral hydrate, SSP	1,1-Ethanediol, 2,2,2-trichloro- [CAS]	302-17-0			Formulation, transmucosal, systemic
Chlorambucil		305-03-3			
Chloramine-B		127-52-6			
Chloramine-T		.127-65-1			
Chloraminophenamide		121-30-2			
Chloramphenicol		56-75-7			•
Chlorazanil		500-42-5			
Chlorbenzoxamine		522-18-9			
Chlorbetamide		97-27-8			-
Chlorcyclizine		82-93-9			
Chlordantoin		5588-20-5			
Chlordiozonovido		58-25-3		•	

	 •	•			•			 			 . — .	<u>.</u>	 	<u>.</u>
Example of Indication			Sjogren's syndrome	Cancer, general		Pain, neuropathic		Insomnia						

					_
			Patent		
AP/ Generic Name	API Chemical Name	CAS No.	Reference	Example of Therapeutic Use	
Chlorauanide		500-92-5			
Chlorhexadol		3563-58-4			<u>:</u>
chiorbavidina Knowell	2,4,11,13- Tetraazatetradecanediimidamide, N.N"- bis/4-chlorophenyl)-3,12-diimino- [CAS]	55-56-1	· .	Formulation, other	<u> </u>
chlorhaxidina Perio	2,4,11,13- Tetraazatetradecanedlimidamide, N.N bis(4-chloroplenyl)-3,12-dilmino- [CAS]	55-56-1		Formulation, modified-release, >24hr	·
Chloride		69-27-2			
Chlormadinone Acetate		302-22-7			
Chlormerodrin		62-37-3.		•	·
Chlormezanone		80-77-3			
Chlormidazole		3689-76-7			
Chlornaphazine		494-03-1			
Chloroazodin	٠	502-98-7			
Chlorophyll		1406-65-1			
Chloroprednisone		52080-57-6			
Chloroprocaine		3858-89-7			
Hydrochloride					
Chloropyramine	·	59-32-5			
Chloroquine		54-05-7			
Chlorothen		148-65-2			
Chlorothlazide		58-94-6			
Chlorotrianisene		569-57-3			
Chloroxine		773-76-2			
Chloroxylenol		88-04-0			
Chlorozotocin		54749-90-5			
chlorohenamine	2-Pyridinepropanamine, Gamma-(4-chlorophenyl)-N,N-dimethyl- [CAS]	132-22-9		Formulation, modified-release, other	
Chlorohenesin		104-29-0	-		
Chlorphenesin		886-74-8			
Chloroheniramine		132-22-9			· <u> </u>
				•	٠

ation			•.*		<u>:</u>	· · · · · · · · · · · · · · · · · · ·				•				1		
Example of Indication		Xerostomia		Periodontitis.					,		:	-			-	Allerov deneral

			Patent	nt	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Chlorohenoxamide	-	3576-64-5			
Chlorohenoxamine		77-38-3			
Chlorphentermine		461-78-9		•	
Chlororoethazine	. 1	84-01-5			•
Chlororoguanii		537-21-3			
	4,4'-Sulfonyldianiline + 1-(3,4-			•	
NOO coccept : flooringsmelde	Dichlorophenyl)5-isopropy biguanide	537-21-3 80-08-0		•	Antimalarial
Chloratamazina		50-53-3			
Chlororopamide		94-20-2		•	
Chlororothixene		113-59-7		,	
Chlorauinaldol		72-80-0			
Chlortetracycline		57-62-5 ··			
Chlorihalidone		77-36-1			
Chlorthenoxazin(e)		132-89-8		-	
Chlorzoxazone		95-25-0			
Cholic Acid		81-25-4			
Choline Alfoscerate		28319-77-9			
Choline Chloride		67-48-1			·
Choline Sallcylate		2016-36-6			
Oncline cancy are					•
	Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-	, u			Earmilation modified-release other
choline theophyllinate, Amarin	purine-2,6-dione (1:1) [CAS]	4488-40-0			
	Ethanaminium, 2-[[(2,3-dihydroxyphosphinyl]oxy]-	•	•		
choline-L-alfoscerate	[CAS]	28319-77-9	٩	55028955	Cognition enhancer
Chromocarb.		4940-39-0	·		
Chromonar		804-10-4			•
Chrysoidine		532-82-1			
	Guanidine, N-[6-(4-chlorophenoxy)hexyl]-	200484-11-3	Sn	5696140	Anticancer, other

:		·		
Example of Indication	Infection, malaria		Amnesia	Cancer, general

			Patent	¥	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	Glycine, N-[2-[5-(aminoiminomethyl)-2- hydroxyphenoxy]-6-[3-(4,5-dihydro-1-				
	methyl-1H-imidazol-2-yl)phenoxyl-3,5- difluoro-4-pyrldinyl -N-methyl- [CAS]	183305-24-0	MO MO	9638421	Antianginal
					••
	Benzamide, 2-[(2-chloro-4- lodophenyllaminol-N-(cyclopropylmethoxy)-				
CI-1040	3,4-difluoro- [CAS]	212631-79-3	8	9837881	Anticancer, other
	1H-Imidazole, 2-(2,2-diphenylcyclopropyl)-				
cibenzoline	4,5-dihydro- [CAS]	53267-01-9	BJ.	141/1/4	Anuarmyuning
	Pregna-1,4-diene-3,20-dione 16,17-	·.			
• • •	(cyclottexymeen) (construction) (construction) (construction) (construction)		Ļ		· · · · · · · · · · · · · · · · · · ·
ciclesonide	(118,16Alpha). [CAS]	126544-47-6	<u>"</u>	4123333	- Annasanna
	Furo[3,4-c]pyrldin-7-cl, 3-(4-chiorophenyl)-	82747-56-6	<u>v</u>		Antihypertensive, other
cicletanine	1,3-dinydro-6-memyr-, (+/-)-10A9.	80042-R2-R			
Cicletanine		0.30-04-22			۲.
ciclonicate	3-Pyridinecarboxylic acid, 3,3,5- trimethylcyclohexyl ester, trans- [CAS]	53449-58-4	ä	1910481	Vasodilator, peripheral
Ciclonicate	••	53449-58-4	·		
Cicionicate		29342-05-0			
- Ciclopiio	2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4				-
oielonico olamina	metnyr-, compa. witi z-aniinoeulano (1:1) [CAS]	41621-49-2	ရှ	3883545	Antifungal
Ciclosidomine		66564-16-7			
ciclosporin A, Chong Kun Dang	Cyclosporin A- [CAS]	59865-13-3	\perp		Formulation, optimized, microemulsion
	Phosphonic acid, [[2-(4-amino-2-oxo-1(2H)				
· · · · · · · · · · · · · · · · · · ·	pyrimidinyl)-1- (hydroxymethyl)ethoxyjmethyl]-, (S)- [CAS] 113852-37-2	113852-37-2	<u>B</u>	253412	Antiviral, other
	Phosphonic acid, [[2-(4-amino-2-oxo-1(2H)	-			
lab four and	pyrimidinyi)-1- (hydroxymethyi)ethoxyjmethyi]-, (S)-[CAS]			-	Antiviral, other
Citenline		53267-01-9			
		•	1		.:

					 •		· . ·		· 	:	<u> </u>
Example of Indication	Angina, unstable	Cancer, general	Arrhythmia, general	Asthma		Cancer, lung, small cell	Infection, fungal, general	Transplant rejection, general	linfection, cytomegalovirus	or the solution of the solutio	medion, jerpes simples vites

	٠		Patent	T T	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	4H-Pyrido[3,2,1-]k]carbazol-11(8H)-one, 5,6,9,10-tetrahydro-10-[(2-metnyl-1H-	120635-74-7	 Ü	, 297651	GI inflammatory/bowel disorders
clansetron	Imidazor-1-yılınduyıl-ş (r.y. 1920)	82009-34-5	í		
Cilastatin	- 1- Conjugate Object				
].	6H-Pyridazino[1,2-a][1,2]diazepine-1- carboxylic acid, 9-[[1-(ethoxycarbonyl)-3- phenylpropyljamino]ocjahydro-10-oxo-, [1S 88768-40-5 [1Alnha,9Alpha(R*)]]- [CAS]	88768-40-5 90139-06-3	GB	2128984	Antihypertensive, renin system
cilazabrii	Cyclo(L-arginylglycyl-L-Alpha-aspartyl-D-ohenvlalanyl-N-methyl-L-valyl) [CAS]	188968-51-6	급	770622	Anticancer, other
Cilettigliade	2 S.P. ridinadicarboxylic acid, 1.4-dihydro-				
	2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxvethyl-3-phenyl-2-propenyl ester-				
cilnidinine	[CAS]	102106-21-8	ы	161877	Anthypertensive, orner
Cilnidinine	•	132203-70-4			
	Cis-4-cyano-4-[3-(cyclopentyloxy)-4- methoxyphenyl]cyclohexane-1-carboxylic	• • •		٠.	. •
	acid	153259-65-5	Sn	5602157	COPD treatment
cilomilast	Ht broadsland by the				
oliostazol	[2(1H)-Quinolinone, o-[4-(1-2)-outexyr in tetrazol-5-yl)butoxyj-3,4-dihydro-[CAS]	73963-72-1	8	2033893	Antithrombotic
Cimetidine		51481-61-9	_		
	3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane, 9-(cyclopropylmethyl)-7-(3-hydroxy-1-oxo-2-n-anylmethyl-promide, [7(S)-				
cimetroplum bromide	(1Alpha,28,48,5Alpha,78)]-[CAS]	51598-60-8	ള	3853886	Antispasmodic .
	1-napthalenemethanamine,Alpha-methyl-N- (3-(3-(trifluoromethyl)phenyllpropyll-,				
i cinacatest hydrochloride	(AlphaR)-, hydrochloride	364782-34-3			Hormone
Cinchonidine .		485-71-2			
Cinchonine		118-10-5			
Cinchonhan	:	132-60-5			
Cinepazet		23887-41-4	\downarrow		
Cinenazide		23887,46-9			

Example of Indication	
Irritable bowel syndrome	•
Limentancion conoral	•
	•
Cancer, lung, non-small cell	
Hypertension, general	•
	٠.
Chronic obstructive pulmonary disease	•
Peripheral vascular disease	
Muscle spasm, general	
	•
Hyperparathyroidism	

s Name seate			Patent	. ·	
ше					
	API Chemical Name	CAS No.	Refe	Reference.	Example of Therapeutic Use
	Piperazine; 1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-				
			9	7010	المعطرينيون عربواناموروا
	propenyil-, (Z)-2-butenedioate (1:1) [CAS]	26328-04-1	9	1218591	Vascullator, peripriera:
Cinitarride	_	66564-14-5			
Cimagnac		20168-99-4			
Cinnemacing		8-98-06			
Character		298-57-7			
Ollifai Islia				•	· · · · · · · · · · · · · · · · · · ·
				000	. Confidence of the control of the c
cinolazepam .	hydroxy-2-oxo- [CAS]	75696-02-5	۳ ۵	2820282	nyphond sedanye
<u> </u>	[1,3]Dloxolo[4,5-g]cinnoline-3-carboxylic	28657-80-9	85	1296753	Quinolone antibacterial
		104-28-9			
Ciliovate	,	58473-74-8			
Cinromide		00079-11-7			
Cioteronel		090/2-11-7			
cipamfylline (b	_	132210-43-6	ם	383585	Antipranticaling and green
	4.H-Imidazole, 4-[(1R,2R)-2-(5,5-dimethyl-1- hexynyljcyclopropylj- (CAS)	213027-19-1	US	6008240	Psychostimulant
	Propanoic acid, 2-[4-(2,2- dichlorocyclopropy])phenoxy]-2-methyl-	•	1	0000	in a coming (Antiothory consists of the consis
ciprofibrate	[CAS]	52214-84-3	3	1382820	hypompaeniich milanieroscierosis.
	3-Quinolinecarboxylic acid, 1-cyclopropyl-6- fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- rc.4sr	85721-33-1	Sn	4670444	Quinolone antibacterial
	3-Quinolinecarboxylic acid, 1-cyclopropyl-6-				
	fluoro-1,4-dinydro-4-oxo-7-(1-piperaziny); + (6Alpha, 11B, 16Alpha)-6,9-Difluoro-				
	11,21-dihydroxy-16,17-[(1-			•	
	methylethylidene)bis-(oxy)]-pregna-1,4- i diana-3 20-dione				
ciprofloxacin+fluocinolone,SAL					Formulation, fixed-dose combinations
Ciramadol		63269-31-8	╛		

	· .·	 				<u> </u>	
Example of Indication	ripheral vasc	insomnia	Infection, urinary tract	Eczema, atopic	Attention deficit disorder Hyperipidaemia, general	Infection, general	Outits

. .

API G neric Name API Cl Benzam fluoroph cisapride piperidir poperitare	ADI Chemical Name		Patent Patent	=	
neric Name			Dofo		
		CAS No.		Reference	Example of Inerapeutic Use
	oro-N-[1-[3-(4- ethoxy-4-	81098-60-4	. G	76530	Gastroprokinetic
			·		
dimetho tetrahyd	propanediyl)]Ibis[1-[(3,4- dimethoxyphenyl)mettyl]]-1,2,3,4- tetrahydro-6,7-dimethoxy-2-methyl-, {1R-			.	
[1Alpha		96946-42-8	US.	5453510	Muscle relaxent
)-, (SP-4-2)-	15663-27-1	US	4177263	Anticancer, alkylating
Citatonram		59729-33-8			
	5-Isobenzofurancarbonitrile, 1-{3-		•		
(dimeth:	(dimethylamino)propyl]-1-(4-tluorophenyl)- [1.3-dihydro-monohydrobromide [CAS]	59729-32-7	gg B	1526331	Antidepressant
	Cytidine 5'-(trihydrogen diphosphate), P'-[2-				•
(trimeth . inner se	(trimethylammonio)ethyljester, nyaroxide; inner salt [CAS]	987-78-0	굡	39006541	Cognition enhancer
90		1195-16-0			
Citric Acid		77-92-9			
Citrulline		372-75-8	·		
Ethana	Ethanamine, N.N-dimethyi-2-[(1-methyl-1H-				
cizolirtine citrate (1,2,3-pi		142155-44-0			Urological
	4-(3-(4-(2-Methyl-Imidazol-1-yl)- phenyisulianyil-phenyi)-tetrahydro-pyran-4- carboxylic acid amide		-		trontment
CJ-13610			·		COLD legalielie
1H-PM	1H-Pyrgno[3',4':6,7]indolizino[1,2-		·	•	
b]quino hydroxi	-ethyl-4- nojethyl}-				A storage of the
CKD-602		213819-48-8	2 5	429050	Anticancer antimetabolite
cladribine Adenos	Adenosine, 2-chloro-2'-deoxy- [CAS]	4291-63-8	<u>.</u>	8008/I	Amedical, andicascome
tin		30544-61-7			
Ciglioparii					

	 	•			•	· .	-11
Example of Indication	Surren adjunct	Depression, general	Infarction, cerebral	Incontinence	Chronic obstructive pulmonary disease	ovarian	Cancer, leukaemia, nalry cell

Name e cid	[CAS]	CAS No.	Patent Refere	Reference	Example of Therapeutic Use
te 10 10 10 10 10 10 10 10 10 10 10 10 10	[CAS]	CAS No.	Refe	rence	Example of Therapeutic Use
te in Acid		81103-11-9	_		•
te y in Acid			e e	3	Macrolide antibiotic
Acid Acid In		•			
Acid				•	
Acid romide in					٠.
Acid sromide in			7		
sromide in		58001-44-8			
romide in		55905-53-8		. }	
romide in		15686-51-8	•		
romide in		442-52-4			
romide In		37148-27-9			
Sromide sin		96125-53-0.			
n Bromide kacin	3,5-Pyridinedicarboxylic acid. 4-(2,3-	:			
e m Bromide kacin	gicniorophenyl)-1,4-diriyuro-2,0-diriyariyr. methyl (1-oxobutoxy)methyl ester (±) [CAS] 167221-71-8		WO.	9512578	Antihypertensive, other
omide	2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-2-fluoro-B-L-arabinofuranosyl)-5-methyl-		•	•	
Clidanac Clidinium Bromide Clinafloxacin	·	163252-36-6	•		Antiviral, other
Clidinium Bromide Clinafloxacin		28968-07-2			
Clinafloxacin		3485-62-9	·		
		105956-97-6	İ		•
Clindamycin	•	18323-44-9			
	L-threo-Apha-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-[[(1-	•		· ·.	
pyrrolidinyl)carbonylle pyrrolidinyl)carbonylle trans)-+ retinoic acid	pyrrolidinyl)carbonyllamino]-1-thio-, (2S- frans)- + retinoic acid	·		•	
clindamycin + tretinoin, Yaman					Formulation, fixed-dose combinations
	-Threo-Alpha-D-galacto-octopyranoside,	•	· ·		
methyl 7-chloro-6,	methyl 7-chloro-6,7,8-trideoxy-6-[[(1- methyl-4-propyl-2-	•	 -	•.	`
pyrrolidinyl)carbo (dihvdrogen phos	//jaminoj-1-thlo-, 2-	18323-44-9		<i>:</i>	
clindamycin		24729-96-2			Formulation, parenteral, other
Clinofibrate		30299-08-2			
Clinarast		88931-51-5			

tlon g,		virus	ā
Example of Indication Infection Infection, respiratory tract, lower		Hypertension, general Infection, hepatitis-B vir	Acne Infection, gynaecological

Name	ADI Chemical Name		Patent	ı,	
Name	Di Chemical Name		-		m
		CAS No.	Here	Reference	Example of Inerapeutic Use
	1H-1,5-Benzodlazepine-2,4(3H,5H)-dione,	:			
Clobenfurol	7-chloro-1-methyl-5-phenyl- [CAS]	22316-47-8	BB	1214682	Anxiolytic .
	•	3611-72-1			
Clopenoside	•	29899-95-4			
Clobenzepam		1159-93-9			
Clobenzorex		13364:32-4			
Clobenztropine		5627-46-3			
Clobetasol		25122-41-2			
	Pregna-1,4-diene-3,20-dione, 21-chloro-9-			•	٠
muc olohetasol Sollec	fidoro-11,1/-dinydroxy-10-fileuryr-, (118,163)-1CAS)	25122-41-2			Formulation, dermal, topical
		54063-32-0			
	Pregna-1,4-diene-3,11,20-trione, 21-chloro-			•	·
	9-fluoro-16-methyl-17-(1-oxobutoxy)-, (168)- [CAS]	25122-57-0	89	1253831	Antipruntic/inflamm, allergic
Clobutinol		14860-49-2	·		
Clocapramine		47739-98-0			
Clocinizine		298-55-5			
Cloconazole		77.1.75-51-0		.	•
Ciocortolone		4828-27-7			
um. Ablogen	Phosphonic acid, (dichloromethylene)bis., disodlum salt- ICASI	22560-50-5	*_*		Osteoporosis treatment
	Phosphonic acid. (dichloramethylene)bis-				
clodronate disodium, Leiras disc		22560-50-5	·	-	Anticancer, hormonal
		10596-23-3		·	
	2-chloro-9-(2-deoxy-2-fluoro-8-D- arabinofurasonyl)adenine		•		Anthonocy partimotoholito
сюfarabine					Alucation, attitionabilities
)-e	3-(p-chioroanilo)-10-(p-chlorophenyl)-2,10- dihydro-2-(isopropylimino)-phenazine				Formulation, optimized,
clofazimine		2030-63-9			microencapsulate
Clofenamide		671-95-4		·	-
Clofibrate		637-07-0		:	
Clofibric Acid		882-09-7			

Example of Indication	
	·
•	
Soriasis	
•	
Pain, cancer	•
Hypercalcaemia of malignancy	
Cancer, leukaemia, chronic lymphocytic	
-	•
Infection, tuberculosis	

-			Patent	¥	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Cloflucarban		369-77-7			
Clofoctol		37693-01-9			
Cloforex		14261-75-7		,	
Clomacran		5310-55-4			
Clomestrone		4091-75-2		٠	•
Clom tacin		25803-14-9	•		
Clomethiazole		533-45-9			
Clometocillin :		1926-49-4			
Clomiphene		911-45-5			
Clomipramine		303-49-1			
Clomocyclin		1181-54-0			
A COLOR	2H-1,4-Benzodiazepin-2-one, 5-(2-	1622-61-3	. S	4316897	Antievileptic
cionazepani	Chicago Cario 2	7			
clonidine, Alza	1 H-Imidazol-2-amine, N-(2,5- dichlorophenyl)-4,5-dihydro- [CAS]	4205-90-7	Sn	4060084	Formulation, transdermal, patch
Clonitazene	•	3861-76-5	·-		
Clonitrat		2612-33-1		٠	•
Clonixin		17737-65-4			
Clopamide		636-54-4		.	
Clopenthixol		982-24-1			
Cloperastine		3703-76-2			
Clopidogrel		113665-84-2			
	Thieno[3,2-c]pyridine-5(4H)-acetic acid, Alpha-(2-chlorophenyl)-6,7-dihydro-,	120202-48-4			
clopidogrel hydrogen sulfate	methyl ester, (S)-, sulfate (1:1) [CAS]	90055-48-4	EP	99802	Antithrombotic
Clopirac		42779-82-8			
Cloprednol.		5251-34-3			
cioranolol	2-Propanol, 1:(2,5-dichlorophenoxy)-3- [(1,1-dimethylethyl)amino]- [CAS]	39563-28-5 54247-25-5	US 4	4310549	Antihypertensive, adrenergic
Cloranolol		39563-28-5			
Clorazepic Acid		23887-31-2			
Ciorexolone		2127-1-7			
cloricumenė	Acetic acid, [[8-chloro-3-[2- (diethylamino)ethyl)-4-methyl-2-oxo-2H-1- benzoovran-7-viloxyl-, ethyl ester [CAS]	68206-94-0	SD	4349566	Vasodilator, coronary
Conscionation	tooling the state of the state				

		•	•			•	•		•	·.		. •		· .			· .	
Example of Indication						Epilepsy, general	Hypertension, general.					 infarction, Injugatulai	:				Peripheral vascular disease	

			Patent	n	
		•		•	
API Generic Name	API Chemical Name	CAS'No.	Refe	Reference	Example of Therapeutic Use
Clorindione		1146-99-2			
Clorprenaline		3811-25-4			
Clortermine		10389-73-8			
Clospirazin		24527-27-3			
Chestebol		1093-58-9			
Clothiapine		2058-52-8			•
	2H-Thieno[2,3-e]-1,4-diazepin-2-one, 5-(2-				
clotiazenam	chlorophenyi)-7-ethyr-1,3-dinyaro-1-memyr- ICASI	33671-46-4	S	3849405	Anxiolytic ·
clotrimazole	1-[(2-chlorophenyl)diphenylmethyl]-1H- imidazole	23593-75-1	SI	3705172	Antifungal
	Pragna-1 4-diana-3 20-dione 9-fluoro-11-				•
·	hydroxy-16-methyl-17,21-bis(1-			•	• .
	oxopropoxy)-, (118,168)-, mixt. with 1-[(2-	•			
clotrimazole + betamethasone	chlorophenyl)alphenylmetnylj-1 H-imidazole [CAS]	92522-91-3			Formulation, fixed-dose combinations
	1-[(2-chlorophenyl)diphenylmethyl]-1H-				
	imidazole	•	٠	•	
clotrimazole, Bentley					Formulation, dermai, topical
Cloxacillin		61-72-3			
	Oxazolo[3,2-d][1,4]benzodlazepin-6(5H)-				
	. Jone, 10-chloro-11b-(2-chlorophenyl)-	24166-13-0	SN	3772371	Anxiolytic
Cioxazorani	ביטיין וודינפוומווזימוס וכייסי	24166-13-0			
Cioxacolalli		53608-96-1			
Cloxuanin		130-16-5			
clozapine	5H-Dibenzo[b,e][1,4]diazepine, 8-chloro-11-(4-methyl:1-piperazinyl)-[CAS]	5786-21-0	ns	3539573	Neuroleptic. :
	Trans-2-[3-methoxy-4-(2-p-chlorophenylthio)ethoxy-5-(N'-methyl-N'-hydroxyureidyllmethylphenyl]-5-(3,4,5-	·			
CMI-392	timeutoxyphenyi)tenariyatorian	193739-23-0	SN	5648486	Antipsortasis
	2-Naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-				
CMT-3	3,10,12,12a-tettanyuroxy-1,11-oloxo-, (4aS,5aR,12aS)-[CAS]	15866-90-7	SO	5837696	Anticancer, other

	Example of Indication	
	Anxiety, general	٠.
	••	
	Infection, fungal, general	
	Infection, onychomycosis	•
•		
		_
	Schizophrenia	
	Psoriasis	
	Cancer, sarcoma, Kaposl's	

API Generic Name API Chemical Name CAS No. CNI-1493 Decanedianide, N.N.bis[3,5-bis[1-6]] (Gaminofuniomethyl)hydrazono]ethylphenyl (GAS) 164301-51-3 CNI-1493 N-12-chloro-5 (methylthio)phenyl]hwethyl (GAS) 160754-76-7 16370-90-1 Cocaethylene N-12-chloro-5 (methylthio)phenyl]guandine (CAS) 160754-76-7 13870-90-1 Cocaethylene 5,10 methylthio)phenyl]guandine (CAS) 160754-76-7 160754-76-7 Cocaethylene 5,10 methylthio)phenyl]guandine (CAS) 160-36-2 160-36-2 Coclesine 5,10 methylthio)phenyl]guandine (CAS) 160-36-2 160-36-2 Colestilen 1-Hexanaminium, N.N.N-trimethyl-6-(2-6) 160-36-2 160-36-2 Colestilan 1-Hexanaminium, N.N.N-trimethyl-6-(2-6) 164-36-8 164-36-8 Colestilan 11-Imidazole, 2-methyl, polymer with colestilan (chloromethyl)oxirane (CAS) 16658-42-4 164-36-6 Colestilan (Chloromethyl)oxirane (CAS) 16658-42-4 16658-42-4 16658-42-4 Colestilan (Chloromethyl)oxirane (CAS) 138605-00-2 16658-42-4 16658-42-4 Collestilan (CAS) <t< th=""><th>CAS No. 164301-51-3 160754-76-7 13870-90-1 529-38-4 50-36-2 76-57-3 52-28-8</th><th>Reference US 575057 WO 942759</th><th>nce 50573</th><th>Example of Therapeutic Use</th></t<>	CAS No. 164301-51-3 160754-76-7 13870-90-1 529-38-4 50-36-2 76-57-3 52-28-8	Reference US 575057 WO 942759	nce 50573	Example of Therapeutic Use
Decanediamide, N.N.bis[3.5-bis[1- [(aminotininomethyl)hydrazono]ethyl)pheny 164301-51-3 Ip, tetrahydrochloride [CAS] 160754-76-7 Interhydrochloride [CAS] 160754-76-7 Interhydrochloride 13870-90-1 Interhydrochloride 13870-90-1 Interhydrochloride 13870-90-1 Interhydrochloride 13870-90-1 Interhydrochloride 14-86-8 Interhydrochloride 138605-00-2 Interhydrochloride 13881-02-9 Interhydrochloride 14-0xde, (R)- (CAS] Interhydrochloride 1247-71-8 Interhydrochloride 14-0xoch-(56.7.8-1) Interhydrochloride 14-0xoch-(16-8) Interhydrochloride	164301-51-3 160754-76-7 13870-90:1 529-38-4 50-36-2 76-57-3 52-28-8			
N-{2-chloro-5-(methylithio)phenyl}-N-methy N-{2-chloro-5-(methylithio)phenyl}-N-methy N-{2-chloro-5-(methylithio)phenyl}-N-methy N-{2-chloro-5-(methylithio)phenyl}-N-methy S2-28-8	160754-76-7 13870-90:1 529-38-4 50-36-2 76-57-3 52-28-8			Anti-Inflammatory
13870-90-1	13870-90:1 529-38-4 50-36-2 76-57-3 52-28-8		9427591	Analgesic, other
Section	529-38-4 50-36-2 76-57-3 52-28-8 64-86-8	1:1:1		
## Phosphate	50-36-2 76-57-3 52-28-8 64-86-8	1.1		
## Phosphate	76-57-3 52-28-8 64-86-8			
Phosphate	52-28-8 64-86-8	-		
1-Hexanaminium, N.N.N-trimethyl-6-(2-propernylamino)-, polymer with (chloromethyl)oxirane, 2-propen-1-amine and N-2-propenyl-1-decanamine, hydrochloride [CAS]	64-86-8			•
1-Hexanaminium, N.N.N-trimethyl-6-(2-bropenylamino)-, polymer with (chloromethyl)oxirane, 2-propen-1-amine and N-2-propenyl-1-decanamine, hydrochloride [CAS]	64-86-8			Anticancer, antimetabolite
1-Hexanaminium, N,N,N-trimethyl-6-(2-propenylamino)-, polymer with (chloromethyl)oxirane, 2-propen-1-amine and N-2-propenyl-1-decanamine, hydrochloride [CAS] (chloromethyl)oxirane [CAS] (chloromethylaminopropioniyl)forskolin-gropate (CAS] (chloromethylaminopropioniyl)forskolin-gropate (CAS] (chloromethylaminopropioniyl)forskolin-gropate (CAS] (CA				
(chloromethyl)oxirane, 2-propen-1-amine and N-2-propenyl-1-decanamine, hydrochloride [CAS] 182815-44-7 (chloromethyl)oxirane [CAS] 26658-42-4 (chloromethyl)oxirane [CAS] 26658-42-4 (chloromethyl)oxirane [CAS] 26658-42-4 (chloromethyl)oxirane [CAS] 26658-42-4 (chloromethyl)oxirane [CAS] 26658-42-4 (chloromethylaminopropionyl)forskolin- 138605-00-2 [CAS] 3,5,9-Trioxa-4-phosphapentacosan-1- aminium, 4-hydroxy-N,N,N-trimethyl-10- oxo-7-[(1-oxohexadecyl)oxy]-, hydroxide, 63-89-8 (inner salt, 4-oxide, (R)- [CAS] 138331-02-9 (inner salt, 4-oxide, (R)- [CAS] 1398-78-3 (inner salt, 4-oxide, (R)- [CAS] 1398-78-3 (inner salt, 4-oxide, (R)- [CAS] 1247-71-8 (inner salt, 4-oxide, (R)- [CAS] 1247-71-8 (inner salt, 4-oxide, (R)- [CAS] 1398-78-3 (inner salt, 4-oxide, (R)- [CAS] 1398-8 (inner salt, 4-oxide, (R)- [CAS] 1398-8 (inner salt, 4-oxide, (-		
and N-2-propenyl-1-decanamine, hydrochiloride [CAS] 1H-Imidazole, 2-methyl-, polymer with (chloromethyl)oxirane [CAS] 26658-42-4 6-(3-dimethylaminopropioniyl)forskolin- [CAS] aropate 3,5,9-Trioxa-4-phosphapentacosan-1- aminium, 4-hydroxy-N,N,N-trimethyl-10- oxo-7-[(1-oxohexadecyl)oxy]-, hydroxide, 63-89-8 inner salt, 4-oxide, (R)- [CAS] 1398-78-3 11398-78-3 11247-71-8 1-Pyrrolidineacetamide, 2-oxo-N-(5,6,7,8-ketahydro-2,3-dimethyllurol2,3-blquinolin-	· :			
in hydrochlofide [CAS] 14-Imidazole, 2-methyl-, polymer with (chloromethyl)oxirane [CAS] 26658-42-4 6-(3-dimethylaminopropionyl)forskolin- (CAS] aropate (CAS) 3,5,9-Trioxa-4-phosphapentacosan-1- aminium, 4-hydroxy-N,N,N-trimethyl-10- oxo-7-[(1-oxohexadecyl)oxy]-, hydroxide, (63-89-8 inner salt, 4-oxide, (R)- [CAS] (39837-49-7 inner salt, 4-oxide, (R)- [CAS] (1398-78-3 inner salt, 4-oxide, (R)- [CAS] (139			7	. من معمل موسود المساد
11+-Imidazole, 2-methyl-, polymer with (chloromethyl)oxirane [CAS] 26658-42-4 (chloromethyl)oxirane [CAS] 26658-42-4 6-(3-dimethylaminopropionyl)forskolin- 138605-00-2 (CAS] 3,5,9-Trioxa-4-phosphapentacosan-1- aminium, 4-hydroxy-N,N,N-trimethyl-10- 0xo-7-[(1-oxohexadecyl)oxyl-, hydroxide, 63-89-8 inner salt, 4-oxide, (R)- [CAS] 1398-78-3 1 1 1 1 1 1 1 1 1 1		S	699/096	Hypolipaemic/Antiatrieroscierosis
aropate (CAS) (CAS) (138605-00-2 (CAS) (138505-00-2 (CAS) (CAS) (138505-00-2 (CAS) (ج چ	59155421.	Hypolipaemic/Antiatherosclerosis .
6-(3-dimethylaminopropionyl)forskolin- 138605-00-2 [CAS] 3,5,9-Trioxa-4-phosphapentacosan-1- aminium, 4-hydroxy-N,N,N-trimethyl-10- oxo-7-[(1-oxothexadecyl)oxyl-, hydroxide, 63-89-8 inner salt, 4-oxide, (R)- [CAS] 138331-02-9 1398-78-3 1-Pyrrolidineacetamide, 2-oxo-N-(5,6,7,8-letrahydro-2,3-dimethyfurol2,3-blguinolin-	26658-42-4			•
3,5,9-Trioxa-4-phosphapentacosan-1- aminium, 4-hydroxy-N,N,N-trimethyl-10- oxo-7-[(1-oxohexatecyl)oxy]-, hydroxide, inner salt, 4-oxide, (R)- [CAS] 13831-02-9 1398-78-3 1-Pyrrolidineacetamide, 2-oxo-N-(5,6,7,8- letrahydro-2,3-dimethylfuro[2,3-biguinolin-	·	EP. 2%	222413	Cardiostimulant
0xo-7-[(1-0xohexadecyl)oxy]-, hydroxide, 63-89-8 138331-02-9 1398-71-27 1398-78-3 1247-71-8 1247-71-8 1247-71-8				
1-Pyrrolidineacetamide, 2-oxo-N-(5,6,7,8-iterahydro-2,3-dimethylfurol2,3-blquinolin-	. 2-6	SU **	4826821	Lung Surfactant
1-Pyrrolidineacetamide, 2-oxo-N-(5,6,7,8-letrahydro-2,3-dimethylfuro[2,3-b]quinolin-	138331-02-9	-		Formulation, implant
1-Pyrrolidineacetamide, 2-oxo-N-(5,6,7,8-iterahydro-2,3-dimethylfuro[2,3-b]quinolin-	1398-78-3			
	1247-71-8			
			•	
135463-81-9	135463-81-9 EP	ᄀ	427636	Cognition enhancer
disodium combretastatin-A-4-3-O-phosphate	·		÷	·
combretastatin A-4 prodrug		-	1	Anticancer, other

Example of Indication	· ·
Psoriasis	
ain, neuropathic	
ancer, colorectal	
perlipidaemia, general	
ypercholesterolaemia	
Heart failure	٠.
Respiratory distress syndrome, infant	•
Regeneration, bone	
Azheimer's disease	
Pancer, thyroid	

			1		
			Patent	¥	
API Generic Name	API Ch mical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
compound.B, Pharmacor			Sn	6362165	Antiviral; anti-HIV
	[1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazol4,5-dil]1-benzazepin-6(1H)-yl)carbonyliphenyl]		•		
conivaptin hydrochloride	monohydrochloride [CAS]	168626-94-6	§	9503305	Gl inflammatory/bowel disorders
Connettivina	Hyaluronic acid [CAS]	9004-61-9			Vulnerary
Convallatoxin		508-75-8			
Coparaffinate		8001-60-3			
Corticorelin Ovine					
Corticosterone		50-22-6			
Cortisone .		53-06-5			
Cortivazol		1110-40-3			
Cosyntropin		1.6960-16-0			
Cotarnine		82-54-2		.]	
Cotinine		486-56-6			
	Benzenesulfonamide, 4-amino-N-2-				
	pyrimidinyl-, mixt. with 5-[(3,4,5-trimethoxvahenyl)methyl]-2,4-				
co-trimazine .	pyrimidinediamine [CAS].	39474-58-3			Trimethoprim and analogues
Coumetarol		4366-18-1			
876-948	1H-Indene-3-acetamide, 5-fluoro-2-methyl- N-(phenylmethyl)-1-[(3,4,5- hrimethoxopenylmethylenel-, (1Z)-, ICASI, 200803-37-8	200803-37-8	. 0%	WO 9747303	Anticancer, other
CP-461			NS.	5948779	Anticancer, other
CPC-211	Acetic acid, dichloro-, sodium salt [CAS]	2156-56-1			Neuroprotective
CPI-1189	CPI 1189 [CAS]	210475-67-5	ΝO	9631462	Cognition enhancer
CRA-0450			8	WO 0202549	Anxiolytic
creatinol-O-phosphate	Guanidine, N-methyl-N-[2- (phosphonooxy)ethyl]- [CAS]	6903-79-3			Antianginal
CRL-5861	Oxirane, methyl-, polymer with oxirane, block [CAS]	106392-12-5	ns	4837014	Antisickling
				· ,	

		·	 ·		·
Example of Indication Infection, HIV/AIDS	/ Hyponatraemia		Infection, urinary tract	Barrett's oesophagus Cancer, prostate Acidosis, lactic Dementia, AIDS-related Unspecified	Anaemia, slokle cell

	-				
	:		Patent	T	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therap utic Us
	(2R,6S)-3-[2(S)-Benzyloxypropyl]-6,11,11-trimethyl-1,2,3,4,5,6,-hexahydro-2,6-methano-3-benzazocin-10-ol				:
crobenetine			80	9914199	Neuroprotective
croconazole	1H-Imidazole, 1-[1-[2-{(3-chlorophenyl)methoxy]phenyljethenylj- [CAS]	77175-51-0)E	3021467	Antifungal
cromoglicic acid, Transphyto	4H-1-Benzopyran-2-carboxylic acid, 5,5'- [(2-hydroxy-1,3-propanedlyl)bis(oxy)]bs4- oxo- [CAS]	53736-52-0.			Formulation, mucosal, topical
Cromolyn		16110-51-3			
cromolyn sodium, Durect	4H-1-Benzopyran-2-carboxylic acid, 5,5'- {(2-hydroxy-1,3-propanediyl)bis(oxy)]bis[4- oxo-, disodium salt [CAS]				Formulation, modified-release, other
cromolyn sodlum, Emisphere	.4H-1-Benzopyran-2-carboxylic acid, 5,5'- [(2-hydroxy-1,3-propanediyl)bis(oxy)]bis[4- oxo-, disodium salt [CAS]				Formulation, oral, other
	4H-1-Benzopyran-2-carboxylic acid, 5,5'- [(2-hydroxy-1,3-propanediyl)bis(oxy)]bis[4-	3.75.308±		•	Formulation inhalable solution
Cropropamide		633-47-6	1		
Crotamiton .		483-63-6			
Crotethamide		6168-76-9			
Crystacide	-	•	SO	4557935	Formulation, dermal, topical
CS-502			Eb	799823	Analgesic, other
CS-758	4-[(1E,3E)-4-[trans-5-[[1B,2R]-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyljthio]-1,3-dioxan-2-yl[-1,3-butadlenyl]-3-fluorobenzonitrile				Antifungal

Example of Indication	• •
Ischaemia, cerebral	
Infection, fungal, general	
Conjunctivitis	
Achmo	
3	
Asthma	
Asthma	
	_
Infection, dermatological Pain, general	
Infection, fungal, general	

			L		
			Patent		
API G neric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxyllc acid, 6-[(1R)-1-hydroxyethyl]-4-methyl-7-				
CS-834	oxo-s-[[(sh.p-s-oxo-s-py)(onaliny)]inog;, (s.c.) dimethyl-1-oxopropoxy)methyl ester, (4R,5S,6S)- [CAS]	157542-49-9	EP .	 599512	Beta-lactam antibiotic
	[(2H-benzo[d]1,3-dioxalan-5-methyl)amino][4-(6,7-dimethoxyquinazolin-	·			
CT-052923	4-yl)piperazinyi[methane-1-thione				Cardiovascular
	N-(4-bromophenyl)-6-(5-chloro-2- methybhenyl)-f1,3,5ltriazine-2,4-diamine			:	
CT-32228		00000			Anticancer, other
Cupric Citrate		955-82-0 955-82-0			
Cuproxoline		13007-93-7			
CVT-2584	Ethanol, 2,2-[[6-[[(4-methoxyphenyl)methyl]amino]-9-(1-methoxyphenyl)-9H-purin-2-yl]imino]bis-[CAS]	199986-75-9	WO W	9805335	Cardiovascular
	((S)-6-amino-5-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)-3-				. :
	methyl-1-phenyl-2,4-(1H,3H); pyrmidinedione			,	
CX-659S					Dermatological:
Cyacetacide		140-87-4			
Cyamemazine		3546-03-0			
Cyanidin Chloride	•	2-86-829	C	00172745	Anticancer other
Crelacilin		3485-14-1			
Cvclandelate		456-59-7	:	-	
Cyclazocine		3572-80-3			
Cyclexanone		15301-52-7			
Cyclexedrine		532-52-5			
cyclidrol, Corvi	3-Cyclohexene-1-methanol, 5-hydroxy- Alpha, Alpha, 4-trimethyl- [CAS]	498-71-5		.	COPD treatment, Respiratory
cyclin D1 inhibitors, Topo		·	g	6033843	Anticancer, hormonal
	•				

	7-11	7	7	1	1	1	7	_	۰,	Г	_	_	_	 T	_	-	 T:	_	_	T	-	_	_	_	7		÷	-	T		·	_:	_	1	_		_	_	_	_		-	_	_	_	_	_	_	_	 _		_	_	_	7	_	_		_	_		-	_	7		_		_	_	_	_	_	_	_	_	_	_	_	т	7	_	_	.	•		_	_	_	_	_	_	_			_			_	_	Г	7	_			_			_	
Example of Indication Infection, general Cancer, general Eczema, general Cancer, general Cancer, general	Cancer, breast							Cancer, preast	Connor hroset		Digitalina, Chivina	Dmonhitie phronic				•										Cancer, general			1	·· -		•	•		czema.		•		•		•			Hestenosis				· .			_				and the second	Cancer deneral		•	•		•	•			Hestenosis	Dectanosis					•	•	_	•	-					וווכספייו מבייבים	Infection, general	Infection, general	interest and and a second		•	•	· -				_		· ·	•			•	•			i	5	ö	Ċ	ť		•	-	

API Generic Name API Chemical Name B Cyclobarbital Cyclobendazole cyclobenzaprine, Aza cyclobenzaprine, Vela Cyclopentamine Cyclopentolate Cyclopen					
4PI Chemical Name 1-Propanamine, 3-(5H-dibenzo[a,d]cyclohepten-5-yildene)-N,N-dimethyl-ICAS] 3-(5H-Dibenzo[a,d]cyclohepten-5-yildene)-N,N-dibenzo[a,d]cyclohepten-5-yildene)-N,N-dibenzo[a,d]cyclohepten-5-yildene)-N,N-dibenzo[a,d]cyclohepten-5-yildene)-N,N-dibenzo[a,d]cyclohepten-5-yildene)-N,N-dimethyl-ICAS] N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide monohydrate 2(1H)-Pyridinone, 6-cyclohexyi-1-hydroxy-4-methyl-, cmpd with 2-aminoethanol(1:1) ICAS]			•	Patent	
1-Propanamine, 3-(5H-dibenzo[a,d]cyclohepten-5-yildene)-N,N-dimethyl-ICAS] 3-(5H-Dibenzo[a,d]cyclohepten-5-yildene)-N,N-dibenzo[a,d]cyc	6		CAS No.	Reference.	Example of Therapeutic Use
1-Propanamine, 3-(5H-dibenzo[a,d]cyclohepten-5-yildene)-N,N-dimethyl-ICAS] 3-(5H-Dibenzo[a,d]cyclohepten-5-yildene)-N,N-dibenzo[a,d]cyclohepten-5-yildene)-N,N-dibenzo[a,d]cyclohepten-5-yildene)-N,N-dimethyl-ICAS] N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide - monohydrate 2(1H)-Pyridinone, 6-cyclohexyi-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1)			82-92-8		
1-Propanamine, 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-ICAS] 3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propamide 1-Propanamine, 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-ICAS] M.N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide monohydrate 2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1) M.SYS [CAS]	arbital		52-31-3		
1-Propanamine, 3-(5H-dibenzo[a,d]cyclohepten-5-yildene)-N,N-dimethyl-ICAS] 3-(5H-Dibenzo[a,d]cyclohepten-5-yildene)-N,N-dibenzo[a,d]cyclohepten-5-yildene)-N,N-dibenzo[a,d]cyclohepten-5-yildene)-N,N-dimethyl-ICAS] 1-Propanamine, 3-(5H-dibenzo[a,d]cyclohepten-5-yildene)-N,N-dimethyl-ICAS] N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide monohydrate 2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1) ICAS]	endazole ·		31431-43-3		
3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)- N,N-dimethyl-1-propamide dibenzo[a,d]cyclohepten-5-ylidene)-N,N- dimethyl-[CAS] af N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2- oxazaphosphorin-2-amine-2-oxide monohydrate 2(1H)-Pyrldinone, 6-cyclohexyl-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1) M-SYS [CAS]	:	ine, 3-(5H- cyclohepten-5-ylidene)-N,N- \S)	303-53-7		Formulation, modified-release, other
1-Propanamine, 3-(5H-dibenzo[a,d]cyclohepten-5-yiidene)-N,N-dimethyi-[CAS] N,N-Bis(2-chloroethy)]tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide monohydrate 2(1H)-Pyridinone, 6-cyclohexyi-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1)		zo[a,d]cyclohepten-5-yildene)-· I-1-propamide			Formulation, modified-release, immediate
dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-[CAS] I N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide monohydrate 2(1H)-Pyrldinone, 6-cyclohexyl-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1)		ine 3-(5H-	-		
N.N-Bis(2-chloroethiyl)tetrahydro-2H-1,3,2- oxazaphosphorin-2-amine-2-oxide monohydrate monohydrate 2(1H)-Pyrldinone, 6-cyclohexyl-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1)		ing, 3-(3n)- cyclohepten-5-ylidene)-N,N-	303-53-7	•	Formulation, oral, other
af N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2- oxazaphosphorin-2-amine-2-oxide monohydrate monohydrate 2(1H)-Pyrldinone, 6-cyclohexyl-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1) M-SYS [CAS]			512-16-3	 - -	
af N.N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2- oxazaphosphorin-2-amine-2-oxide monohydrate monohydrate 2(1H)-Pyrldinone, 6-cyclohexyl-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1)	imarol		518-20-7		
af N.N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2- oxazaphosphorin-2-amine-2-oxide monohydrate Pharm 2(1H)-Pyrldinone, 6-cyclohexyl-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1) iM-SYS [CAS]	ine		52109-93-0		
al N.N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide monohydrate monohydrate 2(1H)-Pyrldinone, 6-cyclohexyl-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1)	- iu		2624-43-3		
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2- oxazaphosphorin-2-amine-2-oxide monohydrate	-		516-21-2		-
N.N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2- oxazaphosphorin-2-amine-2-oxide monohydrate Pharm 2(1H)-Pyrldinone, 6-cyclohexyl-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1)	ethycaine		139-62-8		-
Al. N.N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2- oxazaphosphorin-2-amine-2-oxide monohydrate Pharm 2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1) M-SYS [CAS]	um lodide		6577-41-9		4 · · ·
N.N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide — monohydrate — Pharm 2(1H)-Pyrldinone, 6-cyclohexyl-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1)	entamine		102-45-4		•
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide monohydrate Pharm 2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1)	enthiazide		742-20-1		
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide - monohydrate -Pharm 2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1)	entobarbital		76-68-6		
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide — monohydrate Pro-Pharm 2(1H)-Pyrldinone, 6-cyclohexyl-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1) CAM-SYS [CAS]	intolate .		512-15-2		•
ide, Pro-Pharm 2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1) ne, FOAM-SYS [CAS]		-1,3,2- . \			
2(1H)-Pyridinone, 6-cyclohexyi-1-hydroxy-4 methyl-, cmpd with 2-aminoethanol(1:1) ne, FOAM-SYS [CAS]		· .	50-18-0 6055-19-2	. •	Formulation, parenteral, targeted
ne, FOAM-SYS [CAS]	2(1H)-Pyridir methyl-, cmp				
	M-SYS		41621-49-2		Formulation, transdermal, other
	rine		68-41-7		
	iazide		2259-96-3		
Cyclovalone 57	lone	•	579-23-7		
Cymarin			508-77-0	•	

	· · · · · · · · · · · · · · · · · · ·	 · .	· · · · · · · · · · · · · · ·
ple of spasm,	Muscle spasin, general Sleep disorder, general	Cancer, general	Vaginitis

			Ŀ		
		,	Pat nt	ĭ	
API Generic Name	API Chemical Name	CAS No.	Ret	Reference	Example of Therapeutic Use
	•			•	
	Costramic soid (A-Mathyll) phonyll.	•		•	•
	(3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-				
cymserine	trimethylpyrrolo[2,3-b]indol-5-yl ester [CAS] 145209-39-8	145209-39-8	8	WO 9902154	Cognition enhancer
Cynarin(e)		30964-13-7			
CYP26 inhibitors, derm .			SN	6063606	Dermatological
Cyproheptadine		129-03-3			
	(18,28)-6-Chloro-1,2-dihydro-17-hydroxy-			•	
cvoroterone	3 H-cyclopropal 1, zjpregna-1, 4, o-ulene- 3.20-dione [CAS]	2098-66-0	•	•	Radio/chemoprotective
Cysteamine		60-23-1			
	[[4-[[3-[[4-[1-(4-hydroxyphenyl]-1-methyl-				
	ethyljphenoxylmethyljphenyljmethoxyl-	•			
cystic fibrosis ther, BI	prenyimmomenyi-, eary each				Cystic fibrosis treatment
	2(1H)-Pyrimidinone, 4-amino-1-[5-0-			:	
cytarabine ocfosfate .	Inydroxy(octadecyloxy)priosprimyj7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-	65093-40-5	Н	239015	Anticancer, antimetabolite
	2(1H)-Pyrimidone, 4-amino-1-8-D-arabino	147.04.4			Formulation modified-release other
cytarabine, Deportam .	ruranosyı- [CA5]	++6-1+1			
	N-(Pyridin-4-yl)-(1-(4-chlorobenzyl)-indol-3-				
D-24851	A Procedure		•		Anticancer, other
	8-Methoxyquinoline-5-[N-(2,5-				
D-4418	alchioropyriair-3-yi)jearuuxarinde	,			Antiasthma
	Benzeneacetamide, 4-(2-aminoethoxy)-N-				
DA-5018	(3-(3,4-dimetry/pneny))propy))-4-metroxy-, monohydrochloride [CAS]	174661-97-3	Sn	5242944	Analgesic, other
DA-6034			S	6025387	GI inflammatory/bowel disorders
DA-7867			E	9957803	Antibacterial, other
DA-7911			준	56034	Antiarthritic, other
			}		

· · ·	·	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·
Example of Indication	Alzheimer's disease Unspecified	Chemotherapy-induced injury; general Cystic fibrosis	Myelodysplastic syndrome Cancer, brain	Asthma Asthma Pain, musculoskeletal Crohn's disease Infection, general Arthritis, rheumatold

CAS No. CAS No.	•	Patent Reference	Example of Th rapeutic Use
### APT Crientical Native 3-(1-Methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo-[4,3-dipyrimklidn-5-y)-N+[2-(1-methyl-y)-N+[2-(1-methyl-y)-N+2-(1-methyl-19-deoxy-5-0-[2-deoxy-2-(10-methyl-19-deoxy-5-0-[2-deoxy-2-(10-methyl-19-deoxy-5-0-[2-deoxy-2-(10-methyl-19-deoxy-5-0-[2-deoxy-2-(10-methyl-19-deoxy-5-0-[2-deoxy-2-(10-methyl-19-deoxy-5-0-[2-deoxy-2-(10-methyl-19-deoxy-5-0-[2-deoxy-2-(10-methyl-19-deoxy-5-0-[2-deoxy-2-(10-methyl-19-deoxy-5-0-[2-deoxy-2-(10-methyl-19-deoxy-5-0-[2-deoxy-2-(10-methyl-19-deoxy-5-0-[2-deoxy-2-(10-methyl-19-deoxy-5-0-[2-deoxy-2-(10-methyl-19-deoxy-3-0-[2-deoxy-2-(10-methyl-19-deoxy-3-0-[2-deoxy-2-(10-methyl-19-deoxy-3-0-[2-deoxy-2-(10-methyl-19-0-[2-deoxy-2-(10-methyl-19-0-[2-deoxy-2-(10-methyl-19-0-[2-deoxy-2-(10-deoxy-2-(10-deoxy-3-deox		כוכווכנ	
3-(1-Metryl-7-oxo-3-propyl-6,7-dilhydro-1H- pyrazolo-[4.3-dipyrindidn-5-yl]-N-[2-(1- metryl-pyrolidn-2-yl)etryl]-4- propoxybenzenesulfonamide 152923-56-3 1521-01:hloro-38-de(metroxycarbonyl)-7- demetryl-19-deoxy-56-O-[2-deoxy-2-(10- metryl-19-deoxy-56-O-[2-deoxy-2-(10- metryl-19-deoxy-19-19-deoxy-2-(10- metryl-19-deoxy-19-19-deoxy-2-(10- metryl-19-deoxy-19-19-deoxy-2-(10- metryl-19-deoxy-19-19-deoxy-2-(10- metryl-19-deoxy-19-19-deoxy-2-(10- metryl-19-deoxy-19-19-deoxy-2-(10- metryl-19-deoxy-19-19-deoxy-2-(10- metryl-19-deoxy-19-19-deoxy-2-(10- metryl-19-deoxy-19-deoxy-2-(10- metryl-19-deoxy-19-deoxy-2-(10- metryl-19-deoxy-19-deoxy-2-(10- metryl-19-deoxy-19-deoxy-2-(10- metryl-19-deoxy-19-deoxy-2-(10- metryl-19-deoxy-19-deoxy-2-(10- metryl-19-deoxy-19-deoxy-19-deoxy-2-(10- metryl-19-deoxy-19-deoxy-19-deoxy-2-(10- metryl-19-deoxy-19-deoxy-19-deoxy-2-(10- metryl-19-deoxy-19			
Payazolo-[4,3-d]pyimidin-5-yl)-N-[2-(1-methylpytrolidin-2-yl)ethyl-4- methylpytrolidin-2-yl)ethyl-4- propoxybenzenesulfonamide 4342-3-4 152923-56-3 5,31-Dichloro-38-de(methoxycarbonyl)-7- demethyl-19-deoxy-56-O-[2-deoxy-2-(10-methylundecanamido]-8-0- glucopyranurosyl-38-lN-[3 dimethylistomycin A eglycone 171500-79-1 Apha-D-mannipytranosyl-N15- methylistomycin A eglycone 171500-79-1 virginiamycin M1, 26-((2-dihydro-171500-79-1 (icethylamino)ethyl)sulfonyl)-26,27-dihydro- (icethylamino)ethyl)sulfonyl)-26,27-dihydro- (icethylamino)ethyl)sulfonyl)-26,27-dihydro- (icethylamino)ethyl)sulfonyl)-26,27-dihydro- (icethylamino)ethyl)sulfonyl)-26,27-dihydro- virginiamycin M1, 26-((2-dimethylamino)-N-methyl-1- phenylatanino)-N-methyl-1- phenylatanino)-N-methyl-1- phenylatanino-16-(5-(1)-azabiodic 2-2)oct-3-ythio)methyl)-4-oxo- L-2-piperidinecarboxylic ecid) virginiamycin 106-60-5 sodium Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17- on (17Alpha)-[CAS] 117-10-2- on (17Alpha)-[CAS] 117-10-10- on (17Alpha)-[CAS] 117-10- on (17Alpha)-[CAS] 117-10- on (17Alpha)-[
metrylpyriotidin-2-y)ethylj-4-		·	
Propoxybenzenesulfonamide 4342-3-4	•	٠.	
152923-56-3	•		
sazine 4342-3-4 omycin 5,31-Dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-[2-deoxy-2-(10-methylundecanamido)-8-D-quocopyrannosyl-38-[N-i3-dimethylundecanamido)-8-D-quocopyrannosyl-38-[N-i3-dimethylundecanamido)-8-[2-deoxy-2-(10-methylundecanamido)-8-[N-i3-dimethylistomycin A aglycone methylistomycin A aglycone methylistomycin M1, 28-((2-dimethylamino)-N-methyl-1-phenylalanino)-N-methyl-1-phenylalanino)-N-methyl-1-phenylalanino)-N-methyl-1-phenylalanino)-N-methyl-1-phenylalanino)-N-methyl-1-phenylalanino)-N-methyl-2-condimethylanino)-N-methyl-1-phenylalanino)-N-methyl-1-phenylalanino)-N-methyl-1-phenylalanino)-N-methyl-1-phenylalanino)-N-methyl-1-phenylalanino)-N-methyl-1-condimethylanino)-N-methylanino)-N-methyl-1-condimethylanino)-N-methylanino)	Ψ¥.	353014	Male sexual dysfunction
Imab 152923-56-3 pemycin 5,31-Dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-[2-deoxy-2-(10-methylunidocanamido)-8-D-glucopyranuosyll-38-IN-[3-deoxy-2-(10-ylundevanamido)-8-D-glucopyranuosyll-38-IN-[3-deoxy-2-(10-ylundevanamido)-8-D-glucopyranuosyl-38-IN-[3-deoxy-2-(10-ylunderylanino)-10-propyljcarbamoyll-42-O-Apha-D-mannepyranosyl-N15-methylistomycin A eglycone 177500-79-1 ristin Virginiamycin M1, 26-((2-deoxy-2-dihydro-ylunderylanino)-N-methyl-1-phenylanino)-N-methyl-1-phenylanini-9-(5-((1-deoxy-2-dihydro-ylunderylanino)-N-methyl-1-phenylanini-9-(5-((1-deoxy-2-dihydro-ylunderylanini-9-(5-(3-deoxy-2-dihydro-ylunderylanini-9-(5-(3-deoxy-2-dihydro-ylunderylanini-9-(5-(3-deoxy-2-dihydro-ylunderylanini-10-N-methyl-1-phenylanini-10-N-methyl-1-phenylanini-10-(3-deoxy-3-diin-20-yno[2,3-d]isoxazol-17-17-230-88-5 ol. (17Alpha)-[CAS] 79094-20-5 on (17Alpha)-[CAS] 177-10-2 on (17Alpha)-[CAS] 177-10-2	342-3-4		
50-76-0	52923-56-3		•
5,31-Diehloro-38-de(methoxycarbonyl)-7- demethyl-19-deoxy-56-O-[2-deoxy-2-(10- methylundecanamido)-8-D- glucopyranurosyl-38-IN-i3- (dimethylamino)propyljcarbamoyl]-42-O- Alpha-D-mannepyranosyl-N15- methylistomycin M1, 26-((2- diethylamino)ethyl)sulfonyl)-26,27-dihydro- (diethylamino)ethyl)sulfonyl)-4-oxo- (26R,278)-, mixt with 4-(4- dimethylamino)-N-methyl-L- phenylalamino)-N-methyl-L- phenylalamino)-1-((1-1-2-2-)-1-0-1-0-1-0-1-0-1-0-1-0-1-0-1-0-1-0-1	0-92-0		
171500-79-17-0-7-0-17-0-7-0-17-0-17-0-17-0-1			
methylundecanamidol-8-D-glucopyranurosyll-8-IN-13- dimethylamino)propyllcarbamoyll-42-O-glucopyranurosyl-N15- methylristomycin A aglycone 171500-79-1 112362-50-2 Virginiamycin M1, 26-((2-Giethylamino)ethyl)sulionyl)-26,27-dihydro-gleftylamino)-N-methyl-1-phenylalanina)-N-methyl-1-phenylalanina)-5-(5-((1-azabicyclo(2.2.2)oct-3-yithio)methyl)-4-oxo-1-2-pipendinecarboxylic acid) virginiamycin 126602-89-9 106-60-5 106-60-5 106-60-5 106-60-5 106-60-5 117-10-2		•	
Comparation Comparation	•	•	
dimetrylamino)propyljcarbamoyl]-42-0- Alpha-D-mannopyranosyl-N15- metryliristomycin A aglycone 171500-79-1 virginiamycin M1, 26-((2- (diethylamino)ethyl)sulfonyl)-26,27-dihydro- (diethylamino)-N-methyl-L- phenylalanino)-N-methyl-L- phenylalanino)-N-methyl-L- phenylalanino)-5-(5-((1- azabicyclo(2.2.2)oct-3-yithio)methyl)-4-oxo- 1.2-pipendinecarboxylic acid) virginiamycin 126602-89-9 n sodium S1- [CAS] 9041-08-1 Heparin-, sodium salt [CAS] 79094-20-5 olevulinic Acid Pregna-24-dien-20-yno[2,3-d]isoxazol-17- 17230-88-5 on (17Alpha)- [CAS] 117-10-2 on on 117-10-2 on on 117-10-2 on on 117-10-2 on on on 117-10-2 on on on on on on on	•		•
Apha-D-mannopyranosyl-N15-methylristomycin A aglycone 171500-79-1 112362-50-2 112362-50-2 112362-50-2 112362-50-2 112362-50-2 1266127-dihydro-ciethylamino)ehtyl)sulfonyl)-26,27-dihydro-ciethylamino)-N-methyl-L-phenylalanino)-N-methyl-L-phenylalanino)-N-methyl-L-phenylalanino)-N-methyl-L-phenylalanino)-S-(5-((1-azebicyclo(2.2.2)oct-3-ythio)methyl)-4-oxo-1-2-piperidinecarboxylic acid) virginiamycin 126602-89-9 1-2-piperidinecarboxylic acid) virginiamycin 126602-89-9 10-2-piperidinecarboxylic acid) virginiamycin 126602-89-9 10-2-piperidinecarboxylic acid) virginiamycin 106-60-5 106-60-5 106-60-5 117-10-2 11	•	•	
171500-79-1 1715000-79-1 1715000-79-1 1715000-79-1 1715000-79-1 1715000-79-1 1715000-79-1 1715000-79-1 1715000-79-1 1715000-79-1 1715000-79-1 1715000-79-1 1715000-79-1 1715000-79-1 1715000-79-1 1715000-79-1 17150000-79-1 17150000-79-1 17150000-			· · · ·
ristin virginiamycin M1, 26-((2- (diethylamino)ethyl)sulfonyl)-26,27-dihydro- (diethylamino)ethyl)sulfonyl)-26,27-dihydro- (dimethylamino)-N-methyl-L- phenylalanine}-5-(5-(1- azabicyclo(2.2.2)oct-3-yithio)methyl)-4-oxo- 1-2-piperidinecarboxylic acid) virginiamycin S1- [CAS] n sodium Heparin-, sodium salt [CAS] 106-60-5 oid sodium Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17- on (117-10-2)		.· 	· · · · · · · · · · · · · · · · · · ·
ristin 112362-50-2 Virginiamycin M1, 26-((2- (direthylamino)ethyl)sulfonyl)-26,27-dihydro- (direthylamino)-15-(1- phenylalanine)-5-(5-((1- azabicyclo(2.2.2)oct-3-yithio)methyl)-4-oxo- 126602-89-9 n sodium S1- [CAS] 126602-89-9 n sodium Heparin-, sodium salt [CAS] 9041-08-1 iolevulinic Acid 79094-20-5 pregna-2,4-dien-20-ymo[2,3-d]isoxazol-17-01, (17Alpha)- [CAS] 17230-88-5 on (17Alpha)- [CAS]	. 1500-79-1		repute announce
Virginiamycin M1, 26-((2- (diethylamino)ethyl)sulfonyl)-26,27-dihydro- (diethylamino)ethyl)sulfonyl)-26,27-dihydro- (26R,27S)-, mixt with 4-(4- (dimethylamino)-N-methyl-L- phenylalanine}-5-(6-(1- azabicyclo(2,2.2)oct-3-yithio)methyl)-4-oxo- 1.2-piperidinecarboxylic acid) virginiamycin 1.2-piperidinecarboxylic acid) virginiamycin 126602-89-9 In sodium Heparin-, sodium salt [CAS] 9041-08-1 Indevulinic Acid 79094-20-5 Inde-60-5 106-60-5 Indevulinic Acid 17230-88-5 Indevulinic Acid 17230-88-5 Indevulinic Acid 17230-88-5 Indevulinic Acid 177-10-2	12362-50-2		
in + quinupristin Solum salt (CAS) (126R)-2-89-9 (1260		•	
(dimethylamino)-N-methyl-L- phenylalanine)-5-(5-((1- azabicyclo(2.2.2)oct-3-ylthio)methyl)-4-oxo- 1-2-piperidinecarboxylic acid) virginiamycin. 126602-89-9 n sodium Heparin-, sodium salt [CAS] 9041-08-1 Jogoulinic Acid olevulinic Acid Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17- ol, (17Alpha)- [CAS] 17230-88-5 ol, (17Alpha)- [CAS] 117-10-2	<u>.</u> :		
phenylalanline)-5-(5-((1- azabicyclo(2.2.2)oct-3-yithio)methyl)-4-oxo- L-2-piperidinecarboxylic acid) virginiamycin. L-2-piperidinecarboxylic acid) virginiamycin. S1-[CAS] In sodium Heparin-, sodium salt [CAS] IOB-4-20-5 IOB-40-5 IOB-60-5		· 	
azabicyclo(2.2.2)oct-3-ytmlo)metryl)-4-oxo- 1-2-pipendinecarboxylic acid) virginiamycin 1.2-pipendinecarboxylic acid) virginiamycin 1.26602-89-9 1.26602-89-9 1.26602-89-9 1.2602-89-9 1.26602-89-9 1.			
in + quinupristin S1- [CAS] 126602-89-9 n sodium Heparin-, sodium salt [CAS] 9041-08-1 IOBevulinic Acid 79094-20-5 oid sodium Pregna-2,4-dien-20-ymo[2,3-d]isoxazol-17- oid, (17Alpha)- [CAS] 17230-88-5 oid (17Alpha)- [CAS] 117-10-2	•		
n sodium Heparin-, sodium salt [CAS] 9041-08-1 79094-20-5 106-60-5 ol sodium Pregna-2.4-dien-20-yno[2,3-d]isoxazol-17- ol, (17Alpha)- [CAS] On 117-10-2	6602-89-9 EP	248703	Antibiotic, other
79094-20-5 106-60-	141-08-1 US	4303651	Anticoagulant
106-60-5 106-60-5	3094-20-5		
oid sodium Pregna-2/4-dien-20-yno[2,3-d]isoxazol-17- ol, (17Alpha)- [CAS] 117-10-2	36-60-5		
Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17- ol, (17Alpha)- [CAS] 17230-88-5 on 117-10-2	дi	80699	Anticoagulant
on (17Alpha)- [CAS] 17230-88-5			
no	230-88-5 GB	905844	Menstruation disorders
	17-10-2		
Dantrolen (7261-97-4	7261-97-4		
1,2,4-Triazolo[4,3-a]pyrldine, 5,6,7,8-	. 000		•
tetranydro-3-12-14-(2-metrylphenyl)-1- 7.2022-12-3 1.2042-13-0 1.2	822-13-0 US	4252721	Ophthalmological

	Example of Indication	•
		••
	Sexual dysfunction, male, general	· ·
•		
•	-	
		_
	. :	
		•
	Infection, dermatological	
•		
	Infection, respiratory tract,	
	- 1	
	Thromboprophylaxis	
	Thrombosis, venous	
•		•
	Glaucoma	•
_		

			ļ.		•
		•	Patent	ıt.	
API G neric Name	API Chemical Name	CAS No.	Ref	Reference	Example of Th rapeutic Use
	4-[[4-(2,4,6- trimethylphenyl)amino]pyrimidin-2- vllaminolbenzonitrile				
dapivirine		244767-67-7		•	Antiviral, antl-HIV
dapoxetine	(+)-(S)-N,N-dimetryl-Alpha-[2-(1-naphthyl-oxy)ethyl]benzylamine HCl	119356-77-3	. в	288188	Male sexual dysfunction
dapsone	4,4'-Sulfonyldianlline	80-08-0			Formulation, dermal, topical
daptomycin .	Daptomycin [CAS]	103060-53-3	<u>a</u>	178152	Peptide antibiotic.
Darbepoetin Alfa					
darifenacin	3-Pyrrolidineacetamide, 1-[2-(2,3-dihydro-5; benzofuranyl)ethyl]-Alpha,Alpha-diphenyl-, (S)- (CAS)	133099-04-4		388054	Urological
	5,12-Naphthacenedione, 8-acetyl-10-[(3-				
	amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxyl-7,8,9,10-tetrahydro-	•		•	.•
	6,8,11-trihydroxy-1-methoxy-, (8S-cis)-				·
daunorubicin ·	[CAS]	20830-81-3	ĽŠ.	5441745	Formulation, optimized, liposomes
DAX, SciClone	3-diallyl-8-cyclohexylxanthine				Cystic fibrosis treatment
	7-tert-Butyldimethylsilyl-10-				-
DB-67:	inyuloxycanipioniecin				Anticancer, other .
d-Camphocarboxylic		18530-30-8			
ACIO DCE-087	Dayron		٥	ER1 AREE	Eormulation other
DDT	- Control	50-29-3	3		onicial onicial
Deaminooxytocin-		113-78-0			
Deanol		108-01-0			
Debrisoquin		1131-64-2	•		
Decamethonium Bromide		541-22-0		•	
Decimemide		14817-09-5		·	
decitabine	1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-6-D-enythro-pentofuranosyl)-[CAS]	23339-46-0 2353-33-5			Anticancer, antimetabolite
declopramide	Benzamide, 4-amino-3-chloro-N-(2- (diethylamino)ethyl)- [CAS]	891-60-1	0%	9732582	Anticancer, other

				, T: T		·.		 .		, ,	, ,		·	
io					•	S				-	1	Ì	o o	
Indication	S	tion	dermatological			Kaposi's							syndrome	
e E	HIV/AIDS	Premature ejaculation	mato	blädder	٠		2	eral	,s					colorectal
nge Pe		ture		eractive t		ancer, sarcomá,	e constant	r, general	fibrosis				yelodysplastic	r, colo
Example	Infection,	Prema	Acne Infection,	Overa		Cance		Cancer,	Cystic			·	Myeloc	Cancer,
							<u></u>	 	191	<u>.</u>		·		ىب

			Patent	int	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therap utic Us
Deferiprone		30652-11-0			
Deferoxamine		70-51-9			
deflazacort	5'H-Pregna-1,4-dieno[17,16-d]oxazole- 3,20-dione, 21-(acetyloxy)-1:1-hydroxy-2'- methyl-, (118,168)- [CAS]	14484-47-0 . 74712-90-6	85	1077393	Ногтопе
Deflazacort		14484-47-0			
Defosfamide		3733-81-1			
	N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4- chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-	•	,		
	dioxohexahydropyrimidin-4-	:		•	
:	yijcarbonyijamino}-L-pnenyialanyi-4- (carbamoylamino}-D-phenyialanyi-L-leucyi-	•			
degarelix	:	214766-78-6			Anticancer, hormonal
	L-threo-2,3-Hexodiulosonic acid gamma-				
dehydroascorbic acid, Progenics		490-83-5			Cognition enhancer
Dehydrochofic Acid		81-23-2	•		
Dehydroemetine		4914-30-1			
delapril	Glycine, N.(2.3-dihydro-1H-inden-2-yl)-N- [N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L- alanyl]-, (S)- [CAS]	83435-66-9 83435-67-0	EP	51391	Antihypertensive, renin system
	Glycine, N-(2,3-dihydro-1H-inden-2-yl)-N- IN-11-(ethoxycarbonyl)-3-phenyipropyl]-L-		.:		
delapril+manidipine, Chiesi	alanylj., (S)-3,5-Pyrldinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester [CAS]			2733911	Formulation, fixed-dose combinations
delavirdine	Piperazine, 1-{3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]- [CAS]	136817-59-9	. OM	9109849	Antiviral, anti-HIV
Delavirdine Mesylate					
Delmadinone Acetate		13698-49-2			•
Delmopinol ·		79874-76-3			
				•	

Example of Indication	
	Т.
	i —
sthma.	
	╌
· · ·	
ancer, prostate	т
· .	
Azheimer's disease	
	1
ypertension, general	.
	_
	<u> </u>
ypertension, general	
rifection, HIV/AIDS	
	$\overline{}$
	_

			Patent	nt .	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therap utic Use
	2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2	9894-87-9	Ę	408029	Anxiolytic
uelorazepairi	למים ביים מיים ביילוגופות סייום	2000			
delucemine hydrochloride	3,3-Bis-(m-fluorophenyl)-N-methylorobylaminė hydrochloride- [CAS]	186495-99-8	•	•	Neuroprotective
Demanyl Phosphate		6909-62-2	:		
		56-94-0	Ŀ		-
	2-Naphthacenecarboxamide, 7-chloro-4- (dimethylamino)-1,4,4a,5,5a,6,11,12a-				
	octahydro-3,6,10,12,12a-pentahydroxy-				
	1,11-dioxo-, [43- (4Alpha,4aAlpha;5aAlpha,6B,12aAlpha)]-				
demeclocycline, Elan	[CAS]	127-33-3	·		Formulation, modified-release, <=24111
Dem colcine		477-30-5	·		
Demedestone -		10116-22-0			
Demexiptiline		24701-51-7		•	
· ·	Benzeneacetic acld, Alpha-(2-ethylbutoxy)-	•			
denaverine hydrochloride	Apna-pnenyl-, z-(dimenylamino)euryl ester.hydrochloride [CAS]	3321-06-0	DE	4133785	Analgesic, NSAID
Denileukin Diffitox		173146-27-5			
Denonamine		71771-90-9			
Denopterin		22006-84-4			
Deoxycholic Acid		83-44-3			
Deoxycorticosterone		64-85-7			
Deoxycorticosterone		.56-47-3		٠.	
Ac tate					
Deoxydihydrostreptomy		26086-49-7		,	
cin		501-15-5			
Deoxyepinepurne		161982-62-3			
D preoride					
	L-Valine, N-{(3S,4E)-3-hydroxy-7-mercapto 1-oxo-4-hepteny]-D-valy -D-cysteinyl-{2Z}-				
depsipeptide	2-annio-z-buenbyr, (4-1) lactorie, cyclic (1-2)-disulfide [CAS]	128517-07-7	·E	352646	Anticancer, antibiotic.
Deptropine		604-51-3			
Degualinium Chloride		522-51-0			
			١.		•

Example of Indication	Ischaemia, cerebral		Infection, general	Pain, musculoskeletal			Cancer, general
-----------------------	---------------------	--	--------------------	-----------------------	--	--	-----------------

		•	Patent	nt	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	Benzoic acid, 2-hydroxy-5-[[4-[3-[4-(2-methyl-1H-Imidazol[4,5-c]pyridin-1-		•		
dersalazine	yljmethyl]-1-piperidinyl]-3-oxo-1-phenyl-1-propenyl]phenyl[azo] (Z) [CAS]	188913-57-7 188913-58-8	Sn	5747477.	Anti-inflammatory
Deseroidine		131-01-1	· .		
	Butanediamide, N'-[5-[[4-[[5-				
	(acetylhydroxyamino)pentyl)amino]-1,4-				
desferrioxamine mesylate	aminopentyl)-N-hydroxy-[CAS]	70-51-9	•		Antidote
Desflurane		57041-67-5			-
Desipramine		50-47-5			
Deslanoside		17598-65-1			
	5H-Benzo(5,6)cyclohepta(1,2-b)pyridine, 8- chloro-6,11-dinydro-11-(4-piperidinylidene)-				Antiallarais non-actions
desloratadine	[CAS]	100643-71-8	3	- 1	Anuaneigic, non-assima
desiórelia	Luteinizing hormone-releasing factor (plg), 6-D-tryptophan-9 (N-ethyl-L-prolinamide)-10-deglycinamide-TCAS)	57773-65-6		4034082	Releasing hormones
desmopressin	Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine-[CAS]	16679-58-6	E	2948345	Hormone
desmopressin, Columbia	Vasopressin; 1-(3-mercaptopropanoic acid)-8-D-arginine- [CAS]	·			Formulation, transdermal, other
Desogestrel		54024-22-5			
	Estra-1,3,5(10)-triene-3,17-diol (178)-,				
desogestrel + estradiol, Akzo	mbx, with (1 /Alpha)-13-euryr-11-meuryrette 18,19-dinorpregn-4-en-20-yn-17-ol [CAS]	122364-17-4			Menopausal disorders
	18,19-Dinorpregn-4-en-20-yn-17-ol, 13- ethyl-11-methylene-, (17Alpha)- [CAS]	54024-55-5		·	Formulation, oral, other
desogestrel+ethinylestrad (1)	18,19-Dinorpregn-4-en-20-yn-17-ol, 13- ethyl-11-methylene-, (17Alpha)- [CAS]	54024-22-5 71138-35-7	. S	3927046	Formulation, oral, other
	19:Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17Alpha)-, mixt. with(17Alpha)-13-ethyl-11-methylene-18,19-dinorpregn-4-en-				Him asono building solicities
desogestrel+ethinylestrad (2)	20-yn-17-0l-[CAS]	/1/38-30-/	1		הייון יויסטווים וויסטווים ביים ביים וויסטווים ביים ביים ביים ביים ביים ביים ביים
Desomorphine		427-00-9			
Desonide.		638-94-8			
Desoximetasone	-	382-67-2			
					·

Example of Indication Colitis, ulcerative Poisoning, metal
olits, ulcerative
Rhinitis, allergic, perennial
ancer, prostate
Enuresis
Juspecified
tormone replacement therapy
Contraceptive, female
Contraceptive, female

			Patent.	ent.	
API G neric Name	API Chemical Name	CAS No.	Ref	Reference	Example of Therapeutic Use
Detaxtran		9015-73-0			
Devacade .			8	9308176	Analgesic, other
Dexamethasone	•	50-02-2	_		
dexamethasone sodiúm phosphate	Pregna-1,4-diene-3,20-dlone, 9-fluoro- 11,17-dihydroxy-16-methyl-21- (phosphonooxy)-, disodlum salt,- (118,16Alpha)- [CAS]	2392-39-4 312-93-6	<u>.</u>	:	Formulation, mucosal, topical
dexamethasone, Oculex	Pregna-1,4-diene-3,20-dione,9-fluoro- 11,17,21-trinydroxy-16-methyl-, (118,16Alpha)- [CAS]	50-02-2			formulation, other
dexanabinol	6ห-Dibenzelpidipyrän.9-methanol, 3-(1,1-dimethy/jinegyl):6a.7,10,10a-tetrahydro-1-lydròxy-6;6-dimethyl-, (6aS-trans)- [CAS]	112924-45-5	<u> </u>	427518	Neuroprotective
dexecadotril	Glycinė, N-{2-{(acetylthio)methyl]-1-oxo-3- phenylpropyl]-, phenylmethyl ester, (R)- [CAS]	112573-72-5	<u> </u>	318377	Alimentary/Metabolic, other
dexefaroxan	1H-Imidazole, 2-(2-ethyl-2,3-dihydro-2-benzoturanyl)-4,5-dihydro- [CAS]	89197-00-2 89197-32-0	. G	. 398 ·	Cognition enhancer
Dexetimide		21888-98-2		.	
dexibuprofen	Benzeneacetic acid, Alpha-methyl-4-(2-methylpropyl)-, (AlphaS)- [CAS]	51146-56-6			Anaigesic, NSAID
dexketoprofen, Menarini	Benzeneacetic acid, 3-benzoyl-Alpha- methyl-, (S)- [CAS]	22161-81-5	•		Anti-inflammatory
	Pentanoic acid, 4-{(3,4-dichlorobenzoy))amino}-5-{(3-methoxoropy))amino}-5-oxo- (B)-				
dexloxiglumide	[CAS]	119817-90-2	급	0344184	Gi Inflammatory/bowel disorders
dexmedetomidine	1H-Imidazole, 4-[1-(2,3- :- dimethylphenyl)ethyl]-, (R)- [CAS]	113775-47-6 86347-15-1	<u>a</u>	187471	Hypnotic/Sedative
Dexm detomidine		113775-47-6			
dexmethylphenidate HCl Celnana	2-Piperidineacetic acid, Alpha-phenyl-, methyl ester, flydrochloride, (AlphaR,2R)-	10262-68-1			Devrhoefimulant
Dexpanthenol		81-13-0	1		
dexrazoxane	2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bls-, (S)- [CAS]	24584-09-6	H	1910283	Radio/chemoprotective
Dextran-1	Dextran (CAS)	9004-54-0			Plasma substitute
				-	

•		<u> </u>	<u> </u>	
Example of Indication Pain, general	Inflammation, ocular Inflammation, ocular	Head trauma Unspecified Azhelmer's disease	Pain, general Inflammation, general Irritable bowel syndrome Anaesthesia	Attention deficit disorder Chemotherapy-induced injury, general

			Patent	in the	
API Generic Name	API Chemical Name	CAS No.	3	ference:	Example of Therapeutic Use
Dextranomer		56087-11-7			
Dextroamphetamine		51-64-9			
dextromethorphan HBr,	Morphinan, 3-methoxy-17-methyl-, (9Alpha,13Alpha,14Alpha)-, hydrobromide, monchydrate		Sn	4221788	Formulation, oral, other
dextromethorphan, IriSys	Morphinan, 3-methoxy-17-methyl-, (9Alpha,13Alpha,14Alpha)- [CAS]	125-71-3			Formulation, fixed-dose combinations
Dextromoramide		357-56-2			
	Benzeneethanol, Alpha-[2-(dimethylamino)-				
dextropropoxyphene, Benzon	i-merryletryj-Apria-prenyr; proparoare (ester), [S-(R*,S*)]- [CAS].	469-62-5	"		Formulation, modified-release, other .
Dezocine		53648-55-8			
DF-1012	N-Tropyl 7-azaindol-3-ylcarboxamide	163220-65-3	ÓΜ	9504742	Respiratory
	di D-fariototirenose 9 8'-6 9' dianhydride		•		
DFA-IV		•	:US	5700832	Antianaemic
d-F nchone		4695-62-9			
p-Glucuronolactone		32449-92-6			•
Diab II	Diab II	309956-85-2	US	6153632	Antidiabetic
•	2-Anthracenecarboxylic acid, 4,5-				
diacerein ·			US	4244968	Antiarthritic, other
Diampromide		552-25-0		· ·	
Diamthazole		136-96-9			
Dihydrochloride		E02.4.20.E			
Diatrizoate Codium		737-31-5	1		
diazepam emulsion, Pharmacia	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dinydro-1-methyl-5-phenyl- [CAS]	439-14-5	· .		Formulation, parenteral, other
diazepam, Dumex-Alpharma	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-!CAS].	439-14-5			Formulation, transmucosal, systemic
diazepam, Elan	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl- [CAS]	439-14-5			Formulation, transmucosal, systemic
Diaziquone		57998-68-2		٠	
Diazoxide		364-98-7	•		,
		r	, ,	•	

API Generic Name A		_	1	,	•
ic Name			Fatent	Ħ	
	API Chemical Name	CAS No:	Refe	Reference	Example of Therapeutic Use
		34493-98-6			
	D-Streptamine, O-3-amino-3-deoxy-Alpha-		•		
	D-glucopyranosyl-(1-6)-O-[2,6-diamino-			•	
· ·	C.O. 4, Orten account - All Ordonar - Chifete	24402-08-R		٠.	
dibekacin sulfate (s	(salt)[CAS]	58580-55-5	GB	1349302	Aminoglycoside antibiotic
		4498-32-2			
Dibromopropamidine		496-00-4			
		61-12-1			· ·
Dichloralphenazone		480-30-8			
Dichloramine T		473-34-7			
Dichlorisone		7008-26-6			
Dichlorobenzyl Alcohol		1777-82-8			
		• .		,	
Dichlorophen		97-23-4			
Dichlorophenarsine		536-29-8			·.
Hydrochloride			7		
nide		120-97-8			
harma .	Hyaluronic acid + benzeneacetic acid, 2- [(2,6-dichlorophenyl)amino]- [CAS]				Formulation, transdermal, systemic
'	Benzeneacetic acld, 2-[[2,6- dichlorophenyljamino]- [CAS]	15307-86-5			Formulation, mucosal, topical
	Benzeneacetic acid, 2-[(2,6-				
diclofenac once-daily, SSP [C	dichiorophenyi)aminoj-, monosodium sait [CAS]	15307-86-5	•		Formulation, modified-release, <=24hr
m.	Benzeneacetic acid, 2-{(2,6-				
diclofenac potassium	dichlorophenyl)amino]-, monopotassium salt- [CAS]	15307-81-0			Anti-inflammatory
Dicloxacillin		3116-76-5			
Dicumarol		66-76-2			
Dicyclomine		77-19-0			
	nosine, 2,3'-dideoxy- [CAS]	,	Sn	4861759	Antiviral, anti-HIV
Dideoxyadenosine		4097-22-7		7	
	Benzamide, N,3,4-trihydroxy- [CAS]	4	S)	4263322	Anticancer, antimetabolite
Dienestrol		84-17-3	-		•

,	Example of Indication	
•		:
		•
•	Infection, general	٠
•	-	
	-	
-		
•		
٠.		••
·		
	•	
		٠.
	Keratosis	•
	Pain neneral	
•		
	Pain, general	
•		
• •	Pain, general	<i>∴</i> ,
!		
	Infection, HIV/AIDS	
	Cancer, general	
٩.		

API Genetic Name			. .
19-Norpregna-4;-diene-21-nitrile, 17-	-	•	
19-Norpregna-4;9-diene-21-nitrile, 17- 19-Norpregna-4;9-diene-21-nitrile, 17- 19-Norpregna-4;9-diene-21-nitrile, 17- 19-Norpregna-4;9-diene-21-nitrile, 17- 19-Norpregna-4;9-diene-21-nitrile, 17- 19-Norpregna-4;9-diene-21-nitrile, 17- 19-Norpregna-4;9-diene-21-nitrile, 17- 19-Norpregna-4;9-diene-21-nitrile, 17- 19-Norpregna-4;9-diene-21-nitrile, 17- 19-Norpregna-4;9-diene-21-nitrile, 17-21- 19-Norpregna-4;9-diene-3;2-dieney-1-phenyl- 19-Norpregna-4;9-dieney-3;2-dieney-1-phenyl- 19-Norpregna-4;9-dieney-3;2-dieney-1-phenyl- 19-Norpregna-1-phenyl-1-phenyl- 19-Norpregna-1-phenyl-1-phenyl- 19-Norpregna-1-phenyl-1-phen	CAS No. Reference		Example of Therapeutic Use
19-Norpregna-4,9-diene-21-nitrile, 17- hydroxy-3-oxo-(17Alpha) + Estra-1,3,5(10)- triene-3,17-diol(17B) 702-54-5 celected		GB 1524917 Menstruat	Menstruation disorders
triene-3,17-diol(178) stradiol, sequentia ne rbamazine 1-Propanone, 2-(dietrylamino)-1-phenyl- (CAS) inide (SiR)-5-Etryl-9,10-diffuoro-1,4,5,13-tetrahydro-5-hydroxy-3H,15H-oxepinol3,4.6,indoltzinol1,2-bjquinoilne-3,15-dione Pregna-1,4-diene-3,20-dione, 17,21-bis(acetyloxy)-6,9-diffuoro-1-hydroxy-16-acetate Pregna-1,4-diene-3,20-dione, 17,21-bis(acetyloxy)-6,9-diffuoro-1-hydroxy-16-acetate 220997-97-7 10ne 220997-97-7 10ne 220997-97-7 10ne 22494-42-4 22494-42-4 22494-42-4 22494-42-4 22557-86-4	(6		
Case Case		Formulation	Formulation, fixed-dose combinations
CAS 1-70-6 511-70-6 511-70-6 511-70-6 511-70-6 511-70-6 511-70-6 511-70-6 511-70-6 511-70-6 511-70-6 511-70-6 511-70-6 511-70-6 511-70-6 511-70-6 511-70-6 511-70-6 511-70-6 511-70-70-7 511-70-7 511-70-70-7 511-70-70-7 511-70-70-7 511-70-70-7 511-70-70-7 511-70-70-7 511-70-70-7 511-70-70-7 511-70-70-7 511-70-70-7 511-70-70-7 511-70-70-7 511-70-70-7 511-70-70-7 511-70-70-7 511-70-70-7 511-70-70-7 511-70-70-7	702-54-5		
Case 1-Propanone, 2-(diethylamino)-1-phenyl 2-Propanone, 2-(diethylamino)-1-phenyl 2-Propanone, 2-(diethylamino)-1-phenyl 2-Propanone, 2-(diethylamino)-1-phenyl 2-Propanone, 2-Propanone, 2-(diethylamino)-1-phenyl 2-Propanone, 2-(diethylamino)-1-phenyl 2-Propanone, 2-	. 60-91-3		
December 1-Propanone, 2-(diethylamino)-1-phenyl- 1-Propanone, 2-(diethylaminone)-1-phenyl- 1-Propanone, 2-(diethylam	511-70-6		
1-Propanone, 2-(diethylamino)-1-phenyl- 1-Propanone, 2-(diethylaminone, 2-(diethylaminon	90-89-1	: ·	
Ebestrol 56-53-1 80387-96-8 90387-96-8 90387-96-8 90387-96-8 90387-96-8 90387-96-8 90387-96-9 90387-96-9 90387-96-9 90387-96-9 90387-96-9 90387-97-7 90387-97-7 90387-97-7 90387-97-7 90387-97-7 90387-97-7 90387-97-7 90387-97-7 90387-97-7 90387-97-7 90387-97-7 90387-97-7 90387-97-7 90387-98-7 90387-98-4 90387-98	. 90-84-6	Formulatio	Formulation, modified-release, <=24hr
80387-96-8	. 56-53-1		
role 20170-20-1 nide 28782-42-5 retrahydro-5-hydroxy-3H,15H- 51484-40-3 oxepinol3',4'6,indolizino[1,2-b]quinoline- 22097-97-7 strahydroxy-3H,15H- 2557-49-5 Pregna-1,4-diene-3,20-dione, 17,21- 2557-49-5 bis(acetyloxy)-6,9-diffuoro-11-hydroxy-16- 33564-31-7 lone 6/9/2607 2',4'-diffuoro-4-hydroxy[1,1'-biphenyi]-3- 23674-86-4 carboxylic acid 22494-42-4 ate 22494-42-4 1ate 22494-42-4 752-61-4 752-61-4	ľ		
## 1997/82-42-5 ## 1997/82-42-5 ## 1997/82-42-5 ## 1997/82-42-5 ## 1997/82-42-5 ## 1997/82-49-3 ## 1997/82-49-5 ## 1997/82-49-5 ## 1997/82-49-5 ## 1997/82-49-5 ## 1997/82-49-5 ## 1997/82-49-5 ## 1997/82-61 ## 1997/82-61 ## 1997/82-61 ## 1997/82-61 ## 1997/82-61 ## 1997/82-61 ## 1997/82-61 ## 1997/82-61 ## 1997/82-61 ## 1997/82-61 ## 1997/82-61 ## 1997/82-61 ## 1997/82-61 ## 1997/82-61 ## 1997/82-61 ## 1997/82-61 ## 1997/82-61 ## 1997/82-61 ## 1997/82-61	20170-20-1	•	
(5A)-5-Ethyl-9,10-difluoro-1,4,5,13- (5A)-5-Ethyl-9,10-difluoro-1,4,5,13- tetrahydro-5-hydroxy-3H,15H- oxepino 3'.4':6,indolizino 1,2-b quinoline- 3,15-dione	28782-42-5		
(5R)-S-Ethyt-9,10-diffuoro-1,4,5,13- tetrahydro-S-hydroxy-3H,15H- oxepino 3',4':6,indolizino[1,2-b]quinoline- 3,15-dione 220997-97-7 22097-97-7 22097-97-7 22097-97-7 22097-97-7 22097-97-7 22097-97-7 22097-97-7 22097-97-7 22097-97-7 22097-97-7 22097-97-7 22097-97-7 22097-97-7 22097-98-4 22097-97-7 22097-98-4 220	51484-40-3		
1,15-dione 220997-97-7			
Pregna-1,4-diene-3,20-dione, 17,21- Dis(acetyloxy)-6,9-diffluoro-11-hydroxy-16- acetate methyl-, (6Alpha,115,163)-[CAS] 98106-17-3 98106-17-3 6/9/2607 2/4-difluoro-4-hydroxy[1,1'-biphenyi]-3- 23674-86-4 22494-42-4 752-61-4	220997-97-7	Anticancer, other	other
Pregna-1,4-diene-3,20-dione, 17,21- bis(acetyloxy)-6,9-difluoro-11-hydroxy-16- asset-31-7 sasset-31-7 sasset-3	2557-49-5		•
carboxylic acid cabo+4.16,16 3-[CAS] 33564-31-7			
17-3 17-3 2/4'-difluoro-4-hydroxy[1,1'-biphenyi]-3- carboxylic acid 23674-86-4 22494-42-4 23674-86-4 752-61-4	Sn	3980778 Antipsoriasis	<u>S</u>
2',4'-difluoro-4-hydroxy[1,1'-biphenyi]-3- carboxylic acld 22494-42-4 late 23674-86-4 752-61-4	98106-17-3		
122494-42-4 1ate 23674-86-4 752-61-4	80	147E040	Ciego
ate	3		
	23674-86-4		
	752-61-4		
	71-63-6		
Digoxin 20830-75-5	20830-75-5		•

	<u> </u>	
Example of Indication Endometriosis	Contraceptive, female Obesity	Cancer, general Pain, post-operative

			Patent	÷	
API Generic Name	API Chemical Nam	CAS No.	Refe	Reference.	Example of Therapeutic Use
	Card-20(22)-enolide, 3-[(O-2,6-dideoxy-B-				
· .	D-ribo-nexopyranosyr-(1-4)-O-2,6-dideoxy- 6-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-	,			
	B-D-ribo-hexopyranosyl)oxy]-12,14-				
digoxin, Beiersdorf	dihydroxy-, (38,58,128)- [CAS]	20830-75-5	Si	4088750	Formulation, oral, enteric-coated
Dihexyverine		561-77-3			
Dihydralazine		484-23-1			
Dihydrocodeine		125-28-0			
Dihydrocodeinone Enol		466-90-0			
Acetate					
dihydroergocryptine, Poli	Ergocryptine, dihydro- [CAS]	25447-66-9			Formulation, other
	Ergotaman 3,6,18-trione, 9,10-dihydro-12-hydroxv-2-methyl-5-(phenylmethyl)	•		••••	
dihydroergotamine SR, Ethypha		511-12-6		6495535	Formulation, modified-release, other
			•	•:	
	Frgotaman-3',6',18-trione, 9,10-dinydro-12'- hvdroxv-2'-methyl-5'-(phenylmethyl)				
dihydroergotamine, bloMerieux	(5'Alpha, 10Alpha)-¡CAS]	511-12-6			Formulation, modified-release, other
		•			
	Ergotaman-3',6',18-trione, 9,10-dihydro-12'				
dihydroergotamine, Tempo	nydroxy-z-meury-3-threnyuneuryry, (5'Alpha; 10Alpha)- [CAS]	511-12-6			Formulation, inhalable, solution
Dihydromorphine		509-60-4			
Dihydrostreptomycin		128-46-1			
Dihydrotachysterol		. 6-96-29	'		
Dihydroxyaluminum		13682-92-3	_		
Aminoacetate		:		-	
Dihydroxyaluminum		539-68-4	•		
Sodium.Carbonate					
Diisopromine		5966-41-6	Ť		
Diisopropyl Paraoxon		3254-66-8			
Diisopropylamine		660-27-5			٠.
Dichloroacetate		1.].	

			Patent	• .
API Generic Nam	API Chemical Name	CAS No.	Reference	Example of Therapeutic Use
; ;	Benzoic acid, 3,4,5-trimethoxy-, (tetrahydro 11+-1,4-diazepine-1,4(5H)-diyldi-3,1-			
dilazep	propanedlyl ester [CAS]	35898-87-4	JP 510950	51095086 · Vasodilator, coronary
Difevalol		75659-07-3		
Diloxanide		579-38-4		
diloxanide furoate	2-Furancarboxylic acid, 4- [(dichloroacetyl)methylamino]phenyl ester [CAS]	3736-81-0		Amoebicide
	1,5-Benzothlazepin-4(5H)-one,,3-			
.·	(acetyloxy)-5-1z-(almetnylamino)etnylj-2,3- dihydro-2-(4-methoxyphenyl)-, (2S-cis)-	,	•	
diltiazem	[CAS]	42399-41-7	EP 322277	Antianginal
Diļtiazem		42399-41-7		
Diltiazem .		•	-	:
Hydrochloride .		•	<u>. </u>	
Diltiazem				
שלמד המזדמד דמב			-	
	1,5-Benzothlazepin-4(5H)-one, 3- (acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3- dihydro-2-(4-methoxychenyl) (2S-cis)-	:	· · ·	
diltiazem once-daily, Bago	[CAS]	42399-41-7		Formulation, modified-refease, <=24hr
	1,5-Benzothiazepin-4(5H)-one, 3-		-	
• • • • • • • • • • • • • • • • • • • •	(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3- dihydro-2-(4-methoxyphenyl)-, (2S-cis)-	33286-22-5	••	
diltiazem once-daily, Biov	[CAS]	•	US 5529791	Formulation, modified-release, <=24hr
	1,5-Benzothiazepin-4(5H)-one, 3- (acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-	•		
diltiazem once-daily, Elan	dihydro-2-(4-methoxyphenyj)-, (2S-cis)- [CAS]	42399-41-7	··	Formulation, modified-release, <=24hr
	1,5-Benzothlazepin-4(5H)-one, 3-		- -	
	(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3- dihydro-2-(4-methoxyphenyl)-, (2S-cis)-		•••	
diltiazem once-daily, Biovall-2	[CAS]		_	Formulation, modified-release, <=24hr
	1,5-Benzothiazepin-4(5H)-one, 3- (acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3- dihydro-2-(4-methoxyphenyl)-, (2S-cis)-	33286-22-5		
diltlazem SR, Ethypharm		42399-41-7	•	Formulation, modified-release, other

		٠
	Example of Indication	•
		•
•		•
	•••	•
		-
		.•
-		•
	i eraco	
	8	•
•	Hypertension general	
• .	: 	٠.
	Angina, general	•
-	Hypertension, general	
		•
· .		
	Hypertension, general	

·. :

		Patent		·
API Chemical Name	CAS No.	Reference	ce	Example of Therapeutic Use
(1,5-Benzothiazepin-4(5H)-one,3- (acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-				
•	42399-41-7			Formulation, modified-release, <=24hr
1,5-Benzothiazepin-4(5H)-one, 3- (acetyloxy)-5-[2-(dimethylamino)ethylj-2,3- dinydro-2-(4-methoxypienyl)-, (2S-cis)-		·		
	42399-41-7	- :		Formulation, modified-release, <=24hr
1,5-Benzothiazepin-4(5H)-one, 3- (acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3- diharto-2-(4-methoxonbenu)- (25-cis)-			· ·.	
	12399-41-7	·		Formulation, modified-release, <=24hr
1,5-Benzothiazepin-4(5H)-one, 3- (acetyloxy)-5-[2-(dimethylamino)ethyl)-2,3- dibudro-2-14-methoxunbenul)- (2S-cis)-		·	•	
	12399-41-7			Formulation, modified-release, other
1,5-Benzothiazepin-4(5H)-one, 3 (acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3- dihydro-2-(4-methoxyphenyl)-, (2S-cis)-	ξ. ·			
	12399-41-7		, .	Formulation, oral, solubility-enhanced
1,5-Benzothiazepin-4(5H)-one, 3- (acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3- dihydro-2-(4-methoxyphenyl)-, (2S-cis)- (QAS)	2399-41-7	•		Formulation, modifled-release, <=24hr
1,5-Benzothiazepin-4(5H)-one, 3- (acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3- dihydro-2-(4-methoxyphenyl)-, (2S-cis)- (CAS)	3286-22-5 2399-41-7			Formulation, modified-release, other
1,5-Benzothiazepin-4(5H)-one, 3- (acetyloxy)-5-[2-(dimethylamino)ethylj-2,3- dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	3286-22-5 2399-41-7	: ':		Formulation, modified-release, mutti
((1-5-Benzothiazepin-4(5H)-one, 3- (acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3- dihydro-2-(4-methoxyphenyl)-, (2S-cis) [CAS]	2399-41-7			Formulation, modified-release, multi
N 186N 186N 195N 195N 195N 195N 195N 195N 1		-(4-methoxyphenyl)-,(2S-cis) -(4-methoxyphenyl)-,(2S-cis)(4-methoxyphenyl)-, (2S-cis)(4-methoxyphenyl)-, (2S-cis)-		1,3- 42399-41-7 1,3- 42399-41-7 1,3- 42399-41-7 1,3- 33286-22-5 42399-41-7 1,3- 33286-22-5 42399-41-7 1,3- 39286-22-5 42399-41-7 1,3- 1,3- 1,3- 1,3- 1,3- 1,3- 1,3- 1,3-

Angina, general	•
Hypertension, general	.
Angina, general.	
	$\left[\right]$
•	
Angina, general	T
	•
Angina, general	• •
:	
Andine, general	
	T
	•
Andina, general	• •
Angina, general	•
·	
Hypertension, general	

	•		Patent	int .	
API Generic Name	API Chemical Name	CAS No.	Ref	Reference	Exampl of Th rapeutic Use
	1,5-Benzothlazepin-4(5H)-one, 3-				
	(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-				:.
<u>`</u>	dihydro-2-(4-methoxyphenyl)-1,5-	:		,	
diltiazem, once-daily, Mundiph	benzothiazepin-4(5H)-one, (2S-cls)- [CAS] 42399-41-7	42399-41-7			Formulation, modified-release, <≂24hr
	1,5-Benzothlazepin-4(5H)-one, 3-		L		
•	(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-			;	
	dihydro-2-(4-methoxyphenyl)-, (2S-cis)			:	
diltiazem, once-daily, Synthe	CASI	42399-41-7	읍	322277	Formulation, modified-release, <=24hr
	1.5-Renzothiazerin-4(5H)-one 3-				
	(acatylow)-5-[9-(dimethylamino)ethyl]-9 3-		٠.,		
,	dibydro-2-(4-methoxynheny) - (28-cis)	•			
ditiazem, SURECAPS	[CAS]	42399-41-7			Formulation, modified-release, <=24hr
Dimecrofic Acid		7706-67-4			
Oimefline		1165-48-6	Ŀ		
		26200 04.0			
Dimeniorian		0-10-6066			
Dimenhydrinate		523-87-5			
Dimenoxadol		509-78-4	,	• ;	
Dimepheptanol		545-90-4			
Dimercaprol		59-52-9			
Dimetacrine		4757-55-5		•	
Dimethadione		695-53-4			
Dimethazan		519-30-2			
Dimethindene		5636-83-9			
Dimethisoguin		. : .9-08-98	-		
Dimethisterone	:	1-64-1			
Dimethocaine		94-15-5			
Dimethoxanate		477-93-0			
Dimethyl Sulfoxide		2-89-29			
Dimethylthiambutene		524-84-5			
Dimetofrine		22950-29-4	·		-
Dimorpholamine	-	119-48-2			
·	Prosta-5;13-dien-1-olc acid, 11,15- dihydroxy-9-oxo- (52,11Alpha,13E,15S)-	•	•	•	
dinoprostone, Controlled Ther		363-24-6			Formulation, modified-release, <=24hr
diosmectite	Smecta- [CAS]	110070-78-5	FR .	2770778	Antidiarrhoeal

Example of Indication Angina, general Angina, general	Labour, Induction
---	-------------------

		TABLEIV	· . ≥	•	
		•			
API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	
	4H-1-Benzopyran-4-one, 7-[[6-O-(6-deoxy-				•
· ·	Alpha-L-mannopyranosyl)∹betaD-				:
	hydroxy-4-methoxyphenyl)- [CAS]	520-27-4	DE 2602314	Vasoprotective, systemic	· · ·
Diosmin		520-27-4	T		
Dioxadrol		6495-46-1	 - -		
Dioxaphetyl Butyrate		467-86-7			
Dioxethedrine		497-75-6	 		٠
Dioxybenzone		131-53-3			• .
Diphemanil		62-97-5	:		
Dinhonadione		R2-66-6	-		
Diphencyprone		886-38-4			
Dinhenhydramine		58-73-1			•
Diphenidol		972-02-1			
Dinhanoxylate		915-30-0	,		
Diphenylpyraline		147-20-6			
Diphetarsone		515-76-4			
					. •
Diphtheria &			· ;		
Tetanus Toxoids And		,	-		
Acellular Pertussis			· ,		
· Vaccine Adsorbed					
Dipipanone .		467-83-4	•		
	Propanoic acid, 2,2-dimethyl-, 4-[1-hydroxy-	,			:··
dipivefrin		52365-63-6	US 3809714	Antiglaucoma .	
Dipivefrin		52365-63-6			·
Dipyridamole		58-32-2			
Dipyroc tyl		486-79-3		•	
Dipyrone		5907-38-0			
	Uridine 5'-(pentahydrogen tetraphosphate)-				
diquafosol tetrasodium	5-ester with uridine, tetrasodium salt [CAS]	211427-08-6		Ophthalmological	٠
			•		
		•		,	
			· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	
		305			· · · · · · · · · · · · · · · · · · ·
•			· · · ·		

٠,	-	1.	·	 			٠		 _					÷	· :-	•	_			•		
l e	•	.									. :	٠,		- -								-
Indicatio	•											•	٠.					: .	.		٠.	
			ļ .	ľ	٠.						•		•							Í		
60		ŀ		.		.						•	.:				.					ndrome
· d				.							• :	•	•			юща					-	ye sy
Exa								•					•			Glaucon						Dy e
	•	•			•	•							•		.		لسنحا	٠.:		-		

API Generic Name Erythromycin, 9-deoxo-11 [imino[2-(2-methoxyethoxy imino[2-(2-methoxyethoxy imino[2-(2-methoxyethoxy imino[2-(2-methoxyethoxy imino[2-(2-methoxyethoxy imino[2-(2-methoxyethoxy imino[2-(2-methoxyetho	deoxy-9,11- /jethylidene]oxy]1- lisodium salt a-[2-[bis(1- Ipha-phenyl-	CAS No. [1 62013-04-1 [1 62013-04-1 [1 57248-88-1 [1 57248-88-1 [1 65717-97-7 [1 915/3737]	Patent Referent DE 251	Reference	Example of Therapeutic Use
ric Name vcin midronate midronate, Gador	-laxa	3737	2	ence	Example of Therapeutic Use
ycin midronate midronate, Gador mide	- ka	3737		2515075	
ycin nidronate midronate, Gador nide	-lax	3737		2515075	
ycin nidronate midronate, Gador nide	-fáxe	3737		2515075	•
ycin nidronate nidronate, Gador		7373	1 7 7	2515075	
ycin nidronate nidronate, Gador		737	1.		Macrolide antibiotic
midronate midronate, Gador nide		-7	, ,		
nidronate nidronate, Gador nide		-7			
nidronate nidronate, Gador nide		-7	1, 1		
nidronate, Gador		-7		1,77443	Osteoporosis treatment
nidronate, Gador nide		-7		•	
nidronate, Gador		-7			•
nide		55717-97-7 9/5/3737		200473	Formulation, oral, enteric-coated
nide		9/5/3737	ŀ		
			•		
·			<u> </u>		
disopyramide SR, Ethypharm [[CAS]	-	3737-09-5		•	Formulation, modified-release, other
2-Pyridineacet	2-Pyridineacetamide, Alpha-[2-[bis(1-				
	methylethyl)aminojethylj-Alpha-phenyl-			•	
disopyramide, AstraZeneca [[CAS] ·	8	3737-09-5	7		Formulation, modified-release, <=24nr
2-Pyridineacet methylethyl)an	2-Pyridineacetamide, Alpha-[2-[bis(1-methylethyl]aminojethyl]-Alpha-phenyl-		•		
disopyramide, Biovail [CAS]		3737-09-5			Formulation, modified-release, <=24hr
Distigmine Bromide		15876-67-2			
Disulfamide		671-88-5			
Disulfiram		97-77-8			
Disulfiram :	-		••		
Ditazol		18471-20-0		•	
Dithiazanine lodide		514-73-8			
	9(10H)-Anthracenone, 1,8-dihydroxy-		-		
dithranol, Bioglan [CAS]	•	1143-38-0			Formulation, dermal, topical
Ditiocarb Sodium		148-18-5	÷		
Dixanthogen		502-55-6			•
Dixyrazine		2470-73-7			
DJ-927		2	٥ و	WO 01027115	Anticancer, other

:		-		· 		3.	· .	·			 	7
Example of Indication	onsilitis	.	percalcaemia of malignancy	aget's disease	rhythmia, general	Arrhythmia, general	rhythmia, general			soriasis	ancer, general	
. ш	<u> </u>	<u> </u>	<u>£</u>	ا يف	 ₹	Ā	₹	<u></u>	L,	<u> </u>	 ලී	1

			L		
		:	Patent	Ħ	
API Generic Name	API Chemical Name	CAS No.	R fe	R ference	Exampl of Therapeutic Use
		:			
•	(-)-7-[(7S)-7-Amino-5-azaspiro[2,4]heptan-		• •		•
•	5-vil-6-fluoro-1-[(1R,2S)-2-fluoro-1-	_		:	•
	cyclopropyll-1,4-dihydro-8-methoxy-4-oxo-	•		÷	
	3-quinolinecarboxylic acid hydrochloride	•		•	
	monohydrate	:	•		
DK-507k					Quinolone antibacterial
pr-Lactic Acid-		598-82-3			
	Cytidine, 2'-deoxy-2'-methylene-,				
DMDC .	monohydrochloride [CAS]	113648-25-2	<u></u>	8807049	Anticancer, antimetabolite
	5,6-dimethylxanthenone-4-acetic acid		•	•	
DMXAA					Anticancer, other
ONA Stealth Nucleosides. Koron				6132776	Antiviral, anti-HIV
Dobocilato Calcium		20123-80-2			
Dobeshare Calcium					
	1,2-Benzenediol, 4-[2-[[3-(4-	34368-04-2		``. 	
dobutamine	ojethylj-, (+/-)- [CAS]	49745-95-1	US.:	3987200	Cardiostimulant
Dobutamine		34368-04-2			
Docarpamine		74639-40-0		. •	
	(10 96) M Carbon, 9 shoardleonoring M.				
	(27,53)-N-Calboxy-C-piletry isoseriles, N- Itert-brityl ester 13-ester with 58,20-enoxy-		•	·	
,	1.2Aloha, 4.78, 103, 13Aloha-				
٠	4-acetate 2-	114977-28-5	-		
docetaxel	benzoate- [CAS]	148408-66-6	<u>.</u>	253738	Anticancer, other
Docetaxel		114977-28-5			
	(2H,3S)-N-Carboxy-3-phenylisoserine, N-				
	tert-butyl ester, 13-ester with 58,20-epoxy-				
	1,2Apna,4,71s,101s,13Alpna- theyahldroxytax-11-en-0-one 4-acetate 2-	114977-28-5	•	•	
docetaxel formulation, Aventis		148408-66-6			Formulation, other
docosahexaenoic acid. Martek		. ·	EP.	707487	Hypolipaemic/Antiatherosclerosis
			1		
docosanoi .	1-Docosanoi [CAS]	661-19-8	Ш	469064	Antiviral, other
			SN	4752617	Formulation, dermal, topical
Desirate Colours		128-49-4			
Docusale Calcium		577-11-7	-		
Docusare Socium		11111	1		

Example of Indication Infection, general Cancer, lung, general Infection, HIV/AIDS Cancer, breast Hyperlipidaemia, general Infection, herpes simplex virus Infection, herpes simplex virus prophylaxis

			Patent .	141	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
			•		
	Methanesulfonamide, N-[4-[2-[methyi[2-[4-				
	{{methylsulfonyl}aminojphenoxyjethyljamin	115058-11-8	<u>```</u>	245997	Antiarrhythmic
doretiilde	ojeniyijinenyij- (ovo)	11.05.01	Ŧ		
Dofetilide		115256-11-6		:	
Dofetilide		.	•		
Dolasetron		115956-12-2	_		
	1H.Indole-3-carbowlic acid -octahydro-3-				
	oxo-2,6-methano-2H-quinolizin-8-yl ester,		• •		
dolasetron mesilate.	(2Alpha,6Alpha,8Alpha,9AlphaB)-, monomethanesulfonate-[CAS]	115956-13-3	· 6	266730	Antiemetic
			٠.		
Dolasetron Mesylate					
			•		. •
Dolasetron Mesylate					
Domiodol		61869-07-6			٠
Domiphen Bromide		538-71-6			
Domitroban		112966-96-8			
				:	
	2H-Benzimidazol-2-one, 5-chloro-1-[1-[3-	•.	•		·. · · ·
domperidone	S		<u>ร</u>	4066772	Antiemetic:
Domperidone		57808-66-9			
Donepezil		120014-06-4			
	1 Indon-1 one 9 2 dibudto-5 6.	:			
	L CASI	120011-70-3	<u>``</u>	296560	Cognition enhancer
חחוופהפדוו וואמוסמומים	in the state of th		I		
donitrioten mesviate	Piperazine, 1-(((3-(2-aminoethyl)-1H-indol-5-yl)oxy)acetyl)-4-(4-cyanophenyl)-[CAS]	170912-52-4			Antimigraine
Dopamine	•	51-61-6	-	•	
Dopexamine		86197-47-9			
	urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N-(4-[2-(4-			:	
	morpholinyl)ethoxyj-1-napthalenylj-	285983-48-4			Antiarthritic, immunological

· · · · · · · · · · · · · · · · · · ·	ansea	111 . 1	
ndication	. =		
	y-induced	disease	rheumatoid
Example of I	omiting	heimer's di	er heur 's
Example Fibrillation, 6	Chemc	Alzhein	Migraine Arthritis,

			Patent	in .	
API Generic Name	API Chemical Nam	CAS No.	Refe	Reference.	Example of Therapeutic Use
doranidazole	(±)-1,2,4-Butanetriol, 3-((2-nitro-1H- imidazol-1-yl)methoxy)[CAS]	137339-64-1	V	WO 9414778	Radio/chemosensitizer
en constant of the constant of	(1R,5S,6S)-2-[(3S,5S)-5- (sulfamoylaminomethyl)pyrrolidin-3-yljthio- 6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-		{		
	Z-enr-g-carooxync acid	- 10-0100+1	5	0/0070	בפוקיות מוווסותכ
	4H-Thleno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-,7,7-			· · (!	
Dorzolamide	Gioxide (45-trans)- [CAS]	120279-96-1	<u>.</u>	296879	Antiglaucoma
		15057 3-30-1			
	4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-7,7-				
•	dloxide (4S-trans) + ethyl 2-propanol, 1- [(1 1-dimethyl)aminol-3-[[4-(4-mombolity)- 120279-96-1	120279.9Å-1	:		
dorzolamide + timolol	1,2,5-thiadiazol-3-yi[oxy]-, (S), (Z)-2-butenedioate (1:1) (sat) [CAS]	26839-75-8 26921-17-5		• • •	Formulation, fixed-dose combinations
٠		•			
	Aluminium, (µ7-(7-((6-0-(6-deoxy-2,3,4-tri-		•	•	
·	O-suffo-Alpha-L-mannosylpyranosyl)-2,3,4-		•		
•	hydroxy-2-(4-methoxy-3-(sulfooxy)phenyl-				
dosmalfate ·	4H-1-benzopyran-4-onato(7-)))tetradeca-μ- hydroxyheneicosahydroxytetradeca- [CAS]	122312-55-4			Antiulcer
dosulepine		113-53-1			Antidepressant
Dotarizine		84625-59-2			
Dothlepin		113-53-1	-		
Doxacurium Chloride		106819-53-8	<u> </u>		
Doxapram		309-29-5		•	
	noxy-2-			•	
doxazosin	benzodioxin-2-yl)carbonyl]- [CAS]	\neg	8	2007656	Antihypertensive, adrenergic
Doxazosin		74191-85-8			
			٠	•	

•	Example of Indication	
	Surgery adjunct	
	•	
•	Infection, urinary tract	
	٠.	•
		•
•	Glaucoma	
•		
	::···	
	Glaucoma	
٠	•	
•		
•	:	
•	Ulcer, dastric	
	· I	
. •		
•		•
•	Hypertension, general	
•		

			Patent	int .	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	Piperazine, 1-(4-amino-6.7-dimethoxy-2-				
	quinazolinyl)-4-[(2,3-dlhydro-1,4-		•		•
doxazosin-GITS	benzodioxin-2-yl)carbonyl]- [CAS]	74191-85-8			Formulation, modified-release, <=24hr
Doxefazepam		40762-15-0		•	
Doxenitoin		3254-93-1	ŀ		
Doxepin		1668-19-5			-
	1-Propanamine, 3-dibenz[b,e]oxepin-				
doxepin, GenDerm	11(6H)-ylidene-N,N-dimethyl-	1668-19-5		:	Formulation, dermal, topical
		;.			
	9,10-secoergosta-5,7,10(19),22-tetraene-		•		
doxercalciferol	1,3-diol (1Alpha, 3B, 5Z, 7E, 22E) [CAS]	•	S	5104854 · ·	Hormone
Doxercalciferol		54573-75-0	•		
doxifluridine	Uridine, 5'-deoxy-5-fluoro- [CAS]		SÀ	4071680	Anticancer, antimetabolite
Doxifluridine		9/2/3094			
	ì	-			
· · · · · · · · · · · · · · · · · · ·	1H-Purine-2,6-dione, 7-(1,3-dioxolan-2-		•		-
doxofylline	[y/methyl]-3,7-dihydro-1,3-dimethyl-[CAS]	\cdot	ဒ္ဓ	4187308	Antiasthma
Doxofylline .		69975-86-6			
Doxorubicin		23214-92-8			
	5,12-Naphthacenedione, 10-((3-amino-			• • • •	
	2,3,6-trideoxy-Alpha-L-lyxo-			-	
•	hexopyranosyl)oxyl-7,8,9,10-tetrahydro-	•		·.	•
doxorubicin citrate, TLC .	6;8,11-trihydroxy-8-(hydroxyacetyl)-1- methoxy-, (8S-cis)- [CAS]	23214-92-8	<u>a</u>	191824 F	Formulation, optimized, liposomes
			T	-	
· .	5,12-Naphthacenedione, 10-[(3-amino-				
	2,3,6-trideoxy-Alpha-L-lyxo-		•	••	
	hexopyranosyl)oxyl-7,8,9,10-tetrahydro-	<u> </u>	•	•	
doxorubicin Extra	-	23214-92-8			Formulation, parenteral, other
Doxorubicin					
Hydrochloride : :		•	•	•	
Doxorubicin				•	
Hydrochloride		•		• •	

· .

 			•					•	٠.	-
Exampl of Indication	Hypertension, general	Pruritus	Hyperparathyroidi	Cancer, colorectal	Asthma		Cancer, breast		Cancer, general	

	• .		Patent	
API Generic Name	API Chemical Name	CAS No.	Reference	Example of Therapeutic Use
	tridox-Ainha-1-hoo-hexonyrenosyloxit			
· ·	7.8.9.10-tetrahydro-6.8.11-trihydroxy-8-	•	•	
doxorubicin, Advectus	(hydroxyacetyl)-1-methoxy-,(8S)-cis- [CAS] 23214-92-8	23214-92-8	•	Formulation, optimized, nanoparticles
		·		
			. •	
·	5,12-Naphthacenedione,10[(3-amino-2,3,6-		_	• • •
·	tridoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-		•	
doxorubicin, Bio Alliance	7,8,9,10-tetrahydro-6,8,11-trihydroxy-8- (hydroxyacetyl)-1-methoxy-,(8S)-cis-[CAS]	23214-92-8	· ·	Formulation, optimized, nanoparticles
	5,12-Naphthacenedione, 10-((3-amino-	•		
· · ·	2,3,6-trideoxy-Alpha-L-lyxo-			
	hexopyranosyl)oxy)-7,8,9,10-tetrahydro-		-	
	6,8,11-trihydroxy-8:(hydroxyacetyl)-1-,	•	· ·	٠
dóxorubicin, FeRx	methoxy-(8S-cis)- [CAS]	23214-92-8		· Formulation, parenteral, targeted
doxorubicin, inhaled		23214-92-8		Formulation, inhalable, solution
	5,12-Naphthacenedione, 10-I(3-amino-	•	· .	
	2,3,6-trideoxy-Alpha-L-lyxo-	٠.	•	
	hexopyranosyl)oxyl-7;8,9,10-tetrahydro-			
	6.8,11-trihydroxy-8-(hydroxyacetyl)-1-		•	
doxorubicin, Mitsubishi	methoxy-, (8S-cis)-[CAS]			Formulation, optimized, liposomes
			•	
:	5,12-Naphthacenedione, 10-((3-amino-			
	z.s.o-trideoxy-Apna-L-iyxo- hexopyanosylloxy-7 8.9.10-tetrahydro-	:	•	
	6.8,11-trihydroxy-8-(hydroxyacetyl)-1-			
doxorubicin, NeoPharm	•	23214-92-8		Formulation, optimized, liposomes
•.	5,12-Naphthacenedione, 10-((3-amino-		. , . :	· .
•	L.S.O-ulueOxy:Alpi la-L-iyxO- hexonyranosylloxyl-7 8 9 10-fetrahydro-		•	
	6,8,11-trihydroxy-8-(hydroxyacetyl)-1-	• •	-	
doxorubicin, Nippon Kayaku	methoxy-(8S-cis)- [CAS] :		_	Formulation, optimized, nanoparticles

	Example of Indication	•
•		
•	Cancer, brain	
		•.
•		٠.
	Cancer, liver	
		:
•	٠. ٠	
•	Cancer, liver	•
		•
•		•
-	Cancer stomach	
		•
•		٠
	Cancer, prostate	
		.•
		-
•	Cancer deneral	•
-	- 1	

				4 5.4 7 6
		•	Patent	
API Generic Name	API Chemical Name	CAS No.	Reference	Example of Therapeutic Use
-				
doxorubicin, Pro-Pharm	5,12-Naphthacenedione,10((3-emino-2,3,8-tidoxy-Alpha-L-lyxo-hexopyranosyl)oxy}7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(frydroxyacetyl)-1-methoxy-,(8S-cis)- [CAS] 23214-92-8	23214-92-8		Formulation, parenteral, targeted
	5,12-Naphthacenedione,10[(3-amino-2,3,6-	•		
doxorubicin, Regulon	tridoxy-Alpha-L-lyxo-hexopyranosyl)oxyj- 7,8,9,10-tettahydro-6,8,11-trihydroxy-8- (hydroxyacetyl)-1-methoxy.,(8S-cis)- [CAS] 23214-92-8	23214-92-8	· · ·	Formulation, optimized, liposomes
· .	5,12-Naphthacenedione, 10-[(3-amino- 2,3,6-trideoxy-Alpha-L-lyxo-		·	
doxorubicin, SIRTeX	>-tetrahydrô- racetyl)-1-	23214-92-8		Formulation, optimized, microencapsulate
(5,12-Naphthacenedione, 10-[(3-amino- 2,3 A-tridenavi-Alpha-I-base			
doxorubicin, Stealth	-tetrahydro- acetyl)-1-	23214-92-8	US 5213804	Formulation, optimized, liposomes
	5,12-Naphthacenedione, 10-[(3-amino-		: <i>·</i>	
	L.s.o-urueoxy-zapna-t-ryxo- hexopyranosyl)oxyj-7,8,9,10-tetrahydro- 6,8,11-frihydroxy-8-(hydroxyacetyl)-1-	· ·		
doxorubicin, Supratek	·	23214-92-8	·	Formulation, other
	5.12-Naphthacenedione,-10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxyl-7,8,9,10-tetrahydro-			
doxorubicin, Targesome	6,8,11-trihydroxy-8-(hydroxyacetyl)-1- methoxy-, (8S-cis)- [CAS]			Formulation, optimized, liposomes

ř	·	 <u> </u>			·		 •	 	· —	 		 •	 	 	
	Example of Indication		Cancer, general		· · · · · · · · · · · · · · · · · · ·	Cancer, general		Cancer, liver			Cancer, sarcoma, Kaposi's		 Cancer, oesophageal		 Cancer, general
	•	•		-	•										

			Datent	: :	•
ADI Ganorio Namo	ADI Chemical Name	CAS No.	Reference	ą	Example of Therapeutic Use
Designation		17086-28-1	 - 		
Doxycycline	· · · · · ·	(monohidrate)	· 		
		(יווטווטווטוואטומוק),	· 	•	
	· .	564-25-0			
·.		(anhydrous)			
•	2-Naphthacehecarboxamine, 4-		:		
	(dimethylamino)-1,4,4a,5,5a,6,11,12a-	•			•
-	octahydro-3,5,10,12,12a-pentahydroxy-6-	٠	<u>·</u> .	•	
;	methyl-1,11-dioxo-[4S-	. •	- -		
	(4Alpha,4aAlpha,5Alpha,5aAlpha,6Alpha,1				Formulation, modified-release,
doxycycline, Atrix	[2aAlpha]]- [CAS]	564-25-0	• :	•	immediate ·
	2-Nanhtharenecarhoxamide 4-		L		
•	(dimethylamino)-1 4 4a 5.5a 6.11.12a-		<u>. </u>	•	
	loctahydro-3 5 10 12 12a-pentahydroxy-6-				
	methyl-1 11-dioxo- [4S-	•	-		
	14415ho 40Alaho EAlaho Ealaho GAlaho 1				·
downwithe Collegenex	(4Aprila, tampila, organia, organia, organia, i organia, i organia	564-25-0	· .		Formulation, oral, other
doxycyciile, conadenex	- Carolla Jacob	460 04 6	-	-	
Doxylamine		0-17-604	· .		
	N.N.Dimethyl-2-[1-phenyl-1-(2-	•	•••	•	
	pynonyjeuroxyjeurananie		•		Formulation, transmucosal, systemic
י יי דובו לפווווים ואסט					
	[3-D-2',3'-didehydro-2',3'-dideoxy-5-				•
•	fluorocytidine		-		· · · · · · · · · · · · · · · · · · ·
DPC-817			\neg		Antiviral, anti-rilv
DPI-3290			US 5681830	830	Analgesic, other
	•				
•	5-Amino-7-[(3S,4R)-(1-aminocyclopropyl)-				· :
. ` ·	(3-fluoropyrrolidin-1-yi]-1-[(1R,2S)-2-fluoro-	•	· ·		•
	[1-cyclopropyl]-1,4-dihydro-8-methyl-4-oxo-				
	3-quinolinecarboxylic acid		· -		
DQ-113			-		Quinolone antibacterlai
Drofenine		1679-76-1			
Droloxifene		82413-20-5	<u> </u>		
Drometrizole		2440-22-4			
Dromostanolono		58-19-5	-		
Droillosiarionolle		3			
•	6H-Dibenzo[b,d]pyran-1-01, 6a,7,8,10a- tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-				
dronabinol, Pars	trans)-[CAS]	1972-08-3			Antiemetic.

	 					• •		.•
Example of Indication		Periodontitis	Periodonitits	 Rhinitis, allergic, general	Infection, HIV/AIDS Pain, general		Infection, general .	Chemotherapy-induced nausea and vomiting

			Patent		
API Generic Name	API Chemical Name	CAS No.	Reference	nce	Example of Therapeutic Use
	2-n-Butyl 3-[4-(3-di-n-butylamino-				
	propoxy)benzoyl]5-		<u> </u>	•	
	methylsuitonamidobenzoruran hydrochloride		· ·		
dronedarone hydrochloride					Antiarrhythmic
Droperidol .		548-73-2			
Droprenilamine		57653-27-7	•	:	•
Dropropizine		1.7692-31-8			
Drospirenone		67392-87-4			
Drotaverine		14009-24-6	· ;		
Drotebanol		3/2/3176			
			. <u>. </u>	:	•
	2H,5H-1,3-Oxazino[5,6-	•	_		·
dróxicam	methyl-3-(2-pyridinyl)-, 6,6-dioxide.[CAS]	90101-16-9	EP .	99770	Anti-inflammatory
Droxicam		90101-16-9 .			
2000000	-Tuncine A 3-dibudroxy- three-[CAS]	23651-95-8	EP .	128684	Antiparkinsonian
Drovidona		∞			
- Control of the cont			-		
•	1,2-Benzisothiazol-3(2H)-one, 2-[4-[4-(7-				
DU-125530	cnioro-2,3-dinydro-1,4-denzodioxir-5-yy-1- piperazinyljbutylj-, 1,1-dioxide [CAS]	161611-99-0	 	633260	Anxiolytic
Duloxetine		116539-59-4		,	
	2-Thiophenepropanamine, N-methyl-				
diiloveline hydrochloride	Gamma-(1-naphthalenyloxy)-, hydrochloride (S)- ICASI	136434-34-9	US 53	5362886	Antidepressant
duramycin. MoliChem			W .	9428726	Formulation, inhalable, solution
Durapatite		1306-06-5		· ").	
	4-Azaandrost-1-ene-17-carboxamide, N-				
ditactorida	(2,5-bis(trifluoromethyl)phenyl)-3-oxo-, (5Aloha, 178)- [CAS]	164656-23-9	· Si	5565467	Prostate disorders
Dutasteride	·	164656-23-9			
-	N,N-dilsopropyl-4-[4-(3-aminobenzo[d]isoxazol-6-yloxy)butoxy]-3-				
NW-1141	methoxybenzamide	•			Osteoporosis treatment
]		

Example of Indication Arrhythmia, general	Inflammation, general Parkinson's disease	general : : : : : : : : : : : : : : : : : : :	Benign prostatic hyperplasia Osteoporosis
			<u> </u>

٠.

•			Pat nt	ıt.	· · · · · · · · · · · · · · · · · · ·
API Generic Name	API Chemical Name	CAS No.	Refer	er nce	Example of Therapeutic Use
	(R)-(-)-7-((4-aminomethyl-4-methyl-3-(Z)-		•	· ·	
	methyloxyimino)pyrrolidin-1-yl)-1-	:	<u>. :</u> .	· .	
DW-286a	dinydro[1,8]naphthyridine-3-carboxylic acid				Quinolone antibacterial
DW-471			8	5922871	Antiviral, other
	2-Naphthalenepropanoic acid, 7-				
	iminoethyl)-3-pyrrolidinyljoxyjphenylj-,			• •	
DX-9065a	monohydrochloride, pentahydrate, [S- (R*,R*)]- [CAS]	155204-81-2		<u>:,</u>	Antithrombotic
	o motion of to to the options of				
		:			
DY-9760e	imidazol-4-ylmethyl)-5,6-dimethoxy- [CAS]	160522-00-9	NS	5681954	Neuroprotective ·
Dyclonine) :	586-60-7			
Dydrogesterone		152-62-5			·
Dymanthine		124-28-7			
Dyphylline		479-18-5.			
•	- Liberadica O and C descriptions of				
	acid, 6-[(1R)-1-hydroxyethyl]-3-[[(3S,5S)-5-	•	٠.		
	[(R)-hydroxy(3R)-3-pyrrolidinylmethyl]-3-			•	
E-1010	pyrrolidinyljurioj-4-metnyi-7-0xo-, monohydrochloride, (4R,5S,6S)- [CAS]	186319-97-1			Beta-lactam antibiotic
	N. Cihiya (1.11.19.fi razabanathullularidia. A		. •		
	yl-1H-indol-6-yl)acetamide			·.	
E-2101			-		Muscle relaxant
E2F antagonists, TopoTarget			WO	9606943.	Anticancer, other
	Benzamide, 4-amino-5-chloro-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2-{(1-methyl-2-hirani)-2-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-		:		
E-3620		151213-86-4	G.	554794	Antacid/Antiflatulent

	 <i>:</i>	. ,			
Example of Indication	Infection, hepatitis-B virus	Thrombosis, general	Ischaemia, cerebral	Infection, general	Muscle spasm, general Cancer, general
. W.		_ <u>_</u> El	<u> </u>	<u> </u>	

			L		
	:		Patent	nt	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	Alnha D. Cluconyraphea 3-0 dayl-2-				
•	denv6-0-(2-denv3-0-((3B)-3-				
	methoxydecyl)-6-O-methyl-2-(((11Z)-1-oxo-	.`		•	
	11-octadecenyl)amino)-4-O-phosphono-8-		•	٠.	·
	D-glucopyranosyl)-2-((1,3-	• .		•	
	dioxotetradecyl)amino)- 1-(dihydrogen				
E-5564	phosphate), tetrasodium sait [CAS]	185954-98-7	占	536969	Septic shock treatment.
	Pyridine, 4-(4-fluoropheny!)-1,2,3,6-				
	tetrahydro-1-[4-(1H-1,2,4-triazol-1-yl)butyl]-			·.·	
	, z-nydroxy-1,z,3-propanetricarpoxylate	020120-14-9		•	Nelloleotic
	1.1/ Aminoculfondobond E.10 4:				
	diffuorophenyl)-4,5-dihydro-3-		•		
	trifluoromethyl-1-H-pyrazole	•	•••		
E-6259					Antiarthritic, other
		•			:
•	[2-(8,9-Dioxo-2,6-diazabicyclo[5.2.0]non-			: 	
EAA-90.	11(7)-en-2-yl)-ethyljphosphonic acid	•			Analgesic, other
e-Acetamidocaproic Acid		57-08-9		•	
e-Amin caproic Acid		60-32-2			
	1-Butanone, 1-[4-(1,1-		•	•	
		40.40	_		. cardiac and observed
ebastine	(dipnenyimetnoxy)-1-piperidinyij- [CAS]		1	134124	Alkaner gro, nor-asuma
Ebastine		90729-43-4			
• • •	1th-Imidazole, 1-(2,4-dichloro-40,11-dihudro, Ed. dihenzole dicholohenten-5-vi).	108306.80.0	•		
eberconazole			ES	2012297	Antifungal ·
	Benzenesulfonamide, N-[[[2-[[[2-		·		
••	thiazolyimethylithiolethyllaminolmethylenel-	•			
ebrotidine	4-bromo- [CAS]	100981-43-9	G.	159012	Antiulcer
1	anzisoselenazol-3(2H)-one, 2-phenyl-		. 0		·
epselen			7	1,64	Neuropioreone .
Eburnamonine		474-00-0			
Ecabapide		104775-36-2			

:

			•
Example of Indication Sepsis Schizophrenia	Unspecified Pain, neuropathic	Rhinitis, allergic, seasonal	Ulcer, duodenal Haemorrhage, subarachnold

		•	Patent		
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	1-Phenanthrenecarboxylic acid:	·	Ŀ	·	
ecabet · ·	dimethyl-7-(1-methylethyl)-6-sulfo-, [1R-	33159-27-2 86408-72-2	 	DE - 3239172	Antiulcer
	d. 1.0vo. 3.				
· :	Inhenylpronyll- phenylmethyl ester. (S)-	•			
ecadotril	[CAS]	112573-73-6.	<u></u>	318377 ·	Antihypertensive, other
Ecgonidine		484-93-5			
Ecgonine		481-37-8			
Echothiophate lodide		513-10-0			
Econazole		27220-47-9			•
	5H-Benzold]naphth[2,1-b]azepin-12-ol, 11-				
ecopipam	(6aS-trans)- [CAS]	112108-01-7	EP	230270	Anorectic/Antiobesity
	Prosta-8,13-dien-1-oic acid, 11,15-				
ecraprost	dihydroxy-8-(1-oxobutoxy)-, butyl ester, (11Alpha,13E,15S)- [CAS]	136892-64-3	Ch.	423697	Vasodilator, peripheral
Ectylurea		95-04-5			
-	9,10-Secocholesta-5,7,10(19)-triene-	•	,		
ED-71	, 1,3,25-triol, 2-(3-hydroxypropoxy)-, {(1Apha,28,38,52,7E)- {CAS}	104121-92-8	<u></u>	184206	Osteoporosis-treatment
	o-5-methyl-2-		·		
edaravone	phenyl- [CAS]	89-25-8	٩	62108814	Neuroprofective
Edatrexate		80576-83-6			
Edetate Calcium		62-33-9			
Disodium					
Edetat Disodium		139-33-3			
Edetat Sodium		64-02-8		•	
		150-38-9			
	Butanamide, N-[[2-[[4,5-dimethyl-3- isoxazovi) amino] sulfonyl]-4-(2-		·		
	oxazolyl)[1,1"-biphenyl]-2-y][methyl]-N,3,3-	•			
edonentan .		210891-04-6	•	-	Cardiostimulant ·
			ŀ		

•	Example of Indication	٠.
٠		
	Ulcer gastric	
•		••
•	Hypertension, ge	
	•	
•••	٠	
•		
, _		
	Character	<u> </u>
•	Cocard	
٠.		
	Peripheral vascular disease	
• -		
•		
•		·
	Carechologia	٠
•	infarction, cerebral	•
•		
		•
		<u>.·</u>
•	•	
		_:
		· .
•••	Heart failure	

			1		
		• • •	Patent	ent	
API Generic Name	API Chemical Name	CAS No.	Ref	Reference	Example of Therapeutic Use
	[N-[2-[4,7-Bis[(carboxy-kappaO)methyl]-10- (carboxymethyl)-1,4,7,10-				
. •	tetraszacyclododec-1-yi-	· ;		٠.	
	kappaN1,kappaN4,kappaN10jacetylj-D-		<u> </u>	· ·	
:	phenylalanyl-L-cysteinyl-L-tyrosyl-D-	•	<u>. </u>	:	
	tryptopnyl-t-tysyl-t-tareonyl-t-cysteinyl-t-	•		· ·. ·	
edotreotide	(Second of Second 204318-14-9	Ċ.	6183791	Anticanor homosal	
edoxudine	Uridine, 2'-deoxy-5-ethyl- [CAS]	15176-29-1	GB	1170565	Antiviral, other
Edrecolomab.		156586-89-9	ŀ.	 - -	
Edrophonium		116-38-1			
Efailth	Butanedioic acid, lithium salt [CAS]	16090-09-8			Antipruntic/Inflamm, alleraic
	Propanoic acid, 2-[4-[2-[(3,5-dimethylohenylaminol-2-		ŀ		
efaproxiral sodium	oxoethy[]phenoxy]-2-methyl- [CAS]	131179-95-8	S	5705521.	Radio/chemosensitizer
	2H-3,1-Benzoxazin-2-one, 6-chloro-4-	:		,	
efavirenz	(cyclopropyletnynyl)-1,4-dinydro-4- (trifluoromethyl)-, (S)- [CAS]	154598-52-4	OM	9403440	Antiviral anti-HIV
efietirisine	thylj-1-			Ţ.	A III. III III
Effornithing			9	2311840	Antiallergic, non-asthma
		6/03/-3/-0			
eflornithine	DL-Omithine, 2-(difluoromethyl)- [CAS]	70052-12-9	S	4413141	Protozoacide dermal tonical
Efloxat			7		made in the contract of
eflucimibe	Benzeneacetamide, Alpha-(dodecylthio)-N- (4-hydroxy-2,3,5-trimethylphenyl)- (S)- [CAS]	202340-45-2	···		Hypolipaemic/Antiatherosclerosis
	3-pyridinecarboxylic acid; 5-(5,5-dimethyl-		-		
	2.6-dimethyl-4-(3-nitrophenyl)-, 2- (111011-53-1)/phenylphen	111011-53-1			
efonidipine	oxide [CAS]	,	EB EB	230944	Antihypertensive, other
	5-Chloro-4-[3-[N-[2-(3,4-dimethoxyphenyi)]ethylj-N-		<u> </u>		
EGIS-7229	methylamino]propylamino]- 3(2H)- pyridazinone fumarate [CAS]	150800-12-7 190333-92-7		4243381	Antiarrhythmic
]	1		

	Example of Indication	•
•		
•		
	··:	
	Cancer, lung small cell	•
	harring	
•	ion and ince	
_		
	Eczema, seborrhoeic	•
•		٠.
	Cancer, brain	
	•	•
	Infection, HIV/AIDS	•
	Allergy, general	
_		
	Infection, trypanosomiasis, African, Hirsutism	
•		
	Hyperlipidaemia, general	
		•
 -	Hypertension, general	
	Arrhythmia, general	
,		•

.:

••

	:	•	Patent	int	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference :	Example of Therapeutic Use
eglumegad	Bicyclo[3.1.0]hexane-2,6-dicarboxylic acid, 2-amino-, (15,25,5R,6S)- [CAS]	176199-48-7 209216-09-1			Anxiolytic
egualen	1-Azulenesulfonic acid, 3-ethyl-7-(1- methylethyl)-,	97683-31-3 99287-30-6	<u>C</u>	147915	Antiulcer
Elcosapentaenoic Acid		10417-94-4	1		
elarofiban	3-Pyridinepropanoic acid, B-[((3R),-1-[1-oxo-3-(4-piperidinyl)propyl]-3- piperidinyl)carbonyllaminol-, (3S)- ICASI	198958-88-2	, Ç	9741102	Antithrombotic
Elcatonin					
Eledoisin		69-25-0			
eletriptan	1H-Indole, 3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)- (R)- [CAS]	ī	. a	5607951	Antimioraine
Elgodipine		119413-55-7		ŀ	
Ellagic Acid		476-66-4			
Elliptinium		58337-35-2			
Eltoprazine		98224-03-4	Γ		
elvucitabine	B-L-2',3'-Didehydro-2',3'-dideoxy-5- fluorocytidine	181785-84-2		:	Antiviral, other
elzasonan	yl)benzylidene]thiomorpholin-3-one monohydrochloride- [CAS]	220322-05-4 361343-20-6			Antidepressant
Embelin		550-24-3			
Embramine		3565-72-8			
emedastine	1H-Benzimidazole, 1-(2-ethoxyethyl)-2- (hexahydro-4-methyl-1H-1,4-dlazepin-1-yl)-87233-61-2 , (E)-2-butenedioate (1:2) [CAS]		6	79545	Antiallergic, non-asthma
Emepronium Bromide		3614-30-0	1.		
Emetine .		483-18-1	1.		
Emitefur		110690-43-2	П		
	17Alpha-Acetoxy-6Alpha-methyl-19-nor- 18,29-dihydrocyclopropa[1,2]pregn-4-ene- 3,20-dione+Estra-1,3,5(10)-triene-3,17-		·. ·	• •	
EMM-210525	diOi(173)	· .	-:-		Formulation, fixed-dose combinations
			ŀ		

-			· · ·		•	٠.			•		•		•				
Example of Indication	Anxiety, general	Ulcer, gastric		Thrombosis, general			Migraine		-	Infection, hepatitis-B virus	Depression, general		Phinitis alleraic general				Hormone replacement therapy
	•								•				•		-		•

			Patent	ant	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Emodin .		518-82-1			٠
emorfazone	3(2H)-Pyridazinone, 4-ethoxy-2-methyl-5- (4-morpholinyl)- ICASI	38957-41-4	ď	7224030	Anti-inflammatory
EMR-62203 · ·			9	9806722	Male sexual dysfunction
	2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2- fhydroxymethyl)-1,3-oxathiolan-5-yl) (2R-				
emtricitablne	cis)- [CAS]	143491-57-0	ΜÖ	9214743	Antiviral, anti-HIV
Emylcamate		78-28-4			
	L-Proline, 1-[N-[1-(ethoxycarbonyl)-3- phenylpropyl-L-alanyll-, (S)-, (Z)-2-				
enalapril	butenedioate [CAS]	76095-16-4	Sn	4374829	Antihypertensive, renin system
Enalaprilat		76420-72-9			
Enallylpropymai		1861-21-8	·		
Encainide		2-96-82199		,	
Enciprazine		. 6.98-9289			
Endralazine		39715-02-1			
enfenamic acid	Benzoic acid, 2-[(2-phenylethyl)amino}-	23049-93-6	N.	103066	Anti-inflammatory
	9, 2-chloro-1-(difluoromethoxy)-1,1,2-		Т	Τ	
enflurane			US	3469011	Anaesthetic, inhalation
Enilconazole .		35554-44-0			
Eniluracil.		59989-18-3			•
ENMD-0995	S-3-amino-phthalidoglutarimide		. Sn	5712291	Anticancer, other
Enocitabine		55726-47-1	Т.	T	
Enol-3-IPA	1H-indole-3-propanoic acid, Apha-oxo-		. G	106813	Hypnotic/Sedative
	1,8-Naphthyridine-3-carboxylic acid, 1- ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-				
enoxacin		74011-58-8	ņs	4359578	Quinolone antibacterial
enoxaparin sodium		9005-49-6 9041-08-1	EP '	40144	Antithrombotic
enoximone	-2H-imidazol-2-one, 1,3-dihydro-4-methyl-5-	77671-31-9	. d3	59948	Cardiostimulant
Enoxolone		471-53-4	:		
Elloanorie			7		


ï

Example of 11 Impotence Infection, HIV/All Anaesthesia Cancer, myelome Infection, general Infection, general Heart failure
--

API Ceneric Name API Chemical Name CAS No. 4,5+Heptadenoic acid, 7(3-hydroxy-2-(3-hydroxy-4-phenoxy-1-buteny)-5-oxocyclopentyl, methyl ester, [1,4pha,28(1E,3R').34pha]- [CAS] 73121-56-9 11,4pha,28(1E,3R').34pha]- [CAS] 73121-56-9 11,4pha,28(1E,3R').34pha]- [CAS] 73121-56-9 11,4pha,28(1E,3R').24hpa]- [CAS] 17256-08-8 12,4pha,28(1E,3R').24hpa]- [CAS] 187256-08-8 14,4pha,28(1E,3R').24hpa,29-(2-(2-4)-4)-4-rethoxyphenyl)-5-propoxy- (15-(1Apha,28,34hpa))- [CAS] 187256-08-8 14,4pha,28(1E,3R').24hpa,28(3-4hpa)- [CAS] 187256-08-8 2,4propoxy- (15-(1Apha,28,34hpa))- [CAS] 187256-08-8 2,4pha,28(1A,4hpa,28,34hpa)- [CAS] 187152-3-9 3,4pha,10-24,4pha,28(1A,54)- [CAS] 187152-3-9 4,4pha,28(1A,4hpa,28,4hpa,28,4hpa,28,4hpa,28,4hpa,28,4hpa,28,4hpa,39,48,4hpa,39,					
### College Art Collembra Art Collembra Art Collembra 4,5-Heptadianoic.acid, 7-(3-hydroxy-2-(3-hydroxy-2-(3-hydroxy-1-butanyl)-5-covocyclopentyl; methyl ester, [1] Alpha,28(1E,38*),3Alpha]-[CAS] 14+Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-2,3-dihydro-3-(2-(2-hydroxyettloxy)-4-methoxyphenyl)-5-cycopycyttloxy-4-methoxyphenyl)-5-cycopycyttloxy-4-methoxyphenyl)-5-cycopycyttloxy-4-methoxyphenyl)-5-cycopycyttloxy-3-(hydroxymethyl)-2-fropenamide, 2-cyano-3-(4,5-dihydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]- [CAS] 2-Fropenamide, 2-cyano-3-(4,5-dihydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]- [CAS] 3-Thiazolidineacetic acid, 5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-(E,E)- [CAS] 1-ysine-cis-5,8,1,1,4,17-eicosapentanoate with L-lysine-cis-4,7,10,13,18,19-doahexanoate 1-benzopyran-6-yl-hydrogen 1-benzopyran-6-yl-hydrogen 1-propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-pipentdinyl)-[CAS] 1-propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-pipentdinyl)-[CAS] 1-propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-pipentdinyl)- [CAS] 1-propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-pipentdinyl)-1-methylethyll-1-hydroxy-2-(methylamilio)-ethyll-1-hydroxy-2-(methyll-1-hydroxy-2-(methyll-1-hydroxy-2-(methyl	•		Patent	ut .	
4,5-Heptadianolo.acid, 7-(3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butanyl)-5- oxocyclopentyll-, methyl estar, [1] Alpha,28(1E,387),3Alpha]- [CAS] 11H-Indene-2-carboxylic acid, 1-(1,3-hydroxypthoxy)-4-methoxyphenyl)-5- propoxy-, (15-(1Alpha,23,3Alpha)-,[CAS] 2-Propenamide, 2-cyano-3-(4,5-dihydroxy-3-hitophenyl)-N,N-diethyl- [CAS] 3-nitrophenyl)-N,N-diethyl- [CAS] 6H-Purin-6-one, 2-amino-1,9-dihydroxy-2-methylenecyclopentyll- [CAS] 2-methylenecyclopentyll- [CAS] 6H-Purin-6-one, 2-amino-1,9-dihydroxy-2-hitoxo-, [E,E)- [CAS] 1-hygine-cis-5,8,11,14,17-eicosapentanoate with L-lysine-cis-4,7,10,13,16,19-dahexanoate phosphatelpotassium- [CAS] 1-banzopyran-6-yl-hydrogen phosphatelpotassium- [CAS] 1-phopanone, 1-(4-ethylphenyl)-2-methyl-3- (1-piperidinyl)- [CAS] 1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-(1-methylethyl)-1-ascopia-3-methyl-3-(1-methylethyl)-1-ascopia-3-methyl-3-(1-methylethyl)-2-methyl-3-m			Refe	Reference	Example of Therapeutic Use
1 (1.4) (1.3-1) (1.4)	4,5-Heptadlenoic.acid, 7-(3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butanyl)-5-				
114-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-2,3-dihydro-3-(2-(2-hydroxyethoxy)-4-methoxyphenyl)-5-propoxy-, (1S-(1Alpha,2B,3Alpha))-,[CAS] 2-Propenamide, 2-cyano-3-(4,5-dihydroxy-3-introphenyl)-N,N-diethyl-,[CAS] GH-Purin-6-one, 2-amino-1,9-dihydro-9-(1,13,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyll-,[CAS] L-lysine-cis-5,8,11,14,17-eicosapentanoate with L-lysine-cis-4,7,10,13,18,19-doahexanoate tetramethyl-2-4,8,12-trimethyltidecyl)-2H-1-benzopyran-6-yl-hydrogen phosphatelpotassium-,[CAS] 1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)-,[CAS] 1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)-,[CAS] 1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-amine, 9,13b-dihydro-,[CAS] 14-Dibenz(c,filmidaze(1,5-ajazepin-3-amine, 9,13b-dihydroxy-2-(methylamino)-ethyl]-	ASI		. 8	2025431	Prostaglandin
benzodioxol-5-yl-2,3-dirydro-3-(2-(2-hydroxyethoxy)-4-methoxyphenyl)-5-hydroxyethoxy)-4-methoxyphenyl)-5-propoxy-, (1S-(1Apha,2B,3Alpha))-,[CAS] 2-Propenamide, 2-cyano-3-(4,5-dirydroxy-3-nitrophenyl)-N.N-diethyl- [CAS] 6H-Purin-6-one, 2-amino-1,9-dirydro-9-(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]- [CAS] 7-Thiazolidineacetic acid, 5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-, (E,E)- [CAS] 1-Prine-cis-5,8,11,14,17-eicosapentanoate with L-lysine-cis-4,7,10,13,16,19-doahexanoate beta-acopyran-6-yl-hydrogen phosphatelpotassium-;[CAS] 1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)-[CAS] (1-piperidinyl)- [CAS]	11. Place of worker Canapar 11.	•			
hydroxyetthoxy)-4-methoxyphenyl)-5- propoxy-, (1S-(1Apha,28,3Alpha))-, [CAS] 2-Propenamide, 2-cyano-3-(4,5-dihydroxy-3-nitrophenyl)-N,N-diethyl- [CAS] 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((1S,3R,4S),4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]- [CAS] 7-Thiazolidineacetic acid,5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-, (E,E)- [CAS] L-lysine-cis-5,8,11,14,17-eicosapentanoate with L-lysine-cis-6,8,11,14,17-eicosapentanoate with L-lysine-cis-6,8,11,14,17-eicosapentanoate with L-lysine-cis-4,7,10,13,16,19-doahexanoate 1-benzopyran-6-yl-hydrogen phosphatelpotassium-;[CAS] 1-propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)-,[CAS] 1-piperidinyl)-,[CAS] 1-piperidinyl)-,[CAS] 1-piperidinyl)-,[CAS] 1-piperidinyl)-,[CAS] 1-piperidinyl-,[CAS] 1-piperidinyl-,[CA	benzodioxol-5-yl)-2,3-dihydro-3-(2-(2-		•		
2-Propenamide, 2-cyano-3-(4,5-dihydroxy-3-nitrophenyl)-N.N-diethyl- [CAS] 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((18,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl- [CAS] 7-Thiazolidineacetic acid,-5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-(E,E)-(E,E)-(CAS] 1-hysine-cis-5,8,11,14,17-eicosapentanoate with L-lysine-cis-4,7,10,13,16,19-doahexanoate 1-benzopyran-6-yl-hydrogen phospentalpyl-3-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphatelpotassium- (CAS) 1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)- [CAS] 1-piperidinyl)- [CAS] 1-piperidinyl)- [CAS] 1-piperidinyl)- [CAS] 1-piperidinyl- (CAS)	CAS		· · · Sn	5817693	Antihypertensive; other
GH-Purin-6-one, 2-amino-1,9-dihydro-9-(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopenhyl-1 [CAS] GH-Purin-6-one, 2-amino-1,9-dihydro-9-(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopenhyl-1 [CAS] L-Pysine-cis-4,7,10,13,18,19-doahexanoate with L-lysine-cis-4,7,10,13,18,19-doahexanoate tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate]potassium-[CAS] L-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)-[CAS] (1-piperidinyl)-[CAS] L-Biogal Uridine, 2-deoxy-5-(1-methylethyl)-[CAS] (1-piperidinyl)- [CAS] (1-piperidinyl)- [CAS] (1-piperidinyl)- [CAS] (1-piperidinyl)- [CAS] (1-piperidinyl)-3-(1-methylethyl)-3-(1-methy	9. Brononomide 9. month 9.74 E. ellindesser				
6H-Purin-6-one, 2-amino-1,9-dihydro-9- ((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)- 2-methylenecyclopentyl]- [CAS] pheryl-2-propenylidene)-4-oxo-2-thioxo-, (E,E)- [CAS] L-lysine-cis-5,8,11,14,17-eicosapentanoate with L-lysine-cis-6,8,11,14,17-eicosapentanoate with L-lysine-cis-4,7,10,13,16,19- doahexanoate L-ascorbic acid 2-{3,4-dihydro-2,5,7,8-} tetramethyl-2-{4,8,12-trimethyltridecyl})-2H- 1-benzopyran-6-yl-hydrogen phosphate]potassium- [CAS] (1-piperidinyl)- [CAS]			-	426468	Antiparkinsonian
(115,381,48)-4hydroxy-3-(hydroxymethyl)- 2-methylenecyclopentyl- [CAS] 3-Thiazolidineacetic acid,5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-(E,E)- [CAS] L-lysine-cis-5,8.11,14,17-eicosapentanoate with L-lysine-cis-4,7,10,13,18,19-doahexanoate tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate]potassium-[CAS] 1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-pipertdinyl)- [CAS] (1-pipertdinyl)- [CAS]					
## Single	onburn-b-one, z-amino-1,9-oinydro-9- ((18,3R,4S)-4-hydroxy-3-(hydroxymethyl)-				··· ·
3-Thiazolidineacetic acid, 5-(2-methyl-3-phenyl-2-propenylidene) 4-oxo-2-thioxo-(E,E)-[CAS] L-Vsine-cis-5,8,11,14,17-eicosapentanoate with L-lysine-cis-4,7,10,13,16,19-doahexanoate L-ascorbic acid 2-[3,4-dihydro-2,5,7,8-teramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate]potassium-[CAS] (1-piperidinyl)-[CAS]			EP 4	481754	Antiviral, other
3-Thiazolidineacetic acid, 5-(2-metryl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-, (E,E)-[CAS] L-lysine-cis-5,8,11,14,17-eicosapentanoate with L-lysine-cis-4,7,10,13,18,19-doahexanoate. L-ascorbic acid 2-[3,4-dihydro-2,5,7,8-tetrametryl-2-(4,8,12-trimetryltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphatelpotassium-[CAS] 1-Propanone, 1-(4-etrylphenyl)-2-metryl-3-(1-pipertdinyl)-[CAS] 1-Propanone, 1-(4-etrylphenyl)-2-metryl-3-(1-pipertdinyl)-[CAS] 1-Propanone, 1-(4-etrylphenyl)-[CAS] amine, 9,139-dihydro-1CAS] (R)-4[1-hydroxy-2-(metrylamino)-etryl]-12-hichanonelid		3-22-9	•		
(E,E)- [CAS] L-lysine-cis-5,8,11,14,17-eicosapentanoate with L-lysine-cis-4,7,10,13,16,19- doahexanoate L-ascorbic acid 2-{3,4-dihydro-2,5,7,8- tetramethyl-2-(4,8,12-trimethyltridecyl)-2H- 1-benzopyran-6-yl-hydrogen phosphate]potassium- [CAS] 1-Propanone, 1-(4-ethylphenyl)-2-methyl-3- (1-piperidinyl)- [CAS] 1-Propanone, 1-(4-ethylphenyl)-2-methyl-3- (1-piperidinyl)- [CAS] 1-Piperidinyl-1-(AS] amine, 9,139-dihydro-1-alazepin-3- amine, 9,139-dihydro-1-CAS] (R)-4-[1-hydroxy-2-(methylamino)-ethyl]-	3-Thiazolidineacetic acid, 5-(2-methyl-3- phenyl-2-propenylidene)-4-oxo-2-thioxo-,	: :			-
L-lysine-cis-5,8,11,14,17-eicosapentanoate with L-lysine-cis-4,7,10,13,16,19-doahexanoate. L-ascorbic acid 2-{3,4-dllydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphatejpotassium-[CAS] 1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)-[CAS] 1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)-[CAS] 1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)-1-(2AS] amine, 9,139-dilydro-1-(2AS] (R)-4-[1-hydroxy-2-(methylamino)-ethyl]-1-2-hononediol			EP 4	47109	Symptomatic antidiabetic
L-ascorbic acid 2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphatelpotassium- [CAS] 1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)- [CAS] (1-piperidinyl)- [CAS] 1-Probanz[c,filmidazö[1,5-ajazepin-3-amine, 9,139-dihydro-1CAS] amine, 9,139-dihydro-1CAS] (R)-4-[1-hydroxy-2-(methylamino)-ethyl]-12-hiphanoliol	L-lysine-cis-5,8,11,14,17-eicosapentanoate with L-lysine-cis-4,7,10,13,16,19- doahexanoate	· ·			Antiviral, other
Hosphatejjotassium-[CAS] 1-benzopyran-6-yl-hydrogen phosphatejjotassium-[CAS] 1-Propanone, 1-(4-ethylphenyl)-2-methyl-3- (1-piperidinyl)- [CAS] 1-Propanone, 1-(4-ethylphenyl)-1-methyl-3- 1-Propanone, 1-(4-ethylphenyl)-2-methyl-3- 1-Propanone, 2-deoxy-5-(1-methylethyl)-1-CAS] 1-Propanoliol 1-Propanoliol 1-Propanoliol 1-Propanoliol 1-Propanoliol 1-Propanoliol 1-Propanoliol 1-Propanoliol	L-ascorbic acid 2-[3,4-dlhydro-2,5,7,8-		 		
phosphatejpotassium- [CAS] 1-Propanone, 1-(4-ethylphenyl)-2-methyl-3- (1-piperidinyl)- [CAS] 16 18 11H-Dibenz[c,filmidazö[1,5-ajazepin-3-amine, 9.13b-dihydro- [CAS] 19 11H-Dibenz[c,filmidazö[1,5-ajazepin-3-amine, 9.13b-dihydro- [CAS] 12-honzonediol	terrametnyi-z-(4,8,1z-trimetnyitridecyi)-zH- 1-benzopvran-6-vi-hvdroden	•		•	
1-Propanone, 1-(4-ethylphenyl)-2-methyl-3- (1-piperidinyl)- [CAS] 1e Uridine, 2-deoxy-5-(1-methylethyl)- [CAS] 1e 1H-Dibenz[c,fjlmidazö[1,5-ajazepin-3-amine, 9,13b-dihydro-"[CAS] (R)-4-[1-hydroxy-2-(methylamino)-ethyl]-		•	۔۔ ۵	127471 .	Neuroprofective .
Biogal Uridine, 2'-deoxy-5-(1-methylethyl)- [CAS] Ol 1H-Dibenz[c,filmidazö[1,5-a]azepin-3-amine, 9,13b-dihydro-¡CAS] (R)-4-[1-hydroxy-2-(methylamino)-ethyl]-		0.00	-		1
le CASI Ol 1H-Dibenz[c,f]imidazö[1,5-a]azepin-3-amine, 9.13b-dihydro-Y-2-(methylamino)-ethyl]-12-bi-banaciol		$\cdot \Big[$	_	1400aa	Muscie relaxant
oral, Bl amine, 9,13b-dihydro- [CAS] (R)-4-[1-hydroxy-2-(methylamino)-ethyl]-			DE .	2918260 .	Antiviral, other
oral, Bl amine, 9,13b-dihydro-¡CAS] (R)-4[1-hydroxy-2-(methylamino)-ethyl]-	299-4	2-3	-		
1H-Dibenz[c,fi]midazö[1,5-a]azepin-3- amine, 9,13b-dihydro- ¡CAS] (R)-4-[1-hydroxy-2-(methylamino)-ethyl]-	26774	1-90-3	_		
1H-Dibenz[c,fjimidazo[1,5-a]azepin-3- amine, 9,13b-dinydro- [CAS] (R)-4-[1-hydroxy-2-(methylamino)-ethyl]-		. 0-86	-		
(R)-4-[1-hydroxy-2-(methylamino)-ethyl]-		43-7 DE		3008944 A	. , Antiasthma
	(R)-4-[1-hydroxy-2-(methylamino)-ethyl]- 1,2-benzenediol	·	<u> </u>		
epinephrine	51-43-4			Ĭ.	Formulation, inhalable, dry powder

·	- :	·	1:	· ·.	· ———	· ·	. :	·
e of Indication	duodenal	iston, pulmonary n's disease	hepatitis-B virus	hy, diabetic	herpes simplex virus	cerebral	aralysis herpes simplex virus	SS
Example	Ulcer, du	Hyperrension, Parkinson's di	infection,	Neuropathy,	Infection,	Infarction,	Spastic paralysis	Asthma Anaphylaxis

			-		
. (•	Patent	ant.	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Epirizol	٠	18694-40-1	Ė		
	5,12-Naphthacenedione, 10-[(3-amino-		•	•	
·. ·	hexprovance/loxyl-7.8.9.10-tetrahydro-	•		•	
	6,8,11-trihydroxy-8-(hydroxyacetyl)-1-	56390-09-1 -		۱. ن	
epirubicin .	methoxy-, (8S-cis)- [CAS]	56420-45-2	gg	1457632	Anticancer, antibiotic
Epitiostanol		2363-58-8			
	Pregn-4-ene-7,21-dicarboxylic acid, 9,11-		:		
	methyl ester (7Alpha,11Alpha,17Alpha)-			•••	
eplerenone	[CAS]	107724-20-9	Э	122232.	Antihypertensive, diuretic
	1-Propanone, 1-(2-fluorophenyl)-3-(4-				
	hydroxyphenyl)-, O-(2 (2) (E)-2-	•		•	
eplivanserin	butenedioate (2:1) (sait) [CAS]	130580-02-8	ш	373998	Anxiolytic
	Prosta-5,13-dien-1-oic acid, 6,9-epoxy-				
·	111,15-dihydroxy-,	35121-78-9	ה ה	00000626	
in a second of the second of t	יייייייייייייייייייייייייייייייייייייי	7-1-2-10	3	20000	TIOSING TOTAL
Epostan	•	80471-63-2			
Eprazinone	-	10402-90-1	•		
Epristeride		1:19169-78-7		•	
	3-[2-Butyl-1-(4-carboxybenzyl)-1H-imidazol-	•			
				•	
eprosartan		133040-01-4	8	403159	Antihypertensive, renin system
Eprozinol :		32665-36-4			•
	4-methyl-2-[4-(4-(pyrimidin-2-yl)- piperazino)-butylj-2H,4H-1,2,4-triazin-3,5-				
eptapirone .	dione	179756-85-5	·		Antidepressant
	Platinum, [(4R,5R)-2-(1-methylethyl)-1,3-		٠.	•	
	dioxolane-4,5-umetriariamine- kappaN4,kappaN5][propanedjoato(2-)-		·		
eptaplatin	•	146665-77-2	Š Š	9216539	Anticancer, alkylating
Eptastigmine		101246-68-8			
٠	1,6-Methano-1H-4-benzazonin-10-0i,				÷ .
eptazocine		72522-13-5	SD	4082744	Analgesic, other
Eptifibatide .		188627-80-7			
•					



RECEIVED 1 0 MAR 2004

WIPO PCT

THE UNITED SIMILES OF AVIBRICA

TO ALL TO WHOM THESE PRESENTS SHALL COMES

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

March 05, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/487,064

FILING DATE: July 11, 2003

RELATED PCT APPLICATION NUMBER: PCT/US03/41273

By Authority of the COMMISSIONER OF PATENTS AND TRADEMARKS

W. MONTGOMERY Certifying Officer

PRIORITY
DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH ROLE (4) OR (6)

PART (2) OF (2) PART(S)

Example of Indicati Hypertension, general Hypertension, pulmonary Hypertension, general Depression, general	. •	•	•	• • •	•	*	
	nple of		ertension, general	pulmona		ession, g	

		:	Patent	=	
ADI Generio Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Entitorin		517-09-9			
		474-86-2			•
ERA-923	[ERA 923 (CAS)	352233-89-7	EP .	802183	Female contraceptive
	Acetic acid, [[2-oxo-2-[(tetrahydro-2-oxo-3-thismylaminolethylthiol- ICAS]	84611-23-4	EP		Respiratory
Francoine		564-36-3			
Fraction		564-37-4			
Ergotoff Moeviates		8067-24-1			
31		2-62-09			
Francterol		57-87-4			
		•		· · · · · · · · · · · · · · · · · · ·	
	(5/Alpha)-12'-Hydroxy-2'methyl-			. <i>:</i>	:
ernotamine tertrate. TEMPO	(prenyimenty) ergominarra, (c. c. indiana)	113-15-5	•	. ,	Formulation, inhalable, systemic
Eritadonino		23918-98-1	٠		
Littagemine	4-Quinazolinamine, N-(3-ethynylphenyl)-				
- - - - - - - - - - -	6,7-bis(2-methoxyethoxy)-;	183319-69-9	×0	9630347.	Anticancer, other
eriounio	The language of the language o	153832-46-3			
Ertapenem		_	T		
	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic	•			
	acid, 3-11(35,55)-5-11(3-	· ·	•		
	carboxyphenyi)aminojcarbonyij-3- pvrrolidinyllthiol-6-[(1R)-1-hydroxyethyl]-4-				
	methyl-7-oxo-, monosodium salt,	. 6	. (. 00.020	oto logom catificatio
ertapenem sodium	(4R,5S,6S)- [CAS]	153773-62-1	<u> </u>	9315070	Dela-latiani an includio
Erythrityl Tetranitrate		7297-25-8		•	
Frythrocentaurin		50276-98-7			
ateriate anistrate	Erythromycin, 2'-acetate, octadecanoate	96128-89-1	Sn	4599326	Macrolide antibiotic
Enthromingin Acietrate		96128-89-1			•
English mircin Fetolate		3521-62-8		٠	
3		23067-13-2			
Erythromycin	· · · · · · · · · · · · · · · · · · ·				
Erythromycin.		3847-29-8			
Lactobionate			•		
Erythromycin		134-36-1	•	·.•	
Propionate					
				·. ·:	•

graine graine graine Graine	· · ·		, , , , , , , , , , , , , , , , , , , 		 	; , , , , , , , , , , , , , , , , , , ,	· · ·
		Contraceptive, Respiratory dis		raine ncer, lung, non-small	Infection, GI	Infection, general	

: .

٠:

· .			Patent	=	; ;
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Erythromycin Stearate		643-22-1			
erythromycin stinoprate	Erythromycin, 2'-propanoate, compd. with N-acetyl-L-cysteine (1:1) [CAS]	84252-03-9	G	57489	Macrolide antibiotic
erythromycin	Erythromycin [CAS]	114-07-8			Formulation, dermal, topical
Enthrophleine		36150-73-9		:	
Esaprazole		64204-55-3			
osetlalonzan ovalata	5-Isobenzofurancarbonitrile, 1-[3- (dimethylamino)propylj-1-(4-fluorophenyl)- 1 3-dihydro-, (S)- ICASI	128196-01-0	<u> </u>	347066	Antidepressant
Femilin		531-75-9			
Eseridine		25573-43-7			
esmolol	Benzenepropanoic acid, 4-[2-hydroxy-3-{(1-methylethyl)amino]propoxy]-, methyl ester, (+/-)- [CAS]	81147-92-4	US	4387103	Antihypertensive, adrenergic
	Magnesium, bis (5-methoxy-2-(((4-				
•	methoxy-3;5-dimethyl-2- pyridinyl)methyl)sulfinyl)-1H-				
esomeorazole-magnesium		161973-10-0	i. sn	5877192	Antispasmodic
estazolam	4H-[1,2;4]Triazolo[4,3- a][1,4]benzodiazepine, 8-chloro-6-phenyl- [CAS]	29975-16-4	CS	3987052	Hypnotic/Sedative
estradiol	Androst-4-en-3-one, 17-hydroxy-, (17B)- [CAS]	58-22-0	US.	5460820	Formulation, transdermal, patch
estradiol	Estra-1,3,5(10)-triene-3,17-diol (178)- ICAS]	50-28-2	EP .	430491	Formulation, transdermal; systemic
Estramustine		2998-57-4			
	Estra-1,3,5(10)-triene-3,17-diol (178)-, 3- [bis(2-chloroethyl)carbamate] 17- /dihydronan phosshate) (OAS)	2998-57-4 4891-15-0 52205-73-9		· · · · · · · · · · · · · · · · · · ·	Anticancer, alkylating
Fetriol		50-27-1	·		
estroden		<u>.</u>	WO	9924041	Menopausal disorders
Estrone		53-16-7		:	
	1-Piperazinecarboxyllo acid, 4-methyl- 6-(5-chloro-2-pyridlnyl)-6,7-dihydro-7-oxo-5H-ournol3,4-bibvrazin-5-vl ester (S)- ICASI	138729-47-2	Š	5786357	Hypnotic/Sedative
eszopicionie	ואווסומלמי אואיותים או מיניין לאווסומלא		7		

	Example of Indication
supraventricular supraventricular supraventricular symptoms, symptoms, symptoms, symptoms,	
supraventricular supraventricular symptoms, symptoms, symptoms, symptoms,	
supraventricular supraventricular ohageal reflux symptoms, symptoms,	
supraventricular supraventricular hageal reflux symptoms, tate	Jeneral
supraventricular hageal reflux nction, female symptoms, tate symptoms,	
supraventricular hageal reflux hageal reflux symptoms, symptoms, symptoms,	
hageal reflux totion, female symptoms, symptoms,	supraventricular
hageal reflux totion, female symptoms, symptoms,	
ymptoms, ate	hageal reflux
ction, female ymptoms, ymptoms,	
ymptoms,	ction, female
ate symptoms,	ymptoms,
ate symptoms,	
ate symptoms,	
symptoms,	ate
	symptoms, ·
	-
	•

					•
			Pätent	٠.	
API Generic Name ··	API Chemical Name	CAS No.	Ref rence	93	Example of Therapeutic Use
		7681-79-0			
Ctafonono		90-54-0			
Etaminhullin.		314-35-2		•	
Etanoroont		185243-69-0			
Etanidazolo		22668-01-5			
Etamore		7432-25-9			
Etaydalono		27511-99-5			
Ethacridine		442-16-0			
Ethacumic Acid		58-54-8			
Ethadione		520-77-4			
Ethambutol		74-55-5	·		
Ethamivan		304-84-7			
Ethamsvlate		.2624-44-4			
Ethanolamine		141-43-5	:		
Ethaverine		486-47-5			
Ethehlorwaol		113-18-8			
Ethenzamide		938-73-8			
Ethiazide		1824-58-4			
Ethinamate		126-52-3	-)
Ethinvl Estradiol		57-63-6		.	
	19-Norpregna-1,3,5(10)-trien-20-yne-3,17- idiol; 3-(2-propanesulfonate), (17Alpha)-				
ethinyl estradiol sulfonate	[CAS]	28913-23-7	DE: 194	1949095	Formulation, modified-felease, >24nr
Ethionamide		536-33-4	-		
Ethisterone		434-03-7	-		
Ethoheptazine		77-15-6	-		
Ethopropazine		522-00-9			
Ethosuximide		77-67-8			
Ethotoin		86-35-1	1		
Ethoxzolamide		452-35-7	-	•	
Ethybenztropine .		524-83-4	+		
Ethyl Alcohol		64-17-5	- -	:	
Ethyl Biscoumacetate		548-00-5	-		\
Ethyl Chloride		75-00-3	+		
Ethyl Dibunate		2560-69-0	-		

			: · · _		· · · · · · · · · · · · · · · · · · ·
Example of Indication				Cancer, prostate	
	 •	•		•	•

		. •	Patent	ut.	
API Generic Name	API Chemical Name	CAS No.	Refe	Référence	Example of Therapeutic Use
Ethyl Eth r		60-29-7			
ethyl icosapentate	5,8,11,14,17-Eicosapentaenoic acid, ethyl. ester. (all-Z)- [CAS]	86227-47-6	<u>-</u>	61043143	Antithrombotic
	1H-1,4-Benzodiazepine-3-carboxylic acid,				
	7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-	00177-84.0	<u>u</u>	3657223	Anxiolytic
enly initiazepare	יייייייייייייייייייייייייייייייייייייי	20177.04.0	Т		
Ethyl Lotiazepate		2-111-04-5].		
Ethylamine .		75-04-7	\cdot		
Ethylene	•	74-85-1			
Ethyl strenol		965-90-2			
Ethylidene Dicoumarol		1821-16-5			
Ethylmethylthiambutene		441-61-2			
		٠			
Ethylmorphine		76-58-4			
Ethylnorepinephrine		536-24-3	· .		
		1231-93-2			•
ethynytcytidine	Uridine, 3'-C-ethynyl- [CAS]	180300-49-6	.ow	9618636	Anticarcer, antimetabolite
Etidocaine		36637-18-0			
	21-2-2009	2809-21-4			
etidronate disodium	, disodium salt- [CAS]	7414-83-7	ns	4137309	Osteoporosis treatment ·
Etidronic Acid		2809-21-4			
Etifelmin		341-00-4			
. disconnection	4H-3,1-Benzoxazin-2-amine, 6-chloro-N-	21715-46-8	Sn	3725404	Anxiolytic
Ftilefrin			1		
, cooperation	1. Turneine 3-hudravar uthul aster [CAS]	37178-37-3	. 8	5354885	Antiparkinsonian
eillevouopa			+	T	
	androsta-1,4-diene-17-carboxylic acid, 17- [(dichloroacetyl)oxy]-11-hydroxy-3-oxo-, ethyl ester, (118,17Alpha)-		, . ·	· · · · · · · · · · · · · · · · · · ·	
etiprednol dicloacetate		199331-40-3	_		GI inflammatory/bowel disorders
Etiroxate		17365-01-4		-	
Etizolam		40054-69-1		•	
etodolac	Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-[CAS]	41340-25-4	ŲŠ	3939178	Antiarthritic, other
Etodroxizine		17692-34-1			
Etodroxizine		1,036-04-1	1		

			Patent	Ħ	;
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	Benzoic acid, 2-([3- /trifiroromethyllohenyllaminol-, 2-(2-			•	
etofenamate .	hydroxyethoxy)ethyl ester [CAS]	30544-47-9	GB.	1285400	Anti-inflammatory, topical
	3-Pyridinecarboxylic acid, 2-{2-(4-		•••••	·. ·. :	
etofibrate	oxopropoxyjethyl ester [CAS]	31637-97-5	US.	3723446	Hypolipaemic/Antiatherosclerosis
Etofylline		519-37-9			
	Bonnanio poil 2.14 chilocopanovo).9.				. •
	methyl-, 2-(1,2,3,6-tetrahydro-1,3-dimethyl-	0.04.70.01	1	. 3000000	Hundinsemin/Antiathemsis
etofylline clofibrate	2,6-dioxo-/H-purin-/-yi)emyi ester [CAS]	13425-39-3	3	. 020000	1) pui pagiling ang ang ang ang ang ang ang ang ang a
Frontied Technical		1954-28-5			
Etomidate		33125-97-2			•
Etomidoline		21590-92-1		,	
Etonitazene		911-65-9		٠	•
	18,19-Dinorpregn-4-en-20-yn-3-one, 13-, ethyl-17-hydroxy-11-methylene, (17Alaha)-				
etonogestreľ	[CAS]	54048-10-1			Formulation, Implant
Etoperidone		52942-31-1			
			•		•
· ·	Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-		· :		. ·
	glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-5-				
·	[(4-hydroxy-3,5-dimethoxyphenyl)-, [5R- [5Alpha,5a8,8aAlpha,98(R*)]]- [CAS]	33419-42-0	GB	1205966	Anticancer, other
	Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-			.	
	6(5aH)-one, 5-{3,5-dimethoxy-4- (phosphonooxy)phenyl]-9-{(4,6-0-		•		. :
	ethylidene-3-D-glucopyranosyl)oxy]-				
etoposide phosphate	3,0,64,3-tellariyulo-, [3.7] [5Alpha,5aß,8aAlpha,98(R*)]]- [CAS]	117091-64-2	Е	302473	Anticancer, other
etoricoxib	2,3-Bipyridine, 5-chloro-6'-methyl-3-(4- Imethylsulfonyllphenyl) [CAS]	202409-33-4	NO M	9803484.	Antiarthritic, other
Etoxadrol		28189-85-7	j.		
Etozolin		.73-09-6		-	
	2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, ethyl	54250.48.0			Antiosoriasis
etretinate	lester, (all-t)- (OAS)	0-01-0000	3		

· · · · · · · · · · · · · · · · · · ·	•		
Example of Indication Inflammation, general		Contraceptive, female	Cancer, testicular Arthritis, osteo
	•	•	• •

		1			
			Patent	i.	
API G neric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Etryptamine :		2235-90-7			
Etymemazine	•	523-54-6		•	•
Eucatropine		100-91-4	Ĺ		
Eugenol		97-53-0			
	Manganese, chloro[[2,2-[1,2-ethanediylbis[(nitrilo-kappaN)methylldyne]]bis(6-kappaN)methylldyne]]bis(6-kappaN)methylldyne]]bis(6-kappaN)methylldynelynelyneg				
EUK-134 .	[[CAS]	81065-76-1	US.	6046188	Cardiovascular
EUK-189			SN	6046188	Radio/chemoprotective
Evan's Blue		314-13-6			
everolimus	Rapamycin, 42-O-(2-hydroxyethyl)- [CAS]	159351-69-6	WÓ	9409010	Immunosuppressant
éxalamide	Benzamide, 2-(hexyloxy)- [CAS]	53370-90-4	GB (726786	Antifungal,
Exalamid		53370-90-4			
Exametazime		105613-48-7			
	10H,13H-Benzo[de]pyrano[3',4':6;7]indolizino[1,2-b]quinoline-10,13-dione, 1-amino-9-ethyl-5-filuoro-1,2,3,9,12,15-hexahydro-9-hydroxy-		•		
exatecan mesylate	4-metnyl-, (15,95)-, monomethanesulfonate (sait) [CAS]	171335-80-1			Anticancer, other
ехетезтапе	Androsta-1,4-diene-3,17-dione, 6-methylene- [CAS]	107868-30-4	띰	3622841	Anticancer, hormonal
Exifone		52479-85-3			
exisulind	1H-Indene-3-acetic acid 5-fluoro-2-methyl-1-((4-(methylsulfonyl)phenyl)methylene)-, (2)- [CAS]	59973-80-7			Anticancer, other
Exosurf®		99732-49-7			
ezetimibe	2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- [CAS]	163222-33-1	Sn	5846966	Hypolipaemic/Antiatherosclerosis
Ezetimibe		163222-33-1			
Factor IX		9001-28-9			
Factor VIII		9001-27-8			

kample of Indication	Unspecified Chemotherapy-induced Injury, general Transplant rejection, general Infection, fungal, general	Cancer, pancreatic Cancer, breast Polyp	, rpercholesterolaemia
Exau	Unspeci Chemot general general Transpl Infection	Cance	. Ay

API Generic Name Factor XIII	•		Patent		•
ic Name	•				
	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
		9013-56-3			
-				•	
•	1H-Inden-5-ol, 2,3-dihydro-3-(1H-imidazol-			•	
fadolmidine	4-ylmethyl)-, monohydrochloride [CAS]	189353-32-0	Š Š	9712874	Analgesic, other
		102676-47-1			
	9.10-Secocholesta-5,7,10(19)-triene-				
	1,3,25-triol, 26,26,26,27,27,27-hexafluoro-,				
falecalcitriol ((1Alpha,38,5Z,7E)- [CAS] .	83805-11-2	٩,	03099022	Osteoporosis treatment
	1,3-Propanediol, 2-[2-(2-amino-9H-purin-9-	104007-87-4		61085388	Antiviral other
famciclovir .	ylenyl-, diacelate (ester); [cAs]		T		
	Propanimidamide, 3-[[[2-	•			.·
] (aminoiminomemy) arminoj-4- kris-atvimostrulikio] M. (aminostifond).	•			
is in the second of the second	(CAS)	76824-35-6	SO	4283408	Antiulcer
	4-pvridinamine	504-24-5			Neuroprotective
	-2)-Croning by live of the California (5-				
	3-Cullifolitiecal bodylic acid, 0-liaol 0-1 (0-			• •	
	1-piperazinyl-4-oxo monohydrochloride	164150-85-0	. '	· .	
fandofloxacin hydrochloride	ICASI		ns	5496947	Quinolone antibacterial
		114432-13-2			
rancolarone					
••	(5B.6S)-6-[1(R)-Hydroxyethyl]-2-[2(R)-		•	•	
	tetrahydrofuryll-2-penem-3-carboxylic acid-			•	
faropenem daloxate	5-methyl-2-oxo-1,3-dioxol-4-ylmethyl ester	•			Beta-lactam antibiotic
		•		٠	
	4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-		•••		
•	carboxylic acid, 6-(1-hydroxyethyl)-7-oxo-3-				-
	(tetrahydro-2-furanyl)-, monosodium salt,	122547-49-3		410727	Beta-lactam antibiotic
Taroperiei sociuii	1-Alanine N-[(2S)-3-(acetylthio)-2-(1,3-				
	benzodioxol-5-yimethyl)-1-oxopropyl]-,	•			
fasidotril	phenylmethyl ester [CAS]		ابت	419327	Antihypertensive, renin system
	1H-1,4-Diazepine, hexahydro-1-(5-	103745-39-7	ü	187371	Neuroprofective
	Isoquinolinyisalionyi)-[cxc]		T		
Fazadinium Bromide		48064-00-9	1		
	2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-{2- (aminocarbonyl)oxy]-3-butoxypropyi]-5-		٠.		
febarbamate	ethyl-5-phenyl- [CAS]	\cdot	3	30/3963	Psychosumoran
Febupro		3102-00-9			,

cample of Indication	perparathyroidism ection, gynaecological cer, duodenal inal cord injury	nfection, urinary tract	Infection, ocular Hypertension, general Vasospasm, general
Exar Pain,	Hyperpar Infection, Ulcer, due Spinal co	Infect	Infection, Hyperten Vasospa

e. methyl- [CAS] I, 2-i3-cyano-4-(2methyl- [CAS] acid [CAS] acid, 4-(2,3- fro-2,6-dimethyl-, c acid, Gamma- c acid, Gamma- io, 6-chloro- ydroxyphenyl)- [4-(1,3-	- ~	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
leric Name API Chemical Name 5-Thiazolecarboxylic acid, 2-i3-cyano-4-(2-methyl-ropoxyl)phenyl]-4-methyl- [CAS] 21he 1,3-Propanediol, 2-phenyl-, dicarbamate (CAS) 1,1-Biphenyl]-4-acetic acid (CAS) 1,1-Biphenyl]-4-acetic acid (CAS) 2,5-Pyridinedicarboxylic acid, 4-(2,3-dimethyl-ethyl methyl ester [CAS] 2,5-Pyridinedicarboxylic acid, 3-edimethyl-ethyl methyl ester [CAS] 2,5-Pyridinedicarboxylic acid, Gamina-oxo-[CAS] 2,1-Biphenyl]-4-butanoic acid, Gamina-oxo-[CAS] 2,1-Biphenyl]-4-butanoic acid, Gamina-oxo-[CAS] 2,1-Biphenyl]-4-butanoic acid, Gamina-oxo-[CAS] 2,3-4-5-terrahydro-1-(4-bytcoxyl-ethyl-1-chlorobenzoicloxol-5-ylmethyl]-1-chloro-2,3-4,5-terrahydro-1-(4-bytcoxyl-ethyl-1-chlorodioxol-5-ylmethyl]-1-chlorodiox	~ - ` , ` - - - - - - - - - 		Refer	rence	Example of Therapeutic Ose
5-Thiazolecarboxylic acid, 2-13-cyano-4-(2-methyl-propoxyl)phenylj-4-methyl- [CAS] [1, 1-Biphenyl]-4-acetic acid [GAS] [1, 1-Biphenyl]-4-butanoic acid, 4-(2,3-dichlorophenyl)-1,4-dilhydro-2,6-dimethyl-ethyl methyl ester [GAS] [1, 1-Biphenyl]-4-butanoic acid, Gamima-oxo-[CAS] [I, 1-Biphenyl]-4-butanoic acid, Gamima-oxo-(chorobenzoyl)phenoxyl-2-methyl-1-oxo-(chorobenzoyl)phenoxyl-2-(chorobenzoyl)phenoxyl-2-methyl-1-oxo-(chorobenzoyl)phenoxyl-2-(chorobenzoyl)phenoxyl-2-(chorobenzoyl)phenoxyl-2-(chorobenzoyl)phenoxyl-2-(chorobenzoyl)phenoxyl-2-(chorobenzoyl)phenoxyl-2-(chorobenzoyl)phenoxyl-2-(chorobenzoyl)phenoxyl-2-(chorobenzoyl)phenoxyl-2-(chorobenzoyl)phenoxyl-2-(chorobenzoyl)phenoxyl-2-(chorobenzoyl)phenoxyl-2-(chorobenzoyl)phenoxyl-2-(chorobenzoyl)phenoxyl-2-(chorobenzoyl)phenoxyl-2-(chorobenzoyl)phenoxyl-2-(chorobenzoyl-2-(chorobenzoyl-2-(chorobenzoyl-2-(chorobenzoyl-2-(chorobe		:	<u>·</u>		•
sine 1,3-Proparediol, 2-phenyl-, dicarbamate [CAS] 11,1-Biphenyl]-4-acetic acid, 4-(2.3-dichlorophenyl)-1,4-dilydro-2,6-dimethyl-ethyl methyl ester [CAS] 11,1-Biphenyl]-4-butanoic acid, 4-(2.3-dichlorophenyl)-1,4-dilydro-2,6-dimethyl-ethyl methyl ester [CAS] 11,1-Biphenyl]-4-butanoic acid, 3-5-pyridinedicarboxylic acid, 4-(2.3-dichlorophenyl)-4-butanoic acid, 3-(2.3-dichlorophenyl)-4-butanoic acid, 3-(2.3-dichlorophenyl)-4-butanoic acid, 3-(2.3-dichlorophenyl)-4-butanoic acid, 3-(4.4-dilydroxylehyl)-1-chlorophenzaephne-7,8-dichlorophenzaephne-7,8-d	` 			•	•
ine thylpropoxy)phenyl-4-methyl- [CAS] ine 1,3-Propanediol, 2-phenyl-, dicarbamate [CAS] in 1-Biphenyl-4-acetic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-ethyl methyl ester [CAS] ssin (1,1-Biphenyl)-4-butanoic acid, 4-(2,3-dichlorophenyl)-4-butanoic acid, 2-(3-dimethyl-ethyl methyl ester [CAS] if a (1,1-Biphenyl)-4-butanoic acid; Gamima-oxo- [CAS] if a (1,1-Biphenyl)-4-butanoic acid; Gamima-oxo- [CAS] if a (1,1-Biphenyl)-4-butanoic acid; Gamima-oxo- [CAS] if a (1,1-Biphenyl)-4-butanoic acid; Gamima-oxo- [CAS] if a (1,1-Biphenyl)-4-butanoic acid; Gamima-oxo- [CAS] if a (1,1-Biphenyl)-4-butanoic acid; Gamima-oxo- [CAS] if a (1,1-Biphenyl)-4-butanoic acid; Gamima-oxo- [CAS] if a (1,1-Biphenyl)-4-butanoic acid; Gamima-oxo- [CAS] if a (1,1-Biphenyl)-4-butanoic acid; Gamima-oxo- [CAS] if a (1,1-Biphenyl)-1- if a (1	- - 		•		
ine 1,3-Propanediol, 2-phenyl-, dicarbamate [CAS] [CAS] [1,1'-Biphenyl]-4-acetic acid [GAS] [1,1'-Biphenyl]-4-butanoic acid, Garrimate acid, GAS] [1,1'-Biphenyl]-4-butanoic acid, Garrimatoxo- [CAS] [1,1'-Biphenyl]-4-butanoic a		144060-53-7	8	9209279	Antigout
Ine 1,3-Propanediol, 2-phenyl-, dicarbamate [CAS] [CAS] [1,1'-Biphenyl]-4-acetic acid [GAS] 3,5-Pyridiradicarboxylic acid, 4:(2,3-dichlorophenyl)-1,4-dilydro-2,6-dimethylethyl methyl methyl ester [CAS] all [1,1'-Biphenyl]-4-putanoic acid, Garrimacoxo-[CAS] all [1,1'-Biphenyl]-4-putanoic acid, Garrimacoxo	1	123618-00-8	•		
1.3-Propanediol, 2-prentyr, urdanoaniana 1.3-Propanediol, 2-prentyr, urdanoaniana 1.3-Propanediol, 2-prentyr, urdanoaniana 1.3-Propanediol, 2-prentyl acid, 4-(2.3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-title 1.1-Biphenyl]-4-butanoic acid, Gamma-oxo-[CAS] 1.1-Biphenyl]-2-methyl-1-methylethyl ester [CAS] 1.1-Biphenyl]-1- 1.3-Benzazepine-7,8-diol, 6-chloro-2,3-4,5-tetrahydro-1-(4-hydroxyphenyl)-1- 1.0H-Phenothiazine, 10-[[4-(1,3-benzodioxol-5-ylmethyl]-1- 1.3-benzodioxol-5-ylmethyl]-1- 1.3-benzodioxol-5-				:	
(1,1'-Biphenyl]-4-acetic acid [CAS] (1,1'-Biphenyl]-4-acetic acid [CAS] (1,1'-Biphenyl]-4-butanoic acid; Gamina-oxo-[CAS] (1,1'-Biphenyl]-4-butanoic acid; Gamina-oxo-oxo-[CAS] (1,1'-Biphenyl]-2-methyl-1-oxo-oxo-oxo-oxo-oxo-oxo-oxo-oxo-oxo-o		25451-15-4	· Sn	4868327	Antiepileptic
1,1,1-Biphenyl,4-acetic acid LAS) 3,5-Pyridinedicarboxylic acid, 4:(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-ethyl methyl ester [CAS] 2,5-Pyridinedicarboxylic acid, 4:(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-ethyl methyl ester [CAS] 1,1-Biphenyl]-4-butanoic acid; Gamima-oxo-[CAS] 1,1-Biphenyl]-4-butanoic acid; Gamima-oxo-[CAS] 1,1-Biphenyl]-4-butanoic acid; Gamima-oxo-[CAS] 1,1-Biphenyl]-2-methyl-1,1-methylethyl ester [CAS] 1,1-3-Benzazepine-7,8-dioi, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1 1,0H-Phenothiazine, 10-[[4-(1,3-benzodioxol-5-ylmethyl]-1-		:	G	197840	Anti-inflammatory, topical
is,5-Pyridiredicarboxylic acid, 4:(2,3-dihelthyl-ethyl methyl ester [CAS] ssln tine ic Acid ic Acid in Heranine ic Acid in Heranine it Acid in Heranine it Acid in Heranine it Acid in Heranine it Acid in Heranine it Acid		2/20-32-9		T	
ssin titue cethyl methyl ester [CAS] azate ira Acid all filine inc Acid amine tollorobenzoyl)phenoxy-2-methyl-1-chloro-2,0-dimennyl-4-butanoic acid; Gamina-oxo- [CAS] amine ita Acid filine amine froganoic acid, 2-4-(4-chloro-2,3-4,5-tetrahydro-1-(4-hydroxyphenyl)-1-chlorobenzoyl)phenoxyl-2-methyl-1-chlorobenzoyl)phenoxyl-2-methyl-1-chlorobenzoyl)phenoxyl-2-methyl-1-chlorobenzoyl)-1-chlorobenzoyl)phenoxyl-2-methyl-1-chlorobenzoyl)phenoxyl-2-methyl-1-chlorobenzoyl)phenoxyl-2-methyl-1-chlorobenzoyl)phenoxyl-2-methyl-1-chlorobenzoyl)phenoxyl-2-ylmethyl)-1-chlorobenzoyl)phenoxyl-2-ylmethyl)-1-chlorobenzoyl)phenoxyl-2-ylmethyl)-1-chlorobenzoyl)phenoxyl-2-ylmethyl)-1-chlorobenzoyl)-1-chlorobenzoyloxyl-2-ylmethyl-1-chlorobenzoyloxyl-2-ylmethyl-1-chlorobenzoyloxyl-2-ylmethyl-1-chlorobenzoyloxyl-2-ylmethyl-1-chlorobenzoyloxyl-2-ylmethyl-1-chlorobenzoyloxyl-2-ylmethyl-1-chlorobenzoyloxyl-2-ylmethyl-1-chlorobenzoyloxyl-2-ylmethyl-1-chlorobenzoyloxyl-2-ylmethyl-1-chlorobenzoyloxyl-2-ylmethyl-1-chlorobenzoyloxyl-2-ylmethyl-1-chlorobenzoyloxyl-2-ylmethyl-1-chlorobenzoyloxyl-1-chlorobenzoyloxyl-1-chlorobenzoyloxyl-1-chlorobenzoyloxyl-1-chlorobenzoyloxyl-1-chlorobenzoyloxyl-1-chlorobenzoyloxyl-1-chlorobenzoyloxyl-1-chlorobenzoylo	arboxylic acid, 4:(2,3-	•	•	• .	•••
ssin titue citilin citilin citilin citiline citili	_		<u>v</u>	4284B11	Antihypertensive, other ··
titne lcillin (1,1'-Biphenyl]-4-butanoic acid; Gamina- oxo- (CAS) voc (CAS		2	Т		
itine icillin icillin icilin icin-Biphenylj-4-butanoic acid; Gamima- oxo- [CAS] irine icic Acid icic Acid all icic Acid ic		7-69-96		-	
cillin (1,1'-Biphenyl]-4-butanoic acid; Gamina- cxo- (CAS] cxo- (CAS) cxo		59859-58-4			
razate razate razate razate ric Acid al filine smine ric Acid ric A		1926-48-3	7		-
oxo- [CAS] Interpolation Interpola			<u>`</u>	. 1077476	Anti-inflammatorv
ifamine line sir Acid line all line line all line line all line line line line all line line line line line line line li	• • •		-1	2010	, , , , , , , , , , , , , , , , , , ,
Propanoic acid, 2-[4-(4-chlorobenzoyi))phenoxy]-2-methyl-, 1-methylethyl ester [CAS] 1H-3-Benzazepine-7,8-djol, 6-chloro-2,3-4,5-tetrahydro-1-(4-hydroxyphenyl)-[CAS] 10H-Phenothiazine, 10-[[4-(1,3-benzodioxol-5-ylmethyl)]-1-		4378-36-3			
Propanoic acid, 2-[4-(4-chlorobenzoyi))phenoxy]-2-methyl-, 1-methylethyl ester [CAS] 1H-3-Benzazapine-7,8-diol, 6-chloro-2,3-4,5-tetrahydro-1-(4-hydroxyphenyl)-[CAS] 10H-Phenothiazine, 10-[[4-(1,3-benzodioxol-5-ylmethyl)]-1-		1209-98-9	1	·	
Propanoic acid, 2-[4-(4-chlorobenzoyi))phenoxy]-2-methyl-, 1-methylethyl ester [CAS] 1H-3-Benzazapine-7,8-diol, 6-chloro-2,3-4,5-tetrahydro-1-(4-hydroxyphenyl)-[CAS] 10H-Phenothiazine, 10-[[4-(1,3-benzodioxol-5-ylmethyl)-1-		28947-50-4			
Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxyl-2-methyl-, 1-methylethyl ester [CAS] 1H-3-Benzazepine-7,8-diol, 6-chloro-2,3-4,5-tetrahydro-f-(4-hydroxyphenyl)-[CAS] 10H-Phenothiazine, 10-[[4-(1,3-benzodioxol-5-ylmethyl)-1-		17969-20-9			
Propanoic acid, 2-{4-(4-chlorobenzoyl)phenoxyl-2-methyl-, 1-methylethyl ester [CAS] 1H-3-Benzazepine-7,8-diol, 6-chloro-2,3-4,5-tetrahydro-f-(4-hydroxyphenyl)-[CAS] 10H-Phenothiazine, 10-[[4-(1,3-benzodioxol-5-ylmethyl)-1-		13042-18-7			
Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester [CAS] 1H-3-Benzazepine-7,8-diol, 6-chloro-2,3-4,5-tetrahydro-1-(4-hydroxyphenyl)-[CAS] 10H-Phenothiazine, 10-[[4-(1,3-benzodioxol-5-ylmethyl]-1-		53597-27-6	•		
Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester [CAS] 114-3-Benzazepine-7,8-diol, 6-chloro-2,3-4,5-tetrahydro-1-(4-hydroxyphenyl)-[CAS] 10H-Phenothiazine, 10-[[4-(1,3-benzodioxol-5-ylmethyl)-1-		3736081			
Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester [CAS] 1H-3-Benzazepine-7,8-diol, 6-chloro-2,3-4,5-tetrahydro-1-(4-hydroxyphenyl)-[CAS] CAS] 10H-Phenothiazine, 10-[[4-(1,3-benzodioxol-5-ylmethyl)-1-		458-24-2			
Propanoic acid, 2-{4-(4-chlorobenzoyi)phenoxyl-2-methyl-, 1-methylethyl ester [CAS] 1H-3-Benzazepine-7,8-diol, 6-chloro-2,3-4,5-tetrahydro-1-(4-hydroxyphenyl)-[CAS] CAS] 10H-Phenothiazine, 10-[[4-(1,3-benzodioxol-5-ylmethyl)-1-		583-03-9			
Propanoic acid, 2-{4-(4- chlorobenzoyi)phenoxy]-2-methyl-, 1- methylethyl ester [CAS] 1H-3-Benzazepine-7,8-diol, 6-chloro- 2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)- [CAS] 10H-Phenothiazine, 10-[[4-(1,3- benzodioxol-5-ylmethyl)-1-		2000	1		
1H-3-Benzazepine-7,8-diol, 6-chloro-2,3.4,5-tetrahydro-1-(4-hydroxyphenyl)-[CAS] [CAS] 10H-Phenothiazine, 10-[[4-(1,3-benzodioxol-5-yimethyl)-1-	•	26129-32-8 49562-28-9		• •	Formulation, modified-release, <=24hr
en (CAS) CAS	oine-7,8-diol, 6-chloro-				•
len IOH-Phenothiazine, 10-[[4-(1,3-benzodioxol-5-ylmethyl)-1-		٠.			Antihinadansive Other
10H-Phenothiazine, 10-[[4-(1,3-benzodioxol-5-yimethyl)-1-	7		1	22330	Anunypenensive, ones
		31879-05-7			
		13392-18-2			
benzodioxol-5-yimethyl)-1-	zine, 10-[[4-(1,3-		_		
	::·	37561-27-6	Œ	2092639	Antispasmodic
tenoverine tenoverine		1848-01.7			
Fenoxazoline		0 00 0000			
Fenoxedii		240p3-40-0			

API Generic Name						
CAS No. Reference 15302-16-6 15302-1		:		Pate	z	•
15302-16-6 15302-16-6 15302-16-6 15302-16-6 15302-16-6 15302-18-0 153		API Chemical Name	CAS No.	Refe	rence	Example of Therapeutic Use
15687-18-0 15687-18-0 15687-18-0 15687-18-0 15687-18-0 15687-18-0 15687-18-0 15686-61-0 15686-61-0 15686-61-0 15686-61-0 15686-61-0 15686-61-0 15686-61-0 15687-37-0 15687-37-0 15687-37-0 15687-37-0 15687-37-0 15687-37-0 15687-37-0 15687-37-0 15687-37-0 15687-37-0 15687-38-7 15687-37-0 15687-37-0 15687-37-0 15687-38-7 15687-38-7 15687-38-7 15687-38-7 15687-38-7 15687-38-7 15687-38-9 156			15302-16-6			
125-60-0 125-60-0	Earnentadiol		15687-18-0		•	
125-60-0 125-60-0	Feminiane		3540-95-2			
15686-61-0 156			125-60-0	·		
15686-61-0 156						
Early Earl	Fenoroporex		15686-61-0			
Propanamide, N-(4-hydroxyphenyl)- [CAS] 65648-68-6 BE 847942	Fenguizone		20287-37-0		•	
Fropanamide, N-phenyl-N:11-(2-phenylethyl)-4-piperidinyl-(CAS) 437-38-7		Betinamide N-(4-hydroxyohenyi)- [CAS]	65646-68-6		847942	Anticancer, other
## ## ## ## ## ## ## ## ## ## ## ## ##			5053066			
Propanamide, N-phenyl-N-[1-(2-) 437-38-7 18046-21-4 18046-21-4 18046-21-4 18046-21-4 18046-21-4 18046-21-4 18046-21-4 18046-21-4 18046-21-4 18046-21-4 18046-21-4 18046-21-4 18046-21-4 18046-21-4 18046-21-4 18046-21-4 18046-21-4 18046-21-6 18046-21-6 18046-21-6 18046-21-	Fontany		437-38-7			
18046-21-4 97-24-5 97-24-5 14-(phenylthio)phenylmethoxylethyl)-2- 12479-26-6 124-(phenylthio)phenylmethoxylethyl)- 73151-29-8 US 4221803 124-(phenylthio)phenylmethoxylethyl)- 73151-29-8 US 4221803 124-(phenylthio)phenylmethoxylethyl)- 12479-26-6 12479-26-6 12704-50-1 12708-41-5 1270	ota.	Propanamide, N-phenyl-N-[1-(2- phenylethyl)-4-piperidinyl]- [CAS]	437-38-7			Formulation, transmucosal, systemic
11-1midazole, 1-[2-(2,4-dichlorophenyl)-2- 12-(2,4-dichlorophenyl)-2- 12-(1-2-(2,4-dichlorophenyl)-2- 12-(2,4-dichlorophenyl)-2- 12-(2,4-dichlorophenyl)-2- 12-29-8 US 4221803 12-29-8 US 4221803 12-29-8 US 4221803 12-29-8 US 4221803 12-29-9 US 4221803 12-29-29-6 US 4221803 US 422180			18046-21-4			
H+Imidazole, 1-[2-(2,4-dichlorophenyl)-2- 72479-26-6 124-(phenylthio)phenylmethoxylethyl- 73151-29-8 U.S. 4221803 134-(phenylthio)phenylmethoxylethyl- 73151-29-8 U.S. 4221803 13151-29-8 U.S. 4221803 13151-29-8 U.S. 4221803 13151-29-8 U.S. 4221803 13151-29-8 U.S. 4221803 U.S. 44-5-10-45 13151-39-8 U.S. 44-5-10-5-10-5 13151-39-8 U.S. 44-5-10-5-10-5 13151-39-8 U.S. 44-5-10-5-10-5-10-5-10-5-10-5-10-5-10-5-	E nticlor		97-24-5	·		
Benzenemethanol, Alpha-II(2-h)ydroxy-1,1- 36981-91-6 dimethylethylaminolmethyll-, (+/-)- [CAS] 67704-50-1 dimethylethylaminolmethyll-, (+/-)- [CAS] 67704-50-1 dimethylethylaminolmethyll-, (+/-)- [CAS] 67704-50-1 dimethylethylaminolmethyll-, (+/-)- [CAS] 67704-50-9 dimethylethyllaminolmethyll-, (+/-)- [CAS] 67704-50-9 dimethyllaminolmethyll-, (+/-)- [CAS] 67704-50-9 dimethyllaminolmethyllaminolmethyllaminolmethyllaminolmethyllaminolmethyllaminolmethyllaminolmethyllaminolmethyllaminolmethyllaminolmethyllaminolmethyllaminolmethyllaminolmethyllaminolmethyllaminolme		1H-Imidazole, 1-[2-(2,4-dichlorophenyl)-2- [[4-(phenyithio)phenyl]methoxylethyl]-	72479-26-6 73151-29-8		4221803	Antifungal
Benzenemethanol, Alpha-I[(2-hydroxy-1,1- 36981-91-6 dimetry/ethy/)aminojmethy/j-, (+/-)-, [CAS] 67704-50-1 dimetry/ethy/)aminojmethy/j-, (+/-)-, [CAS] 67704-50-1 630775-47-8 30748-29-9 15708-41-5 WO 9426263 Junate 1336-80-7 1336-80-7 Sultane Polyglucose sorbitol carboxymethy/ ether-coated non-stoichiometric magnetite 299-29-6 Polyglucose sorbitol carboxymethy/ ether-coated non-stoichiometric magnetite 2-((1R)-3-(bis(1-methy/ethy/)amino)-1-pheny/propy/)-4-(hydroxymethy/)Pheny/ ester. (2E)-2-butenedioate (1:1) (Salt).	ide	i local	5868064			
Control of the cont		- 1- North 199 H. P. H. P. L.	96081-01-6		. :	<i>:</i> ·
Control Cont		dimethylethyl)amino]methyll-, (+/-)- [CAS]	67704-50-1			Anti-inflammatory, topical
## State 15708-41-5 15708-41-5 15708-41-5 15708-41-5 1336-80-7 133	joi		63075-47-8	•		
Edetate 15708-41-5 WO 9426263 nate 1336-80-7 Polyglucose sorbitol carboxymethyl ether-coated non-stoichlometric magnetite 2-((1R)-3-(bis(1-methylethyl)mnino)-1-phenylpopyl)-4-(hydroxymethyl)Phenyl ester, (2E)-2-butenedioate (1:1) (Salt)-	Febrazone		30748-29-9	٠		
nate Polyglucose sorbitol carboxymethyl ether-coated non-stoichlometric magnetite 2-((1R)-3-(bis(1-methyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)Phenyl ester, (2E)-2-butenedioate (1:1) (Salt)-	um E		15708-41-5			
nate Polyglucose sorbitol carboxymethyl ether-coated non-stoichlometric magnetite 2-((1R)-3-(bis(1-methylethyl)Phenyl ester, (2E)-2-butenedioate (1:1) (Salt).	i				9426263	Septic shock treatment
Polyglucose sorbitol carboxymethyl ether-coated non-stoichlometric magnetite 2-((1R)-3-(bis(i-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)Phenylester. (2E)-2-butenedioate (1:1) (Salt)-	Ferrocholinate		1336-80-7			
Polyglucose sorbitol carboxymethyl ether- coated non-stoichiometric magnetite 2-((1R)-3-(bis(1-methylethyl)amino)-1- phenylpropyl)-4-(hydroxymethyl)Phenyl ester. (2E)-2-butenedioate (1:1) (Satt).	Ferrous Gluconate		299-29-6			
coated non-stoichiometric magnetite 2-((1R)-3-(bis(1-methylethyl)amino)-1- phenylpropyl)-4-(hydroxymethyl)Phenyl ester, (2E)-2-butenedioate (1:1) (Satt)-		Polyglucose sorbitol carboxymethyl ether-	٠			
2-((1R)-3-(bis(1-methylethyl)armino)-1- phenylpropyl)-4-(hydroxymethyl)Phenyl ester, (2E)-2-butenedioate (1:1) (Satt).	ferumoxytol	coated non-stoichiometric magnetite	·	•		Imaging agent
		2-((1R)-3-(bis(1-methylethyl)amino)-1- phenylpropyl)-4-(hydroxymethyl)Phenyl		•		
286930-03-8		ester (ZE)-Z-buterredoa's (1.1) (San). [CAS]	286930-03-B			Urological

_•							•		:								•				.		<u>.</u>	
· ·	le of Indication	•	•					breast .		-	esia, adjunct	:		1, gynaecological		•		tory distress syndrome,			•	sls; cancer		rence - · ·
	Example			:	:	<u>. </u>		Cancer			Anaesthesia,		·	Infection,	<u> </u>			Respiratory	ing .		•	Diagnosis;		Incontinence

		•	Patent		
API Generic Nam	API Chemical Name	CAS No.	Reference	ence.	Example of Therapeutic Use
Fexofenadine		83799-24-0			
	Benzeneacetic acid, 4-[1-hydroxy-4-		•	•	
	[4(hydroxydiphenylmethyl)-1- piperidinyljbutyl]-Alpha,Alpha-dimethyl-,	153439,40-8	<u> </u>	5375693	Antiallergic, non-asthma
fexofenadine HCI	nydrochioride (CAS)		1	ŀ	
•	Benzeneacetic acid, 4-[1-hydroxy-4- [4(hydroxydlphenylmethyl)-1-	0.00		•	
fevotenadine	piperidinyijbdryij-Alpha;Alpha-uirieuryi- Invdrochloride [CAS]	153439-40-8			Formulation, modified-release, <=24hr
Fibrostat		·	CA	2132416	Vulnerary
	-\enimidazolidine\-			.:	
	Spilot 413-1-06125/pyrati 7-7-mindaening 2,5-2-carboxamide, 6-fluoro-2,3-difydro-2,5-	136087-85-9		418834	Symptomatic antidiabetic
ildar estat	יייייייייייייייייייייייייייייייייייייי	ŀ	-		
	8-Phenyl-3-[4-[(3aR,9bR)-1,3a,4,9b-				
	tetrahydro-9-methoxy[1]benzopyrano[3,4-		-		
	c]pyrrol-2(3H)- vilbutvilovrazino[2, 3:4.5]thieno[3.2-	•	;-	•	
•	djpyrimidine-2,4(1H,3H)-diane				
fiduxosin		208993-54-8	+		Prostate disorders
	4-Azaandrost-1-ene-i17-carboxamide, N-			• •	
finasteride	(CAS)	98319-26-7	EP	155096	Prostate disorders
	Benzonitrile, 4-(3-(4-fluorophenyl)-2-		•	· · :	· .
fiorozolo	hydroxy-1-(1H-1,2,4-triazor-1-yi)-propyi)- ICASi	160146-16-7	4	476944	Urological .
Finexide .		34161-24-5			
	N-(4-Acetyl-1-piperazinyl)-4-	133920-70-4	<u>. 6</u> 0M	9101979	Cognition enhancer
Flavonithol		146426-40-6			
riavopinaci	4H-1-Benzopyran-8-carboxylic acid, 3-	٠			
	methyl-4-oxo-2-phenyl-, 2-(1-	15301-69-6 3717-88-2	US 22	2921070	Urological
liavoxate .	· · · · · · · · · · · · · · · · · · ·	15301-69-6	-		
Flavokate		54143-55-4			
- Lecanne	Benzamide,N-(2-piperidinylmethyl)-2,5-		 		
. Of states of chinically	bis(2,2,2-trifluoroethoxy)-,monoacetate	54143-55-4 54143-56-5		•	Formulation, modified-release, <=24hr
necaling acciate, On	(2,12)				

Example of Indication Rhinitis, allergic, seasonal Wound healing Neuropathy, diabetic	Benign prostatic hyperplasia Benign prostatic hyperplasia Urinary retention Alzheimer's disease

API Chemical Name						
API Chemical Name				Pate	int	
3-Guinolinecarboxylic acid, 6;8-difluoro-1- (2-fluoroethy)-1,4-dividor-7;(4-methyl-1- piperaziny)-4-oxo-[CAS] 2Pt-Benzimidazol-2-one, 1,3-dihydro-1-(2- (4-(3-(trifluoromethyl))pipenyl)-1- piperaziny)-gasinylethyl- [CAS] Benzol acid, 2-[B-(trifluoromethyl))-4- quinolinylaminol-, 2,3-dihydroxypropyl setr [CAS] Benzol acid, 7- [[[(difluoromethylhi)-acetyl aminol-3-[[[1-]]]- (2-hydroxyethyl)-1H-tetrazol-5- yilthio methylyl-7-methoxy-8-oxo-, (6R-cis) 99665-00-6 [(CAS] CAS] Androst-6-sh-17-one, 16-fluoro-, (16Alpha), 112869-71-9 SPH-Pregma-1,4-flenol[17,16-d]oxazole-1- hydroxy-2-methyl-, (116,169)- [CAS] Special-3-3-8-3-1- HH-1,2,4-Triazole-1-eithanol, Alpha-(24-1) yimethyl-(CAS] Special-3-3-3-4- HH-1,2,4-Triazole-1-eithanol, Alpha-(24-1) yimethyl-(CAS] Special-3-3-3-4- HH-1,2,4-Triazole-1-eithanol, Alpha-(24-1) yimethyl-(CAS] yimethyl-(CAS] Special-3-3-4- piperazinyl-3-4- piperazinyl-1-1- piperazinyl-3-4- piperazinyl-1-1-1- piperazinyl-1-1-1-1- piperazinyl-1-1-1-1- piperazinyl-1-1-1-1-1- piperazinyl-1-1-1- piperazinyl-1-1-1-1-1- piperazinyl-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1	API Generic Name	API Chemical Name	CAS No.	Refe	rence	Example of Therapeutic Use
Carlouroeury Carl		3-Quinolinecarboxylic acid, 6,8-difluoro-1-	79Å60-53-0			
2H-Benzimidazol-2-one, 1,3-dihydro-1-(2-) 2H-Benzimidazol-2-one, 1,3-dihydro-1-(2-) 4-(3-ttrilluoromethyl)plenyl)-1- 167933-07-5 167933-07-5 167933-07-5 167933-07-5 167933-07-5 167933-07-5 167933-07-5 167933-07-5 167933-07-5 167933-07-5 167933-07-5 167933-07-5 167933-07-5 167933-07-5 167933-07-5 167933-07-5 167933-07-5 167933-07-5 167933-07-5 16793-07-5 1673-07-5 1	fleroxacin	piperazinvl)-4-oxo-[CAS]	79660-72-3	ns	4398029	Quinolone antibacterial
2H-Benzimidazoi-2-one, 1,3-dihydro-1-(2- (4-(3-(trifluoromentyl)phenyl)-1- pipeiazinyljethyl)-1-(SAS) Benzoie ecid, 2-[[8-(trifluoromethyl)-4- quinolinyljamino]-2,3-dihydroxypropyl ester [OAS] 5-Oxa-1-azabicyzlold, 2,0joct-2-ene-2- carbóxyic acid, 7- [[[(difluoromethyl)thiojaceyljamino]-3-[[[]	Flesinoxan		98206-10-1			
(4-(3-(trifluoromentyl)phenyl)-1- pipeirazinyl)athyl)-1[GAS] Benzole acid, 2-[[B-(trifluoromethyl)]-4- quinolinylamino]-,2,3-dihydroxypropyl gate (GAS) 5-Oxa-1-azabicyclo(4,2.0]pot-2-ene-2- carbóxylic acid, 7- [[(difluoromethyl)thio]aceyl/lamino]-3-[[[1-]		2H-Benzimidazol-2-one, 1,3-dihydro-1-(2-	-			
pipeirazinyljethyl)-[GAS] Benzolc acid, 2-[B-(trifluoromethyl)-4-cquinolinyljaminoj-2,3-dilydroxypropyl estle (GAS] 5-Oxa-1-azabicyclof 2.0joct-2-ene-2-carboxylic acid, 7-[(difluoromethyl)thio]acetyljaminoj-3-[[[1-6]]-6]-6-carboxylic acid, 7-[(2-tydioxyethyl)-1H-tetrazol-5-yilthio]methyl]-7-methoxy-8-oxo-, (6R-cis)-92823-03-6-carboxylic acid, 7-[(GAS]-6]-6-carboxylic		(4-(3-(trifluoromethyl)phenyl)-1-		•		
Benzolo acid, 2-[IB-(trifluoromethyl) 4- cuinolinylamino]-, 2,3-dihydroxypropyl cate CAS 23779-99-9 US 3644368 5-Oxa-1-azabicyclo[4.2 6]oct-2-ene-2- carboxylic acid, 7. [[(dilluoromethyl)tho]acetyl]amino]-3-[[[1-] 92823-03-5 (2-hydroxyethyl)-1H-tetrazol-5- yilthio]methyl]-7-methoxy-8-oxo-, (6R-cls) 99665-00-6 (2-hydroxyethyl)-7-methoxy-8-oxo-, (6R-cls) 99665-00-6 (2-hydroxyethyl)-7-methoxy-8-oxo-, (6R-cls) 99665-00-6 (2-hydroxyethyl)-7-methoxy-8-oxo-, (6R-cls) 99665-00-6 (2-hydroxyethyl)-7-methoxy-8-oxo-, (6R-cls) 99655-00-6 (2-hydroxyethyl)-7-methoxy-9-fluoro-1 1480-19-9 (2-hydroxyethyl)-1-chenol, Alpha-(2,4- chycloxyethyl-1-chenol, Alpha	flibanserin	piperazinyl)ethyl)- [CAS]	167933-07-5		•	Reproductive/goriada, general
ester (coxylic acid, 7-corr) yearnowy (GR-cis) ester (carboylic acid, 7-corr) yearnowy (GR-cis) ester (carboylic acid, 7-corr) yearnowy (GR-cis) ester (CAS) (GR-cis) ester (CAS) (GR-cis) ester (CAS) (GR-cis) ester (CAS) (GR-cis) ester (CAS) (GR-cis) ester (CAS) (GR-cis) ester (GAS)		Benzolo acid, 2-[[8-(trifluoromethyl)-4-			· .	
5-Oxa-1-azablcyclo[4.2.6]oct-2-ene-2- carboxylic acid, 7- [[[(difluoromethyl)thio]acetyl]amino]-3-[[[1- (2-hydroxyethyl)-1H-tetrazol-5- ylithio]methyll-7-methoxy-8-oxo-, (6R-cis)- [CAS] [CASA-1-2-1-2-1-2-1-2-1-2-1-2-1-2-1-2-1-2-1-	floctafenine	ester [CAS]	23779-99-9	SD	3644368	Analgesic, NSAID
(2-hydroxyethyl)-1H-tetrazol-5- yijthio methyl-1H-tetrazol-5- yijthio methyl-7-methoxy-8-oxo-, (6R-cis)- 92823-03-5 EP 128536 (2-hydroxyethyl)-1H-tetrazol-5- 99665-00-6 EP 128536 (2-hydroxyethyl)-1H-tetrazol-5- 99665-00-6 EP 128536 (2-hydroxyethyl)-7-methoxy-8-oxo-, (6R-cis)- 99665-00-6 EP 128536 (2-hydroxyethyl)-1H-tetrazol-1-9-9 76568-02-0 (2-hydroxyethyl)-1H-tetrazol-1-9-9 76568-02-0 (2-hydroxyethyl-1H-tetrazol-1-9-9 76568-02-0 (2-hydroxyethyl-1H-tetrazol-1-9-9-9-9-9-9-9-9-9-9-9-9-9-9-9-9-9-9-		5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-				· · · · ·
[[[(difluoromethyl)thio]acetyl]amino]-3- [[1-] ([2-hydioxyethyl)-T-methoxy-8-oxo-, (6R-cis)- yi[thio]methyl]-7-methoxy-8-oxo-, (6R-cis)- yi[thio]methyl]-1-methyl-, (116,163)- [CAS] yi[thio]methyl]-1-methyl-, (116,163)- [CAS] yi[thio]methyl]-1-methyl-, (116,163)- [CAS] yi[thio]methyl]-1-methyl-, (116,163)- [CAS] yi[thio]methyl]-1-methyl-, (116,163)- [CAS] yi[thio]methyl]-1-methyl-, (116,163)- [CAS] yi[thio]methyl]-1-methyl-, (116,163)-1-0- yi[thio]methyl-, (116,163)-1-0-0- yi[thio]methyl-, (116,163)-1-0-0- yi[thio]methyl-, (116,163)-1-0-0- yi[thio]methyl-, (116,	•	carboxylic acid, 7-				
(2-hydroxyethyl)-1H-tetrazol-5- yijthio]methylj-7-methoxy-8-oxo-, (6R-cis)- yijthio]methylj-7-methoxy-8-oxo-, (6R-cis)- yijthio]methylj-7-methoxy-8-oxo-, (6R-cis)- yijthio]methylj-7-methoxy-8-oxo-, (6R-cis)- yijthio]methylj-7-methoxy-8-oxo-, (6R-cis)- yimethylj-[CAS]		[[[(difluoromethyf)thio]acetyf]amino]-3-[[[1-				- ·
yljthiolmethyll-7-methoxy-8-oxo-, (6R-cis)-, 92823-03-5 [EP 128536 99665-00-6 [EP 128556 99665-00-					•.	
[CAS] 99665-00-6 P. 128330 99665-00-6 P. 128330 99665-00-6 P. 128330 P. 1283330 P. 128330 P. 1283330 P. 128330 P. 128330 P. 128330 P. 1283330 P. 1283330 P]methyl]-7-methoxy-8-oxo-, (GR-cis)-	92823-03-5		4000	. والمعلومات الشويسوماولات
99665-00-6 2295-58-1 519-95-9 76568-02-0 76568-0 76568-0 76568-0 76568-0 76568-0 76568-0 76568-0 76568-0 76568-0 76568-0 76568-0 76568-0 76680 76680 76680 76680 76680 76680 76680	flomoxef ·	[CAS]	9-00-59966	tí	128536	Cepnalospolin, injectable
2295-58-1 519-95-9 76568-02-0 76568-0 76680 766	Flomoxef		99665-00-6			
519-95-9 76568-02-0 76568-02-0 5250-39-5 50-91-9 700-91-9	Flopropione		2295-58-1			
76568-02-0 5250-39-5 50-91-9 70623-48-4 70623-48-4 70623-48-4 70623-48-4 70623-48-4 70623-48-4 70623-48-4 70623-48-4 70623-48-4 70623-48-4 70623-48-4 70623-48-4 70623-48-4 70623-5-in-17-one, 16-fluoro-, (16Alpha) 70623-71-9 70625-71-9 706550 706550 706569 706569 706569 706569 706569 706569 706569 706569 706569 706569	Florantyrone		519-95-9			
5250-39-5 50-91-9 30223-48-4 1480-19-9 Androst-5-eir-17-one, 16-fluoro-, (16Alpha); 112859-71-9 57H-Pregna-1,4-dieno[17,16-d]oxazole- 3,20-dione, 21-(acetylöxy)-9-fluoro-11- hydroxy-2-methyl-, (118,168)- [CAS] 1847-24-1 34214-51-2 11H-1,2,4-Triazole-1-eihanol, Alpha-(2,4-difazol-1-eihanol, Alpha-(2,4-difa	Floseouinan		76568-02-0			
50-91-9 30223-48-4 1480-19-9 Androst-5-ein-17-one, 18-fluoro-, (16Alpha), 112859-71-9 5'H-Pregma-1,4-dieno[17,16-d]oxazole- 3,20-dione, 21-(acetyloxy)-9-fluoro-11- hydroxy-2'-methyl-, (118,168)- [CAS] 19888-56-3 hydroxy-2'-methyl-, (118,168)- [CAS] 19888-56-3 1847-24-1 34214-51-2 diffuorophenyl]-Alpha-(1H-1,2,4-triazol-1- diffuorophenyl)-Alpha-(1H-1,2,4-triazol-1- yimethyl)- [CAS] 2022-85-7	Floxacillin		5250-39-5	·		
30223-48-4 Androst-5-eir-17-one, 16-fluoro-, (16Alpha), 112859-71-9 EP 246650 [CAS] 5/H-Pregna-1,4-dleno[17,16-d]oxazole-, 19888-56-3 US 3461119 hydroxy-2'-methyl-, (116,168)- [CAS] 3693-39-8 1H-1,2,4-Triazole-1-ethanol, Alpha-(2,4-difazol-1-difluorophenyl)-Alpha-(1H-1,2,4-triazo	Floxuridine		50-91-9			
Androst-5-ein-17-one, 18-fluoro-, (16Alpha), 112859-71-9 EP 246650 [CAS]	Fluacizine		30223-48-4			
Androst-5-en-17-one, 18-fluoro-, (16Alpha), 112859-71-9 EP 246650 [CAS] 57H-Pregna-1,4-dieno[17,16-d]oxazole- 3,20-dlone, 21-(acetyloxy)-9-fluoro-11- hydroxy-2-methyl-, (118,168)- [CAS], 3693-39-8 147-24-1 111-1,2,4-Triazole-1-ethanol, Alpha-(2,4-difazol-1-ethanol, Alpha-(2,4	Fluanisone		1480-19-9			
CAS 5'H-Pregna-1,4-dieno[17,16-d]oxazole- 3,20-dione, 21-(acetyloxy)-9-fluoro-11- hydroxy-2'-methyl-, (116,168)- [CAS] 19888-56-3 US 3461119 3693-39-8 1847-24-1 1H-1,2,4-Triazole-1-ethanol, Alpha-(2,4-difazol-1-ethanol, Alpha		Androst-5-en-17-one, 16-fluoro-, (16Alpha),	440850 74 0	8	SAEREO	·
5'H-Pregna-1,4-dieno[17,16-d]oxazole- 3,20-dione, 21-(acetyloxy)-9-fluoro-11- hydroxy-2'-methyl-, (116,168)- [CAS] 19888-56-3 US 3461119 3693-39-8 1847-24-1 34214-51-2 diffuorophenyl]-Alpha-(1H-1,2,4-triazol-1- yimethyl)- [CAS] 86386-73-4 EP 96569	fluasterone	[CAS]	8-17-809711	5	240000	Caldiorascular
114-1,2.4-Triazole-1-ethanol, Alpha-(2,4-difiazol-1-yimethyl)-[CAS] 2052-85-7 2052-85-7		5'H-Pregna-1,4-dieno[17,16-d]oxazole-3,20-dione, 21-(acetyloxy)-9-fluoro-11-hudroxy-2-methul. (118,168)- [CASI	19888-56-3	SD	3461119	Antipruritic/inflamm, non-allergic
1H-1,2,4-Triazole-1-ethanol, Alpha-(2,4-diffucrophenyl)-Alpha-(1H-1,2,4-triazol-1-g8386-73-4 EP 96569	Flichonida	· · · · · · · · · · · · · · · · · · ·	3693-39-8	T -		
34214-51-2 1H-1,2,4-Triazole-1-ethanol, Alpha-(2,4- diffuorophenyl)-Alpha-(1H-1,2,4-triazol-1- ylmethyl)- [CAS] 86386-73-4 EP 96569			1847-24-1		·,	
1H-1,2,4-Triazole-1-eithanol, Alpha-(2,4-diffuorophenyl)-Alpha-(1H-1,2,4-triazol-1-g86386-73-4 EP 96569 y/methyl)- [CAS]	flucloxacillin, CSL		34214-51-2			Formulation, other
gimetryll-[CAS] 86386-73-4 EP 96569 ne		1H-1,2,4-Triazole-1-ethanol, Alpha-(2,4-		٠.	•	
	fluconazole ·	ginuoropheny)-Apha-(in-i,z, r-mazori-	86386-73-4	. –	96569	Antifungai
	Flucytosine		2022-85-7			-
Fludarabine 21679-14-1	Fludarabine		21679-14-1			

Example of Indication infection, general Keratosis infection, general infection, general infection, general	 •	 	· 				 ,	 ·	<u> </u>		.	 		 	 7
	Examble of	Infection, general		Sexual dysfunction, female		 Infection, general							general		

			l		
	٠		Patent	Ħ	•
ADI Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
				 :	
	9H-Purin-6-amine, 2-fluoro-9-(5-O-	75607-67-9.	Sn	4357324	Anticancer, antimetabolite
		105851-17-0			
Fludeoxyglucose F18		0000	Ţ.		•
Fludiaz pam		3900-31-0			
Fludrocortisone		127-31-1			
Flufenamic Acid		530-78-9			
Fluindlone		957-56-2			
	4H-Imidazo[1,5-a][1,4]benzodiazepine-3-				
•	carboxylic acid, 8-fluoro-5,6-dihydro-5-	78755-81-4	G	27214	Neurological
flumazenii	meiny-o-oxo-, enly oxo- (oxo-)	56430-99-0			
Fiumecinoi		42835.25-6			1
Flumequin		040E 47.9			
Flumethasone		Z133-17:3	ŀ		
Flumethiazide		148-56-1			
	Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-30484-77-6	30484-77-6	g	1968710	Antimicraine
flunarizine	(3-pheriyl-2-propenyl)-,(E)- [CAS]	52458-50-7	5	01 /0021	
finarizina	Piperazine,1-[bis(4-fluorophenyl)methyl]-4- 27848-84-6 (3-phenyl-2-propenyl)-,(E)-[CAS]	27848-84-6 52468-60-7			Formulation, fixed-dose combinations
	Pregna-1 4-diene-3,20-dione, 6-fluoro-		_	•	
	11,21-dihydroxy-16,17-[(1-methylethylidena)bls(oxy)].	•			
flunisolide	(6Alpha, 118, 16Alpha) - [CAS]	3385-03-3	ရှ	3124571	Anuasuma
	2H-1,4-Benzodiazepin-2-one, 5-(2- fluoropheryl)-1,3-dihydro-1-methyl-7-nitro-		. !		
flunitrazepam	[CAS]	1622-62-4	.S	3116203	Hypnouc/Sedanve
Elun yanrofen		66934-18-7			
Fluocinolone Acetonide		67-73-2			
		258-19-7			•
Fluocinonide		44767 00 7			
Fluocortin Butyl		41/01-23-7			
Fluocortolone		152-97-0	1		
Fluorescein		2321075	.		
			•••		
Fluorescein Sodium					

·			•	
Example of Indication. Cancer, leukaemia, chronic lymphocytic		ne , allergic, genera		
	• •		•	•

					•
	•	٠.	Patent	·.	
ADI Conorio Mamo	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Ari Generic Manie		2924-67-6	·		
Fluoresone		106 10 1			
Fluorometholone		450-10-1	T		
Fluorosalan		4775051	1		
finorouracii microsponde	2,4(1H,3H)-Pyrimidinedione, 5-fluoro- (CAS)	51-21-8			Formulation, transdermal, enhanced
		00000	:		• •
· · · · · · · · · · · · · · · · · · ·	Benzenepropanamine, N-methyl-Gamma- I.4./trifluoromethyl)phenoxyl-, (+/-)- [CAS]	54910-89-3 56296-78-7	ns	4314081	Antidepressant
Dispurmentaring		76-43-7			
Fluorymesterone		2709-56-0			
Chiporolone Aretate		2119-75-7			
Cimbonating		69-23-8			
riupnenazinie	Carbamic acid. [2-amino-6-[1(4-	33400-45-2			
O. reiseine	fluorophenyl)méthyljamino]-3-pyridinylj-;	56995-20-1 75507-68-5	SD	4481205	Analgesic, other
Fluprednidene Acetate		1255-35-2	•	· .	
· · · · · · · · · · · · · · · · · · ·		53-34-9			-
Flupreanisololle		40507-23-1	·	• •	
Fluproquazone		1524-88-5			
Flurandrenolide		17617-93-1			
Flurazepam			•		
flurbiprofen	[1,1'-Biphenyl]-4-acetic acid, 2-Iluoro-Alpha methyl-[CAS]	5104-49-4	SD	3793457	Anti-inflammatory
pool I management = 2 - 12 - 13	([1,1'-Biphenyl]-4-acetic acid, 2-fluoro-	5104-49-4	,		Formulation, transdermal, patch
Iluruproje other condite	Erythromycin, 8-fluoro-mono(ethyl hutanedioate) (ester)- [CAS]	82730-23-2	B	5629.1	Macrolide antibiotic
Elizabetone Acetate.		2529-45-5		٠	
rial objection in the research		333-36-8			*
Flurouny		406-90-6			
Flurabiliono		1841-19-6			
flutamide	Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]- [CAS]	13311-84-7	Sn	4329364	Anticancer, hormonal
	Oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-11b-(2-fluorophenyl)-o 2 7 11b-terefucio-7-(2-fluoroxethyl)-	· · .			
	[CAS]	27060-91-9	ရှ	3905956	Anxiolytic .

Exampl of indication Exampl of indication Depression, general. Pain, post-operative Pain, general Infection, respiratory tract, lower Iower		•	· · · · ·		<u> </u>	
	of Indication		post-operative	Pain neneral	ion, respiratory	

			Patent	. t	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
		80474-14-2		 :	
•					
	Androsta-1,4-diene-17-carbothioic acid,		•	•	
	6,9-difluoro-11,17-dihydroxy-16-methyl-3-		•	•	
	oxo-, S-(fluoromethyl) ester,	80474-14-2	•		المرازا بالمع ماطما مطما ممازا السيام
fluticasone propionate:	(6Alpha, 118, 16Alpha, 17Alpha)- [CAS] .	90566-53-3			Formulation, Initiation, Solution
	2H-1,4-Benzodiazepin-2-one, 7-chloro-1-	•		:	
	(cyclopropylmethyl)-5-(2-fluorophenyl)-1,3-	1			
flutoprazepam	dihydro- [CAS]	25967-29-7	GB	1253368	Anxiolytic .
	1H-Imidazole, 1-[(2-fluorophenyl)(4-	119006-77-8		352352	Antifungal
Hutimiazole	The state of the s	63516-07-4	<u> </u>		
riuropium promue					
	6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1		•	•	
	(1-memylemyl)-: n-ii.doi-2-yij-5,3- dibdoo.	•			•
flivoetefin	(±)- [CAS]	93957-55-2	Ep	114027	Hypolipaemic/Antiatherosclerosis
		93957-54-1			
Linvasianii	4 Destruction E-mothows 1.14.				:
	(trifluoromethyl)phenyl]-O-(2-	54739-18-3	•		
iluvoxamine	aminoethyl)oxlme, (E)- [CAS]	61718-82-9	ġ	1535226	Antidepressant
	1-Pentanone,5-methoxy-1-[4-			•	
	(trifluoromethyl)phenyl]-0-(2-				Formulation, modified-release, other
fluvoxamine .	aminoethyl)oxime, (E)- [CAS]				
Folic Acid		59-30-3			
Folinic Acid	-	58-05-9			
F menizole		7554-65-6			
	Benzamide, N-[3-chloro-2-[[methyl[2-(4-				
·	morpholinyl)-2-	18053-31-1	٩	6001999	ochimita violetina d
fominoben	oxoethyljaminojmethyljphenylj- [CAS]	24600-36-0	3	300,1900	הפטרומים) פייווים וויים
F mivirsen		144245-52-3			
Fomocaine		17692-39-6			
Fonazine		7456-24-8			
Condonorini		114870-03-0		•	
Louinaballilas					

general ermatological ssterolaemia n, general compulsive disorder	r	·;	•	 •	 		<u> </u>		 	- †	 · .	:	•	•	· —	· ·	 · ·	_
Example c Asthma Asthma Infection, der Obsessive-c Obsessive-c		Example of Indication		Asthma	Psychosis, general	Infection, dermatological		Hypercholesterolaemia		Depression, general	 compuisive				Eczema, general			

Atol Con via Nome	ADI Ch mical Name	CAS No.	Patent Refer	nce	Example of Therapeutic Use
אבו מפון ווכ משווני					
	Alaha-D-Gluconyranoside methyl O-2-	•	•		
٠	Acone C. culfo-2-fulformino)-Alpha-D-	•		· .	•
					··
	glucopyratiosyl-(1)-y-consylation				
	glucopyranuronosyl-(1-4)-O-2-deoxy-3,0-di-				
	O-sulfo-2-(sulfoamino)-Aipha-D-			:	•
	glucopyranosyl-(1-4)-O-2-O-sulfo-Alpha-L-	•			
	idopyranuronosyl-(1-4)-2-deoxy-2-				
fondanarinux sodium	(sulfoamino)-, 6-(hydrogen sulfate) [CAS]	104993-28-4			Anticoagulant
Earmoholone		2454117		,	
	Androst-4-ene-3.17-dione, 4-hydroxy-			•	
formestane		566-48-3	G	346953	Anticancer, hormonal
Epinocontol .		2825-60-7		•	
רטווווסרטיווו	T. T. T. A. I.O. burdenmer E. [4 burdenmer.]				
	Formamine, IV-[2-1]yu/Oxy-3-[1-1]yu/Oxy-2- Iro (4-mothoxymbery)-1-	•			:
	methylathylaminolethyllohenvil-, (R*:R*)-	43229-80-7	•	•	
· · · · · · · · · · · · · · · · · · ·	(+/-)-[CAS]		99	1415256	- Antiasthma
io io io io io io io io io io io io io i	F. T. M.				
:	בייייייייייייייייייייייייייייייייייייי			•	•
•	III2-(4-metnoxypneny))-1-	7.00.00.00		•,	•
	methylemyljaminojemyljpinenji, rivinenjijminojemyljemyljaminojemyljemyljamino	10520-00-1	•	. •	Formulation inhalable, dry powder
formoterol	(±)-[CAS]	13313-01-6	1		
•			•	,	
· ·	Carbamic acid, ((15,2R)-3-(((4-		,		
	aminophenyl)sulfonyl)(2-	•		•	
	methylpropyl)amino)-1-(phenylmethyl)-2-	•		•	•
	(phosphonooxy)propyl)- C-((3S)-tetrahydro-			. ·	
fosamprenavir calcium	3-furanyl ester, calcium salt (1:1) [CAS]				Antiviral, and-rily
		34156-56-4		•	
	Phosphinecarboxylic acid, dihydroxy-,	4428-95-9			
foscarnet	oxide, trisodium salt [CAS]	63585-09-1	S.	4839445	Antiviral, ourer
Fosfestrol		522-40-7			
	2,4-difluoro-Alpha, Alpha-bis(1H-1,2,4-	•	•		
	triazol-1-ylmethyl)benzył alcohol,		-,- -		
	dihydrogen phosphate (ester).			•	
fosfluconazole		194798-83-9			Antidrigal
	c acid, (3-methyloxiranyl)-, (2R-	23155-02-4 26016-08-8	ä	1223923	Antibiotic, other
fosfomycin	(CIS)-[UAS]	Ţ	F		
Fosfomycin		4-20-02-1	1		
		-			•

Example of Indication Thrombosis, venous Cancer, breast	Asthma Asthma	Infection, cytomegalovirus Infection, fungal, general Infection, general

·			Patent	'	:
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
•	Phosphonic acid, (3-methyloxiranyl)-, (2R-			•••	
·	cis)-, compd. with 2-amino-2-				
losfomycin trometamol	(injuracy), its proposed (i.i.) [CAS]	78964-85-9	G.	27597	Antibiotic, other.
Fosfosal		6064-83-1		:	
	L-Proline, 4-cyclohexyl-1-[[[2-methyl-1-(1-				•
· ·	oxopropoxy propoxy {4- hhenvibuty phosohiny acety -	88889-14-9			•
fosinopril .	(2Apha,48)- [CAS]		EP.	96869	Antihypertensive, renin system
, classical and a second	2,4-Imidazolidinedione, 5,5-diphenyl-3-	92134-98-0	. , Sn	4260769	Antiepileptic
inospinerijyonii	Phosphonic acid, [1-III(2-				
•.	chloroethyl)nitrosoaminojcarbonyljaminojet	02118-97-9	0.	117959	Anticancer, alkylating
rotemustine	ilyir, denyl este total	106560-14-9			
Fropenem .	1H-Carbazole-6-carboxamide, 2,3,4,9-		9	. 001000	Antimiaraino
frovatriptan	tetrahydro-3-(methylamino)-, (R)-[CAS]	22	2	3322/30	Allumigranie
Fructose		57-48-7			
Fructose-1,6-		488-69-7			
diphosphate				-	
	2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-			•	
			•		Antiviral, anti-HįV
FTY-720	1,3-Propanediol, 2-amino-2-(2-(4- octylphenyl)ethyl)-, hydrochloride [CAS]	162359-56-0	WO	9408943	Immunosuppressant .
firdosteine	Alanine, 3-((3-hydroxypropyl)thio)- [CAS]	13189-98-5	US	5047428	Antitussive
fulvestrant	Estra-1,3,5(10)-triene-3,17-diol, 7-[9- [(4,4,5,5,5-pentafluorópentyl)sulfinyljnonyl]- i, (7Alpha,17B)- [CAS]	129453-61-8	GD .	346014	Anticancer, hormonal
	2,4,6,8-Decatetraenediolc acid, mono[5 methoxy-4-[2-methyl-3-(3-methyl-2				
	buterlylloxicallyll - Cxxxpiret - Joseph 7-1 ester, [3R-	•••			
fumaqiline	[3Alpha,4Alpha(2R*,3R*),58,68(all-E)]}- [CAS]	23110-15-8			Protozoacide
Firmadilin		23110-15-8			
				•	

Typertension, general spilepsy, generalized, tonicalonic sancer, melanoma. Migraine Infection, HIV/AIDS Transplant rejection, general Cough
general
east

API Generic Name			Patent	1	Example of Therapeutic Use
API Generic Name			1		Example of Therapeutic Use
E iltodono	API Chemical Name	CAS No.	Reference	rence	
		139-91-3			
Furazabol · ·		1239-29-8		-	
Furazolidone		67-45-8			
Furazolium Chloride		51:18-17-2			
		3460-67-1			
	. Complete Management of the complete of the c			· ·	:· :
inrosemide	Benzoic acid, 5-{aminosuitonyi)-4-cniore-2- [(2-furanyimethyl)amino]- [CAS]	54-31-9		:	Formulation, modified-release, other
Fursultiamine		804-30-8	-	·	
Furtrethonium		7618-86-2			
Fusidic Acid		0669/8/9			
G1 VM BloSciences	1-(5-bromofur-2-vi)-2-bromo-2-nitroethene		:		Antifungal
625		·	NO (9804252	Antimalarial
GABA-A Alpha5 inverse			wo	0206285	Cognition enhancer
	Cyclohexaneacetic acid, 1-(aminomethyl)-	60142-96-3	SA.	4152326	Antiepileptic
Bacaparini					
	Benzoic acid, 4-[[6- [(aminoiminomethyl)amino]-1- oxohexvlloxvi- athyl ester	39492-01-8	•	•	
asbexate	monomethanesuifonate [CAS]	56974-61-9	<u>S</u>	3751447	Gl inflammatory/bowel disorders
gahoxadol	Isoxazolo[5,4-c]pyridin-3(2H)-one, 4,5,6,7-	64603-91-4	₹	1125288	Hypnotic/Sedative
Gadobenate		127000-20-8	`		
Dimealumine			1		
Gadobutrol		138071-82-6		.	
Gadodlamide	T.	131410-48-5		·	
Gadonentetic Acid		80529-93-7		-	
Gadoteridol		120066-54-8			
Gadoversetamide		131069-91-5			,
Gadoxetic Acid		135326-11-3			
	(4aS,6B,8aS)-6-Hydroxy-3-methoxy-11- methyl-5;6,9,10,11,12-hexahydro-4aH-		•	:. :.	
galantamine	benzofuro[3a,3,2-e,f][2]benzazepine				Formulation, modified-release, other
Calanthamine		357-70-0			

Exampl of Indication	Hypertension, general	Infection, gynaecological Infection, malaria Azheimer's disease Epilepsy, general	Pancreatitis Sleep disorder, general	Alzheimer's disease
•	•	• .		•

		-			
	-		Patent	=	Example of Therapeutic Use
API Generic Name	API Chemical Name	CAS No.		Kererence	Example of meraporate
	[6-Alanine, 2-[4-[(2,6-dideoxy-2-filloro- Alaba 4-sloamanosyl)oxyl-1 2 3 4 6 11-			•	
	hexaburano 5.12-tribudroxy-7-methoxy-	•			
	6,11-dioxo-2-naphthacenyll-2-oxoethyl	140637-82-7	•	000707	Anticoncer aptibiotic
galarubicin hydrochloride	.	140637-86-1	<u>.</u>	424038	Carolina (Carolina)
Gallamine Triethiodide		65-29-2			
in Apid		149-91-7		:	
Callic Acio	4H-Pvran-4-one, 3-hydroxy-2-methyl-,			. •	•
	gallium complex	·	٠٠.	•	Anticancer, other
gallium maltolate					
rallium nitrate	Nitric acid, gallium sait [CAS]	13494-90-1	SD	4529593	Osteoporosis treatment
	Benzeneacetonitrile, Alpha-[3-[[2-(3,4-				
	dimethoxyphenyl)ethyl]methylamino]propyl]			•	
:	3,4,5-trimethoxy-Alpha-(1-methylethyl)-	1.6662-47-8	GB	1367677	Aritianginal
galiopamii	[avo]	16662-47-8			•
Gallopamii		56-19-9	·	٠.	
y-Aminobutyric Acid		221-00			
Ganax lone		30330-36-6			
	rin-6-one, 2-amino-1,9-dihydro-9-[[2- ry-1-(hydroxymethyl)ethoxy]methyl]-	107910-75-8	. 0		Antiviral other
ganciclovir	[CAS]	82410-32-0	انا	1001	
	(N.Ac.D-Nai,D-pGl-Phe,D-Pai,D-handen)	124904-93-4	ЕР	312052	Releasing hormones
ganirenx	Carbamic acld, (2-ethylphenyl)-, (3aS,8aS)-			•	
	1,2,3,5a,6,6a-flexariyu.5-1,53,5 trimethylpyrrolo(2,3-b]indol-5-yl ester,				
	hydrochloride	223585-99-7	ם	1023297	Cognition enhancer
ganstigmine nydrochionae	THE ALL STREET		Ŀ		
	1-Piperazineaceiic acio, 4-[I(3ry/5-[+*] [imino[(methoxycarbonyl)amino]methyl]phe prid-2-axx-5-oxazolidinyl]methyl]-			· .	
	ethylester (CAS)	183547-57-1	Ш	741133	Antithrombotic
			,		••••••

a of malignancy of malignancy		·	
Example of In Cancer, breast Cancer, myeloma Hypercalcaemia o Angina, general	Infection, cyronegarovnus Infertility, female	Altheimer's dispace	- 1

			Patent		
API Generic Nam	API Chemical Name	CAS No.	Refe	Reference	Example of Th rapeutic Use
	3-Quinolinecarboxylic acid, 1-cyclopropyl-8- (difluoromethoxy)-7-((1R)-2,3-dihydro-1-	. :	• .		
garenoxacin -	methyl-1H-isoindol-5-yl)-1,4-dinydro-4-oxo- monomethanesulfonate [CAS]	223652-82-2	. 1		Quinolone antibacterial
garnocestim	5-73-macrophage inflammatory protein 2Alpha (human gene gro2)- [CAS]	246861-96-1	:		Radio/chemoprotective
	3-Quinolinecarboxylic acid, 1-cyclopropyl-6- fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1				
gatifloxacin	piperazinyl)-4-0xo-, (+/-)- [CAS]			230295	Quinolone antibacterial
Gatifloxacin		112811-59-3			
Gefarnat		51-77-4			
gefitinib	4-Quinazolinamine, N-(3-chloro-4- fluorophenyl)-7-methoxy-6-(3-(4- morpholinyl)propoxy) [CAS]	184475-35-2	WO	WO 9633980	Anticancer, other
nemcabene calcium	calcium 6,6'-oxybis(2,2- dimethyinexanoate)	209789-08-2			Hypolipaemic/Antiatherosclerosis
Comcitatine		95058-81-4			
gemcitabine hydrochloride	Cytidine, 2-deoxy-2', 2-difluoro- ,monohydrochloride [CAS]		88	2136425	Anticancer, antimetabolite
	Prosta-2,13-dien-1-olc acid, 11,15- dibudoxx-16,16-dimethyl-9-oxo-methyl				
gemeprost	ester, (2E,11Apha,13E,15R)- [CAS]		eg.	1540427	Prostaglandin
Gemenrost		64318-79-2			
gemfibrozil	Pentanoic acid, 5-(2,5-dimethylphenoxy)- 2,2-dimethyl- [CAS]	25812-30-0	.sń	3674836	Hypolipaemic/Antiatherosclerosis
Gemfibrozil		25812-30-0			· .
	1,8-Naphthyridine-3-carboxylic acld, 7-(3- : (aminomethyl)-4-(methoxyimino)-1- pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-		-		
gemifloxacin	dihydro-4-oxo-[CAS]	9:	S	5869670	Quinolone antibacterial
gentamicin	Gentamicin [CAS]	1403-66-3			Formulation, implant
Gentian Violet		548-62-9			
Gentiopicrin		20831-76-9			
			•		

Example of Indication Infection, respiratory tract, lower Chemotherapy-induced injury, bone marrow, neutropenia Infection, respiratory tract, general Hyperlipidaemia, general Hyperlipidaemia, general Hyperlipidaemia, general Infection, respiratory tract, general Infection, general Infection, general Infection, general		· ' '			· · · · · · · · · · · · · · · · · · ·	· ········	 	· · · · · · · · · · · · · · · · · · ·	
	िक	on, respiratory	nerapy-induced arrow, neutropei i, respiratory tra		lung, non-small	Cancer, pancreatic	'1 1 -1	respiratory	

			l		
		•	Patent		
ADI Conorio Name	API Chemical Name	CAS No.	R f	r nce	Example of Therapeutic Use
Art Generic Acid		490-79-9	•		
Gentisic Acid		18840-47-6			
Gepefrine		0 11001	†		
genicone-ER	2,6-Piperdinedione, 4,4-dimethyl-1-[4-[4-(2 pyrimidinyl)-1-piperazinyljbutyl]- [GAS]	·	·		Formulation, modified-release, other
destodane	18,19-Dinorpregna-4,15-dlen-20-yn-3-one, 13-ethyl-17-hydroxy-, (17Alpha)-¡CAS]	109852-02-0 60282-87-3	g _B	1569135	Formulation, fixed-dose combinations
	18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17Alpha).mlxt with 19-Norpregna-1,3,5(10)-trlen-20-yne-13,17				,
postodone + ethinylast. Schari	diol (17Alpha)				Formulation, modified-release, >24hr
		1253-28-7			
Gestinone Capidate		16320-04-0	•		
v-Hydroxybutyrate		591-81-1			
	(4S)-11-[(E)-[(1,1-dimethyl]-4-ethyl-4-	:		:	
	hydroxy-1-12-dinydio-14rr- pyrano[3',4':6,7]indolizino[1,2-b]quinoline-	•		·. . ·	
	(3,14(4H)-dione	292618-32-7			Anticancer, other
Giractid		24870-04-0			
Gitoxin		4562-36-1			
	N.N.Bis[2-[N-[2-(N2,N5-dimethyl-DL- lysylamino)-ethyl[carbamoy]1H-indol-6-yl]- 1H-indole-2,5-dicarboxamide				
GL-406349		3 20 0000			Antiungai
Glafenine		3020-07-3			
Glatiramer		0-12-40102			
glatiramer acetate	L-Glutamic acid, polymer with L-alanine, lu- lysine and L-tyrosine, acetate (salt) [CAS]		. 0	5800808.	Multiple sclerosis treatment
Glibornuride		26944-48-9			
وانومان	Benzenesultonamide, N- [[(hexahydrocyclopenta c]pyrrol-2(1H)- v)amino carbony 1-4-methyl- [CAS]	211.87-98-4		1153982	Antidiabetic
giciacios					

· 	• •	· · · ·		·	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·
Example of Indication	Depression, general	Contraceptive, female	Contraceptive, female	Cancer, brain	Infection; fungal, general	Multiple sclerosis, relapsing- remitting Diabetes, Type II
	٠.				•	•

				•	
			Patent		Evample of Therapeutic-Use
API Generic Name	API Chemical Name	CAS NO.	200	T	Evample of merepers
Gliclazide		21187-98-4			
	1H-Pyrrole-1-carboxamide, 3-ethyl-2,5-			•	
	dinydro-4-fileuryr-1-1-11111-1-1011015u methylcyclohexyllaminolcarbonyllaminolsu		•		:
alimeninde	Ifonyijphenyijethyl]-2-oxo- [CAS]	93479-97-1	WO.	9303724	Antidiabetic
v-l inolenic Acid.		506-26-3	:		
	Pyrazinecarboxamide, N-[2-[4- [[[(cyclohexylamino)carbonyl]amino]sulfony				 Antidiahotin
epizidijā	[]phenyl]ethyl]-5-methyl- [CAS]	29094-61-9	2	3003300	Aillaideac
	Benzenesulfonamide, N- [(cyclohexylamino)carbonyl]-4-[2-(3,4-	٠		···	
edobinoilo	dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo- (2(1H)-isoquinolinyl)ethyl]- [CAS]	33342-05-1	. 85	1277847	Antidiabetic
	3-Isoxazolecarboxamide, N-[2-[4-				
· · · · · · · · · · · · · · · · · · ·	[[[(cyclohexylamino)carbonyl]aminojsulfony [[phenyl]ethyl]-5-methyl-[CAS]	24477-37-0			Antidiabetic
Glisoxepid		25046-79-1			
Glucametacin		52443-21-7			
Glucoheptonic Acid		87-74-1			
Gluconic Acid		526-95-4			
Glucosamine		3416-24-8			
olucosamine sulfate	D-Glucose, 2-amino-2-deoxy-, sulfate (salt) [CAS]	29031-19-4	DE .	1953689	Antlarthritic, other
Glucosulfone Sodium		554-18-7			
	B-D-Glucopyranose, 1-(N,N-bis(2-				
giufosfamide	chloroethyl)phosphorodiamidate)- [CAS]	132682-98-5	핌	3835772	Anticancer, alkylating
Glutamic Acid		56-86-0			
Glutaraldehyde		111-30-8			
Glutethimide		77-21-4			
Glyburide		10238-12-8	$\cdot $		
Glybuthfazol(e)		535-65-9			
Glybuzole		1492-02-0			
Glycerol		56-81-5	\cdot		
Glycocyamine		352-97-6			
Glycol Salicylate		87-28-5			
	-	•	•	:	

Example of Indication Diabetes, Type II	Cancer, general

API Chemical Nam	CAS No. 3691-74-5	Patent Refer	Patent Refer nce	Example of Therapeutic Use
		Refer	uce.	Example of Therapeutic Use
	3691-74-5 506 51-0			
	0-14-0			
	0-10-000	•		
	451-71-8			
	339-44-6			
-	1228-19-9		·	
				Anti-infective, other
· · · · · · · · · · · · · · · · · · ·	12244-57-4			
	10233-88-2	-		
LuteInizing hormone-releasing factor (plg), 6-[O-(1,1-dimethylethyl)-D-serine]-10-				
drazide [CAS]	65807-02-5	S	4100274	Releasing hormones
- S	186452-09-5			Antiparkinsonian
2-(Phosphonomethyl)pentanedioic acid		Sn	5672592	Analgesic, other
1H-Indazole-3-carboxamide, 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-; endo-1GSS]	107007-99-8 109889-09-0	. da	200444	Antiemetic
	119914-60-2	·		
Spiro[benzofuran-2(3H), 1-{2]cyclohexane]-3,4-dione, 7-chlore-2'4,6-trimeth-oxy-6rmethyl-, (1'S-trans)- [CAS]	126-07-8			Formulation, dermal, topical
	90-05-1			·
	852-42-6			
	489-84-9		<u></u>	
	93-14-1			
Sj	81674-79-5	B	2098201	Anti-inflammatory
		186452-09-5 107007-99-8 109889-09-0 119914-60-2 126-07-8 90-05-1 852-42-6 489-84-9 93-14-1	186452-09-5 107007-99-8 109889-09-0 119914-60-2 126-07-8 90-05-1 852-42-6 93-14-1 81674-79-5 GB	186452-09-5 107007-99-8 109889-09-0 119914-60-2 126-07-8 90-05-1 852-42-6 93-14-1 81674-79-5 GB

Example Infection, ge Infection, ge Parkinson's Pain, neurol Chemother and vomitin

AP! Generic Name Guamecycline Guanabenz Guanabenz Guanabenz Guanabenz Guanoxabenz Guanoxabenz Guanoxan gugulipid Gusperimus Gusperi	mical Nam	CAS No.	Patent Refere	Patent Reference	Example of Th rapeutic Use
seric Name cycline enz lrel cine mical Nam	CAS No. 16545-11-2	Refe	rence	Example of Th rapeutic Use	
imus Se Se Se Se Se Se Se Se Se S	17(20)-diane-3,16-diane-[CAS]	16545-11-2			
imus seam labenz cine cine cine can san san nide ol propionate	17(20)-diane-3,18-diane-[CAS]	500,100	į		
imus Se Se Se Imus Inide Inide	17(20)-diene-3,18-dione [CAS]	5051-62-7	- -		
inus Se Se Inde Inde In Inde	17(20)-diene-3,16-dione [CAS]	40580-59-4.		 	
imus sam nide	17(20)-diane-3,16-diane-[CAS]	55-65-2			
imus 30A 30A 30A am nide ol propionate	17(20)-diene-3,16-dione [CAS]	29110-47-2		•	
imus 30A 30A ycin yam nide ol propionate	17(20)-diene-3,16-dione [CAS]	24047-25-4		·	
imus 30A 84 84 nide ol propionate	17(20)-diene-3,16-dione [CAS]	2165-19-7			
imus 30A 30A 30A 30A 30A 30A 30A 30A 30A 30A		95975-55-6	<u>.</u>	447706	Hypolipaemic/Antiatherosclerosis
ionate		104317-84-2			
e opionate	rofumaric acid 1-[3-[-[6,7-2(S)-methyl-1 (R)-(3,4,5-			•	
e opionate	benzyl)-1,2,3,4-			• •	
e opionate	Sodulioninium - z-yilon				Muscle relaxant
a opionate	-2-[3,5-difluorophenyl]-3,5-		•	÷	
e opionate		•			Anorectic/Antiobesity
e opionate					·.
e opionate	[N-(2- dioxanylmethyl)amino]-1-propyl}-		•		
e opionate	dazinone hydrochloride		Sn	6194411	Prostate disorders
e opionate		1394-02-1			
e opionate	•	23092-17-3		·	
pionate		3093-35-4			•
	4-diane-3 20-dione, 21-chloro-			•	
	5-11-hydroxy-16-methyl-17-(1-	66852-54-8	.sn	4619921	Antipsoriasis
	y)-, (ordina, 1 19, 100) (cm)		_		
•		36167-63-2	<u> </u>	138374	Antimalarial
	einyi)- [cvo]		Т		
	Pregna-1,4-diene-3,20-dione, 2-chloro-6,9- difluoro-11,17,21-trihydroxy-16-methyl-, costato 418 16Ataba-17,861	50629-82-8	Sn	4076737	Antipruritic/inflamm; allergic
	io, i original - [orio]	20 00 0	7:		
Haloperidol		25-00-5			

Example of Indication	Anaesthesia, adjunct Obesity Benign prostatic hyperplasia	Psoriasis Infection, malaria

			Patent	
ADI Generic Name	API Chemical Name	CAS No.	Reference	Example of Therapeutic Use
Haloperidoi		•		
Decanoate			-	
Halonredone Acetate	•	57781-14-3		
Holon ain		777-11-7		
rigical giii		679-84-5	:	
naioproparie		151-67-7		
Halothane		F0400 07.4		
Haloxazolam		39120-97-1		
	2(R)-Acetamido-N-benzyl-3-		· ·	
	methoxypropionamide		WO 9733861	Antieplieptic
narkosende	18 Alcha-Bromo-38-hydroxy-5 Alpha-			
	androstane-17-one	·:		· All face Inchine
HE-2000				Africantockeletel
Healos			WO 9/143/6	Winschildsheidtai
Ucmotonombivin		14459-29-1		
nematopol priym		7237-81-2		
нергопісате		500-88-A		
Heptabarbital		203-00-2		
Heptaminol		3/2-00-/		
Hetacillin		3511-16-8		
Hefastarch		9004-62-0		
Hexachlorophene	•	70-30-4		
		28728-55-4	•	
Hexafluorenium		317-52-2	· :	
Bromide		7.00		:
Hexamethonium		00-50-4 0044 7F A		
Hexamidine		301.1-73-4	1	
Hexapropymate		358-52-1		
Hexedine		5980-31-4		
		84-16-2	-	
nexestroi		2691-45-4		
H xestrol bis(p-			:	,
diethylaminoethyl ether)			· ·	
Property Codium		144-00-3		
nexemal Socialis			<i>:</i>	•

ABLE I

388

Example of Indication Epilepsy, general Infection, HIV/AIDS Regeneration, bone	
---	--

			Patent		
ADI Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Terotialise		141-94-6			
Lexellollie :		100 00 1			
Hexobarbital		20.52-1	†		
Hexobendine		54-03-5			
Hexocyclium Methyl		115-63-9			
				-	
Hoversline		3215-70-1			
Hextend	Hextend [CAS]		Sn	5407428	Plasma substitute
11		532-76-3			•
Hexylcaine					
Hyarochioriae	11 Endrow androstenedione				
HF-0299		•			Osteoporosis treatment
	Benzeneacetic acid, 4-[2-hydroxy-3-[(1-		 -		
	hiemyleuryjaminojpropozyj, 2 hricyclo[3.3.1.13,7]dec-1-ylethyl ester, (22)-	191009-31-2	•		Antiglaucoma.
HGP-2	Z-onteriedicate (1:1) (said 1:2)]:	
	8-Azoniabicyclo[3.2.1]octane, 3-(3-ethoxy-		٠.	· .	
	1,3-dioxo-2-phenylpropoxy)-8,8-dimethyl-, (3-endo)- methyl sulfate [CAS]	113932-41-5		•	Antiepileptic
nidmsmin	Hydrosmin- (CAS)	120250-44-4			Vasoprotective, systemic
Hotomino		51-45-6			
nistamine dihudrochlorida	histamine dihydrochloride		<u>a</u>	0493468	Anticancer, immunological
}		493-80-1	Ľ		
Histapyrrodine					
	Luteinizing hormone-releasing factor (pig), 6-{1-(phenylmethyl)-D-histidine}-9-(N-ethyl-	76712-82-8	· · ·	217659`	Releasing hormones
histrelin	HM 101 (CASI	217311-70-1	ı		Osteoporosis treatment
IOI-MH	(E)-4-[2-12-(0		1		
·	methoxybenzenesulfonamide)- Iohenvilethenvilovridine-1-oxide	•	·,	.:	
HMN-214					Anticancer, other
Homatropine		87-00-3			
Homocamfin		535-86-4			
Lomorhiorovelizina		848-53-3			
		18679-90-8			
nopanieme Aciu					}. -

wample of Indication urgery adjunct staucoma staucoma spilepsy, general spilepsy, general Sancer, melanoma Osteoporosis Cancer, general	•	 ٠		 		 		,	i 	
	mple of		Surgery adjunct	Glaucoma	Epilepsy, general		Precocious puberty Osteoporosis	Cancer, general		

			Patent	nt	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
HP-228	Glycinamide, N-acetyl-L-norleucyl-L- glutaminyl-L-histidyl-D-phenylalanyl-L- arginyl-D-tryptophyl- [CAS]	172617-89-9		759770	Analgesio, other
Huperzine A		102518-79-6			
hyaluronan	Hyaluronic acid [CAS]	9004-61-9			Formulation, other
Hycanthone		3105-97-3			
Hydnocarpic Acid.		459-67-6			
Hvdralazine		86-54-4		•	
Hydrastine		118-08-1			
Hydrastinine		6592-85-4			
Hydrochlorothiazide		58-93-5			
	7	125-29-1			
hydrocodone	Morphinan-6-one, 4,5-epoxy-3-hydroxy-17- methyl-,(5Alpha)- [CAS]	466-99-9			Formulation, modified-release, other
Hydrocortamate		76-47-1			
Hydrocortisone		50-23-7			
hydrocortisone aceponate	Pregn-4-ene-3,20-dione, 21-(acetyloxy)-11- hydroxy-17-(1-oxopropoxy)-; (113)-[CAS] 74050-20-7	74050-20-7	DE	2826257	Dermatological
hydrocortisone butyrate propio	Pregn-4-ene-3,20-dione, 11-hydroxy-17-(1-oxobutoxy)-21-(1-oxopropoxy)-, (118)-[CAS]	72590-77-3	30	: . 2910899	Antipruritic/Inflamm, allergic
hvdrocortisone-17-butvrate	Pregn-4-ene-3.20-dione, 11,21-dihydroxy-17-(1-oxobutoxy)-, (118)- JGASi	13609-67-1			Formulation, optimized, microemulsion
Hydroflumethiazide		135-09-1			
	Morphinan-6-one, 4,5-epoxy-3-hydroxy-17-methyl-,(5Alpha)-, mixt with acetamide, N-				
	(4-hydroxyphenyl)-, mix with morprinan-e- one,17-(cyclopropylmethyl)-4,5-epoxy-3,14-103-90-2 dihydroxy-, (5Alpha)-	103-90-2 16590-41-3			and the state of t
hydromorphone		466-99-9			Formulation, fixed-dose combinations
Hydroquinidine		1435-55-8	\cdot	•	
Hydroquinine	٠	522-66-7		·	
Hydroquinone		123-31-9			
			į.		

	. · · -		· · · · · · · · · · · · · · · · · · ·	
Example of Indication	Pain, post-operative	Restenosis	Pain, general	Unspecified Eczema, atopic Paln, general

			Patent	· .	:
APi Gen ric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Hadrovocohalamin		13422-51-0	•		
II yai OAccomanini		1518-86-1			
nyaroxyamphetalline		118-42-3		-	•
Hydroxychloroquine		50.40.4	1		
Hydroxydione Sodium		1-01-56	1.		
Hydroxypethidine ·		468-56-4			
Hydroxychenamate		50-19-1			
Hydroxynronyl Cellulose		9004-64-2	<u> </u>		
Hydroxystilbamidine		495-99-8			
		490-98-2		•	
Hydroxyzine		68-88-2	·		
Hylan G-F 20			•	•	
11.		90-33-5			•
нут сг топе			1		
	benzeneacetic acid, Alpha(nydroxymethyl)-, 8-methyl-8-azabicyclo [3.2.1.]oct-3-yl exter [3/S)-endo], sulfate (2:1), dihydrate				
hyoscyamine sulfate		101-31-5			Formulation, oral, orally-disintegraung
hvnericia	Phenanthro[1,10,9,8-opqra]perylene-7,14-dione, 1,3,4,6,8,13-hexahydroxy-10,11-dimethyl- [CAS]	548-04-9			Anticancer, other
IACET		180468-34-2			
ibandronic acid	Phosphonic acid, [1-hydroxy-3- (methylpentylamino)propylidene] bls- [CAS]	114084-78-5	EP.	252504	Osteoporosis treatment
ibonamine	Propanoic acid, 2-methyl-, 4-{2- (methylamino)ethylj-1,2-phenylene ester- ICASI	66195-31-1	89	1551661	Cardiostimulant
, , mannina	Propanoio acid, 2-methyl-, 4-{2- (methylamino)ethyl]-1,2-phenylene ester- ICASI	66195-31-1.		·	Formulation, mucosal, topical
Ibritimomeh Tillyetan		206181-63-7			
	Phosphonic acid, [[4-[[(4-bromo-2-cyanophenyl)amino]carbonyl]phenyl]methyl		EP.	402033.	Hypolipaemic/Antiatherosclerosis
Colomban	, in the state of				

		·.		•••				•				<u>. </u>		_
Example of Indication						Ulcer, Gl, general	1 .		Hypercalcaemia of malignancy	Heart failure	Surgery adjunct		e imachinochaire	пуреппрусепаенна

			1		
			Patent	ŧ	
ADI Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	1-Propanone, 2-methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]-			. 6	A net coefference
budilast	[CAS]	50847-11-5	<u>.</u>	215436.	Aluanuia
Hufanac		1553-60-2			
on one of the other of the othe	Benzeneacetic acid, Alpha-methyl-4-(2-methylpropyl)-, 2-pyridinylmethyl ester (CAS)	64622-45-3	·	2658610	Antipruritic/Inflamm, non-allergic
ihinrofen	Benzeneacetic acid, Alpha-methyl-4-(2-methylpropyl)-[CAS]	15687-27-1			Formulation, modified-release, other
Ihinroxam		53648-05-8			
Ibutilide		122647-31-8	1		
	Methanesulfonamide, N-[4-[4- (ethyllheptylamino)-1-hydroxybutyl]phenyl]-, 122647-31-8	122647-31-8	٠ <u>.</u> ق	60239458	Antiarrhythmlc
ibutilide fumarate	(4/)-, (E)-Z-Datelledioate (2:1) (5ai) [5:0]		us.	6288122	Antisickling · ·
ICA-17043	Devtrin-[CAS]	9004-53-9			Urological
ICODEXITIO, CAPD, INL LADS	- Ceval I myo				
	5,12-Naphthacenedione, 9-acetyl-7-((3-		•	•	
i dan ibicio	hexpyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S-cis)- [CAS]	58957-92-9 86189-66-4	Sn	4471052	Anticancer, antiblotic
Idazoxan		79944-58-4			
	2-(2,3-dihydro-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-1,4-benzodioxin-6-yl)-2,3-dihydro-3,5,7-				
MR-1016	trihydroxy-4H-1-benzopyran-4-one phosphatidylcholine complex	134499-06-2	, Gi	209038	Anticancer, hormonal
ouvordy.	2,5-Cyclohexadiene-1,4-dione, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-ICASI	58186-27-9		58057	Neuroprotective
·					

	:	(· ·	<u> </u>	• •	· .				·			· .		<u>∵</u>	7
Example of Indication	Asthma		Eczema, contact	Inflammation, general			Fibrillation, atrial	Anaemia, sickle cell	Renal failure		Cancer, leukaemia, acute			Cancer, ovarian	Ischaemia, cerebral	

-			l		
			Patent	E	
API Generic Name	API Ch mical Name	CAS No.	ب ۳	R f renc	Exampl of Therapeutic Use
	4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-				
	5-methyl-, (3aS,4R,7R,8aS,9S,10aR,12aS,12bR,13S,		•		
	13a5)-7,12a-bis(acetyloxy)-15- (benzoyloxy)- 22,47,895,040,105,42,125,135,135		•••		:
	dodecahydro-9-hydroxy-5,8a,14,14-			•	
	tetramethyt-2;8-dioxo-6,13a-methano-		· ·		
	cyclodeca (1,2-d) dioxyl-4-yl ester, 2R,3S) (IGAS)	186348-05-0	S	5264591	Anticancer, other
Idoxifene		116057-75-1			
	Alpha-D-Glucopyranoside, methyl O:2,3,4-tri-O-methyl-6-O-sulfo-Alpha-D-				
	glucopyranosyl-(1-4)-O-2,3-dl-O-methyl-B-				
	D-glucopyranuronosyl-(1-4)-O-2,3,6-trt-O- suito-Alpha-D-glucopyranosyl-(1-4)-O-2,3-			:	
	di-O-methyl-Alpha-L-idopyranuronosyl-(1-	· .	•	:	
idraparinux sodium	4)-, ris(nydrogen sunate) norasodium san. [CAS]	149920-56-9	Ą	698456	Antithrombotic
idrocilamide	2-Propenamide, N-(2-hydroxyethyl)-3-phenyl- [CAS]	6961-46-2	US.	3659014	Anti-Inflammatory, topical
Ifenorodil		23210-56-2			
ifenprodil tartrate	(7)-2-(4-benzyl piperidino)-1-p- hydroxyphenylpropanol tartrate	23210-58-4	SD.	3509164	Neuroprotective
iiosfamide	2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-,2-oxide [CAS]	3778-73-2	Sn	3732340	Anticancer, alkylating
iguratimod	N-I3-(Formylamino)-4-oxo-6-phenoxy-4H- chromen-7-yl] methanesulfonamide	123663-49-0	DE 1	3834204	Antiarthritic, other
ilaprazole	1H-Benzimidazolə, 2-{((4-methoxy-3-methyl-2-pyridinyl) methyl-3-(1H-pyrrol-1-yl)- [CAS]	172152-36-2	US	5703097	Antiulcer
					•

cample of Indication		<u> </u>	cer, colorectal		Thrombosis, venous			Cancer, lung, general	othrilis, rheumatoid	er, GI, general
Exam	 : 		Cance		Throm	٠.	<u> </u>	Canc	Arthri	Ulċer,

	A P. Chamber I Name	CAS No.	Patent Refére	Patent Reférence	Example of Therapeutic Use
API Generic Name	API Chemical Manne.				
	Butanediamide, N4-nydroxy-tv1-(1-r- Indol-3-ylmethyl)-2-(methylamino)-2-		•	· ·	
ilomastat	Oxoemyrz-(z-menyrpropyr, (o (* * * * * *) [CAS]	142880-36-2	Sn	5892112	COPD treatment
			•	• :	
onoridone	Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyll- [CAS]	133454-47-4	S	5776963	Neuroleptic
		:			· .
	Pentanoic acid, 5-[hexahydro-5-hydroxy-4-				
isonost trometamol	(3-hydroxy-4-metnyr-t-octen-o-ynyvy-<(11)- pentalénylidenej-{CAS}	78919-13-8		3417638	Prostaglandin
II.X23-7553	1Apha,25-Hydroxy-16-yne vitamin.D3				Anticancer, other
	4-((Methyl-1-piperazinyl)methyl)-N-[4-				
	methyl-3-[[4-(3-pyridinyl)-2-		:	•	
	methanesulfonate			EE91184	Anticancer other
imatinib		152459-95-5	$\cdot \Gamma$	2021104	
					÷
	4-Imidazolidinecarboxylic acid, 3-[2-[[1-	•	•	•	
	oxopropyll-1-methyl-2-oxo-, [4S-	89371-37-9	e.	95163	Antihypertensive, renin system
imidapril	[3[H*(H*)],4H*]]- [CAS]	1.00000	Т		
	4-Imidazolidinecarboxylic acid, 3-[2-[[1-ethoxycarbonyl]-3-phenylpropyl]amino]-1-				
	oxopropyl]-1-methyl-2-oxo;[4S- [3[R*(R*)],4R*]], monohydrochloride				Chalcalanting
imidapril hydrochloride, Ark					Musculoskeletai
imidazole salicylate	Benzolc acid, 2-hydroxy-, compd. with 1H-; imidazole (1:1) [CAS]	36364-49-5	. sn	4329340	Anti-inflammatory
	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic	64221-86-9	•	· . • · ·	
	((minomethy)aminojethy)thioj-7-oxo-, [5R-74431-23-5]	74431-23-5	GB	1570990	Beta-lactam antibiotic
imipenem	SAlpha, balpha(n)]] [CAO] .	50 40 7	1.		
Imipramine		20-49-7			
Imipramine N-Oxide		1-98-879			
imignimod	TH-Imidazo[4,5-c]quinoiin-4-amine, 1-(2- methylpropyl)- [CAS]	99011-02-6	<u>П</u>	145340	Antiviral, other
				•	•

Example of Indication Emphysema, smoking-related Schizophrenia Cancer, general Cancer, leukaemia, chronic myelogenous Hypertension, general Cachexia Pain, general Infection, general Infection, general And general Infection, man papilloma virus	 •	• ,			: :	· .	٠					· · · ·		. · ·	 ·	.; :	_
	₹			Schizophrenia		Peripheral vascular disease	Cancer, general	temia;			· · · · · · · · · · · · · · · · · · ·	Cachexia	Pain, general				

Pate Pate					· - -	
API Chemical Name API				Pate Pafe	nt ronce	Example of Therapeutic Use
10-23-0 10-2	API Generic Name	API Chemical Name	CAS NO.		2012	
Benzenezestamide, Alpha-cyclopentyl-4-	molamine		318-23-0			
17469-98-4 Phosphonic acid. 17469-98-4 Phosphonic acid. 13425-98-4 Phosphonic acid. 13425-98-4 Phosphonic acid. 13425-98-4 Phosphonic acid. 13425-98-4 Phosphonic acid. 124351-88-5 1243		Benzeneacetamide, Alpha-cyclopentyl-4- ((2,4-dimethyl-9H-pyrido(2,3-b)indol-9-	`			
13425-98-4		y)methy)-N-((1R)-2-hydroxy-1-	•		705831	Hypolipaemic/Antiatherosclerosis
Sone Phosphonic acid, (cycloheptylaminojmethylene]bis, 124351-85-5	mpilapide	Conday (displayed	13425-98-4			
Phosphonic acid, ([cycloheptylamino]methylene]bis, 124351-85-5 Icasclium disodium salt [CAS] 124351-85-5 Icascline (24351-85-5 Icascline (24351-85-5 Icascline (24517-78-5 Icascline (24517-78-5 Icascline (24517-78-5 Icascline (1414-inden-7-yloxy)methyl) (25043-22-3 Icascline (1414-inden-4(or 7)-yloxy)-3- (2607-88-3 Icascline (1414-inden-4(or 7)-yloxy)-3- (2607-88-3 Icascline (1414-inden-4(or 7)-yloxy)-3- (2607-88-3 Icascline (1414-inden-4(or 7)-yloxy)-3- (2607-88-3 Icascline (1414-inden-1-4)-5-(2- ((1414-inden-1-4))-1-5-(2- ((1414-inden-1-4)))-1-5-(2- ((1414-inden-1-4))))-1-5-(2- ((1414-inden-1-4)))-1-5-(2- ((1414-inden-1-4))))-1-5-(2- ((1414-inden-1-4)))-1-5-(2- ((1414-inden-1-4))))-1-5-(2- ((1414-inden-1-4))))-1-5-(2- ((1414-inden-1-4))))-1-5-(2- ((1414-inden-1-4)))-1-5-(2- ((1414-inden-1-4))))-1-5-(2- ((1414-inden-1-4)))-1-5-(2- ((1414-inden-1-4)))-1-5-(2- ((1414-inden-1-4)))-1-5-(2- ((1414-inden-1-4	mprosultan		99323-21-4			
Phosphonic acid, [(cycloheptylamino)methylene]bis-, 124351-85-5 124351-85-5 124351-85-5	naperisone		3000			
124351-85-5 124351-85-5 124351-85-5 124351-85-5 124351-85-5 124351-85-5 124351-85-5 124351-85-5 124351-85-5 124351-85-5 124351-85-5 124351-85-5 124351-85-5 124351-73-6 124351-85-5 124351-85-5 124351-85-5 124351-85-5 124351-85-5 124351-73-5		Phosphonic acid, [(cycloheptylamino)methylene]bis-, ciecali,mesalt ICAS	138330-18-4			Musculoskeletal
nic Acid ne acidine 4-chloro-N-(2-methylindolin-1-yl)-3- be sulfamoylbenzamide 40507-78-6 40507-78-6 azine Achloro-N-(2-methylindolin-1-yl)-3- inde Morpholine, 2-[(1H-inden-7-yloxy)methyl]- (CAS] (CAS] ine (CAS] 2-Propanol, 1-[1H-inden-7-yloxy]-3- (CAS] (1-methylethyl)aminol- [CAS] D-enythro-Pentonamide, 2,3,5-trideoxy-N- (2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2- (((1,1-dimethylethyl)aminol)carbonyl)-2- (((1,1-dimethylethyl)aminol)carbonyl)-3- (((1,1-dimethylethyl)aminol)carbonyl)-4- (((1,1-dimethylethyl)aminol)carbonyl)-3- (((1,1-dimethylethyl)aminol)carbonyl)-3- (((1,1-dimethylethyl)aminol)carbonyl)-4- (((1,1-dimethylethyl)aminol)carbonyl)-2- (((1,1-dimethylethyl)aminol)carbonyl)-3- (((1,1-dimethylethyl)	ncadronate disodium		19/351-85-5			
10 10 10 10 10 10 10 10	ncadr nic Acid		C-00-10-421	1		
de 40507-78-6 de 4-chloro-N-(2-methylindolin-1-yl)-3- sulfamoylbenzamide 774517-78-5 Inide Morpholine, 2-f(1H-Inden-7-yloxy)methyl]- 60828-23-3 ine (CAS) 65043-22-3 ine (C	ndalpine	•	63/58-79-2			
de sulfamoylbenzamide 74517-78-5 GB sulfamoylbenzamide 74517-78-5 Inide Norpholine, 2-{(1H-Inden-7-yloxy)methyl)-60929-23-9 JP (CAS)	ndanazoline		40507-78-6		:	
inide. Morpholine, 2-{(1H-Inden-7-yloxy)methyl}-60929-23-9 ICAS Idazine Information (1-1-1H-Inden-7-yloxy)-3-60607-68-3 Information (1-1-1H-Inden-4(or 7)-yloxy)-3-60607-68-3 Information (1-1-1H-Inden-4(or 7)-yloxy)-3-6 Information (1-1-1H-Inden-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1		4-chloro-N-(2-methylindolin-1-yl)-3- sulfamoylbenzamide	26807-65-8	GB.	1203691	Antihypertensive, diuretic
### ### ##############################			74517-78-5			
## (\$5043-22-3 \$100-87-5 \$2-3 \$100-87-5 \$100-87-5 \$100-87-5 \$100-87-5 \$100-87-5 \$100-87-5 \$100-87-5 \$100-87-5 \$100-87-5 \$100-87-7 \$100-8	Indecalitive	Morpholine, 2-[(1H-Inden-7-yloxy)methyl]-	60929-23-9 . 65043-22-3 .	<u>ا</u>	52083773	Cognition enhancer
## 150378-17-9 2-Propanol, 1-(1H-inden-4(or 7)-yloxyl-3-60607-68-3 [(1-methylethyl)amlno]- [CAS] 68906-88-7 150378-17-9	ad lovezine		65043-22-3			
2-Propanol, 1-(1H-inden-4(or.7)-yloxy]-3- 60607-68-3 [(1-meftyleltyl)amlino]- [CAS] 68906-88-7 GB [(1-meftyleltyl)amlino]- [CAS] 68906-88-7 GB [(1-meftyleltyl)amlino]- [CAS] 68906-88-7 GB [(1,1-dimethyleltyl)amlino]- 23,5-trldeoxy-N- (2,3-diftydro-2-hydroxy-1H-inden-1-yl)-5-(2- (((1,1-dimethyleltyl)amlino]carbonyl)-4-(3- pyridinylmethyl), [15-[1Alpha(R*),2-Alpha]]-, 150378-17-9 [phenylmethyl), [15-[1Alpha(R*),2-Alpha]]-, 150378-17-9 [phenylmethyl), [16-[1Alpha(R*),2-Alpha]]-, 150378-17-9 [phenylmethyl]-, [16-[1Alpha(R*),2-Alpha(R*),2-Alpha(R*)]-, 150378-17-9 [phenylmethyl]-, [16-[1Alpha(R*),2-Alpha(R*),2-Alpha(R*)]-, 150378-17-9 [phenylmethyl]-, 16-[1Alpha(R*),2-Alpha(R*),2-Alpha(R*)]-, 16-[1Alpha(R*),2-Alpha	Judiochloride			•		
2-Propanol, 1-(1H-inden-4(or 7)-yloxyl-3- 60607-68-3 [(1-methylethyl)amlnol- [CAS] 68906-88-7 GB [(1-methylethyl)amlnol- [CAS] 150378-17-9 [C2,3-ciirydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)aminol)carbonyl)-4-(3-pyridinylmethyl), [15-[1Alpha(R*),2-Alpha]]-, 150378-17-9 [phenylmethyl), [15-[1Alpha(R*),2-Alpha]]-, 150378-17-9 [aulfate (1:1) (salt) [CAS] Acetamide, N-methyl-N-(3-(3-(2-2-1) - 2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-			30190-87-5	•		
nir D-erythro-Pentonamide, 2.3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethylamino)carbonyl)-4-(3-pyridinylmethyl), [1S-[1Alpha(R¹),2Alpha]]-, [50378-17-9 sulfate (1:1) (salt) [CAS] Acetamide, N-methyl-N-(3-(3-(2-hhenylate))) Acetamide, N-methyl-N-(3-(3-(2-hhenylate))) Acetamide, N-methyl-N-(3-(3-(2-hhenylate))) apyrimidin-7-		2-Propanol, 1-(1H-inden-4(or 7)-yloxyl-3-	60607-68-3 68906-88-7	85	1290343	Antihypertensive; adrenergic
D-enythro-Pentonamide, 2.3,5-trideoxy-N-(2,3-dirydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl), [15-[1Alpha(R*),2Alpha]]-, 150378-17-9 sulfate (1:1) (salt) [CAS] Acetamide, N-methyl-N-(3-(3-(2-thickyroarbonyl)pyrazolo(1,5-à) pyrimidin-7-	HUGHIOIOI		150378-17-9			
D-erythro-Pentonamide, 2,3,5-tr/deoxy-N-(2,3-cirydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl), [15-[1Alpha(R**),2Alpha]]-, 150378-17-9 sulfate (1:1) (salt) [CAS] Acetamide, N-methyl-N-(3-(3-(2-thickyro-1))-2-(thickyro-1))pyrazolo(1,5-à) pyrimidin-7-thickyro-1-2-(1,5-à)	ndinavir		2 2 2 2	-		
D-erythro-Pentonamide, 2,3,5-trldeoxy-N- (2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2- (((1,1-dimethylethyl)amino)carbonyl)-4-(3- pyridinylmethyl), [15-[1Alpia(R*),2Alpha]]-, 150378-17-9 sulfate (1:1) (salt) [CAS] Acetamide, N-methyl-N-(3-(3-(2- thienylcarbonyl)pyrazolo(1,5-à) pyrimidin-7-				_		
pyridinylmethyl)-1-piperazinyl)-2- (phenylmethyl), [1S-[1Alpha(R*),2Alpha]]-, 150378-17-9 sulfate (1:1) (salt) [CAS] Acetamide, N-methyl-N-(3-(3-(2-hhenylcarbony))pyrazolo(1,5-à) pyrimidin-7-		D-erythro-Pentonamide, 2,3,5-trideoxy-N- (2,3-dihydro-2-hydroxy-1H-inden:1-yl)-5-(2- (((1,1-dimethylethyl)amino)carbonyl)-4-(3-	• • • • • • • • • • • • • • • • • • • •			
Acetamide, N-metryl-N-(3-(3-(2-thinhyl-nyl-nyl-nyl-nyl-nyl-nyl)pyrazolo(1,5-à) pyrimidin-7-thinhyl-nyl-nyl-nyl-nyl-nyl-nyl-nyl-nyl-nyl-n	ndinavir sulfate	pyridinylmetfryl)-1-piperazinyl)-2- (phenylmethyl), [1S-[1Alpha(R¹),2Alpha]]-, sulfate (1:1) (salt) [CAS]	150378-17-9 157810-81-6	 	0541168	Antiviral, anti-HIV
100 420 CC		Acetamide, N-methyl-N-(3-(3-(2-thienylcarbonyl)pyrazolo(1,5-à) pyrimidin-7-	325715-02-4	S	6399621	 Hypnotic/Sedative
	indiplon	yi)phenyi)- [CAS]	2001000			

Example of Indication	
	٠,
Atheroscierosis	•
Hypercalcaemia of malignancy	
	٠,
	٠.
	٠.
Hypertension, general	
Alzheimer's disease	
·	
· · · · · · · · · · · · · · · · · · ·	
Infection, HIV/AIDS	
Insomnia	

:

API Generic Name API Ch mical Name API Generic Name 1H-Indazole-3-carboxamide, N-(3.9-dimathyl-3,9-diazabicyclo(3.3.1)non-7-yl)- indsetron 1,4-Benzenedisulfonamide, N-(3-chloro-1H-indopeyanine Green 1,4-Benzamide, N-(1-(2-X))-(CAS)		CAS No.	Patent R ference	nce	Example of Therapeutic Use
en. Inine Green Inine Green Inine Green Inine Green Inine Green Inine Green Inine Green Inine Green Inine Green Inine Green Inine Green Inine Green Inine Green Inine Green Inine Green Inine Acid Inine Acid Inine Inin			H fe		Example of Therapeutic Use
en. Inline Green Men Men Ala Pranobex Ala Inlic Acid Ic Acid Ic Acid Inlic Acid			•		
inine Green sin fen fen fen fin fin fin fin fin fin fin fin fin fi		. !		 -	·
	~	160472-97-9	+	-	Audemen
	_	165668-41-7	•		Anticancer, other
		63610-08-2	-		
	<u>86</u>	3599-32-4	Ė		
n ranobex ranobex iacinate ne ic Acid Acid Acid Acid Acid onic Acid			-		
n ranobex ranobex iacinate le fe Acid onic Acid		53-86-1			Formulation, modified-release, other
ranobex ranobex racinate ne ic Acid Acid Acid onic Acid		31842-01-0	1		
ranobex iacinate ne ic Acid Acid sollon le onic Acid		26844-12-2 38821-52-2		-:	Antihypertensive, adrenergic
ranobex lacinate ne ic Acid Acid Acid Acid onic Acid			Sn	5993810	Labour inducer
ranobex iacinate ne ic Acid Acid Acid Acid Acid Ie		170277-31-3			
iacinate ne ic Acid Acid Acid onic Acid onic Acid	8	36703-88-5			
iacinate ne ic Acid Acid Acid Acid onic Acid	80	87-89-8		:	
ne lic Acid Acid Acid Sollon Ie onic Acid	3	6556112			
ic Acid Acid Acid Acid Acid onlor Acid Acid Acid Acid Acid Acid	8	80663-95-2			
Acid Acid Sollon Ie Onic Acid	<u> </u>	3115057	7		
Acid Acid Sollon Le Onic Acid	1	136949-58-1			
a Acid)()	10397-75-8			
le onic Acid	11	16034-77-8			
tollon le onic Acid	4	440-58-4			The second secon
. Acid		7553-56-2			Formulation, of al, ourse
nic Acid xyquin	9	606-17-7		•	
i onic Acid doxyquin		92339-11-2			
		577-91-3			
		30-26-7.	<i>*</i> :	•	Cognition enhancer
	2	75-47-8			
lodopyracet	6	300-37-8			
lodopyrole	8	87-58-1			
lodoquinol	80	83-73-8			•
lofetamine 123	2	75917-92-9			

Example of Indication Nausea and vomiting, general Cancer, lung, non-small cell Labour, induction Labour, induction Alzheimer's disease

					•
			Patent	<u> </u>	
ADI Conorio Mamo	TAPI Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Ari denencivanie		2618-25-9			
loglycamic Acid -		0 20 00 00			•
lohexol		0-02-20100			
emorelemic Acid		25827-76-3			
ionegianno Acid		78649-41-9			
Iomepro		A0166-93-0	[
lopamidol					
lopanoic Acid		96-83-3	1		
00000		89797-00-2			
ioneinoi		9-62-66			
Iopnenayiate		96-84-4		. 7	
lophenoxic Acid		73334-07-3			
lopromide		71172-08-0			
lopr nic Acid		6-00-01414	I		
lopydol		55/9-92-0			
Convocate		5579-93-1			
thelemie Asid	•	. 5576-90-6	· ·		
omaiaillic Acid		79770-24-4			•
lotrolan		87771-40-2	·		
lov rsol		59017-64-0			
loxagiic Acid		4.07.703.79.E			
loxilan		101133-12-0	Ç	0401420	Analoesic, other
P-751	(3R,4R)-(delta6)-THC-DMH-11-oic acid			241046	
oidacrine		62732-44-9			
	Stigmastan-15-one, 22,29-epoxy-3,4,6,7,29-pentahydroxy-			• .	·. ·
	(3Alpha,48,5Alpha,6Alpha,78,148,22S)- (CAS)	137571-30-3	Sn	6046185	Antiasthma
		5587-89-3			
Ipodale		22254-24-6			
pratropium bromiue		senpt 17.0		···	Formulation, inhalable; solution
ipratroplum bromide:		6-71-09600			
	(endo,syn)-(±)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-a-omiahirocio(3,2,1)octane				
aratronium AeroDose	ס-מדסרוומחוסלסיסיסיסיסיסיסיסיסיסיסיסיסיסיסיסיסיסיס				Formulation, inhalable; topical
planopium porcess					

	Example of	
. ••		
•		
•		
		•
-		
•		
	Pain, neuropathic	
	Asthma	
	Chronic obstructive pulmonary.	•
•	Asthma	
_		

٠:

•			Patent	ııt	; ;
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	Hydrazinecarboxamide, 2-[1,2,3,6- tetrahydro-3-hydroxy-1-(1-methylethyl)-6-	7,10,0107	: '		Haemostatio
Iprazocnrome	CAC-Janania-G-Day	12-0-21			
ipriflavone	4H-1-Benzopyran-4-one, 7-(1- methylethoxy)-3-phenyl- [CAS]	35212-22-7	Д	214647.	Osteoporosis freatment
Iprindole		5560-72-5			
Iproclozide		3544-35-2	•		
Iproniazid		54-92-2	·		
Ipsapirone		95847-70-4			
irbesartan	2-n-butyl-4-spirocyclopentane-1-[((2-tetrazol-5-yl)biphenyl-4-yl)methyl]-2-imidazolin-5-one	138402-11-6	wo	9114679.	Antihypertensive, renin system
	Butanedioic acid, mono[2-[2-				
IRFI-042	(acetyrinlo)eutyll-2,3-dinydro-4,6,7- trimethyl-5-benzofuranyl) ester, (+/-)- [CAS] 134867-62-2	134867-62-2	Sn	5114966	Cardiovascular
	N-Cyclopentyl-1-methylimidazo[1,2-a]quinoxalin-4-amine		· ·		7
IRFI-165		191349-26-5	<u>а</u>	865442	Antidepressant
Iridomyrmecin		485-43-8			
	-Imidazolidinone, 1-[2-[4-[3-[4- fluoronband)-2-dibudro-1H-Inden-1-vl]-1-104113-57-7	104113-57-7			
irindalone	piperazinyljethylj-, (1R-trans)- [CAS]	96478-43-2		183349	Antidepressant
Irinotecan	_	97682-44-5	·		
irofulven	Spiro[cyclopropane-1,5-[5H]inden]-7'(6'H)- one, 6'-hydroxy-2',4',6'-trimethyl-, (R)- [CAS]	125392-76-9	. හු	5563176	Anticancer, other
Iron Sorbitex		1338-16-5			
irsogladine	1,3,5-Triazine-2,4-diamine, 6-(2,5- dichlorophenyl)- (CAS)	57381-26-7 57381-28-9 57381-33-6	Sn	4657807	Antihypertensive, diuretic
IS-741	Cyclohexanecarboxamidė, N-{2- [(ethylsulfonyl)amino]-5-(trifluoromethyl)-3- pyridinyl)- [CAS]	141283-87-6	 .	465913	GI infiammatory/bowel disorders
isaglitazone	Z ₁ 4-Thiazolidinedione, 5-[[6-[(2- fluorophenyl)methoxy]-2- naphthalenyl]methyl]-[CAS]	161600-01-7	US.	5594016	Antidiabetic
	·				

- 1	•	, T. T	T. T T		· · · · · · · · · · · · · · · · · · ·				:		·
ple of Indication	. (steoporosis		Wpertension, general	Atherosclerosis.	Depression, general	epression, general	er, prostate	Hypertension, general	Pancreatitis	tes, Type II
Exampl	· .	Osteo		Hyper	Atherc	Depre	Depre	Cancer,	Нурег	Pancr	Diabetes,

•					
		•	Patent		
API Generic Name	API Chemical Name	CAS No.	Refe	Reference:	Example of Therapeutic Use
ISAtx-247			NZ	502362	Immunosuppressant
Isboarel		89667-40-3			
	D-Streptamine, O-6-amino-6-deoxy-Alpha- D-glucopyranosyl-(1-4)-O-l3-deoxy-4-C-			: .	
Isepamicin	methyl-3-(methylamino)-8-L- arabinopyrancsyl-(1-6)]-N1-(3-amino-2- hydroxy-1-oxopropyl)-2-deoxy-, (S)- [CAS]	58152-01-5 58152-03-7		4029882	Aminoglycoside antibiotic
Isoaminile	1-	77-51-0			
Isobutyl p-		94-14-4			
Aminopenzoale Isocarhoxazid		59-63-2			
isoconazole	1-[2-(2-6-dichlorobenzyloxy)-2-(2-,4-dichlorophenyl)ethyl]	24168-96-5	GB	1244530	Antifungal
Isoconazole		27523-40-6			
Isoetharine		530-08-5			
	razineethanol, 4-{3-fluoro-10,11- o-8-(1- lethyl)dibenzo[b,f]thiepin-10-yl]-	106819-39-0 106819-41-4		. 60	Nourritoth
isofloxythepin	[CAS]	70931-18-9	95	2010543	Neurolephio
isoflurane	Ethane, 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro- [CAS]	26675-46-7	US .	3535388	Anaesthetic, inhalation
Isoflurophate		55-91-4			
Isoladol		530-34-7			
Isomethadone		466-40-0			
Isometheptene		503-01-5			
Isoniazid		54-85-3			
Isonixin		57021-61-1			
Isopromethazine		303-14-0	$\overline{}$		
Isopropamide lodide		71-81-8			
Isopropyl Aicohol		67-63-0			
	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-		·	•	·.
isopropyl unoprostone	0x00eCyloyClopentyr, 1-neurycenycexe, (1R-(1Alpha(Z), 28,3Alpha,5Alpha))- [GAS] 120373-24-2	120373-24-2	EP	289349	Prostaglandin
Isoproterenol		7683-59-2			

e of Indication it rejection, general	dermatological	fungal, general	Sia	
Example o	Infection, der	infection, fun	Angesthesia	

			Patent	• •	
ADI Generic Name	API Chemical Name		Refe	Reference	Example of Therapeutic Use
leseorhide		652-67-5	-		-
isosorbide dinitrate	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate (ICAS)	87-33-2.	-: , -	· · :	Formulation, modified-release, other
isosorbide mononitrate	citol, 1,4:3,6-dlanhydro-, 5-nitrate	16051-77-7			Formulation, modified-release, other
leothin ndvl					
Sotretinoin	Retinoic acid, 13-cis- [CAS]		S)	4843096	Antiacne
is valery! Diethylamide		533-32-4	:		
Jeovepa		55453-87-7			
Soxepac		34552-84-6			
ISOXICALII		395-28-8		·	
	. 1. A. Taring incorporation of 1.4.4.		:		· .
ieraclinioa	s.o-rynumeuraa.ooyin. ava., 7(1) benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl ethyl ester [CAS]	75695-93-1.	GB.	2037766	Antihypertensive, other
	6H-Thieno[3,2-fi[1,2,4]trlazolo[4,3-al[1,4]diazepine, 4-(2-chlorophenyl)-6,9-				
	dimethyl-2-[2-[4-(2-methylopenyllethyl-ICAS]	117279-73-9	Ë	268242.	Antlasthma
ISIADAIAIII			Sn	5447926	Formulation, mucosal, topical
Secretary of the secret		123258-84-4	r 1		
Itaseil Oli ITF-282	ITF 282 [CAS]	93615-44-2.	GB	2115821.	Antianaemic
itopride	Benzamide, N-[[4-[2- (dimethylamino)ethoxyjphenyl]methylj-3,4- dimethoxy-, monohydrochloride [CAS]	122892-31-3	GII.	306827	Gastroprokinetic
	3H-1,2,4-Triazoi-3-one, 4-[4-[4-[2-(2,4-dichloropheny]-2-(1H-1,2,4-triazol-1-				
itroconstole	ylmethyl)-1,3-dioxolan-4- ylmethoxylphenyl]-1-piperazinyllphenyl]- 2,4-dihydro-2-(1-methylpropyl)- [CAS]	84625-61-6	С	. 6711	Antifungal
Itramin Toevlate		13445-63-1			
Infamilie Losyiano					

			Patent	•	
API Generic Name	API Chemical Name	CAS No.	Reference	nce	Example of Therapeutic Use
	1-Naphthalenepropanoio acid, 6-[2-[[2-(8- azaspiro[4,5]dec-8-yicarbonyl)-4,6- dimethylohenyilaminol-2-oxoethylj-, (8R)-				
itriglumide.	[CAS]	201605-51-8	0M	9800404	Anxiolytic
	D-Alaninamide N-acetyl-3-(2-naphthaleny)		•	· .	,
· · .	D-aianyr-4-Ciron-D-priorityladigy C-(2-) pyridinyl)-D-alanyl-L-seryl-N6-(3-)	• •	•	•	
iturelix	pyridinylcarbonyl)-E-ysy-r-20 pyridinylcarbonyl)-D-lysyl-L-leucyl-N6-(1- methylethyl)-L-lysyl-L-prolyl- [CAS]	112568-12-4	OM	8901944	Fertility enhancer
	7,8-dimethoxy-3-(3-[[(1S)(4,5-dimethoxybenzocyclobutan-1-				
	yi)methyijmethyiaminojpropyi)-1,3,4,5- tetrahydro-2H-benzazepin-2-one	· · ·	<u> </u>	•	Antianginal
ivabradine hydrochlonde	nydrocnioride	·	1		
	17-Oxa-4-azabicycio(14.1.0)heptadecane-			· · .	
	5,9-dione, 7,11-dinydroxy-8,8,10,12,16- pentamethyl-3-(1-methyl-2-(2-methyl-4-		·	•	
	thiazolyl)ethenyl, (1R,3S,7S,10R,11S,12S,16R) [CAS]	219989-84-1	·		Anticancer, other
·	5H-Cyclopentalpjpyndine-o-caruoxylic . acid, 5-(1,3-benzodioxol-5-yl)-2-butyl-7		·	,	· · · · · · · · · · · · · · · · · · ·
J-104132	[2[(2S)-2-carboxypropyl]-4-methoxyphenyl]- [6,7-dihydro-, (5S,6R,7R)- [CAS]	198279-45-7	.6. OM	9737665	Antihypertensive, other
	5H-Indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione, 12-8-D-glucopyranosyl-				
	12,13-dihydro-2,10-dihydroxy-6-((2- hydroxy-1-(hydroxymethyl)ethyl)amino- ICASI	174402-32-5	· · ·		Anticancer, other
	1-[(3R,4R)-1-Cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1,3-	• •			
J-113397	dihydro-2H-benzimidazole-2-one				Analgesic, other
Janex-1	Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-[CAS]	202475-60-3			Anticancer, other

Example of Indication	•	
: .		
Anxiety, general	•	
	ι.	
••		
. •		
Infertility, female		
	;	
	_	
	. •	
Angina, general	•	
	_	
٠	•	
Cancer, breast		
:		
Heart failure		
	•	
• • • • • • • • • • • • • • • • • • • •	_ :	
•		
Cancer, bladder		
٠		
Pain, general		
Cancer, leukaemia, general		
	_	

			Patent	. =	
ADI G neric Nam	API Chemical Nam	CAS No.	Refe	Refer nce	Example of Therapeutic Use
iosamicio.	Leucomycin V, 3-acetate 4B-(3-methylbutanoate) [CAS]	16846-24-5	<u>-</u>	41021759	Macrolide antibiotic
		;		•	· · · · · · · · · · · · · · · · · · ·
177.510	1,4-Benzothiazepine, 2,3,4,5-tetrahydro-7-methoxy-4-[1-oxo-3-[4-(phenylmethyl)-1-piperidinyl]propyl]- [CAS]	145903-06-6	, Ø	9212148	Cardiovascular
			S.	6287840	Protozoacide
NI FI		487-79-6			
Kalmic Acid	Kalimate-[CAS]	92354-70-6			Urological
Kalikin		342-10-9			
KB-130015	Acetic acid (2,6-diiodo-4-((2-methyl-3-benzofuranyl)methyl)phenoxy)- [CAS]	147030-48-6			Antiarrhythmic
	Methanesulfonamide, N-[3-amino-4-[2-[[2-				
· · · · · · · · · · · · · · · · · · ·	(3,4-dimethoxyphenyl)ethyl]methylamino]ethoxy lahenyl-, monohydrochloride [CAS]	177596-55-3	. · o	9604231	Antiarrhythmic
Linean		853-34-9			
A DUZUITE	2-(2-Chlorophenyl)-2-(methylamino)-		£.		
ketamine	cyclohexanone hydrochloride	6740-88-1			Formulation, transmucosal, nasal
ketanserin	2,4(1H,3H)-Quinazolinedione, 3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-[CAS]	74050-98-9 83846-83-7	ED .	13612.	Antihypertensive, other
	4H-[1,3]Oxazino[3,2-d][1,4]benzodiazepine- 4,7(6H)-dione,11-chloro-8,12b-dihydro-2,8-	27223-35-4	B	1222294	Anxiolytic
Kerazoiani		27762-78-3		: 	·
Ketnoxai		469-79-4			
Velopellidorie	\$		•	L .	· · · ·
ketoconazole	1,3-dioxolan-4-yijmethoxyjphenyij-, dis- ICAS]	65277-42-1	SN	4335125	Antifungal
ketoprofen iysine salt	DL-Lysine, mono(3-benzoyl-Alpha- methylbenzeneacetate) [CAS]	173011-11-5	EP	502502	Formulation, transdermal, systemic
ketorolac	1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-74103-06-3 2,3-dihydro-, (+/-)- [CAS]	74103-06-3 74103-07-4	e E	53021	Analgesic, NSAID

Example of Indication Infection, general Infection, myocardial Infection, trypanosomiasis, American. Arrhythmia, general Arrhythmia, general Pain, post-operative Hypertension, general	Infection, fungal, general Pain, general

				-	
			Patent	٠	
API Generic Name	API Chemical Name	CAS No.	Reference	ence	Example of Therapeutic Use
Ketorolac Tromethamine					•
Kototifon		34580-13-7			
Notice functots	10H-Benzolf4.5]cyclohepta-[1,2-b]thlophen- 10-one, 4,9-dihydro-4-(1-meltyl-4- plperidinylidene)-, (E)-2-butenedioate (1:1)- ICASI	34580-14-8	······································		Formulation, modified-release, <=24hr
Netotilari Julianaje	10-H-Benzo[4,5]cyclohepta[1,2-b]thiophen- 10-one, 4,9-dinydro-4-(1-methyl-4- piperidinylidene)-, (E)-2-butenedioate (1;1)-34580-13-7	34580-13-7 34580-14-8	GB	1355539	Antiasthma
Velonien nyabolasia		82-02-0			
Knellin		9001-29-0			Dermatological
	4-Thiazòiidinecarboxamide, N-(1,1-dimethylethyl)-3-[2-hydroxy-3-[[2-[[5-isoquinolinyloxy)acetyl]amino]-3-:	· · ·	·· ·		
KNI-272	(methylthio)-1-oxopropyljamino]-1-oxo-4- phenylbutyl]-, [4R-[3[2S*,3S*(R*)],4R*]]- :[CAS]	147318-81-8	Sn Sn	5644028	Antiviral, anti-HIV
	(R,R)-2-(2,4-Difluorophenyl)-3-(4-metryleneplperidin-1-yl)-1-(1,2,4-triazol-1-n)-2-triazol-1-		. *-		Antifungal
KP-103	,		S)	6110961	Antidepressant .
KP-15/			<u>8</u>	9919305	Cognition enhancer
	L-glycero-B-L-manno- Heptopyranosylamine, 4-deoxy-4- IIII(2E,4E)-1-oxo-2,4- tetradecadienylaminojacetyljaminoj-N-1H-	151276-95-8		9015811	Anticancer, antibiotic
KRN-5500	Alpha-D-Glucopyranoside, B-D- fructofuranosyl, mixt. with 1-ethenyl-2-				
KT-136	pyrrolidinone homopolymer compd. with iodine [CAS]	121.602-88-8			Formulation, demal, topical

Example of Indication	
	•
•	
sthma	•
	•
sthma	
Photodamage	
:.	•
SOIA/VIH coitectal	
-	
infortion general :	
Depression, general	
Inspecified	
	. •
	•
: 	
	·
icer, decubitus	

			90000		
.,			ָּרְ מַנְּעַ וּ מַנְּעַ	·	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of I neighbourg use
	(-)-2-[(2S)-1,2,3,4-tetrahydro-2-[[(2R)-2-			•	
•	nyaroxy-z-(4- hydroxohenyl)ethyllamino]naphthalen-7-	••			
	yloxy]-N,N-dimethylacetamide			:	٠.٠
KIII -7911	hydrochloride monohydrate	•	•		Urological
	6H.Pvrazolof4.5.1-delacridin-6-one,5-[(3-		·		
	aminopropyl)amino]-7,10-dliydroxy-2-[[(2-	•	•		
-	hydroxyethyl)amino]methyl]-,	207862-44-0			Anticancer, alkylating
KW-2170	dinydrachionde [CAS]	20102			
NAM-EDD2	1H.Purine-2,6-dione, 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dinydro-7-methyl- (E)- [CAS]	155270-99-8			Antiparkinsonian
• •	3,3,3-Trifluoro-2-hydroxy-2-methyl-N-(10-	·.·.		•	
	oxo-4,10-dihydrothieno[3,2-C][1]			.· .	
	penzoiniepin-9-yijpropariamine 5,5 urokud		••		Urological ·
	Urea, N-(2,3-dihydro-1-methyl-2-oxo-5-				
	phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-	118101-09-0	<u>.</u>	284256	Anticancer, other
	ineutyphony (1) [Oro]	4350:00-8			Metabolic and enzyme disorders
L-5-hydroxytryptophan .	L-1 ryprophan, p-nyuroxy- [cho]	2000			
745937	Methanesulfonamide, TN-[6-1(2,4- difluorophenyl)thio]-2,3-dihydro-1-oxo-1H- inden-5-vil-1CASI	158205-05-1	WO.	9413635	Analgeșic, NSAID
10001					
			•	٠.:	
	Phosphonic acid, [3-1](24,35)-2-(-(14)-17) [3,5-bis(trifluoromethyl)phenyljethoxyl-3-(4-		•	· .	
1-758298	fluorophenyl)-4-morpholinyl]methyl]-2,5- dihydro-5-oxo-1H-1;2,4-triazol-1-yl]-[CAS]	172673-20-0	. ОМ	WO 9523798	Antiemetic
1-826141			OΜ	9722585	Antiasthma
lohatalol	5-[1-hydroxy-2-[(1-methyl-3- bhenvioroov)\aminojethyi]salicylamide HCl	32780-64-6 36894-69-6	SU	4012444	Antihypertensive, adrenergic
	3.5-Pyridinedicarboxylic acid, 4-[2-[3-(1,1-		Ì		•
	dimetrylethoxy)-3-oxo-1-propenyljphenyll-1,4-dihydro-2,6-dimethyl-, diethyl ester, (E)		9		Antihunartensive other
lacidipine '	[CAS]	103890-78-4	١.	2104530	Almayberrenavo care.

ample of Indication	
drinary calculus.	
Cancer, lung, non-small cell Parkinson's disease	
incontinence	
Jancer, general	
Pain, general	
Chemotherapy-Induced nausea and vomiting Unspecified	•
ypertension, general	

-				[
			Patent	. =	:
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Lactic Acid					
jactitol	D-Glucitof, 4-O-B-D-galactopyranosyl- ICAS]	585-86-4			Hepatoprotective
l actitol		585-86-4			
Lactulose		4618-18-2			
lafutidine	Acetamide, 2-[(2-furanylmethyl)sulfinyll-N- [4-[[4-(1-piperidinylmethyl)-2-pyridinyl]oxy]- 2-butenyll-, (Z)- [CAS].	118288-08-7	EP .	282077	Antiulcer
Lafutidine		118288-08-7; 169899-19-8			
Lamifiban		144412-49-7			
amivudine.	2(1H)-Pyrimidinone, 4-amino-1-[2- (hydroxymethyl)-1,3-oxathiolan-5-yl]-, (2R- cis)- [CAS]	134678-17-4	. G	513917	Antiviral, anti-HIV
lamotrigine	1,2,4-Triazine-3,5-diamine, 6-(2,3-dichlorophenyl)- [CAS]	84057-84-1	. С	21121	Antiepileptic
	Benzenepropanoic acid, 4-[2-hydroxy-3-[[2-		•		
	It4* morpholiny(carbony))aminojethyljaminojpro poxyj-, (2,2-dimethyl-1,3-dioxolan-4- v)methyl ester, (S-(R*,R'))- HCL				
landiolof		133242-30-5	G.	397031	Antlarrhythmic
lanicemine	(S)-Alpha-phenyl-2-pyridine ethanamine dihydrochloride	153322-05-5			Neurological
anicuidar	Methyl 6,11-dihydro-11-{1.{2-{4-{-2- quinolylmethoxy)phenyljethyl]-4- pipendinylidene]-5H-imidazo[2,1- b][3]benzazepine-3-carboxylate	197509-46-9	. OM	9734897	Radio/chemosensitizer
lanoconazole	1H-Imidazole-1-acetonitrile, Alpha-[4-(2-chlorophenyl)-1,3-dithiolan-2-yildene]-, (E)-(CAS)	101530-10-3	Sn	4738976	Antifungal
l anoteplase		171870-23-8			-
Lanreotide		108736-35-2	•		
lensoprazole	1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-tifluoroethoxy]-2-pyrldyl]methyl]sulfinyl]-[GAS]	103577-45-3	Gi	174726	Antiulcer

· ·:

	· · · · · · · · · · · · · · · · · · ·		· .	•	
Example of Indication Infection, neurological	Ulcer, gastric	Infection, HIV/AIDS Epilepsy, partial (focal, local)	Tachycardia, general	Unspecified Cancer, general	Infection, fungal, general
		•	•		

			Patent		· · ·
ADI Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
lanthanum carbonate	(3+) saft	587-26-8	S.	5968976	Urological
	4-Quinazolinamine, N-[3-chloro-4-[(3-fluorobenzyl)methoxy phenyl)-6-[5-[[[2-fraethyls-ifraethyllaminolimethylliuran-2-		• • •		
	yij bis (4-methylbenzenesulfonate)		٠.	:.	·:
lapatinib ditosylate	Illionorly driene	388082-78-8	•		Anticancer, other
laquinimod		248281-84-7			Multiple sclerosis treatment
	2-Naphthalenol, 5,8,7,8-tetrahydro-6-			. · ·	
lasofoxifene	prenyr-a(***(***)**).*2,3** dihydroxybutanedioate [CAS]	190791-29-8	WO	9716434	Menopausal disorders
	5-0xa-1-azabicyclo[4.2.0]oct-2-ene-2-				. •
latamoxef	[[(1-methyl-1H-tetrazól-5-yl)thio]methyl]-8- loxo- [CAS]	64952-97-2 64953-12-4	ĠB	1547351	Beta-lactam antibiotic
	j				
•	- 91-Canada and 7 (2 Linear Control of Contr	•	,	· · : · ·	:
:	hydroxy-5-phenylpentyl)cyclopentyl)-, 1-				· · · · · · · · · · · · · · · · · · ·
latanoprost	methylethyl ester, (1R- (1Alpha(Z),28(R*),3Alpha,5Alpha))- [CAS]	130209-82-4	.Wo	9002553	Prostaglandin
lauroguadine		135-43-3			
Laurolinium Acetate		146-37-2			
Lawsone		83-72-7			
4X-111	1-(Z,Z,Z,Z-eicosa-5,8,11,14,17- pentaenoyloxy)-3-(Z,Z,Z,Z-eicosa- 5,8,11,14,17-pentaenoyloxy)-propane				Neuroleptic
l azabemide		103878-84-8		·	
	Benzenecarboximidic acid, 4-[(2S)-3- (cyclopentylmethylamino)-2-[(2-			• •	
LB-30057	naphthalenyisulionyi)aminoj-3-oxopropyij-, hydrazide [CAS]		WO.	9749673	Antithrombotic

Example of Indication Hyperphosphataemia Cancer, breast Multiple sclerosis, general Infection, general Schizophrenia Schizophrenia	· ·		ı	· 		-1	·		_		- i	 					···	
	7	ig is		· · · · · · · · · · · · · · · · · · ·	ancer, breast			· •	ormone replacement therapy		general		laucoma ·		•	chizophrenia	•	-

	•		Patent		
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
			3		
L-Cystine,	•				
Inositol,		:	•	٠.	
G			•	•	* .
Propionate, Urea				•	
L fetamine		7262-75-1			
· Objection	4-Isoxazolecarboxamidə, 5-metnyl-N-[4-	75706-12-6 .	<u>a</u>	13376	Antiarthritic, immunological
enulonna (enulonna	1 Incorpolationary of Sampling No. 14-	104981-93-3			
leflunomide	(trifluoromethyl)phenylj- [CAS]	75706-12-6	SD	5610173	Anticancer, other
I elopyrrole		5633-16-9			
	4-Thia-1-azabicyclo[3.2.0]heptane-2-				-
	carboxylic acid, 6-				.·
	[(aminopherylacerylamino]-0,5-amerylacycy. (5-methyl-2-oxo-1,3-dioxol-4-				
	yl)methyl ester, [2S-	80734-02-7 86273-18-9	H	61206	Penicillin, oral
lenampicum (I antinan ICASI	37339-90-5	[Anticancer, immunological
יייייייייייייייייייייייייייייייייייייי				•	
napr reger			I		
	3,5-Pyridinedicarboxylic acid, 1,4-dihydro- 2,6-dimethyl-4-(3-nitrophenyl)-, 2-{(3,3-		•		
	diphenylpropyl)metnylaminoj-i, 1- dimethylethyl methyl ester-, hydrochloride	100427-26-7			
lercanidipine	[CAS]	132866-11-6	Sn	4705797	Antihypertensive, ower
lerisetron	1H-Benzimidazole, 1-(phenylmethyl)-2-(1- piperazinyl)- [CAS]	143257-98-1	Sn	5256665	Antiemetic
		132449-46-8			
resopuici	Benzoic acid, 4-((3-(1,8-dihydro-8-oxo-9H-	·.			
leteptinim	purin-9-yl)-1-oxopropyl)amino)-,	138117-50-7	Sn	6338963	Antiparkinsonian
letosteine	4-Thiazolidinecarboxylic acid, 2-[2-[(2-ethoxy-2-oxoethyl)thiojethyl]- [CAS]	53943-88-7	SN	4032534	COPD treatment
ietrozola.	Benzonitrile, 4,4'-(1H-1,2,4-triazol-1- vimethylene)bis- [CAS]	112809-51-5	. <u>G</u>	236940	Anticancer, hormonal
ibinor one i		480-17-1		:	•
Leuc cyanium	•	53714-56-0		ŀ	
Leuprolide		200 11 100]		
•				•	

d v o o o o o o o o o o o o o o o o o o		Example of Indication	
Arthritts, rheumatoid Cancer, ovarian Cancer, stomach Hypertension, general Nausea and vomiting, Parkinson's disease Bronchitis, chronic Cancer, breast			. :
Arthritis, theumatoid Gancer, ovarian Infection, general Gancer, stomach Aypertension, general Hypertension, general Bronchitis, ohronic Gancer, breast Cancer, breast		• .	٠ (
Arthritis, rheumatoid Cancer, ovarian Cancer, stomach Cancer, stomach Hypertension, general Nausea and vomiting, Parkinson's disease Bronchitis, chronic Cancer, breast		•	
Arthritis, rheumatoid Gencer, ovarian Cencer, stomach Cancer, stomach Hypertension, general Nausea and vomiting, Parkinson's disease Bronchitis, ohronic Cancer, breast			
Cancer, ovarian Infection, general Cancer, stomach Hypertension, general Nausea and vomiting, Parkinson's disease Bronchitis, ohronic Cancer, breast		Arthritis, rheumatoid	
Infection, general Cancer, stomach Hypertension, general Nausea and vomiting, Parkinson's disease Bronchitis, ohronic Cancer, breast		Gancer, ovarian	
infection, general Cancer, stomach Hypertension, general Nausea and vomiting. Parkinson's disease Bronchitis, chronic Cancer, breast			
Infection, general Cancer, stomach Hypertension, general Nausea and vomiting. Parkinson's disease Bronchitis, ohronic Cancer, breast			
infection, general Cancer, stomach Hypertension, general Nausea and vomiting. Parkinson's disease Bronchitis, ohronic Cancer, breast		• •	
Infection, general Cancer, stomach Hypertension, general Nausea and vomiting. Parkinson's disease Bronchitis, ohronic Cancer, breast			
Cancer, stomach Hypertension, general Nausea and vomiting, Parkinson's disease Bronchitis, chronic Cancer, breast			
Hypertension, general Nausea and vomiting. Parkinson's disease Bronchitis, chronic Cancer, breast		ancer, s	
Hypertension, general Nausea and vomiting. Parkinson's disease Bronchitis, chronic Cancer, breast		•	
Hypertension, general Nausea and vomiting. Parkinson's disease Bronchitis, ohronic Cancer, breast			•
Hypertension, general Nausea and vomiting, Parkinson's disease Bronchitis, chronic Cancer, breast	•	٠	
Nausea and vomiting. Parkinson's disease Bronchitis, chronic Cancer, breast	—:-	Hypertension, general	
Parkinson's Bronchitis, (and vomiting,	
Parkinson's Bronchitis, Cancer, bre			
Parkinson's Bronchitis, Cancer, bre			
		Parkinson's disease	
Cancer, breast	•••		
		Cancer, breast	· .
	•		

:

						_
		•	Pat nt	=	:	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use	
la modide acetate	Luteinizing hormone-releasing factor (plg), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide-, monoacetate (salt) [CAS]	53714-56-0 74381-53-6			 Formulation, Implant	·
ia moralin	Luteinizing hormone-releasing factor (pig), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10- deglycinamide- [CAS]	53714-56-0			Formulation, implant	 ;
I ovallornhan		152-02-3				
levamisole	Imidazo(2,1-b]thiazole, 2,3,5,6-tetrahydro-6/14769-73-4 phenyl-, (S)-{CAS}	14769-73-4. 16595-80-5	. Sn	4584305	Anthelmintic	
l avamisola		14769-73-4				
l everomakalim		94535-50-9	·			•
levetiracetam	1-Pyrrolidineacstamide; Alpha-ethyl-2-oxo- , (S)- [CAS]	102767-28-2	. B	162036	Antiepileptic	
lavobeiaxolol	2-Propanol, 1-(4-(2- (cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino) hydrochloide-[CAS].	116209-55-3			Formulation, mucosal, topical	· · · · · ·
				·		
levobunolol	1(2H)-Naphthalenone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, (S)-[CAS]	27912-14-7 47141-42-4	Sn	3641152	Formulation, mucosal, topical	
levobupivacaine	2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (S)- [CAS]	27262-47-1	0 <u>%</u> .	9510276	Anaesthetic, injectable	
levocabastine	4-Piperidinecarboxylic acid, 1-{4-cyano-4- (4-fluorophenyl)cyclohexyl]-3-methyl-4- phenyl-, [3S-[1(cis),3Alpha,4B]]- [CAS]	79449-98-2 79516-68-0 79547-78-7	Sn	4369184	Ántialiergic, non-asthma	
levocetirizine	Acetic acid, (2-(4-((4-chiorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, (R)-[CAS]	130018-77-8	, OM	9406429	Antialjergic, non-asthma	- , -
l evedona		59-92-7		·		••
levodropropizine	1,2-Propanediol, 3-(4-phenyl-1-piperazinyl), (S)- [CAS]	99291-25-5	. С	147847	Antitussive	
levofloxacin	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-,(S)- [CAS]	100986-85-4 138199-71-0	G.	206283	Quinolone antibacterial	
				•		•

Example of Indication Cancer, prostate Cancer, prostate Infection, helminth, general Epilepsy, general Glaucoma Anaesthesia Anaesthesia Allergy, general Cough Cough Cough Infection, respiratory tract, lower		· · · · · · · · · · · · · · · · · · ·		·		· · · · ·	•
	Example of	Cancer, prostate. Cancer, prostate	helminth,	Epilepsy, general	Glaucoma Anaesthesia	Rhinitis, allergic, Allergy, general	n, respiratory

		-			
			Patent		
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
I evomethadyl Acetate		1477-40-3			
levomoprolol	2-Propanol, 1-(2-methoxyphenoxy)-3-[(1-methylethyl)aminol, (S)- [CAS]	27058-84-0 5741-22-0 77164-20-6		15418	Antihypertensive, adrenergic
evonordestrel, Leiras	18,19-Dinorpregn-4-en-20-yn-3-one, 13- ethyl-17-hydroxy-, (17Alpha)- [CAS]	797-63-7			Formulation, implant
Levophacetoperane		24558-01-8			
l ev nr poxyphene		2338-37-6			,
		77-07-6			
evosimendan	Propanedinitrile, [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyljhydrazonoj-, (R)- [CAS]	131741-08-7 141505-33-1	EP	383449	Cardiostimulant
evosimendan		141505-33-1			
evosulpirlde .	Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-, (S)- [CAS]	23672-07-3	GB	2014990	Antlemetic
Levothyroxine Sodium					
evovirin	1-6-L-nbofuranosyl-1,2,4-triazole-3- carboxamide				Antiviral, other
extoafant	L-Leucine, N-methyl-N-[[4-{(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonyl]-, ethyl ester. (CAS)	139133-26-9	WO	9203423.	Neurological
LF:15-0195			OM	9624579	Immunosuppressant
LF-16-0687	2-Pyrrolidinecarboxamide, N-[3-[[4- (aminoiminomethyl)benzoyljaminojpropyl]- 1-[[2,4-dichloro-3-[[(2,4-dimethyl-8- quinolinyl)oxyjmethyljphenyl]sulfonyl]-, (2S) [CAS]	209733-45-9	E	2756562	Neuroprotective
LGD-1550	2,4,6-Octatrienoio acid, 7-(3,5-bis(1,1-dimethylethyl)phenyl)-3-methyl- (2E,4E,6E) [CAS]	178600-20-9			Anticancer, other
				·	

			ľ		
	-		Patent	±.	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Ι.		9002-67-9		•	
יים		9034-40-6	:	٠.	
	1H-Benzimidazole, 5-((3-chlorophenyl)-1H- 115575-11-6	115575-11-6		,	Formulation, other
igrozoie	Illingacoral James 1911 Constanting Consta		T		
	TH-Pyrrolizine-5-aceuc acid, o-14-chlorophenyl)-2,3-dihydro-2,2-dimethyl-7-chenyl, CASI	156897-06-2			Antiarthritic, other
licoreione	formal fo	153504-81-5			
Licosimei	Phosphonic acid, [1-amino-3-		. 0	Q702827	Urological
idadronate	(dimethylamino)propylideriejois-1043)	ļ			
Lidamidine		66871-56-5	ŀ		•
idocaine	Acetamide, 2-(diethylamino)-N-(2,6- dimethylphenyl)- [CAS]	137-58-6	•		Formulation, transdermal, patch
idofanin		59160-29-1			
l Idoffazina		3416-26-0			
- Incompanie	Prosta-2,13-dien-1-oic acid, 11,15-				··
	dihydroxy-17,20-dimethyl-9-oxo- (2E,11Alpha,13E,15S,17S)-, [CAS]	74397-12-9	B9	2041368	Prostaglandin
incomination in		154-21-2			•
incomycii		58-89-9		,	
Lilluaire	Acetamide, N-((3-(3-fluoro-4-(4-				
. Silvezolid	morpholinyl)phenyl)-2-oxo-5- oxazolidinyl)methyl)-, (S)- [CAS]	165800-03-3		9507271	Antibiotic, other
I inclose Acid		60-33-3			
Linglenic Acid		463-40-1			
iothwoning.		6893023			
Linace		9001-62-1			
	Pregna-1,4-diene-3,20-dione, 9-fluoro- 11.17-dilydroxy-16-methyl-21-[(1-				
Lipo-dexamethasone palmitate	-[CAS]	14899-36-6	·		Formulation, optimized, microemulsion
lipo-flurbiprofen	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alphamethyl-, 1-(acetyloxy)ethyl ester [CAS]	91503-79-6	•	60208910	Formulation, optimized, microemulsion
Lipogel HA			<u>.</u>	525655 :	Formulation, optimized, aposonies
LiquiVent	perfluorooctylbromide .	423-55-2	US.	5437272	Lung Surfactant
				٠.	

of Indication so mdrome mdrome mdrome sumatological	id ogical	
ogical	gical all	eo Indrome Indrome Indrome Indrome Indrome Indrome Indrome
ogical	e odical	erpetio armatological eumatoid eumatoid distress syndrome,
e ogical	e e ogical	erpetio yndrome sırmatological eumatold 3r
ogical	e e ogical	erpetic Indrome Indrome Indrome Indrome Indrome Indrome Indress syndrome,
ogical	ogical id	ndrome rmatological iumatoid distress syndrome,
jea l	ical	ndrome
ical	jeal	ndrome rmatological umatoid distress syndrome,
ical	lical	ndrome rmatological umatoid distress syndrome,
jeal	<u> ica</u>	rmatological jumatoid distress syndrome,
lical	leal .	rmatological iumatoid distress syndrome,
		umatoid r
		umatoid r
		umatoid r
sumatoid	sumatoid	umatoid r
sumatoid	sumatoid	iumatoid r
		·

	المتعادية والمتعادية والمتعاد والمتعادية والمتعادية والمتعادية والمتعادية والمتعادية والمتعادية والمتعادية والمتعادية والمتعادية والمتعادية والمتعادية والمتعادية والمتعادية والمتعادية والمتعادية والمتعادية والمتعادية وال				•
•			Patent	: ·	· coll officeroacted F to older or F
API Generic Name	API Chemical Name	CAS No.,	E	Reference	Example of Therapeuric Use
	Carbamothioic acid, (6-methoxy-2- pyridinyl)methyl-, O-(5,6,7,8-tetrahydro-2-;	. •	•		
iranaftate	naphthalenyl) ester [CAS]	88678-31-3	GB.	2124617	Antifungal
lieinooril	L-Proline, 1-[N2-(1-carboxy-3- phenylpropyl)-L-lysyll-, (S)- [CAS]	76547-98-3 83915-83-7	EP.	12401	Antihypertensive, rehin system
lieofalline		100324-81-0		:	
Lisoryillic		18016-80-3	·	, ,	
lisurida hudraden maleata	Urea, N'-[(BAlpha)-9,10-didehydro-6- methylergolin-8-yl]-N,N-diethyl-, (Z)-2- butenedioate (1:1) [CAS]	19875-60-6 305-13-5	·		Antiprolactin
Lithium Citrate		919-16-4			-
lithium	Carbonic acid, dilithium salt [CAS].	554-13-2			Formulation, modified-release, <=24hr
	Renzemide N.Pchloro-4-(5H-pyrrolof2-1-				
Totachan	Contention Content C	168079-32-1	SD	5736540	Cardiovascular
1.1P-1082			Sn	6207160	Immunosuppressant
11 (inhs	S-2,7,8-Trimethyl-8-(8-carboxyethyl)-6- hydroxychroman				Antihypertėnsive, other
MP.160			US.	5643893	Antiasthma
LMP-420			S	5643893	Antiarthritic, other
	, ,			·:	
inhaclatin	Platinum, (1,2-cyclobutanedimethanamine- N,N)[2-tydroxypropanoato(2-)-O1,O2]-, (SP-4-3-(S),(trans)]-,[CAS]	135558-11-1	. "	4115559	Anticancer, alkylating
inh line		90-69-7			
l obenzarit		63329-53-3			
Lodoxamide		53882-12-5			
	2,2'-((2-chloro-5-cyano-1,3- phenylene)dilmino)bis(2-oxoacetate):2-		:		
lodoxamide tromethamine	Ramno-z-(ayaroxymeniyi)- i, z-propanedisi. [(1:2)	63610-09-3	Sn	4439445	Antiasthma
I of ntanil		61380-40-3	•	-	
					-

	- 1		· T	_	- 1	<u> </u>	<u> </u>	· -			-	٠.١			-	1			٦
Indication	gical	<u> </u>		.						S	·.	ıral					•	-	
. 20	ermatolo	on, general		1.			, bipolar			s, venous	•	on, general	rheumatoid	lung, small cell					
Example	Infection, dermatological	Hypertension,			Acromegaly	·	Depression,		Heart failure	Thrombosis,		Hypertension,	Asthma Arthritis, ri	Cancer, lu				Asthma	

			İ		
	•		Patent	·. =	- :
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Th rapeutic. Use
lofenramine	Ethanone, 1-(4-chlorophenyl)-2-[[3-(10,11-dinydro-5H-dibenz[b,f]azepin-5-ylpropyl]methylamino]- [CAS]	23047-25-8 26786-32-3	89	1177525	Antidepressant
			. !		
lofexidine	dichlorophenoxy)ethyl]-4,5-dihydro- [CAS]		2	1161355	Aumilyperiensivo, adicinergio
Loflucarban		790-69-2			
	3-Quinolinecarboxylic acid, 1-ethyl-6,8- difluoro-1,4-dihydro-7-(3-methyl-1-	98079-51-7	. a	140116	Quinolone antibacterial
lomefloxacin	piperazinyı/-4-0xu-[cwa]	٩			
Lomerizine		101477-55-8			
	Piperazine, 1-[bis(4-fluorophenyl)methylj-4- [(2,3,4-trimethoxyphenyl)methyl]		. !		
lomerizine hydrochloride	dihydrochloride- [CAS]	101477-54-7	Ш	159566	Anumigraine
lomitvlline	7-(5-oxohexyl)theophylline	10226-54-7	DE	2207860	Neurological
lomustine	Urea, N-(2-chloroethyl)-N'-cyclohexyl-N- nitroso- [CAS]	13010-47-4	ج	48075526	Anticancer, alkylating
I omistine		13010-47-4	•		
	1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-				
ionafamib	benzol5,6jcycioneptat, ,z-bipyricin- 11-yij-1- piperidinyi]-2-oxoethyi]- [CAS]	193275-84-2	SD	5874442	Anticancer, other
Lonapalene		91431-42-4			
Lonazolac		53808-88-1			
lonidamine	1H-Indazole-3-carboxylic acid,, 1-[(2,4-dichlorophenyl)methyl]- [CAS]	50264-69-2	DE	2310031	Radio/chemosensitizer
loperamide	4-(p-chlorophenyl)-4-hydroxy-N,N-dimethyl- Alpha,Alpha-diphenyl-1-piperidine butyramide HCl	34552-83-5 53179-11-6	Sn	3714159	Antidiarrhoeal
	1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-	•			
loperamide oxide	Alpha, Alpha-diphenyi-, .1-oxide, uaris- [CAS]	106900-12-3	EP	219898	Antidiarrhoeal
	4-(p-Chlorophenyl)-4-hydroxy-N,N-dimethyl Alpha, Alpha-diphenyl-1- nineridinebutvramide HCl			· . ·	
loperamide · · ·		53179-11-6		·	Formulation, dermal, topical

	· :			
Example of Indication Hypertension, general.	Infection, respiratory tract, tower.	Cancer, lung, non-small cell	Cancer, breast Diarrhoea, general	Diarrhoea, general Pain, general

			ľ		
		٠	Patent	ŧ	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	1(2H)-Pvrimidineacetamide. N-(4-(((2.6-		•		
	dimethylphenoxy)acetyl)amino)-3-hydroxy-				
	5-phenyl-1-(phenylmethyl)-			•	i .
	pentyl)tetrahydro-Alpha-(1-methylethyl)-2-				
•	oxo-, (1S-(1R*(R*),3R*,4R*))- + 2,4,7,12-	•	•••		
	Tetraazatridecan-13-oic acid, 10-nydroxy-z-				
	memyi-5-(1- mothylothylyppapapapapapapapapapapapapapapapapapa			•	
		•		•	
•		155213-67-5		٠	
lopinavir + ritonavir		192725-17-0			Antiviral, anti-HIV
	1H-Imidazo[1,2-a][1,4]benzodiazepin-1-				
	one, 6-(2-chlorophenyl)-2,4-dihydro-2-[(4-	61197-73-7			
	methyl-1-piperazinyl)methylene}-8-nitro-	•	_	-	:
loprazolam · .	[CAS]	70111-54-5	<u>8</u> 8	1496426	Hypnotic/Sedative
Loprinone		106730-54-5			
					· ·
	1-Azabicyclo[4.2.0]oct-2-ene-2-carboxylic		•		
,	acid, 7-[(aminophenylacetyl)amino]-3-	76470-66-1	a	14475	Cenhalosoorin, oral
ioracarbei ·	ביים - יוני יוני יוני יוני יוני יוני יוני יו		١.		
Loracarbef		121961-22-6			
Lorajmine		47562-08-3			
				•	· ·
	1-Fiperiolilecarouxylic acid, 4-(8-5-inoto-5,0-1)-	•	-	•	
loratadine	bjpyridin-11-ylidene)-, ethyl ester- [CAS]	79794-75-5	<u>П</u>	EP., 42544	Antiallergic, non-asthma
			:		-
lorazepam	2H-1,4-Benzodiazepin-2-one, 7-cnioro-5-(2) chlorophenyl)-1,3-dihydro-3-hydroxy-	846-49-1	•		Formulation, oral, orally-disintegrating
lorcainide	Benzeneacetamide, N-(4-chlorophenyl)-N- 58934-46-6 [1-(1-methylethyl)-4-piperidinyl]-[CAS] 59729-31-6		. "	2642856	Antiarrhythmic
	2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2		-		
·	chlorophenyl)-1,3-dihydro-3-hydroxy-1- methyl- ICASI	. 848-75-9	. g	3296249	Hypnotic/Sedative
		1		-	
•					•

Example of Indication Infection, HIV/AIDS Infection, respiratory tract, lower Infection, respiratory tract, general Epilepsy, general Insomnia	• •	··· (· · · · · · · · · · · · · · · · · · ·			• •
HIV/A resplir	ndication			80	general	
	6			로 · · · ·	lllergic,	nsomnia

						_
		•	Patent	. =		
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use	
morivoral	2H-Thleno[2,3-e]-1,2-thiazine-3-carboxamide, 6-chloro-4-hydroxy-2-methyl-N-2-nvirdinyl-1,1-dioxide-ICASI	70374-39-9	<u> </u>	313935	Analgesic, NSAID	
		114798-26-4				
Losartan						
losartan potassium	1H-Imidazole-5-methanol, 2-butyl-4-chloro- 1-[[2-(1H-tetrazol-5-y)][1,1'-biphenyl]-4- yl]methyl]-, monopotassium salt (CAS)	124750-99-8	<u>П</u>	253310	Antihỳpertensive, renin system	
				··		
loteprednol etabonate	Androsta-1,4-diene-17-carboxylic acid, 17- [(ethoxycarbonyl)oxy]-11-hydroxy-3-οxο-, chloromethyl ester, (118,17Alpha)- [CAS]	82034-46-6	GB.	2079755.	Anti-inflammatory, topical	
Lotrafiban		171049-14-2			•	
Ovastatin		75330-75-5		•		
Oxanine		10/2/1977			•	
COVEDENCE	Pentanole acid 4-1(3.4-					
	dichlorobenzoyl)amino]-5-[(3-	.· 		 :		
loxialumide	methoxypropyl)pentylamino]-5-0xo-, (±)- [CAS]	107097-80-3	NO.	8703869	GI inflammatory/bowel disorders	,
		68767-14-6			_	_
loxoprofen		80382-23-6 87828-36-2	БÜ	55588	Antiarthulic, other	
	1-[3[[2-[5-chloro_1-(4-fluorophenyl)-3-1H-indolyl]ethyl]methylamino]propyl]-2-imidazolidinone hydrochloride		, OM	9516684	Neuroleptic	
Lubeluzole		144665-07-6			•	
	(-)-7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-					
lubiprostone	y]heptanoic acid	136790-76-6			Laxative	·
lucanthone	Thioxanthen-9-one, 1-((2- (diethylamino)ethyl)amino-4-methyl- (CAS) 479-50-5	479-50-5	•		Radio/chemosensitizer	
Lucanthone Hydrochloride		548-57-2				· · ·
Lumefantrine		82186-77-4				_,
		.,		· ·.	•	

Exampl of indication Pain, post-operative Pancreatitis Pancreatitis Arthritis, rheumatoid Psychosis, general Constipation Cancer, brain

			Patent	=	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
lumiracoxib	Benzeneacetic acid, 2-((2-chloro-6- fluorophenyl)amino)-5-methyl- [CAS]	220991-20-8			Analgesic, NSAID
lurtotecan hydrochloride, OSI	11H-1,4-Dioxino[2,3-gipyrano[3,4':6,7]indolizino[1,2-b]quinoline-9,12[8H,14H]-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-[[4-methyl-1-piperaziny]]methyl], dihydrochloride, [S}-[CAS]	155773-58-3			Formulation, optimized, liposomes
lutetium texaphyrin	Lutetium, bis(acetato-O)[9,10-diethyl-20,21-bis-[2-[2-methoxyethoxy)ethoxy]ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanolato-N1,N18,N23,N24,N25]-, [PB-7-11-23324)-[CAS]	156436-90-7	WO	9906411	, Radio/chemosensitizer
LV-216	Zinc[2-(2,6-dichloroanilino)phenyljacetate	. ,			Anti-inflammatory
אן 104	Hexadecanamide, N-[4-[[2-[2-[2-[[O-(N-acetyl-Alpha-neuraminosyl]-(2-3)-O-B-D-galactopyranosyl-(1-4)-O-[6-deoxy-Alpha-L-galactopyranosyl-(1-3)]-B-D-giucopyranosyl]exploxy]ethoxy]ethoxy]ethoxy]metryl]phenyl]-2-tetradecyl- [CAS]	: 158792-45-1			Cọgnition enhancer
LY-156735	ß-methyl-6-chloromelatonin ∴		ЕР	655243	Hypnotic/Sedative
LY-283111	Benzolc acid, 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxyj- [CAS]	161172-51-6			Anticancer, other
LY-293558	3-Isoquinolinecarboxylic acid, decahydro-6- [2-(1H-tetrazol-5-yl)ethyl]-, [3S- (3Alpha.,4aAlpha,68,8aAlpha.)]- [CAS]	154652-83-2			Anaigesic, other
	1,4-Dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone, 10-{(3-chloro-4: methoxyphenyl)methyll-6,8-dimethyl-3-(2-methylpropyl)-16-{(15)-1-{(25,3R)-3-phenyloxiranyllethyll-,35,10R,13E,16S)-				
LY-355703		18256-67-7 25053-27-4	9	9707798	Anticancer, other
Lyapolate Socium					

e		
Example of Indication Pain, general Cancer, ovarian Atherosclerosis Arthritis, rheumatoid Dementia, senile, general Sleep disorder, general Cancer, melanoma	Pain, neuropathic	Cancer, lung, non-small cell

				1	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Lymecycline					
Lynestrenol		52-76-6			
Lypressin		50-57-7			
Lysin Acetylsalicylate		62952-06-1			
icylate	L-Lysine, 2-hydroxybenzoate [CAS]	. 29535-08-9	ΟM	9624331	Analgesic, NSAID
lysophospholipids, Atairgin			OΜ	9843093	Diagnostic
	Dichloro[(4aR, 13aR, 17aR, 21aR)- 1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a, 18, 19, 20,21, 21a-elicosalvdro-1,7-nitrilo-7H,		. :		
	dibenzo(b,h] [1,4,7,10]tetraazacyclo- heptadecine-		•		
	kappaN5,kappaN13,kappaN18,kappaN21,	· .			
M-40403			.s	6180620	Anticancer, other
	Benzeneacetamide, N-(2-hydroxyethyl)- Aloha-methyl-4-(2-methyloropyl) (+/-)-	· :-			· .
mabuprofen	•	82821-47-4	В	3121595	Anti-inflammatory
Mabuteroi		56341-08-3			
Macrophage Colony-		81627-83-0			
Stimulating Factor		•			
MADU		840-50-6		٠	
Mafenide		138-39-6	٠.		
mafenide acetate	Benzenesulfonamide; 4-(aminomethyl)- monoacetate [CAS]	13009-99-9			Vulhèrary
mafösfamide	Ethanesultonic acid, 2-[[2-[bis(2- chloroethyl)amino]tetrahydro-2H-1,3,2- oxazaphosphorin-4-yl[thio]-, P-oxide, cis- (±)-[CAS]	88859-04-5 98845-64-8	EP	393575	Anticancer; alkylating
magaldfäte	Aluminum magnesium hydroxide sulfate (AISMg10(OH)31(SO4)2), hydrate [CAS]	74978-16-8	Sn	2923660	Antacid/Antiflatulent
magaldrate, FDS	Aluminum magnesium hydroxide sulfate, hydrate [CAS]	74978-16-8	-		Formulation, modified-release, other
Mag nta i		632-99-5			
Magnesium		1.32-49-0			
Ac tylsalicytate			1		

, , , ,	 	· · · · · · · · · · · · · · · · · · ·		· .
Example of Indication		Unspecified	Burns Cancer, renal	Gastro-oesophageal reflux

					!
			Patent		
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Magnesium Carbonate		39409-82-0			
Hydroxide					-
magnesium chloride, Glenfair	Magnesium chloride (MgCl2) [CAS]	7786-30-3	\cdot		Formulation, oral, enteric-coaled
Magnesium Citrate		3344-18-1			
magnesium gluconate. Sopar	D-Gluconic acid; magnesium salt (2:1) ICAS)	3632-91-5			Formulation, other
Mannacium I actate		18917-93-6			
Magnestum Salicylate		18917-89-0			
Malathion		121-75-5			
Maiotilate		59937-28-9			
Mandelic Acid		90-64-2		:	
Mand lic Acid Isoamyl		5421045			
Ester					
Mangafodipir		118248-94-5			
		(free acid);		•••	
		155319-91-8	•		
		(hexahydrogen)			
	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-			· .	
	(diphenylmethyl)-1-piperazinyljethyl methyl 89226-50-6	89226-50-6			
manidipine	ester [CAS]	89226-75-5		20.45	Alimiyballandy onld
Mannomustine		551-74-6	•		
mannose-6-phosphate, BTG	mannose-6-phosphate				Vulnerary
Maprotiline		10262-69-8		.	
	1H-Benzimidazol-2-amine. 5.6-dichloro-N-	•			
maribavir	(1-methylethyl)-1-6-L-ribofurariosyl- [CAS]	176161-24-3			Antiviral, other
	N-{2,2-Dimethyl-1(S)-(N-methylearbamoyl)propyl]-N,3(S)-dihydroxy-2/R)-ischinkleincinamide	154039-60-8	, ox	9402447	Anticancer, other
marmasiai	- Club Provensionarium		1		

٠.		•	Patent	ıt.	
API Generic Name	API Chemical Name	CAS No:	Refe	Reference	Example of Therapeutic Use
	1,3-Cyclohexanedlol, 4-metrylene-5-(2- (octahydro-1-(1-(3-kydroxy-3- metrylbutoxy)ethyl)-7a-methyl-4H-inden-4- yiidene)ethylidene)-, (1S- (1A inha (18-) 394 4F1(5-38*52).7aAlbha))-		· · · · · · · · · · · · · · · · · · ·		
maxacalcitol	[CAS]	103909-75-7	US.	4891364	Ноттопе
	3H-Imidazo[2,1-a]isoindol-5-01, 5-(4- chiorophenyl)-2,5-dihydro- [CAS]	22232-71-9	us .	3763178	Anorectic/Antiobesity
Mazipredone		13085-08-0			
MC-5723			. sn	6043259	Cardiovascular
MCC-478	(2-amino-6-(4-methoxyphenyithlo)-9-[2- (phosphonomethoxy)ethyl]purine bis(2,2,2- trifluoroethyl) ester)				Antiviral, other
MCI-154	3(2H)-Pyridazinone, 4,5-dihydro-6-[4-(4- pyridinylamino)phenyl]-, monohydrochloride [CAS]	98326-32-0 98326-33-1	ËP	145019	Cardiostimulant
m-Cresvi Acetate		122-46-3			
MDAM	Gamma-Methylene-10-deazaaminopterin				Anticancer, antimetabolite
MDI-101			.sn	4885311	Antiacne
MDI-403		403849-94-5	ns	4677120	Antiacne
MDL-100907	4-Piperidinemethanol, Alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-, (R)-,[CAS]	139290-65-6			Hypnotic/Sedative
mebendazole	methyl-5-benzoylbenzimidazole-2- carbamate	31431-39-7	GB :	1307308	1307308 · Anthelmintic ·
mebeverine	Benzoic acld, 3,4-dimethoxy-, 4:[ethyl[2-(4-methoxyphenyl)-;1-methylethyljamino]butylester [CAS]	3625-06-7			Antispasmodic
Mebhydroline		524-81-2			
Mebrofenin		78266-06-5			
Mebutamate		64-55-1			
mecamylamine HCl, Targacept	Bicyclo(2:2.1)heptan-2-amine, N,2,3,3- tetramethy- [CAS]	60-40-2 '			Neurological
Mechlorethamine		51-75-2			

Example of Indication Hyperparathyroidism Obesity Unspecified Heart failure Acne Acne Acne Acne	_ 1	
sorde	l syndrome	
Example Hyperparatt Hyperparatt Unspecified Unspecified Acne Acne Acne	Irritable bowel	hspecified

•			Patent	ŧ	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Mechlorethamine Oxide Hydrochloride		302-70-5		:	
	4-Thia-1-azabicyclo[3.2.0]heptane-2-				
mecillinam	carboxylic acid, 6-[[(hexahydro-1H-azepin- 1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, [2S-(2Aloha,5Alpha,6.beta.)]- [CAS]	32887-01-7 32887-03-9	. 89	1293590	Penicillin, injectable
Meclizine		569-65-3			
Meclocycline		2013-58-3			
	Benzoic acid, 2-[(2,6-dichloro-3-methylphenylamino]-, monosodium salt	6385-02-0			•
meclofenamate	[CAS]	644-62-2		•	Antiarthritic, other
Meclofenamic Acid		644-62-2			
Meclof noxate	•	51-68-3			
Mecloqualone		340-57-8	-		
Mecysteine		18598-63-5			
Hydrochloride					
Medazepam		12/6/2898			
medifoxamina	Ethanamine, N,N-dimethyl-2,2-diphenoxy- ICASI	32359-34-5	Æ	M5498	Antidepressant
Madrodestone		977-79-7	·		•
Medronic Acid		1984-15-2		-	
Medroxvorogesterone		520-85-4			
	Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl- (6Alpha)			· ·.	
medroxyprogesterone acetate		71-58-9			Formulation, fixed-dose combinations
Medrysone		2668-66-8			-
Mefenamic Acid		61-68-7			
Mefenorex		17243-57-1			
Mefexamide		1227-61-8			
mefloatine	4-Quinolinemethanol, Alpha-2-piperidinyl- 2.8-bis(trifluoromethyl), (R*,S*)-(±)-[CAS]	51773-92-3 53230-10-7 69191-18-0	GB	1594282	Antimalarial
Mefloquine	-	51773-92-3			
Mofrieida		7195-27-9			-
ineli usine					

ation	\				ia	
Example of Indicatio		Infection, general	Arthritis, osteo		Contraceptive, female	

					•
•••			Patent	=	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Inerapeutic Use
Monoctrol Acetate		595-33-5			
Meglumin Acetrizoate		22154-43-4			
Meglumine Diatrizoate		131-49-7			
meatutol	2-hydroxy-2-methyl-1,3-propandicarboxylic acid	503-49-1	US.	3629449.	Hypolipaemic/Antiatherosclerosis
melagaftan	Glycine, N-[(1R)-2-[(2S)-2-[[[[4- (aminoiminomethyi]phenyl]methyl]amino]c arbonyi]-1-azetidinyl]-1-cyclohexyl-2- oxoethyl- [CAS]	159776-70-2.	WO	9616671	Antithrombotic
			٠.		
	N-I(3R)-1,2,3,4-Tetrahydrolsoquinolinium-3 ytearbonyi]-(1R)-1-(4-chlorobenzyl)-2-[4-		: •		
melanocortin-4 adodist	cyclohexyl-4-(1H-1,2,4-triazol-1- ylmethyl)piperidin-1-ylj-2-oxoethylamine(1)				Anorectic/Antiobesity
Molarconrol		494-79-1			
Melengestrol		5633-18-1			
melevodopa	Alanine, 3-(3,4-dihydroxyphenyi)- methylester [CAS]	7101-51-1	. G	252290	Antiparkinsonian
Melinamide	-	14417-88-0			
Melitrac n		5118-29-6.			
meloxicam	2H-1,2-Benzothlazine-3-carboxamide, 4- hydroxy-2-methyl-N-(5-methyl-2-thlazolyl), 1,1-dioxide- [CAS]	71125-38-7	. S N	4233299	Antiarthritic, other
melperone	1-Butanone, 1-(4-fluorophenyj)-4-(4-methyl-1822-79-3 1-piperidinyi)- [CAS]	1622-79-3. 3575-80-2	BE .	651144	Neuroleptic
Melphalan		148-82-3			
Melphalan Hydrochloride				:	*
1	Benzenemethanol, 2-chloro-Alpha-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-				
meluadrine.	(H)-, (H, H)-2,3-ulliyaloxybarahedidare (1:1) (salt) [CAS]	134865-37-5	ᇤ	420120	Labour inhibitor
Memantine		19982-08-2			
				١.	•

Example of Indication Hyperlipidaemia, general Thrombosis, general Parkinson's disease Arthrits, rheumatold

			Patent	ŧ	•
API Generic Name	API Chemical Name	CAS No.	Refe	Reference.	Example of Therapeutic Use
	Tricyclo[3.3.1.13,7]decan-1-amine, 3,5-dimethyl, hydrochloride [CAS]	41100-52-1	G.	392059	Cognition enhancer
.1	Acetamide, 2-[[(5R,6S)-6-[(1R)-1- hydroxyethyl-2-methyl-7-oxo-4-thia-1-				
MEN-10700	azabicyclo[3.2.0]hept-2-en-3- yl]methyl]methylamino]- [CAS]	195874-55-6	. MO	9406803	Beta-lactam antibiotic
	- 40 March Managed Fild O. (9:9 ming-		· ·	•	
	5,12-Naphuracenedione, 7:11-7-(5-amilio 2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)-			•	•
	2,6-dideoxy-Alpha-L-lyxo- hexpovranosviloxvi-7.8,9.10-tetrahydro-	. •			
	6,9,11-trihydroxy-9-(hydroxyacetyl)-, hydrochloride, (7S,9S)- [CAS]	169317-77-5	MO	9509173	Anticancer, antibiotic
Menadiol		481-85-6			
Menadione		58-27-5			
Menadoxime		573-01-3			
Menbirtone		3562-99-0			
Menodaril		71628-96-1	٠.		•
MENT	7Alpha-Methyl-19-nortestosterone				Formulation, transdermal, systemic
Monthol		89-78-1			
menthol	Cyclohexanol, 5-methyl-2-(1-methlethyl)- [CAS]	1490-04-6			Formulation, dermal, topical
Menthyl Valerate		89-47-4			
Mechentine		46464-11-3			
Menarfynol		77-75-8			
mepartricin	Partricin, methyl ester [CAS]	11121-32-7	Sn	3780173	Antirungal
Mepartricin		11121-32-7			
Mepazine		6-68-09		:	
M penzolate Bromide		76-90-4			
		57-42-1	-		
Mephenesin		59-47-2	-		
Menhenoxalone		70-07-5			
Mephentermine		100-92-5	·		
Mephenytoin		50-12-4			
Wenhobarbital		115-38-8			
			:		

nple of Indication tta, AIDS-related on, general	r, breast Iceptive, male	on, Candida, general
Example Dementia, A	Cancer, breas	Pruritus Infection, C

			١	İ	
			Pat nt	ŧ	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Menindolol		23694-81-7		,	
Manitioetana		21362-69-6			
Menivacaine		·			•
	-1-methyl-2.	8-88-96	٠.		
	piperidinecarboxamide	· .			Formulation, modified-release, >24hr
Hepivacanio Honivaca		17854-59-0	·.		
Mephanican		1247-42-3			
Meprobamate		57-53-4			
	Buta-4,20,22-trienolide, 3-[(6-deoxy-4-O-methyl-Alpha-L-mannopyranosyl)oxy]-14-				
meproscillarín	ì	33396-37-1	띰	1910207	Cardiostimulant
meptazinoi	ahydro-1-methyl-1H-	54340-58-8 59263-76-2	GB	1285025	Analgesic, other
meouitazine	10H-Phenothlazine, 10-(1-azabicyclo[2.2]oct-3-yimethyl]-[CAS]	29216-28-2	85	1250534	Antiallergic, non-asthma
Meratein Sodium	$\overline{\cdot}$	4386-35-0		, l	
Meralinido		8069-64-5		• .	
Merhromin		129-16-8		•	
Mercaptomerin Sodium		21259-76-7			· · · · ·
Marcimaliviic Acid		86-36-2	·		
Mercuric Chloride,		10124-48-8			
Ammoniated		1191-80-6			
Mercuric Oxygvanide		1335-31-5			
	Carbamic acid, ((3-((((3-methoxy-4-(5-oxazoly))pheny))amino)carbony)amino)phenylumethyl- (3S)-tetrahydro-3-furanyl ester		•		
merimepodib	[CAS]	198821-22-6	Sn ·	5807876	Antiviral, other

	·		
Indication	go		C virus
ple of Inc	post-operative	illure	Infection, hepatitis-C
Exam	Pain, po	Heart failure Pain, general	Infection

API Chemical Name 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[(dimethylamino)carbonyl]-3- pyrrolidinyljthio]-6-(1-thydroxyethyl)-4- methyl-7-oxo-, [4R- [3(38*,58*),4Alpha,58,68(R*)]]-[CAS] Benzoic acid, 5-amino-2-hydroxy- [CAS] Benzoic acid, 5-amino-2-hydroxy- [CAS] Carbamic acid, [[(88)-1,6-dimethylergolin-8- yllmethyli-, phenylmethyl ester [CAS] [CAS]					•	•
### API Chemical Name CAS No. Reference		· .	:	Pate		
1-Azabicyclo(3.2.0)hept-2-ine-2-carboxylic acid 3-l[5-[diinethylamino)castonyli ⁻³ pyroidianylihioj-6-(1-hydroxyelbyl) ⁻⁴ methyl-7-oxo- [4A- met	API Generic Nam	API Chemical Name	CAS No.	Refe	rence	Example of Inerapeutic Ose
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-tjf-(dimethylamino)carboxyli3-9 secos-03-2 EP 126587 is card, 3-tjf-(dimethylamino)carboxyli3-4 secos-03-2 EP 126587 is cardiallylylin-6-(1-hydroxyethyl)3-4 secos-03-2 EP 126587 is cardiallylylin-6-(1-hydroxyethyl)3-45-4 Secos-03-6 Sec					•	
acid, 3-ligh (idimetry/amino)carbonyij-3- pyrrolidinyijthiol-6-(1-hydroxyeiby/)-4- methy/7-oxo-, [4R-		1-Azabicurlora 2 Olhent-2-ene-2-carboxvlic		_		
aymoid of in primition of the procession of the		onia o fire (Aimethylamino)carhonyll-3-				, , , , , , , , ,
######################################		acio, Olioticalismostifications and acide	:		-	::
(3(38.5.57).4Alpha,50.60(R1)]]- [CAS] 96036-03-2 EP 126587 13(38.5.57).4Alpha,50.60(R1)]]- [CAS] 89-57-6 WO 5541170 19767-45-4 19767-45-4 19767-45-4 19767-45-4 19767-45-4 19767-45-4 19767-45-4 19767-45-4 19767-45-4 19767-45-4 19767-45-4 19767-45-4 19767-45-4 19767-45-6 19767-45-6 19767-45-6 19767-45-6 19767-45-6 19767-42-6 1		pyrionality junojo (1. 1. joing 2015)				
192-18-2 197-18-2 197-18-2 197-18-2 197-18-4 197-18-4 197-18-4 197-18-4 197-18-4 197-18-4 197-18-4 197-18-4 197-18-4 197-18-4 197-18-4 197-18-4 197-18-5	-	٠.	96036-03-2		126587	Beta-lactam antibiotic
89-57-6 Benzoic acid, 5-amino-2-hydroxy- [CAS] 89-57-6 Benzoic acid, 5-amino-2-hydroxy- [CAS] 89-57-6 19767-45-4 528-33-0 1424-00-6 1424-00-6 1424-00-6 1424-00-6 1424-00-6 1424-00-6 1424-00-6 1424-00-6 1424-00-6 1424-00-6 1424-00-6 1424-00-6 1424-00-6 1424-00-6 17692-51-2 176-99-3 176-99-3 176-99-3	neiopenen.	ŀ	492.18.9	ŀ	· - -	•
Benzoic acid, 5-amino-2-tydroxy- [CAS] 89-57-6 WO 5541170 II Benzoic acid, 5-amino-2-tydroxy- [CAS] 89-57-6 WO 5541170 II 19767-45-4 5588-33-0 1424-00-6 72-33-3 172-33-3 172-33-3 172-33-3 172-33-3 172-33-3 172-33-3 173-58-0 176-9-9-9 176-99-3 176-99-3 176-99-3 176-99-3 176-99-3	Mersalyl · ·		135-10-2	T		
Benzoic acid, 5-amino-2-hydroxy- [CAS] 89-57-6 WO 5541170 II 19767-45-4 5588-33-0 1424-00-6 1424-00-6 172-33-3 135-58-0 135-58-0 135-58-0 135-58-0 135-58-0 135-58-0 135-58-0 135-58-0 135-58-0 135-58-0 135-58-0 1489-37-0 17692-31-2 176935 176935 176935 176935 176935 176935 176935 176935 176935 176935 176935 176935	Mesalamine		89-57-6			
Benzoic acid, 5-amino-24tydroxy; IUAs) 9 19767-45-4 5588-33-0 1424-00-6 172-33-3 135-58-0 135-58-0 135-68-0 135-68-0 13734-52-9 17692-97-0 54-49-9 54-49-9 77692-31-1 Carbamic acid, [[(88)-1,5-dimethyleigolin-8, 1831-37-9 y methyli., phenylmethyl ester [CAS] [CAS]		3	11		EE41170	Formilation oral other
19767-45-4 5588-33-0 5588-33-0 5288-33-0 1424-00-6 1424-00-6 172-33-3 135-58-0 135-0 13	nesalazinė	Benzoic acid, 5-amino-2-nydroxy- [CAS]	0-/0-80			
5588-33-0 521-11-9 1424-00-6 1424-00-6 72-33-3 72-33-3 72-33-3 72-33-3 72-33-3 72-33-3 72-33-3 72-33-3 72-33-3 72-33-3 72-33-9 72-33-9 72-33-9 72-33-9 72-33-9 72-33-9 72-33-9 72-33-9 72-33-9 72-49 76-99-3 76-99-3	Mocna		19767-45-4	·		
221-11-9 521-11-9 1424-00-6 72-33-3 135-58-0 84031-17-4 6489-97-0 6489-97-0 6489-97-0 6489-97-0 6489-97-0 6489-97-0 6489-97-0 7734-52-9 7734-52-9 7734-52-9 7734-52-9 776-99-3 7734-2-5 76-99-3 776-99-3 776-99-3 521-06-6	Mesoridazine		5588-33-0			
521-11-9 1424-00-6 1424-00-6 172-33-3 172-33-3 172-33-3 172-33-3 172-33-3 172-33-3 172-58-0 1735-58-0 1770-16-5 1770-16-5 1770-16-5 1770-16-5 1770-16-5 1770-16-5 1770-16-5 1770-16-5 1770-16-5 1770-16-6 178-178-178-178-18 178-178-18-18-18-18-18-18-18-18-18-18-18-18-18	Mesoridazine					
521-11-9 1424-00-6 1424-00-6 72-33-3 72-33-3 135-58-0 84031-17-4 6489-97-0 21730-16-5 56-06-1 586-06-1	Besvlate	: :				
1424-00-6 72-33-3 135-58-0 135	M charolone		521-11-9			
72-33-3 135-58-0 84031-17-4 6489-97-0 21730-16-5 56-06-1 5734-52-9 7734-52-9 7734-52-9 7734-52-9 7734-52-9 17692-51-1 Carbamic acid, [[(8B)-1,6-dimethylergolin-8-21631-37-8 yilmethyli-, phenylmethyl ester [CAS]	a stationary		1424-00-6			
135-58-0 84031-17-4 84031-17-4 84031-17-4 6489-97-0 21730-16-5 586-06-1 586-06-1 586-06-1 58734-52-9 7789-51-2 7789-51-2 57734-52-9 5	W st rolone		72-33-3			
1931-17-4 84031-17-4 6489-97-0 21730-16-5 586-06-1 586-06-1 586-06-1 586-06-1 58734-52-9 7789-51-2 7789-51-2 7789-51-2 7789-51-1 57734-52-9 62-51-1 57734-52-9 62-51-1 57734-52-9 62-51-1 57734-52-9 62-51-1 57734-50-1 57734-52-9 62-51-1 57734-50-6 531-06-6	Vestranol		125,58-0	Γ		
6489-97-0 21730-16-5 10.2 21730-16-5 586-06-1 5734-52-9 7734	// sulfen		0.00-00-0			
6489-97-0 21730-16-5 10.2 10.2 10.2 10.2 10.2 10.2 10.2 10.2	Metaclazepam		4-71-10040	ŀ	-	
21730-16-5 no1 no2 Carbamic acid, [[(8B)-1,6-dimethylergolin-8,21631-37-8 yl]methylj-, phenylmethyl ester [CAS] [CAS] [CAS] ECAS] 21730-16-5 54-49-9 17692-51-2 2706-42-5 [GB] 1401935 [CAS] [MetamplcIllin		6489-97-0			
586-06-1 586-06-1 54-49-9 54-49-9 3734-52-9 17692-51-2 17692-51-2 2706-42-5 1401935 1401935 1401935 1400dicarbonimidic diamide, N,N-dimethyl 657-24-9 16AS 62-51-1 914-00-1 914-00-1 76-99-3 1531-06-6 1531-0	Metabramine	y.	21730-16-5			
Metazocine 54-49-9 Metazocine 3734-52-9 Metazocine 17692-51-2 Carbamic acid, [[(8B)-1,6-dimethylergolin-8 21631-37-8 1401935 metergoline yllmethyli-, phenylmethyl ester [CA\$] 2706-42-5 GB 1401935 metformin [CAS] [CAS] 62-51-1 Hethacycline 76-99-3 Methadone 76-99-3 76-99-3 531-06-6	W tabr t renol		586-06-1			
54-49-9 3734-52-9 17692-51-2 Carbamic acid, [[(8B)-1,6-dimethylergolin-8 21631-37-8 yl]methyli-, phenylmethyl ester [CAS] [CAS	Weraproterenol			•	•	•
54-49-9 3734-52-9 17692-51-2 17692-51-2 17692-51-2 17692-51-2 17692-51-2 17692-51-1 17692-51-1 17692-51-1 17692-51-1 17692-51-1 17692-51-1 17692-51-1 17692-51-1 17692-51-1 176-99-3 176	Sulfate				•	
3734-52-9 Carbamic acid, [[(8B)-1,6-dimethylergolin-8 21631-37-8 yljmethylj-, phenylmethyl ester [CAS] imidodicarbonimidic diamide, N,N-dimethylergolin-8 2706-42-5 [CAS] [C	Motorominol		54-49-9			
17692-51-2 Carbamic acid, [[(88)-1,6-dimethylergolin-8 21631-37-8 1401935 1401935 1401935 1401935 1401935 16042-5 1401935 16042-5 16042 1604	Motozocine		3734-52-9			
Carbamic acid, [[(88)-1,6-dimethylergolin-8 21631-37-8 yl]methyll-, phenylmethyl ester [CAS] 2706-42-5 GB 1401935 limidodicarbonimidic diamide, N,N-dimethyl-657-24-9 [CAS] 62-51-1 76-99-3 76-99-3	Melakoonio		17692-51-2	•	•	
[CAS] 657-24-9 657-24-9 [CAS] 62-51-1 62-51-1 76-99-3 76-99-3	. Orillariation	Carbamic acid, [[(8B)-1,6-dimethylergolin-8-wilmethyli-, phenylmethyl ester [CA5]	21631-37-8 2706-42-5	85	1401935	Antiprolactin
[CAS] 82-51-1 62-51-1 76-99-3 531-06-6		imidodicarbonimidic diamide, N,N-dimethyl-				Formulation, modified-release, <=24hr
	metformin		6-4-7-100	1		
	Methacholine		62-51-1			
	Methacycline		914-00-1			
	Methadone		76-99-3			
	Mothofinadono		531-06-6			

Example of Indication	Infection, respiratory tract, tower	olitis, ulcerative			Amenorrhoea Diabetes, Type II	
· X	Infect	ह	<u> </u>	11 11	Otat	

API Generic Name API Chemical Name Methamphetamine Methandrostenolone Methandrostenolone Methapyrilene Methapyrilene Methapyrilene Methidiazine Methidia Methicolone Methidia Methicolone Methidia Methicolone Methidia Methicolone Methicolone Methicolone Methicolone	CAS No. 537-46-2 521-10-8 72-63-9 72-63-9 53-46-3 91-80-5 72-44-6 50-11-3 554-57-4 1982-37-2 100-97-0 153-00-4 130-73-4	Ref rence	Example of Therapeutic Use
olone Sodium	537-46-2 521-10-8 72-63-9 53-46-3 91-80-5 72-44-6 50-11-3 554-57-4 100-97-0 153-00-4 130-73-4 130-73-4		
olone Sodium	521-10-8 72-63-9 53-46-3 91-80-5 72-44-6 50-11-3 554-57-4 100-97-0 153-00-4 130-73-4 130-73-4		
olone Sodium	72-63-9 53-46-3 91-80-5 72-44-6 50-11-3 554-57-4 1982-37-2 100-97-0 153-00-4 130-73-4		
Sodium ine	53-46-3 91-80-5 72-44-6 50-11-3 554-57-4 1982-37-2 100-97-0 153-00-4 130-73-4 15696-06-0		
Sodium	91-80-5 72-44-6 50-11-3 554-57-4 1982-37-2 100-97-0 153-00-4 130-73-4 130-73-4		
Sodium	72-44-6 50-11-3 554-57-4 1982-37-2 100-97-0 153-00-4 130-73-4 130-73-4		
Sodium	554-57-4 554-57-4 1982-37-2 100-97-0 153-00-4 130-73-4 5696-06-0		
Sodium ine	554-57-4 1982-37-2 100-97-0 153-00-4 130-73-4 5696-06-0		
Sodium ine	1982-37-2 100-97-0 153-00-4 130-73-4 5696-06-0		
Sodium ine	100-97-0 153-00-4 130-73-4 5696-06-0		
Sodium	153-00-4 130-73-4 5696-06-0		
Sodium ine	130-73-4 5696-06-0		
Sodium ine	0-90-9695,		
Sodium			
Sodium	132-92-3		
Sodium	0-99-09		
Sodium ine	. 126-31-8		
Sodium ine	503-40-2		
Sodium	63-68-3	•	·
Sodium ine	1910-68-5	· ·	
Sodium ine	467-43-6		
Sodium	2/2/4969		
e Sodium	532-03-6		
e Sodium azine	(22151-68-4		
e Sodium azine	59.05-9	IIS 2512572	Anticancer: antimetabolite
lethotrimeprazine		1	
	.1-66-09		
Meth xamine	390-28-3		
Methoxsalen	298-81-7		
Methoxyflurane	76-38-0	•	
M thoxyphenamine	93-30-1	•	

general

			Patent	ant	sall oftenorement to clamore
API Generic Name	API Chemical Name	CAS NO.	Pe	Kererence	Example of Therapeutic Ose
M thoxypromazine		61-01-8			
Methscopolamine	•	155-41-9			
Methscopolamine			٠		
Nitrate		:		•	
Methsuximide		77-41-8			
Methyclothlazide		135-07-9			
Methyl Blue		28983-56-4			
Methyl Nicotinate		. 2-09-66			
M thyl Propyl Ether		557-17-5			
		119-36-8			
Methyl tert-Butyl Ether		1634-04-4			
Methylbenzethonium		25155-18-4			•
Chloride					
Methylcobalamin		13422-55-4	٠.	٠	
methyldopa	L-Tyrosine; 3-hydroxy-Alpha-methyl- (CAS) 555-30-6	555-30-6			Formulation, modified-release, <=24hr
Methylene Blue		61-73-4			
Methylergonovine		113-42-8	;		
Methylhexaneamine		105-41-9			
methylphenidate	2-Piperidineacetic acid, Apha-phenyl-, methyl ester [CAS]	113-45-1 298-59-9			Formulation, modified-release, multi
Methylprednisolone		83-43-2			
methylprednisolone aceponate	Pregna-1,4-diene-3,20-dione, 21- (acetyloxy)-11-hydroxy-6-methyl-17-(1- oxopropoxy)-, (6Alpha,118)- [CAS]	86401-95-8	EP .	72547	Antipruritic/inflamm, allergic
	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-6-methyl-21-[[8-[methyl(2-				
methytprednisolone suleptanate		90350-40-6	Д	59137500	Antiasthma
M thylthiouracil		56-04-2		·	
Methyltrienolone		965-93-5			
Methyprylon		125-64-4			
Methysergide		361-37-5			
Metiazinic Acid		13993-65-2			
					•

· · ·		
_		
dication		<u>a</u>
	general	disorder
1 to		Gelicit d
	pertension	[B]
d d d		ruritus sthma
M. I. M. M. M. M. M. M. M. M. M. M. M. M. M.		# Z #

•		•	Pat nt	E	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference.	Example of Therapeutic Use
metioranolol	Phenol, 4-{2-hydroxy-3-{(1-methylethyl)amlno]propoxy]-2,3,6-trlmethyl-1-acetate [CAS]	22664-55-7	. 85	GB 1206148	Antihypertensive, adrenergic
metoclopramide	Benzamide, 4-amino-5-chloro-N-[2- (diethylamino)ethyl]-2-methoxy- (CAS)	364-62-5			Formulation, modified-release, <=24hr
Metocurine lodide		7601-55-0			-
Metofenazate		388-51-2.			
	inesulfonamide, 7-chloro-1,2,3,4 2-methyl-3-(2-methylphenyl)-4-	. 0.43.0374	. 51	7	Antihvnertensive. diuretic
metolazone	oxo-[CAS]	14008-44-7		2	
Metopimazine		143-52-2			
Metoprolol		37350-58-6			•
	2-Propanol; 1-{4-(2-methoxyethyl)phenoxy]-51384-51-1	51384-51-1			Formulation, modified-release, other
meroproidi Metralindole		54188-38-4			
Metrizamide		31112-62-6		·.	
Metrizolc Acid		1949-45-7			
Metr n S		13946-02-6			
Metyrapone		54-36-4		-	
Metyrosine		672-87-7			
Mexazolam		31868-18-5			
Mexenone		1641-17-4	-	-	
Mexiletin		31828-71-4		•	•
	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3,3-dimethyl-6-[[[[]3-fimethylsulfonyl)-2-oxo-1-		. :		
mezlocilin	imidazolidinyijcarbonyijaminojphenylacetyij 42057-22-7. aminoj-7-oxo-, [2S-[2Alpha,5Alpha,6B(S')]]51481-65-3 [CAS]	42057-22-7. 51481-65-3 72539-76-5 .	89	1301961	Penicillin, injectable
MFH-244	Benzenecarboximidic acid, 3,4,5-trihydroxy, ethyl ester, hydrochloride.	95933-76-9	NS.	4623659	Cardiovascular
mianserin	Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl[CAS] 24219-97-4	21535-47-7. 24219-97-4		1173783	Antidepressant

:			<i>:</i> ·	 ٠.	•	 		:	 				· · <u>·</u>	٠.	•	, ,		
Example of Indication	Gastro-oesophageal reflux					Hypertension, general						•		Infection, general	Reperfusion Injury		Depression, general	

			١		
•			Patent	ı.	
API Generic Name	API Ch mical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Mibefradil		116644-53-2		•	
Miboplatin		103775-75-3	٠.		
Micafungin		235114-32-6	•		
	1H-Imidazole, 1-(2,4-dichlorophenyl)-2[2,4-dichlorophenyl)methoxylethyl]				Formulation, modified-release, other
Micronomicin		52093-21-7			
midaxifylline	1H-Purine-2,8-dione, 8-(1- aminocyclopentyi)-3,7-dihydro-1,3-dipropyl- [CAS]	151159-23-8	. Sn	5378844	Cardiovascular
midazolam	4H-Imidazo[1,5-a][1,4]benzodiazepine, 8- chloro-6-(2-fluorophenyl)-1-methyl-[CAS]	59467-70-8 59467-94-6		4280957	Anaesthetic, injectable
midecamycin	Leucomycin V, 3,4B-dipropanoate [CAS]	35457-80-8	US	3761588	Macrolide antibiotic
midecamycin acetate	Leucomycin V, 3B,9-diacetate 3,4B- dipropanoate [CAS]	55881-07-7	àſ	49124087	Macrolide antiblotic
midesteine	2-Triophenecarbothloic acld, S-[1-methyl-2 oxo-2-[(tetrahydro-2-oxo-3-thienyl)aminolethyl ester ICAS]	94149-41-4	8	120534	COPD treatment
midodrine	Acetamide, 2-amino-N-[2-(2,5-dimethoxyphenyl)- [CAS]	42318-56-0 42794-76-3	8	164571	Urològical
	Benzamide, N-(2,3,10,11,12,13-hexatydro- 10-methoxy-9-methyl-1-oxo-9,13-epoxy- 1H,9H-diindolo[1,2,3-gh:3',2',1'-				•
midostaurin	imjpyrrolo[3,4-jj[1,7]benzodiazonin-11-yl)- N-methyr-, (9Alpha,10B,11B,13Alpha)- [CAS]	120685-11-2	<u>.</u>	296110	Anticancer, other
rnifepristone	Estra-4,9-dien-3-one, 11-[4- (dimethylamino)phenyl]-17-hydroxy-17-(1- propynyl)-, (118,178)- [CAS]	84371-65-3	EP .	57115	Abortifacient.
Mifepristone		84371-65-3			
miglitol	3,4,5-PiperIdinetriol, 1-(2-hydroxyethyl)-2- (hydroxymethyl)-, [2R- (2Aipha,38,4Alpha,58)]- [CAS]	72432-03-2	G	55431	Antidiabetic
			!		•

mple of Indication	ion, Candida, general	i di di	 ion, general ion, general	ysema, general	tinence	er, leukaemia, acute. genous	ion	ites, Type I
Example	Infection, C	l-inspecified	Infection, g	Emphysema,	Incontinence	Cancer, leuka myelogenous	Abortion	Diabetes,

						r
			Patent	E		
AP! Generic Name	API Chemical Name	CAS No.	Ref	Ref rence	Example of Therapeutic Use	* -1
	3,4,5-Piperidinetriol, 1-butyl-2- (hydroxymethyl)-(2R-(2Alpha, 38, 4Alpha,					:-
migiustat	58)) [CAS]	72599-27-0	出	2758025	Metabolic and enzyme disorders	
mildronate	Hydrazinium, 2-(2-carboxyethyl)-1,1,1; trimethyl-, inner salt-;(CAS)	76144-81-5	8	8001068	Cardiostimulant	•
minacipran	Oyclopropanecarboxamide, 2- (aminomethyl)-N;N-diethyl-1-phenyl-, cis- (±)-[CAS]	101152-94-7 92623-85-3	SN:	4478836	4478836 Antidepressant	· .
Miloxacin		37.065-29-5			•	
mlirinone	[3,4'-Bipyridine]-5-carbonitrile, 1,6-dihydro-2-methyl-6-oxo- [CAS]	78415-72-2	US .	4313951	Cardiostimulant	~~~
millefosine	Ethanarninium, 2- [[(hexadecyloxy)hydroxyphosphinyl]oxy]- N.N.N-trimethyl-, hydroxide, inner salt [CAS]	53949-20-5 58066-85-6	EP .	225608	Anticancer, other.	·
minaprine	4-Morpholineethanamine, N-(4-methyl-6- phenyl-3-pyridazinyl)- [CAS]	25905-77-5 25953-17-7	GB .	1345880	Antidepressant	· ·
	2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxa-14S-	:	•			
minocycline	(4Alpha,4aAlpha,5a.alpha.,12aAlpha)]- [CAS]	10118-90-8			Formulation, optimized, microparticles	т.
minodronic acid	Phosphonic acid, (1-hydroxy-2-imidażo(1,2-a)pyridin-3-ylethylidene)bis-, [CAS]	180064-38-4	. G	354806	Anticancer, other	•
minoxidil	2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide [CAS]	38304-91-5	Sn	4139619	Vasodilator, peripheral	
Miokamycin	•	55881-07-7				,
mirazapine	Pyrazino[2,1-a]pyrldo[2,3- c][2]benzazepine, 1,2,3,4,10,14b- hexahydro-2-methyl-[CAS]	85650-52-8	GB	1543171	Antidepressant	
Mirtazapine		61337-67-5				
misoprostal	Prost-13-en-1-oic acld, 11,16-dihydroxy-16- methyl-9-oxo-, methyl ester, (11Alpha,13E)59122-46-2 (±)- [CAS]		Sn	4301146	Prostaglandin .	·

Example of Indication Gaucher's disease Heart failure Cancer, skin, general Depression, general Infection, oral Hypertension, general Hypertension, general Ulcer, gastric	· · · · · · · · · · · · · · · · · · ·	٠ ا.		·				·——	 •		
	1 6	Heart failu	general	Heart failure	Cancer, skin,	epression, general			epression,	Ulcer, gastric	

					:
ADI Generic Name	API Chemical Name	CAS No.	Pat I Refe	Pat nt Reference	Example of Therapeutic Use
	Erythromycin, 8,9-didenydio-N-denieuryrs-deoxo-6,11-dideoxy-6,9-epoxy-12-O-metryl-N-(1-metrylehryl)-11-oxo-, (2E)-2-	L 90 000		00394800	Gaetronrokinatic
mitemcinal	butenedloate (2:1) [CAS]	154802-95-7	_	3024303	desiron de la companya de la company
mitialinide	Calcium (2S)-2-benzyk-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate, dihydrate-[CAS]	145525-41-3	. <u>a</u>	507534	Antidiabetic
Mitobronitoi		488-41-5		•	
Mitoguazone		459-86-9			
mitolactol	Galactitol, 1,6-dibromo-1,8-dideoxy- [CAS]	10318-26-0	Sn	3993781	Anticancer, alkylating
	- Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-		·		
	dione, 6-amino-8- [[(aminocarbonyl)oxy]methyl]- 1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-				
mitomycin	methyl-, [1aS- (1aAlpha,8ß,8aAlpha,8bAlpha)]- [CAS]	20-07-7	· :	٠	Formulation, parenteral, other
Mitotane		53-19-0			
	uthracenedione, 1,4-dihydroxy-5,8- [(2-hydroxyethyl)amino]-thyl			·. ·.	office according
mitoxantrone	[CAS]	70476-82-3	3	418/248	Anticancer, ourer
miloxantrone	9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-{(2-hydroxyethyl)amino]ethyl]amino]- 65271-80-9 CAS]	65271-80-9 70476-82-9	···	· .	Formulation, optimized, liposomes
MIV-210	(3-Fluoro-2'-3'-dideoxy guanosine)				Antiviral, other
	Isoquinolinium, 2,2'-[(1,8-dioxo-4-octene-1,8-diy])bis(oxy-3,1-propanediyl)]bis[1,2,3,4 tetrahydro-6,7-dimethoxy-2-methyl-1-			·	
mivacurium	((3,4,5-trimetrioxypheny)/metryy-, dichloride, [R-[R*,R*-(E)]]- [CAS]	106861-44-3	Gi	181055	Muscle relaxant
Mivazerol ·		125472-02-8			
mizolastine	4(1H)-Pyrimidinone, 2-[[1-[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-4-piperidinyl]methylamino]- [CAS]	108612-45-9	FP	217700	Antiallergic, non-asthma
Mizorlbine		50924-49-7			
			•		

sophago ssophago ssophago ssophago servical ceast sia, adju sia, adju sia, adju sia, adju	dication eal reflux			virus		<u> </u>
	iple of In	s, Type II	icer,	breast general hepatitis-B	Sia,	Rpinitis, allergic, gene

					•
ADI Conorlo Namo	API Chemical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
MKC-733	(R)-N-(3-quinuclidinyl)-7-oxo-4,7- dihydrothieno[3,2-blpyridine-6- carboxamide hydrochloride	194093-42-0	Ē,	09216888	Gastroprokinetic
MLN-519	6-Oxa-2-azabicyclo[3.2.0]heptane-3,7-dione, 1-[(1S)-1-hydroxy-2-methylpropyl]-4-propyl-, (1R,4R,5S)- [CAS]	211866-70-5	WO	9915183	Neuroprotective
MLN-576	4-Methoxy-benzola]phenazine-11- carboxylic acld (2-(dimethylamino)-1-(R)- methylethyl)-amide				Anticancer, other
moclobemide	Benzamide, 4-chloro-N-[2-(4-morpholinyl)ethyl]- [CAS]	71320-77-9	<u></u>	326023	Antidepressant
modafinii	Acetamide, 2-{(diphenylmethyl)sulfinyl}- [CAS]	68693-11-8.	필·	2809625	Psychostimulant
товхірті	3-Isoquinolinecarboxylic.acid, 2-[2-[[1- (ethoxycarbonyl)-3-phenylpropyljamino]-1- oxopropylj-1,2,3,4-tetrahydro-6,7- dimethoxy- (3S-(2(R*(R*)),3R*))- [CAS]	103775-10-6 103775-14-0	Sn	4344949	Antikypertensive, renin:system
Mofarotene		125533-88-2			
Mofebutazone		2210-63-1	_		
Mofediline		119386-96-8			
mofezolac	5-Isoxazoleacetic acid, 3,4-bis(4- methoxyphenyl)- [CAS]	78967-07-4	ËP	26928	Analgesic, NSAID
	N-[4-(aminomethyl)benzyl]-8(S)-[1-[4-[2-(4-aminophenyl)-acetamido]butyryl]piperidin-4-yl]-2-(napitthalen-1-ylmethyl)-1,3-dioxo-2,3,5,8-tetrahydro-1H-[1,2,4]triazolo[1,2-a]-				
MOL-6131	pyridazine-5(H)-carboxamide			·	Antiasthma
Molindon		7416-34-4			
Molindone Hydrochloride			· _		
molsidomine	Sydnone imine, N-(ethoxycarbonyl)-3-(4- morpholinyl)- [CAS]	25717-80-0	Sn	3769283	Vasodilator, coronary

i.

of Indication	eal reflux	iā		rai	·	 general		ea			·	·. :	. ;	
Evample of In	stro-oeso	Ischaemia, cerebral	 Cancer, general	Depression, general	Narcolepsy	 Hypertension, gen		Pain, post-operative	•	•	· .	Asthma		

		-	Patent		
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	Pregna-1,4-diene-3,20-dione, 9,21-	105102-22-5		• .	
mometasone	(118,16Alpha)- [CAS]	83919-23-7	Ci	57401	Antipruritic/inflamm, allergic
Monatepil		103377-41-9			
Monobenzone		103-16-2			
monolaurin ·	Dodecanoic acid, monoester with 1,2,3- propanetriol [CAS]	27215-38-9	Sn	4885282	Dermatological
Montelukast		158966-92-8			
	Cyclopropaneacetic acid, 1-[[[1-[3-[2-(7-Chloro-2-quinoliny])etheny]]phenyi]-3-[2-(1-			- · · ·	
. washirland continue.	hydroxy-1: methylethyl)phenyl]propyl]thlo]methyl]-, mono sordium salt (R-/F)L (CAS)	151767-02-1	· .	•	Antiasthma
Mont place		122007-85-6			
Monerone		1050-79-9			
Monidamol		13665-88-8	·		•
Moprolol		5741-22-0			•
moracizine	Carbamic acid, [10-{3-{4-morpholinyl}-1- oxopropyl-10H-phenothiazin-2-yl]., ethyl ester [CAS]	29560-58-5 31883-05-3	Sn	3864487	Antiarrhythmic
Morazon		6536-18-1			
Moricizine		31883-05-3			-
Moroxydine		3731-59-7	•		
Morphazinamide		952-54-5			
Morphine		57-27-2			
morphine sulfate	ulfate	64-31-3	7.		Formulation, modified-release, immediate
morphine, Takeda	Morphinan-3,6-diol, 7,8-didehydro-4,5- epoxy-17-methyl- (5Alpha,6Alpha)-, hydrochloride, trihydrate- [CAS]	57-27-2 6055-06-7			Formulation, parenteral, other
morphine-6-glucuronide, UFC	morphine-6-glucuronide				Formulation, inhalable, systemic
. drimanoom	Spirofimidazof1.2-alpyridine-3(2H),4'- piperidinj-2-one, 1'-{3-{3-chloro-10,11- dinydro-5H-dibenz[b,f]azepin-5- uhronylihezahydro-, {4-\text{-}ICAS]	89419-40-9 98043-60-8	. Su	4337260	Neuroleptic
iii Osapiaii iii ia	The second secon		7)		

of Indication		ventricular	
Example of Inc	lchthyosis Asthma	cardia,	Pain, general Pain, cancer Pain, general

•					
			Patent	ŧ	•
API G neric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
chinameter.	Benzamide, 4-amino-5-chloro-2-ethoxy-N- ((4-((4-fluorophenyl)methyl)-2- mombolinylmethyl)- ICASI	112885-41-3 112885-42-4	£.	243959 .	GI inflammatory/bowel disorders
- aniideshiil				 - 	
٠.	Gadolinum, bis(aceterato-rappao)(9,10-10-10-10-10-10-10-10-10-10-10-10-10-1	•			
:	methoxy)ethoxy)-4,15-dimethyi-				
	8,11-imino-3,16;16,13-dinitrilo-1,18-	•		. •	•
	benzodiazacycloeicosine-5,14-		•		
•	dipropanalato-kappaN1, kappaN18,	•			
	kappaN23, kappaN24, kappaN25), (PB-7-			• • •	. Actions and a little
motexafin gadolinium	11-233'2'4) [CAS]	246252-06-2			Hadio/cnemosensinzei .
Motrefinide		56281-36-8			
Moveltinril		85856-54-8		. !	
Movalactam		64952-97-2			
Movetine		3572-74-5			
orizonal distriction of the state of the sta		10539-19-2			
MOXAVELLIO		34816-55-2			
Moxestroi					-
	3-Origonipocarhoxvije acid 1-evelopropvi-6-	:	•		
•	fluoro-1,4-dihydro-8-methoxy-7-(ociahydro-		•		
	6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-;	*B@906.86.R	L	19546249	Ouinolone antibacterial
moxifloxacin .	nydrochiolide (483-613)-				
Moxifi xacin .		151096-09-2			
Moxisvlyte		54-32-0	_		
opposite opping on the contract of the contrac	Phenol, 4-[2-(dimethylamino)ethoxy]-2- methyF5-(1-methylethyl)-, acetate (estar), methylloride [CAS]	984-52-3			Male sexual dysfunction
monsylyte hydrodinonic	5-Pyrimidinamine, 4-chloro-N-(4,5-dihydro-				
	1H-imidazol-2-yi)-6-methoxy-2-methyl- [CAS]	75438-57-2	DE.	2849537.	Antihypertensive, other
	(-)-(S)-2-Methyl-2-(1-oxo-2,3-dihydro-1H-			 	
M-PGA	(isoindol-2-yl)pentanedioic acid	·	SO	5712291	Anticancer, other
	Platinum diamminedichloro-, (SP-4-2) + (R)-4-11-hydroxy-2-(methylamino)-ethyl)-			· 	
	1,2-benzanediol	•	Sn	6224883	Formulation, parenteral, other
INITI-3010					

·	5	· ·	· · · · · · · · · · · · · · · · · · ·							·	-
,	or indicatio			· · ·			sspiratory trac		on, general	general	•
	Ехашы	Gastritis	· · .		, Jan 19 19 19 19 19 19 19 19 19 19 19 19 19		Infection, re general	mootence	Hypertension,	Cancer, ge	

API Generic Name 2,4(1H,3H)-Pyrimidinedia MPI-5020 [CAS] MPI-5020 [CAS] MPI-5020 MS-209 MS-209 MS-209 MS-275 MS-275 MS-377 Muscarine Muscarine Muzolimine Mx-1013	one, 5-fluoro-diphenylacetyl)cloASj (CAS) (cAS) (pyridin-3-yl-methyl]benzamide	ω	Patent US 577 EP 600	50146 50481	Example of Therapeutic Use Formulation, parenteral, other Immunostimulant, other Antiasthma Radio/chemosensitizer
eric Name a- in ne ne nine	<u> </u>	69-0 1-3 1-9		9 -	Example of Therapeutic Use Formulation, parenteral, other Immunositimulant, other Antiasthma Radio/chemosensitizer
a. in ne ine	9	81-2 49:3 8-00-8 1-9			Formulation, parenteral, other immunostimulant, other Antiasthma Radio/chemosensitizer
ln ne nine	<u> </u>	8 0			Antiasthma Antiasthma Radio/chemosensitizer
in ne nine	9	9-0			Antiasthma Radio/chemosensitizer
in ne nine	, " <u>e</u>	9-0-8			Radio/chemosensitizer
in ne nine	9	8-0			•
MS-325 MS-377 Mupirocin Muscarine Muzolimine		9-0-9	1 1 1 1		Anticancer, antimetabolite
MS-377 Mupirocin Muscarine Muzolimine	- 0	오	1. 1 .1. 1	1	
Muscarine Muscalimine		2650-69-0 00-54-9		839805	Neuroleptic
Muscarine Muzolimine		00-54-9	-	: :	
Muscarine Muzolimine			1		
Muzolimine		55294-15-0			
			SU SU	6153591	Hepatoprotective .
	4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-		-		
6-methoxy-7-methyl-3-oxo-5- isobenzofuranyl)-4-methyl-, 2-(4- myconhenolate mofetti morpholinyl)ethyl ester, (E)- [CAS		116680-01-4 128794-94-5	6. OM	9119498	Immunosuppressant
٥		24280-93-1	-		
	4-hexanoic acid. 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, monosodium		:		
salt, (4E)-		37415-62-6	:		Formulation, oral, enteric-coated
Illycopilerione and commit		467-18-5			
Myropini M-		3569-99-1	 		
(Hydroxymethyl)nicotina					•
M'N'N'.		83-81-8			
Tetraethylpntnalamide N≿Formylsulfisomidine		795-13-1			

	<u>.</u>					· · · · · · · · · · · · · · · · · · ·	
Example of Indication	Cancer, breast Vaccine adjunct Asthma	Cancer, breast	Cancer: lung, general Schizophrenia	Unspecified	Transplant rejection, general	Transplant rejection, general	

			L		
			Patent		
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
N4-β-p- Glucosylsulfanilamide		53274-53-6	. /		
N4-		547-52-4		:	
Sulfanilylsulfanilamide		•	:		
Nabilone		51022-71-0			
nabumetone	2-Butanone, 4-(6-methoxy-2-naphthalenyl)-	42924-53-8	GB	1476721	Anti-inflammatory
N-acetylcysteine	L-Cysteine, N-acetyl- [CAS]	616-91-1			Anticancer, other
N-Acetylmethionine		65-82-7	·		
nadifloxacin	1H,5H-Benzo[i]]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1 piperidinyl)-5-methyl-1-oxo-, (+/-)- [CAS]	124858-35-1	SU	4399134	Quinolone antibacterial
nadolol	2,3-Naphthalenedlol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro-[CAS]	42200-33-9		4346106	4346106 Artithypertensive, adrenergic
Nadoxolol		54063-51-3			
nafamostat	Benzoic acid, 4-[(aminoimiriomethyl)amino] 80251-32-7, 6-(aminoiminomethyl)-2-naphthalenyl 81525-10-2 ester- [CAS]	80251-32-7 81525-10-2 82956-11-4	<u>.</u>	450232	Gl inflammatory/bowel-disorders
nafarelin	Luteinizing hormone-releasing factor (pig), 6-13-(2-naphthalenyl)-D-alanine]-[CAS]	76932-56-4 86220-42-0	<u>a</u>	21234	Releasing hormones
Nafcillin		147-52-4			
Nafronyl		31329-57-4			
7 - 7 - 7	2-Furanpropanoic acld, tetrahydro-Alpha- (1-naphthalenylmethyl)-, 2- (diethylamino)ethyl ester	31920-57.4			Formulation, modified-release, other
naftifine	1-Naphthalenemethanamine, N-methyl-N 65472-88-0 (3-phenyl-2-propenyl)-, (E)- [CAS]		Sn	4282251	Antifungal
naftopidil	1-Piperazineethanol, 4-(2-methoxyphenyl)- Alpha-[(1-naphthalenyloxy)/methylj-[CAS] _ [57149-07-2		. su	. 3997666	Antihypertensive, adrenergic
			•		

	•
Example of Indication	
	(
Arthritis, osteo Cancer, general	
	•
Acne	• •
- - -	
	•
Pancreatitis .	
Endometriosis	٠:
Unspecified	-
Infection, dermatological	
lypertension, general	

			١		
			Patent	tu	• •
API Generic Name	API Chemical Nam	CAS No.	Refe	Referenc	Example of Th rapeutic Use
	Morphinan-3,6,14-triol, 17-	20594-83-6			
nalbuphine .	(5Alpha,6Alpha)-[CAS]	23277-43-2	S	3393197	Analgesic, other
Nalidixic Acid		389-08-2			
nalmefene	Morphinan-3,14-diol, 17- (cyclopropylmethyl)-4,5-epoxy-6-methylene ,(5Alpha)-[CAS]	55096-26-9	. <u>a</u> j	56167687	Dependence treatment
Nalorohine		62-67-9			
Naloxone		465-65-6			
naloxone	Morphinan-6-one, 17-allyl-4,5Alpha-epoxy- 3,14-dihydroxy-, hydrochioride [CAS]	357-08-4			Septic shock treatment
nattexone	Morphinan-6-one, 17-(cyclopropylmethyl)- 4,5-epoxy-3,14-dihydroxy-, (5Alpha)-[CAS],	16590-41-3 16676-29-2	ŠN	3332950	Dependence treatment
NAMI	Imidazolium trans(imidazole)(dimethylsulfoxide)tetrachl ororuthenate (III)				Anticancer, other
naminidil	Guanidine, N-cyano-N'-(4-cyanophenyl)-N'' [(1R)-1,2,2-trimethyloropyl]-[CAS]	220641-11-2			Dermatological
Nandrolone		434-22-0	·		
Naphazoline		835-31-4			٠
Naphazoline					
Hydrochloride		00.10			
Naphthal n		31-20-3			
	Methanaminium, 1-carboxy-N, N, N- trimethyl- salt with (R)-6-methoxy- Alpha- methyl-2-nanhfhaleneacetic acid (1:1)				
naproxen betainate	sodium salt [CAS]	104124-26-7	US	4672077	Antiarthritic, other
naproxen sodium	2-Naphthaleneaceitic acid, 6-methoxy- Apha-methyl-, sodium salt, (S)- [CAS]	26159-34-2	GB.	GB 1211.134	Analgesic, NSAID
naproxen sodium	2-Naphthaleneacetic acid, 6-methoxy- Apha-methyl-, sodium salt, (S)- [CAS]	26159-34-2			Formulation, modified-release, other
naproxen	2-Naphthaleneacetic acid, 6-methoxy- Apha-methyl-, (S)-[CAS]	22204-53-1			Formulation, modified-release, multi
· · · · · · · · · · · · · · · · · · ·					

	Example of Indication	
	Pain, general	
		•
	Poisoning, drug	
:		
•		
	Addiction, narcotic/opiate	
	Cancer, general	
•	Alopecia, general	
•	-	
	· .	· .
•	Arthritis, rheumatoid	
	Arthritis, general	
•	Pain, general	
		_

			ŀ	•	
•			Patent	=	
AP! Generic Name	API Chemical Name	CAS No.	R fe	R ference	Example of Therapeutic Use
naratriptan	1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)- [CAS]	121679-13-8	습	303507	Antimigraine
Waratriptan Warochloride			٠.		
More in		131-28-2			
Narcharbital		125-55-3			•
Natamycin		7681-93-8			
nateglinide	D-phenylalanine, N-((4-(1- methylethyl)cyclohexyl)carbonyl)-, trans- [CAS]	105816-04-4	Ë.	196222	Antidiabetic
N-Butyldeoxynojirimycin		72599-27-0		•	
-		149-64-4			
Butylscopolammonium Bromide					
NC-503			Sn	5643562	Anti-inflammatory
NC-531			US.	5643562	Cognition enhancer
NCX-1000			δ.	0061604	Hepatoprotective .
NCX-4016	Benzoic acid, 2-(acetyloxy)-, 2- ((nitrooxy)methyl)phenyl ester [CAS]	175033-36-0	. OM	9716405	Symptomatic antidiabetic
NCX-456 :	Benzoic acid, 5-amino-2-hydroxy-, 4- (nitrooxy)butyl ester [CAS]	256499-26-0	. ``		GI inflammatory/bowel disorders
NCX-950	Alpha'-[[(1,1-dimethylethyl)amino]methyl]-4- hydroxyl-1,3-benzenedimethanol nitrate		·	· /	Antiasthma
n-Docosanol		661-19-8			
NE-100	Benzeneethanamine, 4-methoxy-3-(2- phenylethoxy)-N,N-dipropyl-, hydrochloride [CAS]	149409-57-4	. WO	WO 9307113	Neuroleptic
Nealbarbital		561-83-1	:		
obbito del	2H-1-Benzopyran-2-methanol, Alpha, Alpha'-[iminobis(methylene)]bis(6- iluoro-3,4-dihydro]-, (2H*(R*(8*))))-(1+)-	118457-14-0		EP - 145067	Antihypertensive, adrenergic
nebivoioi	leval.		Ť		

	٠	
	Example of Indication	
	Migraine.	
•		
:		•
		·
••		
	Diabetes, Type II	
		•
		. ·
		•
	Amyloidosis	
	Alzheimer's disease	
	Cirrhosis, hepatic	٠٠.
	Insulin-related metabolic syndrome	
	Inflammatory bowel disease	
	Asthma	.•
	:	
	Schizophrenia	
	Hypertension, general	•

			Į.		
			Patent	ij	
API Generic Namë	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Nebivolol		99200-09-6		.	
nebostinel	N1-(4,4-Dimethylcyclohexyl)-L- isoglutamine	163000-63-3	ED.	0688312	Cognition enhancer
Nehracetam		97205-34-0			
nedaplatin	Piatinum, diammine[hydroxyacetato(2-)- 01,02]-, (SP-4-3)- [CAS]	95734-82-0	Щ.	216362	Anticancer, alkylating
nedocromil	4H-Pyrano[3,2-g]quinoline-2,8-dicarboxylicacid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl- [CAS]	69049-73-6 69049-74-7	EP	555718	Antiasthma
nedocromii sodium, Allergan	4H-Pyrano[3,2-g]quinoline-2,8-dicarboxylic acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-,[CAS]	69049-73-6 69049-74-7			Ophthalmological
Nefazodone	٠	83366-66-9			
nefazodone hydrochloride	3H-1,2,4-Triazol-3-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl[propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-, monohydrochloride [CAS]	82752-99-6 83366-86-9	SN	4338317	Antidepressant
nefiracetam	1-Pyrrolidineacetamide, N-(2,6-dimethylphenyl)-2-oxo- [CAS]	77191-36-7	Sn	4341790	Cognition enhancer.
nefopam	1H-2,5-Benzoxazocine, 3,4,5,6-tetrahydro-5-methyl-1-phenyl-[CAS]	13669-70-0 23327-57-3	Sn	3487153	Analgesic, NSAID
Negamycin		33404-78-3			
Nelfinavir		159989-64-7	-		
	3-Isoquinolinecarboxamide; N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-				,
nelfinavír mesylate	(2(2S*,3S*),3Alpha,4aB,8aB))-, monomethanesulfonate (saft)- [CAS]	159989-65-8		•	Antiviral, anti-HIV.
Nemonapride		75272-39-8			
N ostigmine		59-99-4			
	Cyclo[3-amino-L-alanyl-L-leucyl-N-[2- (acetylamino)-2-deoxy-B-D-glucopyranosyf]		•		
nepadutant	L-asparaginyl-L-Alpha-aspartyr-trypropriyi L-phenylalanylj, (4-1)-lactam [CAS]	183747-35-5	WO	9628467	Antiasthma
петатехапе	1,3,3,5,5-pentamethylcyclohexylamine	202807-80-5 219810-59-0		·	Dependence treatment

• •	Example of Indication	
	Unspecified	
•		'
		•
	Rhinitis, allergio, general	•
	Ocular disorder, general	
		•
•	Depression, general	٠.
	Dementia, senile, general	
	٠	
-		
	. :	
	Infection, HIV/AIDS	
•		•
	Asthma	
	Addiction, alcohol	
-		

			Patent	E	
API Generic Name	API Chemical Name	CAS No.	R fe	ference	Example of Therapeutic Use
neridronic acid	Phosphonic acid, (6-amino-1- hydroxyhexylidene)bis- [CAS]	79778-41-9		• 1	i Musculoskeletal
Neriifolin		466-07-9			
N-Ethylamphetamine		457-87-4			
•	1H-Imidazole, 1-[2-(methylthio)-1-[2- (penyloxy)phenyljethenyl]-, monobydzochloride, (El- [CAS]	130773-02-3	EP	445540	Antifungal
Neticonazole		130726-68-0	-	,	
	D-Streptamine, O-3-deoxy-4-C-methyl-3 (methylamino)-B-L-arabinopyranosyl-(1-6)-			· ·	
netilmicia	O-[2,8-diamlno-2,3,4,6-tetradeoxy-Alpha-D-glycero:hex-4-enopyranosyl-(1-4)]-2-deoxy-56391-56-1 N1-etnyl- [CAS]	56391-56-1 56391-57-2	99	1473733	Aminoglycoside antibiotic
	6H-Dipyrido[3,2-5:2',3'-9][1,4]diazepin-6-				
	CAS	129618-40-2	EP		Antiviral, anti-HIV
NGD-98-2			WO,	9635689	Anxiolytic
Nialamide		51-12-7			
Niaprazine		27367-90-4		-	
Nicametate		3099-52-3			
nicaraven	3-Pyridinecarboxamide, N.N-(1-methyl-1,2-ethanediyl)bis- [CAS]	79455-30-4	G	29602	Neuroprotective
nicardiolne	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester [CAS]	54527-84-3 55985-32-5	SO	3985758	Neuroprotective
nirardinina	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino)ethyl ester ICAS]	54527-84-3 55985-32-5			Formulation, modified-release, other
	Ergoline-8-methanol, 10-methoxy-1,6- dimethyl-, (8/b)-, 5-bromo-3-				
nicergoline	pynanicaanooy, and comp	27848-84-6			Formulation, modified-release, other
Niceritrol		5868053			
				-	

Example of Indication Osteogenesis imperfecta Infection, Candida, general Infection, HIV/AIDS Arxfety, general Haemorrhage, subarachnoid Hypertension, general Unspecified Unspecified

-				1	
A DI Consulto Nomo	ADI Chemical Name	CAS No.	Refe	Reference ·	Example of Therapeutic Use
Michesmide		50-65-7		•	
Nicoclonate		10571-59-2			
Nicofuranose		15351-13-0.			
Nicomol		27959-26-8			
Nicomorphine		639-48-5			
nicorandii	3-Pyridinecarboxamide, N-[2- (nitrooxy)ethyl}-[CAS]	65141-46-0 ·	SO	4792564	Vasodilator, coronary
Nicotinamide		98-92-0			
nicotine	Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- [CAS]	54-11-5			Formulation, inhalable, other
Nicotinic Acid		59-67-6	•		
Nicotinic Acid Benzyl		94-44-0	<u></u>	•.•	· .
Ester		0 40 007			
Nicotinyl Alcohol		100-00-	1		
nifedioine	4-(2'-ritrophenyl)-2,6-dimethyl-3,5- dicarbomethoxy-1,4-dihydropyridine	21829-25-4	 GB	1173862	Vasodilator, coronary
·					
·	2,4(1H,3H)-Pyrimidinedione, 6-[[2-[(2-		•	· .	
	J-1,3-	430836-43-0	· · 0		Antiarrhythmic
nifekalant hydrochloride	dimethyl-, monohydrochloride-(CAS)	0-10-0000FL		309051	
Nifenalol		7413-36-7			
Niflumic Acid :		4394-00-7.			
Nifurate		4936-47-4			
Nifurfoline		3363-58-4			
Nifuroxazide		965-52-6			
Nifuroxime		6236051			
Nifurpirinol		13411-16-0	•		
Nifurorazine		1614-20-6			
Nifurtimox		23256-30-6			
Nifurtoinol		1088-92-2	·		
	2-Thiophenecarboxylic acid, 5-nitro-, [3-(5-nitro-2:furanyl)-2-propenyildenejhydrazide ICASI	39978-42-2		3847911	Antidiarrhoeal
miurziae	i compa				

ample of Siction, nicc Siction, nicc Siction, nicc Siction, nicc Siction, nicc Siction (31 the section (31 the	_		٠		 		 	ـنــ	 -	 		 ·.	 ·	Α.	_	_	<u>.</u>	•	٠.	 		<u> </u>
		∵ *5			-	Npertension, general	ddiction,					Aurhythmia, general									· 	Infection, GI tract

:		· .	Patent	int .	
API Generic Name	API Chemical Name	CAS No.	Refe	Réference	Example of Therapeutic Use
NIK-254	Gentamicin, sulfate (salt) [CAS]	1405-41-0			Formulation, other
Nikethamid		59-26-7			
nilutamide	2,4-1midazolidinedione, 5,5-dimethyl-3-{4-nitro-3-(trifluoromethyl)phenyl}-[CAS]	63612-50-0	SŅ	4472382	Anticancer, hormonal
nllvadipine	3,5-Pyridinedicarboxyilo acid, 2-cyano-1,4-1 dihydro-6-methyl-4-(3-nitrophenyl)-, 3- methyl 5-(1-methylethyl) ester [CAS]	75530-68-6	us.	4338322	Antihypertensive, other
nimesulide	Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)- [CAS]	51803-78-2	Sn	3840597	Anti-inflammatory
Nimetaz pam		2011-67-8			
	3,5-Pyridinedicarboxyllc acid, 1,4-dlhydro-		,		
nimodipine	methoxyethyl 1-methylethyl ester [CAS]	66085-59-4	<u>а</u> .	533014	Neuroprotective
Nimorazole		6506-37-2			
nimustine	Urea, N'-[(4-amino-2-methyl-5- pyrimidinyl)methylj-N-(2-chloroethyl)-N- nitroso-[CAS]	103745-00-2 42471-28-3 55661-38-6	B	1374344	Anticancer, alkylating
Ninopterin		2179-16-0			•
NIP-142	N-[4(S)-(Cyclopropylamino)-3-(R)-hydroxy- 2,2-dimetnyl-7-nitro-3,4-dihydro-2H-1- benzopyran-6-ylj-4- methoxybenzeneacetamide		WO	9804542	Antiarrhythmic
	N-[3,5-Bis(trifluoromethyl)benzyl]-N-[3-[N- [1-(4-fluorobenzyl)benzimidazol-2-yl]- amino]propyl-N-methylurea hydrochloride				Antiprurtio/Inflamm, allergic
niperotidine	N-{2-[[5- [{dimethylamino)methyl]turturyl]thio]ethyl]-2: ntro-N'-piperonyl-1,1-ethenediamine	84845-75-0	. GB	2104071	Antluicer
nipradilol, ophthalmic	2H-1-Benzopyran-3-ol, 3,4-dihydro-8-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, 81486-22-8 3-nitrate [CAS]	81486-22-8 86247-86-1	di di	42299	Formulation, mucosal, topical
Niridazole		61-57-4			
				· 	•

·	<u> </u>	<u> </u>	· '•	
Example of Indication Infection, general Cancer, prostate	Hypertension, general Pain, general	Cancer, brain	Eczema, atopic Ulcer, Gl, general	Glaucoma

			Patent	ŧ	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	3,5-Pyridinedicarboxylic acid, 1,4-dihydro 2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-				
nisoldipine	methylpropyl ester- [CAS]	63675-72-9	<u>B</u>	15:16793	Antihypertensive, other
nitazoxanide	Benzamide, 2-(acetyloxy)-N-(5-nitro:2-thiazolyf)[CAS]	55981-09-4	SN	5387598	Protozoacide
nitisinone	1,3-Cyclohexanedione, 2-[2-nitro-4- (trifluoromethyl)benzoyl]- [CAS]	104208-65-7	G _L	186118	Metabolic and enzyme disorders
ntracrine	1,3-Propanediamine, N,N-dimethyl-N'-(1- nitro-9-acridinyl)- [CAS]	4533-39-5. 6514-85-8	Æ	1458183	Anticancer, other
Nitrazepam		146-22-5			•
nitrendioine	3.5-Pyridinedicarboxylic acid, 1,4-dihydro- 2.6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester- [CAS]	39562-70-4	g	1358951	Antihyperterisive, other
	(1,1'-Biphenyl)-4-acetic acid, 2-fluoro- Anha-methyl. 4-fnitrooxylntyl ester				
nitroflurbiprofen	[CAS]	158836-7.1-6	a	670825	Urological
Nitrofurantoin		67-20-9			
Nitrofurazone		59-87-0			
nitroglycerin	1,2,3-Propanetriol, trinitrate [CAS]	55-63-0		•	Formulation, transdermal, patch
Nitromersol		133-58-4		•	
nitronaproxen	2-Napthaleneacetic acid, 6-methoxy-Alpha- methyl 4-(nitrooxy)butyl ester (AlphaS)- [CAS]	163133-43-5	ом 	9509831	Analgesic, NSAID
nitroxazepine	Dibenz[b,f][1,4]oxazepin-11(10H)-one, 10- [3-(dimethylamino)propyi]-2-nitro-, monohydrochloride [CAS]	16398-39-3	Z	6608671	Antidepressant
Nitroxoline		4008-48-4			
	nenediamine, N-[2-[[[2- thylamino)methyl]-4- yl]methyl[thio]ethyl]-N-methyl-2-nitro				
nizatidine	[CAS]	/oses-41-2	1	48010	Anilaicer
Nizofenone		54533-85-6			
	3-(2-methyloarboxymethyl)-6-methoxy-8- hydroxy-Isocoumarin		<u>.</u>		Anticanner other
NIM-3			5	7	יייייייייייייייייייייייייייייייייייייי

	Example of Indication	
	Hypertension, general	
	Infection, GI tract	•
	Cirrhosis, hepatic	
	Cancer, ovarian	
		•
•	Hypertension, general	
	Incontinence	
•		
	Angina, general	
•		
•	Pain, post-operative	•
		•
		•
•		
$\overline{}$	Uicer, duodenai	
-		
•		
•	Cancer, general	
-		

			Daton		
		•	Jar.		
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	4-Bromo-5-(3-pyridylmethylamino)-6-[3-(4-				
	chlorophenyl)propoxyl-3(ZH)pyridazinone			· :	•
NIAL ZOO					Antithrombotic
		FE9.70.4	1.		
N-Methylephedrine		757.00	1		
N-Methylepinephrine		554-98-4	1		
N-Methylqfucamine		6284-40-8			
				. •	: .
	6-chloro-3-(1-methylcyclopropylamino)-4H-	.: ::	•		•
	thieno(3,2-e)-[1,2,4]thiadiazine-1,1-dioxide			•	Antidiahatic
NN-414 · · · ·					
	(R)-1-(3-(10,11-dibydro-5H-				
•	dibenzola,dicyclonepten-5-ylidene)-1-	•	•		•
	propyi)-3-piperiaine carboxyiic acid		•	•	Symptomatic antidiabetic
NNC-05-1869					
Nogalamycin		1404-15-5			
Nolatrexed		147149-76-6			
	4(1H)-Quinazolinone, 2-amino-6-methyl-5-		. و		Anticancer antimetabolite
nolatrexed dihydrochloride	(4-pyridinylthio)-, dihydrochloride [CAS]	152840-08-4		902000	
	Propanolc acid, 2-methyl-, 5,6,7,8-				
	naphthalenediyl ester, hydrochloride, (+/-)-				
nolomirole	[CAS]	138531-51-8.	9	9529147	Cardiostimulant
	1-Azoniabicyclo[2.2.2]octane, 1-[2-[3-(3,4-			• ;	
•	dichlorophenyl)-1-[[3-(1-	· .			
	piperidinyljethylj-4-phenyl-, chloride, (S)-			-	
	[cAS]	153050-21-6	<u>.</u>	591040	GI inflammatory/bowel disorders
	19-Norpregna-4,6-diene-3,20-dione, 17-	58652-20-3	DE	2522533	Menstruation disorders
ນດາເເອນີຂອນດາ	(acc) (con)	04500 64 5	Т		
Nomifensine		24520-04-5		-	
Noprvisulfamide		576-97-6		.	
Norbolethone		1235-15-0			
Nordazepam		1088-11-5			

			Ľ		
		: -	Patent	-	
API Generic Name	API Chemical Name	CAS No.	Reference	ence	Example of Therapeutic Use
Mordofrin		6539-57-7		-	
	•	(unenocition):			
•		14040 CO 0		·	• •
		14612-03-0	<u>-</u>	•	
•		(H,S*)-(±)-	·,-	•	· ·
		form	•		
Mordibydroniajarotic		27686-84-6	•		. ·
		(meso-form):	-		•
Acia		E00.39.0	<u> </u>	•	
	•	6-00-000	<u> </u>		
-		(unspecified)			
Norelgestromin,			·· :		
Ethinyl Estradiol			•	· ."	
No. of the state o		51-41-2	-		
Notebillebilline		52-78-8			
Noremandiolone		7 00 00		- - -	
Norethindrone		P2-77-90	1		
Norethynodre		68-23-5			
Norfenefrine		536-21-0	·		
				•	
norfloxacin	3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-68077-27.0 1 4-dihydro-4-oxo-7-(1-piperazinyl)- [CAS] 70458-96-7	68077-27-0 70458-96-7	US.	4146719.	Ouinolone antibacterial
Noraesterone		13563-60-5			
Nordestimate	:	35189-28-7	·		
Nordestrel		6533-00-2			
Nornestrienone		848-21-5			
Nortevorohanol		1531-12-0			
Normethadone		467-85-6			
Normethandrone		514-61-4			
Normorphine		466-97-7			
Nornhenazone		89-25-8			
Nornipanone		561-48-8			
Nornseudoenhedrine		492-39-7		·	
		72-69-5	Ċ	, ¹	
Noministerone		6795-60-4			
Moceanine		128-62-1			
West and the Principles of the		1936-40-9	-		
Novembicini					

indication						
6 .	: :		, general			
Example			infection,		1.	

				-	
			Patent	E .	
API Generic Name.	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Novobiocin		303-81-1			
Noxiptllin		3362-45-6	•		
Noxythiolin	·	15599-39-0		:	
	Butanoic adid, 2-[[[5-[4- [(dimethylamino)sulfonyl]phenyl]-; 1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-		· · ·		
NS-1209	pyrrolo[3,2-h]isoquinolin-3- yiidene]amino]oxy]-3-hydroxy- [CAS]	254751-28-5	 MO	9426747	Antlepileptic
	5-(4-chlorophenyl)-6,7,8,9-tetrahydro-1H-pyrolo-(3,2-h]naphthalene-2,3-dione-3				
NS-1231	oxine	•	:		Neuroprotective
NS-126			Sn	5063222	Antiallergic, non-asthma
	2-Methyl-c-5-[4-[5-methyl-2-(4- methylphenyl)-4-oxazolyl]butyl]-1,3-				
NS-220	dioxane-r-2-carboxylic acid		•	• .	Hypolipaemic/Antiatherosclerosis
NS-2330	NS 2330 [CAS]	402856-42-2		 - • .	Cognition enhancer
NS5A inhibitors, Questcor			Sn	6030785	Antiviral, other
NS-7	Pyrimidine, 4-(4-fluorophenyl)-2-methyl-6- ([5-(1-piperidinyl)pentyljoxy]-, monohydrochloride [CAS]	178429-67-9	ОМ	9607641	Neuroprotective
	2-Amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile			,	Importing
NS-8					
NSC-330507 ·	17-Aliyiaminogeidanamycin				Anticancer, antibiotic
NSC-619534	2-chloroethyl phenyl selenone				Anticancer, alkylating
NSC-697726	2,5-diazinidinyl-3-flydroxymethyll6-methyl- 1,4-benzoquinone				Anticancer, antibiotic
N-Sulfanilyl-3,4-xylamide		120-34-3		٠	
VU-6027	2,4-Pyrimidinediamine, 6- (cyclohexylmethoxy)-5-nitroso- [CAS]	220036-08-8			Anticancer, other
NV-07	2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-sec-pentyl-, 2-oxime (CAS)	53745-16-7	S	6455032	Antipruntic/Inflamm, non-allergic
	. P. G				•

1			. · ·	: .	•	· ·	٠. ـــ		•								
Example of Indication		Epilepsy, general		ia, ceret	Rhinitis, allergic, general		Atherosclerosis	Alzheimer's disease	Infection, hepatitis-C virus		Ischaemia, cerebral	incontinence	Cancer, general	Cancer, general	Cancer, general	Cancer, general	Keratosis
•										•			•	•			-

		,	Patent	Ħ	•
API G n ric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	((3R,48R,10aR)-1,2,3,4,4a,5,10,10a- Octahydro-6-methoxy-1-methyl- benz[g]quinoline-3-carboxylic acid-4-(4- nitrophenyl)piperazine amide, hydrogen				
NVP-SRABBO	maleate				Neurological
	(S)-(+)-2-(4-(2- fluorobenzyloxy)benzylamino]propanamide methansulfonate				
NW-1029					Analgesic, other
NXY-059	CPI 22 [CAS]	168021-79-2	SO	5780510	Neuroprotective
Nylidrin		447-41-6			
NZ-314	1-Imidazolidineacetic acid, 3-[(3- nitrophenyl)methyl]-2,4,5-trioxo- [CAS]	128043-99-2	ED.	353198	Symptomatic antidiabetic
NZ-419	5-bydroxy-1-methylimidazolidine-2,4-dione		<u>B</u>	412940	Urological
Obidoxim Chl ride		114-90-9			
OC-108	OC 108 [CAS]	162602-62-2			Vasoprotective, topical
ocinaplon	Methanone, 2-pyridinyl]7-(4- pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]- [CAS]	96604-21-6	G	129847	Anxiolytic
Octabenz ne		1843-05-6			
Octacaine		13912-77-1			
Octam xin		4684-87-1			
Octav rin		549-68-8			
ectenidine	1-Octanamine, N,N'-(1,10-decanediyldi- 1(4H)-pyridinyl-4-yildene)bis- [CAS]	70775-75-6 71251-02-0 86767-75-1	ОМ	8705501	Stomatological
Oct drin		543-82-8			
Octopamine		104-14-3			
Oct tiamine		137-86-0			
octreotide, Atrigel	L-Cysteinamide, D-phenylalanyl-L-cysteinyl L-phenylalanyl-D-tryptophyl-L-fysyl-L- threonyl-N-[2-hydroxy-1- (hydroxymethyl)propyl-, cyclic (2-7)- disulfide, [R-(R*,R*)]- [CAS]	83150-76-9			Formulation, fixed-dose combinations

Example findication
Unspecified
Pain, general
Ischaemia, cerebrai
Neuropathy, diabetic
Renal failure
Venous Insufficiency
Generalized anxiety disorder
Periodontitis
·
Cancer, general

			Patent	nt	i
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Octyl Methoxycinnamate		5466-77-3			
ofloxacin	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+/-)- [CAS]	82419-36-1	8	47005	Quinolone antibacterial
-lod hippurat Sodium		133-17-5			
olanzapine	10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyf-4-(4-methyl-1-piperazinyl)- [CAS]	1	8	454436	Neuroleptic .
Oleandrin		465-16-7			
Oleic Acid		112-80-1			
olmesartan medoxomil	1H-Imidazole-5-carboxylic acid, 4-(1- hydroxy-1-methylethyl)-2-propyl-1-((2-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester [CAS]	144689-63-4	. 0	503785	Antihypertensive, renin system .
olopatadine hydrochloride	11-[(Z)-3-(Dimethylamino)propylidene]- 6,11-dihydrodibenz[b,e]oxepin-2-acetic acid, monohydrochloride	113806-05-6 140462-76-6	G G	235796	Ophthalmological
olpadronic acid	Monosodium 3-dimethylamlno-1- (hydroxypropylidene)-1,1-bisphosphonate		O _M	9619998	Osteoporosis treatment
olsalazine	Benzoic acid, 3,3'-azobis[6-hydroxy- [CAS]	15722-48-2 53200-51-4	Sn	4559330	GI inflammatory/bowel disorders
oltipraz	3H-1,2-Dithiole-3-thione, 4-methyl-5- pyrazinyl- [CAS]	64224-21-1	띰	2705641	Anticancer, other
ОМ-294DP	2-[3(R)-(Dodecanoyloxy)tetradecanamido]- N-[4-[3(R)-hydroxytetradecanamido]-5- (phosphonooxy)pentyl]-4- (phosphonooxy)butyramide				Anticancer, immunological

Exampl findication
Schizophrenia
Hypertension, general
Conjunctivitis
Osteoporosis
Colitis, ulcerative
Cancer, general
Unspecified
on opening

			Patent	nt	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
•	ethyl (52,82,112,142,172)-elcosa- 5,8,11,14,17-pentaenoate + ethyl (42,72,102,132,162,192)-docosa- 4,7,10;13,16,19-hexaenoate	81926-94-5		•	
Omacor		86227-47-6			Hypolipaemic/Antameroscierosis
omapatrilat	7H-Pyrido(2,1-b)(1,3)thlazepine-7-carboxylic acid, octahydro-4-((2-mercapto-1-oxo-3-phenylpropyl)amino)-5-oxo, (4S-(4Alpha(R*),7Alpha,10a3))- (CAS)	167305-00-2	sn	5508272	Antihypertensive, renin system
omeprazole	1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- [CAS]	73590-58-6	Sn	4255431	Aņtiulcer
omiloxetine	Ethanone, 2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)-, rel- [CAS]	176894-09-0			Antidepressant
omoconazole	1H-imidazole, 1-{2-{2-{4- chlorophenoxy)ethoxyl-2-{2,4- dichlorophenyl}-1-methylethenyl]-, (Z)- [CAS]	74512-12-2	ф	8804	Antifungal
Onapristone		96346-61-1			
ondansetron	4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]- [CAS]	99614-01-4 99614-02-5	Sn	4847281	Antlemetic
ONO-3403	Benzoic acid, 4-[(1E)-3-[(2-ethoxy-2-oxoethyl)-2-propenylaminoj-2-methyl-3-oxo-1-propenyl]-, 4-(aminoiminomethyl)phenyl ester, monomethanesulfonate [CAS]	181588-07-2			GI inflammatory/bowel disorders
ONO-4128	1,4,9-Triazaspiro(5.5)undecane-2,5-dione, 1-butyi-3-(cyclohexylmethyl)-9-((2,3-dihydro-1,4-benzodioxin-6-yl)methyl-[CAS]	342394-93-8		•	Antiviral, anti-HIV
ONO-8815 Ly	L-lysine (Z)-7-[(1R,2R,3R,5R)-5-chloro-3- hydroxy-2-[(E)-(S)-4-(1-ethyloyclobutyl)-4- hydroxy-1-butenyl]cyclopentyl]-5- heptenoate				Labour inhibitor

Exampl f Indication
Hypertriglyceridaemia
Hypertension, general
Ulcer, GI, general
Depression, general
Infection, dermatological
Chemotherapy-induced nausea
Unspecified
Infection, HIV/AIDS
Labour, preterm

			Patent	Ħ	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
ONT-093			S	5756527	Radio/chemosensitizer
OPC-14523	Z(1H)-Quinolinone, 1-[3-[4-(3- chlorophenyl)-1-piperaziny]propyl]-3,4- dihydro-5-methoxy- [CAS]	145969-30-8	G.	512525	Antidepressant
OPC-31260	Benzamide, N-[4-[[5-(dimethylamino)- 2,3,4,5-tetrahydro-1H-1-benzazepin-1- yl]carbonyl]phenyl]-2-methyl-	137975-06-5	N N	9105549	Urological
OPC-51803	(5R)-2-{1-(2-chloro-4-(1-pyrolidinyl)benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-isopropylacetamide				Antidiabetic
OPC-6535	2-Pyridinecarboxylic acid, 6-{2-(3,4-diethoxyphenyl)-4-thiazolyl]- {CAS}	145739-56-6	9	9209586	GI inflammatory/bowel disorders
Opiniazid		2779-55-7			
opioid analgesics, Adolor	2-(4-trifluoromethylphenyl)-N-methyl-(1- phenyl-2-(1-pyrolidinyl)ethylacetamide	•			Analgesic, other
Opipramot		315-72-0			
Orazamide		2574-78-9			
orazipone	2,4-Pentanedione, 3-((4- methylsulfonyl)phenyl)methylene)- [CAS]	137109-78-5	G	440324	Antiasthma
Org-12962	Piperazine, 1-[6-chloro-5-(trifluoromethyl)-2 pyridinyl]-, monohydrochloride [CAS]	210821-63-9			Antidepressant
Org-24448.			SN	6166008	Neuroleptic .
oritavancin	7	171099-57-3	Sn	5840684	Peptide antibiotic
orlistat	L-Leucine, N-formyl-, 1-[(3-hexyl-4-oxo-2-oxetanyl)methyljdodecyl ester, [2S-[2Alpha(R*),38]]- [CAS]	96829-58-2	EP	129748	Anorectic/Antiobesity
ormeloxifene	Pyrrolidine, 1-{2-{p-(7-methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl]-, trans- [CAS]	31477-60-8	DE	2329201	Female contraceptive
Ornidazole		16773-42-5			

Exampl of Indication	
enera	
Depression, general	
Unspecified	
Diabetes, insipidus	
Inflammatory bowel disease	
Pain, general	
Unspecified	
Depression, general	
Schizophrenia	
Infection, dermatological	
Obesity	
Contraceptive, female	

ADI C. noric Name	API Chemical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
Ornipressin		3397-23-7			
Ornithine		70-26-8			
(Jisaaawa	Prost-13-en-1-oic acid, 11,15-dihydroxy-17,20-dimethyl-6,9-dioxo-, methyl ester, (11Alpha,13E,15S,17S)- [CAS]	70667-28-4	SN	4278688	Prostaglandin
Orotle Acid		65-86-1			
Ornhenadrine		83-98-7			
Orth cain		536-25-4			
Osalmid		526-18-1			
osenetant	Acetamide, N-[1-[3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl]propyl]-4-phenyl-4-piperidinyl]-N-methyl- [CAS]	160492-56-8	<u>6</u>	673928	Neuroleptic
osaterone acetate	2-Oxapregna-4,6-diene-3,20-dione, 17- (acetyloxy)-6-chloro- [CAS]	105149-00-6	<u>a</u>	193871	Prostate disorders
	1-Cyclohaxene-1-carboxylic acid, 4- (acetylamino)5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3Alpha, (48,5Alpha))-				
oseltamivîr	[CAS]	196618-13-0	οM	9626933	Antiviral, other
OSI-7836	4-Thio-B-D-arabinofuranosylcytosine				Anticancer, antimetabolite
OSI-7904	Pentanedioic acid, 2-{5-[[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino]-1,3-dihydro-1-oxo-¿H-isoindol-2-ylj-, (S)- [CAS]	139887-54-5	WO	9119700	Formulation, optimized, liposomes
ospemifene	Ethanol, 2-[4-[(12)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]- [CAS]	128607-22-7	οM	9607402	Menopausal disorders
oŭĵonium bromide	Ethanaminium, N,N-diethyl-N-methyl-2-[[4- [[2-(octyloxy)benzoyljamino]benzoyljoxy]-, bromide [CAS]	26095-59-0		1181406	Antispasmodic
Ouabain		630-60-4			
Oxaceprol		33996-33-7			
Oxacillin		66-79-5			
Oxaflozane		26629-87-8			

Example of Indication	Ulcer, gastric	Schizophrenia Benign prostatic hyperplasia	Infection, influenza virus Cancer, general	Cancer, general Osteoporosis	Irritable bowel syndrome
-----------------------	----------------	---	---	---------------------------------	--------------------------

)

eric Name	ADI Chemical Name		Patent	ŧ	Example of Thereneutle lies
		CAS No.	Reference	rence	באמוווסום כו וופומאפתיי איי
loxalipiaun	Platinum, (1,2-cyclohexanediamine- N,N)[ethanedioato(2-)-O,OT-, [SP-4-2-(1R- trans)]- [CAS]		G G	393575	Anticancer, alkylating
	1,2,3-Propanetricarboxylic acid, 2-hydroxy- , potassium sodium salt (CAS)	28060-67-5	30	2249274	Urological
rin		15301-80-1			
Ovametacine	•	27035-30-9			
Oxamniquin		21738-42-1			•
	2-Oxaandrostan-3-one, 17-hydroxy-17- methyl-, (5Alpha,178)- [CAS]	53-39-4	S	3128283	Reproductive/gonadal, general
		36531-26-7			
nanium 1 dide		541-66-2			
	2-Oxazolepropanoic acid, 4,5-diphenyl- [CAS]	21256-18-8	GB	1206403	Antiarthritic, other
	2H-Benzimidazol-2-one, 1-{3-{4-} (diphenylmethyl)-1-piperazinyl]propyl]-1,3- dihydro-[CAS]	60607-34-3	GB	1579365	Antiallergic, non-asthma
	7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl- 2H-1,4-benzodiazepin-2-one	604-75-1			Formulation, oral, orally-disintegrating
O mejozexo	Oxazolo[3,2-d][1,4]benzodlazepin-6(5H)- one, 10-chloro-2,3,7,11b-tetrahydro-2- methyl-11b-phenyl- [CAS]	27167-30-2	Sn	3772371	Anxiotytic
apine	5H-Dibenz[b,fjazepine-5-carboxamide, 10,11-dihydro-10-oxo-[CAS]	28721-07-5 29331-92-8	H	2011087	Antiepileptic
		468-61-1		·	
Oxend I ne		33765-68-3			
Oxethazain	•	126-27-2			•
Oxetorone	•	26020-55-3			
	Ethanone, 1-(2,4-dichlorophenyl)-2-(1H- imidazol-1-yl)-, O-[(2,4-		a	151.1870	Antifuna
oxiconazole	dichlorophenyl)methyljoxime, (Z)- [CAS]	04211-43:0	g:	0.04101	in the second se
Oxidr nic Acid		15468-10-7			
Oxiniacic Acid .		2398-81-4			
Oxiracetam		62613-82-5			

Exampl of Indication Cancer, colorectal Sex-chromosome abnormality, Turner's syndrome Arthritis, osteo Arthritis, allergic, general Epilepsy, general Infection, fungal, general
--

A Nome	ADI Chemical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
	3-Oxa-9-azonlatricyclo[3.3.1.02,4]nonane, 9-etryl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-metryl-, bromide, [7(S)-	. 25 2000	<u> </u>	1178305	Antisethma
oxitroplum	(1Alpha,28,48,5Alpha,78)]- [CAS]	30280-73-0	9	333	
Oxolamin		959-14-8			
Ox Ilnic Acid	•	14698-29-4			
Ox phenarsine		538-03-4			
Oxpren lol		6452-71-7			
Oxyb nzone		131-57-7			
. ujuthuko	Benzeneacetic acid, Alpha-cyclohexyl- Alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester- [CAS]	5633-20-5			Formulation, modified-release, other
Oxioinohonhon		485-89-2			
Oxyginenopilen					
	Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5Alpha)-	76-42-6	,		Formulation, transmucosal, nasal
Oxyfedrin		15687-41-9			
Ownent	Octane, 1-bromo- 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8- heptadecalluoro- [CAS]	423-55-2			Haematological
Ovymost r n		145-12-0			
Oxymetazoline		1491-59-4			
oxymetholone, Unimed	Androstan-3-one, 17-hydroxy-2- (hydroxymethylene)-17-methyl-, (5Alpha,178)- [CAS]	434-07-1			Hormone
Oxymethirea		140-95-4			
охутогрнопе	(5Alpha)-4,5-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one [CAS]	76-41-5			Formulation, modified-refease, immediate
Oxvo ndvi		5585-93-3			
Oxvo rline	•	153-87-7			
Oxyphenbutaz ne		129-20-4			
Oxvohencyclimine		125-53-1			
Ownh nicatin		115-33-3			

				51
				,
•			•	
	•			

·			· ·
Exampl f Indication	Incontinence	Pain, general Surgery adjunct Anaemia, general	Pain, general

			Patent	ţ	
API G neric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Oxyph nonium		50-10-2			
Oxypinocamphone		10136-65-9			
oxypurinol	1H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione [CAS]	2465-59-0			Antigout
Oxyt tracycline	1	79-57-2			
ozagrel	2-Propenoic acid, 3-[4-(1H-imidazol-1- yılmethyl)phenyl]-, (E)- [CAS]		89	2025946	Antithrombotic
-0		536-95-8			
(B nzylsulfonamido)ben					
zoic Acid P-100, Pharmacor			Sn	6313177	Antiviral, anti-HIV
P-1202	Pentanoic acid, 5-amino-4-oxo, methyl ester, hydrochloride [CAS]	79416-27-6	Sn	6034267	Dermatological
	Di-(3N-{(2S,3S)-2-amino-3-methyl- pentanoyf)-1,3-thiazolidine)fumarate				
P32/98					Antidiabetic
PA-824			MO	WO 9701562	Antimycobacterial
PACAP 38	Pituitary adenylate cyclase-activating peptide-38 [CAS]	128606-20-2	Sn	5128242	Neuroprotective
paclitaxel	58,20-Epoxy-1,2Alpha,4,78,108,13Alpha- hexahydroxytax-11-en-9-one-4,10- diacetate-2-benzoate-13-(Alpha- phenylhippurate)	33069-62-4		•	Formulation, optimized, nanoparticles
PADRE			Sn	6413935	Immunostimulant, other
pagoclone	1H-Isoindol-1-one, 2-(7-chloro-1,8- naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl- 2-oxohexyl)- (R)- [CAS]	133737-32-3	S	4960779	Anxiolytic
PA! inhibs, thrombosis, Xenova			0 M	9404512	Antithrombotic
	8H-1,4-dioxinq[2,3-e]indol-8-one,2,3,7,9-tetrahydro-2-[(phenylmethyl)aminojmethyl]-, 2(S)-, (2E)-2-butendiōate (1:1)				
palindore fumarate		189681-71-8	1		Neuroleptic
Palivízumab		188039-54-5	7		

Hyperuricaemia Vasospasm, cerebral Infection, HIV/AIDS Diabetes, Type II Infection, tuberculosis Nerve injury, general Cancer, breast Vaccine adjunct	Panic disorder Thrombosis, venous
---	--------------------------------------

•		•	Patent		
API Gen ric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Inerapeutic Use
	3aS-2-[(S)-1-Azabioyclo[2.2.2]oct-3-yl]- 2,3,3a,4,5,6-hexahydro-1-oxo-1H-				
palonosetron	benz(de)isoquinaline nyarocnionae	135729-62-3	SN	5202333	Antiemetic
Pamabrom		606-04-2			
Pamaguine		491-92-9			
pamicogrei	1H-Pyrrole-1-acetic acid, 2-[4,5-bis(4-methoxyphenyl)-2-thiazolyl]-, ethyl ester [CAS]	101001-34-7	dЭ	159677	Antithrombotic
	(3-Amino-1- hydroxyoropylidene)diphosphonic acid-				
pamidronate		40391-99-9			Formulation, implant
Pamidr nic Acid		40391-99-9			
p-Amin benzoic Acid		150-13-0			
p-Aminohippuric Acid		61-78-9			
p-Amin proplophenone		6-69-02			
n-Amin salicylic Acid		65-49-6			
Panavir	4,4'-isopropylidenedithiobis-2,6-di-t- butyiphenol				Neuroprotective
Paneur nium		15500-66-0			
-		87726-17-8			
Pantethine		16816-67-4			
pantoprazole	1H-Benzimidazole, 5-(difluoromethoxy)-2- [[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- [CAS]	102625-70-7	Œ.	166287	Antiuicer
Pant th nic Acid		79-83-4			
Papain, Urea					
Papaverine		58-74-2			770
paracetamol	Acetamide, N-(4-hydroxyphenyl)- [CAS]	103-90-2			Formulation, oral, otner, modiffled- release
Paraflutizide		1580-83-2			
Paraidehyde		123-63-7			
Paramethadione		115-67-3			
Param thasone		53-33-8			
Paranyline		1729-61-9			

Exampl of Indication Chemotherapy-induced nausea and vomiting Thrombosis, cerebral Hypercalcaemia of malignancy	Vasospasm, cerebral	Ulcer, duodenai	Pain, general
---	---------------------	-----------------	---------------

			Patent	int	
API G neric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Parathyr Id H rmone		9002-64-6			
	Propanamide, N-((4-(5-methyt-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)-, sodium salt [CAS]	198470-85-8	ΜO	9738986	Anaigesic, NSAID
Pareth xvcain		94-23-5			
Paravline		555-57-7			
paricalcitol	19-Nor-9,10-secoergosta-5,7,22-triene- 1,3,25-triol, (1Apha,38,7E,22E)- [CAS]	131918-61-1	В	387077	Ногтопе
рагототусіп	O-2-Amino-2-deoxy-Alpha-D- glucopyranosyl-(1-4)-O-[O-2,6-diamino-2,6- dideoxy-B-L-idopyranosyl-(1-3)-B-D- ribofuranosyl-(1-5)]-2-deoxy-D-streptamine	7542-37-2		•	Protozoacide
paroxetine	Piperidine, 3-((1,3-benzodioxol-5- yloxy)methylj-4-(4-fluorophenyl)-, (3S- trans)- [CAS]	61869-08-7		223403	Antidepressant, formulation, oral, orally-disintegrating
Paroxvar pion		70-70-2			
Parsalmid		30653-83-9			
PaTrin-2	4-Bromothenyiguanine				Radio/chemosensitizer
Pazinacione		103255-66-9			٠
pazufloxacin	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acld, 10-(1-aminocyclopropyl)-9- 127045-41-4 fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)- 126905-87-8 [CAS]	127045-41-4 127046-45-1 136905-87-8	30	3913245	Quinolone antibacterial
p-Bromoacetanilide		103-88-8			•
PC-NSAIDs, GrassRoots			Sn	4918063	Formulation, other
PD-0166285	6-(2,6-Dichlorophenyl)-2-[4-(diethylamino- ethoxy)-phenylamino]-8-pyrido[2,3- Djpyrimidine-7-one				Anticancer, other
Pecilocin		19504-77-9			
pefloxacin	3-Quinolinecarboxylio acid, 1-ethyl-8-fluoro- 1,4-dihydro-7-(4-methyl-1-piperazinyl)-4- oxo- [CAS]	70458-92-3	GB	1598915	Quinolone antibacterial

pl of Indication	ost-operative .	yperparathyroldism	Infection, leishmaniasis	sion, general	r, melanoma	on, general	s, general	, general	urinary tract
Exampl	Pain, post-	Нуреграг	Infection,	Depression,	Cancer, I	Infection,	Arthritis,	Cancer,	Infection

API Generic Name Somatotropin Somatotropin asparagine, 1 168-alanine, 1 168-alanine, 1 168-alanine, 1 168-alanine, 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	API Chemical Name Somatotropin (18-aspartic acid, 21- asparagine, 120-lysine, 167-asparagine, 168-alanine, 171-serine, 172-arginine, 174- serine, 179-threonine (human), pegylated [CAS]	CAS No.	Refere	Reference	Example of Therapeutic Use
9					
ъ					
70		218620-50-9			Somatostatin
		4396-1-4			
		137281-23-3			•
		137281-23-3 150399-23-8	S	5248775	Anticancer, antimetabolite
Pem lin P moldine	4H-Pyrido[1,2-a]pyrimidin-4-one, 9-methyl- 3-(1H-tetrazol-5-yl)- [CAS]	100299-08-9 69372-19-6	S	4457932	Antiasthma
P moldine		2152-34-3		٠	•
		79-55-0			
PEN-203	· .		S	5955446	Antiviral, other
P namecillin		983-85-7			
·	cyclopenty/phenoxy)-3- yl)aminoj-,(S)-, sulfate	38363-32-5 38363-40-5	89	1215751	Antihypertensive, adrenergic
Penbutolol		38363-40-5			
·	6H-Purin-6-one, 2-amino-1,9-dhydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]- [CAS]	39809-25-1	q,	60058982	Antiviral, other
Penethamat		808-71-9			•
	loro-3- ,ASJ	26864-56-2	30	2040231	Neuroleptic
Penicillamine		52-67-5			
Penicillin G		61-33-6			
P nicillin G B nzathine		1538-09-6			
Penicillin G Pr calne		6130-64-9			
P nicillin N	4,7	525-94-0			
Penicillin O	3	87-09-2			

	Exampl of Indication Acromegaly	Cancer, mesothelioma Asthma Infection, human papilloma	Infection, herpes simplex virus	
--	---------------------------------	--	---------------------------------	--

•

API Generic Name			Patent	ant .	
API Generic Name					
	API Chemical Name	CAS No.	Ret	Reference	Example of Therapeutic Use
Penicillin V		87-08-1			
P nimepicycline		4599-60-4			!
Penntuss			sn	4221778	Formulation, modified-release, other
P ntaerythritol Chloral		78-12-6			
Penta rythrit I		2209-86-1			•
Dichi r hydrin	•				
Pentaerythritol	٠	597-71-7			
P ntagastrin		5534-95-2			
P ntagestrone		7001-56-1			
Pental.yte	Starch, 2-hydroxyethyl ether [CAS]	9005-27-0	Sn	5407428	Plasma substitute
P ntameth nlum		541-20-8			•
pentamidine	Benzenecarboximidamide, 4,4'-[1,5-pentanediylbis(oxy)]bis- [CAS]	100-33-4			Formulation, inhalable, systemic
P ntaz cin		359-83-1			
Pentetate		12111-24-9			
Pentetic Acid		67-43-6			•
Pent tr otide	•	138661-02-6			
P nthi nate		60-44-6			
Pentifyllin		1028-33-7			
P ntig tid		62087-72-3			
P ntisomid		78833-03-1			
Pent barbital		76-74-4			
P nt linium		52-62-0			
P ntor x		434-43-5			•
pentosan polysulfate	Xylan, hydrogen sulfate, sodium salt [CAS] 37319-17-8	37319-17-8	SD	5180715	Urological
pentostatin	Imidazo[4,5-dj[1,3]diazepin-8-ol, 3-(2-deoxy-8-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-, (R)- [CAS]	53910-25-1	SN	3923785	Anticancer, antimetabolite
pentoxifylline	1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)- (CAS)				Neuroprotective
P nt xyl		147-61-5			
Pentrinitrol		1607-17-6			
Pentylen tetrazole		54-95-5			

rigon			jiroveci		tract airy cell	sclerosis
of Indication	allergic, general	adjunct	Pneumocystis jiroveci ds		urinary temia, h	lateral
Exampl	Rhinitis, a	Surgery a	Infection, prophylax		Inflammation, Cancer, leuke	Amyotrophic

			Patent	int	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
peplomycin	Bleomycinamide, N1-[3-[(1- phenylethyl)aminolpropylj-, (S)- [CAS]	68247-85-8	SD	4195018	Anticancer, antibiotic
Perazine		84-97-9			
P rflubron		423-55-2			
Perf sfamide		62435-42-1; 39800-16-3			
		(nusbecified)			
pergolide	Ergoline, 8-[(methylthio)methyl]-8-propyl-, (88)-, monomethanesulfonate- [CAS]	66104-22-1 66104-23-2	ട്ട	4797405	Antiparkinsonian.
Perhexilin		6621-47-2			
P ricvazin		2622-26-6			
perifosine	Piperidinium, 4- [[hydroxy(octadecyloxy]phosphinyl]oxy]-1,1-dimethyl-, inner salt [CAS]	157716-52-4	<u> </u>	. 294838	Anticancer, other
periliyi alcohol	1-Cyclohexene-1-methanol, 4-(1- methylethenyl)- [CAS]	536-59-4	ജ	5110832	Anticancer, other
Perimethazine		13093-88-4			
perIndopril	1H-Indole-2-carboxylic acid, 1-{2-[[1- (ethoxycarbony)butyl],amino]-1- oxopropyl]octahydro-, [2S- [1[R*(R*)],2Alpha,3aB,7aB]]-, compd. with 2-methyl-2-propanamine (1;1) [CAS]	107133-36-8 82834-16-0 95153-31-4	<u>a</u> .	49658	Antihypertensive, renin system
Peri dvl		53586-99-5		٠.	•
P risoxal		2055-44-9			
perisoxal	1-Piperidineethanol, Alpha-(5-phenyl-3- isoxazolyf)-, 2-hydroxy-1,2,3- propanetricarboxylate (2:1) (salt) [CAS]	2139-25-5	로	04217925	Anti-infiammatory
Perlapine		1977-11-3			
Permethrin		52645-53-1			
perospirone	1H-Isoindole-1,3(2H)-dione, 2-[4-[4-(1,2-benzisothlazol-3-yl)-1-piperazinyljbutyljhexahydro-, cis- [CAS]	129273-38-7 150915-41-6	క	2167004	Neuroleptic
Dernhenazine		58-39-9			
		8030-30-6			

		0 V	Patent Pefere	Patent Deference	Evample of Therapeutic Use
API Generic Name	API Chemical Name	CAS NO.	US US	6331286	Antipsoriasis
		84-12-8			
Pnanquinone		221.50		CANACAC	Imminological
Pharmaprojects No. 4994				3000402	month of the state
Pharmaprojects No. 5325				9703986	Neurolepuc
Pharmaprojects No. 5972				0204426	Antiasthma
Pharmaprojects No. 6362			ns	6057346	Antiviral, anti-HIV
	(R)-N-[4-[2-[[2-Hydroxy-2-(3-pyrdinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(rifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide				
Pharmaprojects No. 6446				0000	Aloreciuminosony
Pharmaprojects No. 6590			0	0206223	Psychostimulant
Pharmaprojects No. 6656			NS	6455026	Genomics-based drug discovery
Pharmaprojects No. 6691			OS.	6299900	Formulation, other
	3-(6-Aminopyridin-3-yl)-N-methyl-N-[(1- methyl-1H-indol-2-yl)methyl]acrylamide				
Pharmaprojects No. 6743					Aniibacieriai, ourei
	1,2,3,4,10,14b-Hexahydro-6-methoxy-2- methyddbanzo[c,f]pyrazino[1,2-a]azepin	·			· · · · · · · · · · · · · · · · · · ·
Pharmaprojects No. 6748					Anudepressanı
Ph nacain		620-99-5			•
Hydrochloride		62.08.0			
Phenacemide		62-04-3			
Phenacetin		105-44-6 105-44-6			
Phenadoxon		407-04-3			
Phenallymal		115-43-5			
Phenamet		3819-34-9			
Phenaz cin	•	127-35-5			
Phenazopyridin		136-40-3			
nyalocinolide Discharide		3149-00-6			
Prendutamide		77-10-1			
Friencycliume		634-03-7			
Frendimenazine		51-71-R			
Pheneizine		2-17-10			

			Datent	
API G neric Name	API Chemical Name	CAS No.	Reference	Example of Therapeutic Use
Dhen et rin		3546-10-9		
Ph netharbital		357-67-5		
Ph nethicillin Potassium		132-93-4		
Phen turid		90-49-3		
Phenformin		114-86-3		
Phenglutarimid		1156-05-4		
Phenindamin		82-88-2		
Phenindione		83-12-5	•	
Ph niprazin		55-52-7		
Pheniramine	-	86-21-5		
Phenm trazin		134-49-6		
Phen barbital		9-90-09		
Phenobutiodil		554-24-5		
Phen c II		103-97-9		
Ph noctide		78-05-7		
Phenolohthalein		77-09-8		•
Phen Iphthalol	٠	81-92-5		
Phenoisulfonphthalein		143-74-8	٠	•
Ph noltetrachl r phthal		639-44-1		
ln .				
Phen p ridin		562-26-5		
Phenosulfazole		515-54-8		•
Phen xybenzamine		59-96-1		
Phenoxypropazine		3818-37-9		•
Phenprobamat	٠	673-31-4		
Phenprocoumon		435-97-2		
phenserine	Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, phenylcarbamate (ester), (3aS-cis)- [CAS] 101246-65-6	101246-66-6		· Cognition enhancer
Phensuximide	•	86-34-0		
Phentermin	•	122-09-8		
Dhontermine				

		•		•				<u>.</u>	 				_	 	 _	
Example of Indication											•			Althornous dispase		

				_
ADI Conorio Namo	ADI Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Phentetlothal in Sodium		18265-54-8		
Ph nt lamin		50-60-2		
phentolamine mesylate, Zonagen	Phenol, 3-(((4,5-dihydro-1H-imidazol-2- yl)metryl)(4-methylphenyl)amino)-, monomethanesulfonate (salt) [CAS]	65-28-1		Formulation, oral, other
nine mesylate, Novartis	Phenol, 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenyl)amino)-, monomethanesulfonate (salt) [CAS]	65-28-1	·	Formulation, oral, other
Ph nyl Acetylsalicylate		134-55-4		
Phenyl Amin salicylate		133-11-9		
Ph nyl Salicylat		118-55-8		
Ph nylbutazone		50-33-9		
Phenylephrine Hydr chlorid		61-76-7	.	
Phenylethanolamine		7568-93-6		
Phenylm rcury Borate	•	102-98-7		
Phenylm thylbarbituric Acid		76-94-8	•	
Phenyipropanolamine .		14838-15-4		
phenylpropanolamine, Alza	Benzenemethanol, Alpha-(1-aminoethyl)-, (R*,S*)-(+/-)- [CAS]	14838-15-4	•	Anorectic/Antiobesity
phenylpropanolamine, Diffucap	Benzenemethanol, Alpha-(1-aminoethyl)-, (R*,S*)-(+/-)- [CAS]	14838-15-4		Formulation, optimized, microparticles
phenylpropanolamine, KV	Benzenemethanol, Alpha-(1-aminoethyl)-, (R*,S*)-(+/-)- [CAS]	14838-15-4		Formulation, other
phenylpropanolamine, Verex	Benzenemethanol, Alpha-(1-aminoethyl)-, (R*,S*)-(+/-)- [CAS]	14838-15-4		Formulation, modified-release, other
Ph nylpropylmethylamin		6-88-66		
Phenyit loxamine		92-12-6		
Phenyramidol		553-69-5		
Ph nytoin		57-41-0		

ı			
	٠	•	

npl of Indication	. езис	epuce .			<i>k</i> 1	, j	
Exampl	Impotence	Impotence			Obesity Cough	Obesity	

			Patent	=	
API G neric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
ohenvtoin. Sirus	2,4-Imidazolidinedione, 5,5-diphenyl- (CAS)	57-41-0			Formulation, oral, other
Ohethenvlat Sodium		510-34-9			
٥		108-73-6			
Ph Icodin		509-67-1			
Ph ledrin		370-14-9			
Phosphocreatine		67-07-2			
Phosphocysteamine		5746-40-7			
_		107-73-3			
Phthalvisulfacetamide		131-69-1			
Phthalvisulfathiazole		85-73-4			
n-Hydroxyeph drine		365-26-4			
		84-80-0			
Physiostiamine		57-47-6			
Phytic Acid		83-86-3			
	D-Mannose, O-6-O-phosphono-Alpha-D-				
•	mannopyranosyl-(1-3)-O-Alpha-D- mannonyranosyl-(1-3)-O-Alpha-D-				
	mannopyranosyl-(1-3)-O-Alpha-D-	·			
PI-88	mannopyranosyl-(1-2)- hydrogen sulphate [CAS]	185077-23-0	-		Anticancer, other
Piberaline		39640-15-8			
. bosoonia	2H-(1,3)Oxazino(3,2-a)indole-10-carboxamide, N-((1-butyl-4-piperidinyl)methyl)-3,4-dihydro- [CAS]	152811-62-6	. 8	9318036	Antlarrhythmic
Dib serod		152811-62-6	T		
Picil r x		62510-56-9			٠
Picloxydine	٠	5636-92-0			
Picoperine		21755-66-8			
Picosulfat Sodium		10040-45-6			
		32828-81-2			
Picumast		39577-19-0			
pidotimod	4-Thiazolidinecarboxylic acid, 3-[(5-oxo-2-pyrrolidinyl)carbonylj- [CAS]	121808-62-6	읍	276752	Immunomodulator, anti-infective
Pidotimod		121808-62-6			

Example of Indication Epilepsy, general	Pancer, melanoma	infection, respiratory tract,
--	------------------	-------------------------------

			Patent	Ħ	
API Generic Name .	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Pifarnin		56208-01-6			
piketoprofen	Benzeneacetamide, 3-benzoyl-Alpha- methyl-N-(4-methyl-2-pyridinyl)- [CAS]	60576-13-8	GB	1436502	Anti-inflammatory, topical
Pik toprofen		60576-13-8			
Pildralazine		64000-73-3			
Pil carpin		92-13-7			
pliocarpine, Alza	2(3H)-Furanone, 3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, (3S-cis)- [CAS]	92-13-7			Fomulation, implant
pliocarpine, MGI	2(3H)-Furanone, 3-ethyldihydro-4-{(1- methyl-1H-imidazol-5-yl)methyl]-, (3S-cis)- [CAS]	92-13-7		·	Stomatological
	2-Propenoic acid, 2-meitryl-, dodecyl ester, polymer with 2-propenoicacid, compd. with (3S-cis)-3-etryldifiydro-4-[(1-methyl-1H-midazol-5-vllmethyl-2(3H)-furanone				
Piloplex	[CAS]	62783-28-2	吕	2636559	Formulation, mucosal, topical
Pilsicainide		88069-67-4			
piisicainide hydrochloride	1H-Pyrrolizine-7a(5H)-acetamide, N-(2,6- dimethylphenyl)tetrahydro-, . monohydrochloride [CAS]	88069-49-2 88069-67-4	Sn	4564624	Antlarrhythmic
Pimeclone		534-84-9			
	15,19-Epoxy-3H-pyrido(2,1- c)(1,4)oxaazacyclotricosine- 1,7,20,21(4H,23H)-tetrone, 3-(2-(4-chloro- 3-methoxycyclohexyl)-1-methylethenyl-8- ethyl-	·			
	5,6,8,11,12,13,14,15,16,17,18,19,24,25,26 ,26a-hexadecahydro-5,19-dihydroxy-14,16- dimethoxy-4,10,12,18-tetramethyl-(3S- (3R*E(1S*,3S*,4R*)),			•	
olmecrolimus	4S',5R',8S',9E',12R',14R',5S',16R',18S 8,19S',26aR')}- [CAS]	137071-32-0		626385	Antipruritic/inflamm, allergic
m crolimus		137071-32-0			-
mefyllin		10001-43-1			
pimecrolimus Pim crolimus Pimefyllin	4S*,5R*,88*,9E*,12R*,14R*,5S*,16R*,18S 8,19S*,26aR*))-[CAS]	137071-32-0 137071-32-0 10001-43-1		& ·	626385

.

.

٠.

nple of Indication	stomia	ma, atopic
Example	Xerostomia Glaucoma Arrhythmia,	Eczema,

.

The second secon					
		_	Patent	ınt	:
API G neric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	Acetic acid, [2-[octahydro-5-hydroxy-6-(3-				
•	nyaroxy-5-meuryr-1-nomenyy-z- pentalenyljethoxyj-, methyl ester, [2R-				
	[2Aipha,3Aipha,4Aipha(1E,3S*,5S*),5B,6a Aiphail- (CAS)	139403-31-9			Dermatological ·
Pimin din		13495-09-5			
Pimobendan		74150-27-9			
	2H-Benzimidazol-2-one, 1-[1-[4,4-bis(4- fluorophenyl]butyl]-4-piperidinyl]-1,3-				
epizowid	dihydro- [CAS]	2062-78-4	FR	M3695	Neuroleptic
Pim zide		2062-78-4			
Pimozide		•		:	
Pinacidil		85371-64-8			
 pinaverium bromide	Morpholinium, 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethylbicyclo[3.1.1]hept-2-yl)ethoxyjethyl]-, bromida- [CAS]	53251-94-8 59995-65-2	d 3	406743	Antispasmodic
Pinaverium Bromide		53251-94-8			
pinazepam	2H-1,4-Benzodlazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-1-(2-propynyl)-[CAS]	52463-83-9	30	2339790	Anxiolytic
Pinaz pam		52463-83-9			
Pindoloi		13523-86-9			
Pioglitazone		111025-46-8			
pioglitazone hydrochloride	2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, monohydrochloride (+/-)- [CAS]	111025-46-8 112529-15-4	Ð	193258	Antidiabetic
Pioglitazone Hydrochloride	-				
Pipacycline		1110-80-1			
Pipamazine		84-04-8			
Pipamper n		1893-33-0			
Pipazethate .	٠	2167-85-3			
Pipebuz n	-	27315-91-9			
Pipecurium Bromide	٠	52212-02-9			

Example of Indication Ulcer, general	2 and a second a second and a second and a second and a second and a second and a second and a second and a second and a second and a second a second a second and a second and a second a second a second a second a second and a second and a second and a second a second a second	Diabetes, Type II
--------------------------------------	---	-------------------

Name romide Cid Bromlde In Adipate	Name 1,169,176-3,17- 5stane-2,16-diyljbis[1,1]- 6 [CAS] dine-6-carboxylic acid, 8 -oxo-2-(1-piperaziny)- 1[[(4-ethyl-2,3-dioxo-1- yljaminojphenylacetylja -7-oxo-[2S- (\$^2)]-[CAS]	4	GB 136 GB 156 GB	Referent Reference GB 1398050 GB 1451911 GB 1508062	Example of Therapeutic Use Muscle relaxant Antibacterial, other Penicillin, injectable
ric Name m bromide c Acid ate Bromide tazin lin KRKA te Adipate	cal Name 4,4'- Apha, 169, 176)-3, 17- androstane-2, 16-diyljbis[1,1]- 5 omide [CAS] yrimidine-6-carboxylic acid, 8 fro-5-oxo-2-(1-piperazinyl)- figycto[3.2.0]heptane-2- i. 6-[[[[(4-ethyl-2,3-dioxo-1- rbonyl]aminolphenylacetyl]a ethyl-7-oxo-[2S- a,66(5*)]]- [CAS]	4 0 7	<u></u>	1398050 1451911 1508062	Example of Therapeutic Use Muscle relaxant Antibacterial, other Penicillin, injectable
m bromide cd Acid ate Bromide tazin kRKA te Adipate	4,4'- Apha,16B,17B)-3,17- androstane-2,16-diyjbis[1,1]- 5 omide [CAS] yrimidine-6-carboxylic acid, 8 Iro-5-oxo-2-(1-piperazinyl)- iloyclo[3.2.0]heptane-2- iloyclo[3.2.0]heptane-2- chonyllaminolphenylacetylja ethyl-7-oxo-[2S- a,6B(S*)]]- [CAS]	4		1451911	Muscle relaxant Antibacterial, other Penicillin, injectable
c Acid c Acid ate Bromide tazin IIn KRKA e Adipate			 	1451911	Antibacterial, other Penicillin, injectable
c Acid c Acid ate Bromide tazin In KRKA te Adipate				1451911	Antibacterial, other
c Acid ate Bromide lin krikk le Adipate				1508062	Penicillin, injectable
c Acid ate Bromide lazin lin KRKA le Adipate				1508062	Penicillin, injectable
ate Bromide lazin In KRKA e Adipate		-		1508062	Penicillin, injectable
lin KRKA		-		1508062	Penicillin, injectable
IIn KRKA ie Adipate		7		1508062	Penicillin, injectable
IIn KRKA Ie Adipate		. 5		1508062	Penicillin, injectable
In КЯКА Ie Adipate		1		1508062	Penicillin, injectable
In кяка ie Adipate		31477-96-1			
ipate					_
ipate					
ipate	4-thia-1-azablcyclo[3.2.0]heptane-2-carboxylic acid, 6[[[[(4-ethyl-2;3-dioxo-1-piperazinyf)amino]phenylacetyf]a				.·
ipate		F0703-84-3			
Piperazine Adipate	na,6B(S*)]]	61477-96-1			Penicillin, injectable
		142-88-1			·
Piperidione		77-03-2			
Piperidolat		82-98-4			
Piperilate	7	4546-39-8			
piperine analogues, BTG			8	002544	Dermarciogical
Pip rocaine		136-82-3			•
Piperonal		120-57-0			
Pio roxan		59-39-2			
Pipervione		4/6/2531			
Pipobroman		54-91-1			
Pip sulfan		2608-24-4			
Pio tiazine		39860-99-6			-

•					
A DI Conorio Namo	ADI Chemical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
minofiazine palmitate	Hexadecanoic acid, 2-[1-[3-[2- [(dimethylamino)sulfonyl]-10H- phenothiazin-10-yl]propyl]-4- piperidinyllethyl ester [CAS]	37517-26-3 39860-99-6	. su	4782077	Neuroleptic
Pipoxolan Hydrochloride		18174-58-8			٠
Pipradr 1		467-60-7			
piprozolin	Acetic acid, [3-ethyl-4-oxo-5-(1-piperidinyl)- 2-thiazolidinylidene]-, ethyl ester [CAS]	17243-64-0	Sn	3971794	GI infiammatory/bowel disorders
Pipr z lin		17243-64-0		•	
Piracetam		7491-74-9			
o'i di mosin	5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-Alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, [8S-18Ahha,10Ahha(S-1)]- [CAS]	72496-41-4	Sn	4303785	Anticancer, antibiotic
		72496-41-4			
Pirarubicin Dirar lac		71002-09-0			
ritat iac	2,6-Pyridinedimethanol, Alpha6-[[(1,1-dimethylethyl)amino]methyl-3-hydroxy-, monoacetate (salt) [CAS]	38029-10-6 38677-81-5 65652-44-0	S	3786160	Antiasthma
Pirbut r 1		38677-81-5			
PirenoxIne		1043-21-6	·	•	
pirenzepine	6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 5,11-dihydro-11-[(4-methyl-1- piperazinyl)acetyl]- [CAS]	28797-61-7 29868-97-1	Œ	1505795	Antiulcer
Pir nz pine		28797-61-7			٠
pirenzepine, Valley Forge	6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]- [CAS]	28797-61-7 29868-97-1			Formulation, mucosal, topical
piretanide	Benzoic acid, 3-(aminosulfonyl)-4-phenoxy- 5-(1-pyrrolidinyl)- [CAS]	55837-27-9	Sn	4010273	Antihypertensive, diuretic
Piretanid		55837-27-9			

545

•

.

.

			Patent	Ħ	:
API G neric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
pirfenidone	2(1H)-Pyridinone, 5-methyl-1-phenyl- [CAS]	53179-13-8			Respiratory
piribedil	Pyrimidine, 2-[4-(1,3-benzodioxol-5- ylmethyl)-1-piperazinyl]- [CAS]	3605-01-4	S	3299067	Vasodilator, peripheral
Piribedil		1/4/3605			
Piridocalne		87-21-8			
Pirifibrate		55285-45-5			
Piritramid		302-41-0			•
Piritr xim		72732-56-0			
pirlindole	1H-Pyrazino[3,2,1-ik]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl- (CAS)	16154-78-2 60762-57-4	SC	276060	Antidepressant
oirmenot	(2-Pyridinemethanol, Alpha-[3-(2,8-dimethyl-1-piperidinyl)propyl]Alpha.phenyl 61477-94-9 cis-(+)-[CAS]	61477-94-9 68252-19-7	Sn	4112103 .	Antiarrhythmic
Pirmen 1		68252-19-7			
Pir ct n		50650-76-5		•	
Piroheptine		16378-21-5			
Pir midic Acid		19562-30-2			
piroxicam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dloxide [CAS]	36322-90-4	Sn	3862319	Anti-inflammatory
Piroxicam		36322-90-4			
piroxicam betadex	8-Cyclodextrin, compd. with 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-121696-62-6 3-carboxamide 1,1-dioxide- [CAS]	121696-62-6 96684-39-8	G _D	153998	Formulation, other
piroxicam cinnamate	2-Propenalc acid, 3-phenyl-, 2-methyl-3-[(2-pyridinylamino)carbonylj-2H-1,2-benzothlazin-4-yl ester, S,S-dioxide [CAS]	87234-24-0	Gi Gi	79639	Antiarthritic, other
piroxicam suppositories	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	36322-90-4			Formulation, transmucosal, systemic
piroxicam, Douglas	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	36322-90-4		·	Formulation, oral, other

			 	 			 		· ·				_
Exampl f Indication	-ibrosis, pulmonary	Parkinson's disease			Depression, general	Fachycardia, supraventricular				Pain, musculoskeletal	nflammation, general	Inflammation, general	

Inflammation, general

			Patent	ŧ	
API G neric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
AVOV motherin	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide ICAS	36322-90-4			Formulation, other
piroxicalii, noiso	All 1 O Barration of control of A		T		
:	ZH-1,Z-Benzonnazine-3-carooxarnius, 4- hydroxy-2-methyl-N-2-pyridinyl-1,1-dioxide-	7,00,000			Formulation. oral. orally-disintegrating
piroxicam, Zydis	[CAS]	300EE-30-4			
Pir zadil		54110-25-7			
Pirpr fen		31793-07-4			
nitorroctofin	6-Heptenoic acid, 7-{2-cyclopropyl-4-(4- fluorophenyl)-3-quinolinyll-3,5-dihydroxy-, calcium selt (2-1), (5-18-, S*-(E))- [CASI	147526-32-7	<u> </u>	304063	Hypolipaemic/Antiatherosclerosis
pivagabine	N-trimethylacetyl-4-aminobutyric acid	69542-93-4			Neurological
pivaloyloxymethyi butyrate	Butanoic acid, (2,2-dimethyl-1- oxopropoxy)methyl ester [CAS]	122110-53-6	<u>u</u>	302349	Anticancer, other
Pivalvibenzhvdrazine		306-19-4			
		33817-20-8			
pivampicillin/pivmecillinam		98445-47-7			Penicillin, oral
Pivcefalexin		63836-75-9			
	4-Thia-1-azablcyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(hexahydro-1H-azepin-1-y])methylene]amino]-3,3-dimethyl-7-oxo-;				
pivmecillinam ·	[2S-(2Alpha,5Alpha,6B)]- [CAS]	32886-97-8	89	1293590	Penicillin, oral
	Benz[g]isoquinoline-5,10-dione, 6,9-bis[(2-aminoethyl)amino]-, (2Z)-2-butenedioate(1:2)	8-70-57979	<u>a</u>	503537	Anticancer, other
e innipara	4-(9,10-dihydro-4H- benzol4,5]cyclohepta[1,2-b]thien-4-	15574.08.6		2346747	Antimioraine
pizotifen	yldene)-1-memyipiterioliis	0.00-1001	;		0
Pizotyline		15574-96-6		•	
PKI-166	Phenol, 4-(4-(((1R)-1-phenylethyl)amino)- 1H-pyrrolo(2,3-d)pyrimidin-6-yl)- [CAS]	187724-61-4			Anticancer, other
p-Lactoph netide		539-08-2			

3	1	•	L	
ı	ı	ſ		ŧ

Y

			Patent	Ħ	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Inerapeutic Use
Plafibrid	•	63394-05-8			
plasminogen activator, Asahi	Plasminogen activator [CAS]	105913-11-9	<u>С</u>	151998	Fibrinolytic
Plasmocid		551-01-9			
Plat nin .		3571-88-8			
Plaun tof		64218-02-6			
PLD-118	Cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1R,2S)- [CAS]	198022-65-0	БР	805145	Antifungal
	(OC-6-43)-Bis(acetato)(1- adamantylamine)ammine-dichloro- platinum (IV)	·		•	
PLD-147					Anticancer, alkylating
oleconaril	i,2,4-Oxadiazole, 3-(3,5-dimethyl-4-(3-(3-methyl-5-isoxazolyl)propoxy)phenyl)-5- (trifluoromethyl)- [CAS]	153168-05-9	. s	5464848	Antiviral, other
		153168-05-9			
Discollain		18378-89-7			
Filcamycin		1000A 97.A			
p- Methyldiph nhydramine		+- /2-+-061			
PMS-601			8	WO 0001677	Antiviral, anti-HIV
	•				
Pneumococcal Vaccine, Diphtheria Conjugate					
Pneumococcal Vaccine, Polyvalent	•	-			
	N-[[(55)-3[4](1,1-dioxido-4-thiomorpholinyl)3.5-difluorophenyl]-2-oxo-5-oxacildinyl]methyl]acetamide]				
PNU-288034					Antibiotic, ourer
Podophyllotoxin		518-28-5			
polaprezinc	Zinc, bis(N-8-alanyl-L-histidinato- N3,OAlpha)-, (T-4)- [CAS]	107667-60-7	B	303380	Antiulcer
Polapr zinc		107667-60-7			

le findication	n, Candida, general	respiratory tract,	HIV/AIDS	, general	duodenal
Example infarction, n	Infection, C Cancer, ge	Infection, re general	Infection, H	Infection, g	Ulcer, duo

		CAS No.	Fatent Refere	Fatent Reference	Example of Therapeutic Use
API G n ric ivanie		545-80-2			
Poldine Metnylsullate		2/3/9011			
Policresulen		9064-92-0			
P lid xide		0.70-000			
P lid canol		9002-92-0			
polidocanol, BTG	Polyethylene glycol monododecyl ether	3055-99-0			Vasoprotective, systemic
		•			
Poliovirus Vaccine Inactivated				•	
poly. ADPRT inhibitors. Isotech			οM	9845253	Anticancer, other
P ly stradi I Phosphate		28014-46-2			
n constant	Polyphenon E (CAS)	188265-33-0			Antiviral, other
r Cyphenon C		346-18-9			
P lymiazide	Photofrin (CAS)	87806-31-3	Sn	4882234	Anticancer, other
		R01-52-5			
Porfiromycin		20100			
	D-threo-Pentitol, 2,5-anhydro-1,3,4- trideoxy-2-C-(2,4-difluorophenyl)-4-((4-(4- (4-(1(15,2S)-1-ethyl-2-hydroxypropyl)-1,5- dihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl)- 1-piperazinyl)phenoxy)methyl)-1-(1H-1,2,4-		<u> </u>		Antifuncal
posaconazole	triazol-1-yl)- [CAS]	7-64-07111	3	2011	
Posaconazole		171228-49-2			
Posatirelin		78664-73-0			Cotogo ciactao
potassium chloride, Amarin	Potassium chloride (KCi) [CAS]	7447-40-7			Formulation, oral, enterio-coaleu
potassium chloride, Liquitard	Potassium chloride (KCI) [CAS]	7447-40-7	ရ	4259315	Formulation, oral, other
potassium chloride, Microcap	Potassium chloride (KCI) [CAS]	7447-40-7			romutation, optimized, microencapsulate
Potaccium Gluconate		299-27-4			
Potassium		1321-14-8			
Guaiac Isulfonate					

Nutrition
Nutrition

			Patent	1	oll officeroacht to classes.
API G neric Name	API Chemical Name	CAS No.	Befe	Reference	Example of Therapeutic Ose
Potassium p-		138-84-1			
Amin b nz at					
Potassium		7722-64-7			
Permanganate					
P vid ne		9003-39-8			
Povid ne-lodin		25655-41-8			
PP-117	3-Pyridinemethanol, hydrofluoride [CAS]	¢2756-44-9	吕	2633028	Formulation, oral, other
	(-)-(E)-(4-(2,4-dichlorophenyl)-1,3-dithiolan- 2-yildene]-1-imidazolylacetonitrile			•	Antimosi
PR-2699					30.13.17
	(S)-(-)-1-[4,4-bis(4-fluorophenyl)butyl]-4-(2-hydroxy-3-phenylaminopropyl)piperazine			,	Antiparkinsonian
809-H-		G673-35-A			
Practolol		25000 14 B			
Praimaline		0-11-000CC			
Pralidoxim Chloride		51-15-0			
	6H-Pyridazino(1,2-a)(1,2)diazepine-1-carboxamide, N-((2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl)octahydro-9-((1-isoquinolinytearbonyl)amino)-6,10-dioxo-				
prainacasan	(15,9S)- [CAS]	192755-52-5			Antiarthritic, immunological
pramipexole	2,6-Benzothlazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (S)- [CAS]	104632-26-0	읎	186087	Antiparkinsonian
Pramip x 1		104632-26-0			
	1-Pyrrolidineacetamide, N-[2-[bis(1-methylethyl)amino]ethyl-2-oxo-,	68497-62-1 72869-16-0 75733-50-5	SD	4145347	Cognition enhancer
pramiracetam		68497-62-1			
Pramirac tam		14334-40-8			
Framiverin	4 9.Dithia-5 8 11 14 17.				
pramiintide	pentaazacycloeicosane, cyclic peptide deriv. [CAS]	151126-32-8	န္ဌာ	5124314	Antidiabetic
Pramiintide		151126-32-8	·		

Example of Indication
Unspecified
Infection, fungal, general
Parkinson's disease
Arthritis, rheumatoid
Parkinson's disease
Amnesia
Diabetes, Type I

			Patent	int	
API G neric Name	API Chemical Name	CAS No.	Refe	Reference ·	Example of Therapeutic Use
Pramoxin		140-65-8			
Oranidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 3-bhenyl-2-propenyl ester, (E)- [CAS]	99522-79-9	EP	173126	Antihypertensive, other
Pranlukast		103177-37-3			
Pran pr fen		52549-17-4			
pranoprofen, Senju	5H-[1]Benzopyrano[2,3-b]pyridine-7-acetic acid, Alpha-methyl- [CAS]	52549-17-4			Formulation, mucosal, topical
Prast r ne		53-43-0			
prasterone, Nippon Organon	Androst-5-en-17-one, 3-hydroxy-, (3B)- [CAS]	53-43-0			Labour inducer
pratosartan	4(3H)-Cycloheptimidazolone, 5,6,7,8- tetrahydro-2-propyl-3-[[2'-(1H-tetrazol-5- y)][1,1'-biphenyl]-4-y]methyl]- [CAS]	153804-05-8	SN	5409947	Antihypertensive, renin system
	1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-8,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt,				
pravastatin	[1.5] [1.4]pha(16S*,deltaS*),2Alpha,6Alpha,86(R* 81093-37-0],8aAlpha]]- [CAS]	81093-37-0 81131-70-6	Sn	4346227	Hypolipaemic/Antiatherosclerosis
Pravastatin S dium		81131-70-6			
	Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-8,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, 15.	,			
pravasiatin, Zydis	[1Alpha(6S*,deltaS*),2Alpha,6Alpha,8B(R* 81093-37-0),8aAlpha]]- [CAS]	81093-37-0 81131-70-6			Formulation, oral, other
Prazepam		2955-38-6			
praziquantel	4H-Pyrazino[2,1-a]isoquinolin-4-one, 2- (cyclohexylcarbonyl)-1,2,3,6,7,11b- hexahydro- [CAS]	55268-74-1	Sn	4001411	Schistosomicide
Praziquantel		55268-74-1			
prazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-[CAS]	19216-56-9 19237-84-4	SI	4092315	Antihypertensive, adrenergic
Prazosin		19216-56-9			

			Patent	Ħ	
API G neric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
orazosin, Alza	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-fCAS]	19216-56-9			Formulation, modified-release, other
Prednicarbat		73771-04-7			
		29069-24-7	. 8	1272841	Anticancer, alkylating
prednimustine Prodnimustine	oxonuoxyj-11,1,1-uniyaioxy-, (111/2)- [cm.]	29069-24-7		T^-	
Dr dais ne		50-24-8			
Prednisolone 21-		5626-34-6			
Diethylamin acetate	1000		T		
	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-[(3,7,11-trimethyl-1-oxo-2,6,10-dodecatrienyl)oxy]	40044 44.0	8		Antiarthrific other
prednisolone famesil	[118,21(2E,6E)]-[CAS]			335143	
Pr dnisolon Sodium		125-02-0			
Or daile a		53-03-2			
or differ		15180-00-4			
Priedilival		599-33-7			•
בן מוואוומפון	icid, 3-(aminomethyl)-5-methyl,	0 0 0			Antionilonic
pregabalin	(S)-[CAS]	0-00-0000+1			
Pr gabalin		148553-50-8			
Pregnan-3α-ol-20-one		128-20-1			
Premarin + trimegestone	Estra-4,9-dien-3-one, 17-(2-hydroxy-1-oxopropyl)-17-methyl-, [178 (S)]- [CAS]	74513-62-5		•	Menopausal disorders
prenalterol	Phenol, 4-[2-hydroxy-3-[(i-methylethyl)amino]propoxy]-, hydrochloride, (S)-[CAS]		GB	1470039	Cardiostimulant
Prenalter I		57526-81-5			
Prenoxdiazine		982-43-4			
Dr nylamine		390-64-7			
r ilytallillo					

			Patent	Ħ	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	Cuprate(1-), (N2-(N-glycyl-L-histidyl)-L-				
prezatide copper acetate, gel	lysinato(2-))-, hydrogen, diacetate- [CAS]	130120-57-9	•		Vulnerary
Dridin 1		511-45-5			,
Prifinium Br mide		4630-95-9			
Prilocaine		721-50-6			
Primaguine .		90-34-6			
Primid n		125-33-7			
Prin mastat		192329-42-3			
PRO-2000			SN	5614599	Antiviral, anti-HIV
Probenecid		57-66-9			
Probucol		23288-49-5			
Pr cainamid		614-39-1			
Hydr chloride	•				
procainamide, Pfizer	Benzamide, 4-amino-N-[2- (diethylamino)ethyl]- [CAS]	51-08-9	ļ		Formulation, other
Procaine		59-46-1			
Procarbazine		671-16-9			
	2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1-methylethyl)amino]butyl]-,				
procaterol	monohydrochloride [CAS]	60443-17-6	89	1496766	Алцаѕита
Procaterol		72332-33-3			
orocaterol, ML Labs		59828-07-8 60443-17-6			Formulation, inhalable, dry powder
Pr chi rperazine		. 8-38-89			•
Prochlorperazine Maleate					
prochlorperazine maleate,IVAX	10H-Phenothlazine,2-chloro-10-[3-(4- methyl-1-piperazinyl)propyl]-, (Z)-2- butenedloate	58-38-8 84-02-6			Formulation, oral, other
procodazol	1H-Benzimidazole-2-propanoic acid [CAS]	23249-97-0	ES	407882	Anticancer, Immunological
Procodazole		23249-97-0			
Drocurlidine		77-37-2			

558	

)

			·	
Example of Indication Wound healing	Infection, HIV prophylaxis	Arrhythmia, general	Asthma	Nausea and vomiting, general Cancer, general

API Generic Name			Patent	Ę	
API Generic Name			. 1	:	
	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Pr cymat	•	13931-64-1			
Prodipine		31314-38-2			
Proflavine		92-62-6			
Pr gabide	•	62666-20-0			
Progest rone		57-83-0			
progesterone, Dekk-Tec	Pregn-4-ene-3,20-dione [CAS]	57-83-0			Formulation, transmucosal, systemic
progesterone, Effik	Pregn-4-ene-3,20-dione- [CAS]	57-83-0	SN	5776495	Formulation, oral, solubility-enhanced
progesterone, 12R	Pregn-4-ene-3, 20-dione [CAS]	57-83-0	·	,	Formulation, modified-release, immediate
	1H-Indole-3-acetic acid, 1-(4- chlorobenzoyl)-5-methoxy-2-methyl-, 2-(4-				,
proglumetacin	(3-((4-()el.koylanilio)-3-(upropylanilio)- 1,5-dioxopen(yl)oxy)propyl)-1- piperazinyl)ethylester, (4-)- [CAS]	57132-53-3 59209-40-4	85	1467568	Anti-inflammatory
Pr olumetacin		57132-53-3			•
proglumide	Pentanoic acid, 4-(benzoylamino)-5- (dipropylamino)-5-oxo-, (+/-)- [CAS]	. 9-09-029	DE	1518125	Antiulcer
Proglumide		6620-60-6			
Proheptazine	٠	77-14-5			
Pr lactin		9002-62-4			
Prolintan		493-92-5			
Prolonium lodide		123-47-7			
Promazine		58-40-2			
Promedol		64-39-1			
Pr m g st ne		34184-77-5		-	
promestriene	Estra-1,3,5(10)-triene, 17-methoxy-3- propoxy-, (178)- [CAS]	39219-28-8	89	1337198	Reproductive/gonadal, general
Pr methazine		60-87-7			
Pronethal 1		54-80-8			
propacetamol	Glycine, N,N-diethyl-, 4- (acetylamiro)phenyl ester [CAS]	66532-85-2 66532-86-3	Sn	4127671	Formulation, parenteral, other
Propac tam I		66532-85-2			

	11		П	à		 			Τ	Π	· T	\top		Ţ	. 1	· -
Indication				ment therapy		general										
9-			Amenorrhoea	ione replacement	Amenorrhoea	Inflammation, ge	r, gastric						•			
Exampl		t	Amer	Hormone	Amer	 Inflar	Ulcer,						Acne			

.

Patent Patent Patent Patent Patent Patent Patent						
Proparation API Chemical Name CAS No. Reference				Pate	int	:
The parameter The paramete	API G neric Name	API Chemical Name	CAS No.	Refe	rence	Example of Therapeutic Use
12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-40-6 12758-10-6 12758-10-6 12758-10-6 12758-10-6 12758-10-6 12758-10-9 12758-	, and described	1-Propanone, 1-{2-{2-hydroxy-3- (propylamino)propoxy]phenyl-3-phenyl- IrcASI	54063-53-5	g _B	1307455	Antiarrhythmic
12758-40-6 1900al	De not not not		54063-53-5			•
104-32-5 104-32-5	Dronagermanium	٠.	12758-40-6			
104-32-5 1,2-propanedio 104-32-5 1,2-dioi, Vinas 1,2-propanedio 1421-14-3 1,2-dioi, Vinas 1,2-propanedio 1421-14-3 1,2-dioi, Vinas 1,2-propanedio 1421-14-3 1,2-dioi, Vinas 1,2-di	Dropolivional		545-93-7			
1,2-diol, Vinas 1,2-propanediol 57-56-6 1,2-diol, Vinas 1,2-propanediol 1421-14-3 1,2-diol, Vinas 1,2-propanediol 1421-14-3 1,2-diol, Vinas 1,2-propanediol 1421-14-3 1,2-diol, Vinas 1,2-propanediol 1,2-propan	Pr namidine		104-32-5			
titid 1421-14-3 theline Bromide 1421-14-3 acaine 499-67-2 y Nitrate ethyj trans-Alpha-acetyl-1-methyl-5-nitrolmidazole-2-acrylate 76448-31-2 ritrolmidazole-2-acrylate 76448-31-2 GB rtofylline 1-(5-oxohexyl)-7-propyl- (CAS) 55242-55-2 GB rtofylline 79-09-4 79-09-4 79-09-4 nic Acid 1-Propanaminium, 3-carboxy-N,N,N-1/2-(1-oxopropoxyl)-, chloride, (R)-1/2-0 79-09-4 GB nic Acid 1-Propanaminium, 3-carboxy-N,N,N-1/2-(1-oxopropoxyl)-, chloride, (R)-1/2-0 15686-91-6 GB nim pine 15686-91-6 GB 22-diphenyl-2-(1-propoxylacetic acid (1-1/2-3) 15686-91-6 Phenol, 2,6-bis(1-methylethyl)- (CAS) 22-diphenyl-2-(1-propoxylacetic acid (1-1/2-2) 10321-12-7 Phenol, 2,6-bis(1-methylethyl)- (CAS) 2078-54-8 US 4056635 ol 10321-12-7 2078-54-8 US 2078-54-8 US 2078-54-8	propane-1,2-diol, Vinas	1,2-propanediol	57-55-6			Formulation, dermal, topical
Social continue Bromide 50-34-0 499-67-2 499-68-2 499-67-2 499-68-2 499-67-2 499-68	Propanidid		1421-14-3			
yl Nitrate 499-67-2 gul Nitrate 2921-92-8 euthyl trans-Alpha-acetyl-1-methyl-5-nitroimidazole-2-acrylate 76448-31-2 ritroimidazole-2-acrylate 76448-31-2 ritroimidazole-2-acrylate 76448-31-2 ritroimidazole-2-acrylate 76242-55-2 ritroimidazole-2-acrylate 55242-55-2 ritroimidazole-2-acrylate 552-29-8 nitroimidazole-2-acrylate 79-09-4 nitroimethyl-2-(1-oxoproxy)-, chloride, (R)- 19783-68-7 caline 15686-91-6 arin 2,2-diphenyl-2-(1-propoxy)acetic acid (1- 54558-98-8 arin 2,2-diphenyl-2-(1-propoxy)acetic acid (1- 54558-98-8 methylpiperid-4-yl) ester hydrochloride 60569-19-9 pine Phenol, 2,6-bis(1-methylethyl)- [CAS]			50-34-0			
yl Nitrate 2921-92-8 azole eithyl trans-Alpha-acetyl-1-methyl-5-nitroimidazole-2-acrylate 76448-31-2 GB 1470220 totylline 1-(5-oxchexyl)-7-propyl- [CAS] 55242-55-2 GB 1470220 totylline 1-(5-oxchexyl)-7-propyl- [CAS] 55242-55-2 GB 1470220 mazine 551-27-9 179-09-4 179-09-4 179-09-4 179-09-4 nic Acid 1-Propanaminium, 3-carboxy-N,N,N-trimet, Sigma 179-09-4 179-09-4 179-09-4 im 1-Propanaminium, 3-carboxy-N,N,N-trimethyl-2-(1-oxopropoxyl)-, chloride, (R)-trimethyl-2-(1-oxopropoxyl)-, chloride, (R)-trimethyl-1-1-1 15686-91-6 15686-91-6 im 2-2-diphenyl-2-(1-propoxyl)acetic acid (1-starbylethyl)-total 54556-98-8 10321-12-7 pine Phenol, 2,6-bis(1-methylethyl)-total 2078-54-8 105 4056835 ol 2078-54-8 105 4056835	Proparacaine		499-67-2			
azole athyl trans-Alpha-acetyl-1-methyl-5- 76448-31-2 nitroimitdazole-2-acrylate 1-f5-oxohexyl)-7-propyl- [CAS] 55242-55-2 GB 1470220 1-f5-oxohexyl)-7-propyl- [CAS] 55242-55-2 GB 1470220 1-f5-oxohexyl)-7-propyl- [CAS] 55242-55-2 GB 1470220 1-f5-oxohexyl)-7-propyl- [CAS] 55242-55-2 GB 1470220 1-f5-oxohexyl)-7-propyl- [CAS] 362-29-8 79-09-4 1-f7-opanaminium, 3-carboxy-N,N,N- 19793-68-7 1-f7-oxopropoxyl-, chloride, (R)- 19793-68-7 GB 2008578 1-f7-oxopropoxyl-, chloride, (R)- 15686-91-6 15686-91-6 15686-91-6 10589-19-9 10321-12-7	Propatyl Nitrate		2921-92-8			
fylline 1H-Purine-2,6-dlone, 3,7-dihydro-3-methyl-se242-55-2 GB 1470220 tofylline 1-(5-oxchexyl)-7-propyl- (CAS) 55242-55-2 GB 1470220 mazine 55242-55-2 GB 1470220 nic Acid 1-Propanaminium, 3-carboxy-N,N,N-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-soften 19793-66-7 GB caine (CAS) 3670-68-6 2008578 nim 2,2-diphenyl-2-(1-propoxy)acetic acid (1-googs-19-9 15686-91-6 Redse-91-6 pine 2,2-diphenyl-2-(1-propoxy)acetic acid (1-googs-19-9 10321-12-7 US 4056635 pine Phenoi, 2,6-bis(1-methylethyl)- [GAS] 2078-54-8 US 4056635 col 2078-54-8 2078-54-8 DS 2078-54-8	oropenidazole	ethyl trans-Alpha-acetyl-1-methyl-5- nitroimidazole-2-acrylate	76448-31-2			Antifungal
tofylline 55242-55-2 illin mazine 551-27-9 nic Acid 1-Propanaminium, 3-carboxy-N,N.N-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(1-oxoproxy)-, chlor		1H-Purine-2,6-dlone, 3,7-dlhydro-3-methyl- 1-(5-oxohexyl)-7-propyl- [CAS]	55242-55-2	g B	1470220	Neuroprotective
Illin 551-27-9 mazine 362-29-8 nic Acid 1-Propanaminium, 3-carboxy-N,N,N-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(B-6-6-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(B-6-6-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(B-6-6-trimethyl-2-(1-oxopropoxy)-, chloride, (B-6-6-6-trimethyl-2-(1-oxopropoxy)-, chloride, (B-6-6-6-6-trimethyl-2-(1-oxopropoxy)-, chloride, (B-6-6-6-6-6-6-(B-6-6-6-6-6-6-6-6-6-6-6-	Pronentofylline		55242-55-2			
mazine 362-29-8 Honganaminium nic Acid 1-Propanaminium, 3-carboxy-N,N,N-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(R)-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(R)-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(R)-	Propicillin		551-27-9			
nic Acid T9-09-4 T9-09-4 1-Propanaminium, 3-carboxy-N,N,N-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-trimethyl-1 19993-66-7 GB 2008578 Image: CASj construction in the construction of the propoxy of the propoxy of the construction in the construction of the construction of the construction in the construction of the construction in the construction in the construction of the construction in	Proniomazine		362-29-8			
1-Propanaminium, 3-carboxy-N,N-N- 119793-68-7 119793-68-7 119793-68-7 119793-68-7 119793-68-7 119793-68-7 119793-68-7 119793-68-7 12085-19-1 12085-19-9 12085-19-9 12085-19-9 10321-12-7	Pr ni nic Acid		79-09-4			
ocaine 3670-68-6 Im 15686-91-6 erin 2,2-diphenyl-2-(1-propoxy)acetic acid (1-popexy)acetic acid	propiony L-camitine, Sigma	1-Propanaminium, 3-carboxy-N,N,N-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-(CAS)	119793-66-7 20084-19-1	. ag	2008578	Vasodilator, peripheral
erin 15686-91-6 erin 60569-19-9 2,2-diphenyl-2-(1-propoxy)acetic acid (1-propoxy)acetic acid (1-prop	Propipocaine		3670-68-6			
erin 60569-19-9 2,2-diphenyl-2-(1-propoxy)acetic acid (1-propoxy)acetic acid (1-prop	Propiram	•	15686-91-6			
2,2-diphenyl-2-(1-propoxy)acetic acid (1- 54556-98-8 methylpiperid-4-yl) ester hydrochloride 60569-19-9 10321-12-7 Phenoi, 2,6-bis(1-methylethyl)- [CAS] 2078-54-8 US 4056835 Ol	Propiverin		60569-19-9			
pine 10321-12-7 Phenol, 2,6-bis(1-methylethyl)- [CAS] 2078-54-8 ol 2078-54-8	propiverine hydrochloride	2,2-diphenyl-2-(1-propoxy)acetic acid (1-methylpiperid-4-yl) ester hydrochloride	54556-98-8 60569-19-9			Urological
ol Phenol, 2,6-bis(1-methylethyl)- [CAS] 2078-54-8 US 4056635	Pr piz pine		10321-12-7			
[0]		Phenol, 2,6-bis(1-methylethyl)- [CAS]	2078-54-8	Sn	4056635	Anaesthetic, injectable
Pronofol	Pr o fol		2078-54-8			
	Propofol					

.

			Datent	ŧ	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
propofol phosphate, Vyrex	Phenol, 2,6-bls(1-methylethyl)- phosphate		ns	6254853	Anaesthetic, injectable
propofol, Maelor	Phenol, 2,6-bis(1-methylethyl)- [CAS]	2078-54-8	gB	2359747	Formulation, optimized, microencapsulate
propofol, SkyePharma	Phenol, 2-6-bis(1-methylethyl)- [CAS]	2078-54-8			Formulation, optimized, microparticles
Prop xycain Hydr chl ride		550-83-4			
Pr poxvohene		469-62-5			-
Propranolol		525-66-6			
propranolol, Biovail	2-Propanol, 1-[(1-methylethyl)aminoj-3-(1-naphthalenyloxy)- [CAS]	525-66-6			Formulation, modified-release, <=24hr
propranolol, Elan	2-Propanol, 1-[(1-methylethyl)amino]-3-(1- 318-98-9 naphthalenyloxy)- [CAS]	318-98-9 525-66-6			Formulation, modified-release, <=24hr
propranolol, EUCAPS	2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- [CAS]	525-66-6			Formulation, modified-release, other
propranolol, Forest	2-Propanol, 1-{(1-methylethyl)amino]-3-(1-naphthalenyloxy)- [CAS]	525-66-6			Formulation, modified-release, other
Pr pylhexedrin		101-40-6			•
		587-61-1			
Pr pylthiouracil		51-52-5			
Pr pyphenaz ne		479-92-5			
duazon		22760-18-5			
Proscillaridin		466-06-8	\cdot		
Prostacyclin		35121-78-9			
Pr staglandin E		745-65-3			
Pr staglandin E2		363-24-6			
Pr staglandin Fza		551-11-1			
		59-58-5			
Protein C		60202-16-6			
Pr theobr min		50-39-5			
Prothipendyl		303-69-5			
Pr ti fat		58416-00-5			
Protionamide		14222-60-7			

of tooling	-		sia		nsion, general	sion, general	ı ısion, general	ision, general							
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Anaesthesia	Anaesthesia	Anaesthesia		Hypertension,	Hypertension,	Hypertension,	Hypertension,							

•

) .

ADI Canada Mamo	ADI Chemical Name	CAS No	Patent Refere	Patent Reference	Example of Therapeutic Use
API Generic Wallie	Ari Chellical Italije				
	10H-Phenothiazine-2-acetic acid, 7-				
protizinic acid	methoxy-Alpha,10-dimethyl-, (+/-)- [CAS]	13799-03-6	S	3450698	Anti-inflammatory
Protizinic Acid		54323-85-2		•	
Protoanemonin		108-28-1			•
Prot kyl 1		136-70-9			
Prot porphyrin IX		553-12-8			
Pr triptylin		438-60-8			
Pr -Urokinas		82657-92-9			
Pr xazole		9692/2/6			
Proxibarbal		2537-29-3			
oroxiaemanium	Propanoic acid, 3,3-(1,3-dioxo-1,3-digermoxanediyl)bis-[CAS]	12758-40-6	Œ	2005110	Antiviral, other
Pr xvohvllin		6-00-609			
Pr zapine		8/2/3426			
Prucal pride		179474-81-8			
prulifloxacin	1H,4H-I1,3JThiazeto[3,2-a]quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyll-4-oxo-(CAS]	12347-62-1	6	315828	Quinolone antibacterial
Destridonorsins		478-73-9			
Pseud ephedrine	·	90-82-4			
	Benzenemethanol, Alpha-{1- (methylamino)ethylf-, hydrochloride, [S- (R*,R*)]-, mixt. with (E)-2-{1-{4- methylphenyl)-3-{1-pyrrolldinyl}-1-		•		
pseudoephedrine + triprolidine	propertyllpyname monoriyarodinama [CAS]	8054-27-1			Formulation, modified-release, other .
pseudoephedrine, Alza	Benzenemethanol, Alpha-[1- (methylamino)ethyl]-, [S-(R*,R")]- [CAS]	90-82-4			Formulation, oral, other
pseudoephedrine, Diffucap	Benzenemethanol, Alpha-[1- (methylamino)ethyl]-, [S-(R*,R")]- [CAS]	90-82-4			Formulation, optimized, microparticles
pseudoephedrine, KV	Benzenemethanol, Alpha-[1- (methylamino)ethyl]-, [S-(R*,R*)]- [CAS]	345-78-8 90-82-4		•	Formulation, modified-release, other
pseudoephedrine, Phoenix .	Benzenemethanol, Alpha-[1- (methylamino)ethylj-, [S-(R*,R*)]- [CAS]	90-82-4			Formulation, fixed-dose combinations

5	3	-	,	
	1	2)	

xample of Indication		nfection, hepatitis-B virus	Infection, respiratory tract, general) Rhinitis, alleraic, general	Infection, respiratory tract, general Asthma	Rhinitis, allergic, general	Unspecified
Exa		Infec	Infec	i.	gene	喜	

			Patent	-
API Generic Name	API Chemical Name	CAS No.	Reference	Example of Therapeutic Use
Psil cybin		520-52-5	•	
PSK-3841	Benzonitrile, 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)- [CAS]	154992-24-2		Dermatological
p-Sulfanilylbenzylamine	_	4393-19-5		,
PT-141			US 6051555	5 Male sexual dysfunction
Dter nt rin		89-38-3		
Puromycin		53-79-2		
	1-Methylpropyl 2-mercaptolmidazolyl disulfide			Antinones other
PX-12				Vilucalical Calei
Pyrant 1		15686-83-6		
Pyrazinamid		98-96-4		
Pyridinol Carbamate		1882-26-4		
Pyrid stigmin Bromlde		101-26-8		
Puridoxal 5. Phosphate		54-47-7		
Pyridoxine		58-56-0		
Hydrocni ride		91-84-9		
Pyriamili		58-14-0		
Pyrin lin		1740-22-3		
Pvrisuccid an 1		33605-94-6		
Pyrithion		1121-30-8		
Pyrithyldlone		77-04-3		
Pyritinol		1098-97-1		٠
Pyrocatechol		120-80-9		
Pyrogallol		87-66-1		
Pvr naridin		74847-35-1		
Pyrovalerone	•	3563-49-3		•
Pyroxylin		9004-70-0		
Pyrrobutamine		91-82-7		
Pyrrocaine		2210-77-7		

			L		
			Patent	i i	
API Generic Name	API Chemical Name	CAS No.	E E	Reference	Example of Inerapeutic Use
Pvrrolnitrin		1018-71-9			
Pvrvinium Pamoate		3546-41-6			
	2H-1,4-Benzodiazepine-2-thione, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-	יי פט ייסרמט	٥	0045000	Hwantin/Sodeline
quazepam	trifluoroethyt)- [CAS]	30/33-22-3	3	20000	
Quazepam	•	36735-22-5			
Ou re tin		117-39-5			
Quetiapine		111974-69-7			
ouetiapine fumarate	Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin- 11-yl-1-piperazinyl)ethoxy]-, (E)-2- butenedioate (2:1) (satt) [CAS]	111974-69-7 111974-72-2	굡	240228	Neuroleptic
metianine fumarate. SR	Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thlazepin- 11-yl-1-piperazinyl)ethoxy]-, (E)-2- butenedioate (2:1) (salt) [CAS]	111974-69-7 111974-72-2			Formulation, modified-release, <=24hr
Oninacillin		1596-63-0			
Oninacrine		83-89-6			
	N-(6-Chloro-2-methoxy-9-acridinyl)-N,N-diethyl-1,4-pentanediamine + 10H-Phenothiazine-10-propanamine, 2-chloro-				
quinacrine, CJD treatment	N,N-dimethyl				Neurological
quinagolide	Sulfamide, N,N-diethyl-N'- (1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy- 1-propylbenzo[g]qulnolin-3-yl)-, (3Alpha,4aAlpha,10aB)- (+t')- [CAS]	87056-78-8 94424-50-7 97805-49-7	G G	77754	Antiprolactin
Quinagolide		87056-78-8			
quinapril	3-Isoquinolinecarboxyilc acid, 2-[2-[[1- (ethoxycarbonyl)-3-phenylpropyljamino]-1- 82586-55-8 oxopropyl]-1,2,3,4-tetrahydro-, [3S- [2[R*(R*)],3R*]]- (CAS]	82586-55-8 85441-61-8 90243-99-5	G	49605	Antihypertensive, renin system
Quinapril		85441-61-8			
Quinapril Hydrochloride	•				

Example of Indication
Insomnia
Schizophrenia
Schizophrenia
Creutzfeldt∿Jakob disease
Iyperprolactinaemia
Umortoneim noneral

	•		Patent	int	•
API Gen ric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	3-Isoquinolinecarboxylic acid, 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-				
guínaprilat	oxopropyi]-1,2,3,4-tetrahydro-, [3S- [2[R*(R*)],3R*]]- [CAS]	82768-85-2	<u>a</u>	46953	Antihypertensive, renin system
Ouinapyramine		20493-41-8			
Quinbolone		2487-63-0			
Quinestradiol		1169-79-5			
Quinestr I		152-43-2			
Quinethaz n	,	73-49-4			
quinfamide	2-Furancarboxylic acid, 1-(dichloroacetyl)- 1,2,3,4-tetrahydro-6-quinolinyl ester [CAS]	62265-68-3	S	3997542	Amoebicide
Quinfamid		62265-68-3			
Quinidin		56-54-2			•
quinidine bisulfate, Eurand	Cinchonan-9-ol, 6'-methoxy-, (9S)-, sulfate (1:1) (salt) [CAS]	747-45-5			Formulation, modified-release, other
Quinine		130-95-0			
Quin cld		525-61-1		٠	
Quinupramin		31721-17-2		•	
Quinupristin		120138-50-3			
R-107500	cis-2,3,3a,8-tetrahydro-N.N- dimethyldibenz[c,f]isoxazolo[2,3-a]azepine- 2-methanamine		ОМ	9614320	Anxiolytic
R-667			ΜÓ	0204439	COPD treatment
Rabeprazole		117976-89-3	•		
rabeprazole sodium	1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy]-3-methyl-2-pyridinyljmethyljsulfinyl]-, sodium salt-[CAS]	117976-89-3 117976-90-6	di di	268956	Antiulcer
Rabeprazole Sodium		·			
Rabeprazole Sodium					
racecadotril	Glycine, N-[2-{(acetythio)methylj-1-oxo-3- phenylpropylj-, phenylmethyl ester, (+/-)- [CAS]	. 112573-72-5 81110-73-8	G.	38758	Antidiarrhoeal

Q	
10	
٠,	

Example of Indication	
Hypertension, general	
Arrhythmia, general	
Anxiety, general	
Emphysema, general	
Ulcer, gastric	
Diarrhoea, general	

			L		
			Patent	Patent	Evamale of Thereneutic Ilee
API Generic Name	API Chemical Name	CAS NO.			Evaluation of the second control of the seco
Rac cadotril		81110-73-8	•		
Racem thorphan		510-53-2			
Raloxif n	٠	84449-90-1			
raloxifene hydrochloride	Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl[[4-[2-(1-piperidinyl)ethoxy]phenyl]-, hydrochloride [CAS]	82640-04-8 84449-90-1	dЭ	62503	Osteoporosis treatment
raltitrexed	L-glutamic acid, N-[[5-[[(1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyljcarbonyl]- [CAS]	112887-68-0	ЕР	239362	Anticancer, antimetabolite
Raltitr xed		112887-68-0			
ramatroban	9H-Carbazote-9-propanoic acid, 3-[[(4-fluorophenyl)sulfonyljamino]-1,2,3,4-tetrahydro-, (R)- [CAS]	116649-85-5	ďЭ	242518	Antialiergic, non-asthma
Ramatr ban		116649-85-5			
Ramifenazone		3615-24-5			
ramipril	Cyclopenta[b]pyrrole-2-carboxylic acid, 1 [2-[1-(ethoxycarbonyl)-3-phenylpropyl]octahydro 87269-97-4, [2S-[1fR*(R*)], 2Alpha,3aB,6aB]]-ICAS] 87333-19-5	87269-97-4 87333-19-5	В	79022	Antihypertensive, renin system
Ramioril		87333-19-5			
Ramipril			٠	•	
Ram setr n		132036-88-5			
raimosetron hydrochloride	Methanone, (1-methyl-1H-indol-3- yl)(4,5,6,7-tetrahydro-1H-benzimidazol-5- yl)-, monohydrochloride, (R)- [CAS]	132907-72-3	EP .	381422	Antlemetic
ramosetron, WOWTAB	Methanone, (1-methyl-1H-indol-3- yl)(4,5,6,7-tetrahydro-1H-benzimidazol-5- yl)-, monohydrochloride, (R)- [CAS]	132907-72-3	43	381422	Formulation, oral, orally-disintegrating
Ramot project No. 1097			Sn	5730892	Dermatological
Ranimustin		58994-96-0			
ranitidine	1,1-Ethenediamine, N-[2-[[[5- [(dimethylamino)methyl]-2- furanyl]methyl[thio]ethyl]-N'-methyl-2-nitro- [CAS]	66357-35-5	ns	4128658	Antiulcer

•				
Exampl findication	Rhinitis, allergic, perennial	Heart failure	Nausea and vomiting, general Chemotherapy-induced nausea and vomiting Unspecified	Ulcer, duodenal

API G neric Name			Datent		
				Ξ.	
Danieldin	API Chemical Name		Refe	Reference	Example of Inerapeutic Use
	_	66357-35-5			
smuth citrate	1,2,3-Propanetricarboxylic acid, 2-hydroxy- bismuth(3+) salt (1:1), compd. with N-(2- (((5-((dimethylamino)methyl)-2- furanyl)methyl)thio)ethyl)-N'-methyl-2-ni1- ethenediamine (1:1)- [CAS]	128345-62-0	G	533281	Antiulcer
[[f f ranitidine, Phoenix	1,1-Ethenediamine, N-[2-[[[5- (dimethylamino)methyl]-2- luranyljmethyl[thio]ethyl]-N-methyl-2-nitro [CAS]	66357-35-5			Formulation, modified-release, other
ranolazine	1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, (+/)- [CAS]	95635-55-5 95635-56-6	<u>.</u>	126449	Antianginal
ine		95635-55-5			
Ranoimase		133737-96-9			
Rapacur nium Bromide		156137-99-4			•
rasagiline mesylate	1H-Inden-1-amine, 2,3-dihydro-N-2- propynyl-, (R)-, methanesulfonate [CAS]	161735-79-1	SN	5457133	Antiparkinsonlan .
		483-04-5			
		182760-08-1			Antifungal
٠	2-Benzofuranacetic acid, 5-(acetyloxy)-2,3-dihydro-4,6,7-trimethyl-, (+)- [CAS]	128232-14-4	Sn	4999350	Symptomatic antidiabetic
	2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis- [CAS]	21416-67-1	GB	1234935	Anticancer, other
Razoxane		21416-87-5			
	Tetradecanoic acid (1R)-1-(2-((2-(2-deoxy-3-((3R)-1-oxo-3-((1-oxotetradecyl)oxy)tetradecyl)amino-4-O-phosphono-3-D-glucopyranosyl)oxyjetryl)amino)-2-oxoetryl)ddecyl ester, compd. with N.N-diethylethanamine (1:1) [CAS]	216014-46-9	·		Immunostimulant, other

Example f Indication Ulcer, duodenal Ulcer, Gl, general Angina, general Angina, general Infection, meningitis, general Nephropathy, diabetic Cancer, general	
--	--

/accine adjunct

API Generic Name API Chemical Name CAS No. Reference Example of Therapoutic Use adultionspropancia add, Alpha-i(4-budinoling-papeancia add, Alpha-i(4-budin						
## API Chemical Name API Chemical Name				Pate	1	 Evample of Thersneitlic lee
CAS 1,24 mind	API Generic Name	API Chemical Name	CAS NO.		Leilce	Evamble of meraparate
CAS 90098-04-7 DE 3324034		4-Quinolinepropanoic acid, Alpha-[(4- chlorobenzoyl)amino]-1,2-dihydro-2-oxo-				
CAS CAS	rebamipide	[CAS]	90098-04-7		3324034	Antiulcer
L-Valinamide, N-((2S)-2-mercapto-1-0xo-4- (3.4,4-trimethyt-2,5-dioxo-1- (3.4,4-trimethyt-2,5-dioxo-1- (CAS)	Rebaminid		90098-04-7			•
CAS Morpholine, 2-l(2-ethoxyphen		L-Valinamide, N-((2S)-2-mercapto-1-oxo-4- (3,4,4-trimethyl-2,5-dioxo-1-				
Morpholine, 2-{(2- ethoxyphenoxy)phenylmethylj-, (R*,S*)- ethoxyphenoxy)phenylmethylj-, (R*,S*)- 128298-28-2 1-Piperidinepropanoic acid, 4- (methoxycarbonyl)-4-(1- oxopropyljphenylamino}-methyl ester- (CAS) 13,7]decane-2-carboxylic- acid, 2-[[1]-(7-chioro-4-quinoilinyl)-5-(2,6- dimethoxyphenyl-1H-pyrazol-3- yljcarbonyljamino]- [CAS] 80125-14-0 EP 699438 Morpholication - 109872-41-5 Benzamide, 4-amino-N-1- azabicycloj(3.3.1jon-4-yl-5-chloro-2- Benzoic acid, 2-ehoro-2- (1-piperidinyl)phenyljamino]-2- (1-piperidinyl)phenyljamino]-2- (1-piperidinyl)phenylpuylamino]-2- (1-piperidinylphenylpuylamino]-2- (1-piperidinylphenylpuylamino]-2- (1-piperidinylphenylpuylamino]-2- (1-piperidinylphenylpuplonyl methanesulforamide L-lysine salt 135062-02-1 WO 0024710 methanesulforamide L-lysine salt 144980-29-0	rebimastat	imidazolidinyi)butyi)-L-leucyi-N,3-dimemyi- [CAS]	259188-38-0			Anticancer, other
CAS (CAS 1.1620-89-8 US 4229449 Us 1.28298-28-2 Us 1.28298-28-2 Us 1.28298-28-2 Us 1.28298-28-2 Us 1.28298-28-2 Us 1.28298-28-2 Us 1.28298-28-2 Us 1.28298-28-2 Us 1.28298-28-2 Us 1.28298-28-2 Us 1.28299-07-2 EP 383579 Us 1.28299-07-2 EP 383579 Us 1.28299-07-2 EP 383579 Us 1.28290-07-2 EP 383579 Us 1.28290-07-2 EP 383579 Us 1.28290-07-2 EP 383579 Us 1.28290-07-2 Us Us 1.28290-07-2 Us Us 1.28290-07-2 Us Us Us Us Us Us Us U		Morpholine, 2-[(2-				
1-Piperidinepropanoic acid, 4-	reboxetine	[CAS]	71620-89-8		4229449	Antidepressant
128298-28-2 1-Piperidinepropanoio acid, 4-	Rebox tine		98769-81-4			
1-Piperidinepropanoio acid, 4- (methoxycarbonyl)-4-((1- oxopropyl)phenylamino)-methyl ester- (CAS)	Remac mide		128298-28-2			
CAS (methoxycarbonyl)-4-((1- 0xopropyl)phenylamino)-methyl ester- (CAS (132875-61-7 132875-61-7 132875-61-7 132875-61-7 132875-61-7 132875-61-7 132875-61-7 132875-61-7 132875-61-7 132875-61-7 132875-61-7 146362-70-1 14		1-Piperidinepropanoic acld, 4-				
CAS 132875-61-7 132875-61-7 132875-61-7 132875-61-7 132875-61-7 132875-61-7 132875-61-7 132875-61-7 146362-70-1 EP 699438 146362-70-1 EP 699438 146362-70-1 EP 699438 146362-14-0 146362-11-5 146362-11-5 146362-11-5 146362-11-5 146362-02-1 146362-02-1 144980-29-0 144980-	•	(methoxycarbonyl)-4-((1-	•			
132875-61-7 Tricyclo[3.3.1.13,7]decane-2-carboxylic acid, 2-[[1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1+Pyrazol-3- 146362-70-1 EP 699438 d	remifentanil	[CAS]	132539-07-2	Ш	383579	Analgesic, other
Tricyclo[3.3.1.13,7]decane-2-carboxylic acid, 2-[[1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-finethoxyphenyl]amino]- [CAS] 80125-14-0	Domifontanil		132875-61-7			
acid, 2-[[[1-(7-chloro-4-quinolinyl)-5-(2,8-dimethoxyphenyl)-11-pyrazol-3-	Acilicaniani	Trimingto 2 4 19 Tidocano-2-cathoxofic				
144980-29-0 146362-70-1 14980-29-0 146362-70-1 14980-29-0 146362-70-1 14980-29-0 144980-29-0 144980-29-0 144980-29-0 144980-29-0 144980-29-0 144980-29-0 144980-29-0 144980-29-0 144980-29-0		acid, 2-[[1-(7-chloro-4-quinoliny])-5-(2,6-				
Benzamide, 4-amino-N-1- 109872-41-5 JP 5818885 methoxy- [CAS] methoxy-4[2-[[3-methyl-1-[2-	reminertant	dimetroxypnenyi)-i r-pyrazor-3- yljcarbonyljaminoj- [CAS]	146362-70-1	l	699438	Neuroleptic
Benzamide, 4-amino-N-1- 109872-41-5 109872-41-5 2azabicyolo[3.3.1]non-4-yl-5-chloro-2- 88721-77-1 JP 5818885 88721-77-1 JP 5818885 88721-77-1 JP 5818885 64721-77-1 135062-02-1 1350	Rem xinrid		80125-14-0			
Methoxy-[CAS] Renzolc acid, 2-ethoxy-4-[2-[[3-methyl-1-[2-[13-methyl-1-[2-[13-methyl-1-[2-[13-methyl-1-[2-[13-methyl-1-[2-[13-methyl-1-[2-[13-methyl-1-[3-[13-methyl-1-[3-[13-methyl-1-[3-[13-methyl-1-[3-[13-methyl-1-[3-[13-methyl-1-[3-[13-methyl-1-[3-[13-methyl-1-[3-[13-methyl-1-[3-[13-methyl-1-[3-[13-[13-[13-[13-[13-[13-[13-[13-[1		Benzamide, 4-amino-N-1-	109872-41-5		•	
Benzoic acid, 2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)]bhenyl]butyl]amino]-2- 135062-02-1 WO 9300337 Oxoethyl]-, (S)- [CAS] 135062-02-1 1	renzapride	methoxy- [CAS]		g,	58188885	Gastroprokinetic
135062-02-1 WO 9300337 135062-02-1 WO 9300337 135062-02-1 135062		Benzoic acid, 2-ethoxy-4-[2-[[3-methyl-1-[2- (1-piperidinyl)phenyl]butyl]amino]-2-				
135062-02-1 136062-02-1	repaglinide	oxoethyl]-, (S)- [CAS]	135062-02-1	9 8	9300337	Antidiabetic
2(R)-4-Isobuty/phenypropionyl methanesulfonamide L-lysine salt wo oo24710 /sine salt	Repaglinide		135062-02-1			
2(R)-4-Isobuty/pheny/propiony/ methanesulfonamide L-lysine salt ysine salt 144980-29-0	Repaglinide	•				
Voline salt WO 0024710 144980-29-0		2(R)-4-Isobutylphenylpropionyl methanesulfonamide L-tysine salt			•	
	repertaxin L-lysine salt			8	0024710	Cardiovascular
10. 11. 10. 11. 10. 11. 10. 11. 10. 11. 10. 11. 11	Repin tan	•	144980-29-0			

			Patent	at	
API G n ric Name	API Chemical Name	CAS No.	Ref	Reference	Example of Therapeutic Use
	1,2-Benzisothiazol-3(2H)-one, 2-(4-(((3,4-				
	yi)methyi)amino)butyi)-, 1,1-dloxide,	11000 77 8	5	E127001	Neuroprotective
repinotan hydrochloride	monohydrochloride [CAS]	144980-//-8	8	100/010	rectioniocours
	4H-Pyrano[3,2-c]quinoline-2-carboxylic acid. 5.6-djhydro-7,8-dimethyl-4,5-dioxo-, 3-				
repirinast	methylbutyl ester [CAS]	73080-51-0	S	4298610	Antiasthma
Repirinast		73080-51-0			
R posal	•	3625-25-0			
	1H-Purine-2,6-dione, 7-[3-[[2-(3,5-				
	dihydroxyphenyl)-2- hydroxyethyljamino]propyl]-3,7-dihydro-1,3- 13055-82-8	13055-82-8			
reproterol	dimethyl- [CAS]	54063-54-6	3	ROBCINI	Zinasullia
R proterol		54063-54-6			
Rescim t I		73573-42-9			
R scinnamin		24615-24-5	1		
R serpilin		131-02-2			
Reserpine		50-55-5	T		
A sibuf g nin		465-39-4			
	1H-Imidazo(4,5-c)quinoline-1- ethanol(ethoxymethyl)-Alpha, Alpha-	•			
resiquimod .		144875-48-9	S	5389640	Antiviral, other
Resorcin I	•	108-46-3		-	
Reteplas		133652-38-7	Γ		
	Carbamic acid, (2-amino-4-(((4- fluorophenyl)methyl)amino)phenyl)-, ethyl	450840 40 7	7	A000056	Antionileptic
rengaome	osiai (Aura)				
retinoic acid, Antigenics	Retinolc acid [CAS]	302-79-4		2001	Anticapper other
Revimid			8	0201230	Milicarical card
R-flurbiorofeo	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha methyl	5104-49-4			Anticancer, other
Rho (D) Immune					
Globulin (Human)			5		Antisethma
Rho-kinase inhibitors, Kirin			1	0100000	Pillasu IIIIa
1.1.					

Epilepsy, general Cancer, leukaemia, acute myelogenous Cancer, myeloma Cancer, prostate Unspecified	Asthma Infection, hepatitis-C virus	Example findication ischaemia, cerebral
---	--	---

			l		
			Patent	nt	
API G neric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Hierapeutic Osc
ribavirin	ribofuranosyl- [CAS]	36791-04-5	S.	4211771	Antiviral, other .
Rihaviriń		36791-04-5			
Ribavirin					٠
Ribavirin					٠
ribavirin + Alpha-interferon, SP	•		S	6172046	Antiviral, other
Riboflavin		146-17-8			
M n ph sphate					
	D-Streptamine, O-2,6-diamino-2,6-dideoxy-	•			
ribostamycin	Alpha-D-glucopyranosyl-(1-4)-O-[6-D- ribofuranosyl-(1-5)]-2-dsoxy- [CAS]	25546-65-0	B	1254883	Aminoglycoside antibiotic .
Ribostamycin		25546-65-0			
Ricin leic Acid		141-22-0			•
Rid gr i		110140-89-1			
rifabutin	Rifamycin XIV, 1',4-didehydro-1-deoxy-1,4-dihydro-5'-(2-methylpropyl)-1-oxo-[CAS]	72559-06-9	SU	4219478	Antimycobacterial
Rifabutin		72559-06-9			
ritalazii	Rifamycin VIII, 1',4-didehydro-1-deoxy-1,4- 129791-92-0 dihydro-3'-hydroxy-5'-[4-{2-methylpropyl}-1-129791-94-2 piperazinyl]-1-oxo- [CAS]	129791-92-0 129791-94-2 133633-12-2	B .	366914	Antimycobacterial
Rifalazii	•	129791-92-0			
rifametane	Ritarrycin, 3-[[]1- (diethylamino)ethylidene]hydrazono]methyl]- [CAS]	94168-98-6	£ P	119571	Antimycobacterial
Rifamide		2750-76-7			
	Rifamycin, 3-[[(4-methyl-1- piperazinyl)imino methyl]-, mixt. with 5- [(3.4.5-trimethoxyphenyl)methyl]-2,4-				
rlfampicin + trimethoprim	pyrimidinediamine [CAS]	61498-94-0			Formulation, fixed-dose combinations
Rifampin		13292-46-1			
Rifamycin SV		6998-60-3	Π		
ritapentine	piperaziny))imino]methyl]- [CAS]	61379-65-5	照	2608218	Antibiotic, other

Infection, hepatitis-C virus Infection, general Infection, Mycobacterium avium complex Infection, general Infection, general Infection, tuberculosis
--

			1		
			Patent	ent	
API Generic Name	API Chemical Name	CAS No.	Her	Heterence	Example of Therapeutic Use
Rifap ntine		61379-65-5			
					•
	Epoxypentadeca[1,11,13]trienimino]benzot uro[4,5-e]-pyrido[1,2-a]benzimidazole- ,1,15(2H)-dione, 25-(acetyloxy)-5,6,21,23-				
	tetrahydroxy-27-methoxy- 2,4,11,16,20,22,24,26-octamethyf-, [2S- (2R*,16Z,18E,20R*,22S*,23S*,24S*,25R*,				•
nfaximin .		80621-81-4	GB	2079270	Antibiotic, other
Rifaximin		80621-81-4			•
rifaximine cream	4-deoxy-4'-methylpyrido[1',2'- 1,2]imidoazo[5,4-c]rifamycin SV	80621-81-4	æ	888895 .	Formulation, dermal, topical
Rilmazaf n		99593-25-6			
rilmenidine	2-Oxazolamine, N-(dicyclopropylmethyl)- 4,5-dihydro- [CAS]	54187-04-1 54249-57-9	Ħ	2362754	Antinypertensive, adrenergic
Rilmenidin		54187-04-1			
riluzole	2-Benzothiazolamine, 6-(trifluoromethoxy)- [CAS]	1744-22-5	Ŧ	50551	Neuroprotective
Riluzole		1744-22-5			
Rimantadin		13392-28-4			
rimazolium metlisulfate	4H-Pyrido[1,2-a]pyrimidinium, 3- (ethoxycarbonyl)-6,7,8,9-tetrahydro-1,6- dimethyl-4-oxo-, methyl sulfate [CAS]	28610-84-6 35615-72-6	æ	2461349	Analgesic, NSAID
Rimazolium Metilsulfate		28610-84-6			
rimexolone	Androsta-1,4-dien-3-one,11-hydroxy-16,17- dimethyl-17-(1-oxopropyl)-, (116,16Alpha,178)- [CAS]	49697-38-3	DE	2301317	Ophthalmological
Rimexolone		49697-38-3			
Rimiterol	•	32953-89-2			
	1H-Pyrazole-3-carboxamide, 5-(4- chlorophenyl)-1-(2,4-dichlorophenyl)-4- methyl-N-1-piperidinyl-, monohydrochloride				
rimonabant	[CAS]	158681-13-1	US	5624941	Anorecuc/Annobesity

Inflammation, ocular	Infection, Gl tract Infection, dermatological Hypertension, general Amyotrophic lateral scierosis	Example of Indication
----------------------	---	-----------------------

			100010		Ritonavir
			155013-67-5		
Antiviral, anti-HIV	9414436	WO	155213-67-5	2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolyl-methyl ester, (5S-(5R*,8R*,10R*,11R*))- [CAS]	ritonavir
			26652-09-5		Ritodrin
Labour inhibitor	3410944	S	23239-51-2 26652-09-5	Benzenemethanol, 4-hydroxy-Alpha-[1-[[2- (4-hydroxyphenyl)ethyljaminojethylj-, (R*,S*)- [CAS]	ritodrine
			84845-57-8	•	Ritipenem
			87051-43-2		Ritanserin
Formulation, oral, orally-disintegrating				4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6- fluoro-1,2-benzisoxazol-3-yl)- piperidinyl]ethyl]-6,7,8,9-tetrahydro-2- methyl- [CAS]	risperidone, Quicklets
Formulation, optimized, microencapsulate			106266-06-2	4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(o- fluoro-1,2-benzisoxazol-3-yl)-1- piperidinyl]ethyl]-6,7,8,9-tetrahydro-2- methyl- [CAS]	risperidone, Medisorb
			106266-06-2		Risperid ne
Neuroleptic	196132	d.	106266-06-2	4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl]-1-piperidinyljethyl]-6,7,8,9-tetrahydro-2-methyl-[CAS]	risperidone
			105462-24-6		Risedr nic Acid .
					Risedronate Sodium
Osteoporosis treatment	304961	Ŧ	115436-72-1	Phosphonic acid, (1-hydroxy-2-(3- pyridiny))ethylidene)bis-, monosodium salt	risedronate sodium
			77287-05-9		Riopr stil
Antiviral, other	3/55251	S	19403-92-0	1,3-Benzenediol, 2,4,6-trilodo- [CAS]	riodoxol
Example of Therapeutic Use	Patent Reference	1 7 6	CAS No.	API Chemical Name	API Generic Name

Schizophrenia Labour, preterm Infection, HIV/AIDS	Schizophrenia Schizophrenia	Paget's disease	Exampl f Indication
---	--------------------------------	-----------------	---------------------

			١		
API Generic Name	API Chemical Name	CAS'No.	Patent Refere	Patent Reference	Example of Therapeutic Use
	구주			•	
ntonavir, son gei	ester, (30-(3rr ,orr ,rrrr // [errer]	7 10 00 0	I		
Rituximab	٠	174722-31-7			
Rivastigmin		123441-03-2		•	
	Carbamic acid, ethylmethyl-, 3-[1- (dimethylamino)ethyljphenyl ester, (S)-	123441-03-2	3		
rivastigmine tartrate		129101-54-8	30	3803/44	Cognition enhances
Rivastigmine					
Tartrate					
Rivastigmine					
taterace		1 100 100			
Rizatriptan		144004-00-0			
	1H-Indole-3-ethanamine, N,N-dimethyl-5- (1H-1,2,4-triazol-1-ylmethyl)-, monohenzoate- [CASI	145202-66-0 159776-67-7	Ÿ	497512	Antimigraine
	1H-indolp-3-ethanamine, N,N-dimethyl-5-				
rizatriptan benzoate, Zydis	H-indoib-3-euranaminte, v. v. v. v. v. v. v. v. (1H-1,2,4-triazol-1-y/methyl)- "monobenzoate- [CAS])			Formulation, oral, orally-disintegrating
RJR-2403	3-Buten-1-amine, N-methyl-4-(3-pyridinyl)-, (3E)-, (2E)-2-butenedioate (1:1) [CAS]	183288-99-5			Cognition enhancer
DNA Starth Nivelensides Koron	5-Formyluridine				Antiviral, other
	2,3-Di-O-acetyl-5-vinylcytidine				Anticancer, antimetabolite
	2-Pyridinesulfonamide, N-[6-(2-hydroxorhonoxy)-2-12-				
Ro-61-1790	(1H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]- 5-methyl- [CAS]		No O	9619459	Cardiovascular
Rociv rin		53716-44-2			
Documentum		143558-00-3			

Exampl f Indication Infection, HIV/AIDS Alzheimer's disease Migraine Alzheimer's disease Infection, hepatitis-C virus Cancer, general Haemorrhage, subarachnoid
--

API Generic Name	API Chemical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
	Pyrrolidinium, 1- [(28,3Alpha,5Alpha,163,176)-17-	104855-17-5		•	
	(acetyloxy)-3-hydroxy-2:(4- morpholiny)]androstan-16-yi]-1-(2-	104855-17-5 104884-91-5 119302-91-9	m T	287150	Muscle relaxant
rofecoxib	(methy/sulfonyl)phenyl)-3-phenyl- [CAS]	162011-90-7	S	5474995	Analgesic, NSAID
R (ecoxib		162011-90-7			
,	Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-				
roflumilast '	[CAS]	162401-32-3	ŏ O	9501338	COPD treatment
rokitamycin	Leucomycin V, 4B-butanoate 3B- propanoate [CAS]	74014-51-0	S	4242504	Macrolide antibiotic
Rokitamycin		74014-51-0			
Rolipram		61413-54-5			
Rolitetracyclin		751-97-3			
R murtide		78113-36-7			
Ronifibrate		42597-57-9	Π		
Ropinirole		91374-21-9			
ropinirole hydrochloride	2H-Indol-2-one, 4-[2-(dipropylamino)ethyi]- 91374-20-8	91374-20-8 91374-21-9	Ð	266033	Antiparkinsonian
ropinirole, GEOMATRIX	2H-Indol-2-one, 4-[2-diopropylamino)ethylj- 91374-20-8	91374-20-8 91374-21-9			Formulation, oral, other
ropivacaine ·	2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (S)- [CAS]	84057-95-4 98717-15-8	₩.	239710	Anaesthetic, local
R pivacaine		84057-95-4			
R quinimex		84088-42-6			
rosaprostol	Cyclopentaneheptanoic acid, 2-hexyl-5-hydroxy- [CAS]	56695-65-9	GB GB	1523355	Prostaglandin
Rosaprostol		56695-65-9			
R saramicin		35834-26-5			
Ros Bengal		632-68-8	T		
Rosiglitazon		122320-13-4	Γ		

Parkinson's disease Parkinson's disease Anaesthesia	Infection, general	Muscle spasm, general Arthritis, osteo Chronic obstructive pulmonary disease	ple of
---	--------------------	--	--------

API Generic Name	API Chemical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
rosiglitazone maleate	2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (Z)- 122320-73-4 2-butenedioate (1:1) (CAS)	122320-73-4 155141-28-0	SU	5002953	Antidiabetic ·
	Imidadicarbonimidic diamide, N,N-dimethyl-				
	, mononydddione, 5-((4-(2-(methyl-2- Thiazolidinedione, 5-((4-(2-(methyl-2- pyridinylamino)ethoxy)phenyl)methyl)-, (Z)-				
	pyridinyraminojernoxy)pnenyijirieuryij-, (z)- 2-butenedioate (1:1)				
rosiglitazone maleate+metformi					Formulation, modified-release, multi
rosoxacin	3-Quinolinecarboxylic acid, 1-ethyl-1,4- dihydro-4-oxo-7-(4-pyridinyl)- [CAS]	40034-42-2	SU	3753993	Quinolone antibacterial
R soxacin		40034-42-2			•
- 4	Tin, dichloro[ethyl 3,4,20,21-tetradehydro-				
	4,9,14,19-tetraethyl-18,19-dinydro- 3,8,13,18-tetramethyl-20-	•			
	phorbinecarboxylato(2-)- kappaN23,kappaN24,kappaN25,kappaN26	•	_		
rostaponin]-, (UC-0-13)-[UM3]	117707 1170			
	(1-methylethyl)-2- (methyl/methylsulfonyllamino)-5-		_		
	ım salt				
rosuvastatin calcium		147098-20-2	٦	2648897	Hypolipaemic/Andauteroscierosis
•	1-Naphthalenol, 5,6,7,8-tetrahydro-6- [propyl[2-(2-thlenyl)ethyl]amino]-, (S)-				
rotigotine		99755-59-6	S	4564628	Antiparkinsonian
Rotraxate		92071-51-7			
R xars ne		121-19-7			
R xatidine Acetate		78628-28-1			
ο ι	Acetamide, 2-(acetyloxy)-N-[3-[3-(1- piperidinylmethyl)phenoxy[propyl]-, monohydrochloride [CAS]	78628-28-1 93793-83-0	ep -	24510	Antiulcer
	L-Alanine, 3-(((3-(4- (aminoiminomethyl)phenyl)-4,5-dihydro-5-				
	isoxazolyi)acetyi)amino)-N- (butoxycarbonyl)-, methyl ester, (R)-,	176022-50-8	50	5849736	Antithrombotic
R xind le		112192-04-8			

Ulcer, gastric	Hyperlipidaemia, general Parkinson's disease	Infection, gonorrhoea Macular degeneration	Example of Indication Diabetes, Type II Diabetes, Type II
----------------	---	---	---

			Patent	n+	
API G neric Name	API Chemical Name	CAS No.	Ref	Reference	Example of Therapeutic Use
roxithromycin	me] [CAS]	80214-83-1 80214-86-4	ED.	33255	Macrolide antibiotic
Roxithromycin		80214-83-1			
	Benzenepropanoic acid, 8-(((1,1-dimethylethoxy)carbonyl)amino)-Alphahydroxy-				
	hydroxy- (1S,2S,4S,7R,8aR,9aS,10aR,12aS,12bR)- 7.12a-bis(acelvloxy)-1-(benzovloxy)-				
	1,3,47,8,9,9a,10,10a,12,12a,12b-dodecahydro-2-hydroxy-5,13,13-trimethyl-8	:		-	
RPR-109881A	75.6Z	192573-38-9			Anticancer, other
	4,9-Ethano-3aH-benz[f]isoindole-3a- carboxylicacid, 1,2,3,4,9,9a-hexahydro-2-[2	.9.			
	(2-methoxyphenyl)-1-oxo-2-propenyl]-9-(4-methylphenyl) (3aR.4S.9S.9aR)-rel-	•			
RPR-130401		210282-69-2	¥0	9829390	Anticancer, other
R-roscovitine			S	6316456	Anticancer, other
	N'N'-bis(3-hydroxyphenyl)pyridazine-3,6- diamine				٠
RS-0406					Neuroprotective
RSR-13		131179-95-8			
Rubijervin		79-58-3			
rubitecan	1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (S)- (CAS)	91421-42-0	รง	6485514	Anticancer, other
Rubitecan		91421-42-0			
	1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-				Formulation parenteral other
rubilecan, onyernanna	injulary to time , (a) taries		Γ		

Cancer, lung, general Cancer, general Cancer, lung, non-small cell Alzheimer's disease Cancer, pancreatic Cancer, general	Example f Indication Infection, general	
---	---	--

.

API Gen ric Name	API Chemical Name	CAS No.	Refere	Reference	Example of Therapeutic Use
	9H,18H-5,21:12,17- Dimethenodibenzo(e,k)pyrrolo(3,4- h)(1,4,13)oxadiazacyclohexadecine-				
ruboxistaurin		169939-94-0			Symptomatic antidiabetic
Rufinamide	-	106308-44-5			
rufloxacin	7H-Pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo- [CAS]	101363-10-4 102052-47-1 106017-08-7	8	165375	Quinolone antibacterial
Duff vacin		101363-10-4			
rupatadine	5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, trihydrochloride- [CAS]	1,56611-76-6	Q	0577957	Antiallergic, non-asthma
Rutin		153-18-4	•		
RWJ-54428	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z]-(2-amino-5-chloro-4-thiazolyl)(hydroxylimino)acetyl]amino]-3-[(3-[[(2-aminoethyl)thio]methyl]-4-pyridinyljthio]-8-oxo-, (6R,7R)-[CAS]	189448-35-9	wo	9713772	Cephalosporin, injectable
S-0139	Olean-12-en-28-olc acid, 27-[[3-[5-hydroxy- 2-[(4-methoxy-1,4-dioxo-2- butenyi)amino]phenyi]-1-oxo-2- propenyi]oxyj-3-oxo- [CAS]	193969-54-9	WO	9727314	Cardiovascular
S-15535	1,4-benzodioxin- en-2-yl)- [CAS]	146998-34-7			Cognition enhancer
S-18886	1-Napthalenepropanoic acid, 6-(((4-chlorophenyl)sulfonyl)amino)-5,6,7,8-tetrahydro-2-methyl (CAS)	165537-73-5			Antithrombotic
S-24730	7-chloro-6-sulfamoyl-2-(1H)-quinoleinone-3 phosphonic acid	٠			Neuroprotective
((;; ; ;					

:

Infection, general Infection, general Infection, beta-lactamase resistant Ischaemia, cerebral Cognitive disorder, general Unspecified	Exampl findication
--	--------------------

		CAS No	Patent Refere	Patent Reference	Example of Therapeutic Use
API Generic Name	78-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-				- 1
	ethoxyiminoacetamido]-3-(1-(N-methylaminopropyl)-1H-imidazo[4,5-				
·	bjpyridinium-4-methyl-3-cephem-4- carboxylate monosulfate			•	
S-3578			T		Coprigiosporini informació
	2-(N-(4-(4- Chlorophenylsulfonylamino)butyl-N-(3-((4-				
	sopropylthiazol-2- yl)methyloxyljbenzyljsulfamoyljbenzoic acid				Antiochmo
S-36496					Ni nagamina
	2-{N-14-(4- Chiorophenylsulfonylamino)butyl]-N-(3-(2- (A-cyclohutylthiazol-2-	·			
	yi)ethyl]benzyl]sulfamoyl]benzoic acid			•	Antiasthma
0.0027					
	(1R,2R,3S,5S)-7-[2-(5- Hvdroxybenzothionhen-3-vicarboxamido)-	•			·
	6,6-dimethylbicyclo[3.1.1]hept-3yl]-5(Z)-				
S-5751 ·	heptenoic acid				Antiallergic, non-asthma
	Imidazo[4,5-d]pyrano[4,3-b]pyridine,				
S-8510	phosphate (1:1) [CAS]	151466-23-8	Ŧ	556008	Cognition enhancer
	2-Naphthalenecarboxylic acid, 1-(3,4-dimethoxynhenyl)-3-(3-ethyl-1-oxopentyl)-4				
	hydroxy-6,7,8-trimethoxy-, methyl ester	1	5		Umplipamia/Antiathorosolorosis
S-8921	[UAS]	151105-007	1	0000	
Sabcom lin	•	159912-53-5	Τ		
Sabeluzole		104383-17-7			
S-Ad n sylmethi nine		29908-03-0			
	(S)-(+)-2-[4-(3- fluorobenzyloxy)benzylaminoloropanamide			•	
safinamide	methansulfonate	133865-89-1 .	P	711309	Antiepileptic
Salacetamide		487-48-9			
Salaz sulfadimidine		8/4/2315			

Alzheimer's disease Hypercholesterolaemia Epilepsy, general	Asthma Allergy, general	1 1	neral .	Example findication
---	----------------------------	-----	---------	---------------------

API Generic Name	API Chemical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
salbutamol, AeroDose	1,3-Benzenedimethanol,Alpha1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-[CAS]	18559-94-9			Formulation, inhalable, topical
saibutamoi, Alza	1,3-Benzenedimethanol, Alpha 1-[[(1,1-dimethylethyl)aminolmethyl]-4-hydroxy-[CAS]	18559-94-9		·	Formulation, modified-release, other
salbutamol, Clickhaler	1,3-Benzenedimethanol, Alpha1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-[CAS]	18559-94-9	•		Formulation, inhalable, dry powder
salbutamol, Easi-Breathe	Benzenedimethanoi, Alpha1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-[CAS]	18559-94-9			Formulation, inhalable, solution
salbutamol, Easyhaler	1,3-Benzenedimethanol, Alpha1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-[CAS]	18559-94-9			Formulation, inhalable, dry powder
saibutamol, HFA aerosol, 3M	1,3-Benzenedimethanol, Alpha1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-[CAS]	18559-94-9			Formulation, inhalable, topical
salbutamol, Premaire	1,3-Benzenedimethanol, Alpha-[((1,1-dimethylethyl)amino)methylj-4-hydroxy-[CAS]	18559-94-9			Formulation, inhalable, solution
salbutamol, Pulvinal	1,3-Benzenedimethanol, Alpha1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-[CAS]	18559-94-9	Ŧ	451745	Formulation, inhalable, dry powder
saibutamol, Turbuhaler	1,3-Benzenedimethanol, Alpha1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-[CAS]	18559-94-9			Formulation, inhalable, topical
Salicin		138-52-3			
Salicyl Alc hol		90-01-7 CE AE 2			
Salicylamide		65-45-2 25205 22 6		-	
Salicylamide O-Acetic Acid		25395-22-6			
Salicylanilide		87-17-2			
Salicylic Acid		69-72-7			
Salicylsulfuric Acid		89-45-2			
Salinazid		89365-50-4			

Asthma Asthma	Asthma Asthma Asthma	Asthma . Asthma	Example of Indication Asthma Asthma
			. 3

•					
API G n ric Name	API Chemical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
salmeterol xinafoate	1,3-Benzenedimethanol, 4-hydroxy-Alpha1- [[[6-(4-phenylbutoxy)hexyljaminojmethyl-, (±)- 1-hydroxy-2-naphthalenecarboxylate (salt)- [CAS]	89365-50-4 94749-08-3	WO	9006775	Antiasthma
Salsalat	•	552-94-3			
Salverine		6376-26-7			
Samarium 183Sm	•	154427-83-5			
L xidr nam					
	L-Tyrosine, N2-(methylsulfonyl)-L-lysyl-1- ((2S)-3-amino-2-		•		
	carboxypropyljcyclopentanecarbonyl-		}		
sampamiar	[CAS]	0.00-100021	j	000000	
Sampatrilat		129981-36-8	Γ		
Sancyclin	•	808-26-4			
Sap rconazol		110588-57-3			
Sapropterin		62989-33-7			
sapropterin hydrochloride	4(1H)-Pteridinone, 2-amino-6-(1,2-dinydroxypropyl)-5,6,7,8-tetrahydro-,dinydrochloride, [6R-[6R*(1R*,2S*)]]- [CAS] 69056-38-8	. 69056-38-8	B	191335	Antidepressant
saquinavir	Buranediamide, N1-[3-[3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [3S-[2[1H*(R*),2S*],3Alpha,4aß,8aß]]- [CAS]	127779-20-8	명 .	432695	Antiviral, anti-HIV
Saquinavir		127779-20-8			
Saguinavir	•				
Saquinavir Mesylate					

Asthma Hypertension, general Hyperphenylalaninaemia	nsion, g
---	----------

·			Patent	nt	
API G n ric Name	API Chemical Name	CAS No.	Ref	Reference	Example of Therapeutic Use
	Butanediamide, N1-[3-[3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-				
	(phenylmethyl)propylj-2-(/2-	•			
saquinavir, soft gel	[2[1R*(R*),2S*],3Alpha,4aB,8aB]] [CAS]	127729-20-8		·	Formulation, oral, other
Saralasin		34273-10-4			
	Benzamide, N-14-14-(acetvlamino)-4-phenyl				
saredutant	1-piperidinyi]-2-(3,4-dichlorophenyi)butyi]- N-methyl-, (S)- [CAS]	142001-63-6	Ÿ	474561	Antiasthma
	3-Pyridinemethanamine, N-((3,4-dihydro- 2H-1-benzopyran-2-vilmethyl)-5-(4-		-		
sarizotan hydrochloride	fluorophenyi)- [CAS]	177975-08-5			Antiparkinsonian
٠	Butanedioic acid, mono[2-(dimethylamino)- 1-[[2-[2-(3-				
sarpogrelate	methoxyphenyljethyljphenoxyjmethyljethylj ester [CAS]	125926-17-2	Д.	398326	Antithrombotic
Satigrel		111753-73-2			
satraplatin ·	Platinum, bis(acetato- O)amminedichloro(cyclohexanamine)-, (OC-6-43)- [CAS]	129580-63-8	m m	328274	Anticancer, alkylating
Satumomab		144058-40-2			
·	N-[3-[[2-(3,4-dimethoxyphenyl]ethyl]amino]propyl]-4-				
SB-237376	muopenzamoe, noi				Antiarrhythmic
SB-238039	(5(-2-phenylamino-4-pyrimidinyi)-4-)(4- fluorophenyi)-1-(4-piperidinyi)imidazole				Anticancer, other
	trans-N-[4-[2-(6-Cyano-1,2,3,4-tetrahydrolsoquinolin-2-yl)ethyl]cyclohexyl]-				
SB-277011	Aquiloillecarboxallide				Neuroleptic
Scarlet Red		85-83-6			

Cancer, prostate Fibrillation, atrial Cancer, general Schizophrenia	Asthma Parkinson's disease	Exampl f Indication
---	-------------------------------	---------------------

	•				
API G n ric Name	API Chemical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
SCH-00013	Benzonitrile, 4-[2-[3,6-dihydro-4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1(2H)-pyridinyli-1-hydroxyethyl]- [CAS]	217863-18-3	Ą	618204	Cardiostimulant
	(2-[10,11-Dihydro-5-ethoxy-5H-dibenzo [a,d] cyclohepten-S-yi]-N, N-dimethyl- ethanamine		•		immunosuppressant
	1-Piperazineacetonitrile, 4-cyclohexyl-				•
Sch-57790	alpha-[4-[(S)-(4- methoxyphenyl)sulfinyl]phenyl]- [CAS]	221660-80-6			Cognition enhancer
Sch-63390	7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-phenylpropyl)- [CAS]	174648-45-4			Antiparkinsonian
Scillar nin		465-22-5			
Sc p lamine		51-34-3			
Sc polamine N-Oxide		97-75-6	\top		
	Benzeneacetic acid, Alpha- (hydroxymethyl)-, 9-methyl-3-oxa-9- azatricyclo[3.3.1.02,4]non-7-yl ester, [7(5)-				
scopolamine, Alza	(1Alpha,28,49,5Alpha,78)]- [CAS]	51-34-3	S S	4282003 6046188	Formulation, transdermal, other Antiasthma
SCS rechnology	9 10 Secocholesta-5 7 10/19)-triene-		T		
secalciferol, Teva	9,10-Secocholesta-5,7,10(19)-triene- 3,24,25-triol, (38,5Z,7E,24R)- [CAS]	55721-11-4	TQ	301167	Osteoporosis treatment ·
secnidazole	1H-Imidazole-1-ethanol, Alpha,2-dimethyl- 5-nitro- [CAS]	3366-95-8	FF FF	M3270	Protozoacide
Secnidazole		3366-95-8			
S c barbital S dium		309-43-3			
	Benzeneethanamine, N,Alpha-dimethyl-N- 2-propynyl-, (R)- [CAS]	14611-51-9	GB	1153578	Antiparkinsonian
Selegilin		14611-51-9			
Selegiline Hydrochloride					
selegiline transdermal, Somers	Benzeneethanamine, N,Alpha-dimethyl-N- 2-propynyl-, (R)- [CAS]				Formulation, transdermal, patch

API Generic Name	API Chemical Name	CAS No.	Refere	nce	Example of Therapeutic Use
seleciline. Zvdis	lpha-dimethyl-N-	14611-51-9			Formulation, oral, orally-disintegrating
Sel n methionine		1464-42-2			
Sematilide		101526-83-4			
S m tiadii		116476-13-2			
	1,3-Cyclohexanediol, 5-((1-(6-ethyl-6-hydroxy-1-methyl-2.4-octadienyl)octahydro-				•
	7a-methyl-4H-inden-4-ylidene)ethylidene)-				
	4-methylene-, (1R-				
	(1Alpha(1R*,2E,4E),3aB,4E(1R*,3S*,5Z),7		5		Anticoncer other
secalcitol ·	aAlpha))- [CAS]		1	910000	Princelloci, Caro
Sepim stat		103926-64-3	Π		
	Benzeneheptanoic acid, zeta-(2,4,5- trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)- 103187-07-1	103187-07-1			:
seratrodast	, (+/-)- [CAS]	112665-43-7	8	232089	Antiasthma
S ratr dast		112665-43-7	1	•	
-	1H-Imidazole, 1-[2-[(7-chlorobenzo[b]thien-				
sertaconazole	[CAS]	99592-32-2	핑	151477	Antifungal
S rtaconaz I		99592-32-2	Γ		
·	2-Imidazolidinone, 1-[2-[4-[5-chloro-1-(4-				
sertindole	piperidinyi]ethyi]- [CAS]	106516-24-9	Ŧ	392959	Neuroleptic
Sertindole					
	1-Naphthalenamine, 4-(3,4-dichlorophenyl)	-79559-97-0 79617-96-2			
sertraline	[CAS]	79617-97-3	땅	30081	Antidepressant
Sertraline		79617-96-2			
Setastin		64294-95-7			
S velam r		52757-95-6			
	2-Propen-1-amine polymer with	152751-57-0	5	100045	
SOFOIGHTON HIS COMMENTED	Propane, 1,1,1,3,3-hexailuoro-2-				
sevoflurane	(fluoromethoxy)- [CAS]	28523-86-6	두	1954268	Anaestneiic, mhaiation
Sevofluran		28523-86-6			

Asthma Asthma Infection, dermatological Schizophrenia Depression, general Renal failure Anaesthesia	
---	--

			.]	,]	_
API Generic Name	API Chemical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
SG-210 ·	2H-1,4-Benzothiazine-2-acetic acid, 3,4-dihydro-3-oxo-4-((4,5,7-trifluro-2-benzothiazolyf)methyf)- [CAS]	143162-65-6		·	Symptomatic antidiabetic
sibutramine	Cyclobutznemethanamine, 1-(4- chlorophenyl)-N,N-dimethyl-Alpha-(2- methylpropyl)- [CAS]	106650-56-0 84485-00-7	в	2098602	Anorectic/Antiobesity
Sibutramin		106650-56-0			
·	(4aS- (4aAlpha,6aAlpha,11bAlpha,13aR*,13bAlp (4aAlpha,6aAlpha,11b,13b-decahydro- ha)-1,2,3,4,4a,5,6a,11b,13b-decahydro- 4,4,6a,9-tetramethyl-13H- haazofathro(2,3,4-mn)vanihan-11-ol		ę.	37003548	Antifungal
Siccord		7 00 0020			
Siccanin		22/33-60-4			
Sildenafil		139/55-83-2			
sildenafil citrate	[CAS] 1H-Indole-7-carboxamide, 2,3-dihydro-1-(3-hydroxypropyl)-5-{(2H)-2-{[2-{2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-	171599-83-0	m . 8	600675	Urological
Silv ri actat		128-00-7			
Silv r Picrat		146-84-9			•
silver sulfadiazine	N'-2-pyrimidinyisulfanilamide monosilver	22199-08-2 68-35-9			Anti-infective, other
Sim trid		154-82-5			
Simfibrat		14929-11-4			
Simvastatin	Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester, [1S-[1Alpha,3Alpha,7B,8B(2S*,4S*),8aB]]-[CAS]	79902-63-9	US	4444784	Hypolipaemic/Antiatherosclerosis

Hyperlipidaemia, general	Infection, general	Dysuria	tmpotence .		Obesity	Example of Indication Neuropathy, diabetic	
--------------------------	--------------------	---------	-------------	--	---------	---	--

			Patent	n.	
API Generic Nam	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Simvastatin		79902-63-9			
Sincalide		25126-32-3			
Sintr pium Br mide		79467-19-9			
Sis micin		32385-11-8			
Sitafloxacin		127254-12-0			
	3-Outpolingearhowlic acid, 7-(7-amino-5-			-	•
	azaspiro[2.4]hept-5-yi)-8-chloro-6-fluoro-1-	•			
	(2-fluorocyclopropyl)-1,4-dihydro-4-oxo-,			•	
sitafloxacin hydrate	[1R-[1Alpha(S*),2Alpha]]-, hydrate	127254-12-0	Ŧ	341493	Quinolone antibacterial
sitamaquina	7,6-Hexanediamine, N,N-diethyl-N'-(6- methoxy-4-methyl-8-quinolinyl)- [CAS]	5330-29-0 57695-04-2			Protozoacide .
	N-(4-Chloro-3-methyl-5-isoxazolyl)-2-[[4,5-				
sitaxsentan sodium	thiophenesulfonamide	184036-34-8	SU	5464853	Antihypertensive, other
Siv i stat		127373-66-4			
sivelestat sodium hydrate	Glycine, N-[2-[[[4-(2,2-dimethyl-1-oxopropoxy)pheny/]sulfony/]amino]benzoy/]- [CAS]	127373-66-4	B	347168	Respiratory
SJA-6017	Butanamide, 2-[[(4-fluorophenyl]sulfonyl]amino]-N-[(1S)-1-fluorophenyl]sulfonyl]amino]-N-[(1S)-1-formyl-3-methylbutyl.)3-methyl-, (2S)-[CAS]	190274-53-4	8	771565	Ophthalmological
01 pr. 1008	6-Fluoro-9-methyl-2-phenyl-4-pyrrolidin-1- ylcarbonyl)-2,9-dihydro-1H-pyrido[3,4- bjindole-1-one	-	Ą	607076	Anxiolytic
SLV-306	(35,2'A)-3-[1-[2'-(Ethoxycarbonyl)-4'-phenyl-butyl- cyclopentan-1-carbonylamino]-2,3,4,5-tetra-hydro-2-oxo-1H-benzapin-1-acetic acid				Antihypertensive, diuretic
SLV-308	2(3H)-Benzoxazolone, 7-(4-methyl-1- piperazinyl)-, monohydrochloride	269718-83-4			Antiparkinsonian

Exampl of Indica Infection, general Infection, leishmaniasis Infection, leishmaniasis Infection, leishmaniasis Infection, leishmaniasis Infection, general Hypertension, general Hypertension, general Parkinson's disease	Indication Irral maniasis pulmonary pulmonery frome sease
---	---

	ADI Chamical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
					•
				•	
	のののでは、現の後ののののののののでは、「中ののののでは、「中ののののでは、「中ののののでは、「中のののでは、「中ののののでは、「中のののでは、「中のののでは、「中のののでは、「中のでは、「中ののでは、「中のでは、」」では、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、」」では、「中のでは、」」では、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、」」」では、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、」」」では、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、」」」は、「中のでは、「中のでは、「中のでは、「中のでは、」」は、「中のでは、「中のでは、「中のでは、」」は、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、」」」は、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、」」」は、「中のでは、」」は、「中のでは、「・」は、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「中のでは、「・」は、「中のでは、「・は、「は、「・」は、「・は、「は、「・は、」は、「は、「は、「は、「は、」は、「は、「は、」は、「は、「は、」は、「は、「は、は、」は、「は、」は、「は、「は、は、は、は、	÷			•
	ログログログログでくだくだくだんでくらんしくログログログログログログログログログログログログログログログログログログログ	•			
	ΥΟΥΟΥΟΥΘΥΘΥΘΥΘΥΘΥΘΥΘΥΘΥΘΥΘΥ				
	奥DDDDDDXDKDKDKDKDKBKBKKAKAK **・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・				
SM-130686	のADA容A般ADADMDM技術符系のADADADADADADADADADADADADADADADADADADAD				Releasing hormones
	0				
	ethanediyibis(nitrilobis(methylene)))tetrakis	. •			
Sm153 lexidronam	pentasodium, (OC-6-21)- [CAS]	160369-78-8			Analgesic, other
S-Methylmethi nine		4727-40-6			
	N-(Aminoiminomethyl)-11-chloro-5,6,7,8-				
<u> </u>	kij[1]benzazocine-2-carboxamide				
SMP-300 ·	monomemanesulionale lilonoliyulale .				Antianginal
	(4S)-4,7,11-triethyl-3,4,12,14-tetrahydro-				٠
	9,10-dinydroxy-3,14-dioxo-1H-				
SN-38, NeoPharm	у.	100286-90-6			Formulation, optimized, liposomes
	((+)-methyl (4S)-3-[[(3-{4-[3-				
	piperidinyl)propyl)amino) carbonyl)-4-(3,4-				٠
	1,2,3,4-tetrahydro-5-pyrimidinecarboxylate			•	•
CNIAD 7044	hydrochloride)			•	Anxiolylic
	2-Naphthalenecarboxamide, N-[2-[4-			•	
SOA-132	hydroxy-5-(3-pyridinylmethoxy)- [CAS]	143964-80-1			Formulation, inhalable, topical

Angina, general Cancer, colorectal Anxiety, general Asthma		Example findication
---	--	---------------------

API Generic Name	API Chemical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
,	L-valinamide, N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl] 1-(2-methylpropyl)-4-oxobutyl]-N-methyl-,				
		498-71-5			
O DF T I					
sobuzoxane	Carbonic acid, 1,2-ethanedlylbis[(2,6-dioxo- 4,1-piperazinedlyl)methylene]bis(2- methylpropyl) ester [CAS]	98631-95-9	æ	140327	Anticancer, other
Sobuzoxane		98631-95-9			
Sodium Arsanilate		127-85-5			
Sodium Arsphenamine		1936-28-3			•
Sodium Chloride					
Sodium Dibunat		14992-59-7			
Sodium Folate		6484-89-5			
Sodium		149-44-0			
Formaldehydesulfoxylat	•				
Sodium		1334-74-3		•	
Glycerophosphate					,
Sodium Hyaluronate					
Sodium lodomethamate		519-26-6		:	
Sodium Nitrite		7632-00-0			
Sodium Nitr prusside		14402-89-2			
sodium oxybate	Butyric acid, 4-hydroxy monosodium salt [CAS]	502-85-2			Psychostimulant
Sodium Oxybate		٠			
Sodium Phenolsulfonate		1300-51-2		1	

Narcolepsy	Cancer, lymphoma, T-cell	Exampl of Indication Cancer, lung, non-small cell
------------	--------------------------	--

API G n ric Name	API Chemical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
Ucyclyd	dium salt- [CAS]	1716-12-7	•		Formulation, other
	Sodium phosphate monobasic monohydrate + sodium phosphate dibasic		<u> </u>	6162464	Formulation, oral, other
	3B-hydroxy-5-androsten-17-one(sodium		- 1		
sodium prasterone sulfate, Akzo	sulfate dihydrate)		쀻	380036	Formulation, mucosal, topical
Sodium Propionate		137-40-6			
sodium salicylate, Amarin	Benzolc acid, 2-hydroxy-, monosodium sait [CAS]	54-21-7			Formulation, oral, solubility-enhanced
Sodium T trad cyl		139-88-8			
sofalcone	Acetic acid, [5-[(3-methyl-2-butenyl)oxyl-2- [3-[4-[(3-methyl-2-butenyl)oxylphenyl]-1- oxo-2-propenyllphenoxyl- [CAS]	64506-49-6	80	1523241	Antiuloer
Sofalcone		64506-49-6			
S lasulf ne		133-65-3			
solifenacin succinate	Butanedioic acid compd with (1S)-(3R)-1- azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1- phenyl-2(1H)-tsoquinolinecarboxylate (1:1) [CAS]	242478-38-2			Urological
Sorbinicate .	D-Glucitol, hexa-3-pyridinecarboxylate [CAS]	6184-06-1	開	883352	Hypolipaemic/Antiatherosclerosis
S rbitol		50-70-4			
Sorivudine		77181-69-2			
sotaloi	Methanesulfonamide, N-[4-[1-hydroxy-2-[[1]3930-20-9 methylethyl)aminojethyl]phenyl]- [CAS] 959-24-0	3930-20-9 959-24-0			Antiarrhythmic
S tal I	•	3930-20-9			
Sotalol Sotalol					. (
Sets 101					
Hydrochloride					
Soter nol	•	13642-52-9			
Sozoiodolic Acid		554-71-2	Γ		
		-			

Overactive bladder	Exampl of Indication Hyperammonaemia Surgery adjunct Labour, induction Pain, general
--------------------	--

Palent P						
Ccfuliminic acid, Tcf(Neacay/L-Alpha- Ccfuliminic acid, Tcf(Neacay/L-Alpha- Ccfuliminic acid, S-amino-1- Optopropyl-7-(3,5-dimethyl-1-piperazinyl)- Optopropyl-7-(2-dimethyl-1-piperazinyl-1-piper	ADI Casaria Nama	ADI Chemical Name	CAS No.	Pate	erence	Example of Therapeutic Use
3-Quinofinecarboxylic acid, 5-amino-1- Cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)- 6,8-dilluoro-1,4-dihydro-4-xx-, cis-(CAS) 110871-86-8 EP 221463 Quinofone antiba 6,8-dilluoro-1,4-dihydro-4-xx-, cis-(CAS) 110871-86-8 Quinofone antiba 6,8-dilluoro-1,4-dihydro-4-xx-, cis-(CAS) 122748-83-2 US 223465 Antifungal 6,8-dilluoro-1,4-dihydro-4-xx-, cis-(CAS) 122748-83-2 US 223465 Antifungal 7,4-dihydroxy-4-4-antibydro-4-xx-, cis-(CAS) 122748-83-2 US 223880 Antifungal 7,4-Dihia-7-ezaspiro(4,4)nonane-8- 6,4-dihydroxy-4-antibydro-1-xx-, cis-(CAS) 12347-97-6 EP 50800 Antihypertensive 7,4-Dihia-7-ezaspiro(4,4)nonane-8- 6,4-dihydroxy-7-Alpha-mercapio-3-oxo-, cis-(CAS) 23847-97-6 EP 50800 Antihypertensive 7,4-Dihydroxy-7-Alpha-mercapio-3-oxo-, cis-(CAS) 23847-97-6 EP 50800 Antihypertensive 7,4-Dihydroxy-4-anti-2-(Cas) 23847-97-6 23847-97-6 23847-97-6 23847-97-6 23847-97-6 23847-97-6	ensolumic acid, ophthalmol	N-(N-acetyl-L-Alpha-	3106-85-2 80619-64-3			Formulation, mucosal, topical
Candicin 1,8 decarboxy/6 acid, 5-emino-1- goldpropyl-7-(3,5-dimethyl-1-piperaziny)- 5,8-dilluoro-1,4-dihydro-4-oxo-, cis- (CAS) 110871-86-8 EP 221463 Quinolone antiba						
Condition 1,4-climpto-year, 4-5 (part) 10871-86-8		3-Quinolinecarboxylic acid, 5-amino-1- cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-	110871-88-8		221463	Quinolone antibacterial
Candicin D, 18-decarboxy-40-demethyl-3,7-dideoxo-N3-(dimethylamino)acetyl)-18-dideoxo-N3-(dimethylamino)acetyl-18-dideoxo-N3-(dimethylamino)acetyl-18-dideoxo-N3-(dimethylamino)acetyl-18-dideoxo-N3-(dimethylamino)acetyl-18-dideoxo-N	spanioxacin	o,o-dilluolo-1,4-dillydio-1 oxo-, co- [cr.w]	110074 00 0	1		
Candicin D, 18-deratboxy-40-dermethyl-3,7- dideoxo-N3*-((dimethylamino)acetyl)-18- (((2-(dimethylamino)acetyl)-18- - (((2-(dimethylamino)acetyl)-1-(2- (((2-(dimethylamino)acetyl)-1-(2- ((((2-(dimethylamino)acetyl)acetyl)acetyl)-1-(2- ((((2-(dimethylamino)acetyl)acetyl)acetyl)acetyl	Sparfloxacin		110871-86-8			
Candicin D, 18-decarboxy-40-demethyl-3,7- dideoxo-N3'-((dimethylamino)acetyl)-18- (((2-(dimethylamino)acetyl)-18- (((2-(dimethylamino)acetyl)-18- ((2-(dimethylamino)acetyl)-18- adid (1:2) [CAS] (25333-96-4 (25333-96-4 (254))-1,3-oxathiolan-4-yl- (22- ((1y)-Pyrimidinone, 4-amino-1-(2- ((1y)-Pyrimidinone, 4-amino-1-	Spart ine		90-39-1			
Candicin D, 18-decarboxy-40-demethyl-3,7-ditideoxo-N3*-((dimethylamino)cathyl)-18-(((2-dimethylamino)cathyl)-18-((2-dimethylamino)cathyl)-18-((2-dimethylamino)cathyl)-5-oxo cyclic 15,19-hemiacetal, comp with L-ascorbic acid (1:2) [CAS]						
acid (1:2) [CAS] acid (1:2) [CAS] 202748-83-2 202748-83-2 202748-83-2 US 5298495 Antifungal 22(1H)-Pyrimidinone, 4-amino-1-(2- (hydroxymethyl)-1,3-oxathiolan-4-yl- (2R- (hydroxymethyl)-1,3-ox		Candicin D, 18-decarboxy-40-demethyl-3,7-dideoxo-N3-((dimethylamino)acetyl)-18-(((2-(dimethylamino)ethyl)amino)carbonyl)-3,7-dihydroxy-N47-methyl-5-oxo cyclic		•	150	
2(1H)-Pyrimidinone, 4-amino-1-(2- (hydroxymethyl)-1,3-oxathiolan-4-yl- (2R- (is)- 160707-69-7 160707-69-7 US 6228860 Antiviral, anti-HIV 1695-77-8 4-{3-(4-Oxo-4,5,6,7-tetrahydroindol- yl)propionylamino benzoic acid ethyl ester yl)propionylamino benzoic acid ethyl ester phenylpropyljamino -1-oxopropylj-, [85- [7(R*(R*)],8R*]]- [CAS] 749-02-0 749-02-0 749-02-0 749-02-0 749-02-0 1,4-Dithia-7-azaspiro[4,4]nonane-8- carboxylic acid, 7-{2-{ 1-(ethoxycarbonyl)-3- }}- phenylpropyljamino -1-oxopropylj-, [85- [7(R*(R*)],8R*]]- [CAS] 83647-97-6 41992-23-8 Formulation, oral 62-01-7 Formulation, oral	SPA-S-843		202748-83-2	8	CS+067C	Allumiyai
2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-4-yl- (2R-cis)- (is)- 160707-69-7 160707-69-7 US 6228860 Antiviral, anti-Hiv 1695-77-8 4-(3-(4-0xo-4,5,6,7-tetrahydroindol-yl)propionylamino]benzoic acid ethyl ester yl)propionylamino]benzoic acid ethyl ester 749-02-0 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, 7-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]-nino]-1-oxopropyl]-, [85-[7[R*(R*)],8R*]]- [CAS] 83647-97-6 41992-23-8 Formulation, oral 52-01-7 Formulation, oral			2000-00-7			
### 1695-77-8 #################################		2(1H)-Pyrimidinone, 4-amino-1-(2- (hydroxymethyl)-1,3-oxathiolan-4-yl- (2R- cis)-		ñ	2228	Anithiral anti-HIV
4-[3-(4-Oxo-4,5,6,7-tetrahydroindol-y)]propionylamino]benzoic acid ethyl ester 749-02-0 1,4-Dithia-7-azaspiro[4,4]nonane-8-carboxylic acid, 7-[2-[[1-(ethoxycarbonyi)-3-phenylpropyl]amino]-1-oxopropyl]-, [8S-[7[R*(R*)],8R*]]- [CAS] 83647-97-6 83647-97-6 83647-97-6 17-Alpha-Pregn-4-ene-21-carboxylic acid, 17-hydroxy-7Alpha-mercapto-3-oxo-, Gamma-lactone, acetate [CAS] 52-01-7 Formulation, oral			1605.77.8			
749-02-0 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, 7-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-, [8S-[7[R*(R*)].8R*]]- [CAS] 83647-97-6 83647-97-6 41992-23-8 17Alpha-Pregn-4-ene-21-carboxylic acid, 17-hydroxy-7Alpha-mercapto-3-oxo-, Gamma-lactone, acetate [CAS] Formulation, oral	sp.339	4-[3-(4-Οxο-4,5,6,7-tetrahydroindol- yl)propionylamino]benzoic acid ethyl ester				Cognition enhancer
1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, 7-[2-[[1-(ethoxycarbonyi)-3-phenylpropy/]amino]-1-oxopropy/]-, [8S-[7[R*(R*)],8R*]]- [CAS] 83647-97-6 83647-97-6 41992-23-8 17-Alpha-Pregn-4-ene-21-carboxylic acid, 17-hydroxy-7Alpha-mercapto-3-oxo-, Gamma-lactone, acetate [CAS] 52-01-7 Formulation, oral	Spip ron		749-02-0			
### ##################################	spirapril	1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, 7-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-, [8S-[7[H*(H*)],8H*]]- [CAS]	83647-97-6	4	50800	Antihypertensive, renin system
41992-23-8 17Alpha-Pregn-4-ene-21-carboxylic acid, 17-hydroxy-7Alpha-mercapto-3-oxo-, Gamma-lactone, acetate [CAS] 41992-23-8 52-01-7	Spirapril		83647-97-6			
17Alpha-Pregn-4-ene-21-carboxylic acid, 17-hydroxy-7Alpha-mercapto-3-oxo-, Gamma-lactone, acetate [CAS] 52-01-7	Spir germanium		41992-23-8			
17Alpha-Pregn-4-ene-21-carboxylic acio, 17-hydroxy-7Alpha-mercapto-3-oxo-, Gamma-lactone, acetate [CAS] 52-01-7	Spironolactone	1	52-01-7			
	spironolactone, oral, Searle	xylic acid,	52-01-7	•		Formulation, oral, other

Infection, fungal, general Infection, HIV/AIDS Infection, HIV/AIDS Hypertension, general Hypertension, general	general	Conjunctivitis Infection, respiratory tract	Example findication
--	---------	---	---------------------

•	•				
			Patent		Example of Therapoutic IIco
Ar I delicito Malito	Pregn-4-ene-21-carboxylic acid, 7-				
spironotactone, topical, Searle		52-01-7	E E	124147	Formulation, dermal, topical
	Benzamide, N-(1,1-dimethylethyl)-4-[[cis-5'-				
	ethoxy-4-[2-(4-morpholinyi)ethoxyj-2'- oxospiro[cyclohexane-1,3-[3H]indol]-	105019-78-4	5	074556	Cardiostimulant
017121700	Morpholine 4-henzovi-2-(3.4-		T		
SR-144190	.Morpnoline, 4-benzoyi-2-(3,4- difluorophenyi)-2-[2-(4- [[(dimethylamino)carbonyi]amino]-4-phenyi- 1-nineridinyilathyi - (2R)- (CAS)	201152-86-5	¥0	9623787	Anxiolytic
	14. Indolo-1-poetic poid 9-1114-14-chipro-				
SR-146131	2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolyljamino]carbonyl]-5,7-dimethyl-[CAS]	221671-61-0	. WO	9915525	Anarectic/Antiobesity
	N-[1-[2-(diethylamino)ethylamino]-7- methoxy-9-oxo-9H-thioxanthen-4-				
SR-271425	yaneu y jiroti i amaa				Anticancer, alkylating
SR-27897	1H-Indole-1-acetic acid, 2-[[[4-(2- chlorophenyl)-2-thiazolyl]amino]carbonyl]- [CAS]	136381-85-6	8	432040	Anticancer, other
SR-31747	Cyclohexanamine, N-(3-(3-chloro-4- cyclohexylphenyi)-2-propenyi)-N-ethyl-, hydrochloride, (Z)- [CAS]	132173-07-0	Ð	376850	Anticancer, other
	Acetic acid, [[(7S)-7-[[(2R)-2-(3- chlorophenyl)-2-hydroxyethyl]amino}-				
SR-58611	5,6,7,8-tetrahydro-2-naphthalenyljoxy}-, ethyl ester, hydrochloride [CAS]	121524-09-2	Ą	303546	GI inflammatory/bowel disorders
			S.	5385900	Formulation, mucosal, topical
	(A)-(-)-2-(2,4-difluorophenyi)-1- (ethylsulfonyi)-1,1-difluoro-3-(1H-1,2,4- triazol-1-yi)-2-propanol	٠			
SS-750			S	6083968	Antifungal
3-alethine	Propanamide, N, N'(dithiod+2,1- ethanediyl)bls(3-amino)- [CAS]	646-08-2			Anticancer, immunological

Cancer, myeloma Cancer, myeloma Irritable bowel syndrome Infection, ocular Infection, fungal, general	gen	Example of Indication Acne Heart failure Anxisty, general	
---	-----	--	--

ADI Generic Name	API Chemical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
	(2S,4R)-1-[5-chloro-1-[(2,4-	•			
	nhanvi)-2-oxo-2.3-dihvdro-1H-indo-3-yi]-4-	•		•	
	hydroxy-N,N-dimethyl-2-pyrrolidine				,
	carboxamide .		5	0155130	Antidepressant
SSH-149415	The state of the s				
	2-(7-chloro-5-methyl-4-oxo-3-pnenyl-4,5-dihydro-3H-pyridazino[4,5-6]Indol-1-yl).N,N-				
200-180575	dimethylacetamide			,	Neuroprotective
	(3-Exo)-8-benzoyl-N-[[(2S)-7-chloro-2,3-				
	dihydro-1,4-benzodioxin-2-yl]methyl]-8- azabicyclo[3.2.1]octane-3-methanamine				
SSR-181507	HCI		SU	6221879	Neuroleptic
	(5aS.8S, 10aR)-5a,6,9,10-tetrahydro,				
	7H,11H-8,10a- methanopyrido[2',3':5,6]pyrano[2,3-	٠.			
SSR-591813	กูดสมาต				Dependence treatment
	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate	87-33-2			Formulation, transdermal, other
001-101	a Marky a (mathyder Hanvill 1-11 2 A)		T		٠
SSY-726	(-)-(R)-3-Methyl-3-(methylsulionyl)-1-(1,2,4- triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]-2- butanol		SU	5147886	Antifungal
	1 Brannaminiim 9-fanahdov)-3-rarbovy-				
ST-200	N,N,N-trimethyl-, chloride, (R)- [CAS]	5080-50-2	Œ	3015635	Cognition enhancer
stachytlin			8 O	9711947	Antiviral, other
Stallimycin		636-47-5			
Stampidine			S	6350736	Antiviral, anti-HIV
Stannous		15578-26-4			
Pyrophosphate			T		
	(OC-6-13)-Dihydrogen dichloro[7,12-diethyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoato(4-)-N21,N22,N23,N24]stannate(2-)	105344-20-1			Hepatoprotective
stannsoporfin		1-02-44-0001			- Charles Const

Dementia, senile, general Infection, influenza virus Infection, HIV/AIDS	Schizophrenia Addiction, nicotine Angina, general	Exampl findication Depression, general Unspecified
--	---	--

			1		
ADI C B Sir Name	ADI Chemical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
		521-18-6			
N I-		10418-03-8			
		(2'H form);			
		302-96-5 (1'H form)		•	
Stanh aureus ther PhageTech			รก	6376652	Genomics-based drug discovery
STATA inhibitors Tularik			ð	9629341	Immunosuppressant
		2010	8	E01511	Antiviral anti-HIV
stavudine	Inymidine, 2,3 -didenyalo-3 -deoxy- [ones] 3000 in 6	0000-17-0] !		
Stavudine		3056-17-5	T		
stavudine, once-daily, BMS	Thymidine, 2',3'-didehydro-3'-deoxy- [CAS] 3056-17-5	3056-17-5			Formulation, modified-release, <=24hr
Stenb I n		5197-58-0			
stepronin	Glycine, N-[1-0x0-2-[(2-thienylcarbonyi)thio]propyl]- [CAS]	72324-18-6	SU	4242354	Antitussive
Stepr nin		72324-18-6			
Stib captat		27279-76-1			
Stiboph n	•	15489-16-4			
Stilbamidine		122-06-5			
stiripentol	1-Penten-3-ol, 1-(1,3-benzodioxol-5-yl)-4,4- dimethyl- [CAS]	49763-96-4			Antieplieptic
Streptod rnase	•	37340-82-2			
Str pt mycin		57-92-1			
Streptonicozid		5667-71-0			
Streptonigrin		3930-19-6			
Str ptozocin		18883-66-4	Τ		
	3-Thiopheneacetic acid, 5- [bis(carboxymethyl)amino]-2-carboxy-4- cyano-, strontium salt (1:2)- [CAS]	135459-87-9	8	415850	Osteoporosis treatment
strontium-89 chloride	Strontium chloride (89SrCiz) [CAS]	38270-90-5			Analgesic, other
Succimer		304-55-2			
Succinimide	•	123-56-8			
Succinylch line		55-94-7			

Osteoporosis Pain, cancer	Cough Epilepsy, general	Infection, MRSA Unspecified Infection, HIV/AIDS Infection, HIV/AIDS	Example of Indication
------------------------------	--------------------------	---	-----------------------

ADI Caparis Nama	ADI Chemical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
Succinylcholine		71-27-2			
Chlorid		146 42 0			
Succinylsulfathlazole		110-40-0			
Succisulfon		5934-14-5			
Suclofenid		30279-49-3			
	Aluminium, hexadeca- <i>u</i> -			•	
	hydroxytetracosahydroxy(µ8-(1,3,4,6-tetra- O-sulfo-β-D-fructofuranosyl-Alpha-D-				
cicrafata	glucopyranoside tetrakis(hydrogen sulfato)(8-)))hexadeca- [CAS]	54182-58-0	گ	58208233 ·	Antiulcer
Sucraifat		54182-58-0			
	Aliminim havadasa-11-			, 	
	hydroxytetracosahydroxy(µ8-((1,3,4,6-tetra- O-sulfo-B-D-fructofuranosyl Alpha-D-	-		-	
sucraffate, APR	glucopyranoside tetrakis(sulfato- kappaO'))(8-)))hexadeca- [CAS]	54182-58-0			Formulation, oral, other
	Propanamide, N-{4-(methoxymethyl)-1-{2- (2-thienyl)ethyl]-4-piperidinyl]-N-phenyl- rc.a.s:	56030-54-7	S	3998834	Analgesic, other
Sufentanii		56030-54-7			
	Propanamide, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenyl-			•	
sufentanil, S BioSystems	[CAS]	30000	1		
sulbactam	4-Thia-1-azabicycio[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-, 4,4-dioxide, (2S-cis)- [CAS]	68373-14-8	<u>ස</u>	2000138	Antibiotic, other
Sulbactam		68373-14-8			
sulbactam + ampicillin		117060-71-6	S	4234579	Antibiotic, other
	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-				
suibenicillin .	[(phenylsulfoacetyl)amino]-, [2S- [2Alpha,5Alpha,68(S*)]]- [CAS]	28002-18-8 41744-40-5	ဓ္ဓ	1289358	Penicilin, injectable
Sulbenicillin		41744-40-5	Ť		
		270-12-0	•		

gene gene gene	Exampl findication
----------------	--------------------

		7 00 005		Sulfamidochrysoldine
		103-12-8		Outlanten -
		32909-92-5		Culfamotr
-		80-35-3	٠	Sulfamethoxypyrldazine
		723-46-6		Sulfamethoxazole
		3772-76-7		Sulfameth midine
		144-82-1		Sulfamethiz le
		57-68-1		Sulfam thazin
		651-06-9		Sulfam ter
		127-79-7		Sulfam razine
		14376-16-0		Sulfaloxic Acid
		152-47-6		Sulfalen
		27031-08-9	•	Sulfaguanole
		57-67-0		Sulfaguanidin
		94-19-9	-	Sulfa thidol
		2447-57-6		
		122-11-2		Sulfadim th xine
٠		115-68-4		Sulfadicramid
		68-35-9		Sulfadiazine
		17784-12-2		Sulfacytin
		485-41-6		Sulfachrys idine
		80-32-0		Sulfachlorpyridazine
		144-80-9		Sulfacetamid
		127-71-9		Sulfabenzamide
		167747-19-5	•	Sules mab
		61318-90-9		Sulc naz le
Antifungal	US 4055652	61318-90-9 [°] 61318-91-0	1H-Imidazole, 1-{2-[[(4-chlorophenyl)methyl]thio]-2-(2,4-dichlorophenyl)ethyl]-, (+/-)- [CAS]	sulconazole ·
Neurological .		3286-46-2 67-16-3	Propanoic acid, 2-methyl-, dithlobis[3-[1- [[(4-amino-2-methyl-5- pyrimidinyl)methyl]formylamino]ethylidene]-3286-46-2 3,1-propanediyl] ester [CAS]	sulbutiamine
Example of Therapeutic Use	Patent Reference	CAS No.	API Chemical Name	API Generic Name
				•

				·
API Generic Name	API Chemical Name	CAS No.	Reference	Example of Therapeutic Use
Sulfanilamide		63-74-1		
Sulfanilic Acid	•	121-57-3		
Sulfanilylurea		547-44-4		
Sulfap rine		599-88-2		•
Sulfaph nazol		526-08-9		
Sulfaproxylin	•	116-42-7		
Sulfapyrazin		116-44-9		
Sulfapyridin		144-83-2		
Sulfarsid		1134-98-1		
Sulfarsphenamine	•	618-82-6		
Sulfasalazin		599-79-1		
sulfasalazine, Pharmacia	pyridinylamino)sulfonyljphenyljazoj- [CAS]	599-79-1		rollitulation, oraș, enterio coacos
Sulfas miz le		632-00-8		
Sulfasymazin		1984-94-7		
Sulfathiazol		72-14-0		
Sulfathlourea	•	515-49-1		
Sulfinalol		66264-77-5		
Sulfinpyraz ne		57-96-5		
Sulfiram		95-05-6		
Sulfis midine		515-64-0		
Sulfis xazol	•	127-69-5		
Sulfobrom phthalein		71-67-0		-
Sodium				
Sulfonethylmethane		76-20-0		
Sulfoniazid		3691-81-4		
Sulfonmethan		115-24-2		
Sulf ridazin		14759-06-9		
Sulfox ne Sodium	•	144-75-2		
	cis-5-fluoro-2-methyl-1-[(p- methylsulfinyl)benzylidenejIndene-3-acetic	38194-50-2	US 3725548	Anti-inflammatory
Sulindac		38194-50-2		

	Inflammation, general	-						•		Arthritis, rheumatoid									Exampl of Indication	
--	-----------------------	---	--	--	--	--	--	---	--	-----------------------	--	--	--	--	--	--	--	--	----------------------	--

			Datent	1	
API G n ric Name	API Chemical Name	CAS No.	Ref	Reference	Example of Therapeutic Use
Sulisatin		54935-03-4			
Sulisobenz n		4065-45-6			
		29334-07-4			
Sulmaz i		73384-60-8			
Sui ctidii		54063-56-8			
Sulphan Blu		129-17-9			
Sulpiride		15676-16-1			
	Benzamide, 5-(aminosulfonyl)-N-{(1-ethyl-2				
sulpiride, Delagrange	pyπolidinyl)methyl]-2-methoxy-[CAS]	15676-16-1			Alimentary/Metabolic, other
	5-Heptenamide, 7-13-hydroxy-2-(3-hydroxy-				
•	4-phenoxy-1-butenyl)-5-oxocyclopentyl]-N-				
sulprostone	,3Alpha]]-[CAS]	60325-46-4	SU	4024179	Prostaglandin
Sulprostone		60325-46-4			
	4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid. 6-				
•	((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (((3,3-dimethyl-7-oxo-4-thia-1-				
	(azabicyclo(3.2.0)hept-2-				
	(28-				
sultamicilin	(2.alpha.(2H*,5S*),5,alpna.,6.beta.(5*)))- [CAS]	76497-13-7	GB	2044255	Penicillin, oral
Sultamicillin		76497-13-7			
Sulthiame	•	61-56-3			
	Benzamide, N-{(1-ethyl-2- pyrrolidinyl)methyll-5-(ethylsulfonyl)-2-				
sultopride	methoxy-[CAS]	53583-79-2	H	M5916	Neuroleptic
Sult pride		53583-79-2			
Suit silic Acid		57775-26-5			
	(4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,8-dihydro-5-(methylamino)-, (5H)-, (2Z)-2-	170386-77-8	Š	9514090	Antinarkinsonian
Sumatriotan		103628-46-2	П		

Parkinson's d	Psychosis, ge	Infection, general	Abortion	·	Exampl
disease	general	eral :			Indication

API G n ric Name	API Chemical Name	CAS No.	Refere	Patent Reference	Example of Therapeutic Use
	namide, 3-[2- nethyl-,	103628-46-2 103628-48-4	8	147107	Antimigraine
	1H-Indole-5-methanesulfonamide, 3-[2- (dimethylamino)ethylj-N-methyl,				Formulation, modified-release, other
	namide, 3-[2- nethyl-	103628-46-2			Formulation, parenteral, needle-free
Smith bont, mayore	amide, 3- nethyl-,	103628-46-2			Formulation, oral, orally-disintegrating
out manipulation of the control of t	1-(4-amino-2,3,5-trimethylphenoxy)-3-(4-[4-				
SUN-N8075	yl)propan-2(s)-ol dimethanesulfonate				Neuroprotective
	Sulfonium, [3-[[4-(3-ethoxy-2-hydroxypropoxy)phenyl]amino]-3-			***************************************	
suplatest tosilate	methylbenzenesulfonic acid (1:1) [CAS]	94055-76-2	÷	59167564	Antiasthma .
Suplatast T sylate		94055-76-2			
		40828-46-4			
Suramin Sodium		129-46-4			
surfactant TA	Beractant [CAS]	108778-82-1	8	9117766	Lung Surfactant
Suricione		53813-83-5			
Suxibuzon		27470-51-5			
SYM-1010			S	5830998	Antiepileptic
SYM-2081	L-Glutamic acid, 4-methyl-, (4R)- [CAS]	31137-74-3			Analgesic, other
SVV-2007	4-(Aminophenyi)-1-methyl-6,7- (methylenedioxy)-N-butyl-1,2- dihydrophthailazine-2-carboxamide				Neuroprotective
Symcl s n		87-90-1			
	1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(4-methox)-7-[3-(4-metho				
Svn-1253	oxo-1,4-dihydroquinoline 3-carboxylic acid		-		Quinolone antibacterial

			Patent	nt	
API G n ric name	E)-[[(1,4-	One lie.			
Syn-2180		214963-75-4	WO	9847895	Antibacterial, other .
Syn-2869	3H-1,2,4-Triazol-3-one, 4-(4-(4-((1R,2R)-2-(2,4-diffuorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-1-piperazinyl)phenyl)-2,4-dihydro-2((4-(triffuoromethoxy)phenyl)methyl)-[CAS]	210562-98-4	US .	6153616	Antifungal
Synephrin		94-07-5			
Syr sing pin		84-36-6			
T-1095	1-Propanone, 3-(5-benzofuranyl)-1-(2-hydroxy-6-((6-O-methoxycarbonyl)-9-D-glucopyranosyl)oxy)-4-methylphenyl- [CAS] 209746-59-8	209746-59-8	TO TO	850948	Antidiabetic
T-1249	L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutaminyl-L-Alpha-glutamiyl-L-tryptophyl-L-Alpha-glutamiyl-L-glutamiyl-L-iysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-ieucyl-L-glutaminyl-L-glutaminyl-L-glutaminyl-L-glutaminyl-L-glutaminyl-L-Alpha-glutamyl-L-glutaminyl-L-hysyl-L-Alpha-glutamyl-L-elucyl-L-glutaminyl-L-hysyl-L-ibutyl-L-alanyl-L-alpha-glutamyl-L-elucyl-L-trytophyl-L-ananyl-L-seryl-L-leucyl-L-trytophyl-L-Alpha-glutamyl-L-tryptophyl-L-Alpha-glutamyl-L-tryptophyl-L-Alpha-glutamyl-L-tryptophyl-[CAS]	251562-00-2	Wo	9959615	Antiviral, anti-HIV
T-3912	1-cyclopropyt-8-methyt-7-[5-methyt-6- (methytamino)-3-pyridinyl]-4-oxo-1,4- dihydro-3-quinolinecarboxylic acid	•		,	Quinolone antibacterial
T-588	Benzo(b)thiophene-5-methanol, Alpha-((2- (diethylamino)ethoxy)methyl)-, hydrochloride, (R)- [CAS]	142935-03-3	핑	565965	Cognition enhancer

Infection, general Diabetes, general Infection, HIV/AIDS Infection, dermatological Alzheimer's disease
--

			1		7
API Generic Name	API Chemical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
	,4,5,6-pentafluoro	195533-53-0			Anticancer, other
T-89			S	5190951	Cognition enhancer
	2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy- 2-[[2-(4-methoxyphenyi)-1- methylathyllaminolethyll				
TA-2005	monohydrochloride, [R-(R+,R+)]- [CAS]	137888-11-0	S	4579854	Antiasthma
·	Other 2(1H)-Quinoline, 8-hydroxy-5-[1-hydroxy-2-[[2-(4-melhoxyphenyl)-1-				
TA-2005, dry powder inhaler	methylethyljaminojethylj-, monohydrochloride,[A-(A*,A*)]- [CAS]				Formulation, inhalable, dry powder
	2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy- 2-[[2-(4-methoxyphenyl)-1-				
TA-2005, HFA Modulite, Chlesi	methylethyljaminojethylj-, monohydrochtoride, [R-(R*,R*)]- [CAS]	٠	WO	189480	Formulation, inhalable, solution
	1,5-Benzothiazepin-4(5H)-one, 3- (acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-				
TA-993	(2R,3R)-rel-(-)-, (2Z)-2-butenedioate [CAS] 122024-98-0	122024-98-0	å	01045376	Antithrombotic
	(R)-Alpha-((E)-5-Amino-N,5-dimethyl-2-hexenamidoj-N-methyl-N-((R)-Alpha-hemovylyhonethyli-2-				
labimorelin	napthalenepropionamide	170851-70-4 193079-69-5			Releasing hormones
		57333-96-7	}		Authoritation
tacalcitol	1,3,24-triol, (1Alpha,36,5Z,7E,24R)- [CAS]	93128-94-3	1	123000	Cupocinato .
Tacalcitol		57333-96-7		•	Decendance treatment
TA-CD			S C	9630049	Dependence nearment
tacedinaline	Benzamide, 4-(acetylamino)-N-(2- aminophenyl)- [CAS]	112522-64-2	E	3613571	Anticancer, other
tacrine	9-Acridinamine, 1,2,3,4-tetrahydro- [CAS]	321-64-2	Ŧ	332147	Cognition enhancer
Tacrin		321-64-2			
Tacr Ilmus		104987-11-3			
•					

-
Example of Indication
Cancer, liver
Alzheimer's disease
Asthma
Asthma
Asthma
Peripheral vascular disease
Growth hormone deficiency
Keratosis
Addiction, cocaine
Cancer, pancreatic
Alzheimer's disease

			Patent	## *	
API Generic Name	ļ	CAS No.	Refe	Reference	Example of Therapeutic Use
	Pyrazino(1',2':1,6)pyrido(3,4-b)indole1,4-				
	o o o o o o o o o o o o o o o o o o o			•	
tadalatii		171596-29-5	S	6143746	Male sexual dysfunction
	liamine, N4-[2,6-dimethoxy-4-	106635-80-7			
		106635-81-8 80085-55-0	Ŝ	4617394	Antimatarial .
		106635-80-7			
Tafenoguin		179067-42-6	S	9612727	Anticancer, other
tafluposide .	L	1,000,1			
	(S)-N-[2-(1,6,7,8-Tetrahydro-2H-indeno-				Lympoth / Condutive
TAK-375			T		1) brown country
	2-[6-[[3-[4-(Diphenylmethoxy)- piperidino]tmidazo[1,2-b]pyridaztn-2-yl-2-				
	methylproplonic acid dihydrate				Antipruritic/inflamm, allergic
TAK-427			T		
	(b)-4-(4-15-memyr-z-prienyr-r,				•
TAK-559					Antidiabetic
Taka-Diastase		9001-19-8			
	7H-1,3-Dioxolo[4,5- h][2,3]benzodiazepine,7-acetyl-5-(4-				
la la moanel	aminophenyi)-8,9-dihydro-8-metnyr-,(8H)- [CAS]	161832-65-1	SU	5639751	Antiepileptic
Talampanel		161832-65-1			
Talampicillin		47747-56-8	T		
	N-[[(2S,3S)-18-Carboxy-2-(2-carboxy-ethyl)-13-ethyl-2,3-dihydro-3,7,12,17-				
	tetramethyl-8-vinyl porphyrin-20-yl]acetyl]-L				
teleporfin sodium	aspartic acid	220201-34-3			Radio/chemosensitizer
Talactin		16188-61-7		-	
Talbutal		115-44-6			
Talin I I		57460-41-0	T	-	
	4H-Thiazolo[4,5-d]azepin-2-amine, 5,6,7,8-101626-70-4	- 101626-70-4 36085-73-1	DE	3503963	Antiparkinsonlan

API Generic Name	API Chemical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
Talipex le		101626-70-4			
tainetant	4-Quinolinecarboxamide, 3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]- [CAS]	174636-32-9	₩ O	9532948	GI inflammatory/bowel disorders
·	lihydro		n N		Anti-Inflammator.
Commitment		2000	T		
Tainiflumate		66898-62-2			
taitirelin	L-Prolinamide, N-{(hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-, (S)- [CAS]	103300-74-9	ď	61033197	Neurological
Taltir lin		103300-74-9			
tamoxifen	Ethanamine, 2-[4-(1,2-diphenyl-1- butenyl)phenoxy]-N,N-dimethyl-, (Ζ)- [CAS] 10540-29-1	10540-29-1	SU ·	4536516	Anticancer, hormonal
Tam xiten		10540-29-1			
tamoxifen, Douglas	Ethanamine, 2-[4-(1,2-diphenyi-1-butenyi)phenoxy]-N,N-dimethyl-, (z)- [CAS] 10540-29-1	10540-29-1			Formulation, other
tamoxiten, liposomal, BTG	Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl- (Z)- [CAS] 10540-29-1	10540-29-1			Formulation, optimized, liposomes
tamsutosin	Benzenesulfonamide, 5-[2-[[2-(2-ethoxyphenoxy)ethyljamino]propylj-2-methoxy-, (R)- [CAS]	106133-20-4 80223-99-0	Ą	34432	Prostate disorders
Tamsulosin		106133-20-4			
tamsulosin, OCAS	Benzenesulfonamide, 5-[2-[[2-(2- ethoxyphenoxy)ethy/]amino]propy/]-2- methoxy-, (R)- [CAS]	106133-20-4 80223-99-0			Formulation, modified-release, other
tamsulosin,immediate-release	Benzenesulfonamide, 5-[2-[[2-(2-ethoxyphenoxy) ethyljamino]propyl]-2-methoxy-, (R) [CAS]	106133-20-4			Formulation, oral, orally-disintegrating
	4,7-Methano-1H-Isoindole-1,3(2H)-dione, hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyljbutyl]-, 2,3,1,5,3,1,5,3,1,5,5,1,5	112457-05-1			·
Tandospirone	propanetricarboxylate (1:1) [CAS]	87760-53-0	7	02402	Antonyac
			ľ		

Exampl of Indication
Irritable bowel syndrome
Inflammation, ocular
Dyskinesia, general
Cancer, breast
Cancer, breast
Benign prostatic hyperplasia
Benign prostatic hyperplasia
Benign prostatic hyperplasia
Anxiety, general

		7			
ADI Generic Name	API Chemical Name	CAS No.	Refere	Reference	Example of Therapeutic Use
Tannoform		9010-29-1			
Taprosten		108945-35-3			
	3-Quinolinecarboxamide, N-[2-[[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-				
tariquidar	isoquinolinyl)ethyl]phenyl]amino]carbonyl]- 4,5-dimethoxyphenyl]- [CAS]	206873-63-4	\ O	9817648 .	Radio/chemosensitizer
	6-[[2-(Dimethyl-emino)ethyl]amino]-3- hydroxy-7H-indeno[2,1-c]quinolin-7-one				
	dihydrachionde	174634-09-4	8 0	9532187	Anticancer, other
Topocaetan		145733-36-4			
Taur ch lic Acid	٠	81-24-3			
Taur Ildine		19388-87-5			
tazanolast	Acetic acid, oxo[[3-(1H-tetrazol-5-yl)phenyl]amino]-, butyl ester [CAS]	82989-25-1	S	4778816	Antiasthma
Tazan last		82989-25-1			
tazarotene	3-Pyridinecarboxylic acid, 6-[(3,4-dihydro- 4,4-dimethyl-2H-1-benzothlopyran-6- yl)ethynyl]-, ethyl ester [CAS]	118292-40-3	TO	284288	Antipsoriasis .
Tazar tene		118292-40-3			
Taz bactam		89786-04-9			
			Ą	58225091	Antibiotic, other
TBC-3711		374680-51-0			Cardiovascular
TCH-346	N-Methyl-N-propargyl-10-aminomethyl- dibenzo(b,f)oxepin				Neuroprotective
tebipenem	5-Hexenoic acid, 4-hydroxy-, polymer with 4-ethenyl-1H-Imidazole [CAS]	82200-24-6			Beta-lactam antibiotic
tecadenoson	Adenosine, N-{(3R)-tetrahydro-3-furanyi}- (CAS)	204512-90-3	₩ O	9808855	Antiarrhythmic
tecastemizole	1H-Benzimidazol-2-amine, 1-((4- fluorophenyl)methyl)-N-4-piperidinyl- [CAS] 75970-99-9	75970-99-9	S	4219559	Antiallergic, non-asthma
Technetium ssmTc Bicisat		121281-41-2		 	

|--|

API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Technetium 99mTc		125224-05-7;			
Mertiatid		104040-01-0			
T chnetium 93mTc		109581-/3-9			
Sestamibi					
Technetium 99mTc		104716-22-5			
Teboroxime			ŀ		
Teclothiazide		5/4/426/			
T ci zan		5560-78-1			
	Spirojcyclopentane-1,9'-				
tedisamil .	bis(cyclopropylmethyl)- [CAS]	90961-53-8	F	102833	Antiarrhythmic .
Tedisamii		90961-53-8			
T flurane		124-72-1			
tegafur	2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1- (tetrahydro-2-furanyl)- [CAS]	17902-23-7	B	1168391	Anticancer, antimetabolite
Tegafur		17902-23-7			
	2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1- (tetrahydro-2-furanyl)-, mixt. with		3		Astropager antimotehnitie
tegatur + uracii, i aino	Z,4(10,30)-pyttilidiiledioile-[eno]		1		
Tegaserod		145158-71-0			
	Hydrazinecarboximidamide, 2-((5-methoxy- 1H-indol-3-vitmethylane)-N-pentyl-, (Z)-2-				
tegaserod maleate		189188-57-6			GI inflammatory/bowel disorders
Telcoplanin		61036-64-4			
telbivudine	ß-L-2'-deoxythymidine .	3424-98-4			Antiviral, other
Tlenzepine		80880-90-6			
	3-De((2.6-dideoxy-3-C-methyl-3-O-methyl-				
	Alpha-L-ribo-hexopyranosyl)oxy)-11,12- dideoxy-6-O-methyl-3-oxo-12,11-				
telithromycin	(oxycarbonyl((4-(4-(3-pyridinyl)-1H- imidazol-1-yl)butyl)imino))- [CAS]	191114-48-4	Ð	680967	Macrolide antibiotic
Telithromycin		191114-48-4			
telmesteine	3,4-Thiazolidinedicarboxylic acid, 3-ethylester, (R)- [CAS]	122946-43-4			COPD treatment

Fibrillation, atrial Cancer, general Cancer, breast Cancer, breast Irritable bowel syndrome Infection, hepatitis-B virus Infection, respiratory tract, general Bronchitis, chronic

			1		
		CAO NO	Patent	Patent Reference	Example of Therapeutic Use
API Generic Name	(1,1'-Biphenyl)-2-carboxylic acid, 4'-((1,4-				-
telmisartan	dimethyl-2'-propyl(2,6'-bl-1H-benzimidazol)- 1'-yl)methyl)- [CAS]	144701-48-4	TP P	502314	Antihypertensive, renin system
Telmisartan		144701-48-4			
telomerase inhibs, Chugai			Ø O	9941261	Anticancer, other
	7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-	040 80 4	ñ	2107467	Hymnolic/Sedative
temazepam	phenyl-2H-1,4-benzodiazepin-2-one	846-50-4	8	019/40/	1 ypiloud Octobrio
Temazepam		846-50-4			
	Benzeneacetic acid, Alpha-cyclohexyl- Alpha-hydroxy-, 4-(diethylamino)-1,1-	-			٠
temiverine hydrochloride hydra	[CAS]	129927-33-9	æ	2222828	Urological
	1,4-Thiazepine-4(5H)-acetic acid, 6-[[1-	100000-00-4			
temocapril	phenylpropyljaminojtetrahydro-5-oxo-2-(2-thienylpropyljaminojtetrahydro-5-oxo-2-(2-thienyl) [2S-[2Alpha.68(R*)]]- [CAS]	110221-44-8	S	4495188	Antinypertensive, renin system
Tem capril	•	111902-57-9			
T m cillin		66148-78-5			
temoportin	Phenol, 3,3',3",3"-(2,3-dihydro-21H,23H- porphine-5,10,15,20-tetrayl)tetrakis- [CAS] 122341-38-2	122341-38-2	d	337601	Radio/chemosensitizer
T moporfin		122341-38-2			
	Imidazo[5,1-d]-1,2,3,5-tetrazine-8- carboxamide, 3,4-dihydro-3-methyl-4-oxo-				
temozolomide	[CAS]	85622-93-1	T C	0601600	Clared anyman's
Tem zolomide		85622-93-1			
	Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-			•	
temozolomide, SkyePharma	[CAS]				Formulation, parenteral, other
	1H-Imidazo(4,5-b)pyridine, 5-methoxy-2- (((4-methoxy-3,5-dimethyl-2-				
tenatoprazole	pynanyijmemyijsumyij- [CAS]	10112004	8	700000	
leneciepiase		120210-48-2			
T nidao		120210-48-2			

Hypertension, general Cancer, head and neck Cancer, general Ulicer, gastric	Example of Indication Hypertension, general Cancer, general Insomnia
---	---

API Generic Name	API Chemical Name	CAS No.	Refere	Reference	Example of Therapeutic Use
teniposide	Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol- 6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4- hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2- thienylmethylene)-8-D-glucopyranosyljoxyl- [5R-[5Alpha,5a6,8aAlpha,9b(R*)]]- [CAS] 29767-20-2	29767-20-2	US .	3524844	Anticancer, other
T niposid		29767-20-2			
tenofovir	Phosphonic acid, (((1R)-2-(6-amino-9H- purin-9-yi)-1-methylethoxy)methyl)- [CAS]	147127-20-6			Antiviral, anti-HIV
Tenofovir	•	147127-20-6			
·	2.4,6,8-tetraoxa-5-phosphanonanedioic acid, 5-(2-(6-amino-9H-purin-9-yi)-1-methylethoxymethyl) bis(1-methylethyl)ester, 5-oxide (F)-, (E)-2-butenedioate (1:1)			:	
tenofovir disoproxil furnarate	•	202138-50-9			Antiviral, anti-HIV
Tenofovir					,
Disoproxil Fumarate					
Tenonitr zol		3810-35-3	Τ		
tenoxicam	2H-Thieno[2,3-e]-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyrldinyl-, 1,1-dioxide [CAS]	59804-37-4	GB	1519811	Antiarthritic, other
Tenoxicam		59804-37-4			
Tenuaz nic Acid		610-88-8			
teprenone	5,9,13,17-Nonadecatetraen-2-one, 6,10,14,18-tetramethyl- [CAS]	6809-52-5			Antiulcer
T pr none		6809-52-5			
terazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrehydro-2-furanyl)carbonyl]- [CAS]	63074-08-8 63590-64-7 70024-40-7	SU	4112097	Antihypertensive, adrenergic
T razosin		63590-64-7			
terbinafine	1-Naphthalenemethanamine, N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-, (E)-[CAS]	78628-80-5 91161-71-6	Ŧ	24587	Antifungal
Terbinafine		91161-71-6			

Infection, HIV/AIDS Infection, HIV/AIDS Hypertension, general infection, dermatological	Exampl findication Cancer, lymphoma, non- Hodgkin's	
--	--	--

			7	•	
API G n ric Name	API Chemical Name	CAS No.	Refere	nce	Example of Therapeutic Use
Terbutaline		23031-25-6			
terbutaline gel, Columbia	1,3-Benzenediol, 5-[2-[(1,1-dimethyfethyl)amino]-1-hydroxyethyl]-[CAS]	23031-25-6			Formulation, mucosal, topical
	Piperazine, 1-[4-[[2-(2,4-dichlorophenyi)-2- (1H-1,2,4-triazol-1-yimethyi)-1,3-dioxolan-4 yijmethoxyjphenyi -4-(1-methylethyi)-, cis-	87915-31-5	S	4358449	Antifungal
		67915-31-5			
Tel Collaz. Ie	1-Piperidinebutanol, Alpha-(4-(1,1-				
terfenadine	dimethylethyl)phenyl]-4- (hydroxydiphenylmethyl)- [CAS]	50679-08-8	S	3878217	Antiallergic, non-asthma
T rfenadine		50679-08-8			
terguride	Urea, N,N-diethyl-N'-[(8Alpha)-6- methylergolin-8-yl]- [CAS]	37686-84-3	EB.	159522	Antiprolactin
Tergurid		37686-84-3			
Terlipr ssin		14636-12-5			
Terodiline		15793-40-5			
Terof namat		29098-15-5		ì	
Terpin		80-53-5			
•	2-Propanol, 1-[(3,4-dihydro-2H-1-benzothiopyran-8-yl)oxy]-3-[(1,1-dimethylethyl)amino]-, hydrochloride, (+\-)- 33580-30-2	33580-30-2	<u> </u>	1308191	Antihypertensive, adrenergic
Tertatoloi		34784-64-0			
tert-Pentyl Alcohol		75-85-4			
	(2S)-2-ethoxy-3-(4-(2-(4- [(methylsulfonyl)oxy]phenyl]ethoxy]phenyl] propanoic acid				Activity
tesaglitazar					THURSTON
tesmilifene hydrochloride	Ethanamine, N.N-Dietriyr-z-(4- (phenylmethyl)phenoxy)- hydrochloride [CAS]	92981-78-7			Radio/chemosensitizer
T st lactone		968-93-4		ŀ	
Testosterone		58-22-0		-	
Testosterone					

Hypertension, general Diabetes, Type II Cancer, breast	Hyperprolactinaemia	Dysmenorrhoea	Example f Indication
--	---------------------	---------------	----------------------

TABLE IV

API Generic Name				1		
CAS Sequence Se		API Chemical Name	CAS No.	Pate Refe	ent erence	
Androsit-4:en-3-one, 17-hydroxy-, (178) - CAS 60763-47-5 DE 2748794 Androlytic	ate, Sche		5949-44-0			Formulation, other .
CAS Cambibs CAS CAS		androst-4:en-3-one, 17:hydroxy-, (176) - [CAS]			•	Formulation, transdermal, systemic
T6-23-3 T6-2	tetrabamate		60763-47-5	E	2748794	Anxiolytic
136-47-0 136-62-4 US 5816702	T trabarbital		76-23-3	Г		
136-47-0 136-47-0	Tetrabenazine		58-46-8			
### 127-18-4 ##	T tracain		136-47-0	-		
### Denzolc acid, 4-(būtylamino)-, 2- ous (dimethylamino)ethyl ester [CAS] 94-24-6 Cass	Hydrochi ride					
Benzolc acid, 4-(būtylamino)-, 2-	ıylene		127-18-4			
2-Naphthacenecarboxamide, 4- (dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,6,10,12,12a-pentahydroxy-6- methyl-1,11-dioxo-, [4S- (Alpha,4aAlpha,5aAlpha,68,12aAlpha]]- (CAS) 2-Naphthacenecarboxamide, 4- (dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,6,10,12,12a-pentahydroxy-6- methyl-1,11-dioxo-, [4S- (4Alpha,4aAlpha,5aAlpha,68,12aAlpha)]- (CAS) (CAS) 10379-14-3 2-4-Pyrimidinediamine, 5-[(3,5-dimethoxy-4-53808-87-0 (2-methoxyethoxy)phenylimethyl-(CAS) 2-4-Pyrimidinediamine, 5-(13,5-dimethoxy-4-53808-87-0 (2-methoxyethoxy)phenylimethyl-(CAS) 3-3992379 130308-02-4 US 3992379 Anticancer, antim		_	94-24-6			Formulation, transdermal, systemic
2-Naphthacenecarboxamide, 4- (dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,6,10,12,12a-pentahydroxy-6- methyl-1,11-dioxo-, [4S- (4Alpha,4aAlpha,5aAlpha,63,12aAlpha)]- (2-Naphthacenecarboxamide, 4- (dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,6,10,12,12a-pentahydroxy-6- methyl-1,11-dioxo-, [4S- (4Alpha,4aAlpha,5aAlpha,63,12aAlpha)]- (CAS] 8 Gamble [CAS] 9	Tetracycline		60-54-8			
2-Naphthacenecarboxamide, 4- (dimethylamino)-1, 4, 4a, 5,5a, 6, 11, 12a- octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, [4S- (4Alpha,4aAlpha,5aAlpha,6B,12aAlpha)]- 60-54-8 Formulation, other Fo		2-Naphthacenecarboxamide, 4- (dimethylamino)-1,4,48,5,5a,6,11,12a- octahydro-3,6,10,12,12a-pentahydroxy-6- methyl-1,11-dioxo-, [4S- (4Alpha,4aAlpha,5aAlpha,68,12aAlpha)]- (CAS)	60-54-8			
methyl-1,11-dioxo-, [45- (4Alpha,4aAlpha,5aAlpha,68,12aAlpha)]- (CAS] 60-54-8 Formulation, other r z line 60-54-8 60-54-8 Formulation, other r z line 60-54-8 60-54-8 Formulation, other r z line 60-54-8 60-54-8 Formulation, other r z line 60-54-8 60-54-8 Formulation, other r z line 60-54-8 60-54-8 Formulation, other r z line 60-54-8 60-54-3 Formulation, other r z line 60-54-8 60-54-3 Formulation, other r z line 60-54-8 Formulation, other r z line 60-54-8 Formulation, other r z line 60-54-8 Formulation, other r z line 60-54-8 Formulation, other r z line 60-54-8 Formulation, other r z line 60-54-8 Formulation, other r z line 60-54-8 Formulation, other r z line 60-54-8 Formulation, other r z line 60-54-8 Formulation, other r z line 60-54-8 Formulation, other r z line 60-54-8 Formulation, other r z line 60-54-8 Formulation, other r z line 60-54-8 Formulation, other r z line 60-54-8 Formulation, other r z line 60-54-8 Formulation, other r z line Formu		2-Naphthacenecarboxamide, 4- (dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,6,10,12,12a-pentahydroxy-6-				
Procter & Gamble [CAS]		a,68,12aAlpha)}-				
ine 84-22-0 ine 518-34-3 52094-70-9 in 52094-70-9 10379-14-3 am 10379-14-3 127502-06-1 min 2,4-Pyrimidinediamine, 5-[[3,5-dimethoxy-4-53808-87-0 53808-87-0 US 3992379 Trimethoprim and 4302-95-8 rim 53808-87-0 4302-95-8 US 5816702 Anticancer, antimular and 4302-95-8	L		0000	T		
ine 518-34-3 52094-70-9 52094-70-9 52094-70-9 52094-70-9 52094-70-9 52094-70-9 52094-70-9 52094-70-9 52094-70-9 52094-70-9 52094-70-9 52094-70-9 52094-70-9 52094-70-9 52094-70-9 52094-70-9 727502-06-1 52092-79-9 Trimethoprim and 74515-38-1 53808-87-0 US 3992379 Trimethoprim and 74515-38-1 53808-87-0 <t< th=""><th></th><th></th><th>84-22-0</th><th>T</th><th></th><th></th></t<>			84-22-0	T		
n 52094-70-9 am 10379-14-3 min 127502-06-1 2,4-Pyrimidinediamine, 5-[[3,5-dimethoxy-4-53808-87-0] 127502-06-1 (2-methoxyethoxy)phenyl[methyl]-[CAS] 74515-38-1 US 3992379 Trimethoprim and 53808-87-0 p Cytidine, 2'-deoxy-2'-(liuoromethylene)-, (2E)- [CAS] 4302-95-8 US 5816702 Anticancer, antimum	Tetrandrine		518-34-3		•	
am 10379-14-3 10379-14-3 min 127502-06-1 127502-06-1 127502-06-1 2,4-Pyrimidinediamine, 5-[[3,5-dimethoxy-4-53808-87-0 (2-methoxyethoxy)phenyl[methyl]-(CAS] 74515-38-1 US 3992379 Trimethoprim and 4302-95-8 6 Cytidine, 2'-deoxy-2'-(liuoromethylene)-, (2E)- [CAS] 4302-95-8 US 5816702 Anticancer, antimus	T trantoin	•	52094-70-9			
127502-06-1	T trazepam		10379-14-3			
2,4-Pyrimidinediamine, 5-[[3,5-dimethoxy-4-53808-87-0 [2-methoxyethoxy)phenyl[methyl]-[CAS] 74515-38-1 US 3992379 Trimethoprim and 53808-87-0 53808-87-0 53808-87-0 Cytidine, 2'-deoxy-2'-(fluoromethylene)-, [2E)- [CAS] 130306-02-4 US 5816702 Anticancer, antimethoxy-4-53808-87-0 US 5816702 Anticancer, antimethoxy-4-53808-87-0 US 5816702 Anticancer, antimethoxy-4-53808-87-0 US 5816702 Anticancer, antimethoxy-4-53808-87-0 US 5816702 Anticancer, antimethoxy-4-53808-87-0 US 5816702	Tetrofosmin		127502-06-1	T		
rim 53808-87-0 4302-95-8 4302-95-8 US 5616702		2,4-Pyrimidinediamine, 5-[[3,5-dimethoxy-4 (2-methoxyethoxy)phenyi[methyf]-(CAS]	53808-87-0 74515-38-1	S	3992379	
Cytidine, 2'-deoxy-2'-(fluoromethylene)-, [2E)- [CAS] 130306-02-4 US 5616702	Tetroxoprim		53808-87-0	Π		
(2E)- [CAS] 130306-02-4 US 5616702	Teven I®	A till of lower of (fluoromethylano)	4302-95-8	T		
	tezacitabine	Cytidine, 2'-deoxy-2'-(illuorometrylene)-, (2E)- [CAS]	130306-02-4	S	5616702	Anticancer, antimetabolite

	Cancer, colorectal		Infection, general					Acne		Infection, oral			Pain, general				Addiction, alcohol	Hormone replacement therapy	Hormone replacement therapy	Example of Indication	
--	--------------------	--	--------------------	--	--	--	--	------	--	-----------------	--	--	---------------	--	--	--	--------------------	-----------------------------	-----------------------------	-----------------------	--

TABLE IV

			Batast	
API Gen ric Name	API Chemical Name	CAS No.	Reference	Example of Therapeutic Use
	2-Pyridinesulfonamide, N-(6-(2- hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2			
tezosentan	(1H-tetrazor-5-yi)-4-pyndinyi)-4-pyntinidinyi)- 5-(1-methylethyi)- [CAS]	180384-57-0		Cardiostimulant .
Thalldomide	•	50-35-1		
thalidomide, Celgene	1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3- piperidinyl)- [CAS]	50-35-1		Dermatological ·
Thenaldine		86-12-4		
Thenyldiamine		91-79-2		
Th br mine		83-67-0		
		54504-70-0		
- 1		58-55-9		
theophylline, 3M	1H-Purine-2,6-dione, 3,7-dinydro-1,3- dimethyl- [CAS]	58-55-9	-	Formulation, modified-release, other
theophylline, Altana		58-55-9		Formulation, modified-release, <=24hr
theophylline, Amarin	1H-Purine-2,6-dione, 3, 7-dihydro-1, 3- dimethyl- [CAS]	5967-84-0		Formulation, modified-release, other
theophylline, bioMerleux-Pler	1H-Purine-2,6-dione, 3,7-dihydro-1,3- dimethyl- [CAS]	58-55-9		Formulation, other
theophylline, Biovail		58-55-9		Formulation, modified-release, other
theophylline, Diffutab	1H-Purine-2,6-dione, 3,7-dihydro-1,3- dimethyl- [CAS]	58-55-9		Formulation, modified-release, <=24hr
theophylline, Eisai	1H-Purine-2,6-dione, 3,7-dihydro-1,3- dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Elan		58-55-9		Formulation, modified-release, <=24hr
theophylline, Elan PharmaZome		58-55-9		Formulation, optimized, mlcroparticles
theophylline, Forest		58-55-9		Formulation, modified-release, other
theophylline, Gebro	IH-Purine-2,6-dione, 3,7-dihydro-1,3- dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Key	1H-Purine-2,6-dione, 3,7-dihydro-1,3- dimethyl- [CAS]	58-55-9		Formulation, modified-release, other

1	Bronchitis, chronic	Asthma .	Asthma	Asthma	Asthma	Asthma	Asthma	Asthma	Asthma	Asthma	Asthma						Infection, dermatological		Oedema, general	Example of Indication
---	---------------------	----------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--	--	--	--	--	---------------------------	--	-----------------	-----------------------

TABLE IV

_				
ADI G n ric Name	API Chemical Name	CAS No.	Reference	Example of Therapeutic Use
theophylline. Klinge	1H-Purine-2,6-dione, 3,7-dihydro-1,3- dimethyl- [CAS]	58-55-9		Formulation, other
theophyline, KV	1H-Purine-2,6-dione, 3,7-dihydro-1,3- dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Liquitard	lione, 3,7-dihydro-1,3-	58-55-9		Formulation, modified-release, <=24hr
theophylline, Mayne	1H-Purine-2,6-dione, 3,7-dihydro-1,3- dimethyl- (CAS)	58-55-9		Formulation; modified-release, <=24hr
theophylline, Mundipharma	1H-Purine-2,6-dione, 3,7-dihydro-1,3- dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Napp	lione, 3,7-dihydro-1,3-	58-55-9		Formulation, modified-release, other
theophylline, Scherer		58-55-9		Formulation, modified-release, other
theophylline, Schering-Plough	1H-Purine-2,6-dione, 3,7-dihydro-1,3- dimethyf- [CAS]	58-55-9		Formulation, other
Thiabendazole		104-06-3		
Thiacetazone		104-00-3		
	Carbamic acid, [4-(1-methylethyl)phenyl]-, (3aS,8aS)-3,3a,8,8a-tetrahydro-3a,8- dimethyl-2H-thlenol2,3-blindol-5-yl ester			
thiacymserine	[CAS]	145209-51-4		Cognition enhancer
Thialbarbital		467-36-7	•	
Thiamin		59-43-8		
Thiamin Diphosphate		154-87-0		
O I	•	67-16-3		
Thiamlprin	٠	5581-52-2		
Thiamphenic I		15318-45-3		
Thiamylal		77-27-0		
Thiazesim		5845-26-1		
Thlazinamium		58-34-4		
M thylsulfat		54740-86-9		
Thiazolinobulazone		473-30-3		
Thib nzazolin		6028-35-9		
Thiethylperazine		1420-55-9		

Alzheimer	Asthma Asthma Asthma	Asthma Asthma Asthma	Exampl Asthma Asthma
's disease			f Indication

Allicancer, outer	US 6245/50			thymectacin
		70-19-9		Thurfyl Nicotinate
		9035-58-9		Thr mboplastin
		000-00-0		Thozalin n
		OEE OE O		Hydrochloride
	•	63-56-9	-	Thonzylamine
		13/-26-8		Thiram
		82-99-5		Thiphenamil
Antiviral, anti-HIV			Thiophosphonorormic acid	Thiovir
				Thiothixene
				Thiothixene
				Thiothixene
		5591-45-7		Thiothixene
				Hydrochloride
				Thioridazine
		50-52-2		Thi ridazine
		316-81-4		Thi properazine
		84-06-0		Thi pr pazat
		71-73-8		Thiopental Sodium
Anticancer, immunological			L-Thiotyrosinyl-glycinyl-glycine	Thioimreg
		154-42-7		Thioguanin
		96-27-5		Thioglycerol
		62-46-4		Thioctic Acid
		126445-03-4		Thiocres I
		2730-71-4		Thi c Ichicin
		120-02-5		Thiocarbarson
		91-71-4		Thi carbamizin
		2095-57-0		Thiobutabarbital
		77-32-7		Thiobarbital
		54-64-8	٠	Thimerosal
		5964-24-9		Thim rionat Sodium
Example of Therapeutic Use	Reference	CAS No.	API Chemical Name	API G neric Name
	Patent		•	

			Patent	int	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Thym I		89-83-8	Π		
Thymopentin		69558-55-0			
Thymyl N-		578-20-1		•	
ls amylcarbamate					
Thyropr pic Acid		51-26-3			
Thyr xine		51-48-9			
Tladenol	•	6964-20-1			
	3-Piperidinecarboxylic acid, 1-[4,4-bis(3-mathut-2-thienvi)-3-butenvil (R)- [CAS]	115103-54-3	₩ O	8700171	Antiepileptic
Tipophino		115103-54-3			
Hagapine		34 450 61 3			
Tiamenidin	-	2-10-02410			
tlaneptine	Heptanoic acid, 7-{(3-chloro-6, 11-dihydro-6 methyldibenzo[c,f][1,2]thlazepin-11-y/)amino]-, S,S-dioxide [CAS]		GB	1269551	Antidepressant
Tian ptin		66981-73-5			
tiapride	Benzamide, N-[2-(diethylamino)ethyl]-2- methoxy-5-(methylsulfonyl)- [CAS]	51012-32-9	B B	1394563	Neuroleptic
Tiaprid		51012-32-9			
tiaprofenic acid	2-Thiopheneacetic acid, 5-benzoyl-Alpha- methyl- [CAS]	33005-95-7	B	1331505	Antiarthritic, other
Tiaprofenic Acid		33005-95-7		·	
Tiaramid		32527-55-2			
tiazofurin	4-Thiazolecarboxamide, 2-6-D- ribofuranosyl- [CAS]	60084-10-8	Ω.	54432	Anticancer, antimetabolite
Tiaz furin		60084-10-8			
Tibezonium lodide	•	54663-47-7			
tibolone	19-Norpregn-5(10)-en-20-yn-3-one, 17- hydroxy-7-methyl-, (7Alpha,17Alpha)- [CAS]	5630-53-5	Q	389035	Menopausal disorders
Tibolone		5630-53-5			
Ticarcillin		34787-01-4			
uctopidine .	Thieno[3,2-cjpyrdine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro- [CAS]	53885-35-1 55142-85-3	GB	1554424	Antithrombotic

Epilepsy, general Depression, general Cancer, leukaemia, chronic myelogenous Hormone replacement therapy

			Patent	ent	
API Gen ric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Ticlopidin		55142-85-3			
Ticrynafen		40180-04-9			
Tlemonium I dide		144-12-7	Γ		
<u>~</u>	4-(3-hydroxy-3-phenyl-3-thien-2-yl-propyl)- 4-methylmorpholinium methylsulfate	6252-92-2		·	Antispasmodic
tigecycline .	2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[[(1,1-dimethylathylamino]-etiylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-[CAS]	220620-09-7	#	582829	Tetracycline
Tigemonam		102507-71-1			
Tigloidine		495-83-0			
Tilidin		20380-58-9			
Tilisoi I		85136-71-6			-
tilmacoxib	Benzenesulfonamide, 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluoro- [CAS]	180200-68-4	W _O	9619463	Alimentary/Metabolic, other
tiludronic acid	Phosphonic acid, [[(4- chlorophenyl)thlo]methylene]bis- [CAS]	89987-06-4	TP T	100718	Osteoporosis treatment
Tiludr nic Acid		89987-06-4	T		Anthropic Char
Timentin	٠	86482-18-0			Ninolone, cure
timepidium bromide	Piperidinium, 3-(di-2-thienylmethylene)-5- methoxy-1,1-dimethyl-, bromide- [CAS]	35035-05-3	GB	1358446	Antispasmodic
Timepidium Bromide		35035-05-3			
Timip r n		57648-21-2	Γ		
Timolol		26839-75-8			
timoloi maleate	(-)-1-(t-butylamino)-3-[(4-morpholino-1,2,5- thiadiazol-3-yi)oxy]-2-propanolmaleate (1:1) salt	26839-75-8 26921-17-5	GB	1253709	Antihypertensive, adrenergic
	2-Propanol, 1-(tert-butylamino)-3-((4-morpholino-1,2,5-thiazol-3-yl)oxy, (-)-	98991-17-5			Formulation, mucosal, topical
timolol maleate, waxamoto	Ingleaw (1.1) (sail) (Soc)		Γ		

Glaucoma	Polyp Paget's disease Infection, general	Example f Indication	
----------	--	----------------------	--

			1		
API G n ric Name	API Chemical Name	CAS No. :	Patent Refere	Patent Reference	Example of Therapeutic Use
	2-Propanol, 1-[(1,1-dimethylethyl)amino]-3- [[4-(4-morpholinyl)-1,2,5-thiadiazol-3- ulovyl-151- (7)-2-hitenedioate (1:1) (sait) 28839-75-8	26839-75-8			
timolol, antiglaucoma	[CAS]	26921-17-5			Antiglaucoma
timotot onkthatnic	2-Propanol, 1-[(1,1-dimethylethyl)amino]-3- [[4-(4-morpholinyl)-1,2,5-thiadiazol-3- viloxvl-, (S)- [CAS]	26839-75-8	•		Antiglaucoma
	2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-				
	[[4-(4-morpholinyl)-1,2,5-madiazor-3- yl]oxyl-, (S)-, (Z)-2-butenedioate (1:1) (salt) ICASI				Formulation, mucosal, topical
mindred supractions		444-27-9	T		
		113471-15-1			
lin Etnyl Etl purpulin	(4,5-dihydro-1H-imidazol-2-		;		Voncilita polishopi
unazolne	yijunoj- [onoj	10007 01 0	T		
Tinidazol		24227-54-5	Ţ		
Inoridine		910-86-1			
II Carilo		20040 SE B			
Ti cl marol	<u> </u>	0-00-81077	T		
tipopopopolo	1H-Imidazote, 1-[2-[(2-cnloro-3- thienyl)methoxy]-2-(2,4- dichlorophenyllathyll-ICAS)	61675-64-7 65899-73-2	SU	4062966	Antifungal
Tioc naz i		65899-73-2			
tiopronin .	Glycine, N-(2-mercapto-1-oxopropyi)- [CAS]	1953-02-2	S	3246025	Urological
Ti or nin	-	2/2/1953			
	3-Oxa-9-azonlatricyclo(3.3.1.02,4)nonane, 7-((hydroxydi-2-thlenylacetyl)oxy)-9,9-				
tiotropium bromide	dimethyl-, bromide- (1Alpha,28,48,5Alpha,78) [CAS]	136310-93-5	Ŧ	418716	COPD treatment
Ti tropium Bromide		136310-93-5			
Tioxolone		4991-65-5			
Tipepidine		5169-78-8			

Homocystinuria	Infection, fungal, general	Glaucoma	Example of Indication
----------------	----------------------------	----------	-----------------------

		Γ	61951-99-3		Tixoc rtoi
			13825-74-6	•	Titanium Sulfate
			55837-29-1		Tiropramide
Antispasmodic	2503992	DE	55837-29-1	Benzenepropanamide, Alpha- (benzoylamino)-4-[2-(diethylamino)ethoxy]- N,N-dipropyl-, (+\-)- [CAS]	tiropramide
-					Tirofiban Hydrochloride
Anlithrombotic	478363	Ŧ	142373-60-2	L-Tyrosine, N-(buty/sulfonyi)-O-(4-(4- piperidinyi)butyi]-, monohydrochloride- [CAS]	tirofiban hydrochloride
			144494-65-5		Tir fiban
Neuroprotective	8701706 .	WO	110101-65-0 110101-67-2	Pregna-1,4,9(11)-triene-3,20-dione, 21-(4- (2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1- piperazinyl]-16-methyl-, (16Alpha)-, monomethanesulfonate- [CAS]	tirilazad mesylate
			110101-66-1		Tirilazad
			51-24-1	•	Tiratric I
			2/314-9/-2		Tirapazamin
Radio/chemosensitizer	2204574	E	27314-97-2 5424-08-6	1,2,4-Benzotriazin-3-amine, 1,4-dioxide- [CAS]	tirapazamine
			71/31-58-3		Tiquizium Bromide
Antispasmodic	4205074	S	71731-58-3	2H-Quinolizinium, 3-(di-2- thienylmethylene)octahydro-5-methyl-, bromide, trans-,[CAS]	tiquizium bromide
Antiviral, anti-HIV			174484-41-4	N-[3-[1(R)-[4-Hydroxy-2-oxo-8(R)-(2- phenylethyl)-6-propyl-5,6-dihydro-2H-pyran 3-y/]propyl[phenyl]-5- (trilluoromethyl)pyridine-2-sulfonamide	tipranavir
Anticancer, other	9716443	o .	192185-68-5 192185-72-1	2(1H)-Quinotone, 6-(amino(4- chtorophenyl)(1-methyl-1H-imidazol-5- yl)methyl)-4-(3-chtorophenyl)-1-methyl [CAS]	
Example of Therapeutic Use	Patent Reference	Patent Refere	CAS No.	API Chemical Name	API Gen ric Name

	Muscle spasm, general	Infarction, myocardial	Haemorrhage, subarachnoid	Cancer, lung, non-smafi cell		Infection, HIV/AIDS	Cancer, breast	Example findication
--	-----------------------	------------------------	---------------------------	------------------------------	--	---------------------	----------------	---------------------

)

	ADI Chemical Name	CAS No.	Patent Refere	nce	Example of Therapeutic Use
tixocortol pivalate		55560-96-8 61951-99-3	ab	1475795	Antiallergic, non-asthma
tixocortoi pivalate enema	Pregn-4-ene-3,20-dione, 21-((2,2-dimethyl- 1-oxopropyl)thio]-11,17-dihydroxy-,(118)- [CAS]	55560-96-8	S.	4014909	Formulation, mucosal, topical
tizanidine	2,1,3-Benzothiadiazol-4-amine, 5-chloro-N- (4,5-dihydro-1H-imidazol-2-yl)-[CAS]	51322-75-9	8	1429926	Muscle relaxant
Tizanidine		51322-75-9			
TLK-199	Glycine, L-Gamma-glutamyl-S- (phenylmethyl)-L-cysteinyl-2-phenyl-, diethyl ester, (2R)- [CAS]	168682-53-9	S	5679643	Immunostimulant, other
	Glycine, L-Gamma-glutamyl-3-[[2-		•		
TLK-286	onyl]-L-alanyl-2-phenyl-, (2R)- [CAS]	158382-37-7	เร	5545621	Anticancer, other
TNF-B analogue, SRC VB			골	2035185	Anticancer, immunological
TNP-470		129298-91-5			
TO-186	Pregna-1,4-diene-3,20-dione, 9-fluoro- 116,17,21-trihydroxy-16.betamethyl-, 17- butyrate 21-propionate [CAS]	5534-02-1			Antiprurtito/inflamm, allergic
Tobramvcin		32986-56-4			
tobramycin, Nektar	O-3-amino-3-deoxy-Alpha-D- glucopyranosyl-(1,6)-O-(2,6-diamino-2,3,6- trideoxy-Alpha-D-ribo-hexopyranosyl-(1-4)- 2-deoxy- [CAS]	32986-56-4			Formulation, inhalable, topical
rohramycin. PathoGenesis	O-3-amino-3-deoxy-Alpha-D- glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6- trideoxy-Alpha-D-ribo-hexopyranosyl-(1-4))- 2-deoxy- [CAS]	32986-56-4			Formulation, inhalable, solution
tocainide	Propanamide, 2-amino-N-(2,6-dimethylphenyl)- [CAS]	41708-72-9	S	4218477	Antiarrhythmic
T cainide		5634-42-4	T		
Tocamphyl		1 74 1000	-		

		Fibriliation, ventricular	Infection, respiratory tract, lower	Infection, respiratory tract, general		Cancer, general	Cancer, ovarian	Myelodysplastic syndrome	Spastic paralysis	Colitis, ulcerative	Rhinitis, atlergic, general	Example of Indication
--	--	---------------------------	--	--	--	-----------------	-----------------	--------------------------	-------------------	---------------------	-----------------------------	-----------------------

ate ate B-Chloroadenosine 3'5'-cyclic phosphate B-Chloroadenosine 3'5'-cyclic phosphate B-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpyridine,9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thlenyl)- SH-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpyridine,9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thlenyl)- SH-2,3-Benzodiazepine, 1-(3,4-dihydro-7,8-dimethoxy-4-methyl-[CAS]] Methyl-[CAS] Methyl-[CAS] Methyl-[CAS] Benzonesulfonic acid, methyl(3-methylphenyl)- (CAS] Benzenesulfonic acid, 4-ethenyl-, homopolymer, sodium salt odium Benzolic acid, 2-((3-chloro-2-methylphenyl)amino]- (CAS] Benzolic acid, 2-(3-chloro-2-methylphenyl)amino]- (CAS]				Patent	ent	
Benzenesulfono acid. 4-ethanyl- Cartial Cardian Sath Vyphenyl-methyl-methyl-methyl-methylphenyl-methylphenyl-methyl-methyl-methyl-methylphenyl-methylphenyl-methy		API Chemical Name	CAS No.	Refe	erence	Example of Therapeutic Use
Be	tocladesine	8-Chloroadenosine 3'5'-cyclic phosphate	41941-56-4			Anticancer, other
14679-73-3 15301-93-6 15301-93-6 15301-93-6 15301-93-6 15301-93-6 15301-93-6 15301-93-6 15301-93-6 15301-93-6 15301-93-6 15301-93-6 15301-93-6 15301-93-6 15301-93-6 15301-93-6 15301-93-6 15301-93-6 15301-93-6 15301-93-6 15301-93-6 15301-93-7 15301-93	Tocoretinate		40516-48-1			
15301-93-6 15301-93-6 15301-93-6 15301-93-6 154	Todralazine		14679-73-3			-
SH-Pyrazolo[3,4-c]-1,2,4-iriazolo[4,3-a] Signatural	T fenacin		15301-93-6			
3-(2-thienyl)- 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxy-4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-dimethoxy-4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-5-di-156-19-0-di-156-19-		5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine,9-cyclopentyl-7-ethyl-6,9-dinydro				
SH-2,3-Benzodiszepine, 1-(3,4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-4-dimethoxy-5-dimethyl-(CAS) 22345-47-7 GB 1334271 Anxiolytic 22345-47-7 GB 1334271 Anxiolytic 22345-47-7 GB 1345-47-7 GB 13	tofimilast	3-(2-thienyl)-	185954-27-2			Antiasthma
Carbamothiolc acid, 4-ethanyl-, sodium sait Senzoic acid, 2-(3-chloro-2-methylphenyl)aminol-, [CAS] 13710-19-5 13710-19-5 13710-19-5 13710-19-5 134308-13-7 EP 237929 Antibacterial, oth methylphenyl)aminol-, [CAS] 13710-19-5 13710-19-5 134308-13-7 EP 237929 Antibacterial, oth methylphenyl)aminol-, [CAS] 13710-19-5 EP 237929 Antibacterial, oth methylphenyl)aminol-, [CAS] 13710-19-5 EP 237929 Antibacterial, oth methylphenyl)aminol-, [CAS] 13710-19-5 EP 237929 Antibacterial, oth methylphenyl)aminol-, [CAS] 13710-19-5 EP 237929 Antibacterial, oth methylphenyl)aminol-, [CAS] 13710-19-5 EP 237929 Anti-inflammatory and methylphenyl)aminol-, [CAS] 13710-19-5 EP 237929 Anti-inflammatory and methylphenyl)aminol-, [CAS] 13710-19-5 EP 237929 Anti-inflammatory and methylphenyl)aminol-, [CAS] 13710-19-5 EP 237929 Anti-inflammatory and methylphenyl)aminol-, [CAS] 13710-19-5 EP 237929 Anti-inflammatory and methylphenyl)aminol-, [CAS] 13710-19-5 EP 237929 Anti-inflammatory and methylphenyl)aminol-, [CAS] 13710-19-5 EP 237929 Anti-inflammatory and methylphenyl)aminol-, [CAS] 13710-19-5 EP 237929 Anti-inflammatory and methylphenyl)aminol-, [CAS] 13710-19-5 EP 237929 Anti-inflammatory and methylphenyl)aminol-, [CAS] 2333-94-0 26171-23-3 26171		5H-2,3-Benzodiazepine, 1-(3,4-			•	
22345-47-7 1156-19-0 1156-19-0 1156-19-0	tofisopam	methyl-[CAS]	22345-47-7	GB	1334271	Anxiolytic
e Hethanone, (3,4-difhydroxy-5- nitrophenyl)(4-methylphenyl)- [CAS] Hethanone, (3,4-difhydroxy-5- nitrophenyl)(4-methylphenyl)- [CAS] Hethanone, (3,4-difhydroxy-5- nitrophenyl)(4-methylphenyl)- [CAS] Hethanone, (3,4-difhydroxy-5- nitrophenyl)(4-methylphenyl)- [CAS] Hethanone, (3,4-difhydroxy-5- methylphenyl), (4-methylphenyl)- [CAS] Hethanone, (3,4-difhydroxy-5- methylphenyl), (4-methylphenyl)- [CAS] Hethanone, (3,4-difhydroxy-5- methylphenyl), (4-methylphenyl)- [CAS] Hethanone, (3,4-difhydroxy-5- methylphenyl), (4-methylphenyl), (2,3,4-tetrahydro-1,4- methylphenyl), (4-methylphenyl), (50838-36-3) Hethanone, (3,4-difhydroxy-5- methylphenyl), (4-methylphenyl), (2,3,4-tetrahydro-1,4- homopolymer, sodium salt Henzoic acid, 4-ethanyl-, homopolymer, sodium salt Henzoic acid, 4-ethanyl-, homopolymer, sodium salt Henzoic acid, 4-ethanyl-, homopolymer, sodium salt Henzoic acid, 4-ethanyl-, homopolymer, sodium salt Henzoic acid, 4-ethanyl-, homopolymer, sodium salt Henzoic acid, 4-ethanyl-, homopolymer, sodium salt Henzoic acid, 4-ethanyl-, homopolymer, sodium salt Henzoic acid, 4-ethanyl-, Henzoic acid, 4-ethanyl-, homopolymer, sodium salt Henzoic acid, 4-ethanyl-, Henzoic acid	Tofis pam		22345-47-7			
e	T lazamide		1156-19-0			
e Methanone, (3,4-clihydroxy-5- nitrophenyl)(4-methylphenyl)- [CAS] 194308-13-7 EP 237929 Antiparkinsonian Carbamothiolc acid, methyl(3- methylphenyl)-, O-(1,2,3,4-tetrahydro-1,4- methanonaphthalen-6-yl) ester [CAS] 50838-36-3 GB 1364407 Antifungal Benzenesulfonic acid, 4-ethenyl-, homopolymer, sodium salt Benzoic acid, 2-((3-chloro-2- methylphenyl)anlinoj- [CAS] 13710-19-5 DE 1543295 Anti-inflammatory Acid 13710-19-5 DE 1543295 Anti-inflammatory 2933-94-0 26171-23-3	Tolazoline		59-98-3			
Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)- [CAS] 134308-13-7 EP 237929 Antiparkinsonian	Tolbutamide		64-77-7			
Carbamothiolc acid, methyl(3-methylphenyl)-, O-(1,2,3,4-tetrahydro-1,4-methanonaphthalen-6-yl) ester [CAS] 50838-36-3 GB 1364407 Antifungal	tolcapone	Methanone, (3,4-dihydroxy-5- nitrophenyl)(4-methylphenyl)- [CAS]	134308-13-7	Ŧ	237929	Antiparkinsonian
Carbamothiolc acid, methyl(3- methylphenyl)-, O-(1,2,3,4-tetrahydro-1,4- methanonaphthalen-6-yl) ester [CAS] 50838-36-3 GB 1364407 Antifungal 3 50838-36-3 GB 1364407 Antifungal 50838-36-3 GB 1364407 Antifungal 664-95-9 G64-95-9 Benzenesulfonic acid, 4-ethenyl-, homopolymer, sodium salt Benzolc acid, 2-(3-chloro-2- methylphenyl)aminoj- [CAS] 13710-19-5 DE 1543295 Anti-inflammatony 27877-51-6 27877-51-6 2833-94-0 26171-23-3	T icapone		134308-13-7			
Carbamothiolc acid, methyl(3-methylphenyl)-, O-(1,2,3,4-tetrahydro-1,4-methanonaphthalen-6-yl) ester [CAS] 50838-36-3 GB 1364407 Antifungal 1 50838-36-3 664-95-9 </th <th>Tolcapone .</th> <th></th> <th></th> <th></th> <th></th> <th></th>	Tolcapone .					
### Solution	tolciclate	1,4-	50838-36-3	BD BD	1364407	Antifungal
### definition of the image of	Tolciclate		50838-36-3			
Benzenesulfonic acid, 4-ethenyl-, homopolymer, sodium salt 28038-50-8 Antibacterial, otherwise Penzolic acid, 2-((3-chloro-2-methylphenyl)aminoj- [CAS] 13710-19-5 DE 1543295 Anti-inflammatory Acid 27877-51-6 27877-51-6 2933-94-0 26171-23-3 26171-23-3	Tolcyclamid		664-95-9			
um 28038-50-8 Antibacterial, oth Benzoic acid, 2-{(3-chloro-2-methylphenyl)aminoj- [CAS] 13710-19-5 DE 1543295 Anti-inflammatory Acid 27877-51-6 2933-94-0 2933-94-0 26171-23-3		Benzenesulfonic acid, 4-ethenyl-, homopolymer, sodium salt				
Benzoic acid, 2-{(3-chloro-2- methylphenyl)amino]- [CAS] 13710-19-5 DE 1543295	tolevamer sodium		28038-50-8			
lc Acid	tolfenamic acid	Benzoic acid, 2-{(3-chloro-2- methylphenyl)amino]- [CAS]	13710-19-5	DE .	1543295	Anti-inflammatory
	Tolfenamic Acid		13710-19-5			
	Tolindate		27877-51-6			
	Toliproloi		2933-94-0			
	Tolmetin		26171-23-3	Γ		

Cancer, colorectal Asthma Anxiety, general Infection, dermatological Inflammation, general Inflammation, general

	ADI Chemical Name	CAS No.	Refere	Reference	Example of Therapeutic Use
T Inaffate		2398-96-1			
Tol nidin		4201-22-3			
Chloride		92-31-9			
	2-Oxazolidinone, 5-(hydroxymethyl)-3-(3-methylphenyl)- [CAS]	29218-27-7	GB	1250538	Antidepressant
Tol xatone		29218-27-7			
Tolp rison		728-88-1	Γ		
Tolpr pamine		5632-44-0			
T ir stat		82964-04-3			
	Carbamic acid, (2-methylphenyl)-,				
tolserine	(3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8- trimethylpyrrolo[2,3-b]indol-5-yl ester (CAS) 145209-30-9	145209-30-9			Cognition enhancer
tolterodine	Phenol, 2-(3-(bis(1-methylethyl)amino)-1- phenylpropyl)-4-methyl-, (R)- [CAS]	124937-51-5	EB	325571	Urological
Tolterodine		124937-51-5	Π		·
tolterodine, extended-release	Phenol; 2-(3-(bis(1-methoylethyl)amino)-1-phenylpropyl)-4-methyl-, (R)-[CAS]				Formulation, modified-release, <=24hr
phonen	Benzamide, N-[4-[(7-chloro-2,3,4,5- tetrahydro-5-hydroxy-1H-1-benzazepin-1- yl)carbonyl]-3-methylphenyl]-2-methyl- ircas:	150683-30-0	D	450097	Cardiovascular
Tolycain		3686-58-6			
topiramate	B-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate [CAS]	97240-79-4	Æ	533483	Antiepileptic
Topiramate		97240-79-4			
topoisomerase inhibitors, BTG			S	5733880	Anticancer, other
topotecan	1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 9-[(dimethylamino)methyl]-4-ethyl-4,10-dihydroxy-, (S)- [CAS]	123948-87-8 .	Ŧ	321122	Anticancer, other
Topotecan		123948-87-8			
innoteran TCS Inex	1H-Pyrano[3',4':6,7]indolizino[1,2- b]quinoline-3,14(4H,12H)-dione, 9- [[dimethylamino)methyl]-4-ethyl-4,10- dihydroxy-, (S)- [CAS]	123948-87-8			Formulation, optimized, liposomes

Alzheimer's disease Incontinence Incontinence Epilepsy, generalized, tonic- clonic Cancer, general Cancer, ovarian	Exampl of Indication
--	----------------------

	·	CAS No.	Patent Refere	nce	Example of Therapeutic Use
API Generic Name brasemide	3-Pyridinesulfonamide, N-[[(1-methylethyl)amino]carbonyl;-4-[(3-methylphenyl)amino]- [CAS]	56211-40-6	S	160	Antihypertensive, diuretic
	ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl) benzyl[(methoxycarbonyl)amino]-2-ethyl-6- (trifluoromethyl)-3,4-dihydroquinoline-1(2H)			ž.	
torcetrapib		262352-17-0			Hypolipaemic/Antiatheroscierosis
·	B-L-2 Deoxycyldine				Antiviral, other
toremifene	Ethanamine, 2-[4-(4-chloro-1,2-diphenyl-1- 89778-26-7 butenyl)phenoxy]-N,N-dimethyl-, (Z)-[CAS] 89778-27-8	89778-26-7 89778-27-8	Ð	95875	Anticancer, hormonal
Toremif ne	•	89778-26-7	T		
Tors mide		56211-40-0			
Tositumomab		2-20-126802			
T suff xacin		100490-00-0	1		
tosufloxacin tosilate	1,8-Naphthyridine-3-carboxylic acid, 7-(3- amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)- 6-fluoro-1,4-dihydro-4-oxo-, mono(4- methylbenzenesulfonate)- [CAS]	100490-36-6 115964-29-9	S	4704459	Quinolone antibacterial
tramadol	Cyclohexanol, 2-((dimethylamino)methyl]-1-27203-92-5 (3-methoxyphenyl)-, cis-(+/-)-[CAS] 36282-47-0	-27203-92-5 36282-47-0			Analgesic, other
Tramadol		2/203-92-5		-	
tramadol + acetaminophen,Ortho	Cyclohexanol, 2-[(dimethylamino)methyl]-1- (3-methoxyphenyl)-, cis-(+/-)- + Acetamide, N-(4-hydroxyphenyl)-				Formulation, fixed-dose combinations
tramadol SR, Ethypharm	Cyclohexanol, 2-[(dimethylamino)methyl]-1-27203-92-5 (3-methoxyphenyl)-, cis-(+/-)-[CAS] 36282-47-0	27203-92-5 36282-47-0			Formulation, modified-release, other
tramadol, Biovail	Cyclohexanol, 2-[(dimethylamino)methyl]-1-27203-92-5 (3-methoxyphenyl)-, cis-(±)- [CAS] 36282-47-0	36282-47-0	-		Formulation, modified-release, <=24hr

Infection, urinary tract Pain, general Pain, general Pain, general	Exampl of Indication Hypertension, general Atherosclerosis Infection, hepatitis-B virus Cancer, breast
--	--

			Patent Pofere	Patent Poforonce	Example of Therapeutic Use
API Generic Name	API Chemical Name	CAS NO.		2012	
tramadol, Flashtab	Cyclohexanol, 2-[(dimethylamino)methyl]-1-27203-92-5 (3-methoxyphenyl)-, cis-(+/-)-[CAS] 36282-47-0	27203-92-5 36282-47-0			Formulation, oral, orally-disintegrating
tramadol, Labopharm	Cyclohexanol, 2-[(dimethylamino)methylj-1-27203-92-5 (3-methoxyphenyl)-, cis-(±)- [CAS]	27203-92-5 36282-47-0			Formulation, modifiled-release, <=24hr
tramadol. Purdue	Cyclohexanol, 2-[(dimethylamino)methyl]-1-27203-92-5 (3-methoxyphenyl)-, cis-(±)-[CAS]	27203-92-5 36282-47-0			Formulation, modified-release, other
Tramazoline		1082-57-1			
	1H-Indole-2-carboxylic acid, 1-[2-[(1-carboxy-3-phenylpropy)]amino]-1-				
trandolavril	oxopropyljoctahydro-, [2S- [1[R*(R*)]; 2Alpha,3aAlpha,7aB]]- [CAS]	87679-71-8	DE	3151690	Antihypertensive, renin system
Trandolanril		87679-37-6			
randolapril + verapamil. Aven		52-53-9 . 87679-71-8			Formulation, fixed-dose combinations
tranexamic acid	Cyclohexanecarboxylic acid, 4- (aminomethyl)-, trans- [CAS]	1197-18-8	SN	3950405	Antifibrinolytic
Tranexamic Acid		1197-18-8			
tranilast	Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyljamino]- [CAS]	53902-12-8	Sn	3940422	Vuinerary
Tranilact		53902-12-8		1	
trans-retinoic acid, NIH	Retinoic acid [CAS]	302-79-4			Anticancer, other
Transfevoromine		155-09-9			
trapidil	[1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-5-methyl- [CAS]	15421-84-8	8	55956	Vasodilator, coronary ·
Tranidil		15421-84-8			
Trastuzumab		180288-69-1			
Trastuzumab					

	٠.								
Exampl of Indication	Pain, general	Pain, general	Hypertension, general	Hypertension, general	Mensirual disorder, yerrerar	Wound healing	Cancer, general		

			•	•	
	An Chamical Name	CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
API Generic Name	API Circilical value	•			
	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethylester (18(1 Aloha(2),28(1E,3R*),3Alpha,5Alpha)		,	·	rededon mirosel frofice
travoprost, Alcon	[CAS]	157283-68-6			בסווותושתסווי ווותאסמיו מלוומי
Travan v		58712-69-9			
Irakali A Irakonrudi mesulate	1-Piperidineethanol, 4-hydroxy-Alpha-(4-hydroxyphenyl)-ß-methyl-4-phenyh, (AlphaS,6S)-methanesulfonate [CAS]	134234-12-1 188591-67-5			Analgesic, other
	1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-	19794-93-5 25332-39-2	SN	4215104	Antidepressant
trazodone	Control	19794-93-5			
Traz d n		155576-45-7			
Tremacamra		10161-33-8			
Trenbolone		E400 04 7			
Tr ng st ne		2136-04-7			
treosulfan	1,2,3,4-Butanetetroi, 1,4- dimethanesulfonate, [S-(R*,R*)]- [CAS]	299-75-2	Q M	8401506	Anticancer, alkylating
rearinitans	Benzenebutanoic acid, 2,4,5-triethoxy- Gamma-oxo- [CAS]	41828-92-0	GB	1387733	Antispasmodic
. oronordan		41826-92-0			
Trepibutone	JAGOO O Place of a Time of a Time				
ronroction	Prosta-5,13-dlen-1-old add, 0,9-epoxy- 11,15-dihydroxy-, f52,9Aloha,11Aloha,13E,15SJ- [CAS]	35121-78-9 61849-14-7	Sn	6054486	Formulation, parenteral, other
uspinosimo.	Retinoic acid (CAS)	302-79-4			Formulation, dermai, topical
tretinoin, Ortho	Retinoic acid [CAS]	302-79-4	SI	4247547	Antlacne
tretinoin Rache	Retinolc acid- [CAS]	302-79-4			Anticancer, other
	6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1- [(3,4,5-trimethoxyphenyl)methyl]-, (S)- [CAS]	18559-59-6 30418-38-3	র	6802416	Antiasthma
neiodailoi		21650-42-0			•
Tr toquin 1		24305-27-9			
TEH	TOLEGASI	226214-49-9	L	-	Antithrombotic
TRI-50b, iv	1 HI 300 [CA3]	226214-49-9			Antithrombotic
TRI-50b, oral	TRI 50b [CAS]	ethora:].		

	-		-7-	 		<u> </u>	•	-	 	 -		
Example findication	Glaucoma	Pain, general					Hypertension, pulmonary	Acne	Cancer, leukaemia, acute myelogenous		Thrombosis, general	

Triamcinolone acetonide, IDEA [CAS] Iriamcinolone acetonide, IDEA [CAS] Iriamcinolone acetonide, IDEA [CAS] Iriancinolone acetonide, IDEA [CAS] Iriancinolone acetonide, IDEA [CAS]	themical Name a-1,4-diene-3,20-dione, 9-fluoro-dihydroxy-16,17-{(1	0,77,0	Reference		Example of Therapeutic Use
olon olon. le ne acetonide, Astra ne acetonide, IDEA	oha)-		Gefer		en meraperario
olon. le ne acetonide, Astra ne acetonide, IDEA	oha)-	02-76-1 24-94-7 6-25-5 76-25-5	-		
olon. le ne acetonide, Astra ne acetonide, IDEA	oha)-	24-94-7 6-25-5 76-25-5			•
stonide, Astra	oha)-	6-25-5 76-25-5			
stonide, Astra	oha).	6-25-5			
acetonide, Astra	oha)-	16-25-5			
	oha)-	r6-25-5	-		
	ne, 9-fluoro- (118,16Alpha)- ne, 9-fluoro- ne, 9-fluoro- (118,16Alpha)-	6-25-5			
	oha)-	6-25-5			legicot oldolodal actolismos
T	oha)-	٠			romulation, tilitatable, topical
	tha)-	•			
	, (116,16Alpha)- 16, 9-fluoro- 1(116,16Alpha)-				
		4	_		carried femological authorities
	oha)-	76-25-5			rolliniauoti, uariscollina, circa
11.21.	ha)-		_		
3					
·	<u> </u>		_		Total and and
CONTRACTOR TO STORY		76-25-5			Formulation, outer
1		31002.79-6	T		
Triamcinolone	٠				
Benetonid			T		
Triamcin I ne		2-1C-119C			
L vacetonid			1		
TI Vaccionia					
Transfer	Trioning [CAS]	236392-56-6	SO	6458816	Anticancer, antimetabolité
		60 76 0			
Triaziquon		0-07-00			
	8-chloro-6-(2-chlorophenyl)-1-methyl-4H-				
	1,2,4]-triazolo[4,3-a][1,4]benzodiazepine	28911-01-5	S	3980790	Hypnoughsedanve
		28911-01-5			
I riaz lam	AH-11 2 ATT riazolo[4.3-			ı	
al[1,4	41-1,1,4,1,1,1,1,2,2,2,1,3,1,1,1,1,1,1,1,1,1,1,1	28911-01-5			Formulation, transmucosal, nasal
T	4H-[1,2,4]Triazolo[4,3-				
cillus chlore	chlorophenyl)-1-methyl- [CAS]	28911-01-5			Formulation, transmucosar, systemic
		10310-32-4			
Iribenosia		52-68-6			
Trichlorfon		100 C7 E			
Trichlorm thiazide		133-0/-0			

- E			· ·	ig l				
f Indication		neral	. snot	leukaemia, general				
Exampl	Asthma	Eczema, general	Ulcer, aphthous	Cancer, leu	Insomnia	Insomnia	Insomnia	

			Patent	Ħ	
ADI C. noric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Ticklein thing		555-77-1			
		79-01-6			
i richi r unyiene		40.00			
Triclobisonium Chloride		5-06-8/		i	
Triol carban		101-20-2			
Triplofonol Dinorazina		5714-82-9			•
		306-52-5		٠	
Tricionos		3380-34-5			•
		85-90-5			
Tricionnyi		125-99-5			
Triontin		112-24-3			
de la company de	1,2-Ethanediamine, N.N2-bis(2aminoethyl)-dibudrochloride (CAS)			٠.	Metabolic and enzyme disorders
menning analysis and a second		102-71-6			
		51-18-3			
Triethylen phosphorami		545-55-1			
Triethylenethlophosphor		52-24-4			
amide		447 00 E			
Triflu perazine	•	0-60-711			
Trifluoperazine Hydrochloride					·
Triflineridol		749-13-3			0
Trifluor mazine		146-54-3			
trifluridine	Thymidine, Alpha, Alpha, Alpha-trifluoro- [CAS]	. 8-00-02	SN	3201387	Antiviral, other
Trifliridín		8-00-02			
triflusal	Benzoic acid, 2-(acelyloxy)-4- (trituoromethyl)- [CAS]	322-79-2	SN	4096252	Antithrombotic
Triffmeal		322-79-2			·
Trihexyph nidyl		52-49-3			

	•						_				 	
Example f Indication					Wilson's disease					Infection, herpes virus, general	Thrombosis, general	

					•
			Patent	Ħ	
omely change in a	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
API Generic Name	ile, 4,5-epoxy-				
	3,17-dihydroxy-, (4Alpha,5Alpha,17B)-	13647-35-3	ns	3296255	Anticancer, hormonal
triostane	[pvo]	13647-35-3			
Trilostane		25705-16-5			
Trimazosin		90199 91-8			
Trimebutine		02102-01-0			
timohi itina malaata	Benzoic acid, 3,4,5-trimethoxy-, 2- (dimethylamino)-2-phenylbutyl ester, (Z)-2-, butenedioate (1:1) [CAS]	34140-59-5	<u> </u>	2151716	Antispasmodic
		616-68-2			
I'rim cain		84-96-8			
ırımeprazin		5011-34-7			
ı rimetazidin		127-48-0			
Irim thadi n		68-91-7			
Trimethaphan Camsylate					
Trimothohonzamide		138-56-7			
Trim thousing		738-70-5			
I'm mopilii		635-41-6			
I rimetozinte		52128-35-5			
I rimetr Xat	1				
timetrevate obcommate	<u>-</u> []	52128-35-5 82952-64-5	ള	4391809	Antifungal
Hillion of American		739-71-9			
	5H-Dibenz[b,fjazepine-5-propanamine, 10,11-dihydro-N,β-trimethyl-, (Z)-2-bi-tranedinate (1-1) fCASI	521-78-8 739-71-9			Antidepressant
trimipramine mareate		69900-72-7			
Trimoprostii		3902-71-4			
Irioxsalen				<u> </u>	•
. :	Benzamide, 3-(aminosulfonyl)-4-chloro-N- (octahydro-4,7-methano-2H-isoindol-2-yl)-,	73803-48-2	дC	7305585	Anthypertensive, diuretic
mpamide		73803-48-2			
Tripamide		78.41-1			•
Triparanol		04 04 0			
Tripelennamine		0-10-16	4		

1	east					don, Pneumocystis jiroveci		ertension, general		
	Cancer, br					Infection,	-	Hweet	:	

			Patent	=	
ADI Canario Namo	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Ari dellello italiio		486-12-4			
Lipr Haln	Luteinizing hormone-releasing factor (pig),	124508-66-3	2	4010125	Releasing hormones
triptorellin	6-D-tryptophan- [CAS]	T	7		
Trint r lin		57773-63-4			
Trithiozino		35619-65-9			
	Morpholine, 4-[thioxo(3,4,5-	35619-65-9	S	3862138	Antiulcer
mtozine		14504-73-5			
I niodualine	Phosphonic acid, [[[4-				
TRK-530	(methyithio)phenyijthiojmethyienejois-, disodium salt [CAS]	151425-92-2	O _M	9410181	Antiarthritic, other
	2-Propenamide, N-[(5Alpha,68)-17-		•		
	dihydroxymorphinan-6-yll-3-(3-furanyl)-N-methyl- monohydrochloride, (2E)- [CAS]	152658-17-8	WO	9315081	Antipruritic/inflamm, non-allergic
Dotoceli		2244-21-5			,
IT CIOS II POIGSSIMII	3-2-(chloroethvl)-2-(bis(2-				
	chloroethyljaminojtetrahydro-2H-1,3,2- oxazaphosphorin 2-oxide	22089-22-1	gg	1188159	Anticancer, alkylating
Traf afamid		22089-22-1			
J FOI SIGNING		97322-87-7			
Ir giitazon	•	9/9/2751			
Ir leandomycin		588-42-1			
I roinitrate Prospirate	N-(1-adamantyl)-2-(2-dimethylamine ethoxy)acetamide	53783-83-8	DE	1941218	Antiviral, other
Tromantadin		53783-83-8			
Homania and		77-86-1			
romernamine		6878-98-4			
Iropacin		65189-78-8			
ir p sin		1508-75-4			
ir picamide)
Societa indemediate Societa	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 2-carboxy-2-ohenylethyl ester, (+/-)- [CAS]	65189-78-8			Antiarthritic, other
ropine moonetachase, spore					

			·			 	T-1	г т	·
Example findication	Cancer, prostate	Arthritis, rheumatoid	Pruritus		-	Infection, herpes simplex virus			

			Patent	E	
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
moisetron	1H-Indole-3-carboxylic acid, 8-methyl-8- azzalicyclo[3.2.1]cct-3-yl ester, endo-[CAS] 89565-68-4	89565-68-4	85	2125398	Antiemetic
Tr wie tron		89565-68-4			•
Tr enect mycin		88669-04-9			
	3Alpha-Hydroxyspiro[1AlphaH,5AlphaH-			•	
trospium chloride	benzilate	10405-02-4			Urological
Trosplum Chloride		10405-02-4			
	3Alpha-Hydroxyspiro[1AlphaH,5AlphaH- nortropane-8,1'-pyrrolidinium] chloride				
trospium chloride, extended re	benzilate .	10405-02-4		•	Formulation, modified-release, other
	3Alpha-Hydroxyspiro[1AlphaH,5AlphaH-nortropane-8,1'-pyrrolidinlum] chloride			į	
trospium chloride. Pfleger	benzilate	10405-02-4		•	Formulation, parenteral, other
Tr vafl xacin		147059-72-1			
	1,8-Naphthyridine-3-carboxylic acid, 7-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-,71 Ainha 5Alnha 6Aloha)	147059-72-1			
trovafloxacín mesilate	monomethanesulfonate- [CAS]	147059-75-4	ള	5164402	Quinolone antibacterial
troxacitabine	2(1H)-Pyrimidinone, 4-amino-1-(2- (hydroxymethyl)-1,3-dioxolan-4-yl)-, (2S- cis)-[CAS]	145918-75-8			Anticancer, other
Troverutin		7085-55-4			
troxinide	Benzamide, 3,4,5-trimethoxy-N-3- piperidinyl-, (+/-)- [CAS]	30751-05-4	SO	3647805	Antiulcer
Troxinide		99777-81-8			
Trunan Red		574-64-1			
Tryparsamide		554-72-3			
Tryptophan		73-22-3			
TOD		9002-71-5			

				,				 	- 1	· ·	 	1
Example findication	Chemotherapy-induced nausea and vomiting	Pollakisuria	Pollakisuria	Pollakisuria	·	Infection, respiratory tract, general	Cancer, leukaemia, acute myelogenous	Ulcer, gastric				

			Patent	1	Thorsperit
API Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Osc
	6,14-Ethenomorphinan-7-methanol, 17- (cyclopropylmethyl)-Alpha-(1,1- dimethylethyl)-,5-epoxy-18,19-dihydro-3- hydroxy-6-methoxy-Alpha-methyl-,	•			Anter learned and the control
60-NSL	[5Alpha,7Alpha,(S)]- [CAS]	52485-79-7			Formulation, utilisaetina, parci
	Nonanedioic acid, bis[(2- (ethoxycarbonyl)phenyl) ester		Sn	6180669	Antlacne
TU-2100			Т		
Triamin h ptane		123-82-0			
Tuberoidin		69-33-0			
Tubocurarin Chloride		57-94-3			
	Benzenemethanol, 2-chloro-Alpha-[[(1,1-dimethylethyl)aminojmethyl- [CAS]	41570-61-0	DE	2244737	Antiasthma
		41570-61-0			
	N-(Propargyl-(3R)aminoindan-5-yl)-ethyl methyl carbamate				Counition enhancer
TV-3326					
	-G-nihudavahat Z Z Z a a a a a Lian circon				2
	Acencado, (=7(s,>,a,>,r,r,r,r,r,r,r,r,r,r,r,r,r,r,r,r,r	140694-43-5	Sn	4837342	Antithrombotic
1 Y-11223	6,7,8,9-Tetrahydro-2-methyl-5H-				
	cyclohepta[b]pyridine-3-carbonyiguaniuine maleate			0000100	o in the state of
TY-12533			3	6299929	Amainyminc
TYB-3215	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate (CAS)	87-33-2			Formulation, modified-release, other
Tybamat		4268-36-4			
Tvi xanol		25301-02-4			
index it	4-(1,1,3,3-Tetramethylbutyl)phenol				•
tyloxapol, Discovery	[CAS]	25301-02-4			Formulation, inhalable, topical
Tymazoline		24243-97-8			
Timomino		51-67-2			

Example findication	
	• ,
Pain, cancer	
Acne	
Asthma	
Azhelmer's disease	
Unspecified	•
Unspecified .	
Angina, general	
Cystic fibrasis	

API Gen ric Name API Chemical Name CAS No. Ref Tage 1.7 Tyr pan ate Sodium Tyr pan			
## API Chemical Name 7246-21-1	Pateill	900	Example of Therapeutic Use
1249-21-1 1240		2	
Benzoic acid, 2-ii3- (trifluoromethyl)phenyljaminoj-, butyl ester (5730-25-0) (CAS)	1-12-91		
CAS Enracic acid, 2-[i] (triflucromestry)phenyljaminoj-, butyl aster (triflucromestry)phenyljaminoj-, butyl aster 112.38-9 112.3	9-92-026		
Inic Acid	น	961852	Antioruritic/Inflamm, non-allergic
Interest	1		
st n 4-(4-Chloro-5-(3-filuoto-4-methoxyphenyl)im/dazol-1-im	6-98-7		
4-[4-Chioro-5-(3-iluoro-4-methoxyphenyl)imidazol-1-midazol-1-yilbenzenesulfonamide- [CAS] 66-75-1 1,2,3-Propanetricarboxylic acid, 2-hydroxy-potasslum sodium salt (5:6:6), hydrate (CAS] 2,4(1H,3H)-Pyrimidinedione, 6-[[3-[4-(2-methoxyphenyl)-1-piperazinylipropyljamino]-1,3-dimethyl-1-piperazinylipropyljamino]-1,3-dimethyl-1-piperazinylipropyljamino]-1,3-dimethyl-1-piperazinylipropyljamino]-1,3-dimethyl-1-piperazinylipropyljamino]-1,3-dimethyl-1-piperazinylipropyljamino]-1,3-dimethyl-1-piperazinylipropyljamino]-1,3-dimethyl-1-piperazinylipropyljamino]-1,3-dimethyl-1-piperazinylipropyljamino]-1,3-dimethyl-1-1-3-6 57-13-	0373-36-6		
1979entententicarboxylic acid, 2-hydroxy- 1,2,3-Propanetricarboxylic acid, 2-hydroxy- 2,4(1H,3H)-Pyrimidinedione, 6-[[3-4-2- 3,461-75-1 3,4661-75-1 3,4661-75-1 1,2,3-Propanetricarboxylic acid, 3,461-75-1 3,461-75-1 1,2,3-Propanetricarboxylic acid, 3,461-45-1 1,2,3-Propanetricarboxylic acid, 3,461-4 1,2,3-Propanetricarboxylic acid, 3,461-4 1,2		`	Anti-inflammatory
Viustard 12,3-Propanetricarboxylic acid, 2-hydroxy-potasslum sodium salt (5:6:6), hydrate (CAS) 55049-48-4 (CAS) 2.4(1H,3H)-Pyrimidinedione, 6-[[3-44-(2-methoxyphenyl]-n-piperazinyl]propyl[amilno]-1,3-dimethyl-1cAS] 34661-75-1 (CAS) 34661-75-1 (CAS) 57-13-6 nas 10-rea [CAS] 37-49-8 nas 57-73-6 nas 10-rea [CAS] 302-49-8 nas 57-73-6 57-73-6 nas 10-rea [CAS] 302-49-8 nas 57-73-6 57-73-6 nas 58-96-8 57-73-6 <	-75-1		
1,2,3-Propanetricaroxyne acut, 2-1,9-2-9-9 1,2,3-Propanetricaroxyne acut, 2-1,9-2-9-9-9-9-9-9-9-9-9-9-9-9-9-9-9-9-9-9			
2,4(1H,3H)-Pyrimidinedione, 6-[[3-14-(2-methoxyphenyl)-1-piperazinyl]propyljamlno]-1,3-dimethyl-34661-75-1 [CAS] Diperazinyl]propyljamlno]-1,3-dimethyl-34661-75-1 Urea [CAS] Direa [CAS	ns	4400535	Urological .
International			
Intermedia CAS 34661-75-1 Intermedia Urea (CAS 57-13-6 Intermedia Urea (CAS 57-13-6 Intermedia Urea (CAS 57-13-6 Intermedia Urea (CAS 57-13-6 Intermedia SA 57-13-6 Intermedia SA 57-13-6 Intermedia SA SA		ļ	
18 19 19 19 19 19 19 19	gg GB	1309324	Antihyperensive, adreneigic
Pharmacia Urea [CAS] 57-13-6 5 10 cea [CAS] 57-13-6 10 cea [CAS] 302-49-8 302-49-8 5 51-79-6 51-79-6 63-39-8 63-39-8 63-39-8 Ilfarma Jurdine [CAS] 80449-31-6 cholic acid, Axcan 3Alpha,78-dihydroxy-58-cholan-24-oic acid 128-13-2 cholic acid, Mitsub (CAS] 3Alpha,78-dihydroxy-58-cholan-24-oic acid 128-13-2 cholic acid, Mitsub (CAS] 3Alpha,78-dihydroxy-58-cholan-24-oic acid 128-13-2 cholic acid, Mitsub (CAS] 3Alpha,78-dihydroxy-58-cholan-24-oic acid 128-13-2 cholic acid, Novartis (CAS] 3Alpha,78-dihydroxy-58-cholan-24-oic acid 128-13-2 cholic acid, Novartis (CAS] 3Alpha,78-dihydroxy-58-cholan-24-oic acid 128-13-2	661-75-1		
Sphate 57-13-6 sphate 51-79-6 Sphate 63-39-8 uridine [CAS] 63-39-8 Axcan 58-96-8 3Alpha,73-dihydroxy-58-cholan-24-oic acid 128-13-2 Axcan-2 [CAS] Mitsub (CAS] Axcan-2 (CAS] Axcan-3Alpha,78-dihydroxy-58-cholan-24-oic acid 128-13-2 Axcan-3Alpha,78-dihydroxy-58-cholan-24-oic acid 128-13-2 Ritsub (CAS] 3Alpha,78-dihydroxy-58-cholan-24-oic acid 128-13-2 Rowartis [CAS] Axcan-2 (CAS)	13-6	. !	Antipsoriasis
Shoshate 51-79-6 Shoshate 63-39-8 Undine [CAS] 80449-31-6 SAlpha,78-dihydroxy-58-cholan-24-oic acid 3Alpha,78-dihydroxy-56-cholan-24-oic acid 3Alpha,78-dihydroxy-56-cholan-24-oic acid 3Alpha,78-dihydroxy-58-cholan-24-oic acid 128-13-2 cid, Axcan-2 (CAS) 3Alpha,78-dihydroxy-58-cholan-24-oic acid 128-13-2 cid, Mitsub (CAS) 128-13-2 galpha,78-dihydroxy-58-cholan-24-oic acid 3Alpha,78-dihydroxy-58-cholan-24-oic acid 128-13-2	13-6		Antipruritic/Inflamm, allergic
thosphate 51-79-6 Untdine [CAS] 63-39-8 SAlpha,78-dihydroxy-58-cholan-24-oic acid 3Alpha,78-dihydroxy-56-cholan-24-oic acid 128-13-2 128-13-2 CAS 3Alpha,78-dihydroxy-56-cholan-24-oic acid 3Alpha,78-dihydroxy-58-cholan-24-oic acid 128-13-2 128-13-2 cid, Mitsub (CAS) 3Alpha,78-dihydroxy-58-cholan-24-oic acid 128-13-2 cid, Mitsub (CAS) 128-13-2 cid, Mitsub (CAS) 128-13-2 cid, Novartis (CAS) 128-13-2	8-67-6		
1-73-0 21-73	202		
cid, Axcan-2 (CAS) 63-39-8 cid, Axcan-2 (CAS) 58-96-8 cid, Axcan-2 (CAS) 128-13-2 cid, Axcan-2 (CAS) 128-13-2 cid, Mitsub (CAS) 128-13-2 cid, Novartis (CAS) 128-13-2	0.87-		
Lordine [CAS] 58-96-8 B0449-31-6 80449-31-6 SAlpha,7B-dihydroxy-5B-cholan-24-olc acid 128-13-2 ICAS] 128-13-2 Icid, Axcan-2 ICAS] Icid, Mitsub ICAS] Icid, Novartis ICAS]	B-66-		
cid, Axcan-2 (CAS) 3Alpha,7B-dihydroxy-5B-cholan-24-oic acid 3Alpha,7B-dihydroxy-5B-cholan-24-oic acid cid, Axcan-2 (CAS) 3Alpha,7B-dihydroxy-5B-cholan-24-oic acid (CAS) (CAS) 3Alpha,7B-dihydroxy-5B-cholan-24-oic acid 3Alpha,7B-dihydroxy-5B-cholan-24-oic acid (CAS) (CAS)	Ð	348360	Formulation, other
ic acid, Axcan [CAS] (CAS] (CAS) (CA	449-31-6		
can [CAS] 3Alpha,7B-dihydroxy-5ß-cholan-24-oic acid can-2 [CAS] 3Alpha,7B-dihydroxy-5ß-cholan-24-oic acid seub [CAS] 3Alpha,7B-dihydroxy-5B-cholan-24-oic acid seub [CAS]	8.13.0		Formulation, other
3Alpha,7B-dihydroxy-515-cholan-24-ore acutoran-2 (CAS) 3Alpha,715-dihydroxy-513-cholan-24-ole acidoranbolanbolanbolanbolanbolanbolanbolanbol	201.0		
3Alpha,78-dihydroxy-58-cholan-24-oic acid (CAS) 3Alpha,78-dihydroxy-58-cholan-24-oic acid ovartis (CAS)	8-13-2.		Formulation, other
3Alpha,78-dihydroxy-58-cholan-24-olc acid s [CAS]	8-13-2		Formulation, oral, other
	8-13-2		Gallstone therapy
128-13-2	28-13-2		

·			·	, , , , , , , , , , , , , , , , , , , 	·
Example of Indication	Inflammation, general	Hypertension, general	Eczema, contact	Schizophrenia Cirrhosis, primary billary	

API Gen ric Name API Chemical Nursodiol Ushercell Uzarin Valacyclovir Valacyclovir Valdetamid Valdetamid Valdetamid Valgenciolovir Valganciclovir Valganciclovir Valganciclovir Valganciclovir Valganciclovir	API Chemical Name L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yı]methoxyjettyi ester [CAS]		Patent Refere	. ag	Example of Therapeutic Use
n ric Name io1 clovir clovir amid amate Bromide ciclovir			Refer		Example of Therapeutic Use
rin clovir smid amate Bromide ciclovir		77			
clovir clovir amid amate Bromide slovir		T	7	T	Ecomidation microsal fonical
clovir clovir amid amate Bromide slovir			3.	27/2000	בייים ביים בייים בייים בייים בייים בייים בייים בייים בייים בייים ב
clovir Ib amid amate Bromide		20231-81-6	1		
흥		124832-26-4	<u> </u>	308065	Antiviral, other
	Honomide 4-(5-methyl-3-phenyl	124832-26-4		•	
B		181695-72-7	Sn	5859257	Antiarthritic, other
9		512-48-1			
·		90-22-2			
	((2-amino-1,6-dihydro-6-oxo- yl)methoxy)-3-hydroxypropyl	175865-59-5 175865-60-8	<u> </u>	694547	Antiviral, other
Valganciciovii		175865-60-8			
1/oln cotomid		4171-13-5			
	L-Valine (3R)-3-((2-amino-1,6-dihydro-6- oxo-9H-purin-9-yl)methyl)-4-((1- oxooctadesul)oxyhint ester (CAS)	195156-77-5			Antiviral, other
	Pentanoic acid, 2-propyl-, sodium salt (2:1)		Sn	4988731	Antiepileptic
,	Pentanoic acid, 2-propyl-, sodium salt (2:1)	76584-70-8			Formulation, modified-release, <=24hr
	Pentanoic acid, 2-propyl-, sodium salt- CASI	1069-86-5			Formulation, modified-release, <=24hr
	Swith Valeric acid, 2-propyl-, sodium salt [CAS]	1069-66-5			Formulation, modified-release, <=24hr
Valor ic Acid	\Box	99-66-1			
		2430-27-5			
	Pentanamide, N-(2-amino-2-oxoethyl)-2- propyl- (CAS)	92262-58-3	S	5585358	Antiepileptic
	Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amlno)-Alpha-L-lyxo-hexopyranosyl)oxy)-2-naohthacenyl)-2-oxoethyl ester (25-cis)-				
valrubicin		56124-62-0	S	4035566	Anticaricer, amunione
Valrubicin		56124-62-0			

		•				•			·
Exampl of Indication	Contraceptive, female	Infection, herpes simplex virus	Arthritis, rheumatoid	Infection, cytomegalovirus	Infection, herpes simplex virus Epilepsy, generalized, tonic- clonic	Migraine Epilepsy, general	Epilepsy, general	Epilepsy, general	Cancer, bladder

			Datont	•	
	And Observation Name	CAS No.	Refer	Reference	Example of Therapeutic Use
API G neric Name	L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yı][1,1'-biphenyi]-4-yı]methyl]-	137862-53-4	<u> </u>	443983	Antihypertensive, renin system
Valsarian		137862-53-4			
Valsaitaii		121584-18-7			
	Piperazine, 1-(3-(1,4-dihydro-5-methyl(-4-oxo-7-propylimidazo(5,1-f)(1,2,4)-triazin-2-	000			Male sexual dysfunction
vardenafil	yl)-4-ethoxyphenyl)sulfonyl)-4-ethyl- [CAS]	\$24102-a0-4			-
varespladib sodium	Acetic acid, ((3-(aminooxoacetyl)-2-ethyl-1-172732-68-2 (phenyimethyl)-1H-indol-4-yl)oxy)- [CAS] 172733-42-5	172732-68-2	G	675110	Septic shock treatment
Varicella Virus					
Vaccine, Live					
	3,5-Pyridinedicarboxylic acid, 1,4-dihydro- 2,6-dimethyl-4-(3-nitrophenyl)-, 2-14-[4- (diphenylmethyl)-1-piperazlnyllphenyllethyl 118308-55-5 (3,000-00-00-00-00-00-00-00-00-00-00-00-00	116308-55-5 133743-71-2	. 🖧	257616	Neuroprotective
vatanidipine hydrochioride	The first series and the first series of the f		S	6007817	Radio/chemosensitizer
S					•
voeuronium. hromida	Pipertdinlum, 1- [(28,3Alpha,5Alpha,168,178)-3,17- bis(acetyloxy)-2-(1-pipertdiny))androstan- 16-yll-1-methyf-, bromide [CAS]	50700-72-6	S S	4237126	Muscle relaxant
Wedicinalization Bromide		50700-72-6			
Vecul Illum clonica		104675-29-8			
Venacrine		93413-69-5			
Venialaxiii	Oyctohexanol, 1-{2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, hydrochloride	93413-69-5 99300-78-4	GB	2227743	Antidepressant
veniaraxine nyaracinoriae	Cyclohexanol, 1-{2-(dimethylamino)-1-(4-methoxphenyl)ethyl]-, hydrochloride	99300-78-4			Formulation, modified-release, <=24hr
Venialaxine An	Cyclohexanol, 1-{2-(dimethylamino)-1-{4- methoxyphenyl)ethylj-, hydrochloride	99300-78-4			Formulation, modified-release, other
ventafaxine, Phoenix	(CAS)	66644-81-3			
V ralipride					

					,			
Exampl findication	Hypertension, general	Sexual dysfunction, male, general	Sepsis	Hypertension, general Cancer, general	Anaesthesia, ädjunct	Depression, general	Depression, general	Depression, general

			Patent		
ADI Gen ric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
Vorspamil		52-53-9			
	Benzeneacetonirile, Alpha-[3-[2-(3,4-dimethoxyphenyl)ethylmethylaminolpropyl] 3,4-dimethoxy-Alpha-(1-methylethyl)-	52-53-9			Formulation, modified-release, other
verapamii Sh, Eurypiidiii	Benzeneacetonitrile, Alpha-[3-[2-(3,4-dimethoxyphenyl)etryl]methylamino]propyl] 3,4-dimethoxy-Alpha-(1-methylethyl)-	52-53-9	, su	4863742	Formulation, oral, other
Verapanni, ciali	Benzeneacetonitrile, Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl] 3,4-dimethoxy-Alpha-(1-methylethyl)-	52-53-9			Formulation, modified-release, other
Verapanin, Myani	Benzeneacetonitrile, Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propylg 3,4-dimethoxy-Alpha-(1-methylethyl)	52-53-9			Formulation, modified-release, <=24hr
Veraponii, Ondo amo	Banzeneacetonitrile, Alpha-[3-[[2-(3,4-dimethoxyphenyl]ethyljmethylamino]propylj 3,4-dimethoxy-Alpha-(1-methylethyl)-	52-53-9	·		Formulation, modified-release, other
Vorest Vores	Benzeneacetonitrile, Alpha-(3-[[2-(3,4-dimethoxyphenyl)ethyl]methylaminolpropyl] 3,4-dimethoxy-Alpha-(1-methylethyl):	52-53-9	s	4461759 ·	Formulation, modified-release, <=24hr
Velapanini, voica	23H,25H-Benzo[b]porphine-9,13-dipropanoic acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, monomethyl ester, trans-ICASI		Sn	5238940	Ophthalmological
Vortes offis.		129497-78-5			
Verteportin	Piperazine, 1-(3,4-dimethox/benzoyl)-4- (1,2,3,4-tetrahydro-2-oxo-8-quinolinyl)- [CAS]	81840-15-5	GB	2086896	Cardiostlmulant
Voenarinone		81840-15-5	-		
Vestianitine		3735-45-3			
VF-233	Benzene carboximidamide, N,3,4,5-tetrahydroxy- [CAS]	95933-74-7	S	4623659	Cardiovascular Mala savial dustimetion
VI-0134		+	2	6403597	Male sexual uysimissis:

,			•		٠.			·	
Example of Indication	Hypertension, general	Hypertension, general	Hypertension, general	Tachycardia, supraventricular	, Hypertension, general	· Hypertension, general	Macular degeneration	Heart failure	Reperfusion injury Premature ejaculation

٠			1		
		٠	Patent	ŧ	
ADI G. n. ric Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	9H-Purin-6-amine, 9-8-D-arabinofuranosyl- 24356-66-9		ВĐ	1159290	Antiviral, other
Vidarabine	[NJO]	5536-17-4			٠
Vidarabine	r thereals soid 4 amino (CAS)	68506-86-5	89	1472525	Antiepileptic
vigabatrin	5-rexerroic acio, 4-aminio- [CAS]	0 00 07 000	1		
Vigabatrin		60643-86-8	1		
	2-Benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-				
vilazódone	[CAS]	163521-12-8	<u>.</u>	648767	Antidepressant
Vil xazine		46817-91-8			
Vimin I		21363-18-8			
Vinharbital S dium		125-44-0			
		865-21-4			
	Eburnamenin-14(15H)-one,	474-00-0 4880-88-0	30	1932245	Cognition enhancer.
Vinoumine	היים ביים היים היים היים היים היים היים	1617.00.0			
Vincamine		70704 02.0			
Vinconate		2-00-40707		-	
Vincristine	(57-22-7			
vincristine solution	Vincaleukoblastine, 22-oxo-, șulfate (1:1) (satt) [CAS]	2068-78-2	GP.	207831	Formulation, parenteral, other
	Washingtonia 29.000 [CASI	57-22-7			Formulation, optimized, liposomes
vincristine, Aiza	Vilicaleunopiasurie, 22-000-1000	57 00 7			Formulation, parenteral, other
vincristine, bloMerieux-Pierre	Vincaleukoblastine, 22-oxo- [CAS]	31-22-1			o company parameters
	Vincaleukoblastine, 3- (aminocarbonyl)-O4- 53643-48-4 deacetyl-3-de(methoxycarbonyl)- [CAS] 59917-39-4	53643-48-4 59917-39-4	GB	1463575	Anticancer, other
Vindesine		53643-48-4			
	Aspidospermidine-3-carboxylic acid, 4- (acetyloxy)-6, 7-didehydro-15- [(2R,4R,6S,8S)-4-(1,1-difluoroethyl)- 1,3,4,5,6,7,8,9-octahydro-8- (methoxycarbonyl)-2,6-methano-2H- azecino[4,3-bjindol-8-yl]-3-hydroxy-16- methoxy-1-methyl-, methyl ester,	- APP - 10 - 1	Œ	2707988	Anticancer, other
vinflunine	C:Norwincaleukoblastine, 3',4'-didehydro-	ומייים	1		
vinorelbine	4'-deoxy- [CAS]	71486-22-1	a	10458	Anticancer, other

Example of Indication Infection, herpes virus, general Epilepsy, partial (focal, local) Depression, general	Cancer, general Cancer, lymphoma, Hodgkin's Cancer, general Cancer, leukaemia, acute lymphocytic	Cancer, general
---	--	-----------------

			Patent _	=	The state of the second
ADI Generic Name	API Chemical Name	CAS No.	Refer	Reference	Example of Therapeutic Ose
Tree configuration of the conf	C'-Norvincaleukoblastine, 3',4'-didehydro-	71486-22-1			Formulation, oral, other
8	Eburnamenine-14-carboxylic acid, ethyl	42971-09-5		1405127	Cognition enhancer
vinpocetine	ester, (shipira, rohipira) [cres	42971-09-5			
VInpocetine		109-93-3			
Vinyl Ether		2430-49-1			
Vinylbital		84-55-9			
Viquidil		3306.52.3			
Viridin		477.22.7			•
Visnadine		411-36-1			
Vitamin A		00-20-0			Formulation transmucosal, nasal
vitamin B12, Nastech	Vitamin B12 [CAS]	68-19-9			Ollinate of the second
	[-Ascorbic acid [CAS]	50-81-7			Formulation, modified-release, <=24hr
Vitamin C, Aza		50-14-6			
Vitamin D2		0-26-29		·	
Vitamin D ₃		83-70-5	Ŀ		•
Vitamin Ks		200			
		•			•
Vitamins, Prenatal				•	
	((R,S)-4-(4-(Amino-imino-methyl)-phenyl)-3			•	
Assistant Assistant	dioxoimidazolidin-1-yl)-acetyl-L-N-methyl-		GI GI	842943	Antiasthma
VLA-4 antagonists, Avenus	aspailtr promises				
	1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2- (methylamino)carbonylhydrazine			6040338	Anticancer, alkylating
VNP-40101M			3		
o o o di para	D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1- (hydroxymethyl)ethyljarnino]-2-C- (hydroxymethyl)- [CAS]		굡	56194	Antidiabetic
Voymose		83480-29-9			
Aoguigov	4-Pyrimidineethanol, Alpha-(2,4-				
	(114-1,2,4-triazol-1-yimethyl)-; (R-(R*,S*))-	137234-62-9	Э	440372	Antifungal
voriconazole	[CAS]	127034.62.9	L		
Voriconazole		101604-06-3			

API Gen ric Name Al			Patent		
				•	and the state of t
	Api Chemical Name	CAS No.	Reference		Example of Therapeutic Use
		129731-10-8			
	7-{3-{4-(2-Quinolinyimemyi)-1- piperazinyi]propoxyj-3,4-dihydro-2H-1,4-				
90	benzothiazine-3-one				Antiasthma
VUF-K-8788		81.81.9	+		
Warfarin		10.10	+		
	Tetrachlorodecaoxide [CAS]	92047-76-2	1		Radio/chemoprotective
	0 /2 14 19 (6 -0x0-6H-2 10b-diaza-				
. <u>.</u>	aceanthrenvier-5-viamino)propyil-				•
	piperazin-1-yllpropyl)-5-nitro-2-aza-				
<u>. a</u>	phenalene-1,3-dione			-	Anticancer, other
WMC-79				-	
	•		Sn	5897880	Formulation, transdermal, patch
wound healing matrix, IPM, LAM			Sn	6531121	Cytokine
WP-170		40E0E4.00.8			
Xalinroden		19994-06-0	1		
	Pyridine, 1,2,3,6-tetrahydro-1-[2-(2-				•
	naphthalenyl)ethyl]-4-[3-				
VI	(dimensional property)	90494-79-4		101381	Negrobiolective
	4-Morpholinecarboxamide, N-[2-[[2-			•	•
r.	hydroxy-3-(4-	0 07 0700			
	hydroxyphenoxy)propytjaminojetnylj-, (+/-)- /3210-/3-9 R1801-12-9 R7ASI	81801-12-9	88	2002748	Cardiostimulant
		81801-12-9			
Xamoteroi		131986-45-3			
Xanomeline		437-74-1			
Xanthinol Niacinate		149820-74-6			
Xemil fiban		959-10-4			
Xenbucin		21584.06.7			
		0010	\prod		
	Phenol, 4,5-dimethyl-2-(1,7,7- trimethylbicyclo[2.2.1]hept-2-yl)-, exo-	13741-18-9	gg GB	1206774	Antibacterial, other
xibomol	[CAS]	12741-18-9			
Xib rn		13/41-102			

				•	, , , , , , , , , , , , , , , , , , , 	T
Example findication	Asthma Chemotherapy-induced injury, bone marrow, general	Cancer, colorectal Ulcer, diabetic Unspecified	Amyotrophic lateral sclerosis Heart failure			Infection, general

		CAS No.	Patent Refere	Patent Reference	Example of Therapeutic Use
API Generic Name					
	Glycine, N-((R)-cyclohexyl-2-((2S)-2-((((4- (nydroxyamino)iminomethyl)pheriyl)methyl) amino)carbonyl)-1-azetidinyl)2-oxoethyl	192939-46-1			Antithrombotic
kimelagatran	ethyl ester [CAS]	Ee197 90.4			
Ximoprof n		10100			
vinamida	Benzamide, 5-(aminosultonyl)-4-chloro-N- (2,6-dimethylphenyl)-2-hydroxy- [CAS]	14293-44-8	ည	3567777	Antihypertensive, diuretic
.paimod		14293-44-8			
Alpaimo	Morphinan-3-ol, 17-(cyclobutylmethyl)-8- methyl-6-methylene-, (8B)- [CAS]	77287-89-9			Analgesic, other
Xupitation .	2,5-Piperazinedione, 3-[[5-[[2-(dimethylamino)ethyl]thio]-2-thienyl]methylene]-6-(phenylmethylene)-	174786-49-5	9	WO 9532190	Anticancer, other
XR-5118	monohydrochioride, (32,92/-1023)				
	N,N-(1,2-Ethanediy)bis(imino-2,1- ethanediy)bis(9-methylphenazine-1- carboxamide)		â	934278	Anticanoer, other
XR-5944		508.38.3	1		
Xylometazoline		50 08-6 50 08-6			
Xvlose		0-00-00			
YH-1885	2-Pyrimidinamine, 4-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-N-(4-fluorophenyl)-5,6-dimethyl-, monohydrochloride [CAS]	178307-42-1	WO	9605177	Antiulcer
VM. E41	Benzonitrile, 4-[[(4-bromophenyl)methyl]- 4H-1,2,4-trlazol-4-ylamino]- [CAS]	148869-05-0	8	9305027	Anticancer, hormonal
,	potassium(E)-N-(6-methoxy-5-(2-methoxyphenoxy)-2-(pyrlmidin-2-y)pyrimidin-4-yi)-2-		•		Anticancer, othèr
YM-598	piret grand and a second a second and a second and a second and a second and a second and a second and a second and a second and a second and a second a second and a second and a second and a second and a second and a second and a second and a second and a second and a second a second and a second and a second and a second and a second and a	146-48-5	·		
Yohimbine	Administration 2.(1-octowl)- [CAS]	90596-75-1	Sn	5270304	Anti-inflammatory
YT-148	Thiazolidine, 3-(2,3-dihydro-1H-inden-2-y)acetyl)-4-(1-pyrrolidinylcarbonyl)-, (R)-	130849-58-0	<u> </u>	372484	Cognition enhancer
7,391	[CAS]	200-640001	1		

		·				 	 			
Example findication	Thrombosis, venous		Pain, cancer	Cancer, general	Cancer, general	Ureer, Gl, general		Cancer, prostate	Inflammation, general	Dementia, senile, general

			Patent		
omoly eligano	Api Chemical Name	CAS No.	Reference		Example of Therapeutic Use
API Generic Name	(1H-Indene-5-acetic acid, 2[[[(4-				
7.095	dihydro, monosodium salt) [CAS]	146731-14-8	<u>B</u>	92506077	Antimompone
	Carbamic acid, [3-[[2-methoxy-4-[[[(2-methylphenyl]sulfonyl]amino]carbonyl]phenyl]methyl-1H-indol-5-yl]-,	4077E9.78.6	Ö		Antiasthma
zafiriukast	cyclopentyl ester [CAS]	چ	1		
Zafirlukast		20100101	1		
Zafirlukast		0 00	2	7700777	Antiviral, anti-HIV
zalcitabine	Cytidine, 2,3'-dideoxy- [CAS]	7481-89-2	1	T	
Zalcitabin		7481-88-7			
Zalcitabine		0 00 00007			
Zaldaride		109820-20-8			
	Acetamide, N-[3-(3-cyanopyrazolo[1,5-alburimidin-7-vl)phenyl]-N-ethyl- [CAS]	151319-34-5	G	776898	Hypnotic/Sedative
Zalepion		151319-34-5			
Zalepioli	Dibenzo(b,f)thiepin-2-acetic acid, 10,11-	74711-43-6	<u>م</u>	55053282	Anti-inflammatory
	in your management of the contract of the cont	74711-43-6			
Zaltopr f n	- Princeping - P. O. J. C. S. C.				
	5-Acetamido-2,8-anhydro-3,4,5-uruevxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid [CAS]	139110-80-8	WO	9116320	Antiviral, other
Zananinvii		139110-80-8			
Zanamivir					
Zanamivir					
ijadadada	1-Propanone, 3-(1-(phenylmethyl)-4- piperidinyl)-1-(2,3,4,5-tetrahydro-1H-1- benzazepin-8-vl)- [CAS]	142852-50-4	Gi Gi	487071	Cognition enhancer
Zanapeza		85175-67-3			
Zar Draume	Platinum, amminedichloro(2-	181630-15-9	ណ	727430	Anticancer, alkylating
ZD-0473	Company of the state of the sta		ΜÓ	WO- 9528388	Urological
ZD-0947	N-acetylcolchinol-O-phosphate				Anticancer, other
ZD-6126					
	1H-Tetrazole-5-butanoic acid, Alpha-((4-)((1,4-dihydro-2,7-dimethyl-4-oxo-6-)quinazolinyl)methyl)-2-propynylamino)-2-	153537-73-6	8	2264946	Anticancer, antimetabolite
ZD-9331	Interconductory) (c) (c)				

		·	·
Exampl of Indication Peripheral vascular disease	Asthma Infection, HIV/AIDS Insomnia	Infection, influenza virus Alzheimer's disease	Cancer, ovarian Overactive bladder Cancer, general Cancer, pancreatic

Name API Chemical Name 2(1H)-Pyrimidinone, 1-8-D-ribofuranosyl- [CAS] 7,8-Isoquinolinediol, 4-(3,4- dihydroxyphenyl)-1,2,3,4-tetrahydro-, hydrochloride, (S)-[CAS] Thymidine, 3-azido-3'-deoxy-[CAS] Syll-Infordor-1-encedato) - Information and the said (2:1)-[CAS] amer 2H-Indot-2-one, 5-(2-(4-(1,2-benzisothlazol-3-yl)-1-piperaziny) ethyl)-6-chloro-1,3-dihydro-[CAS]						
c Name API Chemical Name 2(1H)-Pyrimidinone, 1-8-D-ribofuranosyl- [CAS] 7,8-Isoquinolinediol, 4-(3,4- dihydroxyphenyl)-1,2,3,4-tetrahydro-, 1 inderent invarional i				Patent	=	
2(1H)-Pyrimidinone, 1-B-D-ribofuranosyl- (CAS) (CAS) 7,8-Isoquinolinediol, 4-(3,4- dihydroxyphenyl)-1,2,3,4-tetrahydro-, hydrochloride, (S)- [CAS] Thymidine, 3'-azido-3'-deoxy- [CAS] Thymidine, 3'-azido-3'-deoxy- [CAS] Thymidine, 3'-azido-3'-deoxy- [CAS] Thymidine, 3'-azido-3'-deoxy- [CAS] Thymidine, 3'-azido-3'-deoxy- [CAS] Urea, N-(1-benzo[b]thlen-2-yletry/)-N- hydroxy- [CAS] Thymidine, 3'-azido-3'-deoxy- [CAS] (CAS] Thymidine, 3'-azido-3'-deoxy- [CAS] Thymidine, 3'-azido-3'-deoxy- [CAS] Thymidine, 3'-azido-3'-deoxy- [CAS] Thymidine, 3'-azido-3'-deoxy- [CAS] (TAY-Indoi-2-OAS) Thymidine, 3'-azido-3'-deoxy- [CAS] (CAS] Thymidine, 3'-azido-3'-deoxy- [CAS] (CAS] Thymidine, 3'-azido-3'-deoxy- [CAS] (CAS] (CAS] Thymidine, 3'-azido-3'-deoxy- [CAS] (CAS] (CAS] Thymidine, 3'-azido-3'-deoxy- [CAS] (CAS] (CAS] (CAS] Thymidine, 3'-azido-3'-deoxy- [CAS] (CAS] (CAS) Thymidine, 3'-azido-3'-deoxy- [CAS] (CAS]		CAS No.	Refe	Reference	Example of Therapeutic Use	
7,8-Isoquinolinediol, 4-(3.4-dihydroxyphenyl)-1,2,3,4-tetrahydro-finydroxyphenyl)-1,2,3,4-tetrahydro-finydroxyphenyl)-1,2,3,4-tetrahydro-finydroxyphenyl)-1,2,3,4-tetrahydro-finydroxyphenyl)-1,2,3,4-tetrahydro-finges Thymidine, 3-azido-3-deoxy-[CAS] Thymidine, 3-azido-3-deoxy-[CAS] Thymidine, 3-azido-3-deoxy-[CAS] Urea, N-(1-benzojo]thien-2-yiethyl)-N-hydroxy-[CAS] Ithymidine, 3-azido-3-deoxy-[CAS] Urea, N-(1-benzojo]thien-2-yiethyl)-N-hydroxy-[CAS] Ithymidine, 3-azido-3-deoxy-[CAS] Ithymidine,	ŀ		3690-10-6			Anticancer, other
ydrochloride inyarochloride, 3-azido-3-deoxy- [CAS] are Thymidine, 3-azido-3-deoxy- [CAS] are Thymidine, 3-azido-3-deoxy- [CAS] Urea, N-(1-benzo[b]thlen-2-ylethyl)-N- inydroxy- [CAS] Dasic hexakis(\text{Vm-acetato})-\text{Vm-4-oxotetrazinc} hate, Vinas anolsulfonate (2:1)- [CAS] alamer Alat 2H-Indol-2-one, 5-(2-(4-(1,2-benzisothlazol-3-yl)-1-piperaziny)]ethyl)-6-chloro-1,3-dihydro- [CAS]			138086-00-7	م	03190818	Vasodilator, renal
Thymidine, 3'-azido-3'-deoxy- [CAS] ne ne Thymidine, 3'-azido-3'-deoxy- [CAS] Urea, N-(1-benzo[b]thlen-2-ylethyl)-N- hydroxy- [CAS] the (2:1)- [CAS] sate, Vinas shoisulfonate nalamer 2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-6-chloro-1,3-dihydro- [CAS]			112733-06-9			
Thymidine, 3'-azido-3'-deoxy- [CAS] The Thymidine, 3'-azido-3'-deoxy- [CAS] Thymidine, 3'-azido-3'-deoxy- [CAS] Urea, N-(1-benzo[b]thlen-2-ylethyl)-N- hydroxy- [CAS] Thymidine, 3'-azido-3'-deoxy- [CAS] Urea, N-(1-benzo[b]thlen-2-ylethyl)-N- hydroxy- [CAS] Thymidine, 3'-azido-3'-deoxy- [CAS] Thymidine, 1'-a-azido-3'-deoxy- [CAS]			107452-89-1			
erex Thymidine, 3'-azido-3'-deoxy- [CAS] basic Urea, N-(1-benzo[b]thlen-2-ylethyl)-N- hydroxy- [CAS] te (2:1)- [CAS] shoisulfonate halamer 2H-Indol-2-one, 5-(2-(4-(1,2-benzisothlazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro- [CAS]	Thumiding 3-azido-3-deox		30516-87-1	'SN	4724232	Antiviral, anti-HIV .
erex Thymidine, 3'-azido-3'-deoxy- [CAS] Urea, N-(1-benzojojthlen-2-ylethyl)-N- hydroxy- [CAS] tab (2:1)- [CAS] rate, Vinas ralamer Plat 2H-Indol-2-one, 5-(2-(4-(1,2-benzisothlazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro- [CAS]	and the state of t		30516-87-1			
erex Thymidine, 3'-azido-3'-deoxy- [CAS] Urea, N-(1-benzo[o]thlen-2-ylethyl)-N- hydroxy- [CAS] basic hexakis(\text{Vm-acetato}\)-\text{Vm4-oxotetrazinc} Hexanolic acid, \text{ \text{Recylamino}\)-, zinc salt (2:1)- [CAS] and (2:1)- [CAS] Independent (2:1)- [CAS] Alamer 2H-Indol-2-one, \text{ \text{S-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperaziny)}} dihydro- [CAS]						
erex Thymidine, 3'-azido-3'-deoxy- [CAS]. Urea, N-(1-benzo[b]thlen-2-ylethyl)-N-hydroxy- [CAS] basic hexakis(vm-acetato)-\m4-oxotetrazinc Hexanolic acid, 6-(acetylamino)-, zinc salt (2:1)- [CAS] anoisulfonate care and anoisulfonate halomate care anoisulfonate		:	1			
Urea, N-(1-benzo D thlen-2-ylethyl)-N- hydroxy- [CAS] basic hexakis(vm-acetato)-lm4-oxotetrazinc Hexanolic acid, 6-(acetylamino)-, zinc salt (2:1)- [CAS] ande, Vinas anoisulfonate viat 2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperaziny)ethyl)-6-chloro-1,3- dihydro- [CAS]	Thymidine, 3'-azido-3'-deoxy		30516-87-1			Formulation, modified-release, <=24hr
basic hexakis(\text{vm-acetato})-\text{vm4-oxotetrazinc} te (2:1)- [CAS] ate, Vinas anoisulfonate viat 2H-Indot-2-one, 5-(2-(4-(1,2-benzisothiazot-3-yl)-1-piperaziny)ethyl)-6-chloro-1,3-dihydro-[CAS]	Urea, N-(1-benzo[b]thlen-2-)		111406-87-2	급	279263	Antiasthma
basic hexakis(vm-acetato)-\m4-oxotetrazinc Hexanolic acid, 6-(acetylamino)-, zinc salt Hexanolic acid, 6-(acetylamino)-, zinc salt Hexanolic acid, 6-(acetylamino)-, zinc salt (2:1)- [CAS] Index and acid acid acid acid acid acid acid aci	, , , , , , , , , , , , , , , , , , ,		111406-87-2			
basic hexakis(vm-acetato)-\rm4-oxotetrazinc Hexanoic acid, \theta-(acetylamino)-, zino salt (2:1)- [CAS] rate, Vinas snoisulfonate halamer 2H-Indol-2-one, \theta-(2-(4-(1,2-benzisothlazol-3-yi)-1-piperaziny))ethyi)-6-chloro-1,3-dihydro-[CAS]			56775-88-3			
e, Vinas e, Vinas olsulfonate amer 2H-Indol-2-one, 5-(2-(4-(1,2-benzisothlazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-[CAS]	hove vie/m-acetatol-/m4-0x	tetrazinc	12129-82-7		•	Antiviral, other
e, Vinas olsulfonate amer 2H-indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyll-6-chloro-1,3-dihydro-[CAS]	Hexanoic acid, 6-(acetylami	saft	2000071-2	Q.	369088	Antiulcer
nate 2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yi)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-[CAS]			70418-00-E	Т		Anti-inflammatory, topical
2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yi)-1-piperaziny))ethyl)-6-chloro-1,3-dihydro-[CAS]	SI		. 0-10-01-01			
2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-[CAS]	fonate		127-82-2			
2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-[CAS]			16283-36-6			
2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol- 3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3- dihydro-[CAS]			2/2/9014			
2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-[CAS]			123760-07-6	Gi Gi	136791	Anticancer, antibiotic
2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-[CAS]			34758-83-3			
dinyaro-1-cks.j	2H-Indol-2-one, 5-(2-(4-(1,2 3-yl)-1-piperazinyl)ethyl)-6-	-benzisothiazol- hloro-1,3-	122883-93-6 146939-27-7	g G	281309	Neuroleptic
	Gental-ologopia		146939-27-7			
io)-2-methyl-1-	L-Proline, 1-[3-(benzoyithio)	-2-methyl-1-	75178-37-3 81872-10-8			
oxopropyi 4-threnyamo) (11(R1),24pha,4Apha,1CAS) (819)	oxopropyij-4-tprierrymmo)- ,[1(R*),2Alpha,4Alpha]- [CA	Sj	81938-43-4	88	2028327	Antihypertensive, renin system

Example f Indication Cancer, general	Hypertension, general Infection, HIV/AIDS	ဖွ	Infection, herpes simplex virus prophylaxis Ulcer, duodenal Inflammation, dermal	Cancer, liver

Hypertension, general

			١		
		•	Patent	=	
ADI Generic Name	API Chemical Name	CAS No.	Refe	Reference	Example of Therapeutic Use
	1.Pmline 1-f3-(henzovithio)-2-methyl-1-				
	oxopropyll-4-(phenylthio)-				
	[11(R*),2Aipha,4Alpha]- + 6-Chloro-3,4-			-	
	dihydro-2H-1,2,4-benzothlazide-7-				Formulation, fixed-dose combinations
zofenopril + HCTZ	sulfonamide 1,1-dioxide [CAS]	·	1		
C. C. C.	Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-vhethylidene]bis- [CAS]	118072-93-8	E.	531253	Osteoporosis treatment
ZOIEGIONIC ACIU		118072-93-8:			
Zoledronic Acid		165800-06-6			
	•	(monohydrate)			
1.0	2-(p-methylsulfonylphenyl)imidazo(1,2- ·	1222-57-7	ns	33188BO	Antiulcer
Zolimiane .		1222-57-7			
	2-Oxazolidinone, 4-((3-(2-(imethylamino)ethyl)				
zofmitriptan	, (s)- [CAS]		8	9118897	Anumigraine
Zolmitriptan		139264-17-6			
	2-Oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)	139284-17-8			Formulation, modified-release, Immediate
zolmitriptan, Durason	(c),	82626-48-0			
Zolpidem					
	Imidazo[1,2-a]pyridine-3-acetamide, N.N.6-trimetryl-2-(4-metrylphenyl)-(R-(R*R*))-	8-60-1000	a	50563	Hypnotic/Sedative
zolpidem tartrate	2,3-dihydroxybutanediotade (2:1) [CAS]	0.00-6366	-i		
Zolpidem Tartrate					
٠,	Imidazo[1,2-a]pyridine-3-acetamide,N,N,6- trimetryf-2-(4-metrylphenyl)-(R-(R*,R*))- 2,3-dihydroxybyfanediotade (2:1)	A. CO.		•	Formulation, modified-release, other
zolpidem tartrate MR		224-22-0			
Party Party	Imidazo(1,2-a)pyridine-3-acetamide, N, N, 6-trimethyl-2-(4-methylphenyl)- (R-(R*, R*)) 2-dibudroxylutanedioate (2:1) [CAS]	99294-93-6			Formulation, optimized, microparticles
210, 7103		33369-31-2			
Zomepirac	1(2H)-Quinoxalineacetic acid, 3,4-dihydro- 7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-	210245-80-0			Neuroprotective
zonampanel	[cvol				

				· · · · · · · · · · · · · · · · · · ·			
Exampl f Indication Hypertension, general	Hypercalcaemia of malignancy	Gastrits	Migraine	Migraine	Insomnia	Insomnia	Insomnia ischaemia, cerebral

			Patent	=	
API Generic Name	API Chemical Name	CAS No.	Befe	Reference	Example of Therapeutic Use
	1H-pyrazole-4-carboxamide,N-(aminolmino methyl)-5-cyclopropyl-1-(5-quinolinyl)-,monomethanesulfonate	249296-45-5			Cardiovascular
zoniponde mesylate	nzisoxazole-3-methanesulfonamide	68291-97-4	gg gg	2025931	Antieplieptic
zonisamide	[CAS]	60001 07.4	7		
Z nisamid	·	4-76-16700			
	1-Piperazinecarboxylic acid, 4-methyl-, 6 (5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-	43200-80-2	GB	1358680	Hypnotic/Sedative
Zopicione	,	43200-80-2			
Zonole stat		110703-94-1			
Zopou stat		54083-22-6			
	1-Piperazineethanol, 4-(1,1-difluoro- 1,1a,6,10b- tetrahydrodibenzo[a,e]cyclopropa[c]cycloh epten-6-yl)-Alpha-[(5-quinolinyloxy)methyl]-	·			
zosuquidar trihydrochloride	, trihydrochloride, [6(R)- (1aAlpha,6Alpha,10bAlpha)]- [CAS]	167465-36-3			Radio/chemosensitizer
zotenine	Ethanamine, 2-[(8-chlorodibenzo[b,f]thiepin 10-yl)oxy]-N,N-dimethyl- [CAS]		GB	1247067	Neuroleptic
Zotepine		26615-21-4	9	0400775	Antierhothmic
ZP-123			3	0102010	
Z-tamoxifen	Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxyj-N,N-dimethyl-, (Z)- [CAS] 10540-29-1	10540-29-1	·		Anticancer, hormonal
ru-lonenthixol	1-Piperazineethanol, 4-[3-(2-chloro-9H-thioxanthen-9-yildene)propyl]-, (Z)-[CAS]	53772-83-1 982-24-1		270282	Neuroleptic
	1-Piperazineethanol, 4-13-(2-chloro-9H-thioxanthen-9-yildene)propylj-, acetate (ester) (Zh-ICASI	85721-05-7			Neuroleptic
Zuciopenunton acetato	Decanoic acid, 2-[4-[3-(2-chloro-9H-thioxanthen-9-yildene)propyl}-1-ninerazinvllethy ester. (2)- ICAS]	64053-00-5			Neuroleptic
Zuciopeninixol decalibate	things are the second s				

	·				· 	·
Example f Indication	Unspecified Epilepsy, generalized, tonic- clonic	Insomnia	Cancer, leukaemia, acute myelogenous	Schizophrenia Arrhythmia, general	Cancer, colorectal Psychosis, general	Schizophrenia Schizophrenia

This Page is inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

P	BLACK BORDERS
. 🗖	IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
	FADED TEXT OR DRAWING
D	BLURED OR ILLEGIBLE TEXT OR DRAWING
	SKEWED/SLANTED IMAGES
	COLORED OR BLACK AND WHITE PHOTOGRAPHS
	GRAY SCALE DOCUMENTS
	LINES OR MARKS ON ORIGINAL DOCUMENT
	REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
	OTHER:

IMAGES ARE BEST AVAILABLE COPY.
As rescanning documents will not correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox